

# ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment  
ISSN (print): 0250-7005; ISSN (online): 1791-7530

VOLUME 30  
2010

## Editorial Board

<b>B. B. Aggarwal</b>	Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
<b>J. P. Armand</b>	Institut Claudius Regaud, Toulouse, France
<b>V. I. Avramis</b>	Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA
<b>R. C. Bast</b>	Department of Translational Research, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
<b>G. Bauer</b>	Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Germany
<b>E. E. Baulieu</b>	INSERM U488 and College de France, Le Kremlin-Bicetre, France
<b>Y. Becker</b>	Department of Biochemistry, Faculty of Medicine, Hebrew University of Jerusalem, Ein Kerem, Jerusalem, Israel
<b>E. J. Benz, Jr.</b>	Dana-Farber Cancer Institute, Boston, MA, USA
<b>J. Bergh</b>	Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, Sweden
<b>D. D. Bigner</b>	Department of Pathology, Duke University Medical Center, Durham, NC, USA
<b>A. Böcking</b>	Institute for Cytopathology, University of Düsseldorf, Germany
<b>G. Bonadonna</b>	Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
<b>F. T. Bosman</b>	Institute of Pathology, University of Lausanne, Switzerland
<b>G. Broich</b>	Istituto Ortopedico Galeazzi, Milan, Italy
<b>J. M. Brown</b>	Department of Radiation Oncology, Stanford Medical Center, Stanford, CA, USA
<b>Ø. S. Bruland</b>	Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway
<b>M. M. Burger</b>	Novartis, Basel, Switzerland
<b>M. Carbone</b>	Cancer Research Center of Hawaii, Honolulu, HI, USA
<b>J. Carlsson</b>	Department of Biomedical Radiation Sciences, Uppsala University, Sweden
<b>A. F. Chambers</b>	Department of Oncology, London Regional Cancer Center, London, Ontario, Canada
<b>P. Chandra</b>	Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany
<b>L. Cheng</b>	Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA
<b>J.-G. Chung</b>	Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC
<b>E. De Clercq</b>	Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
<b>W. De Loecker</b>	Department of Biochemistry, Katholieke Universiteit Leuven, Belgium
<b>W. Den Otter</b>	VUMC, Department of Urology, Amsterdam, The Netherlands
<b>E. P. Diamandis</b>	Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
<b>G. Th. Diamandopoulos</b>	Department of Pathology, Harvard Medical School, Boston, MA, USA
<b>W. Ebert</b>	Thoraxclinic HD-Rohrbach, Heidelberg, Germany
<b>J. A. Fernandez-Pol</b>	Metalloproteomics, LLC, Chesterfield, MO, USA
<b>I. J. Fidler</b>	Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
<b>G. Gabbiani</b>	Department of Pathology, University of Geneva, Switzerland
<b>R. Ganapathi</b>	Department of Clinical Pharmacology, Taussing Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, USA
<b>A. F. Gazdar</b>	Hamon Center for Therapeutic Oncology Research, University of Texas Southeastern Medical Center, Dallas, TX, USA
<b>A. Giordano</b>	Sbarro Institute for Cancer Research, Temple University, Philadelphia, PA, USA
<b>G. Gitsch</b>	Department of Gynecology and Obstetrics, University of Freiburg, Germany
<b>R. H. Goldfarb</b>	Sopherion Therapeutics, Inc., Princeton, NJ, USA
<b>J. W. Gorrod</b>	Toxicology Unit, John Tabor Laboratories, University of Essex, Colchester, Essex, UK
<b>S. Hammarström</b>	Department of Immunology, University of Umeå, Sweden
<b>I. Hart</b>	Centre for Tumour Biology, Institute of Cancer and CR-UK Clinical Centre, Bart's and The London, Queen Mary's School of Medicine and Dentistry, London, UK
<b>I. Hellström</b>	Harborview Medical Center, Seattle, WA, USA
<b>L. Helson</b>	Department of Experimental Therapeutics, New York Medical College, Valhalla, NY, USA
<b>R. B. Herberman</b>	Intrexon Corporation, Germantown, MD, USA
<b>R. M. Hoffman</b>	Department of Surgery, University of California, San Diego, CA, USA

- C. G. Ioannides** Department of Gynecology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
- S. C. Jhanwar** Laboratory of Solid Tumor Genetics, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
- J. V. Johannessen** Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
- B. Kaina** Institute of Toxicology, University of Mainz, Germany
- B. K. Keppler** School of Medicine, University of Vienna, Austria
- D. G. Kieback** Department of Obstetrics and Gynecology, Elblandklinikum Riesa, Riesa, Dresden, Germany
- R. Klapdor** Medical Clinic, University of Hamburg, Germany
- U. R. Kleberg** Hämatologisch - Onkologisch - Praxis Altona, Hamburg, Germany
- P. Kleihues** Department of Pathology, University Hospital Zürich, Switzerland
- E. Klein** Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden
- S. von Kleist** Institut für Immunologie der Universität der Freiburg, Germany
- S. D. Kottaridis** Department of Virology, Hellenic Anticancer Institute, Athens, Greece
- G. R. F. Krueger** Center of Anatomy II, University of Cologne Medical School, Cologne, Germany
- D. W. Kufe** Division of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA
- Pat M. Kumar** Department of Biological Sciences, Manchester Metropolitan University, Manchester, UK
- Shant Kumar** Department Pathology, University of Manchester Medical School, Manchester, UK
- M. Kuroki** Department of Biochemistry, Fukuoka University School of Medicine, Fukuoka, Japan
- O. D. Laerum** Department of Pathology, The Gade Institute, University of Bergen, Norway
- F. J. Lejeune** Fondation du Centre Pluridisciplinaire d' Oncologie, CHUV, Lausanne, Switzerland
- L. F. Liu** Department of Pharmacology, UMD of New Jersey, Piscataway, NJ, USA
- D. M. Lopez** Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA
- E. Lundgren** Unit of Applied Cell and Molecular Biology, University of Umeå, Sweden
- H. T. Lynch** Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE, USA
- J. Marescaux** IRCAD, University of Strasbourg, France
- J. Mark** Department of Pathology, Kärnshjuket, Skövde, Sweden
- J. F. Marshall** Centre for Tumour Biology, Institute of Cancer and CR-UK Clinical Centre, Bart's and The London, Queen Mary's School of Medicine and Dentistry, London, UK
- D. Medina** Department of Cell Biology, Baylor College of Medicine, Houston, TX, USA
- S. Mitra** Sealy Center for Molecular Science, University of Texas Medical Branch, Galveston, TX, USA
- M. Mueller** Research Group of Tumor and Microenvironment (A101), German Cancer Research Center (DKFZ), Heidelberg, Germany
- F. M. Muggia** New York University Cancer Institute, School of Medicine, NY, USA
- M. J. Murphy, Jr.** Hipple Cancer Research Center, Dayton, OH, USA
- R. Narayanan** Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA
- K. Nilsson** Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University Hospital, Sweden
- J. F. Novak** Department of Biology, Bucknell University, Lewisburg, PA, USA
- S. Pathak** Department of Cell Biology, University of Texas, Houston, TX, USA
- S. Pestka** Department of Molecular Genetics and Microbiology, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA
- G. J. Pilkington** Department of Cellular and Molecules Neurooncology, School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK
- C. D. Platsoucas** College of Sciences, Old Dominion University, Norfolk, VA, USA
- F. Podo** Laboratory of Cell Biology, Istituto Superiore di Sanità, Rome, Italy
- A. Polliack** Department of Haematology, Hadassah University Hospital and Medical School, Jerusalem, Israel
- M. F. Rajewsky** Institute of Cell Biology, University of Essen Medical School, Essen, Germany
- G. Rebel** IRCAD, Hopitaux Universitaires, Strasbourg, France
- M. Rigaud** Laboratory Biochimie et Génétique Molécules, Faculté de Médecine de Limoges, France
- U. Ringborg** Department of General Oncology, Karolinska Hospital, Stockholm, Sweden

<b>M. Roselli</b>	Department of Medical Oncology, University of Rome "Tor Vergata", Italy
<b>A. Schauer</b>	Zentrum Pathologie, Georg-August Universität, Göttingen, Germany
<b>M. Schneider</b>	Department of Organic Chemistry, Bergische University, Wuppertal, Germany
<b>A. Seth</b>	Laboratory of Molecular Pathology, Sunnybrook Research Institute and University of Toronto, Ontario, Canada
<b>G. V. Sherbet</b>	Cancer Research Unit, University of Newcastle-upon-Tyne, UK
<b>G.-I. Soma</b>	Institute for Health Sciences, Tokushima Bunri University, Tokushima, Japan
<b>G. S. Stein</b>	Department of Cell Biology, University of Massachusetts Medical Center, Worcester, MA, USA
<b>T. Stigbrand</b>	Department of Immunology, Umeå University, Umeå, Sweden
<b>D. Tarin</b>	University of California at San Diego, Cancer Center, La Jolla, CA, USA
<b>T. M. Theophanides</b>	Department of Chemistry, Technical University of Athens, Greece
<b>B. Toth</b>	The Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE, USA
<b>P. M. Ueland</b>	Clinical Pharmacology Unit, Department of Pharmacology, University of Bergen, Norway
<b>P. T. Vihko</b>	Department of Clinical Chemistry, University of Oulu, Finland
<b>M. Volm</b>	German Cancer Research Center, Heidelberg, Germany
<b>G. Weber</b>	Laboratory of Experimental Oncology, Indiana University, Indianapolis, IN, USA
<b>B. Westermark</b>	Rudbecklaboratoriet, Department of Genetics and Pathology, University of Uppsala, Sweden
<b>B. Zumoff</b>	Division of Endocrinology and Metabolism, Beth Israel Medical Center, New York, NY, USA

## Acknowledgements

The following Organisations supported many of the works published in Anticancer Research, Volume 30, 2010.

- Aase og Ejnar Danielsen's Foundation, Denmark  
 Academia Sinica, Taipei, Taiwan, R.O.C.  
 Academy of Finland  
 Academy of Sciences of the Czech Republic  
 Agriculture Research Center, Washington State University,  
 Pullman, WA, U.S.A.  
 Albert Hung Foundation, U.K.  
 Alfred und Ursula Kulemann Stiftung, Philipps University  
 Marburg, Germany  
 Alma Toorock Memorial for Cancer Research, Inc.,  
 Brooklyn, NY, U.S.A.  
 American Airlines, Richmond, VA, U.S.A.  
 American Cancer Society, U.S.A.  
 American Cancer Society-Illinois Division, Chicago, IL,  
 U.S.A.  
 American Lebanese Syrian Associated Charities (ALSAC),  
 Memphis, TN, U.S.A.  
 American Research Foundation, U.S.A.  
 Animal Imaging Center, St. Jude Children's Research  
 Hospital, Memphis, TN, U.S.A.  
 Anna-Lisa and Bror Björnssons Foundation, Sweden  
 Arvid Nilsson's Foundation, Hvidovre, Denmark  
 Assar Gabrielsson Foundation, Gothenburg, Sweden  
 Assisi Foundation of Memphis (AMD), Memphis, TN, U.S.A.  
 Association Française contre les Myopathies (AFM), Evry  
 cedex, France  
 Associazione Italiana Contro le Leucemie/Linfoma e  
 Mieloma (AIL), Sezione Francesca Lanzone,  
 La Spezia, Italy  
 Associazione Toscana Ricerche e Cure Oncologiche,  
 Florence, Italy  
 AstraZeneca, Wilmington, NC, U.S.A.  
 Austrian Cancer Aid, Graz, Austria  
 Aventis, Bridgewater, NJ, U.S.A.  
 Avon Foundation, New York, NY, U.S.A.  
 Azienda per I Servizi Sanitari N° 1, Trieste, Italy
- B.D. Biosciences, Franklin Lakes, NJ, U.S.A.  
 Barncancerfonden, U.K.  
 Barnum Foundation for Pancreatic Cancer, U.S.A.  
 Bayer Schering Pharma, AG, Germany  
 BCC, Banco Credito Cooperativo, Fisciano, Italia  
 Beckett Foundation, Reading, UK  
 Beijing Institute for Cancer Research, P.R. China  
 Bengt Ihre Foundation, Swedish Society of Medicine  
 BioMedical Research Institute (BRI), Rockville, MD, U.S.A.  
 Bio-Tech-Pharmaceutical, Fayetteville, AR, U.S.A.  
 Borg Foundation, Darien, IN, U.S.A.  
 Boston University, Boston, MA, U.S.A.  
 Breast Cancer Action Kingston, Ontario, Canada  
 Breast Cancer Hope, London, U.K.  
 Breast Cancer Research Foundation, National Institutes of  
 Health (NIH), Bethesda, MD, U.S.A.  
 Brødrene Hartmann's Foundation, Denmark  
 Bundesministerium für Forschung und Technologie (BMBF),  
 Germany
- Canadian Breast Cancer Foundation, Ontario Chapter,  
 Canada  
 Canadian Breast Cancer Research Alliance  
 Canadian Institutes of Health Research (CIHR)  
 Cancer Research Campaign, U.K.  
 Cancer Research Foundation Norrland, Sweden  
 Cancer Research Institute, NY, U.S.A.  
 Cancer Research U.K.  
 Cancer Research Wales, Cardiff, U.K.  
 Cancer Society of Northern Finland  
 Cancer Society of Stockholm (Cancerföreningen),  
 Stockholm, Sweden  
 Cancerfonden, Sweden  
 CAPES, Brazil  
 Cardiff University China  
 Care Stream Molecular Imaging, Rochester, NY, U.S.A.  
 Cassa di Risparmio di Puglia Foundation, Bari, Italia  
 Chang Gung Memorial Hospital, Kaohsiung, Taiwan,  
 R.O.C.  
 Changhua Christian Hospital, Changhua, Taiwan, R.O.C.  
 Chemo-Romikin, Argentina  
 Chico Hyperbaric Center, Chico, CA, U.S.A.  
 China Medical University and Hospital, Taichung, Taiwan,  
 R.O.C.  
 China Medical University Beigang Hospital, Yunlin, Taiwan,  
 R.O.C.  
 China Medical University, Taichung, Taiwan, R.O.C.  
 China Scholarship Council, Beijing, P.R. China  
 Chinese PLA General Hospital, Beijing, P.R. China  
 Chugai Pharmaceutical Co., LTD., Tottori, Japan  
 Chung Shan University, Taichung, Taiwan, R.O.C.  
 Civilingeniør Frode V. Nyegaard og Hustru's Foundation,  
 Denmark

- Clayton Foundation for Research, Houston, TX, U.S.A.  
 Clinical Experimental Research Division of Oncology,  
 Odense University Hospital, Denmark  
 Clinical Science and Biomedical Laboratory Research and  
 Development Services of the Department of Veterans  
 Affairs, Washington, DC, U.S.A.  
 CNPq, Brazil  
 College of Medicine, Chang Gung University, Taoyuan,  
 Taiwan, R.O.C.  
 College of Pharmacy, Ohio State University, Columbus,  
 OH, U.S.A.  
 College of Pharmacy, University of Louisiana at Monroe,  
 Monroe, LA, U.S.A.  
 Comitato Assistenza Malati e Lotta Contro i Tumori,  
 Sarzana, Italy  
 Comités Aquitaine Charente, France  
 Committee on Chinese Medicine and Pharmacy, Department  
 of Health, Executive Yuan, Taiwan, R.O.C.  
 Compagnia di San Paolo, Turin, Italy  
 Conseil Régional d’Auvergne, Clermont-Communauté,  
 FNADT en Auvergne, France  
 Consejería de Salud de la Junta de Andalucía, Espana  
 Conselho Nacional de Desenvolvimento Científico e  
 Tecnológico (CNPq), Brazil  
 Conselho Nacional de Pesquisa e Desenvolvimento (CNPq),  
 Brazil  
 Consiglio Nazionale delle Ricerche (CNR), Roma, Italia  
 Cooperative Human Tissue Network, The Ohio State  
 University Hospital, Columbus, OH, U.S.A.  
 COST consortium ChemBioRadical, Tuscaloosa,  
 AL, U.S.A.  
 Cretan Association for Biomedical Research (CABR),  
 Crete, Greece  
 Croatian Ministry of Science, Education and Sports  
 Croatian MSES  
 Czech Government  
 Czech Ministry of Health  
  
 Dairy Farmers of Canada  
 Danish Cancer Society, Copenhagen, Denmark  
 Danish Council for Independent Research, Natural Sciences  
 (FNU)  
 Danish Medical Research Council  
 Danish Strategic Research Foundation (FØSU)  
 De Sève Foundation Chair in Nutrition, Canada  
 Department of Education of the Basque Government, Bilbao,  
 Spain  
 Department of Health of the Basque Government, Bilbao,  
 Spain  
  
 Department of Health, China Medical University Hospital  
 Cancer Research of Excellence, Taichung, Taiwan, R.O.C.  
 Department of Health, Taiwan, R.O.C.  
 Department of Medicine, University of Bochum, Germany  
 Department of Orofacial Sciences, University of California,  
 San Fransisco, CA, U.S.A.  
 Department of Pathology, University of Turku, Finland  
 Department of Pharmaceutical Sciences and Translational  
 Cancer Research Center, South Dakota State University,  
 Brookings, SD, U.S.A.  
 Department of Pharmacology, College of Medicine, Howard  
 University, Washington, DC, U.S.A.  
 Department of Scientific Publications, The University of  
 Texas M. D. Anderson Cancer Center, Houston, TX, U.S.A.  
 Department of Surgery, St. Jude Children’s Research  
 Hospital, Memphis, TN, U.S.A.  
 Deutsche Forschungsgemeinschaft, Bonn, Germany  
 Deutsche Krebshilfe e.V., Bonn, Germany  
 DHONT Foundation, Santa Ana, CA, U.S.A.  
 Direktør Einar Hansen og hustru fru Vera Hansen’s  
 Foundation, Denmark  
 Dong-A University, Seo-gu, Busan, Republic of Korea  
 Duke University, Durham, NC, U.S.A.  
  
 Ege University, Izmir, Turkey  
 Else and Mogens Wedell-Wedellsborgs Foundations,  
 Denmark  
 Else Kröner-Fresenius Foundation, Bad Homburg v.d.H.,  
 Germany  
 Elternverein Krebskranker Kinder, Stuttgart, Germany  
 EntreMed Inc., Rockville, MD, U.S.A.  
 Epidemiology and Statistics Group NHS Scotland in Paisley,  
 Scotland  
 Erik, Karin and Gösta Slanders Foundation, Sweden  
 Espoir Societies, France  
 European Commission, The European Union  
 European Community, The European Union  
 EuroTransBio, European Union  
  
 Fabrikant Einar Willumsen’s Mindelegat, Denmark  
 Faculty of Pharmacy, Kuwait University, Kuwait  
 FAPERJ, Brazil  
 FAPESC, Brazil  
 FEDER Massif Central, Conseil général du Puy de Dôme,  
 France  
 Financiadora de Estudos e Projetos (FINEP), Brazil  
 Finnish Medical Society Duodecim, Finland  
 First Tech International Co., Ltd., Zhongshan City,  
 Guangdong Province, P.R. China

- First University Hospital of Guangxi Medical University,  
Guangxi, P.R. China
- Fondazione EL.B.A., Rome, Italy
- Fondazione Guido Berlucci, Padova, Italy
- Forest Research Institute of Malaysia
- Foundation for Cancer Research, Szeged, Hungary
- Franz Lanyar Foundation, Graz, Austria
- Friedrich-Baur-Institute, Munich, Germany
- Friedrich-Baur-Stiftung, Muenchen, Germany
- Fru Astrid Thaysen's Legat, Denmark
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo  
(FAPESP), Sao Paulo, Brazil
- Fundação de Amparo à Pesquisa do Estado do Pará  
(FAPESPA), Belem, PA, Brazil
- Fundação para a Ciência e a Tecnologia (FCT), Portugal
- GEFLUC, France
- Genentech, Inc., South San Francisco, CA, U.S.A.
- General Secretary of Research and Technology (GSRT),  
Ministry of Development, Greece
- German Academic Exchange Service (DAAD), Germany
- German Cancer Aid / Dr. Mildred Scheel-Foundation, Bonn,  
Germany
- German Children's Cancer Foundation, Bonn, Germany
- German Research Foundation (DFG), Bonn, Germany
- Gothenburg Medical Society, Sweden
- Grant Agency of the Czech Republic
- Guangzhou Scientific Instruments, P.R. China
- Gustav V's Jubilee Foundation, Sweden
- Gustav Vth Jubilee Society, Sweden
- Hamburger Stiftung zur Förderung der Krebsbekämpfung,  
Germany
- Harboe Foundation, Denmark
- Harry S. Truman VA Research Service, Columbia,  
MO, U.S.A.
- HealthCo, Madrid, Spain
- Hellenic Cooperative Oncology Group, Athens, Greece
- Hellenic Ministry of Development-GSRT, Greece
- Hemlata Hospital and Research Center, India
- Hilfe im Kampf gegen Krebs e.V., Wuerzburg, Germany
- Histology Section of the Tissue Core and the Analytic  
Microscopy Core at the Moffitt Cancer Center and  
Research Institute, Tampa, FL, U.S.A.
- Hoffmann-La Roche, Ltd., Switzerland
- Howard University/Johns Hopkins Cancer Center  
Partnership, U.S.A.
- Hungarian Academy of Sciences
- Hungarian Research Foundation
- ICON Clinical Research, Eastleigh, U.K.
- Idaho State University, Pocatello, Idaho, U.S.A.
- Illinois Department of Public Health, IL, U.S.A.
- Illinois Regenerative Medicine Institute, IL, U.S.A.
- Imclone Systems, Inc., New York, NY, U.S.A.
- Imgenex - Institute of Life Sciences, India
- Immunotech, Prague, Czech Republic
- Indo-US Foundation, India & U.S.A.
- Innogenetics NV, Gent, Belgium
- Institut du Cancer, France
- Institut National de Recherche Agronomique (INRA-France,  
PHASE Department), France
- Institut National du Cancer (INCa), Boulogne Billancourt,  
France
- Institute and Centre for New Antivirals and Antineoplastics,  
Prague, Czech Republic
- Institute of Cellular and System Medicine, National Health  
Research Institutes (NHRI), Taiwan, R.O.C.
- Institute of Life Sciences - Imgenex, India
- Instituto Nacional de Ciencia e Tecnologia (INCT) Processos  
Redox em Biomedicina, Brazil
- Isle of Man Anticancer Association, U.K.
- Istanbul University Cerrahpasa Medical Faculty,  
Department of General Surgery, Breast Services, Turkey
- Istanbul University, Research Foundation, Turkey
- Istituto Toscano Tumori (ITT), Florence, Italy
- Italian Association for Cancer Research (Associazione  
Italiana per la Ricerca sul Cancro; I' AIRC), Italy
- Italian Ministry of Education
- Italian Ministry of Health
- Italian Ministry of Health Research
- Italian Ministry of Research
- Jagiellonian University Medical College, Krakow, Poland
- Japan Science and Technology Agency (JST), Saitama, Japan
- Japanese Smoking Research Foundation
- Japanese Society for the Promotion of Science (JSPS),  
Tokyo, Japan
- Japanese Uehara Memorial Foundation
- Jarislowsky Foundation, Canada
- Joan's Legacy Foundation Grant, New York, NY, U.S.A.
- Johan Boserup and Lise Boserup Foundation, Denmark
- Josef-Freitag-Stiftung, Paderborn, Germany
- K.U. Leuven, Belgium
- Kanagawa Nanbyo Foundation, Japan
- Kanazawa Medical University Research Foundation, Japan
- Kansas State University, Center for Basic Cancer Research,  
Manhattan, KS, U.S.A.

- Kaohsiung Medical University Hospital, Taiwan, R.O.C.  
 Karen Elise Jensen's Foundation, Denmark  
 Karolinska Institute, Stockholm, Sweden  
 King Gustav V Jubilee Clinic Cancer Research Foundation,  
 Gothenburg, Sweden  
 Kitasato University School of Medicine, Kanagawa, Japan  
 Kitasato University, Kanagawa, Japan  
 Købmand Sven Hansen og hustru Ina Hansen's Fondation,  
 Denmark  
 Kong Christian den Tiendes Foundation, Denmark  
 Korea Healthcare Technology R&D Project, Ministry of  
 Health, Welfare and Family Affairs, Republic of Korea  
 Korea Research Foundation  
 Korea Science and Engineering Foundation  
 Korean Government  
 Korean Ministry of Education, Science and Technology  
 Krebsliga Zürich, Switzerland  
 Krista og Viggo Petersen's Foundation, Denmark  
 Kuopio University Hospital, Finland  
 Kuwait University Research Administration, Safat, Kuwait  
 Kyowa Hakko Kirin, Tokyo, Japan  
 Kyungpook National University Hospital, Daegu, Korea
- Lady Fairfax Foundation Sydney, NSW, Australia  
 Latvian Medical Academy, Riga, Latvia  
 Lega Italiana per la Lotta contro i Tumori, Italia  
 Leukemia Lymphoma Society, White Plains, NY, U.S.A.  
 Libyan Health Ministry  
 Libyan Medical Specialization Board  
 Ligue contre le Cancer d'Auvergne, France  
 Ligue Contre le Cancer, France  
 Ligue Nationale Contre le Cancer (Comité de la Savoie et de  
 la Haute Savoie), France  
 Lloyd Carr-Harris Foundation, Canada  
 LUA-fondations from the University of Gothenburg, Lund  
 and Uppsala, Sweden  
 Ludwig Institute for Cancer Research, Switzerland  
 Ludwig Maximilians University (LMU), Munich, Germany
- M.D. Anderson Cancer Center for Targeted Therapy,  
 Houston, TX, U.S.A.  
 M.E.N.R.T. (Ministère de l'Éducation Nationale, de la  
 Recherche et de la Technologie), France  
 Max-Planck Institute, Germany  
 McCormick Spices, Sparks, MD, U.S.A.  
 Medical Faculty of the Otto von Guericke University  
 Magdeburg, Germany  
 Medical Faculty of the University of Wuerzburg, Germany  
 Medical Faculty of Umeå University, Sweden
- Medical University of Lodz, Poland  
 Merck Research Laboratories, Whitehouse Station, NJ, U.S.A.  
 Ministerio de Ciencia e Innovación, Espana  
 Ministero dell'Istruzione, dell'Università e della Ricerca  
 (MIUR), Italy  
 Ministry for Health, Welfare & Family Affairs,  
 Republic of Korea  
 Ministry of Education in Taiwan  
 Ministry of Education of China  
 Ministry of Education, Culture, Sports, Science and  
 Technology (MEXT) of Japan  
 Ministry of Education, Youth and Sports of the Czech Republic  
 Ministry of Health & Welfare, Republic of Korea  
 Ministry of Health of the Czech Republic  
 Ministry of Health, Labor and Welfare of Japan  
 Ministry of Higher Education, Science and Technology of  
 the Republic of Slovenia  
 Ministry of Personnel, India  
 Ministry of Research and Technology, Taiwan, R.O.C.  
 MIUR (Ministero dell'Istruzione, Università e Ricerca),  
 University of Genova, Genova, Italy  
 MURST, Italy
- Nakatomi Foundation, Japan  
 Nanoworld Institute-CIRNNOB of the University of Genova,  
 Italy  
 National Agency of Scientific and Technological Promotion  
 (ANPCyT), Argentina  
 National Board of Health and Welfare, Sweden  
 National Cancer Institute (NCI) Cancer Center, NIH,  
 Bethesda, MD, U.S.A.  
 National Cancer Institute (NCI), NIH, Bethesda, MD, U.S.A.  
 National Center for Research Resources (NCRR), NIH,  
 Bethesda, MD, U.S.A.  
 National Cheng Kung University, Tainan, Taiwan, R.O.C.  
 National Health Research Institutes, Zhunan, Miaoli,  
 Taiwan, R.O.C.  
 National Hospital Organization Policy Based Medical  
 Services, Japan  
 National Institute of Biomedical Innovation (NiBio), Osaka,  
 Japan  
 National Institute of Environmental Health and Sciences  
 (NIEHS), Research Triangle Park, NC, U.S.A.  
 National Institute of Health (NIH), Bethesda, MD, U.S.A.  
 National Institute on Aging, NIH, Bethesda, MD, U.S.A.  
 National Natural Science Foundation of China  
 National Research Foundation (NRF) of Korea  
 National Science and Engineering Council (NSERC) of  
 Canada



- National Science Council of the Republic of China  
National Science Council, Taipei, Taiwan, R.O.C.  
Natural Science Foundation of Shandong Province,  
P.R. China  
Natural Sciences and Engineering Research Council of  
Canada (NSERC), Ottawa, ON, Canada  
Nature Science Foundation of China  
Netherlands Organization for Scientific Research  
New Energy and Industrial Technology Development  
Organization, Japan  
New York University Cancer Institute, NY, U.S.A.  
Nihon University, Itabashi-ku, Tokyo, Japan  
NIRS-HIMAC, Japan  
Nordic Cancer Union, Oslo, Norway  
Nordrhein-Westfälische Gesellschaft für Urologie,  
Germany  
Northwestern University Feinberg School of Medicine  
Department of Medicine, Chicago, IL, U.S.A.  
Norwegian Cancer Association  
Norwegian Cancer Society  
Norwegian Research Council  
Novartis Pharma AG, Basel, Switzerland  
Novo Nordisk Foundation, Denmark
- Office of National Statistics in London, U.K.  
Office of Research and Development, U.S. Department of  
Veterans Affairs, Washington, DC, U.S.A.  
Ohio State University, Columbus, OH, U.S.A.  
Okayama Health Foundation, Japan  
Oklahoma Center for the Advancement of Science and  
Technology, OK, U.S.A.  
Ontario Centers of Excellence (OCE), Toronto, Ontario,  
Canada  
Örebro County Research Committee, Sweden  
Osaka Medical Research Foundation for Incurable Diseases,  
Japan  
Ottogi, South Korea
- Paavo Koistinen Foundation, Finland  
Paul-Blümel Stiftung, Hannover, Germany  
Paulo Foundation, Finland  
Pfizer Pharma, Germany  
Pfizer, Inc., New York, NY, U.S.A.  
Pharma Nord, Denmark  
Pharmacyclics, Inc., Sunnyvale, California, U.S.A.  
Pierre Fabre Ibérica, Espana  
Polish Ministry of Science and Higher Education  
Precision Therapeutics Inc., Pittsburgh, PA, U.S.A.  
Presbyterian Health Foundation, OK, U.S.A.
- Quilmes National University, Buenos Aires, Argentina  
Région de Franche-Comté and Ligue Contre le Cancer  
(Département du Doubs) France  
Regione Piemonte, Italy  
Reinhard Nagel Stiftung of the German Association of  
Urology, Germany  
Research Service of the Minneapolis Veterans Affairs  
Medical Center, Minneapolis, Minnesota, U.S.A.  
Ricerca Sanitaria Regione Liguria, Italia  
RIKEN Omics Science Centre, Yokohama, Japan  
Robert Bosch Foundation Stuttgart, Germany  
Roche Diagnostics GmbH, Penzberg, Germany  
Romanian Ministry of Education and Research  
Roswell Park Alliance Foundation, Buffalo, NY, U.S.A.  
Roswell Park Cancer Center, Buffalo, NY, U.S.A.  
Royal Golden Jubilee Ph.D. Program of Thailand  
Ryobi-teien Memorial Foundation, Japan
- Sabine Döriges Stiftung Ludwigsburg, Germany  
Samantha Dickson Brain Tumour Trust, Hampshire, U.K.  
Samyang Genex Corporation, Korea  
São Paulo State Foundation for the Support of Research,  
Brazil  
Schering Company, Berlin, Germany  
School of Dentistry, Nihon University, Itabashi-ku, Tokyo,  
Japan  
Science and Technology Development Plan of Nanjing,  
P.R. China  
Scientific and Technological Projects for Oversea Returned  
Persons, Ministry of Personnel, India  
Scientific Research Foundation for Returned Overseas  
Chinese Scholars, State Education Ministry, P.R. China  
Scientific Research Foundation for Returned Scholars,  
Ministry of Education, P.R. China  
Scientific Research Foundation of Graduate School of  
Nanjing University, P.R. China  
Scientific Research from the Ministry of Education, Science,  
Sports and Culture of Japan  
Seneca Medical Inc., Tiffin, OH, U.S.A.  
Seoul Medical Center Research Institute, Korea  
Seoul Research and Business Development Program, Korea  
Sequus Pharmaceuticals, Menlo Park, CA, U.S.A.  
Shenyang Outstanding Talent Foundation of China  
Shenyang University, Institute of Science and Technology,  
Shenyang, Liaoning, China  
Shionogi, Osaka, Japan  
Sign Path Pharma, Inc., Quakertown, PA, U.S.A.  
Slovak Research and Development Agency

- Slovenian Research Agency  
 Society of Nuclear Medicine, CA, U.S.A.  
 Southern Research Institute, Birmingham, AL, U.S.A.  
 Southern Science Park of Taiwan, R.O.C.  
 Southwest Foundation for Biomedical Research, San Antonio, TX, U.S.A.  
 SSTK Biotech Ltd., Shenzhen, P.R. China  
 State of South Dakota, U.S.A.  
 Stockholm Cancer Society, Sweden  
 Stockholm City Council, Sweden  
 Stockholm County Council, Sweden  
 Sunlight Research Forum, Veldhoven, The Netherlands  
 Susan G. Komen Breast Cancer Foundation, TX, U.S.A.  
 Swedish Cancer Foundation  
 Swedish Cancer Society  
 Swedish Cancer Society, Stockholms Läns Landsting (Stockholm County Council), Sweden  
 Swedish Heart-Lung Foundation  
 Swedish International Development Co-operation Agency (Sida)  
 Swedish Larynx Foundation  
 Swedish Match AB  
 Swedish Medical Association  
 Swedish Medical Research Council  
 Swedish Research Council  
 Swiss National Science Foundation  
 Szeged Foundation for Cancer Research, Hungary
- Taiho Pharmaceutical Co., LTD., Tokyo, Japan  
 Terry Fox Cancer Research Foundation, Chilliwack, BC, Canada  
 Texas Department of Agriculture, U.S.A.  
 Texas Woman's University, Denton, TX, U.S.A.  
 The Augustinus Foundation, Kaneohe, HI, U.S.A.  
 The City of Besançon, France  
 The John R. Crosby Memorial Foundation, Ann Arbor, MI, U.S.A.  
 The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, U.S.A.  
 The Sallie Astor Burdine Breast Foundation, Baton Rouge, LA, U.S.A.  
 The Vehicle Racing Commemorative Foundation, Tokyo, Japan  
 Tissue Bank at South Carolina Cancer Center, Columbia, SC, U.S.A.
- Tissue Bank at the China Medical University, Taichung, Taiwan, R.O.C.  
 Tobacco-Related Disease Research Program, University of California, Los Angeles, CA, U.S.A.  
 Toronto Medical Laboratories, ON, Canada  
 Turku University Hospital, Finland
- U.S. Department of Veterans Affairs, Washington, DC, U.S.A.  
 Uehara Memorial Foundation, Japan  
 Understödsföreningen Liv och Hälsa r.f., Finland  
 United States Department of Defense, Washington, DC,  
 University Hospital of Limoges, France  
 University of Edinburgh, Edinburgh, U.K.  
 University of Hong Kong, Hong Kong, P.R. China  
 University of Iowa Development Hybridoma Studies Bank, Iowa City, Iowa, U.S.A.  
 University of Missouri, Columbia, Missouri, U.S.A.  
 University of Munich, Germany  
 University of Nevada, Reno, NV, U.S.A.  
 University of Reading Research Travel Board, U.K.  
 University of Salerno, Fisciano, Italy  
 University of South Carolina School of Medicine, Columbia, SC, U.S.A.  
 University of Torino, Italy  
 University of Turku, Finland  
 Uppsala University Hospital, Sweden  
 UV Foundation, McLean, VA, U.S.A.
- Vector Core Lab, St. Jude Children's Research Hospital, Memphis, TN, U.S.A.  
 Vehicle Racing Commemorative Foundation, Japan  
 Vitamin D Society, Canada  
 Vygon GmbH, Aachen, Germany
- Washington State University College of Pharmacy, Pullman, WA, U.S.A.  
 Welsh Cancer Intelligence and Surveillance Unit in Cardiff, U.K.  
 Wendy Will Case Cancer Foundation, U.S.A.  
 WESCO Scientific Promotion Foundation, Japan  
 Wilhelm and Martina Lundgren Foundation, Sweden  
 Yonsei University College of Medicine, Seoul, Korea

**Contents, Volume 30, 2010**

**Number 1**

*Experimental Studies*

Alcohol Consumption, Obesity, Estrogen Treatment and Breast Cancer. J. HONG, V.B. HOLCOMB, F. DANG, K. PORAMPORNPILAS, N.P. NÚÑEZ (*Austin, TX, USA*) ..... 1

Direct Effects of Delta Opioid Receptor Agonists on Invasion-associated Activities of HCT-8/E11 Colon Cancer Cells. D. DEBRUYNE, A. LEROY, O. DE WEVER, L. VAKAET, M. MAREEL, M. BRACKE (*Gent, Belgium*) ..... 9

Evaluation of [<sup>99m</sup>Tc-(CO)<sub>3</sub>-X-Y-Bombesin(7-14)NH<sub>2</sub>] Conjugates for Targeting Gastrin-releasing Peptide Receptors Overexpressed on Breast Carcinoma. L.B. RETZLOFF, L. HEINZKE, S.D. FIGUREOA, S.V. SUBLETT, L. MA, G.L. SIECKMAN, T.L. ROLD, I. SANTOS, T.J. HOFFMAN, C.J. SMITH (*Columbia, MO, USA; Sacavém, Portugal*) ..... 19

Disulfide-linked Liposomes: Effective Delivery Vehicle for *Bcl-2* Antisense Oligodeoxyribonucleotide G3139. W. WEECHARANGSAN, B. YU, S. LIU, J.X. PANG, L.J. LEE, G. MARCUCCI, R.J. LEE (*Columbus, OH, USA; Nakhon Nayok, Thailand*) ..... 31

Potent Pleiotropic Anti-angiogenic Effects of TM601, a Synthetic Chlorotoxin Peptide. D.B. JACOBY, E. DYSKIN, M. YALCIN, K. KESAVAN, W. DAHLBERG, J. RATLIFF, E.W. JOHNSON, S.A. MOUSA (*Cambridge, MA; Rensselaer, NY, USA*) ..... 39

The Simian Virus 40 Large Tumor Antigen Activates cSrc and Requires cSrc for Full Neoplastic Transformation. R. ARULANANDAM, M. GELETU, L. RAPTIS (*Kingston, ON, Canada*) ..... 47

Anticancer Activity of Novel Plant Extracts from *Trailliaedoxa gracilis* (W. W. Smith & Forrest) in Human Carcinoid KRJ-I Cells. B. SVEJDA, V. AGUIRIANO-MOSER, S. STURM, H. HÖGER, E. INGOLIC, V. SIEGL, H. STUPPNER, R. PFRAGNER (*Graz; Innsbruck; Himberg, Austria*) ..... 55

MicroSPECT/CT Imaging and Pharmacokinetics of <sup>188</sup>Re-(DXR)-liposome in Human Colorectal Adenocarcinoma-bearing Mice. M.-H. CHEN, C.-H. CHANG, Y.-J. CHANG, L.-C. CHEN, C.-Y. YU, Y.-H. WU, W.-C. LEE, C.-H. YEH, F.-H. LIN, T.-W. LEE, C.-S. YANG, G. TING (*Miaoli; Taoyuan; Taipei, Taiwan*) .... 65

Sansalvamide Induces Pancreatic Cancer Growth Arrest through Changes in the Cell Cycle. M.J. HEIFERMAN, M.R. SALABAT, M.B. UJIKI, M.J. STROUCH, E.C. CHEON, R.B. SILVERMAN, D.J. BENTREM (*Chicago; Evanston, IL, USA*) ..... 73

Effects of Silybinin on the Pharmacokinetics of Tamoxifen and Its Active Metabolite, 4-Hydroxytamoxifen in Rats. C.-S. KIM, S.-J. CHOI, C.-Y. PARK, C. LI, J.-S. CHOI (*Gwangju, Republic of Korea*) ..... 79

Expression of Vascular Endothelial Growth Inhibitor (VEGI) in Human Urothelial Cancer of the Bladder and its Effects on the Adhesion and Migration of Bladder Cancer Cells *In Vitro*. N. ZHANG, A.J. SANDERS, L. YE, H.G. KYNASTON, W.G. JIANG (*Cardiff, UK; Beijing, P.R. China*) ..... 87

Distinct Roles of Cholinergic Receptors in Small Cell Lung Cancer Cells. S. ZHANG, S. TOGO, K. MINAKATA, T. GU, R. OHASHI, K. TAJIMA, A. MURAKAMI, S. IWAKAMI, J. ZHANG, C. XIE, K. TAKAHASHI (*Tokyo, Japan; Ningxia; Guangzhou, China*) ..... 97

Methylation of the <i>DCC</i> Gene Is Lost in Advanced Gastric Cancer. K. HIBI, M. SAKATA, K. SAKURABA, Y.-H. KITAMURA, A. SHIRAHATA, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA ( <i>Yokohama, Japan</i> ).....	107
Cancer Preventive Effect of <i>Kumaizasa</i> Bamboo Leaf Extracts Administered Prior to Carcinogenesis or Cancer Inoculation. T. SEKI, H. MAEDA, ( <i>Kumamoto, Japan</i> ) .....	111
Mifepristone Treatment Improves Length and Quality of Survival of Mice with Spontaneous Lung Cancer. J.H. CHECK, L. SANSOUCIE, J. CHERN, E. DIX ( <i>Camden; Stratford, NJ, USA</i> ).....	119
Does Dexamethasone Inhibit the Antineoplastic Effect of Cisplatin and Docetaxel in Head and Neck Cancer Cells? J. WAGENBLAST, C. ARNOLDNER, W. GSTÖTTNER, S. BISDAS, S. MÖRTEL, A. MAY, M. HAMBEK ( <i>Frankfurt am Main; Tübingen, Germany; Vienna, Austria</i> ) .....	123
Quantitative Structure-Cytotoxicity Relationship of Newly Synthesized Tropolones Determined by a Semiempirical Molecular-orbital Method (PM5). M. ISHIHARA, H. WAKABAYASHI, N. MOTOHASHI, H. SAKAGAMI ( <i>Saitama; Tokyo, Japan</i> ) .....	129
Effects of $\alpha\beta 6$ Gene Silencing by RNA Interference in PANC-1 Pancreatic Carcinoma Cells. W. NIU, X. LIU, Z. ZHANG, K. XU, R. CHEN, E. LIU, J. WANG, C. PENG, J. NIU ( <i>Jinan, P.R. China</i> ) .....	135
Blue Light is Phototoxic for B16F10 Murine Melanoma and Bovine Endothelial Cell Lines by Direct Cytocidal Effect. A. SPARSA, K. FAUCHER, V. SOL, H. DUROX, S. BOULINGUEZ, V. DOFFOEL-HANTZ, C.-A. CALLISTE, J. COOK-MOREAU, P. KRAUSZ, F.G. STURTZ, C. BEDANE, M.-O. JAUBERTEAU-MARCHAN, M.-H. RATINAUD, J.-M. BONNETBLANC ( <i>Limoges, France</i> ) .....	143
The Cytotoxic Agents NSC-95397, Brefeldin A, Bortezomib and Sanguinarine Induce Apoptosis in Neuroendocrine Tumors <i>In Vitro</i> . D.E. LARSSON, M. WICKSTRÖM, S. HASSAN, K. ÖBERG, D. GRANBERG ( <i>Uppsala, Sweden</i> ).....	149
PPAR $\gamma$ Ligand 15-Deoxy-delta 12,14-Prostaglandin J2 Sensitizes Human Colon Carcinoma Cells to TWEAK-induced Apoptosis. S. DIONNE, E. LEVY, D. LEVESQUE, E.G. SEIDMAN ( <i>Montreal, QC, Canada</i> ).....	157
<i>Clinical Studies</i>	
Phase I Trial of Fixed-Dose Rate Gemcitabine in Combination with Bortezomib in Advanced Solid Tumors. T. LUU, W. CHOW, D. LIM, M. KOCZYWAS, P. FRANKEL, M. CRISTEA, K. MARGOLIN, J.H. DOROSHOW, G. SOMLO, S. GAUR, Y. YEN, R.J. MORGAN ( <i>Duarte, CA; Bethesda, MD, USA</i> ) .....	167
Image DNA Cytometry in FNABs of Libyan Breast Disease. F.B.E. ABDALLA, J.M.E. BODER, A. BUHMEIDA, A.I. ELZAGHEID, Y. COLLAN ( <i>Turku, Finland; Sabratha; Benghazi, Libya; Jeddah, Saudi Arabia</i> ) .....	175
Clinical Value of Preoperative Lymphoscintigraphy in Patients with Early Cervical Cancer Considered for Intraoperative Lymphatic Mapping. S. FOTIOU, P. ZARGANIS, G. VORGIAS, E. TRIVIZAKI, K. VELENTZAS, T. AKRIVOS, G. CREATSAS ( <i>Athens, Greece</i> ).....	183
A Multicountry Ecological Study of Risk-modifying Factors for Prostate Cancer: Apolipoprotein E $\epsilon 4$ as a Risk Factor and Cereals as a Risk Reduction Factor. W.B. GRANT ( <i>San Francisco, CA, USA</i> ) .....	189
Clinicopathological Variables Predictive of Clinical Outcome in Patients with FIGO Stage Ib <sub>2</sub> -IIb Cervical Cancer Treated with Cisplatin-based Neoadjuvant Chemotherapy Followed by Radical Hysterectomy. A. GADDUCCI, G. TETI, C. BARSOTTI, R. TANA, A. FANUCCHI, C. ORLANDINI, M.G. FABRINI, A.R. GENAZZANI ( <i>Pisa, Italy</i> ) .....	201

Prolonged Disease Control after Myeloablative Chemotherapy, Autologous Transplantation and Immunotherapy in High-risk Early Breast Cancer. F. RECCHIA, G. CANDELORO, S. NECOZIONE, P. ACCORSI, C.O.C. RECCHIA, V. TOMBOLINI, S. REA ( <i>Avezzano; Rome; L'Aquila; Pescara, Italy</i> ) .....	209
Association of <i>COMT</i> Haplotypes and Breast Cancer Risk in Caucasian Women. N.B. PETERSON, A. TRENTHAM-DIETZ, M. GARCIA-CLOSAS, P.A. NEWCOMB, L. TITUS-ERNSTOFF, Y. HUANG, S.J. CHANOCK, J.L. HAINES, K.M. EGAN ( <i>Nashville, TN; Madison, WI; Rockville, MD; Seattle WA; Lebanon, NH; Tampa FL, USA</i> ) .....	217
A Case of Esophageal Cancer with Multiple Lymph Node Metastases which Responded to Neoadjuvant Chemotherapy (DCF therapy). T. SHIMAKAWA, Y. NARITAKA, S. ASAKA, N. ISOHATA, K. YAMAGUCHI, M. MURAYAMA, S. KONNO, T. KATSUBE, K. OGAWA, H. IDE ( <i>Tokyo, Japan</i> ) .....	221
Late Effects of Abdominal Irradiation in Children: A Review of the Literature. T. BÖLLING, N. WILLICH, I. ERNST ( <i>Münster, Germany</i> ) .....	227
Changes in Soluble CEA and TIMP-1 Levels during Adjuvant Chemotherapy for Stage III Colon Cancer. B. ALDULAYMI, I.J. CHRISTENSEN, G. SÖLÉTORMOS, P. JESS, S.E. NIELSEN, N. BRÜNNER, H.J. NIELSEN ( <i>Hillerød; Copenhagen; Frederiksberg; Hvidovre, Denmark</i> ) .....	233
CpG Island Promoter Methylation (CIHM) Status of Tumor Suppressor Genes Correlates with Morphological Appearances of Gastric Cancer. T. TAHARA, T. SHIBATA, T. ARISAWA, M. NAKAMURA, H. YAMASHITA, D. YOSHIOKA, M. OKUBO, J. YONEMURA, Y. MAEDA, N. MARUYAMA, T. KAMANO, Y. KAMIYA, H. FUJITA, Y. NAKAGAWA, M. NAGASAKA, M. IWATA, I. HIRATA ( <i>Toyoake; Ishikawa, Japan</i> ) .....	239
Absence of Oncogenic Mutations of <i>RAS</i> Family Genes in Soft Tissue Sarcomas of 100 Japanese Patients. Y. JIN, Y. SHIMA, M. FURU, T. AOYAMA, T. NAKAMATA, T. NAKAYAMA, T. NAKAMURA, J. TOGUCHIDA ( <i>Kyoto, Japan</i> ) .....	245
Evaluation of the Prognostic Value of CD44 in Glioblastoma Multiforme. K.-C. WEI, C.-Y. HUANG, P.-Y. CHEN, L.-Y. FENG, T.-W.E. WU, S.-M. CHEN, H.-C. TSAI, Y.-J. LU, N.-M. TSANG, C.-K. TSENG, P.-C. PAI, J.-W. SHIN ( <i>Taoyuan; Tainan, Taiwan, ROC</i> ) .....	253
Massive Fundic Gland Polyposis in a Patient Receiving Protracted Proton-Pump Inhibitor Medication. C.A. RUBIO, R. BEFRITS, J. ÖSTERBERG, J. ÖHD, M.L. MILLER, S. RAMEL ( <i>Stockholm; Dalarcalia, Sweden; Cincinnati, OH, USA</i> ) .....	261
Prognostic Significance of Nuclear DJ-1 Expression in Astrocytoma. Y. MIYAJIMA, Y. SATO, H. OKA, S. UTSUKI, K. KONDO, Y. TANIZAKI, R. NAGASHIO, B. TSUCHIYA, I. OKAYASU, K. FUJII ( <i>Kanagawa; Tokyo, Japan</i> ) .....	265
Primary Effusion Lymphoma in Two HIV-Negative Patients Successfully Treated with Pleurodesis as First-line Therapy. X. YIAKOUMIS, G.A. PANGALIS, M-C. KYRTSONIS, T.P. VASSILAKOPOULOS, F.N. KONTOPIDOU, C. KALPADAKIS, P. KORKOLOPOULOU, G. LEVIDOU, A. ANDROULAKI, M.P. SIAKANTARIS, S. SACHANAS, A. ANDREOPOULOS ( <i>Athens; Heraklion, Greece</i> ) .....	271
Errata .....	277

## Number 2

*Experimental Studies*

- \* Review: Lessons from Immune Responses and Vaccines Against *Murine Polyomavirus* Infection and Polyomavirus-induced Tumours Potentially Useful for Studies on Human Polyomaviruses. T. RAMQVIST, T. DALIANIS (*Stockholm, Sweden*) ..... 279
- Proteomic Analysis of Prostate Cancer Metastasis-derived Prostatomes. K.G. RONQUIST, G. RONQUIST, A. LARSSON, L. CARLSSON (*Uppsala, Sweden*) ..... 285
- Selenomethionine or Methylseleninic Acid Inhibits Mutagenesis of a Reporter Gene in Mouse Bone Marrow. M.S. KUMAR, K.E. POLLOK, M.L. SMITH (*Indianapolis, IN, USA*) ..... 291
- Effects of *Oplopanax horridus* on Human Colorectal Cancer Cells. X.-L. LI, S. SUN, G.-J. DU, L.-W. QI, S. WILLIAMS, C.-Z. WANG, C.-S. YUAN (*Chicago, IL, USA*) ..... 295
- Pharmacological Enhancement of Autophagy Induced in a Hepatocellular Carcinoma Cell Line by High-LET Radiation. A. ALTMAYER, A.C. JUNG, M. IGNAT, S. BENZINA, J.-M. DENIS, J. GUEULETTE, G. NOËL, D. MUTTER, P. BISCHOFF (*Strasbourg, France; Brussels, Belgium*) ..... 303
- Inhibition of Growth and Induction of Differentiation Markers by Polyphenolic Molecules and Histone Deacetylase Inhibitors in Colon Cancer Cells. M.A. LEA, C. IBEH, L. HAN, C. desBORDES (*Newark, NJ; Brooklyn, NY, USA*) ..... 311
- Curcumin Targets FOLFOX-surviving Colon Cancer Cells *via* Inhibition of EGFRs and IGF-1R. B.B. PATEL, D. GUPTA, A.A. ELLIOTT, V. SENGUPTA, Y. YU, A.P.N. MAJUMDAR (*Detroit, MI, USA*) ..... 319
- Inhibitory Effects of Cationic Hybrid Liposomes on the Growth of Human Renal Cell Carcinoma. M. UMEBAYASHI, T. MAKIZONO, H. ICHIHARA, Y. MATSUMOTO, R. UEOKA (*Kumamoto, Japan*) ..... 327
- Sulindac Sulfone Induces a Decrease of  $\beta$ -Catenin in HNSCC. A. SAUTER, H. SOULSBY, K. HORMANN, R. NAIM (*Mannheim, Germany; Coventry, UK; Wiesbaden, Germany*) ..... 339
- Effects of Interleukin-1 Receptor Antagonist and Chemotherapy on Host-Tumor Interactions in Established Melanoma. P.L. TRIOZZI, W. ALDRICH (*Cleveland, OH, USA*) ..... 345
- Expression and Role of Phosphodiesterase 5 in Human Malignant Melanoma Cell Line. T. MURATA, K. SHIMIZU, Y. WATANABE, H. MORITA, M. SEKIDA, T. TAGAWA (*Tsu, Mie, Japan*) ..... 355
- Effect of Collagenase and Hyaluronidase on Free and Anomalous Diffusion in Multicellular Spheroids and Xenografts. L. EIKENES, I. TUFTO, E.A. SCHNELL, A. BJØRKØY, C. DE LANGE DAVIES (*Trondheim, Norway*) ..... 359
- Dominant Uptake of Fatty Acid over Glucose by Prostate Cells: A Potential New Diagnostic and Therapeutic Approach. Y. LIU, L.S. ZUCKIER, N.V. GHESANI (*Newark, NJ, USA*) ..... 369
- Tumor-specific Correlation of Tumor M2 Pyruvate Kinase in Pre-Invasive, Invasive and Recurrent Cervical Cancer. S. LANDT, S. JESCHKE, A. KOENINGER, A. THOMAS, T. HEUSNER, S. KORLACH, K. ULM, P. SCHMIDT, J.-U. BLOHMER, W. LICHTENEGGER, J. SEHOULI, S. KUEMMEL (*Essen; Magdeburg; Berlin; Munich, Germany; London, UK*) ..... 375
- Three-dimensional Cell Culture of Glioma and Morphological Comparison of Four Different Human Cell Lines. Y. MANOME, S. MIZUNO, N. AKIYAMA, K. FUJIOKA, H. SAITO, Y. HATABA, T. KOBAYASHI, M. WATANABE (*Tokyo, Japan; Boston, MA, USA*) ..... 383

The <i>In Vitro</i> Effects of Tricyclic Drugs and Dexamethasone on Cellular Respiration of Malignant Glioma. S.C. HIGGINS, G.J. PILKINGTON ( <i>Portsmouth, UK</i> ) .....	391
Prophylactic Noscapine Therapy Inhibits Human Prostate Cancer Progression and Metastasis in a Mouse Model. I. BARKEN, J. GELLER, M. ROGOSNITZKY ( <i>San Diego, CA, USA; Telz Stone, Israel</i> ) .....	399
The Combination of 5-FU, Leucovorin and CPT-11 (FOLFIRI) Prolongs Survival through Inhibition of Metastasis in an Orthotopic Model of Colon Cancer. Y. ISHIHARA, K. MATSUNAGA, H. IJIMA, G. HASEGAWA, T. SUZUKI, A.SATO, T. KOBAYASHI, M. YANG, R.M. HOFFMAN ( <i>Fukuoka; Tokyo; Fukushima; Shizuoka, Japan; San Diego, CA, USA</i> ) .....	403
Immune Rejection in a Humanized Model of Murine Prostate Cancer. D. SCHAUE, R.C. KOYA, Y.-P. LIAO, A. RIBAS, W.H. MCBRIDE ( <i>Los Angeles, CA, USA</i> ) .....	409
Pharmacological Impairment of S-Nitrosoglutathione or Thioredoxin Reductases Augments Protein S-Nitrosation in Human Hepatocarcinoma Cells. L.M. LÓPEZ-SÁNCHEZ, F.J. CORRALES, C. LÓPEZ-PEDRERA, E. ARANDA, A. RODRÍGUEZ-ARIZA ( <i>Córdoba; Pamplona, Spain</i> ) .....	415
The Influence of Ovarian Cancer Induced Peritoneal Carcinomatosis on the Pharmacokinetics of Albendazole in Nude Mice. M.H. POURGHOLAMI, Z.Y. CAI, S.W.L. CHU, P. GALETTIS, D.L. MORRIS ( <i>Sydney, Australia</i> ) .....	423
Combined $\gamma$ -Tocotrienol and Erlotinib/Gefitinib Treatment Suppresses Stat and Akt Signaling in Murine Mammary Tumor Cells. S.V. BACHAWAL, V.B. WALI, P.W. SYLVESTER ( <i>Monroe, LA, USA</i> ) .....	429
(-)-Gossypol Containing Hen Sera and a Myosin (-)-Gossypol Conjugate Reduces the Proliferation of MCF-7 Cells. J.M. REDDISH, W. YE, Y.C. LIN, M. WICK ( <i>Columbus, OH, USA</i> ) .....	439
Anthraquinones Danthron and Quinizarin Exert Antiproliferative and Antimetastatic Activity on Murine B16-F10 Melanoma Cells. S. ROSSI, C. TABOLACCI, A. LENTINI, B. PROVENZANO, F. CARLOMOSTI, S. FREZZOTTI, S. BENINATI ( <i>Rome, Italy</i> ) .....	445
Antitumor-promoting Activity of Lignans: Inhibition of Human Cytomegalovirus IE Gene Expression. R. PUSZTAI, M. ABRANTES, J. SHERLY, N. DUARTE, J. MOLNAR, M.-J. U. FERREIRA ( <i>Szeged, Hungary; Lisbon, Portugal</i> ) .....	451
* Review: Epithelial–Stromal Interaction in Squamous Cell Epithelium-derived Tumors: An Important New Player in the Control of Tumor Biological Properties. J. PLZÁK, L. LACINA, M. CHOVANEC, B. DVOŘÁNKOVÁ, P. SZABO, Z. ČADA, K. SMETANA Jr. ( <i>Prague, Czech Republic</i> ) .....	455
Ultrasound-enhanced Microfluidic Synthesis of Liposomes. X. HUANG, R. CADDELL, B. YU, S. XU, B. THEOBALD, L.J. LEE, R.J. LEE ( <i>Columbus, OH, USA</i> ) .....	463
Histological Detection of Minimal Metastatic Disease in Inguinal Non-sentinel Lymph Nodes in Penile Cancer. C.M. NAUMANN, A. MACQUARRIE, C. VAN DER HORST, M.F. HAMANN, A. AL-NAJAR, S. KAUFMANN, A. HEGELE, J.B. KORDA, C. BOLENZ, A. JOCHENS, K.-P. JÜNEMANN, I. LEUSCHNER ( <i>Kiel; Marburg; Cologne; Mannheim, Germany</i> ) .....	467
Erlotinib Enhances the Proapoptotic Activity of Cytotoxic Agents and Synergizes with Paclitaxel in Poorly-differentiated Thyroid Carcinoma Cells. M. LANDRISCINA, F. MADDALENA, A. FABIANO, A. PISCAZZI, O. LA MACCHIA, M. CIGNARELLI ( <i>Foggia, Italy</i> ) .....	473
CADPE Suppresses Cyclin D1 Expression in Hepatocellular Carcinoma by Blocking IL-6-induced STAT3 Activation. C. WON, C.S. LEE, J.-K. LEE, T.-J. KIM, K.-H. LEE, Y.M. YANG, Y.-N. KIM, S.-K. YE, M.-H. CHUNG ( <i>Seoul; Wonju; Chungju; Goyang, South Korea</i> ) .....	481

2'-Hydroxycinnamaldehyde Shows Antitumor Activity against Oral Cancer <i>In Vitro</i> and <i>In Vivo</i> in a Rat Tumor Model. S.-A KIM, Y.-K. SUNG, B.-M. KWON, J.-H. YOON, H. LEE, S.-G. AHN, S.-H. HONG ( <i>Gyeongju; Daegu; Taejeon; Gwangju, South Korea</i> ) .....	489
Effects of $\gamma$ -Secretase Inhibitors on the Growth of Leukemia Cells. Y. OKUHASHI, N. NARA, S. TOHDA ( <i>Tokyo, Japan</i> ) .....	495
Curcumin (Diferuloylmethane) Induces Apoptosis and Blocks Migration of Human Medulloblastoma Cells. M. LATHA Y. BANGARU, S. CHEN, J. WOODLIFF, S. KANSRA ( <i>Milwaukee, WI, USA</i> ) .....	499
Interleukin 1 beta ( <i>IL1B</i> ) Gene Polymorphisms Are Not Associated with Gastric Carcinogenesis in Germany. T. WEX, A. LEODOLTER, J. BORNSCHEIN, D. KUESTER, T. KÄHNE, S. KROPF, C. ALBRECHT, M. NAUMANN, A. ROESSNER, P. MALFERTHEINER ( <i>Magdeburg; Remscheid, Germany</i> ).....	505
<i>TLR4</i> and <i>NOD2/CARD15</i> Genetic Polymorphisms and their Possible Role in Gastric Carcinogenesis. L. RIGOLI, C. DI BELLA, F. FEDELE, V. PROCOPIO, M. AMORINI, G. LO GIUDICE, P. ROMEO, F. PUGLIATTI, G. FINOCCHIARO, R. LUCIANÒ, R.A. CARUSO ( <i>Messina, Italy</i> ) .....	513
Cytotoxic Effects of <i>N</i> -(3-Chloro-1,4-dioxo 1,4-dihydro-naphthalen-2-yl)-benzamide on Androgen-dependent and -independent Prostate Cancer Cell Lines. Y.M. KANAAN, D.F. WHITE, J.R. DAS, S. BERHE, O. BAKARE, H. KENGUELE, D. BEYENE, Y. ZHOU, A.A. DAY, R.L. COPELAND Jr. ( <i>Washington, DC, USA</i> ) .....	519
Significant Association of <i>XRCC4</i> Single Nucleotide Polymorphisms with Childhood Leukemia in Taiwan. K.-H. WU, C.-H. WANG, Y.-L. YANG, C.-T. PENG, W.-D. LIN, F.-J. TSAI, D.-T. LIN, D.-T. BAU ( <i>Taichung; Taipei, Taiwan, ROC</i> ) .....	529
Epigenetic Modifiers as Anticancer Drugs: Effectiveness of Valproic Acid in Neural Crest-derived Tumor Cells. A. PAPI, A.M. FERRERI, P. ROCCHI, F. GUERRA, M. ORLANDI ( <i>Bologna, Italy</i> ) .....	535
 <i>Clinical Studies</i> 	
Phase II Study of Liposomal Cisplatin (SPI-77) in Platinum-sensitive Recurrences of Ovarian Cancer. N. SEETHARAMU, E. KIM, H. HOCHSTER, F. MARTIN, F. MUGGIA ( <i>New York, NY; Mountain View, CA, USA</i> ) .....	541
Phase II Clinical Trial of Imatinib Mesylate in Therapy of KIT and/or PDGFR $\alpha$ -expressing Ewing Sarcoma Family of Tumors and Desmoplastic Small Round Cell Tumors. J. CHAO, G.T. BUDD, P. CHU, P. FRANKEL, D. GARCIA, M. JUNQUEIRA, S. LOERA, G. SOMLO, J. SATO, W.A. CHOW ( <i>Duarte, CA; Cleveland, OH, USA</i> ) .....	547
Pelvic Floor Rehabilitation for Continence Recovery after Radical Prostatectomy: Role of a Personal Training Re-Educational Program. D. MARCHIORI, A. BERTACCINI, F. MANFERRARI, C. FERRI, G. MARTORANA ( <i>Bologna, Italy</i> ) .....	553
Phase II Study of Erlotinib in Japanese Patients with Advanced Non-small Cell Lung Cancer. T. TAKAHASHI, N. YAMAMOTO, T. NUKIWA, K. MORI, M. TSUBOI, T. HORAI, N. MASUDA, K. EGUCHI, T. MITSUDOMI, S. YOKOTA, Y. SEGAWA, Y. ICHINOSE, M. FUKUOKA, N. SAIJO ( <i>Shizuoka; Miyagi; Tochigi; Tokyo; Kanagawa; Aichi; Osaka; Ehime; Yamaguchi; Fukuoka, Japan</i> ) .....	557
Repeat Surgery in Patients with Cervical Cancer Stage FIGO IA1: A Series of 156 Cases and A Review of the Literature. L.A. HEFLER, S. POLTERAUER, A. SCHNEITTER, N. CONCIN, G. HOFSTETTER, E. BENTZ, H. LEIPOLD, C. TEMPFER, A. REINTHALLER ( <i>Vienna; Innsbruck; Klagenfurt, Austria</i> ) .....	565



Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: A Cytogenetic Study of 33 Patients Diagnosed Between 1981 and 2008. E. DE BRAEKELEER, N. DOUET-GUILBERT, F. MOREL, M.-J. LE BRIS, A. BASINKO, C. BERTHOU, P. MORICE, C. FÉREC, M. DE BRAEKELEER ( <i>Brest; St-Brieuc, France</i> ) .....	569
Complete Remission of Lung Metastasis Following Adoptive Immunotherapy Using Activated Autologous $\gamma\delta$ T-cells in a Patient with Renal Cell Carcinoma. H. KOBAYASHI, Y. TANAKA, H. SHIMMURA, N. MINATO, K. TANABE ( <i>Tokyo-to; Kyoto; Fukushima, Japan</i> ) .....	575
Successful Neoadjuvant Therapy with Trastuzumab, Paclitaxel and Epirubicin for an Elderly Patient with Inflammatory Breast Cancer. T. SHIMIZU, A. HIRANO, O. WATANABE, J. KINOSHITA, K. KIMURA, M. KAMIMURA, K. DOMOTO, N. KIM, K. OGAWA, M. FUJIBAYASHI ( <i>Tokyo, Japan</i> ) .....	581
Comparison of Circulating MMP-9, TIMP-1 and CA19-9 in the Detection of Pancreatic Cancer. M.T. JOERGENSEN, N. BRÜNNER, O.B.S. DE MUCKADELL ( <i>Odense; Frederiksberg, Denmark</i> ) .....	587
Significant Expression Patterns of Lewis X-related Antigens as a Prognostic Predictor of Low-stage Renal Cell Carcinomas. M. KOBAYASHI, T. MORITA ( <i>Tochigi, Japan</i> ) .....	593
* Review: Reducing Anastomotic Leakage in Oncologic Colorectal Surgery: An Evidence-Based Review. M.A. BOCCOLA, J. LIN, W.M. ROZEN, Y.-H. HO ( <i>Townsville, QLD, Australia</i> ) .....	601
Bevacizumab Is Active as a Single Agent Against Recurrent Malignant Gliomas. C.A. AGHA, S. IBRAHIM, A. HASSAN, D.A. ELIAS, H.M. FATHALLAH-SHAYKH ( <i>Birmingham, AL; Chicago, IL, USA</i> ).....	609
Dendritic Cell Differentiation and Tumor Cell Apoptosis Induced by Components of a Poly-phenylpropanoid Polysaccharide Complex. W.-W. AN, Y. KANAZAWA, M. OZAWA, K. NAKAYA, T. SAITO, A. TANAKA, W.G. BRADLEY ( <i>Niigata; Yokohama, Japan; St. Petersburg, FL, USA</i> ) .....	613
Efficacy of the Progesterone Receptor Antagonist Mifepristone for Palliative Therapy of Patients with a Variety of Advanced Cancer Types. J.H. CHECK, E. DIX, R. COHEN, D. CHECK, C. WILSON ( <i>Camden, NJ, USA</i> ) .....	623
Effect of YB-1 on the Regulation of Micro RNA Expression in Drug-sensitive and Drug-resistant Gastric Carcinoma Cells. E. BELIAN, R. KURUCZ, D. TREUE, H. LAGE ( <i>Berlin, Germany</i> ) .....	629
Assessment of the Prognostic Indices IPI and FLIPI in Patients with Mucosa-associated Lymphoid Tissue Lymphoma. M. TROCH, S. WÖHRER, M. RADERER ( <i>Vienna, Austria</i> ) .....	635
Type 2 and Clear Cell Papillary Renal Cell Carcinoma, and Tubulocystic Carcinoma: A Unifying Concept. C. BRENNAN, J.R. SRIGLEY, C. WHELAN, J. COOPER, B. DELAHUNT ( <i>Woolloongabba, QLD; Woodville, SA, Australia; Hamilton, ON, Canada; Wellington, New Zealand</i> ) .....	641
Prognostic and Predictive Value of Thymidylate Synthase Expression in Primary Colorectal Cancer. M. KARLBERG, K. ÖHRLING, D. EDLER, M. HALLSTRÖM, H. ULLÉN, P. RAGNHAMMAR ( <i>Stockholm, Sweden</i> ) .....	645
Predictors of Survival in Stage IV Metastatic Colorectal Cancer. M. ZACHARAKIS, I.D. XYNOS, A. LAZARIS, T. SMARO, C. KOSMAS, A. DOKOU, E. FELEKOURAS, E. ANTONIOU, A. POLYZOS, J. SARANTONIS, J. SYRIOS, G. ZOGRAFOS, A. PAPALAMBROS, N. TSAVARIS ( <i>Athens; Piraeus, Greece</i> ) .....	653
Specificity of Fusion Genes in Adipocytic Tumors. T. KUBO, Y. MATSUI, N. NAKA, N. ARAKI, A. MYOUI, K. ENDO, N. YASUI, O. OHTANI, K. SUZUKI, T. KIMURA, H. YOSHIKAWA, T. UEDA ( <i>Tokushima; Toyama; Osaka, Japan</i> ) .....	661

Differential Display Code 3 (DD3/PCA3) in Prostate Cancer Diagnosis. J. KLECKA, L. HOLUBEC, M. PESTA, O. TOPOLCAN, M. HORA, V. ERET, J. FINEK, M. CHOTTOVA-DVORAKOVA, M. BABJUK, K. NOVAK, J. STOLZ ( <i>Plzen; Prague, Czech Republic</i> ) .....	665
EGFR Status and Prognosis of Patients with Locally Advanced Head and Neck Cancer Treated with Chemoradiotherapy. G. NUMICO, E.G. RUSSI, I. COLANTONIO, R.A. LANTERMO, N. SILVESTRIS, R. VITIELLO, A. COMINO, M. ABRATE, C. ZAVATTERO, A. MELANO, M. MERLANO ( <i>Aosta; Cuneo; Bari; Savigliano, Italy</i> ) .....	671
A Case of Curative-intent Hepatectomy for Colon Cancer Metastatic to the Scapula and Liver. G. VAIDYANATHAN, M.G. FAKIH ( <i>Buffalo, NY, USA</i> ) .....	677
The Relationship between Obesity and Cancer Mortality in Type 2 Diabetes: A Ten-year Follow-up Study (ZODIAC-21). G.W. LANDMAN, K.J.J. VAN HATEREN, N. KLEEFSTRA, H.J.G. BILO ( <i>Zwolle; Groningen, The Netherlands</i> ) .....	681
The Body Image Drawing Analysis in Women with Breast Disease and Breast Cancer: Anxiety, Colour and Depression Categories. M. ESKELINEN, P. OLLONEN ( <i>Kuopio, Finland</i> ) .....	683
Regulation of mRNA Expression in Drug-sensitive and Drug-resistant Gastric Carcinoma Cells Is Independent of YB-1 Expression. R. KURUCZ, E. BELIAN, D. TREUE, H. LAGE ( <i>Berlin, Germany</i> ) .....	693
Modifications of Nuclear Envelope in Tumour Cells of Human Gastric Carcinomas: An Ultrastructural Study. R.A. CARUSO, L. RIGOLI, F. FEDELE, G. PIZZI, E. QUATTROCCHI, G. FINOCCHIARO, A. LABATE, D. PAPARO, R. LUCIANÒ, A. PARISI, A. VENUTI ( <i>Messina, Italy</i> ) .....	699
* Reviews (pages 279, 455, 601) .....	

## Number 3

### *Experimental Studies*

MMP Inhibition Blocks Fibroblast-dependent Skin Cancer Invasion, Reduces Vascularization and Alters VEGF-A and PDGF-BB Expression. E.C. WOENNE, W. LEDERLE, S. ZWICK, M. PALMOWSKI, H. KRELL, W. SEMMLER, M.M. MUELLER, F. KIESSLING ( <i>Heidelberg; Aachen; Penzberg, Germany</i> ) .....	703
Expression of <i>KISS1</i> and MMP-9 in Non-small Cell Lung Cancer and Their Relations to Metastasis and Survival. S. ZHENG, Y. CHANG, K.B. HODGES, Y. SUN, X. MA, X. YI, S.R. WILLIAMSON, A. LOPEZ-BELTRAN, R. MONTIRONI, L. CHENG ( <i>Hebei; Tangshan, P.R. China; Indianapolis, IN, U.S.A.; Cordoba, Spain; Ancona, Italy</i> ) .....	713
Characterization of Prostate Cancer in Needle Biopsy by Cathepsin B, Cell Proliferation and DNA Ploidy. J. QIAN, D.G. BOSTWICK, K.A. ICZKOWSKI, K. BETRE, M.J. WILSON, C. LE, A.A. SINHA ( <i>Glen Allen, VA; Aurora, CO; Minneapolis, MN, U.S.A.</i> ) .....	719
Molecular Characterization of Invasive Subpopulations from an Esophageal Squamous Cell Carcinoma Cell Line. Y.-K. CHEN, W.-S.W. CHANG, I.-C. WU, L.-H. LI, S.-F. YANG, J.Y.-F. CHEN, M.-C. HSU, S.-H. CHEN, D.-C. WU, J.-M. LEE, C.-H. HUANG, Y.-G. GOAN, S.-H. CHOU, C.-T. HUANG, M.-T. WU ( <i>Kaohsiung; Miaoli; Taipei, Taiwan, R.O.C.</i> ) .....	727
Quantitative Morphometry of Respiratory Tract Epithelial Cells as a Tool for Testing Chemopreventive Agent Efficacy. S. SHARMA, P. GAO, V.E. STEELE ( <i>Research Triangle Park, NC; Bethesda, MD, U.S.A.</i> ) .....	737

Glycolytic Enzyme Inhibitors Affect Pancreatic Cancer Survival by Modulating Its Signaling and Energetics. V. BHARDWAJ, N. RIZVI, M.B. LAI, J.C.K. LAI, A. BHUSHAN ( <i>Pocatello, ID, U.S.A.</i> ) .....	743
* Review: Association Between Birt Hogg <i>Dubé</i> Syndrome and Cancer Predisposition. R. PALMIROTTA, A. SAVONAROLA, G. LUDOVICI, P. DONATI, F. CAVALIERE, M.L. DE MARCHIS, P. FERRONI, F. GUADAGNI ( <i>Rome, Italy</i> ) .....	751
Manipulation of Iron Transporter Genes Results in the Suppression of Human and Mouse Mammary Adenocarcinomas. X.P. JIANG, R.L. ELLIOTT, J.F. HEAD ( <i>Baton Rouge, LA, U.S.A.</i> ) .....	759
Thioredoxin and Thioredoxin Reductase Expression in Thyroid Cancer Depends on Tumour Aggressiveness. D.T. LINCOLN, F. AL-YATAMA, F.M.A. MOHAMMED, A.G. AL-BANAW, M. AL-BADER, M. BURGE, F. SINOWATZ, P.K. SINGAL ( <i>Chapel Hill; Herston, QLD, Australia; Kuwait City, Kuwait; Munich, Germany; Winnipeg, MB, Canada</i> ) .....	767
Chemopreventive Effects of Honokiol on UVB-induced Skin Cancer Development. S. CHILAMPALLI, X. ZHANG, H. FAHMY, R.S. KAUSHIK, D. ZEMAN, M.B. HILDRETH, C. DWIVEDI ( <i>Brookings, SD, U.S.A.</i> ) .....	777
Synthetic Triterpenoids Inhibit Growth, Induce Apoptosis and Suppress Pro-survival Akt, mTOR and <i>NF-<math>\kappa</math>B</i> Signaling Proteins in Colorectal Cancer Cells. X. GAO, D. DEEB, J. HAO, Y. LIU, A.S. ARBAB, S.A. DULCHAVSKY, S.C. GAUTAM ( <i>Detroit, MI, U.S.A.</i> ) .....	785
Broad Selective Efficacy of rMETase and PEG-rMETase on Cancer Cells <i>In Vitro</i> . Y. TAN, M. XU, R.M. HOFFMAN ( <i>San Diego, CA, U.S.A.</i> ) .....	793
Rapamycin-mediated FOXO1 Inactivation Reduces the Anticancer Efficacy of Rapamycin. E. ABDELNOUR-BERCHTOLD, Y. CERANTOLA, D. ROULIN, A. DORMOND-MEUWLY, N. DEMARTINES, O. DORMOND ( <i>Lausanne, Switzerland</i> ) .....	799
Differential Expression of <i>VEGF121</i> , <i>VEGF165</i> and <i>VEGF189</i> in Angiomas and Squamous Cell Carcinoma Cell Lines of the Head and Neck. C. CAI, M.C. BÖTTCHER, J.A. WERNER, R. MANDIC ( <i>Marburg, Germany</i> ) ..	805
Evaluation of Liposomal Curcumin Cytochrome P450 Metabolism. C.M. MACH, J.H. CHEN, S.A. MOSLEY, R. KURZROCK, J.A. SMITH ( <i>Houston, TX, U.S.A.</i> ) .....	811
* Review: Environmental Oestrogens and Breast Cancer: Evidence for Combined Involvement of Dietary, Household and Cosmetic Xenoestrogens. P.D. DARBRE, A.K. CHARLES ( <i>Reading, U.K.</i> ) .....	815
Constituents of <i>Carpobrotus edulis</i> Inhibit P-Glycoprotein of <i>MDRI</i> -transfected Mouse Lymphoma Cells. A. MARTINS, A. VASAS, ZS. SCHELZ, M. VIVEIROS, J. MOLNÁR, J. HOHMANN, L. AMARAL ( <i>Lisbon, Portugal; Szeged, Hungary</i> ) .....	829
Estimation of Relationship between the Structure of Trihaloacetylazulene Derivatives Determined by a Semiempirical Molecular–Orbital Method (PM5) and their Cytotoxicity. M. ISHIHARA, H. WAKABAYASHI, N. MOTOHASHI, H. SAKAGAMI ( <i>Sakado, Saitama; Kiyose, Tokyo, Japan</i> ) .....	837
Calcium Glucarate Inhibits DMBA-induced Oral Carcinogenesis in the Hamster: Histomorphometric Evaluation. C. LAJOLO, A. SGAMBATO, E. MAIORANO, A. LUCCHESI, S. CAPODIFERRO, G. FAVIA, M. GIULIANI ( <i>Rome; Bari, Italy</i> ) .....	843
Significance of Karyopherin- $\alpha$ 2 (KPNA2) Expression in Esophageal Squamous Cell Carcinoma. M. SAKAI, M. SOHDA, T. MIYAZAKI, S. SUZUKI, A. SANO, N. TANAKA, T. INOSE, M. NAKAJIMA, H. KATO, H. KUWANO ( <i>Maebashi, Gunma; Shimotsuga-gun, Tochigi, Japan</i> ) .....	851

<i>Phellodendron amurense</i> Bark Extract Prevents Progression of Prostate Tumors in Transgenic Adenocarcinoma of Mouse Prostate: Potential for Prostate Cancer Management. R. GHOSH, H. GRAHAM, P. RIVAS, X.J. TAN, K. CROSBY, S. BHASKARAN, J. SCHOOLFIELD, J. BANU, G. FERNANDES, I-T. YEH, A.P. KUMAR ( <i>San Antonio, TX; Danvers, MA, U.S.A.</i> ).....	857
SPARC mRNA Expression as a Prognostic Marker for Pancreatic Adenocarcinoma Patients. K. MIYOSHI, N. SATO, K. OHUCHIDA, K. MIZUMOTO, M. TANAKA ( <i>Fukuoka, Japan</i> ) .....	867
Thiochroman Derivative CH4986399, A New Nonsteroidal Estrogen Receptor Down-regulator, Is Effective in Breast Cancer Models. T. YONEYA, K. TANIGUCHI, R. NAKAMURA, T. TSUNENARI, I. OHIZUMI, Y. KANBE, K. MORIKAWA, S.-I. KAIHO, H. YAMADA-OKABE ( <i>Kanagawa, Japan; Tokyo, Japan</i> ) .....	873
MG132, A Proteasome Inhibitor, Induced Death of Calf Pulmonary Artery Endothelial Cells <i>via</i> Caspase-dependent Apoptosis and GSH Depletion. Y.H. HAN, H.J. MOON, B.R. YOU, Y.M. YANG, S.Z. KIM, S.H. KIM, W.H. PARK ( <i>JeonJu, Republic of Korea</i> ) .....	879
LGP1, A Histone Deacetylase Inhibitor Analogue of FR235222, Sensitizes Promyelocytic Leukaemia U937 Cells to TRAIL-mediated Apoptosis. C.W. D'ACUNTO, A. CARRATÙ, M. RODRIQUEZ, M. TADDEI, L. PARENTE, A. PETRELLA ( <i>Salerno; Siena, Italy</i> ) .....	887
Yeast-based Identification of Prostate Tumor Antigens Provides an Effective Vaccine Platform. V. JUNG, E. FISCHER, J. IMIG, S. KLEBER, N. NUBER, F. REINSHAGEN, J. KAMRADT, R. GROBHOLZ, A. KNUTH, C. RENNER, A. WADLE ( <i>Homburg, Germany; Zurich, Switzerland</i> ) .....	895
Water-soluble Taxol Conjugates with Dextran and Targets Tumor Cells by Folic Acid Immobilization. J. NAKAMURA, N. NAKAJIMA, K. MATSUMURA, S.-H. HYON ( <i>Sakyo-ku, Kyoto, Japan</i> ) .....	903
Effects of Insulin-like Growth Factor Binding Protein 7 on Apoptosis in Human Teratocarcinoma Cells <i>In Vitro</i> . W. ENGSTRÖM ( <i>Oxford, U.K.; Uppsala, Sweden</i> ) .....	911
Establishment and Characterization of Multidrug-resistant Gastric Cancer Cell Lines. X. ZHANG, M. YASHIRO, H. QIU, T. NISHII, T. MATSUZAKI, K. HIRAKAWA ( <i>Osaka, Japan; Beijing; Wuhan, China</i> ) .....	915
3-Bromopyruvate Induces Endoplasmic Reticulum Stress, Overcomes Autophagy and Causes Apoptosis in Human HCC Cell Lines. S. GANAPATHY-KANNIAPPAN, J.-F.H. GESCHWIND, R. KUNJITHAPATHAM, M. BUIJS, L.H. SYED, P.P. RAO, S. OTA, B.K. KWAK, R. LOFFROY, M. VALI ( <i>Baltimore, MD, U.S.A.</i> ) .....	923
Enhancement of Radiation-induced DNA Damage and Inhibition of Its Repair by a Novel Camptothecin Analog. G. HUANG, H. WANG, L.-X. YANG ( <i>San Francisco, CA, U.S.A.</i> ).....	937
Emodin, Aloe-emodin and Rhein Induced DNA Damage and Inhibited DNA Repair Gene Expression in SCC-4 Human Tongue Cancer Cells. Y.-Y. CHEN, S.-Y. CHIANG, J.-G. LIN, J.-S. YANG, Y.-S. MA, C.-L. LIAO, T.-Y. LAI, N.-Y. TANG, J.-G. CHUNG ( <i>Taichung, Taiwan, R.O.C.</i> ) .....	945
<i>Clinical Studies</i>	
Pattern of Failure Following Chemoradiation for Locally Advanced Non-small Cell Lung Cancer: Potential Role for Stereotactic Body Radiotherapy. N.P. NGUYEN, M. BISHOP, T.J. BOROK, J. WELSH, R. HAMILTON, D. COHEN, L.M. NGUYEN, V.-H. VINCENT ( <i>Tucson, AZ; Dallas; Houston, TX; Ann Arbor, MI, U.S.A.; Geneva, Switzerland</i> ) .....	953
Severe Intoxication with Methotrexate Possibly Associated with Concomitant Use of Proton Pump Inhibitors. R. SANTUCCI, D. LEVÊQUE, V. KEMMEL, P. LUTZ, A.-C. GÉROUT, A. N'GUYEN, A. LESCOUTE, F. SCHNEIDER, J.-P. BERGERAT, R. HERBRECHT ( <i>Strasbourg, France</i> ).....	963

Acute Promyelocytic Leukemia in Patients Aged Over 60 Years: Multicenter Experience of 34 Consecutive Unselected Patients. F. FERRARA, O. FINIZIO, A. D'ARCO, L. MASTRULLO, N. CANTORE, P. MUSTO ( <i>Naples; Nocera Inferiore; Avellino; Rionero in Vulture (Pz), Italy</i> ) .....	967
Serious Hematologic Complications Following Erlotinib Treatment. G.P. STATHOPOULOS, DIM. TRAFALIS, A. ATHANASIOU, G. BARDI, H. CHANDRINO (Athens; Piraeus, Greece) .....	973
A New Prognostic Score Derived from Phase I Study Participants with Advanced Solid Tumours Is also Valid in Patients with Brain Metastasis. C. NIEDER, A. DALHAUG ( <i>Bodø; Tromsø, Norway</i> ) .....	977
Mutations of <i>PTEN</i> Gene in Gliomas Correlate to Tumor Differentiation and Short-term Survival Rate. Y. YANG, N. SHAO, G. LUO, L. LI, L. ZHENG, P. NILSSON-EHLE, N. XU ( <i>Changzhou, China; Lund, Sweden</i> ) .....	981
Carbonic Anhydrase IX Expression Is Associated with Improved Outcome of High-dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma. A.Z. DUDEK, R.T. YEE, J.C. MANIVEL, R. ISAKSSON, H.O. YEE ( <i>Minneapolis, MN, U.S.A.</i> ) .....	987
Effects of Preoperative Immunochemoradiotherapy and Chemoradiotherapy on Immune Responses in Patients with Rectal Adenocarcinoma. S. SADAHIRO, T. SUZUKI, Y. MAEDA, A. TANAKA, A. KAMIJO, C. MURAYAMA, Y. NAKAYAMA, T. AKIBA ( <i>Isehara, Japan</i> ) .....	993
Front-line Bevacizumab in Serous Epithelial Ovarian Cancer: Biomarker Analysis of the FINAVAST Trial. P. KARIHTALA, J. MÄENPÄÄ, T. TURPEENNIEMI-HUJANEN, U. PUISTOLA ( <i>Oulu; Tampere, Finland</i> ) .....	1001
ELISA Measurement for Urinary 3-Hydroxyproline-containing Peptides and its Preliminary Application to Healthy Persons and Cancer Patients. J. SAITO, Y. IMAMURA, J. ITOH, S. MATSUYAMA, A. MARUTA, T. HAYASHI, A. SATO, N. WADA, K. KASHIWAZAKI, Y. INAGAKI, T. WATANABE, Y. KITAGAWA, I. OKAZAKI ( <i>Shinjuku-ku; Inagi City; Hachioji City; Tachikawa; Minato-Ku, Tokyo; Chiba City; Ichihara; Chiba; Tokorozawa, Saitama; Ebina City; Isehara City, Kanagawa, Japan</i> ) .....	1007
FOLFOX Enables High Resectability and Excellent Prognosis for Initially Unresectable Colorectal Liver Metastases. T. BEPPU, N. HAYASHI, T. MASUDA, H. KOMORI, K. HORINO, H. HAYASHI, H. OKABE, Y. BABA, K. KINOSHITA, C. AKIRA, M. WATANEBE, H. TAKAMORI, H. BABA ( <i>Kumamoto, Japan</i> ) .....	1015
Lysozyme Overexpression in Fundic Gland Polyps. C.A. RUBIO ( <i>Stockholm, Sweden</i> ) .....	1021
Acute Pancreatitis with a Mucinous Cystadenoma of the Pancreas in Pregnancy. S. ASCIUTTI, T.T. KANNINEN, G. CLERICI, E. NARDI, D. CASTELLANI, G.C. DI RENZO, C. CLERICI ( <i>Perugia, Italy</i> ) .....	1025
Correlation Between [ <sup>18</sup> F]Fluorodeoxyglucose Positron-emission Tomography Scan and Histology of Pelvic Nodes in Early-stage Cervical Cancer. E. BENTIVEGNA, C. UZAN, S. GOUY, S. LEBoulLEUX, P. DUVILLARD, J. LUMBROSO, C. HAIE-MEDER, M. SCHLUMBERGER, P. MORICE ( <i>Villejuif, France</i> ) .....	1029
Errata .....	1033
Book Reviews .....	1035

\* Reviews (pages 751, 815)

## Number 4

*Experimental Studies*

- Broad Selective Efficacy of Recombinant Methioninase and Polyethylene Glycol-modified Recombinant Methioninase on Cancer Cells *In Vitro*. Y. TAN, M. XU, R.M. HOFFMAN (*San Diego, CA, USA*) ..... 1041
- Overexpression of P150, a Part of the Large Subunit of the Eukaryotic Translation Initiation Factor 3, in Colon Cancer. J. HAYBAECK, T. O'CONNOR, R. SPILKA, G. SPIZZO, CH. ENSINGER, G. MIKUZ, T. BRUNHUBER, A. VOETSEDER, I. THEURL, W. SALVENMOSER, H. DRAXL, R. BÄNZIGER, F. BACHMANN, G. SCHÄFER, M. BURGER, P. OBRIST (*Zurich; Basel, Switzerland; Graz; Zams; Innsbruck; Hall, Austria*) ..... 1047
- Novel Local Drug Delivery System Using Thermoreversible Gel in Combination with Polymeric Microspheres or Liposomes. T. ARAI, O. BENNY, T. JOKI, L.G. MENON, M. MACHLUF, T. ABE, R.S. CARROLL, P.M. BLACK (*Boston, MA, USA; Haifa, Israel; Tokyo, Japan*) ..... 1057
- \* Short Review: Neoadjuvant Chemotherapy in Barrett's Carcinoma – Prognosis and Response Prediction. M. SCHAUER, W.T. KNOEFEL (*Duesseldorf, Germany*) ..... 1065
- Calponin h1-S175T Point Mutation Enhances Resistance to Actin Cytoskeleton Perturbation in Human Cancer Cells. A. SUGAYA, M. TAKEOKA, N. ITANO, A. TAGUCHI, T. EHARA, S. TANIGUCHI (*Matsumoto, Japan*) ..... 1071
- Evidence of a Tumour Suppressor Function for DLEC1 in Human Breast Cancer. W. AL SARAKBI, S. REEFY, W.G. JIANG, T. ROBERTS, R.F. NEWBOLD, K. MOKBEL (*London, Cardiff; Uxbridge, Middlesex, UK*) ..... 1079
- Gene Expression Analysis by cDNA Microarray in Oral Cancers from Two Western Populations. M.L.S. LUNDE, S. WARNAKULASURIYA, L. SAND, J.M. HIRSCH, E.N. VASSTRAND, S.O. IBRAHIM (*Bergen, Norway; London, UK; Uppsala, Sweden*) ..... 1083
- \* Review: Role of Regulatory T-cells in *H. pylori*-induced Gastritis and Gastric Cancer. A. KANDULSKI, P. MALFERTHEINER, T. WEX (*Magdeburg, Germany*) ..... 1093
- Lovastatin Prevents Carcinogenesis in a Rat Model for Liver Cancer. Effects of Ubiquinone Supplementation. L. BJÖRKHEM-BERGMAN, J. ACIMOVIC, U.-B. TORNDAL, P. PARINI, L.C. ERIKSSON (*Stockholm, Sweden; Ljubljana, Slovenia*) ..... 1105
- Expression of Bone Morphogenetic Protein 7 in Lung Cancer and its Biological Impact on Lung Cancer Cells. J. CHEN, L. YE, F. XIE, Y. YANG, L. ZHANG, W.G. JIANG (*Beijing, P.R. China; Cardiff, UK*) ..... 1113
- A Simple and Effective Method to Analyze Membrane Proteins by SDS-PAGE and MALDI Mass Spectrometry. F. DI GIROLAMO, M. PONZI, M. CRESCENZI, J. ALESSANDRONI, F. GUADAGNI (*Rome, Italy*) ..... 1121
- Motexafin Gadolinium Enhances p53-Mdm2 Interactions, Reducing p53 and Downstream Targets in Lymphoma Cell Lines. A.T.K. SINGH, A.M. EVENS, S.N. PRACHAND, L.I. GORDON (*Chicago, IL, USA*) ..... 1131
- Changes in Cell-Surface Peptidase Activity in Papillary Renal Cell Carcinoma. L. BLANCO, I. PEREZ, B. SANZ, J. GIL, J.I. LÓPEZ, A. UGALDE, A. VARONA, G. LARRINAGA (*Leioa; Cruces/Barakaldo; Bilbao, Spain*) ..... 1137
- One-lung Ventilation and HIF1 $\alpha$  Expression in Lung Cancer and Pneumothorax. S.G. ELEFTHERIADIS, E. SIVRIDIS, A. KOUTSOPOULOS, Z.G. GALATOUDIS, P.A. CHLOROPOULOU, M.I. KOUKOURAKIS, V.N. DIDILIS, G.I. BOUGIOUKAS, A. GIATROMANOLAKI (*Alexandroupolis, Greece*) ..... 1143

Chronic Exposure of Colorectal Cancer Cells in Culture to Fluoropyrimidine Analogs Induces Thymidylate Synthase and Suppresses p53. A Molecular Explanation for the Mechanism of 5-FU Resistance. P.R. SUBBARAYAN, M. SARKAR, G. NELSON, E. BENITEZ, S. SINGHAL, B. ARDALAN ( <i>Miami, FL, USA</i> ) .....	1149
Arsenic Trioxide Suppresses Thymidylate Synthase in 5-FU-resistant Colorectal Cancer Cell Line HT29 <i>In Vitro</i> Re-sensitizing Cells to 5-FU. P.R. SUBBARAYAN, K. LEE, B. ARDALAN ( <i>Miami, FL, USA</i> ) .....	1157
ALCAM, Activated Leukocyte Cell Adhesion Molecule, Influences the Aggressive Nature of Breast Cancer Cells, a Potential Connection to Bone Metastasis. S. DAVIES, W.G. JIANG ( <i>Cardiff, UK</i> ) .....	1163
* Review: Gamma-glutamyltransferase of Cancer Cells at the Crossroads of Tumor Progression, Drug Resistance and Drug Targeting. A. CORTI, M. FRANZINI, A. PAOLICCHI, A. POMPELLA ( <i>Pisa, Italy</i> ) .....	1169
LA-12 Overcomes Confluence-dependent Resistance of HT-29 Colon Cancer Cells to Pt (II) Compounds. L. ŠVIHÁLKOVÁ-ŠINDLEROVÁ, V. FOLTINOVÁ, A. VACULOVÁ, V. HORVÁTH, K. SOUČEK, P. SOVA, J. HOFMANOVÁ, A. KOZUBÍK ( <i>Brno, Czech Republic</i> ) .....	1183
<i>Solanum lyratum</i> Extract Inhibits <i>Helicobacter pylori</i> -mediated Apoptosis in Human Gastric Epithelial Cells. Y.-M. HSU, C.-H. LAI, C.-H. SU, W.-W. KUO, C.-L. KUO, C.-K. HSU, C.-K. WANG, C.-Y. CHANG, J.-G. CHUNG ( <i>Taichung, Taiwan, ROC</i> ) .....	1189
Interaction of Cyclooxygenase 2 Genotype and Smoking Habit in Taiwanese Lung Cancer Patients. C.-J. LIU, T.-C. HSIA, R.-F. WANG, C.-W. TSAI, C.-C. CHU, L.-W. HANG, C.-H. WANG, H.-Z. LEE, R.-Y. TSAI, D.-T. BAU ( <i>Taichung, Taiwan, ROC</i> ) .....	1195
Demethylation of the <i>CD133</i> Gene Is Frequently Detected in Early Gastric Carcinoma. K. HIBI, M. SAKATA, Y.-H. KITAMURA, K. SAKURABA, A. SHIRAHATA, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA ( <i>Yokohama, Japan</i> ) .....	1201
Methylation of <i>TFPI2</i> Gene is Frequently Detected in Advanced Well-differentiated Colorectal Cancer. K. HIBI, T. GOTO, Y.-H. KITAMURA, K. YOKOMIZO, K. SAKURABA, A. SHIRAHATA, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA ( <i>Yokohama, Japan</i> ) .....	1205
Inhibition of MAPK/ERK, PKC and CaMKII Signaling Blocks Cytolysin-induced Human Glioma Cell Death. R.C. SOLETTI, T. ALVES, J. VERNAL, H. TERENZI, G. ANDERLUH, H.L. BORGES, N.H. GABILAN, V. MOURA-NETO ( <i>Rio de Janeiro; Florianópolis, Brazil; Ljubljana, Slovenia</i> ) .....	1209
Increased Serum Progesterone and Estradiol Correlate to Increased COX-2 Tissue Expression in Cervical Intraepithelial Neoplasia. R. SAMIR, T. TOT, A. ASPLUND, G. PEKAR, D. HELLBERG ( <i>Falun; Uppsala, Sweden</i> ) .....	1217
Glutathione Modulators Reverse the Pro-tumour Effect of Growth Factors Enhancing WiDr Cell Response to Chemotherapeutic Agents. M. CARAMÉS, A. ALONSO-VARONA, I. GARCÍA-ALONSO, T. PALOMARES ( <i>Leioa, Vizcaya, Spain</i> ) .....	1223
The Screening of Viral Risk Factors in Tongue and Pharyngolaryngeal Squamous Carcinoma. Y. ZHENG, P. XIA, H.-C. ZHENG, H. TAKAHASHI, S. MASUDA, Y. TAKANO ( <i>Toyama; Takaoka, Japan; Shenyang, P.R. China</i> ) .....	1233
Y-Box-binding Protein-1 is a Potential Novel Tumour Marker for Neuroblastoma. R. WACHOWIAK, S. THIELTGES, T. RAWNAQ, J.T. KAIFI, H. FIEGEL, R. METZGER, A. QUAAS, P.R. MERTENS5, H. TILL, J.R. IZBICKI ( <i>Leipzig; Hamburg; Frankfurt; Magdeburg, Germany</i> ) .....	1239
Synthesis, Radiolabeling and <i>In Vivo</i> Tissue Distribution of an Anti-Oestrogen Glucuronide Compound, <sup>99m</sup> Tc-TOR-G. F.Z. BIBER MUFTULER, P. UNAK, S. YOLCULAR, A. YURT KILCAR, C. ICHEDEF, H. ENGINAR, S. SAKARYA ( <i>Bornova, Izmir; Afyon; Aydin, Turkey</i> ) .....	1243

*Clinical Studies*

A Phase I Dose-Escalation Study of Imatinib Mesylate (Gleevec/STI571) plus Capecitabine (Xeloda) in Advanced Solid Tumors. E. DUGAN, R. TRUAX, K.L. MEADOWS, A.B. NIXON, W.P. PETROS, J. FAVARO, N.H. FERNANDO, M.A. MORSE, G.C. BLOBE, H.I. HURWITZ (*Durham, NC; Morgantown, WV, USA*) ..... 1251

Treatment with Vaginal Progesterone in Women with Low-grade Cervical Dysplasia: A Phase II Trial. L. HEFLER, C. GRIMM, C. TEMPFER, A. REINTHALLER (*Vienna, Austria*) ..... 1257

Unique SNP in CD44 Intron 1 and its Role in Breast Cancer Development. J. ZHOU, P.S. NAGARKATTI, Y. ZHONG, K. CREEK, J. ZHANG, M. NAGARKATTI (*Columbia, SC, USA*) ..... 1263

A Case of Anaplastic Thyroid Cancer with Long-term Survival. H. KOUSSIS, M. MARUZZO, A. SCOLA, E.C. IDE, A. FASSINA, G. MARIONI, O. LORA, L. CORTI, P. KARACHONTZITI, A. JIRILLO (*Padua; Mestre, Italy; Athens, Greece*)..... 1273

Cyclin D1b in Human Breast Carcinoma and Coexpression with Cyclin D1a Is Associated with Poor Outcome. V.G. ABRAMSON, A.B. TROXEL, M. FELDMAN, C. MIES, Y. WANG, L. SHERMAN, S. MCNALLY, A. DIEHL, A. DEMICHELE (*Philadelphia, PA, USA*) ..... 1279

Detection of *HER2* Amplification Using the SISH Technique in Breast, Colon, Prostate, Lung and Ovarian Carcinoma. M.T. RAMIERI, R. MURARI, C. BOTTI, E. PICA, G. ZOTTI, P.L. ALO (*Rome, Italy*) ..... 1287

Venous Coupler for Free-Flap Anastomosis: Outcomes of 1,000 Cases. W.M. ROZEN, I.S. WHITAKER, R. ACOSTA (*Parkville, Victoria, Australia; Swansea, UK; Uppsala, Sweden*)..... 1293

Transient Increase in Serum Thymidine Kinase 1 within One Week after Surgery of Patients with Carcinoma. Z. LI, Y. WANG, J. MA, J. HE, J. ZHOU, E. HE, S. SKOG (*Beijing; Shenzhen, P.R. China*) ..... 1295

\* Review: Erlotinib in the Treatment of Non-small Cell Lung Cancer: Current Status and Future Developments. C. GRIDELLI, P. MAIONE, M.A. BARESCINO, C. SCHETTINO, P.C. SACCO, R. AMBROSIO, V. BARBATO, M. FALANGA, A. ROSSI (*Avellino, Italy*)..... 1301

Prognostic Factors in Non-small Cell Lung Cancer Patients with Postoperative Recurrence Following Third-Generation Chemotherapy. K. YAMAZAKI, K. SUGIO, T. YAMANAKA, F. HIRAI, A. OSOEGAWA, T. TAGAWA, S. FUKUYAMA, H. WATAYA, T. SETO, Y. ICHINOSE (*Fukuoka, Japan*)..... 1311

Liposomal Cisplatin Dose Escalation for Determining the Maximum Tolerated Dose and Dose-limiting Toxicity: A Phase I Study. G.P. STATHOPOULOS, S.K. RIGATOS, J. STATHOPOULOS (*Athens, Greece*) ..... 1317

Primary Pericardial Mesothelioma in an Asbestos-exposed Patient with Previous Heart Surgery. C. RIZZARDI, E. BARRESI, A. BROLLO, P. CASSETTI, M. SCHNEIDER, M. MELATO (*Trieste; Gorizia, Italy*) ..... 1323

\* Review: Clear Cell Carcinoma of the Endometrium: A Biological and Clinical Enigma. A. GADDUCCI, S. COSIO, N. SPIRITO, L. CIONINI (*Pisa, Italy*) ..... 1327

Feasibility Study of S-1 and Intraperitoneal Docetaxel Combination Chemotherapy for Gastric Cancer with Peritoneal Dissemination. Y. FUJIWARA, T. NISHIDA, S. TAKIGUCHI, K. NAKAJIMA, H. MIYATA, M. YAMASAKI, K. YAMAMOTO, J.-H. MOON, M. MORI, Y. DOKI (*Osaka, Japan*)..... 1335

Oestrogen and Progesterone Receptor Expression in Patients with Adenocarcinoma of the Uterine Cervix and Correlation with Various Clinicopathological Parameters. K. BODNER, P. LAUBICHLER, O. KIMBERGER, K. CZERWENKA, R. ZEILLINGER, B. BODNER-ADLER (*Vienna, Austria; Al Ain, United Arab Emirates*) ..... 1341

Long-term Survival Is Linked to Serum LDH and Partly to Tumour LDH-5 in NSCLC. B.C. DANNER, V.N. DIDILIS, S. WIEMEYER, T. STOJANOVIC, J. KITZ, A. EMMERT, L. FÜZESI, F.A. SCHÖNDUBE (*Göttingen, Germany*) ..... 1347



Antimicrobial Central Venous Catheters in Oncology: Efficacy of a Rifampicin–Miconazole-releasing Catheter. J.M. SCHIERHOLZ, K. NAGELSCHMIDT, M. NAGELSCHMIDT, R. LEFERING, N. YÜCEL, J. BEUTH ( <i>Unterach, Austria; Cologne; Coesfeld, Germany</i> ) .....	1353
Possible Associations of <i>APE1</i> Polymorphism with Susceptibility and <i>HOGG1</i> Polymorphism with Prognosis in Gastric Cancer. E. CANBAY, B. AGACHAN, M. GULLUOGLU, T. ISBIR, E. BALIK, S. YAMANER, T. BULUT, C. CACINA, I.Y. ERALTAN, A. YILMAZ, D. BUGRA ( <i>Istanbul, Turkey</i> ) .....	1359
Factors Affecting Bone Marrow Toxicity Following Administration of Carboplatin and Paclitaxel in Patients with Non-small Cell Lung Cancer. A.K. GANTI, F.R. LOBERIZA JR., A. KESSINGER ( <i>Omaha, NE, USA</i> ) .....	1365
Association Between Malaria Incidence and All Cancer Mortality in Fifty U.S. States and the District of Columbia. S. LEHRER ( <i>New York, NY, USA</i> ) .....	1371
ABSTRACTS OF THE 20th ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO), Rome, June 23-25, 2010 .....	1375
Erratum .....	1545
* Reviews (pages 1065, 1093, 1169, 1301, 1327)	

## Number 5

### *Experimental Studies*

The Expression of Galectin-1 in Vulvar Neoplasia. N. KOHRENHAGEN, H.-U. VOELKER, M. KAPP, J. DIETL, U. KÄMMERER ( <i>Wuerzburg, Germany</i> ) .....	1547
Visualisation of Tumour Regression after Local Chemotherapy with Magnetic Nanoparticles – A Pilot Study. S. LYER, R. TIETZE, R. JURGONS, T. STRUFFERT, T. ENGELHORN, E. SCHREIBER, A. DÖRFLER, C. ALEXIOU ( <i>Erlangen, Germany</i> ) .....	1553
Overexpression of Polycomb Protein BMI-1 in Human Specimens of Breast, Ovarian, Endometrial and Cervical Cancer. A. HONIG, C. WEIDLER, S. HÄUSLER, M. KROCKENBERGER, S. BUCHHOLZ, F. KÖSTER, S.E. SEGERER, J. DIETL, J.B. ENGEL ( <i>Würzburg; Regensburg; Lübeck, Germany</i> ) .....	1559
Immunohistochemical Study on an Epithelial-Myoepithelial Intercalated Duct Carcinoma Transplanted to the Nude Mouse. R.E. FRIEDRICH, R. KLAPDOR, C. HAGEL, S. BARTEL-FRIEDRICH ( <i>Hamburg; Halle, Germany</i> ) .....	1565
Expression of Neuron-specific Enolase in Irradiated Salivary Glands of the Rat: A Pilot Study. R.E. FRIEDRICH, M.S. DAVIDOFF, S. BARTEL-FRIEDRICH ( <i>Halle, Germany</i> ) .....	1569
Generation of an Antibody against the Protein Phosphatase 1 Inhibitor KEPI and Characterization of the Epitope. K. DASKALOW, P. BOISGUERIN, B. JANDRIG, F.K.H. VAN LANDEGHEM, R. VOLKMER, B. MICHEEL, J.A. SCHENK ( <i>Golm; Berlin; Potsdam; Bonn, Germany</i> ) .....	1573
<i>TP53</i> Gene Mutations in Prostate Cancer Progression. T.H. ECKE, H.H. SCHLECHTE, K. SCHIEMENZ, M.D. SACHS, S.V. LENK, B.D. RUDOLPH, S.A. LOENING ( <i>Bad Saarow; Berlin, Germany</i> ) .....	1579
Online Monitoring of Cellular Metabolism in the MCF-7 Carcinoma Cell Line Treated with Phytoestrogen Extracts. S. ABARZUA, S. DRECHSLER, K. FISCHER, N. PIETSCHMANN, J. STAPEL, S. DUDA, D.-U. RICHTER, R. EHRET, B. PIECHULLA, V. BRIESE ( <i>Rostock, Germany</i> ) .....	1587

Expression and Distribution of Tenascin in Rat Submandibular Glands Following Irradiation. S. BARTEL-FRIEDRICH, C. LAUTENSCHLÄGER, H.-J. HOLZHAUSEN, R.E. FRIEDRICH ( <i>Halle; Hamburg, Germany</i> ).....	1593
Glycodelin Expression in Correlation to Grading, Nodal Involvement and Steroid Receptor Expression in Human Breast Cancer Patients. C. SCHOLZ, B. TOTH, E. BARTHELL, I. MYLONAS, T. WEISSENBACHER, K. FRIESE, U. JESCHKE ( <i>Munich, Germany</i> ) .....	1599
Basaloid Lesions of Oral Squamous Epithelial Cells and their Association with HPV Infection and P16 Expression. R.E. FRIEDRICH, C. SPERBER, T. JÄKEL, K. RÖSER, T. LÖNING ( <i>Hamburg, Germany</i> ) .....	1605
Long-term Stability of Circulating Nucleosomes in Serum. S. HOLDENRIEDER, J. VON PAWEL, D. NAGEL, P. STIEBER ( <i>Munich; Gauting, Germany</i> ) .....	1613
Coexpression of MAGE-A Peptides and HLA Class I Molecules in Hepatocellular Carcinoma. N. ROCH, A. KUTUP, Y. VASHIST, E. YEKEBAS, V. KALININ, J.R. IZBICK ( <i>Hamburg, Germany</i> ) .....	1617
Morphometrics of the Facial Nerve Following Fractionated External Irradiation: An Experimental Study in Rats. R.E. FRIEDRICH, K. LASSON, R. LAAS, C. HAGEL, S. BARTEL-FRIEDRICH ( <i>Hamburg; Halle, Germany</i> ).....	1625
Proposal for a Standardized PSA Doubling-time Calculation. A. PONHOLZER, N. POPPER, F. BREITENECKER, H.-P. SCHMID, W. ALBRECHT, W. LOIDL, S. MADERSBACHER, P. SCHRAMEK, A. SEMJONOW, M. RAUCHENWALD ( <i>Vienna; Mistelbach; Linz, Austria; St. Gallen, Switzerland; Münster, Germany</i> ) .....	1633
Determination of Glycodelin-A Expression Correlated to Grading and Staging in Ovarian Carcinoma Tissue. A. TSVILIANA, D. MAYR, C. KUHN, S. KUNZE, I. MYLONAS, U. JESCHKE, K. FRIESE ( <i>Munich, Germany</i> ).....	1637
Insulin-like Growth Factor-1 Receptor (IGF-1R) in Primary and Metastatic Undifferentiated Carcinoma of the Head and Neck: A Possible Target of Immunotherapy. R.E. FRIEDRICH, C. HAGEL, S. BARTEL-FRIEDRICH ( <i>Hamburg; Halle, Germany</i> ) .....	1641
Expression of Proteases in Giant Cell Lesions of the Jaws, Tendon Sheath and Salivary Glands. R.E. FRIEDRICH, J. EISENMANN, K. RÖSER, H.A. SCHEUER, T. LÖNING ( <i>Hamburg, Germany</i> ) .....	1645
Expression of Transketolase-like 1 Protein (TKTL1) in Human Endometrial Cancer. M. KROCKENBERGER, J.B. ENGEL, M. SCHMIDT, N. KOHRENHAGEN, S.F.M. HÄUSLER, Y. DOMBROWSKI, M. KAPP, J. DIETL, A. HONIG ( <i>Wuerzburg, Germany</i> ) .....	1653
Centre-independent Detection of Non-small Cell Lung Cancer (NSCLC) by Means of Classification with Receiver Operating Characteristic (ROC)-based Data Transformation. N. BITTERLICH, T. MULEY, J. SCHNEIDER ( <i>Chemnitz; Heidelberg; Giessen, Germany</i> ) .....	1661
Multiplicity of <i>EGFR</i> and <i>KRAS</i> Mutations in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors. L. BENESOVA, M. MINARIK, D. JANCARIKOVA, B. BELSANOVA, M. PESEK ( <i>Prague; Pilsen, Czech Republic</i> ) .....	1667
Prostaglandin Metabolising Enzymes and PGE <sub>2</sub> are Inversely Correlated with Vitamin D Receptor and 25(OH) <sub>2</sub> D <sub>3</sub> in Breast Cancer. M. THILL, D. FISCHER, F. HOELLEN, K. KELLING, C. DITTMER, S. LANDT, D. SALEHIN, K. DIEDRICH, M. FRIEDRICH, S. BECKER ( <i>Luebeck; Krefeld; Essen, Germany</i> ) .....	1673

Osteopontin (OPN) Expression in Thyroid Carcinoma. J. BRIESE, S. CHENG, S. EZZAT, W. LIU, D. WINER, C. WAGENER, A.-M. BAMBERGER, S.L. ASA ( <i>Toronto, ON, Canada; Hamburg, Germany</i> ).....	1681
The Clinicopathological and Prognostic Relevance of Pyruvate Kinase M2 and pAkt Expression in Breast Cancer. C. BENESCH, C. SCHNEIDER, H.-U. VOELKER, M. KAPP, H. CAFFIER, M. KROCKENBERGER, J. DIETL, U. KAMMERER, M. SCHMIDT ( <i>Wuerzburg, Germany</i> ).....	1689
Effects of Phytoestrogen Extracts Isolated from Flax on Estradiol Production and ER/PR Expression in MCF7 Breast Cancer Cells. D.-U.-RICHTER, S. ABARZUA, M. CHROBAK, C. SCHOLZ, C. KUHN, S. SCHULZE, M.S. KUPKA, K. FRIESE, V. BRIESE, B. PIECHULLA, U. JESCHKE ( <i>Rostock; Hamburg; Munich, Germany</i> ) .....	1695
<i>Clinical Studies</i>	
Clinical Management of Borderline Tumours of the Ovary – Experience from the “Berlin Online Tumour Conference for Gynaecological Malignancies”. J. SEHOULI, G. OSKAY-OEZCELIK, K. PIETZNER, F. CHEN, A. COUMBOS, S. DARB-ESFAHANI, B. SCHUBACK, G. HEINRICH, C. KRONENBERGER, M. LORSBACH, W. LICHTENEGGER, R. CHEKEROV ( <i>Berlin; Doberlug-Kirchhain; Fürstenwalde; Giessen, Germany</i> ).....	1701
CEA-, Her2/neu-, BCRP- and Hsp27-positive Microparticles in Breast Cancer Patients. S. LIEBHARDT, N. DITSCH, R. NIEUWLAND, A. RANK, U. JESCHKE, F. VON KOCH, K. FRIESE, B. TOTH ( <i>Munich; Heidelberg, Germany; Amsterdam, Netherlands</i> ) .....	1707
Thyroid Function in Breast Cancer Patients. N. DITSCH, S. LIEBHARDT, F. VON KOCH, M. LENHARD, M. VOGESER, C. SPITZWEG, J. GALLWAS, B. TOTH ( <i>Munich; Heidelberg, Germany</i> )....	1713
Anal Cytology as a Screening Tool for Early Detection of Anal Dysplasia in HIV-infected Women. A. GINGELMAIER, T. WEISSENBACHER, B. KOST, R. KAESTNER, M. SOVRIC, I. MYLONAS, K. FRIESE, F. BERGAUER ( <i>Munich, Germany</i> ) .....	1719
Primary Leiomyosarcoma of the Testis. A Case Report. A.P. LABANARIS, V. ZUGOR, R. SMISZEK, R. NÜTZEL, R. KÜHN ( <i>Nürnberg; Gronau, Germany</i> ) .....	1725
Simulation of Scattering Effects of Irradiation on Surroundings Using the Example of Titanium Dental Implants: A Monte Carlo Approach. R.E. FRIEDRICH, M. TODROVIC, A. KRÜLL ( <i>Hamburg, Germany</i> ).....	1727
Congenital Juvenile Granulosa Cell Tumor of the Testis in Newborns. V. ZUGOR, A.P. LABANARIS, J. WITT, A. SEIDLER, K. WEINGÄRTNER, G.E. SCHOTT ( <i>Gronau; Nürnberg; Bamberg; Erlangen, Germany</i> ).....	1731
Clinical and Surgical Experience with Wilms’ Tumor. Long-term Results of a Single Institution. V. ZUGOR, G.E. SCHOTT, B. LAUSEN, R. KÜHN, A.P. LABANARIS ( <i>Gronau; Erlangen, Nürnberg, Germany</i> ) ....	1735
Usefulness of Combined FDG-PET with CT or Tumour Markers in Lung Cancer Diagnosis. K. KLEY, P. OEHR ( <i>Bonn, Germany</i> ).....	1741
Solitary Testicular Metastasis from Prostate Cancer: A Rare Case of Isolated Recurrence after Radical Prostatectomy. S. JANSSEN, J. BERNHARDS, A. G. ANASTASIADIS, F. BRUNS ( <i>Hannover; Gehrden; Großburgwedel, Germany</i> ) .....	1747
Dysplasia of the Orbit and Adjacent Bone Associated with Plexiform Neurofibroma and Ocular Disease in 42 NF-1 Patients. R.E. FRIEDRICH, C. STELLJES, C. HAGEL, M. GIESE, H.A. SCHEUER ( <i>Hamburg, Germany</i> ).....	1751

Vascular Endothelial Growth Factor (VEGF) in Sera of Oral and Oropharyngeal Squamous Cell Carcinoma Patients. R.E. FRIEDRICH, R. KLAPDOR, C. HAGEL, S. BARTEL-FRIEDRICH ( <i>Hamburg; Halle, Germany</i> ).....	1765
* Short Review: Evidence-based Complementary Oncology: Innovative Approaches to Optimise Standard Therapy Strategies. J. BEUTH ( <i>Cologne, Germany</i> ) .....	1767
IL-6 and VEGF in Small Cell Lung Cancer Patients. E. WÓJCIK, J. JAKUBOWICZ, P. SKOTNICKI, B. SAS-KORCZYŃSKA, J.K. KULPA ( <i>Cracow, Poland</i> ) .....	1773
Extramedullary Plasmocytoma: A Rare Case with Bifocal Manifestation at Uncommon Sites. F. BRUNS, S. JANSSEN, F. LAENGER, C. DOBBELSTEIN, A. MEYER ( <i>Hannover, Germany</i> ) .....	1779
Selenium Substitution During Radiotherapy of Solid Tumours – Laboratory Data from Two Observation Studies in Gynaecological and Head and Neck Cancer Patients. J. BÜNTZEL, O. MICKE, K. KISTERS, F. BRUNS, M. GLATZEL, K. SCHÖNEKAES, G. KUNDT, U. SCHÄFER, R. MÜCKE ( <i>Nordhausen; Bielefeld; Hannover; Suhle; Rostock; Lemgo, Germany</i> ) .....	1783
Adenomatoid Odontogenic Tumour of the Mandible. R.E. FRIEDRICH, J. ZUSTIN, H.A. SCHEUER ( <i>Hamburg, Germany</i> ) .....	1787
Dermal Cyndroma of the Scalp (Turban Tumour) and Subjacent Calvarian Defects. R.E. FRIEDRICH ( <i>Hamburg, Germany</i> ) .....	1793
Serum S100B and LDH Are Not Useful in Predicting the Sentinel Node Status in Melanoma Patients. F. EGBERTS, A. MOMKVIST, J.-H. EGBERTS, K.C. KAEHLER, A. HAUSCHILD ( <i>Kiel, Germany</i> ) .....	1799
Effect of Zoledronate on Persisting Isolated Tumour Cells in Patients with Early Breast Cancer. B. RACK, J. JÜCKSTOCK, E.-M. GENSS, A. SCHOBERTH, C. SCHINDLBECK, B. STROBL, M. HEINRIGS, G. RAMMEL, T. ZWINGERS, H. SOMMER, K. FRIESE, W. JANNI ( <i>Muenchen; Augsburg; Duesseldorf, Germany</i> ).....	1807
Appendices of the Nipple and Areola of the Breast in Neurofibromatosis Type 1 Patients Are Neurofibromas. R.E. FRIEDRICH, C. HAGEL ( <i>Hamburg, Germany</i> ).....	1815
Mental Neuropathy (Numb Chin Syndrome) Leading to Diagnosis of Metastatic Mediastinal Cancer. R.E. FRIEDRICH ( <i>Hamburg, Germany</i> ) .....	1819
Negative Predictive Value of Systematic Ultrasound-guided Prostate Biopsy: Which Tumours Do We Miss? T. KÖPKE, F. OBERPENNING, O. BETTENDORF, E. ELTZE, E. HERRMANN, L. HERTLE, C. WEINING, C. WULFING, A. SEMJONOW ( <i>Münster; Bocholt, Germany</i> ) .....	1823
Limited Effects of Selenium Substitution in the Prevention of Radiation-associated Toxicities. Results of a Randomized Study in Head and Neck Cancer Patients. J. BÜNTZEL, D. RIESENBECK, M. GLATZEL, R. BERNDT-SKORKA, T. RIEDEL, R. MÜCKE, K. KISTERS, K.G. SCHÖNEKAES, U. SCHÄFER, F. BRUNS, O. MICKE ( <i>Nordhausen; Recklinghausen; Neubrandenburg; Hannover; Bielefeld, Germany</i> ) .....	1829
Delay in Diagnosis and Referral Patterns of 646 Patients with Oral and Maxillofacial Cancer: A Report from a Single Institution in Hamburg, Germany. R.E. FRIEDRICH ( <i>Hamburg, Germany</i> ) .....	1833
Prevalence of CA 27.29 in Primary Breast Cancer Patients before the Start of Systemic Treatment. B. RACK, C. SCHINDLBECK, J. JÜCKSTOCK, E.-M. GENSS, P. HEPP, R. LORENZ, H. TESCH, A. SCHNEEWEISS, M.W. BECKMANN, W. LICHTENEGGER, H. SOMMER, K. FRIESE, W. JANNI; for the SUCCESS Study Group ( <i>Muenchen; Duesseldorf; Braunschweig; Frankfurt; Heidelberg; Erlangen; Berlin, Germany</i> ) .....	1837

Distant Metastases and Malignant Cellular Neoplasms Encountered in the Oral and Maxillofacial Region: Analysis of 92 Patients Treated at a Single Institution. R.E. FRIEDRICH, M. ABADI ( <i>Hamburg, Germany</i> ).....	1843
Expression of the Carbohydrate Tumor Marker Sialyl Lewis a (Ca19-9) in Squamous Cell Carcinoma of the Larynx. I. WIEST, C. ALEXIOU, D. MAYR, S. SCHULZE, C. KUHN, S. KUNZE, M. BÜTTNER, P. BETZ, U. JESCHKE ( <i>Munich; Erlangen, Germany</i> ) .....	1849
Clinical Relevance of Thymidine Kinase for the Diagnosis, Therapy Monitoring and Prognosis of Non-operable Lung Cancer. S. HOLDENRIEDER, J. VON PAWEL, T. DUELL, K. FELDMANN, H. RAITH, A. SCHOLLEN, D. NAGEL, P. STIEBER ( <i>Munich; Gauting, Germany</i> ) .....	1855
* Review: Metabolism in Cancer Patients. J. ARENDS ( <i>Freiburg, Germany</i> ) .....	1863
CA19-9 Serum Concentrations – Analysis of the Serum Kinetics During First-line Therapy of Pancreatic Cancer in Relation to Overall Survival. R. KLAPDOR, M. BAHLO, A. BABINSKI, S. KLAPDOR ( <i>Hamburg, Germany</i> ) .....	1869
* Reviews (pages 1767, 1863)	

## Number 6

### *Experimental Studies*

Anti-growth Effect of 1,25-Dihydroxyvitamin D <sub>3</sub> -3-bromoacetate Alone or in Combination with 5-Aminoimidazole-4-carboxamide-1-β-4-ribofuranoside in Pancreatic Cancer Cells. K.S. PERSONS, V.J. EDDY, S. CHADID, R. DEOLIVEIRA, A.K. SAHA, R. RAY ( <i>Boston, MA, USA</i> ) .....	1875
Suppression by L-Methionine of Cell Cycle Progression in LNCaP and MCF-7 Cells but not Benign Cells. M.A. BENAVIDES, K.L.HAGEN, W. FANG, P. DU, S. LIN, M.P. MOYER, W. YANG, K.I. BLAND, W.E. GRIZZLE, M.C. BOSLAND ( <i>Chicago, IL; San Antonio, TX; Birmingham, AL, USA</i> ) .....	1881
Inhibition of Membrane-Type 1 Matrix Metalloproteinase Tyrosine Phosphorylation Blocks Tumor Progression in Mice. C. NYALENDO, H. SARTELET, D. GINGRAS, R. BÉLIVEAU ( <i>Montréal, QC, Canada</i> ) .....	1887
Prognostic Value of LYVE-1-Positive Lymphatic Vessel in Tongue Squamous Cell Carcinomas. N. MATSUMOTO, S. MUKAE, H. TSUDA, A. SAWADA, Y. OKAZAKI, K. NAGAI, Y. AKISHIMA-FUKASAWA, H. OHKI, Y. ISHIKAWA, T. ISHII, K. KOMIYAMA ( <i>Tokyo, Japan</i> ) .....	1897
Effects of Anti-EGFR Antibody Cetuximab on Androgen-independent Prostate Cancer Cells. P. DHUPKAR, M. DOWLING, K. CENGEL, B. CHEN ( <i>Philadelphia, PA, USA</i> ) .....	1905
Alpha Terpineol: A Potential Anticancer Agent which Acts through Suppressing NF-κB Signalling. S.B. HASSAN, H. GALI-MUHTASIB, H. GÖRANSSON, R. LARSSON ( <i>Uppsala, Sweden; Beirut, Lebanon</i> ) .....	1911
Bortezomib Therapeutic Effect Is Associated with Expression and Mutation of <i>FGFR3</i> in Human Lymphoma Cells. W. ZHENG, M. GUAN, L. ZHU, Z. CAI, V. CHUNG, H. HUANG, Y. YEN ( <i>Zhejiang, PR China; Duarte, CA, USA</i> ) .....	1921
Efficacy of Recombinant Adeno-Associated Viral Vectors Serotypes 1, 2, and 5 for the Transduction of Pancreatic and Colon Carcinoma Cells. C. TESCHENDORF, B. EMONS, N. MUZYCZKA, U. GRAEVEN, W. SCHMIEGEL ( <i>Bochum, Germany; Gainesville, FL, USA</i> ) .....	1931

Function and Regulatory Mechanisms of the Candidate Tumor Suppressor Receptor Protein Tyrosine Phosphatase Gamma (PTPRG) in Breast Cancer Cells. S.T. SHU, Y. SUGIMOTO, S. LIU, H.-L. CHANG, W. YE, L.-S. WANG, Y.-W. HUANG, P. YAN, Y.C. LIN ( <i>Columbus, OH, USA</i> ) .....	1937
VEGF Targeting in Mesotheliomas Using an Interleukin-6 Signal Inhibitor Based on Adenovirus Gene Delivery. Y. ADACHI, N. YOSHIO-HOSHINO, C. AOKI, N. NISHIMOTO ( <i>Ibaraki-City; Suita City, Osaka, Japan</i> ) .....	1947
Guggulsterone Suppresses Bile Acid-induced and Constitutive Caudal-related Homeobox 2 Expression in Gut-derived Adenocarcinoma Cells. T. YAMADA, S. OSAWA, Y. HAMAYA, T. FURUTA, A. HISHIDA, M. KAJIMURA, M. IKUMA ( <i>Hamamatsu, Japan</i> ) .....	1953
<i>In Vitro</i> Interaction of High-LET Heavy-ion Irradiation and Chemotherapeutic Agents in Two Cell lines with Different Radiosensitivities and Different <i>p53</i> Status. T. TAKAHASHI, T. FUKAWA, R. HIRAYAMA, Y. YOSHIDA, A. MUSHA, Y. FURUSAWA, K. ANDO, T. NAKANO ( <i>Gunma; Chiba, Japan</i> ) .....	1961
<i>KRAS</i> and <i>BRAF</i> Mutation Analysis from Liquid-based Cytology Brushings of Colorectal Carcinoma in Comparison with Formalin-fixed, Paraffin-embedded Tissue. A. SPATHIS, J. GEORGOULAKIS, P. FOUKAS, M. KEFALA, K. LEVENTAKOS, A. MACHAIRAS, I. PANAYIOTIDES, P. KARAKITSOS ( <i>Athens, Greece</i> ) .....	1969
* Review: On the Origin and Growth of Gliomas. D. SCHIFFER, L. ANNOVAZZI, V. CALDERA, M. MELLAI ( <i>Turin, Italy</i> ) .....	1977
A Novel Gene Delivery System Targeting Tie2 for Cancer Gene Therapy. A. HU, X. WU, Z. LI, H. WANG, J. LI, M. YAO, X. CHEN, S. QU, Y. XU, J. GU ( <i>Shanghai, PR China</i> ) .....	1999
Identification of Stem-like Cells in Head and Neck Cancer Cell Lines. G. SUN, M. FUJII, A. SONODA, Y. TOKUMARU, T. MATSUNAGA, N. HABU ( <i>Tokyo, Japan</i> ) .....	2005
Therapeutic Effects of Hybrid Liposomes on Gastric Carcinoma Involve Apoptosis. H. ICHIHARA, Y. MATSUOKA, Y. MATSUMOTO, R. UEOKA ( <i>Kumamoto, Japan</i> ) .....	2011
COX-2 Expression and Effects of COX-2 Inhibition in Colorectal Carcinomas and their Liver Metastases. H.-U. KASPER, E. KONZE, H.P. DIENES, D.L. STIPPEL, P. SCHIRMACHER, M. KERN ( <i>Münster/Wfl.; Köln; Heidelberg, Germany</i> ) .....	2017
Antiproliferative Effects of Antiestrogens and Inhibitors of Growth Factor Receptor Signaling on Endometrial Cancer Cells. M. BLOCK, S. FISTER, G. EMONS, S. SEEBER, C. GRÜNDKER, A.R. GÜNTHERT ( <i>Göttingen, Germany; Bern, Switzerland</i> ) .....	2025
Protective Effects of the Immunopotentiator from <i>Pantoea agglomerans</i> 1 on Chemotherapeutic Agent-induced Macrophage Growth Inhibition. T. HEBISHIMA, Y. MATSUMOTO, G. WATANABE, G.-I. SOMA, C. KOHCHI, K. TAYA, Y. HAYASHI, Y. HIROTA ( <i>Tokyo; Gifu; Tokushima; Kagawa, Japan</i> ) .....	2033
Inhibition of Wnt Signaling Pathway Decreases Chemotherapy-resistant Side-population Colon Cancer Cells. N. CHIKAZAWA, H. TANAKA, T. TASAKA, M. NAKAMURA, M. TANAKA, H. ONISHI, M. KATANO ( <i>Fukuoka, Japan</i> ) .....	2041
<i>AKT</i> and <i>p21<sup>WAF1/CIP1</sup></i> as Potential Genistein Targets in <i>BRCA1</i> -mutant Human Breast Cancer Cell Lines. M. PRIVAT, C. AUBEL, S. ARNOULD, Y. COMMUNAL, M. FERRARA, Y.-J. BIGNON ( <i>Clermont-Ferrand, France</i> ) .....	2049
The Influence of Electroporation on Cytotoxicity of Anticancer Ruthenium(III) Complex KP1339 <i>In Vitro</i> and <i>In Vivo</i> . R. HUDEJ, I. TUREL, M. KANDUSER, J. SCANCAR, S. KRANJC, G. SERSA, D. MIKLAVCIC, M.A. JAKUPEC, B.K. KEPPLER, M. CEMAZAR ( <i>Ljubljana, Slovenia; Vienna, Austria</i> ) .....	2055

Cisplatin Augments FAS-mediated Apoptosis through Lipid Rafts. C.-R. HUANG, Z.-X. JIN, L. DONG, X.-P. TONG, S. YUE, T. KAWANAMI, T. SAWAKI, T. SAKAI, M. MIKI, H. IWAO, A. NAKAJIMA, Y. MASAKI, Y. FUKUSHIMA, M. TANAKA, Y. FUJITA, H. NAKAJIMA, T. OKAZAKI, H. UMEHARA ( <i>Ishikawa; Tottori, Japan; Wuhan, Hubei, PR China</i> ) .....	2065
* Review: An Overview of Nanotechnology-based Functional Proteomics for Cancer and Cell Cycle Progression. C. NICOLINI, E. PECHKOVA ( <i>Genoa, Rome, Italy</i> ) .....	2073
Long-term Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Pulsed Dendritic Cells. M. KRAEMER, S. HAUSER, I.G.H. SCHMIDT-WOLF ( <i>Bonn, Germany</i> ) .....	2081
Clioquinol Independently Targets NF- $\kappa$ B and Lysosome Pathways in Human Cancer Cells. H. YU, J.R. LOU, W.-Q. DING ( <i>Wuhan, PR China; Oklahoma City, OK, USA</i> ) .....	2087
Proteomic Analysis for Nuclear Proteins Related to Tumour Malignant Progression: A Comparative Proteomic Study Between Malignant Progressive Cells and Regressive Cells. Y. KURAMITSU, E. HAYASHI, F. OKADA, T. TANAKA, X. ZHANG, Y. UEYAMA, K. NAKAMURA ( <i>Ube; Yamagata, Japan</i> ) .....	2093
Antisense Inhibition of Amphiregulin Expression Reduces EGFR Phosphorylation in Transformed Human Breast Epithelial Cells. L. MA, E. HUET, M. SEROVA, Y. BERTHOIS, F. CALVO, S. MOURAH, S. MENASHI ( <i>Beijing, PR China; Créteil; Paris; Marseille, France</i> ) .....	2101
Attenuation of MG132-induced HeLa Cell Death by <i>N</i> -Acetyl Cysteine <i>via</i> Reducing Reactive Oxygen Species and Preventing Glutathione Depletion. Y.H. HAN, Y.M. YANG, S.Z. KIM, W.H. PARK ( <i>JeonJu, Republic of Korea</i> ) .....	2107
Analysis of Apoptotic Effects Induced by Photodynamic Therapy in a Human Biliary Cancer Cell Line. T. NONAKA, A. NANASHIMA, M. NONAKA, M. UEHARA, H. ISOMOTO, I. ASAHINA, T. NAGAYASU ( <i>Nagasaki, Japan</i> ) .....	2113
Differential <i>Ex Vivo</i> Activity of Bortezomib in Newly Diagnosed Paediatric Acute Lymphoblastic and Myeloblastic Leukaemia. J. SZCZEPANEK, M. POGORZALA, B. KONATKOWSKA, E. JURASZEWSKA, W. BADOWSKA, I. OLEJNIK, M. KUZMICZ, E. STANCZAK, I. MALINOWSKA, J. STEFANIAK, G. SOBOL, T. SZCZEPANSKI, K. CZYZEWSKI, M. WYSOCKI, J. STYCZYNSKI ( <i>Bydgoszcz; Poznan; Cracow; Olsztyn; Chorzow; Bialystok; Warsaw; Lublin; Katowice; Zabrze, Poland</i> ) .....	2119
Curcumin Induces Apoptosis in Human Non-small Cell Lung Cancer NCI-H460 Cells through ER Stress and Caspase Cascade- and Mitochondria-dependent Pathways. S.-H. WU, L.-W. HANG, J.-S. YANG, H.-Y. CHEN, H.-Y. LIN, J.-H. CHIANG, C.-C. LU, J.-L. YANG, T.-Y. LAI, Y.-C. KO, J.-G. CHUNG ( <i>Changhua; Taichung; Chiayi; Taiwan, ROC</i> ) .....	2125
Phenethyl Isothiocyanate Inhibits Migration and Invasion of Human Gastric Cancer AGS Cells through Suppressing MAPK and NF- $\kappa$ B Signal Pathways. M.-D. YANG, K.-C. LAI, T.-Y. LAI, S.-C. HSU, C.-L. KUO, C.-S. YU, M.-L. LIN, J.-S. YANG, H.-M. KUO, S.-H. WU, J.-G. CHUNG ( <i>Taichung; Yunlin; Changhua, Taiwan, ROC</i> ) .....	2135
Inhibition of Heme Oxygenase-1 Enhances the Cytotoxic Effect of Gemcitabine in Urothelial Cancer Cells. M. MIYAKE, K. FUJIMOTO, S. ANAI, S. OHNISHI, Y. NAKAI, T. INOUE, Y. MATSUMURA, A. TOMIOKA, T. IKEDA, E. OKAJIMA, N. TANAKA, Y. HIRAO ( <i>Nara, Japan</i> ) .....	2145
SDF1/CXCL12 Is Involved in Recruitment of Stem-like Progenitor Cells to Orthotopic Murine Malignant Mesothelioma Spheroids. B.W. LAU, A.B. KANE ( <i>Providence, RI, USA</i> ) .....	2153
* Review: Liver Regeneration and its Impact on Post-hepatectomy Metastatic Tumour Recurrence. K.A. PASCHOS, N.C. BIRD ( <i>Sheffield, UK</i> ) .....	2161

Effect of Dietary Astaxanthin at Different Stages of Mammary Tumor Initiation in BALB/c Mice. R. NAKAO, O.L. NELSON, J.S. PARK, B.D. MATHISON, P.A. THOMPSON, B.P. CHEW ( <i>Pullman, WA, USA</i> ) .....	2171
Biodistribution of Two Octreotate Analogs Radiolabeled with Indium and Yttrium in Rats. A. LAZNICKOVA, M. LAZNICEK, F. TREJTNAR, H.R. MAECKE, K.P. EISENWIENER, J.C. REUBI ( <i>Hradec Kralove, Czech Republic; Basel; Berne, Switzerland</i> ) .....	2177
Nuclear Morphometry in Prognostication of Breast Cancer in Saudi Arabian Patients: Comparison with European and African Breast Cancer. A. BUHMEIDA, J. AL-MAGHRABI, A. MERDAD, F. AL-THUBAITY, A. CHAUDHARY, M. GARI, A. ABUZENADAH, Y. COLLAN, K. SYRJÄNEN, M. AL-QAHTANI ( <i>Jeddah, Saudi Arabia; Turku, Finland</i> ) .....	2185
Induction of Apoptosis by Gene Transfer of Human <i>TRAIL</i> Mediated by Arginine-rich Intracellular Delivery Peptides. J.-F. LI, Y. HUANG, R.-L. CHEN, H.-J. LEE ( <i>Hualien; Tainan, Taiwan, ROC</i> ) .....	2193
Insulin-like Growth Factors II exon 9 and E-cadherin-Pml I but not Myeloperoxidase Promoter-463, Urokinase- <i>ApaL</i> I nor Xeroderma Pigmentosum Polymorphisms Are Associated with Higher Susceptibility to Leiomyoma. Y.-Y. HSIEH, C.-C. CHANG, Y.-K. WANG, K.-H. HSU, C.-P. CHEN, C.-M. HSU, F.-J. TSAI ( <i>Taichung; Hsin-Chu; Taipei, Taiwan, ROC</i> ) .....	2203
CXCR4, A Potential Predictive Marker for Docetaxel Sensitivity in Gastric Cancer. L. XIE, J. WEI, X. QIAN, G. CHEN, L. YU, Y. DING, B. LIU ( <i>Nanjing, PR China</i> ) .....	2209
Magnetic Paclitaxel Nanoparticles Inhibit Glioma Growth and Improve the Survival of Rats Bearing Glioma Xenografts. M. ZHAO, C. LIANG, A. LI, J. CHANG, H. WANG, R. YAN, J. ZHANG, J. TAI ( <i>Beijing; Tianjin, PR China</i> ) .....	2217
Promoter Polymorphisms and Methylation of E-Cadherin ( <i>CDH1</i> ) and <i>KIT</i> in Gastric Cancer Patients from Northern Brazil. B.D.N. BORGES, E. DA SILVA SANTOS, C.E.M. CARVALHO BASTOS, L.C. PINTO, N.P. ANSELMO, J.A. QUARESMA, D.Q. CALCAGNO, R.M.R. BURBANO, M.L. HARADA ( <i>Belém, Pará, Brazil</i> ) .....	2225
Impact of the Menstrual Cycle on Circulating Cell-free DNA. M. PÖLCHER, J. ELLINGER, S. WILLEMS, O. EL-MAARRI, T. HÖLLER, C. AMANN, M. WOLFGARTEN, C. RUDŁOWSKI, W. KUHN, M. BRAUN ( <i>Bonn, Germany</i> ) .....	2235
Sonodynamically Induced Cell Damage and Membrane Lipid Peroxidation by Novel Porphyrin Derivative, DCPH-P-Na(I). N. YUMITA, Y. IWASE, K. NISHI, T. IKEDA, S.-I. UMEMURA, I. SAKATA, Y. MOMOSE ( <i>Kanagawa; Sendai; Okayama; Chiba, Japan</i> ) .....	2241
<i>Clinical Studies</i>	
A Clear Correlation between WT1-specific Th Response and Clinical Response in WT1 CTL Epitope Vaccination. F. FUJIKI, Y. OKA, M. KAWAKATSU, A. TSUBOI, Y. TANAKA-HARADA, N. HOSEN, S. NISHIDA, T. SHIRAKATA, H. NAKAJIMA, N. TATSUMI, N. HASHIMOTO, T. TAGUCHI, S. UEDA, N. NONOMURA, Y. TAKEDA, T. ITO, A. MYOUI, S. IZUMOTO, M. MARUNO, T. YOSHIMINE, S. NOGUCHI, A. OKUYAMA, I. KAWASE, Y. OJI, H. SUGIYAMA ( <i>Osaka; Nishinomiya, Japan</i> ) .....	2247
Phase I Study of Oral Vinorelbine and Capecitabine in Patients with Metastatic Breast Cancer. A. ANTON, A. LLUCH, A. CASADO, M. PROVENCIO, M. MUÑOZ, J. LAO, B. BERMEJO, A.B. PAULES, J. GAYO, M. MARTIN ( <i>Zaragoza; Valencia; Madrid; Barcelona, Spain</i> ) .....	2255
Effects of $\alpha$ -Difluoromethylornithine on Markers of Proliferation, Invasion, and Apoptosis in Breast Cancer. E. IZBICKA, R.T. STREPPER, I-T. YEH, O. PRESSLEY, M. GRANT, J. V.R. ANDREWS, J. KUHN, J. O'SHAUGHNESSY ( <i>San Antonio; Dallas, TX, USA</i> ) .....	2263



Connexin43, E-Cadherin, $\beta$ -Catenin and ZO-1 Expression, and Aberrant Methylation of the Connexin43 Gene in NSCLC. Y. JINN, N. INASE ( <i>Kanagawa; Tokyo, Japan</i> ) .....	2271
Aberrant Expression of Vimentin Correlates with Dedifferentiation and Poor Prognosis in Patients with Intrahepatic Cholangiocarcinoma. P.V. KORITA, T. WAKAI, Y. AJIOKA, M. INOUE, M. TAKAMURA, Y. SHIRAI, K. HATAKEYAMA ( <i>Niigata, Japan</i> ) .....	2279
Surgical Excision for B3 Breast Lesions Diagnosed by Vacuum-assisted Core Biopsy. S. REEFY, H. OSMAN, C. CHAO, N. PERRY, K. MOKBEL ( <i>London; Tooting, UK</i> ) .....	2287
Cyfra 21-1 as a Tumor Marker for Follow-up of Patients with Squamous Cell Carcinoma of the Oropharynx. K. ALKOTYFAN, S. WIEGAND, H.-H. MÜLLER, J.P. WINDFUHR, J.A. WERNER, A.M. SESTERHENN ( <i>Marburg; Moenchengladbach, Germany</i> ) .....	2291
The Impact of the Extent of Lymph-node Dissection on Biochemical Relapse after Radical Prostatectomy in Node-negative Patients. R. SCHIAVINA, A. BERTACCINI, A. FRANCESCHELLI, F. MANFERRARI, V. VAGNONI, M. BORGHESI, A.M. MORSELLI-LABATE, G. MARTORANA ( <i>Bologna, Italy</i> ) .....	2297
Vincristine in High-grade Glioma. B. AYDIN, M. PATIL, N. BEKELE, J.E.A. WOLFF ( <i>Ankara, Turkey; Houston, TX, USA</i> ) .....	2303
Vulvar Cancer: Prognostic Factors. M.O. NICOLETTO, A. PARENTI, P. DEL BIANCO, G. LOMBARDI, L. PEDRINI, S. PIZZI, P. CARLI, M. DELLA PALMA, D. PASTORELLI, L. CORTI, L. BECAGLI ( <i>Padova, Italy</i> ) .....	2311
Short-term Outcome of Cervical Intraepithelial Neoplasia Grade 2: Considerations for Management Strategies and Reproducibility of Diagnosis. A.C. GUEDES, L.C. ZEFERINO, K.J. SYRJÄNEN, S.M.F. BRENNAN ( <i>São Paulo, Brazil; Turku, Finland</i> ) .....	2319
Polymorphisms of Thymidylate Synthase Gene 5'- and 3'-Untranslated Region and Risk of Gastric Cancer in Koreans. D.J. YIM, O.J. KIM, H.J. AN, H. KANG, D.H. AHN, S.G. HWANG, D. OH, N.K. KIM ( <i>Seongnam, South Korea</i> ) .....	2325
Relationship between Preoperative Serum Markers CA 15-3 and CEA and Relapse of the Disease in Elderly (>65 years) Women with Breast Cancer. F. LUMACHI, S.M.M. BASSO, M. BONAMINI, B. MARZANO, E. MILAN, B.U. WACLAW, G.B. CHIARA ( <i>Padova; Pordenone, Italy</i> ) .....	2331
A Phase IA, Open-label, Dose-escalating Study of PTK787/ZK 222584 Administered Orally on a Continuous Dosing Schedule in Patients with Advanced Cancer. J. DREVS, M. MEDINGER, K. MROSS, S. FUXIUS, J. HENNIG, M. BUECHERT, A. THOMAS, C. UNGER, B.-L. CHEN, D. LEBWOHL, D. LAURENT ( <i>Freiburg; Heidelberg; Berlin, Germany; Leicester, UK; East Hanover, NJ, USA</i> ) .....	2335
Postoperative Concurrent Daily Low-dose Cisplatin-based Chemoradiation Improves the Prognosis of Patients with Pathologic T2b or N1 Cervical Cancer. A. MITSUHASHI, T. UNO, H. USUI, S. TATE, K. HIRASHIKI, K. KATO, H. KIYOHARA, S. KATO, H. ITO, M. SHOZU ( <i>Chiba, Japan</i> ) .....	2341
An Indication for Correlation between the Serum ADA Level and Gastric Cancer Risk. G. RI, S. OHNO, M. FURUTANI, Y. FURUTANI, T. TSUKAHARA, N. HAGITA, H. HARUYAMA, S. NAKAMURA, T. YAMAMOTO, R. MATSUOKA ( <i>Tokyo; Saitama, Japan</i> ) .....	2347
A Case of Spontaneous Regression of Advanced Colon Cancer. H. SHIMIZU, M. KOCHI, T. KAIGA, Y. MIHARA, M. FUJII, T. TAKAYAMA ( <i>Tokyo, Japan</i> ) .....	2351
Pharmacokinetics of Irinotecan in Combination with Biweekly Cetuximab in Patients with Advanced Colorectal Cancer. M. CZEJKA, B. GRUENBERGER, A. KISS, A. FARKOUH, J. SCHUELLER ( <i>Vienna, Austria</i> ) .....	2355

Clinical Significance of Vascular Endothelial Growth Factors C and D and Chemokine Receptor CCR7 in Gastric Cancer. K. DEGUCHI, D. ICHIKAWA, K. SOGA, K. WATANABE, T. KOSUGA, H. TAKESHITA, H. KONISHI, R. MORIMURA, M. TSUJIURA, S. KOMATSU, A. SHIOZAKI, K. OKAMOTO, H. FUJIWARA, E. OTSUJI ( <i>Kyoto, Japan</i> ) .....	2361
Indication for Hepatic Resection in the Treatment of Liver Metastasis from Gastric Cancer. H. MAKINO, C. KUNISAKI, Y. IZUMISAWA, M. TOKUHISA, T. OSHIMA, Y. NAGANO, S. FUJII, J. KIMURA, R. TAKAGAWA, T. KOSAKA, H.A. ONO, H. AKIYAMA, K. TANAKA, I. ENDO ( <i>Yokohama, Japan</i> ).....	2367
Detection of Circulating Tumour Cells in Breast Cancer Patients Using Human Mammaglobin RT-PCR: Association with Clinical Prognostic Factors. P. FERRO, M.C. FRANCESCHINI, B. BACIGALUPO, P. DESSANTI, E. FALCO, V. FONTANA, D. GIANQUINTO, M.P. PISTILLO, F. FEDELI, S. RONCELLA ( <i>La Spezia; Genova, Italy</i> ) .....	2377
Post-transplant Lymphoproliferative Disorders in Liver Transplanted Patients: A Single-centre Experience. D. MARINO, P. BURRA, P. BOCCAGNI, F. CALABRESE, F. CANOVA, C. TRENTIN, C. BOSO, C. SOLDÀ, P. ANGELI, S.M.L. AVERSA ( <i>Padova, Italy</i> ) .....	2383
Association of Hypoxia-inducible Factor 1-alpha Gene Polymorphisms and Colorectal Cancer Prognosis. J. SZKANDERA, G. KNECHTEL, M. STOTZ, G. HOFMANN, U. LANGSENLEHNER, P. KRIPPL, T. LANGSENLEHNER, D. DEHCHAMANI, H. SAMONIGG, W. RENNER, A. GERGER ( <i>Graz; Fuerstenfeld, Austria</i> ) .....	2393
Evaluation of Women with Breast Disease Using Body Image Drawing Analysis. M. ESKELINEN, P. OLLONEN ( <i>Kuopio, Finland</i> ).....	2399
Prognostic Relevance of <i>KIT</i> and <i>PDGFRA</i> Mutations in Gastrointestinal Stromal Tumors. E. BRAGGIO, D. DE ALMEIDA BRAGGIO, I.Á. SMALL, L.F. LOPES, M. VALADÃO, M.E. GOUVEIA, A. DOS SANTOS MOREIRA, E. LINHARES, S. ROMANO, C.E. BACCHI, I.Z. RENAULT, D.P. GUIMARÃES, C.G. FERREIRA ( <i>São Paulo; Rio de Janeiro, Brazil</i> ) .....	2407
Impact of Post-transplant Imatinib Administration on Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia. S. NISHIWAKI, K. MIYAMURA, C. KATO, S. TERAURA, K. OHASHI, H. SAKAMAKI, S. NAKAO, H. HARIGAE, Y. KODERA ( <i>Nagoya; Sendai; Tokyo; Kanazawa, Japan</i> ).....	2415
The Size of Colon Polyps Revisited: Intra and Inter-observer Variations. C.A. RUBIO, J.G. JÓNASSON, G. NESI, J. MAZUR, E. ÓLAFSDÓTTIR ( <i>Stockholm, Sweden; Reykjavik, Iceland; Florence, Italy; Warsaw, Poland</i> ) .....	2419
Number of Hysteroscopies and the Time Interval between Hysteroscopy and Surgery: Influence on Peritoneal Cytology in Patients with Endometrial Cancer. I. JUHASZ-BÖSS, T. FEHM, A. NAUTH, S. BECKER, R. ROTHMUND, K. GARDANIS, B. KRÄMER, D. WALLWIENER, E. SOLOMAYER ( <i>Tübingen; Homburg/Saar, Germany</i> ).....	2425
Frequent Expression of Thymidine Phosphorylase in Epstein-Barr Virus-associated Gastric Carcinoma of Diffuse Type. C. KORIYAMA, S. AKIBA, S. SHIMAOKA, T. ITOH, S.-I. AKIYAMA, Y. EIZURU ( <i>Kagoshima, Japan</i> ).....	2431
HER-2/AKT Expression in Upper Urinary Tract Urothelial Carcinoma: Prognostic Implications. L. IZQUIERDO, D. TRUAN, L. MENGUAL, C. MALLOFRÉ, A. ALCARAZ ( <i>Barcelona; Santander, Spain</i> ) .....	2439
Increased ERCC1 Protein Expression Is Associated with Suboptimal Debulking in Advanced Epithelial Ovarian Cancer. F. LIN, K. LIN, X. XIE, C. ZHOU ( <i>Zhejiang, PR China</i> ) .....	2447

Prognostic Impact of CD133 Expression in Gastric Carcinoma. S. ISHIGAMI, S. UENO, T. ARIGAMI, Y. UCHIKADO, T. SETOYAMA, H. ARIMA, Y. KITA, H. KURAHARA, H. OKUMURA, M. MATSUMOTO, Y. KIJIMA, S. NATSUGOE ( <i>Kagoshima, Japan</i> ) .....	2453
Lack of Prognostic Value of Topoisomerase II Alpha in Patients with Breast Cancer: Analysis with Tissue Microarray. S.-M. SHEEN-CHEN, C.-Y. HUANG, H. ZHANG, C.-C. HUANG, R.-P. TANG ( <i>Taoyuan, Taiwan, ROC; Xiamen, PR China</i> ) .....	2459
Circulating <i>HER2</i> DNA after Trastuzumab Treatment Predicts Survival and Response in Breast Cancer. B.S. SORENSEN, L.S. MORTENSEN, J. ANDERSEN, E. NEXO ( <i>Aarhus, Denmark</i> ) .....	2463
Medical History and Lifestyle Factors Contributing to Epstein-Barr Virus-associated Gastric Carcinoma and Conventional Gastric Carcinoma in Korea. R.H. KIM, M.S. CHANG, H.J. KIM, K.S. SONG, Y.S. KIM, B.Y. CHOI, W.H. KIM ( <i>Seoul; Daejeon, South Korea</i> ) .....	2469
Meeting Report: City of Temples Discusses Signaling Templates in Cancer Cells. Third International Symposium on Translational Cancer Research: Cell Signaling & Cancer Therapy Bhubaneswar, Orissa, India, December 18th through 21st, 2009. V. GANDHI, K. MEHTA, S. PATHAK, B. RAVINDRAN, S. MISHRA, B.B. AGGARWAL ( <i>Houston, TX, USA; Orissa, India</i> ) .....	2477
Errata .....	2481
* Reviews (pages 1977, 2073, 2161)	

## Number 7

### *Experimental Studies*

RB Stabilizes XPC and Promotes Cellular NER. T.M. HARDY, M.S. KUMAR, M.L. SMITH ( <i>Indianapolis, IN, USA</i> ).....	2483
Aberrant Promoter Hypermethylation and Genomic Hypomethylation in Tumor, Adjacent Normal Tissues and Blood from Breast Cancer Patients. Y.H. CHO, H. YAZICI, H.-C. WU, M.B. TERRY, K. GONZALEZ, M. QU, N. DALAY, R.M. SANTELLA ( <i>New York; Stony Brook, NY, USA; Istanbul, Turkey</i> ) .....	2489
(-)-Epigallocatechin-3-Gallate (EGCG) Post-transcriptionally and Post-translationally Suppresses the Cell Proliferative Protein TROP2 in Human Colorectal Cancer Cells. M. SUKHTHANKAR, S. ALBERTI, S.J. BAEK ( <i>Knoxville, TN, USA; Chieti Scalo (Chieti), Italy</i> ) .....	2497
Anticancer Activity of Novel Unnatural Synthetic Isoprenoids. V.R. ADAMS, D.L. DEREMER, B. STEVICH, C.A. MATTINGLY, B. GALLT, T. SUBRAMANIAN, J.M. TROUTMAN, H.P. SPIELMANN ( <i>Lexington, KY, USA</i> ) .....	2505
Epithelial–Mesenchymal Transition in EGFR-TKI Acquired Resistant Lung Adenocarcinoma. H. URAMOTO, T. IWATA, T. ONITSUKA, H. SHIMOKAWA, T. HANAGIRI, T. OYAMA ( <i>Kitakyushu, Japan</i> ) .....	2513
Epigallocatechin-3-gallate, a Natural Polyphenol, Inhibits Cell Proliferation and Induces Apoptosis in Human Ovarian Cancer Cells. S.D. RAO, K. PAGIDAS ( <i>Providence, RI, USA</i> ) .....	2519
Expression and Localization of E-Cadherin in Epithelial Ovarian Cancer. D. KOENSGEN, C. FREITAG, I. KLAMAN, E. DAHL, A. MUSTEA, R. CHEKEROV, I. BRAICU, W. LICHTENEGGER, J. SEHOULI ( <i>Greifswald; Berlin; Potsdam; Aachen, Germany</i> ) .....	2525

Oxaliplatin Resistance Induced by <i>ERCC1</i> Up-regulation Is Abrogated by siRNA-mediated Gene Silencing in Human Colorectal Cancer Cells. R.N. SEETHARAM, A. SOOD, A. BASU-MALLICK, L.H. AUGENLICHT, J.M. MARIADASON, S. GOEL ( <i>Bronx, NY, USA; Melbourne, Australia</i> ) .....	2531
Heat-shock Protein 27 Is Phosphorylated in Gemcitabine-resistant Pancreatic Cancer Cells. K. TABA, Y. KURAMITSU, S. RYOZAWA, K. YOSHIDA, T. TANAKA, S.-I. MAEHARA, Y. MAEHARA, I. SAKAIDA, K. NAKAMURA ( <i>Yamaguchi; Fukuoka, Japan</i> ) .....	2539
Tumor Cure Probability During $\alpha$ -RIT of Ovarian Cancer with Different Radiation Sensitivity. J. ELGQVIST, B.R. JOHANSSON, K. PARTHEEN, A. DANIELSSON ( <i>Gothenburg, Sweden</i> ) .....	2545
Iodination Increases the Activity of Verapamil Derivatives in Reversing PGP Multidrug Resistance. R. BARATTIN, B. GERBY, K. BOURGES, G. HARDY, J. OLIVARES, J. BOUTONNAT, C. ARNOULT, A. DU MOULINET D'HARDEMARE, X. RONOT ( <i>Grenoble; La Tronche, France</i> ) .....	2553
MGMT Activity in Mucosal Epithelium and Squamous Cell Carcinoma of the Head and Neck. R. JACOB, N. SHAFIEI, G. NAGEL, H.J. WELKOBORSKY, W. MANN, B. KAINA ( <i>Koblenz; Mainz; Hannover, Germany</i> ) ..	2561
DNA Microarray Analysis of Signaling Pathway in Macrophages Stimulated by Lignin–Carbohydrate Complex from <i>Lentinus edodes</i> Mycelia (LEM) Extract. M. KAWANO, M.M. THET, T. MAKINO, T. KUSHIDA, H. SAKAGAMI ( <i>Sakado, Saitama; Tokyo, Japan</i> ) .....	2567
Knock-down of Superoxide Dismutase 1 Sensitizes Cisplatin-resistant Human Ovarian Cancer Cells. J.W. KIM, H. SAHM, J. YOU, M. WANG ( <i>Indianapolis, IN, USA</i> ) .....	2577
Effects of Anandamide on Polyamine Levels and Cell Growth in Human Colon Cancer Cells. M. LINSALATA, M. NOTARNICOLA, V. TUTINO, M. BIFULCO, A. SANTORO, C. LAEZZA, C. MESSA, A. ORLANDO, M.G. CARUSO ( <i>Bari; Salerno; Napoli, Italy</i> ) .....	2583
Expression of Fyn Kinase Modulates EMT in Oral Cancer Cells. B. LEWIN, A. SIU, C. BAKER, D. DANG, R. SCHNITT, P. EISAPOORAN, D.M. RAMOS ( <i>San Francisco, CA, USA</i> ) .....	2591
Automated Assessment of Tumour Microvascular Architecture <i>In Vivo</i> . S. BECKER, S. STRIETH, M. CANIS, G. PREISSLER, M.E. EICHHORN ( <i>Munich, Germany</i> ) .....	2597
SMAD4 Mediates Mesenchymal–Epithelial Reversion in SW480 Colon Carcinoma Cells. M. POHL, Y. RADACZ, N. PAWLK, A. SCHOENECK, S.E. BALDUS, J. MUNDING, W. SCHMIEGEL, I. SCHWARTE-WALDHOFF, A. REINACHER-SCHICK ( <i>Bochum; Duesseldorf; Bochum, Germany</i> ) .....	2603
Bone Destruction by Invading Oral Squamous Carcinoma Cells Mediated by the Transforming Growth Factor- $\beta$ Signalling Pathway. T. GODA, T. SHIMO, Y. YOSHIHAMA, N.M.M. HASSAN, S. IBARAGI, N. KURIO, T. OKUI, T. HONAMI, K. KISHIMOTO, A. SASAKI ( <i>Okayama; Tokyo, Japan</i> ) .....	2615
Combination Therapy of 5-Fluorouracil with Rapamycin for Hormone Receptor-negative Human Breast Cancer. Y. HOSONO, S. OSADA, M. NAWA, T. TAKAHASHI, K. YAMAGUCHI, Y. KAWAGUCHI, K. YOSHIDA ( <i>Gifu, Japan</i> ) .....	2625
Identification of a Tumour Associated Antigen in Lung Cancer Patients with Asbestos Exposure. M. YASUDA, T. HANAGIRI, Y. SHIGEMATSU, T. ONITSUKA, K. KURODA, T. BABA, M. MIZUKAMI, Y. ICHIKI, H. URAMOTO, M. TAKENOYAMA, K. YASUMOTO ( <i>Kitakyushu, Japan</i> ) .....	2631
Retrovirus-mediated <i>Drosophila melanogaster</i> Multisubstrate Deoxyribonucleoside Kinase Gene Therapy of Gastric Cancer Cells <i>In Vitro</i> and <i>In Vivo</i> . Z. ZHU, L. ZHAO, A. HE, B. HUANG, A. KARLSSON, H. XU, X. ZHENG ( <i>Shenyang, P.R. China; Stockholm, Sweden</i> ) .....	2641

Epithelial Versus Endothelial CEACAM1 Expression and Angiogenesis in Epididymal Adenomatoid Tumor. N. KILIC, D. TILKI, B. ERGÜN, M. SEITZ, C.G. STIEF, O. REICH, S. ERGÜN ( <i>Essen; Munich; Hamburg, Germany</i> ).....	2651
Antiproliferative Effect of a Novel Nitro-oxy Derivative of Celecoxib in Human Colon Cancer Cells: Role of COX-2 and Nitric Oxide. C. BOCCA, F. BOZZO, A. BASSIGNANA, A. MIGLIETTA ( <i>Torino, Italy</i> ).....	2659
Calcitriol Down-regulates Human Ether à go-go 1 Potassium Channel Expression in Cervical Cancer Cells. E. AVILA, R. GARCÍA-BECERRA, J.A. RODRÍGUEZ-RASGADO, L. DÍAZ, D. ORDAZ-ROSADO, U. ZÜGEL, A. STEINMEYER, D. BARRERA, A. HALHALI, F. LARREA, J. CAMACHO ( <i>México, D.F., México; Berlin, Germany</i> ).....	2667
RUNX3 Promoter Methylation in Colorectal Cancer: Its Relationship with Microsatellite Instability and its Suitability as a Novel Serum Tumor Marker. M. NISHIO, C. SAKAKURA, T. NAGATA, S. KOMIYAMA, A. MIYASHITA, T. HAMADA, Y. KURYU, H. IKOMA, T. KUBOTA, A. KIMURA, M. NAKANISHI, D. ICHIKAWA, H. FUJIWARA, K. KAMOTO, T. OCHIAI, Y. KOKUBA, T. SONOYAMA, H. IDA, K. ITO, T. CHIBA, Y. ITO, E. OTSUJI ( <i>Kyoto; Nagasaki, Japan; Singapore, Singapore</i> ).....	2673
Computational Analysis of mTOR Signaling Pathway: Bifurcation, Carcinogenesis, and Drug Discovery. G. WANG, G.R.F. KRUEGER ( <i>Washington, DC; Houston, TX, USA</i> ).....	2683
<i>MACC1</i> as a Marker for Advanced Colorectal Carcinoma. A. SHIRAHATA, K. SHINMURA, Y. KITAMURA, K. SAKURABA, K. YOKOMIZO, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, K. HIBI ( <i>Yokohama, Japan</i> ).....	2689
Overexpression of <i>MMP-13</i> Gene in Colorectal Cancer with Liver Metastasis. T. YAMADA, T. OSHIMA, K. YOSHIHARA, S. TAMURA, A. KANAZAWA, D. INAGAKI, N. YAMAMOTO, T. SATO, S. FUJII, K. NUMATA, C. KUNISAKI, M. SHIOZAWA, S. MORINAGA, M. AKAIKE, Y. RINO, K. TANAKA, M. MASUDA, T. IMADA ( <i>Kanagawa-ken, Japan</i> ).....	2693
Methylation of the <i>p16</i> Gene Is Frequently Detected in Lymphatic-invasive Gastric Cancer. T. GOTO, H. MIZUKAMI, A. SHIRAHATA, K. YOKOMIZO, Y.-H. KITAMURA, K. SAKURABA, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, K. HIBI ( <i>Yokohama, Japan</i> ).....	2701
Comprehensive Analysis of Genes Involved in the Malignancy of Gastrointestinal Stromal Tumors. M. TSUMURAYA, H. KATO, K. MIYACHI, K. SASAKI, M. TSUBAKI, K. AKIMOTO, M. SUNAGAWA ( <i>Tochigi, Japan</i> ).....	2705
Combined Effects of Bisphosphonate and Radiation on Osteosarcoma Cells. K. RYU, H. MURATA, K. KOTO, N. HORIE, T. MATSUI, Y. NISHIGAKI, T. SAKABE, H. TAKESHITA, M. ITOI, S. KIMURA, E. ASHIHARA, T. MAEKAWA, S. FUSHIKI, T. KUBO ( <i>Kyoto; Saga; Kyoto, Japan</i> ).....	2713
Effect of Astaxanthin Supplementation on Inflammation and Cardiac Function in BALB/c Mice. R. NAKAO, O.L. NELSON, J.S. PARK, B.D. MATHISON, P.A. THOMPSON, B.P. CHEW ( <i>Pullman, WA, USA</i> )....	2721
Colorectal Cancer and Genetic Polymorphism of DNA Double-strand Break Repair Gene <i>XRCC4</i> in Taiwan. D.-T. BAU, M.-D. YANG, Y.-A. TSOU, S.-S. LIN, C.-N. WU, H.-H. HSIEH, R.-F. WANG, C.-W. TSAI, W.-S. CHANG, H.-M. HSIEH, S.-S. SUN, R.-Y. TSAI ( <i>Taichung, Taiwan R.O.C.</i> ).....	2727
Construction and Molecular Characterization of Human Chimeric T-Cell Antigen Receptors Specific for Carcinoembryonic Antigen. N. SHIRASU, H. SHIBAGUCI, M. KUROKI, H. YAMADA, M. KUROKI ( <i>Fukuoka, Japan</i> ).....	2731
Heterogeneous Expression of Serine Protease Inhibitor Maspin in Ovarian Cancer. D.O. BAUERSCHLAG, M. HABERMANN, J. WEIMER, I. MEINHOLD-HEERLEIN, F. HILPERT, M. WEIGEL, M. BAUER, C. MUNDHENKE, W. JONAT, N. MAASS, C. SCHEM ( <i>Aachen; Haus, Germany</i> ).....	2739

Domain Organization and Properties of LB Lysozyme Crystals Down to Submicron Size. E. PECHKOVA, C. NICOLINI ( <i>Genoa; Rome, Italy</i> ) .....	2745
Epithelial and Stromal Expression of Syndecan-2 in Pancreatic Carcinoma. D. HRABAR, G. ARALICA, M. GOMERČIĆ, N. LJUBIČIĆ, B. KRUŠLIN, D. TOMAS ( <i>Zagreb, Croatia</i> ).....	2749
PTHrP Regulates Angiogenesis and Bone Resorption <i>via</i> VEGF Expression. S. ISOWA, T. SHIMO, S. IBARAGI, N. KURIO, T. OKUI, K. MATSUBARA, N.M.M. HASSAN, K. KISHIMOTO, A. SASAKI ( <i>Okayama; Hiroshima, Japan</i> ) .....	2755
IL-8 and IL-6 Bystander Signalling in Human Glioblastoma Cells Exposed to Gamma Radiation. F. PASI, A. FACOETTI, R. NANO ( <i>Pavia, Italy</i> ).....	2769
Melphalan Modulates the Expression of E7-Specific Biomarkers in E7-Tg Mice. E.J. KIM, H. KIM, S. LEE, J.W. KANG, D.H. LEE, H.S. CHOI, J.M. KIM, Y. YANG, Y.Y. SHEEN, S.N. PARK, D.Y. YOON ( <i>Seoul; Daejeon; Sookmyung, Korea</i> ) .....	2773
Cell-free Circulating DNA: Diagnostic Value in Patients with Renal Cell Cancer. S. HAUSER, T. ZAHALKA, J. ELLINGER, G. FECHNER, L.C. HEUKAMP, A. VON RUECKER, S.C. MÜLLER, P.J. BASTIAN ( <i>Bonn; Munich, Germany</i> ) .....	2785
Role of Caspases and CD95/Fas in the Apoptotic Effects of a Nucleotide Analog PMEG in CCRF-CEM Cells. H. MERTLÍKOVÁ-KAISEROVÁ, I. VOTRUBA, M. MATOUŠOVÁ, A. HOLÝ, M. HÁJEK ( <i>Prague, Czech Republic</i> ) .....	2791
Expression of p27, p21 <sup>WAF/Cip1</sup> , and p16 <sup>INK4a</sup> in Normal Oral Epithelium, Oral Squamous Papilloma, and Oral Squamous Cell Carcinoma. A.B. QUEIROZ, G. FOCCHI, C. DOBO, T.S. GOMES, D.A. RIBEIRO, C.T.F. OSHIMA ( <i>Sao Paulo, SP, Brazil</i> ) .....	2799
Analysis of Chemotherapeutic Response Heterogeneity and Drug Clustering Based on Mechanism of Action Using an <i>In Vitro</i> Assay. S.D. RICE, J.M. HEINZMAN, S.L. BROWER, P.R. ERVIN, N. SONG, K. SHEN, D. WANG ( <i>Pittsburgh, PA 15203, USA</i> ) .....	2805
Antiangiogenic Activities and Cisplatin-combined Antitumor Activities of BPR0L075. C.-P. CHEN, C.-B. HU, K.-C. YEH, J.-S. SONG, T.-K. YEH, F.-F. TUNG, L.-L. HWANG, H.-Y. TSENG, Y.-C. HUANG, H.-S. SHY, S.-H. HSIEH, C.-C. SHEN, H.-S. WANG, H.-P. HSIEH, J.-P. LIOU, Y.-S. CHAO, C.-T. CHEN ( <i>Miaoli; Taipei, Taiwan, ROC</i> ) .....	2813
A <sub>3</sub> Adenosine Receptor Antagonist, Truncated Thio-Cl-IB-MECA, Induces Apoptosis in T24 Human Bladder Cancer Cells. H. KIM, J.W. KANG, S. LEE, W.J. CHOI, L.S. JEONG, Y. YANG, J. TAE HONG, D.Y. YOON ( <i>Seoul; Cheongju, South Korea</i> ) .....	2823
Hypoxia and Activated VEGF/Receptor Pathway in Multiple Myeloma. A. GIATROMANOLAKI, M. BAI, D. MARGARITIS, K.L. BOURANTAS, M.I. KOUKOURAKIS, E. SIVRIDIS, K.C. GATTER ( <i>Alexandroupolis; Ioannina, Greece; Oxford, UK</i> ) .....	2831
Immunohistochemical Analysis for Expression of Calpain 1, Calpain 2 and Calpastatin in Endometrial Cancer. D. SALEHIN, I. FROMBERG, C. HAUGK, B. DOHMEN, T. GEORG, R.M. BOHLE, D. BAUERSCHLAG, N. MAASS, M. FRIEDRICH ( <i>Krefeld; Kaiserslautern; Homburg/Saar; Aachen, Germany</i> ) .....	2837
Expression of Ki-67 Antigen and Caspase-3 Protein in Benign Lesions and Esophageal Carcinoma. M. FERREIRA BELLINI, P.M. CURY, A.E. SILVA ( <i>São José do Rio Preto, SP, Brazil</i> ) .....	2845
Curcumin Alters the Migratory Phenotype of Nasopharyngeal Carcinoma Cells through Up-regulation of E-Cadherin. T.-S. WONG, W.-S. CHAN, C.-H. LI, R.W.-M. LIU, W.W.-Y. TANG, S.-W. TSAO, R.K.-Y. TSANG, W.-K. HO, W.I. WEI, J.Y.-W. CHAN ( <i>Hong Kong, China</i> ) .....	2851

Heterogeneity of Radiation- and TNF-alpha-induced Programmed Cell Death in Carcinoma, Sarcoma and Lymphoma Cell Lines. T. BÖLLING, A. KOLKMEYER, B. GREVE, I. ERNST, N. WILLICH, S. KÖNEMANN ( <i>Münster, Germany</i> ).....	2857
Carbonyl Cyanide P-(Trifluoromethoxy) Phenylhydroazone Induces Caspase-independent Apoptosis in As4.1 Juxtglomerular Cells. Y.H. HAN, Y.M. YANG, W.H. PARK ( <i>JeonJu, Republic of Korea</i> ).....	2863
$\gamma$ -Tocotrienol Controls Proliferation, Modulates Expression of Cell Cycle Regulatory Proteins and Up-regulates Quinone Reductase NQO2 in MCF-7 Breast Cancer Cells. T.-C. HSIEH, S. ELANGOVA, J.M. WU ( <i>Valhalla, NY, USA</i> ).....	2869
The Influence of Cyclin D1 A870G Polymorphism on Colorectal Cancer Risk and Prognosis in a Turkish Population. İ. YAYLIM-ERALTAN, S. ARIKAN, Y. YILDIZ, C. CACINA, H.A. ERGEN, G. TUNA, U. GÖRMÜŞ, Ü. ZEYBEK, T. İSBİR ( <i>Istanbul, Turkey</i> ) .....	2875
Induction of Apoptosis by Sphingosine, Sphinganine, and C <sub>2</sub> -Ceramide in Human Colon Cancer Cells, but not by C <sub>2</sub> -Dihydroceramide. E.H. AHN, J.J. SCHROEDER ( <i>Gyeonggi-do, South Korea; East Lansing, MI, USA</i> ).....	2881
Combined Effect of CYP1B1 Codon 432 Polymorphism and N-Acetyltransferase 2 Slow Acetylator Phenotypes in Relation to Breast Cancer in the Turkish Population. Y.K. ÖZBEK, T. ÖZTÜRK, B.M. TÜZÜNER, Z. CALAY, S. ILVAN, F.M. SEYHAN, H.I. KISAKESEN, O. ÖZTÜRK, T. İSBİR ( <i>Istanbul, Turkey</i> ) .....	2885
The Efficacy of Imiquimod on Dysplastic Lesions of the Oral Mucosa: An Experimental Model. V. GKOULIONI, A. ELEFTHERIADOU, I. YIOTAKIS, E. FEREKIDOU, A. CHRISOVERGIS, A.CH. L. D. KANDILOROS ( <i>Athens; Crete, Greece</i> ).....	2891
Estrogen Receptors $\alpha$ and $\beta$ Immunohistochemical Expression: Clinicopathological Correlations in Pituitary Adenomas. B. MANORANJAN, F. SALEHI, B.W. SCHEITHAUER, F. ROTONDO, K. KOVACS, M.D. CUSIMANO ( <i>Toronto, ON, Canada; Rochester, MN, USA</i> ).....	2897
<i>Clinical Studies</i>	
Docetaxel Second-line Therapy in Patients with Advanced Pancreatic Cancer: A Retrospective Study. M.W. SAIF, K. SYRIGOS, R. PENNEY, K. KALEY ( <i>New Haven, CT, USA; Athens, Greece</i> ) .....	2905
Levels of Elevated Circulating Endothelial Cell Decline after Tumor Resection in Patients with Pancreatic Ductal Adenocarcinoma. M.S. SABBAGHIAN, G. ROTHBERGER, A.P. ALONGI, J.-P. GAGNER, J.D. GOLDBERG, L. ROLNITZKY, L. CHIRIBOGA, C.H. HAJDU, D. ZAGZAG, R. BASCH, P. SHAMAMIAN ( <i>New York, NY; Charleston, SC, USA</i> ) .....	2911
Zinc- $\alpha$ 2-glycoprotein: A New Biomarker of Breast Cancer? V. DUBOIS, L. DELORT, F. MISHHELLANY, T. JARDE, H. BILLARD, C. LEQUEUX, O. DAMOUR, F. PENNAULT-LLORCA, M.P. VASSON, F. CALDEFIE-CHEZET ( <i>Clermont-Ferrand; Lyon; Region Lyon Auvergne Rhone-Alpes, France</i> ) .....	2919
Role of Pregabalin in Treatment of Oxaliplatin-induced Sensory Neuropathy. M.W. SAIF, K. SYRIGOS, K. KALEY, I. ISUFI ( <i>New Haven, CT, USA; Athens, Greece</i> ) .....	2927
Effects of the Src Inhibitor Saracatinib (AZD0530) on Renal Function in Healthy Subjects. R.N. DALTON, R. CHETTY, M. STUART, R.B. IACONA, A. SWAISLAND ( <i>London; Cheshire, UK</i> ) .....	2935
* Short Review: Validation of Blood Testing for <i>K-ras</i> Mutations in Colorectal and Pancreatic Cancer. M. ROGOSNITZKY, R. DANKS ( <i>Telz Stone, Israel; Steep, UK</i> ) .....	2943

A 'Hot' Leg: A Rare Case of Isolated Long Bone Metastases from Cervical Cancer. A. DEWDNEY, U. SELVARAJAH ( <i>Romford, UK</i> ) .....	2949
Soluble Carbonic Anhydrase IX Is Not an Independent Prognostic Factor in Human Renal Cell Carcinoma. K. PAPWORTH, J. SANDLUND, K. GRANKVIST, B. LJUNGBERG, T. RASMUSON ( <i>Umeå; Stockholm, Sweden</i> ) .....	2953
Postoperative External Beam Radiotherapy for Resected Pancreatic Adenocarcinoma: Impact of Chemotherapy on Local Control and Survival. K. OGAWA, H. SHIBUYA, N. UCHIDA, H. ONISHI, Y. OKUNO, M. MYOJIN, M. KOBAYASHI, Y. OGAWA, N. KANESAKA, K. SHIBUYA, S. TOKUMARU, R. SASAMOTO, K. KARASAWA, K. NEMOTO, Y. NISHIMURA, JROSG WORKING SUBGROUP of GASTROINTESTINAL CANCER ( <i>Okinawa; Tokyo; Shimane; Yamanashi; Kobe City; Sapporo; Sendai; Kyoto; Saga; Niigata; Yamagata; Osaka, Japan</i> ) .....	2959
Bevacizumab Combined with Two-weekly Paclitaxel as First-line Therapy for Metastatic Breast Cancer P. KOUNTOURAKIS, D. DOUFEXIS, S. MALIOU, A. KARAGIANNIS, E. KARDARA, C. MARGARI, D. SYKOUTRI, A. TZOVARAS, A. ARDAVANIS ( <i>Athens, Greece</i> ) .....	2969
Prognostic Value of Lymphovascular Invasion in Bladder Cancer in Patients Treated with Radical Cystectomy. F. PALMIERI, E. BRUNOCILLA, A. BERTACCINI, M. GUIDI, R. PERNETTI, A.M. MORSELLI-LABATE, G. MARTORANA ( <i>Bologna, Italy</i> ) .....	2973
Influence on Busilvex® Pharmacokinetics of Clonazepam Compared to Previous Phenytoin Historical Data. E. CARRERAS, J.Y. CAHN, C. PUOZZO, N. KRÖGER, G. SANZ, A. BUZYN, A. BACIGALUPO, J.P. VERNANT ( <i>Bacelona; Valencia, Spain; Grenoble; Toulouse; Paris, France; Hamburg, Germany; Genova, Italy</i> ) ..	2977
Pooled Analysis of S-1 Trials in Non-small Cell Lung Cancer According to Histological Type. N. YAMAMOTO, T. YAMANAKA, Y. ICHINOSE, K. KUBOTA, H. SAKAI, A. GEMMA, N. SAIJO, M. FUKUOKA, H. NIITANI ( <i>Shizuoka; Fukuoka; Tokyo; Saitama; Osaka, Japan</i> ) .....	2985
Cervical Manifestation of a Borderline Type Ovarian Cancer with Pseudomyxoma Peritonei – A Case Report. R.B. SCHMUCK, K. PIETZNER, A. BUCKENDAHL, J. SCHÖNLEBE, J. SEHOULI ( <i>Berlin; Dresden, Germany</i> ) .....	2991
Immunohistochemical Study of Claudin 18 Involvement in Intestinal Differentiation During the Progression of Intraductal Papillary Mucinous Neoplasm. Y. SANADA, Y. HIROSE, S. OSADA, Y. TANAKA, T. TAKAHASHI, K. YAMAGUCHI, K. YOSHIDA ( <i>Gifu, Japan</i> ) .....	2995
Successful Right Hepatectomy After Four Treatments of Yttrium-90 Microspheres (SIR-Spheres®) and Concomitant FOLFOX as Bridging Therapy to Resection of Colorectal Liver Metastases. T.C. CHUA, L. BESTER, J. AKTHER, D.L. MORRIS ( <i>Sydney, Australia</i> ) .....	3005
Amyloid Deposition in the Tongue: Clinical and Histopathological Profile. F. ANGIERO, R. SERAMONDI, S. MAGISTRO, R. CRIPPA, S. BENEDICENTI, C. RIZZARDI, G. CATTORETTI ( <i>Monza; Milan; Genoa; Trieste, Italy</i> ) .....	3009
Metastatic Breast Cancer Presenting as a Primary Hindgut Neuroendocrine Tumour. A.F.C. OKINES, E.A. HAWKES, S. RAO, N. VAN AS, H. MARSH, A. RIDDELL, P.O.G. WILSON, P. OSIN, A.C. WETHERSPOON ( <i>London and Surrey, UK</i> ) .....	3015
Protruding and Non-protruding Colon Carcinomas Originating in Gut-associated Lymphoid Tissue. C.A. RUBIO, C. LINDH, J. BJÖRK, H. TÖRNBLOM, R. BEFRITS ( <i>Stockholm, Sweden</i> ) .....	3019
Prognostic Evaluation of COX-2 Expression in Renal Cell Carcinoma. M.K. KANKURI-TAMMILEHTO, K.-O. SÖDERSTRÖM, T.-T. PELLINIEMI, T. VAHLBERG, S.O. PYRHÖNEN, E.K. SALMINEN ( <i>Turku, Finland</i> ) .....	3023



Phase III Study Comparing Sequential <i>Versus</i> Alternate Administration of Cisplatin-Etoposide and Topotecan as First-line Treatment in Small Cell Lung Cancer. S. BAKA, S. AGELAKI, A. KOTSAKIS, M. VESLEMES, P. PAKAKOTOULAS, M. AGELIDOU, A. AGELIDOU, E. TSAROUCHA, G. PAVLAKOU, A. GEROGIANNI, N. ANDROULAKIS, L. VAMVAKAS, K. KALBAKIS, D. MAVROUDIS, V. GEORGOULIAS ( <i>Athens, Greece</i> )....	3031
Phase II Trial of Adjuvant Chemotherapy with Bi-Weekly Carboplatin Plus Paclitaxel in Patients with Completely Resected Non-small Cell Lung Cancer. M. SUGAYA, H. URAMOTO, A. UCHIYAMA, A. NAGASHIMA, R. NAKANISHI, H. SAKATA, K. NAKANISHI, T. HANAGIRI, K. YASUMOTO ( <i>Kitakyushu; Kyushu Kouseinenkin; Iizuka City, Japan</i> ) .....	3039
Hepatic Arterial Infusion with Oxaliplatin, Irinotecan and Doxifluridine for Unresectable Liver Metastases of Colorectal Cancer. Y. CHEN, Z. YAN, J. WANG, X. WANG, J. LUO, Q. LIU ( <i>Shanghai, China</i> ) .....	3045
Trastuzumab plus Capecitabine and Docetaxel as First-line Therapy for HER2-positive Metastatic Breast Cancer: Phase II Results. V. MICHALAKI, S. FOTIOU, S. GENNATAS, C. GENNATAS ( <i>Athens, Greece</i> ) .....	3051
Stereotactic Radiosurgery plus Whole-brain Radiotherapy for Treatment of Multiple Metastases from Non-small Cell Lung Cancer. G. MINNITI, M. SALVATI, R. MUNI, G. LANZETTA, M.F. OSTI, E. CLARKE, A. COSTA, A. BOZZAO, G. TRASIMENI, R. MAURIZI ENRICI ( <i>Rome; Pozzilli (IS), Italy</i> ) .....	3055
Clinicopathological Features in N0 Oesophageal Cancer Patients. C. KUNISAKI, H. MAKINO, T. OSHIMA, S. FUJII, R. TAKAGAWA, J. KIMURA, T. KOSAKA, H.A. ONO, H. AKIYAMA, I. ENDO ( <i>Yokohama, Japan</i> ) .....	3063
Does a New Ultrasound Probe Change the Complication Rates of Transrectal Ultrasound-guided Needle Biopsies of the Prostate? T.H. ECKE, H. GERULLIS, C.J. HEUCK, P. BARTEL, S. HALLMANN, S. KOCH, J. RUTTLOFF ( <i>Bad Saarow; Neuss; Essen, Germany; Bronx, NY, USA</i> ) .....	3071
Preliminary Results of Tranilast Treatment for Patients with Advanced Castration-resistant Prostate Cancer. K. IZUMI, A. MIZOKAMI, T. SHIMA, K. NARIMOTO, K. SUGIMOTO, Y. KOBORI, Y. MAEDA, H. KONAKA, E. KOH, M. NAMIKI ( <i>Kanazawa; Koshigaya, Japan</i> ) .....	3077
Fine-Needle Aspiration Cytology and <sup>99m</sup> Tc-pertechnetate Scintigraphy Together in Patients with Differentiated Thyroid Carcinoma. F. LUMACHI, M. FABBRO, A. TREGNAGHI, L. ANTUNOVIC, F. BUI, D. CECCHIN, P. ZUCCHETTA, A. FASSINA ( <i>Padova, Italy</i> ) .....	3083
Vinorelbine plus 24-Hour Infusion of High-dose 5-Fluorouracil and Leucovorin as Effective Palliative Chemotherapy for Breast Cancer Patients with Acute Disseminated Intravascular Coagulation. P.-H. LIN, Y.-S. LU, C.-H. LIN, D.-Y. CHANG, C.-S. HUANG, A.-L. CHENG, K.-H. YEH ( <i>Taipei, Taiwan, ROC</i> ) .....	3087
CCND1 and CDKN1B Polymorphisms and Risk of Breast Cancer. E. CANBAY, I.Y. ERALTAN, A. CERCEL, T. ISBIR, E. GAZIOGLU, F. AYDOGAN, C. CACINA, A. CENGIZ, M. FERAHMAN, E. ZENGİN, H. UNAL ( <i>Istanbul, Turkey</i> ) .....	3093
Prognostic Significance of Tumour Marker Index Based on Preoperative CEA and CYFRA 21-1 in Non-small Cell Lung Cancer. M. TOMITA, T. SHIMIZU, T. AYABE, A. YONEI, T. ONITSUKA ( <i>Miyazaki, Japan</i> ) .....	3099

\* Review (page 2943)

**Number 8**

**Proceedings of the 13th Annual Meeting of the Society of Biotherapeutic pproaches,  
December 5, 2009, Takamatsu, Japan.**

**Special Issue Edited by G.I. Soma, M. Kuroki, S. Miyake**

Preface .....	3103
* Review: Emerging Strategies for ErbB Ligand-based Targeted Therapy for Cancer. H. TSUJIOKA, F. YOTSUMOTO, K. SHIROTA, S. HORIUCHI, T. YOSHIZATO, M. KUROKI, S. MIYAMOTO ( <i>Fukuoka, Japan</i> ) .....	3107
* Review: Recovery from Immunosuppression-related Disorders in Humans and Animals by IP-PA1, An Edible Lipopolysaccharide. T. HEBISHIMA, Y. MATSUMOTO, G. WATANABE, G.-I. SOMA, C. KOHCHI, K. TAYA, Y. HAYASHI, Y. HIROTA ( <i>Tokyo; Tokushima; Kagawa; Gifu, Japan</i> ) .....	3113
Apoptosis as a Possible Candidate Mechanism for Removal of Tamoxifen-related Endometrial Cells with KRAS Mutations. H. TSUJIOKA, T. HACHISUGA, S. HIKITA, T. UEDA, F. YOTSUMOTO, K. SHIROTA, T. YOSHIZATO, T. KAWARABAYASHI, M. KUROKI, S. MIYAMOTO ( <i>Fukuoka; Kitakyushu, Japan</i> ) .....	3119
Lymphokine-activated Killer Cell Therapy Combined with High-dose Glucocorticoid Showed Clinical Efficacy towards Advanced Lung Carcinoma. M. KATO, S. GOTO, G.-I. SOMA ( <i>Tokyo; Tokushima; Kagawa-ken; Chiba-ken, Japan</i> ) .....	3125
Antitumor Effect of Inhalatory Lipopolysaccharide and Synergetic Effect in Combination with Cyclophosphamide. K. HIROTA, Y. OISHI, H. TANIGUCHI, K. SAWACHI, H. INAGAWA, C. KOHCHI, G.-I. SOMA, H. TERADA ( <i>Chiba; Yamaguchi; Tokushima; Kagawa, Japan</i> ) .....	3129
Cytotoxic Effects of Activated Alveolar Macrophages on Lung Carcinoma Cells <i>via</i> Cell-to-Cell Contact and Nitric Oxide. K. SAWACHI, Y. SHIMADA, H. TANIGUCHI, K. HIROTA, H. INAGAWA, C. KOHCHI, G.-I. SOMA, K. MAKINO, H. TERADA ( <i>Chiba; Kagawa; Tokushima, Japan</i> ) .....	3135
HB-EGF Inhibition in Combination with Various Anticancer Agents Enhances its Antitumor Effects in Gastric Cancer. A. SANUI, F. YOTSUMOTO, H. TSUJIOKA, T. FUKAMI, S. HORIUCHI, K. SHIROTA, T. YOSHIZATO, T. KAWARABAYASHI, M. KUROKI, S. MIYAMOTO ( <i>Fukuoka, Japan</i> ) .....	3143
Preparation of Lipopolysaccharide Derived from <i>Pantoea agglomerans</i> Labeled with Fluorescence as a Tracer for Kinetics Analysis. T. KADOWAKI, H. INAGAWA, C. KOHCHI, M. HIRASHIMA, G.-I. SOMA ( <i>Kagawa-ken; Yamaguchi-ken; Chiba-ken; Tokushima-ken, Japan</i> ) .....	3151
Lipopolysaccharide-activated Alveolar Macrophages Having Cytotoxicity toward Lung Tumor Cells through Cell-to-Cell Binding-dependent Mechanism. H. TANIGUCHI, Y. SHIMADA, K. SAWACHI, K. HIROTA, H. INAGAWA, C. KOHCHI, G.-I. SOMA, K. MAKINO, H. TERADA ( <i>Chiba; Kagawa; Tokushima, Japan</i> ) .....	3159
Role of Lipid Rafts in Phagocytic Uptake of Polystyrene Latex Microspheres by Macrophages. G. NAGAO, K. ISHII, K. HIROTA, K. MAKINO, H. TERADA ( <i>Chiba, Japan</i> ) .....	3167
N-Acetyl Transferase 2 Polymorphisms Associated with Isoniazid Pharmacodynamics: Molecular Features for Ligand Interaction. K. OHKURA, K. FUKINO, Y. SHINOHARA, H. HORI ( <i>Chiba; Tokushima, Japan</i> ) .....	3177
Increased Claudin-1 Protein Expression Contributes to Tumorigenesis in Ulcerative Colitis-associated Colorectal Cancer. T. KINUGASA, Y. AKAGI, T. YOSHIDA, Y. RYU, I. SHIRATUCHI, N. ISHIBASHI, K. SHIROUZU ( <i>Fukuoka, Japan</i> ) .....	3181
WT1 Expression Correlates with Angiogenesis in Endometrial Cancer Tissue. S. DOHI, S. OHNO, Y. OHNO, S. KYO, G.-I. SOMA, H. SUGIYAMA, M. INOUE ( <i>Ishikawa; Saitama; Tokushima; Chiba; Osaka, Japan</i> ) .....	3187

Clinical Features of and Chemotherapy for Cancer of the Small Intestine. D. HIGASHI, Y. ISHIBASHI, T. TAMURA, K. NII, Y. EGAWA, M. KOGA, T. TOMIYASU, T. HARIMURA, R. TANAKA, R. FUTATSUKI, S. NODA, K. FUTAMI, T. MAEKAWA, Y. TAKAKI, F. HIRAI, T. MATSUI ( <i>Chikushino-shi, Japan</i> ) .....	3193
A Retrospective Study of a Calcium Agent (E-Ca) Using Data on Bone Mineral Density Obtained by DXA Method. R. TAKEUCHI, Y. UTO, Y. NAKAGAWA, K. HIROTA, H. TERADA, H. HORI ( <i>Tokushima; Tokyo; Chiba, Japan</i> ) .....	3199
The Relationship between Clinicopathological Factors and the Reduction of Pyrimidine Nucleoside Phosphorylase Activity after Preoperative Administration of 5'-Deoxy-5-fluorouridine. T. HONDA, H. INAGAWA, T. NISHIZAWA, H. YOSHIMURA, I. YAMAMOTO, G.-I. SOMA ( <i>Kanagawa; Kagawa; Chiba; Fukuoka; Tokushima, Japan</i> ) .....	3207
Book Reviews .....	3213
Announcements .....	3222
* Reviews (pages 3107, 3113)	

## Number 9

### *Experimental Studies*

* Review: Multiple Roles of the ERCC1-XPF Endonuclease in DNA Repair and Resistance to Anticancer Drugs. K. KIRSCHNER, D.W. MELTON ( <i>Cambridge; Edinburgh, UK</i> ) .....	3223
* Review: Medicinal Electronics Bricolage Design of Hypoxia-targeting Antineoplastic Drugs and Invention of Boron Tracedrugs as Innovative Future-architectural Drugs. H. HORI, Y. UTO, E. NAKATA ( <i>Tokushima, Japan</i> ) .....	3233
Weekly Paclitaxel with Intermittent Imatinib Mesylate (Gleevec®): Tolerance and Activity in Recurrent Epithelial Ovarian Cancer. T. SAFRA, E. ANDREOPOULOU, B. LEVINSON, L. BORGATO, B. POTHURI, S. BLANK, A. TIERSTEN, L. BOYD, J. CURTIN, F. MUGGIA ( <i>New York, NY; Houston, TX, USA; Padova, Italy; Tel Aviv, Israel</i> ) .....	3243
Transient Metals Enhance Cytotoxicity of Curcumin: Potential Involvement of the NF-κB and mTOR Signaling Pathways. J.R. LOU, X.-X. ZHANG, J. ZHENG, W.-Q. DING ( <i>Oklahoma City, OK, USA</i> ) .....	3249
Topoisomerase I Deficiency Results in Chromosomal Alterations in Cervical Cancer Cells. E. KJELDSSEN, D. TORDRUP, G.M. HÜBNER, B.R. KNUDSEN, F.F. ANDERSEN ( <i>Aarhus C, Denmark</i> ) .....	3257
Assessment of V600E Mutation of <i>BRAF</i> Gene and Rate of Cell Proliferation Using Fine-needle Aspirates from Metastatic Melanomas. V. SVIATOHA, E. TANI, M. GHADERI, R. KLEINA, L. SKOOG ( <i>Solna, Sweden; Riga, Latvia</i> ) .....	3267
Expression of Dysadherin and Cytokeratin as Prognostic Indicators of Disease-free Survival in Patients with Stage I NSCLC. K. ONO, H. URAMOTO, T. HANAGIRI ( <i>Kitakyushu, Japan</i> ) .....	3273
The Role of Akt Activation in the Response to Chemotherapy in Pancreatic Cancer. C.M. PARSONS, D. MUILENBURG, T.L. BOWLES, S. VIRUDACHALAM, R.J. BOLD ( <i>Sacramento, CA, USA</i> ) .....	3279
GFP-Fluorescence-guided UVC Irradiation Inhibits Melanoma Growth and Angiogenesis in Nude Mice. M.-H. TSAI, R. AKI, Y. AMOH, R.M. HOFFMAN, K. KATSUOKA, H. KIMURA, C. LEE, C.-H. CHANG ( <i>Kaohsiung, Taiwan; San Diego; Upland, CA, USA; Sagamihara, Kanagawa; Kanazawa, Ishikawa, Japan</i> ) ..	3291

NF- $\kappa$ B Inhibitors from <i>Brucea javanica</i> Exhibiting Intracellular Effects on Reactive Oxygen Species. J.-A. KIM, E.K. LAU, L. PAN, E.J. CARCACHE DE BLANCO ( <i>Columbus, OH, USA</i> ) .....	3295
Maturation of Tumor Vasculature by Interferon- $\beta$ Disrupts the Vascular Niche of Glioma Stem Cells. R.F. WILLIAMS, T.L. SIMS, L. TRACEY, A.L. MYERS, C.Y.C. NG, H. POPPLETON, A.C. NATHWANI, A.M. DAVIDOFF ( <i>Memphis, TN, USA; London, UK</i> ) .....	3301
Evidence for a Tumour Suppressor Function of SETD2 in Human Breast Cancer: A New Hypothesis. R.F. NEWBOLD, K. MOKBEL ( <i>Uxbridge, Middlesex, UK</i> ) .....	3309
Increased Expression of Macrophage Migration Inhibitory Factor During Progression to Hypopharyngeal Squamous Cell Carcinoma. S. CLUDTS, C. DECAESTECKER, B. JOHNSON, J. LECHIEN, X. LEROY, N. KINDT, H. KALTNER, S. ANDRÉ, H.-J. GABIUS, S. SAUSSEZ ( <i>Mons; Brussels, Belgium; Milwaukee, WI, USA; Lille, France; Munich, Germany</i> ) .....	3313
Efficacy of MDM2 Inhibitor MI-219 Against Lung Cancer Cells Alone or in Combination with MDM2 Knockdown, a XIAP Inhibitor or Etoposide. M. ZHENG, J. YANG, X. XU, J.T. SEBOLT, S. WANG, Y. SUN ( <i>Ann Arbor, MI; San Diego, CA, USA</i> ) .....	3321
Growth Inhibitory and Apoptosis-inducing Effects of Xanthohumol, a Prenylated Chalone Present in Hops, in Human Prostate Cancer Cells. D. DEEB, X. GAO, H. JIANG, A.S. ARBAB, S.A. DULCHAVSKY, S.C. GAUTAM ( <i>Detroit, MI, USA</i> ) .....	3333
Some Considerations for the Study of TGF $\beta$ in Medium of Irradiated T98G Cells: Activation, Release and Consumption. A. FACOETTI, F. PASI, R. NANO ( <i>Pavia, Italy</i> ) .....	3341
Effect of a Neurokinin-1 Receptor Antagonist in a Rat Model of Colitis-Associated Colon Cancer. B. PAGÁN, A.A. ISIDRO, D. COPPOLA, Z. CHEN, Y. REN, J. WU, C. B. APPLEYARD ( <i>Ponce, PR; Tampa, FL, USA</i> ) .....	3345
Sunitinib (SU11248) Inhibits Growth of Human Ovarian Cancer in Xenografted Mice. D.O. BAUERSCHLAG, C. SCHEM, S. TIWARI, J.H. EGBERTS, M.T. WEIGEL, H. KALTHOFF, W. JONAT, N. MAASS, I. MEINHOLD-HEERLEIN ( <i>Aachen; Kiel, Germany</i> ) .....	3355
Sonodynamically Induced Cell Damage Using Rose Bengal Derivative. N. SUGITA, Y. IWASE, N. YUMITA, T. IKEDA, S.-I. UMEMURA ( <i>Tokyo; Kanagawa; Miyaki, Japan</i> ) .....	3361
Identification of Up- and Down-regulated Proteins in Gemcitabine-resistant Pancreatic Cancer Cells Using Two-dimensional Gel Electrophoresis and Mass Spectrometry. Y. KURAMITSU, K. TABA, S. RYOZAWA, K. YOSHIDA, X. ZHANG, T. TANAKA, S.-I. MAEHARA, Y. MAEHARA, I. SAKAIDA, K. NAKAMURA ( <i>Yamaguchi; Fukuoka, Japan</i> ) .....	3367
Influence of Structural Variations on Biological Activity of Anti-PSMA scFv and Immunotoxins Targeting Prostate Cancer. P. BÜHLER, D. WETTERAUER, D. GIERSCHNER, U. WETTERAUER, U. ELSÄSSER BEILE, P. WOLF ( <i>Freiburg, Germany</i> ) .....	3373
Autophagy Inhibition Enhances Sulforaphane-induced Apoptosis in Human Breast Cancer Cells. S. KANEMATSU, N. UEHARA, H. MIKI, K. YOSHIZAWA, A. KAWANAKA, T. YURI, A. TSUBURA ( <i>Osaka, Japan</i> ) .....	3381
The Effect of Bevacizumab on Tumour Growth of Malignant Fibrous Histiocytoma in an Animal Model. Y. OKADA, T. AKISUE, H. HARA, K. KISHIMOTO, T. KAWAMOTO, M. IMABORI, S.-I. KISHIMOTO, N. FUKASE, Y. ONISHI, M. KUROSAKA ( <i>Kobe; Akashi, Hyogo, Japan</i> ) .....	3391
Novel Anti-Tn Single-Chain Fv-Fc Fusion Proteins Derived from Immunized Phage Library and Antibody Fc Domain. T. KUBOTA, T. MATSUSHITA, R. NIWA, I. KUMAGAI, K. NAKAMURA ( <i>Tokyo; Sendai, Japan</i> ) .....	3397

Jun Amino-terminal Kinase 1 Activation Promotes Cell Survival in ErbB2-Positive Breast Cancer. J.S. HAN, D.L. CROWE ( <i>Chicago, IL, USA</i> ) .....	3407
Human Kallikrein 7 Induces Epithelial–Mesenchymal Transition-like Changes in Prostate Carcinoma Cells: A Role in Prostate Cancer Invasion and Progression. L. MO, J. ZHANG, J. SHI, Q. XUAN, X. YANG, M. QIN, C. LEE, H. KLOCKER, Q.Q. LI, Z. MO ( <i>Nanning; Tianjin, P.R. China; Chicago, IL; Bethesda, MD, USA; Innsbruck, Austria</i> ).....	3413
Cytoplasmic Phospholipase A <sub>2</sub> Metabolites Play a Critical Role in Pulmonary Tumor Metastasis in Mice. W.C. JEONG, K.-J. KIM, H.-W. JU, H.-K. BACK, H.K. KIM, S.-Y. IM, H.-K. LEE ( <i>Seoul; Jeonju; Gwanju, Republic of Korea</i> ) .....	3421
Inhibitory Effect of <i>Cordyceps sinensis</i> on Experimental Hepatic Metastasis of Melanoma by Suppressing Tumor Cell Invasion. E. KUBO, N. YOSHIKAWA, M. KUNITOMO, S. KAGOTA, K. SHINOZUKA, K. NAKAMURA ( <i>Nishinomiya, Hyogo, Japan</i> ) .....	3429
Frequency and Role of HPV in the Progression of Epithelial Dysplasia to Oral Cancer. F. ANGIERO, L. BENERINI GATTA, R. SERAMONDI, A. BERENZI, A. BENETTI, S. MAGISTRO, P. ORDESI, P. GRIGOLATO, E. DESSY ( <i>Milan; Brescia, Italy</i> ) .....	3435
<i>MACC 1</i> as a Marker for Peritoneal-disseminated Gastric Carcinoma. A. SHIRAHATA, M. SAKATA, Y. KITAMURA, K. SAKURABA, K. YOKOMIZO, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, K. HIBI ( <i>Yokohama, Japan</i> ) .....	3441
Sporadic Breast Carcinomas with Somatic <i>BRCA1</i> Gene Deletions Share Genotype/Phenotype Features with Familial Breast Carcinomas. K. RHIEM, U. TODT, B. WAPPENSCHMIDT, A. KLEIN, E. WARDELMANN, R.K. SCHMUTZLER ( <i>Cologne; Bonn, Germany</i> ) .....	3445
Caveolin-1 and Doxorubicin-induced P-Glycoprotein Modulate Plasma Cholesterol Membrane Accessibility in Erythrolymphoblastic Cell Line. M. ZHU, L. LE MOYEC, A. STARZEC, V. STIERLE, C. MARBEUF-GUEYE ( <i>Bobigny; Reims, France</i> ).....	3451
TGF-β1 Antisense Impacts the SMAD Signalling System in Fibroblasts from Keloid Scars. G.M. BRAN, U.J. SOMMER, U.R. GOESSLER, K. HÖRMANN, F. RIEDEL, H. SADICK ( <i>Mannheim, Germany</i> ).....	3459
Down-regulation of Heat-shock Protein 70 (HSP-70) Correlated with Responsiveness to Neoadjuvant Aromatase Inhibitor Therapy in Breast Cancer Patients. C.C.P. YIU, N. CHANPLAKORN, M.S.M. CHAN, W.T.Y. LOO, L.W.C. CHOW, M. TOI, H. SASANO ( <i>Sendai; Kyoto, Japan; Hong Kong; Bangkok, Thailand</i> ) .....	3465
Epstein-Barr Virus-infected Cell Line TCC36B Derived from B Lymphocytes Infiltrating Renal Pelvis Urothelial Carcinoma. C.-K. CHUANG, K.-L. CHUANG, C.-H. HSIEH, Y.-C. SHEN, S.-K. LIAO ( <i>Taoyuan; Taipei, Taiwan, ROC</i> ) .....	3473
KITENIN Is Associated with Tumor Progression in Human Gastric Cancer. H.-S. RYU, Y.-L. PARK, S.-J. PARK, J.-H. LEE, S.-B. CHO, W.-S. LEE, I.-J. CHUNG, K.-K. KIM, K.-H. LEE, S.-S. KWEON, Y.-E. JOO ( <i>Gwangju; Namwon; Jeonnam, South Korea</i> ) .....	3479
Two Multidrug-resistance ( <i>ABCB1</i> ) Gene Polymorphisms as Prognostic Parameters in Women with Ovarian Cancer. C. GRIMM, S. POLTERAUER, R. ZEILLINGER, D. TONG, G. HEINZE, A. WOLF, C. NATTER, A. REINTHALLER, L.A. HEFLER ( <i>Vienna, Austria</i> ) .....	3487
Optimized Protocols for Generation of Cord Blood-derived Cytokine-induced Killer/Natural Killer Cells. Y. LI, I.G.H. SCHMIDT-WOLF, Y.-F. WU, S.-L. HUANG, J. WEI, J. FANG, K. HUANG, D.-H. ZHOU ( <i>Guangzhou, PR China; Bonn, Germany</i> ) .....	3493

Quercetin Inhibits Human DLD-1 Colon Cancer Cell Growth and Polyamine Biosynthesis. M. LINSALATA, A. ORLANDO, C. MESSA, M.G. REFOLO, F. RUSSO ( <i>Castellana G., Italy</i> ).....	3501
Effect of Inhibition of the ROCK Isoform on RT2 Malignant Glioma Cells. N. INABA, S. ISHIZAWA, M. KIMURA, K. FUJIOKA, M. WATANABE, T. SHIBASAKI, Y. MANOME ( <i>Tokyo, Japan</i> ) .....	3509
Tumour-Derived Microvesicles (TMV) Mimic the Effect of Tumour Cells on Monocyte Subpopulations. M. BAJ-KRZYWORZEKA, J. BARAN, K. WEGLARCZYK, R. SZATANEK, A. SZAFLARSKA, M. SIEDLAR, M. ZEMBALA ( <i>Cracow, Poland</i> ) .....	3515
Expression of Metalloproteinases MMP-2 and MMP-9 in Sentinel Lymph Node and Serum of Patients with Metastatic and Non-Metastatic Breast Cancer. A. DANIELE, A.F. ZITO, G. GIANNELLI, R. DIVELLA, M. ASSELT, A. MAZZOCCA, A. PARADISO, M. QUARANTA ( <i>Bari, Italy</i> ) .....	3521
Differential Expression of mTOR Signalling Components in Drug Resistance in Ovarian Cancer. H. FOSTER, H.M. COLEY, A. GOUMENOU, G. PADOS, A. HARVEY, E. KARTERIS ( <i>Uxbridge; Guildford, UK; Heraklion; Thessaloniki, Greece</i> ).....	3529
Decreased Srcasm Expression in Esophageal Squamous Cell Carcinoma in a Chinese Population. Y. QI, X. LI, L. ZHAO, J.T. SEYKORA ( <i>Zhengzhou, Henan, PR China; Philadelphia, PA, USA</i> ) .....	3535
Prognostic Relevance of the Proliferation Marker REPP86 for Laryngeal Cancer. C. CORDES, A.-K. MÜNDEL, T. GÖRÖGH, I. LEUSCHNER, P. AMBROSCH, S. GOTTSCHLICH, M. HOFFMANN ( <i>Kiel, Germany</i> ).....	3541
<i>Houttuynia cordata</i> Thunb Extract Inhibits Cell Growth and Induces Apoptosis in Human Primary Colorectal Cancer Cells. K.-C. LAI, Y.-J. CHIU, Y.-J. TANG, K.-L. LIN, J.-H. CHIANG, Y.-L. JIANG, H.-F. JEN, Y.-H. KUO, S. AGAMAYA, J.-G. CHUNG, J.-S. YANG ( <i>Yunlin; Taichung; Tainan, Taiwan, ROC; Saitama, Japan</i> ).....	3549
Increasing P53 Protein Sensitizes Non-Small Cell Lung Cancer to Paclitaxel and Cisplatin <i>In Vitro</i> . V.P. GUNTUR, J.C. WALDREP, J.J. GUO, K. SELTING, R. DHAND ( <i>Columbia, MO; Ft. Detrick, MD, USA</i> ) .....	3557
Inhibition of Heat-shock Protein 27 Expression Eliminates Drug Resistance of Osteosarcoma to Zoledronic Acid. T. MORII, K. OHTSUKA, H. OHNISHI, K. MOCHIZUKI, K. SATOMI ( <i>Mitaka, Tokyo, Japan</i> ) ....	3565
Significant Association of Methylenetetrahydrofolate Reductase Single Nucleotide Polymorphisms with Prostate Cancer Susceptibility in Taiwan. H.-C. WU, C.-H. CHANG, R.-Y. TSAI, C.-H. LIN, R.-F. WANG, C.-W. TSAI, K.-B. CHEN, C.-H. YAO, C.-F. CHIU, D.-T. BAU, C.-C. LIN ( <i>Taichung, Taiwan, ROC</i> ).....	3573
Importance of miR-20a Expression in Prostate Cancer Tissue. M. PESTA, J. KLECKA, V. KULDA, O. TOPOLCAN, M. HORA, V. ERET, M. LUDVIKOVA, M. BABJUK, K. NOVAK, J. STOLZ, L. HOLUBEC ( <i>Pilsen; Prague, Czech Republic</i> ) .....	3579
Effect of Ha-ras <sup>val12</sup> on <i>nm23</i> Expression, Tumor Formation and Metastasis of the Transformants, and Immunomodulation in Tumor-bearing Mice. C.-C. HSIEH, S.-Y. WU, S.-H. LAN, T.-Y. WENG, Y. TSAI, H.-S. LIU ( <i>Taichung; Tainan, Taiwan, ROC</i> ) .....	3585
Down-regulation of P-Glycoprotein Is Associated with Resistance to Cisplatin and VP-16 in Human Lung Cancer Cell Lines. J. WANG, H. WANG, L. ZHAO, S. FAN, Z. YANG, F. GAO, L. CHEN, G.G. XIAO, J. MOLNÁR, Q. WANG ( <i>Dalian; Shijiazhuang, PR China; Omaha, NE, USA; Szeged, Hungary</i> ) .....	3593
A Dihydroxy-pentamethoxyflavone from <i>Gardenia obtusifolia</i> Suppresses Proliferation and Promotes Apoptosis of Tumor Cells Through Modulation of Multiple Cell Signaling Pathways. K. PHROMNOI, S. REUTER, B. SUNG, P. LIMTRAKUL, B.B. AGGARWAL ( <i>Houston, TX, USA; Chiang Mai, Thailand</i> ) .....	3599
Comparison of the Apoptosis-inducing Capability of Sulforaphane Analogues in Human Colon Cancer Cells. M.J. KIM, S.H. KIM, S.-J. LIM ( <i>Seoul; Gangneung, South Korea</i> ).....	3611

A Study of <i>RET</i> Proto-oncogene Polymorphisms in Association with Lung Cancer Risk in the Korean Population. H.K. KIM, H.-Y. JUNG, S. LIM, J. S. SUNG, Y.M. WHANG, U. JO, J. LEE, S.W. SHIN, J.S. KIM, J.S. RYU, Y.H. KIM ( <i>Seoul; Incheon, South Korea</i> ) .....	3621
Inhibition of Growth and Induction of Alkaline Phosphatase in Colon Cancer Cells by Flavonols and Flavonol Glycosides. M.A. LEA, C. IBEH, J.K. DEUTSCH, I. HAMID, C. desBORDES ( <i>Newark, NJ; Brooklyn, NY, USA</i> ) .....	3629
The Wilms' Tumor Suppressor WT1 Regulates Expression of Members of the Epidermal Growth Factor Receptor (EGFR) and Estrogen Receptor in Acquired Tamoxifen Resistance. L. WANG, X. ZHANG, Z.-Y. WANG ( <i>Omaha, NE, USA</i> ) .....	3637
Antiproliferative Effect of LXR Agonists T0901317 and 22(R)- Hydroxycholesterol on Multiple Human Cancer Cell Lines. C.-P. CHUU, H.-P. LIN ( <i>Miaoli County, Taiwan, ROC</i> ) .....	3543
Association Study of Cyclooxygenase 2 Single Nucleotide Polymorphisms and Childhood Acute Lymphoblastic Leukemia in Taiwan. C.-H. WANG, K.-H. WU, Y.-L. YANG, C.-T. PENG, R.-F. WANG, C.-W. TSAI, R.-Y. TSAI, D.-T. LIN, F.-J. TSAI, D.-T. BAU ( <i>Taichung; Taipei, Taiwan, ROC</i> ) .....	3649
Synergistic Cytotoxic Effects of Arsenic Trioxide plus Dithiothreitol on Mice Oral Cancer Cells. C.-W. TSAI, N.-W. CHANG, R.-Y. TSAI, R.-F. WANG, C.-M. HSU, S.-S. LIN, C.-N. WU, S.-S. SUN, M.-H. TSAI, D.-T. BAU ( <i>Taichung, Taiwan, ROC</i> ) .....	3655
The Presence of P-glycoprotein in L1210 Cells Directly Induces Down-Regulation of Cell Surface Saccharide Targets of Concanavalin A. Z. SULOVA', P. DITTE, T. KURUCOVA', E. POLAKOVA', K. ROGOZANOVA', L. GIBALOVA', M. SHEREŠ, L. ŠKVARKOVA', J. SEDLÁK, J. PASTOREK, A. BREIER ( <i>Bratislava, Slovak Republic</i> ) .....	3661
Modulation of Gemcitabine Accumulation by DNA-Damaging Agents: Mechanisms and Specificity in an <i>In Vitro</i> Model. E. METHAROM, P. GALETTIS, S. MANNERS, M. LINKS ( <i>Sydney, Australia</i> ) .....	3669
<i>Clinical Studies</i>	
* Review: Novel Chemoradiosensitizers for Cancer Therapy. P. PAGE, L.-X. YANG ( <i>San Francisco, CA, USA</i> ) .....	3675
* Review: Active Surveillance for Low-risk Prostate Cancer. R. MAZZUCHELLI, I. NESSERIS, L. CHENG, A. LOPEZ-BELTRAN, R. MONTIRONI, M. SCARPELLI ( <i>Ancona, Italy; Indianapolis, IN, USA; Ioannina, Greece; Cordoba, Spain</i> ) .....	3683
* Review: The Evolving Role of Radiofrequency Ablation Therapy of Breast Lesions. B. SOUKUP, S. BISMOHUN, S. REEFY, K. MOKBEL ( <i>London, UK</i> ) .....	3693
p27 <sup>kip1</sup> Expression in Non-small Cell Lung Cancer Is not an Independent Prognostic Factor. N. SIONVARDY, J. FREEDMAN, I. LAZAROV, A. BOLOTIN, S. ARIAD ( <i>Beer Sheva, Israel</i> ) .....	3699
Gastric Tumor from Metastasis of Breast Cancer. D. YAMAMOTO, H. YOSHIDA, K. SUMIDA, Y. UEYAMA, S. KANEMATSU, T. SHOJI, N. SUEOKA, K. TANAKA, Y. TSUBOTA, M. KON ( <i>Hirakata, Osaka, Japan</i> ) .....	3705
Immunological Response after Therapeutic Vaccination with <i>WT1</i> mRNA-loaded Dendritic Cells in End-stage Endometrial Carcinoma. A. COOSEMANS, M. WÖLFL, Z.N. BERNEMAN, V. VAN TENDELOO, I. VERGOTE, F. AMANT, S.W. VAN GOOL ( <i>Leuven; Antwerp, Belgium; Wuerzburg, Germany</i> ) .....	3709

Targeted Therapy for Ewing's Sarcoma: Significance of Heterogeneity. A.C.M. VAN DE LUIJTGAARDEN, W.T.A. VAN DER GRAAF, I. OTTE-HÖLLER, H.W.B. SCHREUDER, Y.M.H. VERSLEIJEN-JONKERS, P.J. SLOOTWEG ( <i>Nijmegen, Netherlands</i> ) .....	3715
Importance of Erythropoietin Receptor Expression in Tumour Tissue for the Clinical Course of Breast Cancer. B. VOLGGER, K. KURZ, K. ZÖSCHG, I. THEURL, A. CIRESA-KÖNIG, C. MARTH, G. WEISS ( <i>Innsbruck, Austria</i> ) .....	3721
Long-Term Death Rate in Uterine Clear Cell Carcinoma and Uterine Papillary Serous Carcinoma. B. LINDAHL, J. PERSSON, J. RANSTAM, R. WILLÉN ( <i>Lund; Uppsala, Sweden</i> ) .....	3727
Pattern of Failures and Clinical Outcome of Patients with Locally Advanced Cervical Cancer Treated with a Tailored Integrated Therapeutic Approach. A. GADDUCCI, M.G. FABRINI, F. PERRONE, B. MANFREDI, A. FANUCCHI, C. LALISCIA, C. BARSOTTI, V. SCOTTI, A.R. GENAZZANI, C. GRECO ( <i>Pisa, Italy</i> ) .....	3731
Combination Therapy with VP16 and Ethinylestradiol for Hormone-Refractory Prostate Cancer: Good Response with Tolerability. H. AZUMA, T. INAMOTO, K. TAKAHARA, N. IBUKI, K. KOYAMA, S. UTIMOTO, Y. FUJISUE, H. UEHARA, K. KOMURA, H. NOMI, T. UBAI, Y. KATSUOKA ( <i>Takatsuki, Osaka, Japan</i> ) .....	3737
Surface-bound TGF- $\beta$ 1 on Effusion-derived Exosomes Participates in Maintenance of Number and Suppressive Function of Regulatory TCells in Malignant Effusions. J. WADA, H. ONISHI, H. SUZUKI, A. YAMASAKI, S. NAGAI, T. MORISAKI, M. KATANO ( <i>Fukuoka, Japan</i> ) .....	3747
Feasibility and Efficacy of Combination Chemotherapy with S-1 and Fractional Cisplatin for Advanced Gastric Cancer. T. TAKAHASHI, Y. SAIKAWA, H. TAKAISHI, H. TAKEUCHI, N. WADA, T. OYAMA, R. NAKAMURA, Y. KITAGAWA ( <i>Tokyo, Japan</i> ) .....	3759
A Case of Esophageal Cancer Showing Complete Remission of Nephrotic Syndrome after Esophagectomy. Y. NARITAKA, S. ASAKA, A. MIYAKI, N. ISOHATA, T. SHIMAKAWA, K. YAMAGUCHI, T. KATSUBE, T. MURAOKA, S. SHIOZAWA, K. YOSHIMATSU, K. OGAWA ( <i>Tokyo, Japan</i> ) .....	3763
Desmoplastic Small Round Cell Tumour Successfully Treated with Caffeine-assisted Chemotherapy: A Case Report and Review of the Literature. S. MIWA, S. KITAMURA, T. SHIRAI, K. HAYASHI, H. NISHIDA, A. TAKEUCHI, T. NOJIMA, H. TSUCHIYA ( <i>Kanazawa; Kahoku, Japan</i> ) .....	3769
Dermatofibrosarcoma Protuberans: A Case Series of 16 Patients Treated in a Single Institution with Literature Review. M. ARCHONTAKI, D.P. KORKOLIS, N. ARNOGIANNAKI, C. KONSTANTINIDOU, S. GEORGOPOULOS, P. DENDRINOS, G. ZARKADAS, G. KOKKALIS ( <i>Athens, Greece</i> ) .....	3775
Re-irradiation of Head and Neck Cancer—Impact of Total Dose on Outcome. S. JANSSEN, M. BAUMGARTNER, M. BREMER, A. WARSZAWSKI, M. STIEVE, A. ECKARDT, J.-H. KARSTENS, A. MEYER ( <i>Hannover, Germany</i> ) .....	3781
Evaluation of FDG–PET for Detecting Lymph Node Metastasis in Uterine Corpus Cancer. M. KLAR, P.T. MEYER, K. HANCKE, I. BRINK, M. ORLOWSKA-VOLK, G. GITSCH, D. DENSCHLAG ( <i>Freiburg, Germany</i> ) .....	3787
Complete Response Obtained by Bortezomib plus Dexamethasone in a Patient with Relapsed Multiple Myeloma with Multiple Plasmacytomas. T. FUKUSHIMA, T. NAKAMURA, M. MIKI, T. SAKAI, H. IWAO, A. NAKAJIMA, T. SAWAKI, Y. FUJITA, M. TANAKA, Y. MASAKI, Y. HIROSE, H. UMEHARA ( <i>Ishikawa, Japan</i> ) .....	3791
Functional Results after Giant Cell Tumor Operation near Knee Joint and the Cement Radiolucent Zone as Indicator of Recurrence. K. KAFCHITSAS, B. HABERMANN, D. PROSCHEK, A. KURTH, C. EBERHARDT ( <i>Mainz; Hanau, Germany</i> ) .....	3795



The Role of Inflammation in Patients with Intraductal Mucinous Neoplasm of the Pancreas and in those with Pancreatic Adenocarcinoma. R. PEZZILLI, M.M. CORSI, A. BARASSI, A.M. MORSELLI-LABATE, G. DOGLIOTTI, R. CASADEI, R. CORINALDESI, G. MELZI D'ERIL ( <i>Bologna; Milan, Italy</i> ) .....	3801
Delayed Elimination of Methotrexate Associated with Co-Administration of Proton Pump Inhibitors. R. SANTUCCI, D. LEVÊQUE, A. LESCOUTE, V. KEMMEL, R. HERBRECHT ( <i>Strasbourg, France</i> ).....	3807
Randomized Follow-up Study of Resected NSCLC Patients: Conventional <i>versus</i> <sup>18</sup> F-DG Coincidence Imaging. J. MONTEIL, A. VERGNENÈGRE, F. BERTIN, F. DALMAY, S. GAILLARD, F. BONNAUD, B. MELLONI ( <i>Limoges, France</i> ).....	3811
Phase II Study of Neoadjuvant Gemcitabine, Pegylated Liposomal Doxorubicin, and Docetaxel in Locally Advanced Breast Cancer. G. ARTIOLI, S. MOCELLIN, L. BORGATO, A. CAPPETTA, F. BOZZA, G. ZAVAGNO, S. ZOVATO, A. MARCHET, D. PASTORELLI ( <i>Padova, Italy</i> ) .....	3817
Psychological Response to Cancer: Role of 5-HTTLPR Genetic Polymorphism of Serotonin Transporter. G. SCHILLANI, E. MARTINIS, M.A. CAPOZZO, D. ERA, T. CRISTANTE, G. MUSTACCHI, M.A. CONTE, M. DE VANNA, L. GRASSI, T. GIRALDI ( <i>Trieste; Ferrara, Italy</i> ) .....	3823
Efficacy of S-1 in Patients with Capecitabine-resistant Breast Cancer–Japan Breast Cancer Research Network (JBCRN) 04-1 Trial. D. YAMAMOTO, S. IWASE, H. YOSHIDA, Y. KURODA, C. YAMAMOTO, K. KITAMURA, H. ODAGIRI, Y. NAGUMO ( <i>Osaka; Tokyo; Fukuoka; Hirosaki, Japan</i> ) .....	3827
Optimal Cutoff Points of CYFRA21-1 for Survival Prediction in Non-small Cell Lung Cancer Patients Based on Running Statistical Analysis. H. TAKAHASHI, K. KURISHIMA, H. ISHIKAWA, K. KAGOHASHI, M. KAWAGUCHI, H. SATOH ( <i>Tsukuba, Ibaraki, Japan</i> ) .....	3833
Combined Chemotherapy with Gemcitabine and Cisplatin for Metastatic Urothelial Carcinomas in Patients 80 Years of Age and Over. N. TANJI, T. FUKUMOTO, N. MIURA, Y. YANAGIHARA, K. AZUMA, T. SASAKI, T. NISHIDA, T. KIKUGAWA, K. SHIMAMOTO, K. AOKI, M. YOKOYAMA ( <i>Toon, Ehime, Japan</i> ) .....	3839
Autologous Stem Cell Transplantation for Patients with Acute Promyelocytic Leukemia in Second Molecular Remission. F. FERRARA, O. FINIZIO, T. IZZO, C. RICCARDI, C. CRISCUOLO, A. CARBONE, E. BORLENGHI, G. ROSSI ( <i>Naples; Brescia, Italy</i> ) .....	3845
Errata .....	3851
* Reviews (pages 3223, 3233, 3675, 3683, 3693)	

## Number 10

### *Experimental Studies*

Inhibition of Notch Signaling Reduces the Stem-like Population of Breast Cancer Cells and Prevents Mammosphere Formation. P. GRUDZIEN, S. LO, K.S. ALBAIN, P. ROBINSON, P. RAJAN, P.R. STRACK, T.E. GOLDE, L. MIELE, K.E. FOREMAN ( <i>Maywood, IL; Boston, MA; Jacksonville, FL, USA</i> ) .....	3853
Inhibition of BCL-2 in Small Cell Lung Cancer Cell Lines with Oblimersen, an Antisense BCL-2 Oligodeoxynucleotide (ODN): <i>In Vitro</i> and <i>In Vivo</i> Enhancement of Radiation Response. Y. LORIOT, P. MORDANT, B.D. BROWN, J. BOURHIS, J.-C. SORIA, E. DEUTSCH ( <i>Villejuif; Paris, France; Berkeley Heights, NJ, USA</i> ) .....	3869
5-Fluorouracil-induced Death of Jurkat T-Cells – A Role for Caspases and MCL-1. D.M. ARESVIK, R.D. PETTERSEN, T.G. ABRAHAMSEN, M.S. WRIGHT ( <i>Oslo, Norway</i> ) .....	3879

* Review: Poly- <i>N</i> -acetyl Glucosamine Gel Matrix as a Non-Viral Delivery Vector for DNA-Based Vaccination. M.L. SALEM, M. DEMCHEVA, W.E. GILLANDERS, D.J. COLE, J.N. VOURNAKIS ( <i>Tanta, Egypt; Charleston, SC; Danvers, MA ; Saint Louis, MO, USA</i> ) .....	3889
Androgen Receptor-mTOR Crosstalk is Regulated by Testosterone Availability: Implication for Prostate Cancer Cell Survival. Y. WU, R.R. CHHIPA, J. CHENG, H. ZHANG, J.L. MOHLER, C. IP ( <i>Buffalo, NY; New Orleans, LA; Chapel Hill, NC, USA</i> ) .....	3895
E-Cadherin Accumulation within the Lymphovascular Embolus of Inflammatory Breast Cancer Is Due to Altered Trafficking. Y. YE, J.D. TELLEZ, M. DURAZO, M. BELCHER, K. YEARSLEY, S.H. BARSKY ( <i>Reno; Las Vegas, NV; Columbus, OH, USA</i> ) .....	3903
Synergistic Effects of Topoisomerase I Inhibitor, SN38, on Fas-mediated Apoptosis. Y. CAO, Z.-X. JIN, X.-P. TONG, S. YUE, T. SAKAI, T. KAWANAMI, T. SAWAKI, M. MIKI, H. IWAO, A. NAKAJIMA, Y. MASAKI, Y. FUKUSHIMA, Y. FUJITA, H. NAKAJIMA, T. OKAZAKI, H. UMEHARA ( <i>Kahoku-gun, Ishikawa; Yonago, Tottori, Japan; Shenyang, PR China</i> ) .....	3911
Methylation-mediated Silencing of <i>TMS1</i> in Pancreatic Cancer and its Potential Contribution to Chemosensitivity. K. RAMACHANDRAN, H. MILLER, E. GORDIAN, C. ROCHA-LIMA, R. SINGAL ( <i>Miami, FL, USA</i> ) .....	3919
Second-generation Substituted Quinolines as Anticancer Drugs for Breast Cancer. B. HEINIGER, G. GAKHAR, K. PRASAIN, D.H. HUA, T.A. NGUYEN ( <i>Manhattan, KS, USA</i> ) .....	3927
Orthotopic Fluorescent Peritoneal Carcinomatosis Model of Esophageal Cancer. S.J. GROS, T. DOHRMANN, T. RAWNAQ, N. KURSCHAT, M. BOUVET, J. WESSELS, R.M. HOFFMANN, J.R. IZBICKI, J.T. KAIFI ( <i>Hamburg; Goettingen, Germany; San Diego, CA, USA</i> ).....	3933
A Positive Relationship Between Filamin and VEGF in Patients with Lung Cancer. H. URAMOTO, L.M. AKYÜREK, T. HANAGIRI ( <i>Kitakyushu, Japan; Gothenburg, Sweden</i> ) .....	3939
Effects of ILTG on <i>DAPK1</i> Promoter Methylation in Colon and Leukemia Cancer Cell Lines. B.A ZORKO, L.B. PÉREZ, E.J. CARCACHE DE BLANCO ( <i>Columbus, OH, USA</i> ) .....	3945
Inhibition of GST-pi Nuclear Transfer Increases Mantle Cell Lymphoma Sensitivity to Cisplatin, Cytarabine, Gemcitabine, Bortezomib and Doxorubicin. D. ROLLAND, M. RAHARIJAONA, A. BARBARAT, R. HOULGATTE, C. THIEBLEMONT ( <i>Grenoble; Nantes; Lyon; Paris, France</i> ) .....	3951
IL-1 Receptor Antagonist Anakinra Enhances Tumour Growth Inhibition in Mice Receiving Peptide Vaccination and $\beta$ -(1-3),(1-6)-D-Glucan. U. HARNACK, H. JOHNEN, G. PECHER ( <i>Berlin, Germany</i> ).....	3959
Salen-Manganese Complexes: Sophisticated Tools for the Analysis of Intercellular ROS Signaling Pathways. S.J. OPHOVEN, G. BAUER ( <i>Freiburg, Germany</i> ).....	3967
Endocrine Gland Derived-VEGF Is Down-regulated in Human Pituitary Adenoma. M. RAICA, M. COCULESCU, A.M. CIMPEAN, D. RIBATTI ( <i>Timisoara; Bucharest, Romania; Bari, Italy</i> ) .....	3981
Evaluation of <i>In Vitro</i> Biological Activity of <i>O</i> -Alkylated Hydroxamic Derivatives of Some Nonsteroidal Anti-inflammatory Drugs. S. KRALJEVIĆ PAVELIĆ, M. SEDIĆ, M. POZNIĆ, Z. RAJIĆ, B. ZORC, K. PAVELIĆ, J. BALZARINI, M. MINTAS ( <i>Rijeka; Zagreb, Croatia; Leuven, Belgium</i> ) .....	3987
PKC $\alpha/\beta$ I Inhibitor Go6976 Induces Dephosphorylation of Constitutively Hyperphosphorylated Rb and G1 Arrest in T24Cells. V. AALTONEN, J. PELTONEN ( <i>Turku, Finland</i> ) .....	3995

Staining with Highly Sensitive Coomassie Brilliant Blue SeePico™ Stain after Flamingo™ Fluorescent Gel Stain Is Useful for Cancer Proteomic Analysis by Means of Two-dimensional Gel Electrophoresis. Y. KURAMITSU, E. HAYASHI, F. OKADA, X. ZHANG, T. TANAKA, Y. UEYAMA, K. NAKAMURA ( <i>Ube; Yamagata, Japan</i> ) .....	4001
Curcumin-altered p53-Response Genes Regulate Radiosensitivity in p53-Mutant Ewing's Sarcoma Cells. J. VEERARAGHAVAN, M. NATARAJAN, T.S HERMAN, N. ARAVINDAN ( <i>Oklahoma City, OK; San Antonio, TX, USA</i> ) .....	4007
Antiproliferative Effects of Rapamycin and Celecoxib in Angiosarcoma Cell Lines. A. BUNDSCHERER, T. VOGT, G. KÖHL, M. LANDTHALER, C. HAFNER ( <i>Regensburg, Germany</i> ) .....	4017
Studies on Combinations of Platinum with Paclitaxel and Colchicine in Ovarian Cancer Cell Lines. N.M. YUNOS, P. BEALE, J.Q. YU, D. STRAIN, F. HUQ ( <i>Sydney, NSW, Australia; Kepong Selangor, Malaysia</i> ) .....	4025
Multimodality Imaging and Preclinical Evaluation of <sup>177</sup> Lu-AMBA for Human Prostate Tumours in a Murine Model. I-H. LIU, C.-H. CHANG, C.-L. HO, S.-P. CHIU, W.-C. LEE, T.-J. CHANG, L.-C. CHEN, Y.-H. WU, C.-H. CHUANG, Y.-K. FU, T.-W. LEE ( <i>Taoyuan; Taipei, Taiwan, ROC</i> ) .....	4039
Sodium Butyrate with UCN-01 Has Marked Antitumour Activity against Cervical Cancer Cells. A.-Z. DECRION-BARTHOD, M. BOSSET, M.-L. PLISSONNIER, A. MARCHINI, M. NICOLIER, S. LAUNAY, J.-L. PRITET, J. ROMMELAERE, C. MOUGIN ( <i>Besançon, France; Heidelberg, Germany</i> ).....	4049
Reversal of Multidrug Resistance in Murine Lymphoma Cells by Amphiphilic Dihydropyridine Antioxidant Derivative. M. CINDRIC, A. CIPAK, J. SERLY, A. PLOTNIECE, M. JAGANJAC, L. MRAKOVIC, T. LOVAKOVIC, A. DEDIC, I. SOLDI, G. DUBURS, N. ZARKOVIC, J. MOLNÁR ( <i>Zagreb; Osijek, Croatia; Szeged, Hungary; Riga, Latvia; Vienna, Austria</i> ) .....	4063
γ-Secretase Inhibitors Induce Erythroid Differentiation in Erythroid Leukemia Cell Lines. Y. OKUHASHI, M. ITOH, A. ARAI, N. NARA, S. TOHDA ( <i>Tokyo, Japan</i> ).....	4071
Nanodiamond and Nanoplatinum Liquid, DPV576, Activates Human Monocyte-derived Dendritic Cells <i>In Vitro</i> . M. GHONEUM, A. GHONEUM, J. GIMZEWSKI ( <i>Los Angeles, CA, USA</i> ) .....	4075
Evaluation of HER-2/ <i>neu</i> Gene Amplification by Fluorescence <i>In Situ</i> Hybridization and Immunohistochemistry in Saudi Female Breast Cancer. H. AL-KHATTABI, A. KELANY, A. BUHMEIDA, J. AL-MAGHRABI, S. LARI, A. CHAUDHARY, M. GAR, A. ABUZENADAH, M. AL-QAHTANI ( <i>Jeddah, Kingdom of Saudi Arabia</i> ).....	4081
Bacillus Calmette-Guerin and BCG Cell Wall Skeleton Suppressed Viability of Bladder Cancer Cells <i>In Vitro</i> . T. KATO, V. BILIM, K. YUUKI, S. NAITO, T. YAMANOBE, A. NAGAOKA, I. YANO, H. AKAZA, Y. TOMITA ( <i>Yamagata; Tokyo; Ibaraki-ken, Japan</i> ) .....	4089
Soluble MICB Serum Levels Correlate with Disease Stage and Survival Rate in Patients with Oral Squamous Cell Carcinoma. S. TAMAKI, M. KAWAKAMI, A. ISHITANI, W. KAWASHIMA, S. KASUDA, Y. YAMANAKA, H. SHIMOMURA, Y. IMAI, Y. NAKAGAWA, K. HATAKE, T. KIRITA ( <i>Kashihara, Nara, Japan</i> ) .....	4097
Isomorph Expression of <i>BAG-1</i> Gene, ER and PR in Endometrial Cancer. O. PORICHI, M.-E. NIKOLAIDOU, A. APOSTOLAKI, N. ARNOGIANNAKI, I. PAPASSIDERI, I. CHATONIDIS, A. TSERKEZOGLU, G. VORGAS, D. KASSANOS, E. PANOTOPOULOU ( <i>Athens, Greece</i> ) .....	4103
Vitamin B2 as a Tracer for Intraoperative Pulmonary Sentinel Node Navigation Surgery. I. MATSUMOTO, Y. OHTA, R. WASEDA, M. TAMURA, M. ODA, G. WATANABE ( <i>Kanazawa, Japan</i> ) .....	4109

Significance of Keratinocyte Growth Factor Receptor in the Proliferation of Biliary Tract Cancer. R. AMANO, N. YAMADA, Y. DOI, M. YASHIRO, M. OHIRA, A. MIWA, K. HIRAKAWA ( <i>Osaka; Tokyo, Japan</i> ) .....	4115
Further Studies on Barretts Mucosa in Baboons: Metaplastic Glandular Cells Produce Sialomucin. C.A. RUBIO, M. OWSTON, A. ORREGO, E.J. DICK Jr. ( <i>San Antonio, TX, USA</i> ).....	4123
Overexpression of Tissue Inhibitor of Metalloproteinase-1 Gene Correlates with Poor Outcomes in Colorectal Cancer. D. INAGAKI, T. OSHIMA, K. YOSHIHARA, S. TAMURA, A. KANAZAWA, T. YAMADA, N. YAMAMOTO, T. SATO, M. SHIOZAWA, S. MORINAGA, M. AKAIKE, S. FUJII, K. NUMATA, C. KUNISAKI, Y. RINO, K. TANAKA, M. MASUDA, T. IMADA ( <i>Yokohama-shi, Kanagawa-ken, Japan</i> ) .....	4127
Methylation of the <i>TFPI2</i> Gene Is Frequently Detected in Advanced Gastric Carcinoma. K. HIBI, T. GOTO, Y.-H. KITAMURA, K. SAKURABA, A. SHIRAHATA, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA ( <i>Yokohama, Japan</i> ).....	4131
<i>SLC34A2</i> as a Novel Marker for Diagnosis and Targeted Therapy of Breast Cancer. D.-R. CHEN, S.-Y. CHIEN, S.-J. KUO, Y.-H. TENG, H.-T. TSAI, J.-H. KUO, J.-G. CHUNG ( <i>Changhua; Taichung, Taiwan, ROC</i> ) .....	4135
The Joint Effect of <i>hOGG1</i> Single Nucleotide Polymorphism and Smoking Habit on Lung Cancer in Taiwan. C.-J. LIU, T.-C. HSIA, R.-Y. TSAI, S.-S. SUN, C.-H. WANG, C.-C. LIN, C.-W. TSAI, C.-Y. HUANG, C.-M. HSU, D.-T. BAU ( <i>Taichung, Taiwan, ROC</i> ) .....	4141
Real-Time PCR: Detection of Oestrogen Receptor-Alpha and -Beta Isoforms and Variants in Breast Cancer. M. AL-BADER, S. AL-SAJI, C.H.J. FORD, I. FRANCIS, B. AL-AYADHY ( <i>Kuwait city, Kuwait</i> ) .....	4147
CRIM1 is Expressed at Higher Levels in Drug-resistant than in Drug-sensitive Myeloid Leukemia HL60 Cells. M. PRENKERT, B. UGGLA, U. TIDEFELT, H. STRID ( <i>Örebro, Sweden</i> ) .....	4157
Clinicopathological Significance of p53, Hypoxia-inducible Factor 1 $\alpha$ , and Vascular Endothelial Growth Factor Expression in Colorectal Cancer. H.-C. KWON, S.H. KIM, S.Y. OH, S. LEE, K.A KWON, H.-J. CHOI, K.-J. PARK, H.-J. KIM, M.S. ROH ( <i>Busan, Republic of Korea</i> ) .....	4163
Differential Suppression of Proliferation in MCF-7 and MDA-MB-231 Breast Cancer Cells Exposed to $\alpha$ -, $\gamma$ - and $\delta$ -Tocotrienols Is Accompanied by Altered Expression of Oxidative Stress Modulatory Enzymes. T.-C. HSIEH, S. ELANGO VAN, J.M. WU ( <i>Valhalla, NY, USA</i> ).....	4169
Up-regulation of Fibronectin and Tissue Transglutaminase Promotes Cell Invasion Involving Increased Association with Integrin and MMP Expression in A431 Cells. S.-H. CHEN, C.-Y. LIN, L.-T. LEE, G.-D. CHANG, P.-P. LEE, C.-C. HUNG, W.-T. KAO, P.-H. TSAI, A.V. SCHALLY, J.-J. HWANG, M.-T. LEE ( <i>Taipei; Keelung, Taiwan, ROC; Miami, FL, USA</i> ) .....	4177
The Novel Quinolone CHM-1 Induces DNA Damage and Inhibits DNA Repair Gene Expressions in a Human Osterogenic Sarcoma Cell Line. H.-Y. CHEN, H.-F. LU, J.-S. YANG, S.-C. KUO, C. LO, M.-D. YANG, T.-H. CHIU, F.-S. CHUEH, H.-C. HO, Y.-C. KO, J.-G. CHUNG ( <i>Taichung; Taipei; Chiayi, Taiwan, ROC</i> ) ....	4187
Inhibition of Myc Effectively Targets <i>KRAS</i> Mutation-positive Lung Cancer Expressing High Levels of Myc. T. FUKAZAWA, Y. MAEDA, J. MATSUOKA, T. YAMATSUJI, K. SHIGEMITSU, I. MORITA, F. FAIOLA, M.L. DURBIN, L. SOUCEK, Y. NAOMOTO ( <i>Okayama, Japan; Cincinnati, OH; Riverside; Irvine; San Francisco, CA, USA</i> ) .....	4193
Antitumour and Cytogenetic Effects of Modified Steroidal Derivatives of Propenoic Acid: <i>In Vivo/In Vitro</i> Studies. A. PAPAGEORGIOU, C. MOURELATOS, G. GEROMICHALOS, E. GEROMICHALOU, P. DALEZIS, T. LIALIARIS ( <i>Thessaloniki; Alexandroupolis; Ioannina, Greece</i> ) .....	4201

The Joint Effect of <i>hOGG1</i> Single Nucleotide Polymorphism and Betel Quid Chewing on Oral Cancer in Taiwan. Y.-A. TSOU, C.-H. HUA, H.-C. TSENG, C.-F. HSU, C.-W. TSAI, S.-S. SUN, R.-Y. TSAI, M.-H. TSAI, D.-T. BAU ( <i>Taichung; Chang-Hua, Taiwan, ROC</i> ) .....	4205
<i>Clinical Studies</i>	
Molecular Predictors of Combination Targeted Therapies (Cetuximab, Bevacizumab) in Irinotecan-Refractory Colorectal Cancer (BOND-2 Study). W. ZHANG, M. AZUMA, G. LURJE, M.A. GORDON, D. YANG, A. POHL, Y. NING, P. BOHANES, A. GERGER, T. WINDER, E. HOLLYWOOD, K.D. DANENBERG, L. SALTZ, H.-J. LENZ ( <i>Los Angeles, CA; New York, NY, USA</i> ) .....	4209
EGFR-Activating Mutations Are Not Present in Breast Tumors of Japanese Patients. H. URAMOTO, H. SHIMOKAWA, Y. NAGATA, K. ONO, T. HANAGIRI ( <i>Kitakyushu, Japan</i> ) .....	4219
L-type Amino-Acid Transporter 1 Expression Predicts the Response to Preoperative Hyperthermo-Chemoradiotherapy for Advanced Rectal Cancer. T. EBARA, K. KAIRA, J.-I. SAITO, M. SHIOYA, T. ASAO, T. TAKAHASHI, H. SAKURAI, Y. KANAI, H. KUWANO, T. NAKANO ( <i>Maebashi, Gunma; Ibaraki; Osaka, Japan</i> ) .....	4223
Concordant Analysis of KRAS Status in Primary Colon Carcinoma and Matched Metastasis. P. MARIANI, M. LAE, A. DEGEORGES, W. CACHEUX, E. LAPPARTIENT, A. MARGOGNE, J.-Y. PIERGA, V. GIRRE, L. MIGNOT, M.C. FALCOU, R.-J. SALMON, O. DELATTRE, P. DE CREMOUX ( <i>Paris, France</i> ) .....	4229
Weekly Chemoradiation (Docetaxel/Cisplatin) Followed by Surgery in Stage III NSCLC; a Multicentre Phase II Study. K.W. MAAS, S.Y. EL SHAROUNI, E.C.J. PHERNAMBUCQ, J.A. STIGT, H.J.M. GROEN, G.J.M. HERDER, B.E.E.M. VAN DEN BORNE, S. SENAN, M.A. PAUL, E.F. SMIT, F.M.N.H. SCHRAMEL ( <i>Nieuwegein; Utrecht; Amsterdam; Zwolle; Groningen; Eindhoven, Netherlands</i> ) .....	4237
Use of Paclitaxel for Advanced Ovarian Cancer in Clinical Practice: Analysis of 541 Patients. Results from a German Multi-centre Observational Study. J. SEHOULI, G. OSKAY-ÖZCELIK ( <i>Berlin, Germany</i> ).....	4245
Impact of Tumor Biology, Particularly Triple-negative Status, on Response to Pre-operative Sequential, Dose-dense Epirubicin, Cyclophosphamide Followed by Docetaxel in Breast Cancer. M. WARM, R. KATES, E.M. GROSSE-ONNEBRINK, M. STOFF-KHALILI, M. HOOPMANN, P. MALLMANN, A. THOMAS, N. HARBECK ( <i>Cologne; Otterfing; Berlin, Germany</i> ) .....	4251
Assessing Risk and Mortality of Venous Thromboembolism in Pancreatic Cancer Patients. W. SHAIB, Y. DENG, D. ZILTERMAN, B. LUNDBERG, M.W. SAIF ( <i>New Haven, CT; New York, NY, USA</i> ) .....	4261
Atlanto-occipital Ligament Calcification: A Novel Sign in Nevoid Basal Cell Carcinoma Syndrome. R. LEONARDI, A. SANTARELLI, E. BARBATO, D. CIAVARELLA, S. BOLOURI, F. HÄRLE, G. PALAZZO, L. LO MUZIO ( <i>Catania; Foggia; Rome; Rioniero in Vulture, Italy; Kiel, Germany</i> ) .....	4265
Dual Role of RASSF1 as a Tumor Suppressor and an Oncogene in Neuroendocrine Tumors of the Lung. G. PELOSI, C. FUMAGALLI, M. TRUBIA, A. SONZOGNI, N. REKHTMAN, P. MAISONNEUVE, D. GALETTA, L. SPAGGIARI, G. VERONESI, A. SCARPA, G. MALPELI, G. VIALE ( <i>Milan; Verona, Italy; New York, NY, USA</i> ) .....	4269
Late Metastasis of Gastrointestinal Stromal Tumour to the Oral Cavity. R.E. FRIEDRICH, J. ZUSTIN ( <i>Hamburg, Germany</i> ) .....	4283
Clinical and Molecular Determinants of Survival in Pancreatic Cancer Patients Treated with Second-line Chemotherapy: Results of an Italian/Swiss Multicenter Survey. A. MANCUSO, S. SACCHETTA, P.C. SALETTI, C. TRONCONI, L. MILESI, M. GARASSINO, O. MARTELLI, A. LEONE, A. ZIVI, L. CERBONE, F. RECINE, R. SOLLAMI, R. LABIANCA, F. CAVALLI, C.N. STERNBERG ( <i>Rome; Milan; Bergamo, Italy; Bellinzona, Switzerland</i> ) .....	4289

Prognostic Impact of Microsatellite Instability in Colorectal Cancer Patients Treated with Adjuvant FOLFOX. G. DES GUETZ, C. LECAILLE, P. MARIANI, M. BENNAMOUN, B. UZZAN, P. NICOLAS, A. BOISSEAU, X. SASTRE, J. CUCHEROUSET, C. LAGORCE, P.O. SCHISCHMANOFF, J.F. MORERE ( <i>Bobigny; Bordeaux; Paris; Montfermeil, France</i> ) .....	4297
Life Stress due to Losses and Deficit in Childhood and Adolescence as Breast Cancer Risk Factor: A Prospective Case-Control Study in Kuopio, Finland. M. ESKELINEN, P. OLLONEN ( <i>Kuopio, Finland</i> ).....	4303
TS, DHFR and GARFT Expression in Non-squamous Cell Carcinoma of NSCLC and Malignant Pleural Mesothelioma Patients Treated with Pemetrexed. H. URAMOTO, T. ONITSUKA, H. SHIMOKAWA, T. HANAGIRI ( <i>Kitakyushu, Japan</i> ).....	4309
Metronomic Oral Cyclophosphamide Prednisolone Chemotherapy Is an Effective Treatment for Metastatic Hormone-refractory Prostate Cancer after Docetaxel Failure. S. LADOIRE, J.C. EYMARD, S. ZANETTA, G. MIGNOT, E. MARTIN, I. KERMARREC, E. MOUREY, F. MICHEL, L. CORMIER, F. GHIRINGHELLI ( <i>Dijon; Reims, France</i> ) .....	4317
Irinotecan/Fluorouracil/Leucovorin or the Same Regimen Followed by Oxaliplatin/Fluorouracil/ Leucovorin in Metastatic Colorectal Cancer. H.P. KALOFONOS, P. PAKOSTAS, T. MAKATSORIS, D. PAPAMICHAEL, G. VOURLI, I. XANTHAKIS, G. ARAVANTINOS, C. PAPADIMITRIOU, G. PENTHEROUDAKIS, I. VARTHALITIS, G. SAMELIS, K.N. SYRIGOS, N. XIROS, M. STAVROPOULOS, P. KOSMIDIS, C. CHRISTODOULOU, H. LINARDOU, M. SKONDRA, D. PECTASIDES, T. ECONOMOPOULOS, G. FOUNTZILAS ( <i>Patras; Athens; Thessaloniki; Ioannina; Chania; Piraeus, Greece; Nicosia, Cyprus</i> ) .....	4325
A Retrospective Analysis of Non-platinum-based First- and Second-line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. A. KOTSAKIS, D. HATZIDAKI, L. VAMVAKAS, N. VARDAKIS, A. KALYKAKI, V. BOZIOELOU, N. ANDROULAKIS, K. KALBAKIS, Z. SARIDAKI, V. GEORGOULIAS, S. AGELAKI ( <i>Athens, Greece</i> ) .....	4335
Cytokeratin 19 Fragment/Carcinoembryonic Antigen Ratio in Pleural Effusion Is a Useful Marker for Detecting Malignant Pleural Mesothelioma. H. SUZUKI, T. HIRASHIMA, M. KOBAYASHI, S. SASADA, N. OKAMOTO, N. UEHARA, M. TAMIYA, Y. MATSUURA, N. MORISHITA, I. KAWASE ( <i>Osaka, Japan</i> )....	4343
Disease-free Interval after Primary Treatment Predicts Prognosis of Recurrent Endometrial Carcinoma. Y. UEDA, Y. MATSUMURA, T. EGAWA-TAKATA, T. MIYAKE, T. MIYATAKE, K. YOSHINO, M. FUJITA, S. MATSUZAKI, T. YOKOYAMA, Y. MIYOSHI, M. YAMASAKI, T. ENOMOTO, T. KIMURA ( <i>Osaka, Japan</i> ) .....	4347
High Prevalence of Human Anti-mouse Antibodies in the Serum of Colorectal Cancer Patients. M. GOTO, K. KURIBAYASHI, Y. UMEMORI, Y. OHE, K. ASANUMA, M. TANAKA, D. KOBAYASHI, N. WATANABE ( <i>Sapporo, Japan</i> ).....	4353
Carboplatin plus Weekly Paclitaxel Treatment in Non-small Cell Lung Cancer Patients with Interstitial Lung Disease. T. SHUKUYA, T. ISHIWATA, M. HARA, K. MURAKI, R. SHIBAYAMA, R. KOYAMA, K. TAKAHASHI ( <i>Tokyo, Japan</i> ) .....	4357
Immunochemical Staining of MT2-MMP Correlates Positively to Angiogenesis of Human Esophageal Cancer. L. CHEN, D. DI, G. LUO, L. ZHENG, Y. TAN, X. ZHANG, N. XU ( <i>Changzhou, Jiangsu, PR China; Lund, Sweden</i> ) .....	4363
Prognostic Value of IL-6 in Localized Prostatic Cancer. J. ALCOVER, X. FILELLA, P. LUQUÉ, R. MOLINA, L. IZQUIERDO, J.M. AUGÉ, A. ALCARAZ ( <i>Barcelona, Spain</i> ).....	4369

Relationship between Thymidylate Synthase (TYMS) Gene Polymorphism and TYMS Protein Levels in Patients with High-risk Breast Cancer. M. FUJISHIMA, H. INUI, Y. HASHIMOTO, T. AZUMI, N. YAMAMOTO, H. KATO, T. HOJO, M. YAMATO, N. MATSUNAMI, H. SHIOZAKI, M. WATATANI ( <i>Osaka, Japan</i> ).....	4373
Cardiopulmonary Toxicity of Different Chemoradiotherapy Combined Regimens for Hodgkin's Disease. A. BUSIA, A. LAFFRANCHI, S. VIVIANI, V. BONFANTE, F. VILLANI ( <i>Milan, Italy</i> ) .....	4381
Errata .....	4389
* Review (page 3889)	

## Number 11

### *Experimental Studies*

MicroRNA-184-Mediated Inhibition of Tumour Growth in an Orthotopic Murine Model of Neuroblastoma. A. TIVNAN, N.H. FOLEY, L. TRACEY, A.M. DAVIDOFF, R.L. STALLINGS ( <i>Dublin, Ireland; Memphis, TN, USA</i> ) .....	4391
Remodeling of the Tumor Microenvironment by Combined Treatment with a Novel Radiosensitizer, $\alpha$ -Sulfoquinovosylmonoacylglycerol ( $\alpha$ -SQMG) and X-irradiation. K. OHTA, H. MURATA, Y. MORI, M. ISHIMA, F. SUGAWARA, K. SAKAGUCHI, M. MIURA ( <i>Tokyo; Chiba, Japan</i> ) .....	4397
Impact of the Src Inhibitor Saracatinib on the Metastatic Phenotype of a Fibrosarcoma (KHT) Tumor Model. M. DONG, L. RICE, S. LEPLER, C. PAMPO, D.W. SIEMANN ( <i>Gainesville, FL, USA</i> ) .....	4405
Real-time Imaging of Tumor Progression in a Fluorescent Orthotopic Mouse Model of Thyroid Cancer. H.S. TRAN CAO, S. KAUSHAL, C.S. SNYDER, W.M. ONGKEKO, R.M. HOFFMAN, M. BOUVET ( <i>San Diego, CA, USA</i> ) .....	4415
Lignans and Norlignans Inhibit Multidrug Resistance Protein 1 (MRP1/ABCC1)-mediated Transport. A. WRÖBEL, P. EKLUND, M. BOBROWSKA-HÄGERSTRAND, H. HÄGERSTRAND ( <i>Wrocław, Poland; Åbo/Turku, Finland</i> ) .....	4423
Vitamin D, Calcidiol and Calcitriol Regulate Vitamin D Metabolizing Enzymes in Cervical and Ovarian Cancer Cells. M. KLOSS, D. FISCHER, M. THILL, M. FRIEDRICH, T. CORDES, D. SALEHIN, K. DIEDRICH, F. KÖSTER ( <i>Lübeck; Krefeld, Germany</i> ).....	4429
Intraductal Tubular Carcinoma of the Pancreas: Case Report with Review of Literature. M. HIOKI, T. NAKAGOHRI, T. IKUMOTO, N. GOTOHDA, S. TAKAHASHI, M. KONISHI, M. KOJIMA, T. KINOSHITA ( <i>Kanagawa; Kobe; Chiba, Japan</i> ) .....	4435
Sporadic <i>TP53</i> Transition Mutations in Chronic Cholecystitis Are Possibly Linked to Gallbladder Carcinogenesis. N. YANAGISAWA, K. YAMASHITA, T. KUBA, I. OKAYASU ( <i>Kanagawa, Japan</i> ) .....	4443
Specific Copy Number Alterations Associated with Docetaxel/Carboplatin Response in Ovarian Carcinomas. L. ÖSTERBERG, K. LEVAN, K. PARTHEEN, U. DELLE, B. OLSSON, K. SUNDFELDT, G. HORVATH ( <i>Gothenburg; Skövde, Sweden</i> ) .....	4451
Proteomic Differential Display Analysis Shows Up-regulation of 14-3-3 Sigma Protein in Human Scirrhoustype Gastric Carcinoma Cells. Y. KURAMITSU, B. BARON, S. YOSHINO, X. ZHANG, T. TANAKA, M. YASHIRO, K. HIRAKAWA, M. OKA, K. NAKAMURA ( <i>Ube; Osaka, Japan</i> ) .....	4459

Effect of Hyperbaric Oxygen on the Anticancer Effect of Artemisinin on Molt-4 Human Leukemia Cells. Y. OHGAMI, C.A. ELSTAD, E. CHUNG, D.Y. SHIRACHI, R.M. QUOCK, H.C. LAI ( <i>Pullman; Seattle, WA; Chico, CA, USA</i> ) .....	4467
Sequential X-Irradiation Induced Acquired Resistance to Oxaliplatin but Increased Sensitivity to Cisplatin in Two Human Teratoma Cell Lines <i>In Vitro</i> . S. EISENMANN, W. VOIGT, T. MÜLLER, W. DEMPKE ( <i>Halle/Saale, Germany</i> ) .....	4471
* Review: Brivanib, A Novel Dual VEGF-R2/bFGF-R Inhibitor. W.C.M. DEMPKE, R. ZIPPEL ( <i>Riesa, Germany</i> ).....	4477
Effect of $\beta 4$ Integrin Knockdown by RNA Interference in Anaplastic Thyroid Carcinoma. T.W. NOH, Y.H. SOUNG, H.I. KIM, H.J. GIL, J.M. KIM, E.J. LEE, J. CHUNG ( <i>Seoul, Republic of Korea; Shreveport, LA, USA</i> ) .....	4485
Altered Expression of Cell Cycle and Apoptotic Proteins in Human Liver Pathologies. A. MITSELOU, D. KARAPIPERIDES, I. NESSERIS, T. VOUGIOUKLAKIS, N. AGNANTIS ( <i>Ioannina; Thessaloniki, Greece</i> ) .....	4493
Sorafenib Modulates the Gene Expression of Multi-drug Resistance Mediating ATP-Binding Cassette Proteins in Experimental Hepatocellular Carcinoma. K. HOFFMANN, C. FRANZ, Z. XIAO, E. MOHR, S. SERBA, M.W. BÜCHLER, P. SCHEMMER ( <i>Heidelberg, Germany</i> ) .....	4503
The Antitumour Effect of $\gamma\delta$ T-Cells is Enhanced by Valproic Acid-induced Up-regulation of NKG2D Ligands. T. SUZUKI, S. TERAOKA, B. ACHARYA, M. NAOE, S. YAMAMOTO, H. OKAMURA, A. GOTOH ( <i>Hyogo; Tokyo, Japan</i> ) .....	4509
Invasion of Human Glioma Cells Is Regulated by Multiple Chloride Channels Including CIC-3. V.C.H. LUI, S.S.S. LUNG, J.K.S. PU, K.N. HUNG, G.K.K. LEUNG ( <i>Pokfulam, Hong Kong, P.R.C.</i> ).....	4515
ITF2357 Interferes with Apoptosis and Inflammatory Pathways in the HL-60 Model: A Gene Expression Study. S. GALIMBERTI, M. CANESTRARO, H. SAVLI, G.A. PALUMBO, D. TIBULLO, B. NAGY, S. PIAGGI, F. GUERRINI, N. CINE, M.R. METELLI, M. PETRINI ( <i>Pisa; Catania, Italy; Kocaeli, Turkey; Budapest, Hungary</i> ) .....	4525
Genistein Increases Gene Expression by Demethylation of <i>WNT5a</i> Promoter in Colon Cancer Cell Line SW1116. Z. WANG, H. CHEN ( <i>Urbana, IL, USA</i> ) .....	4537
Synergism from Combination of Cisplatin and a <i>Trans</i> -Platinum Compound in Ovarian Cancer Cell Lines. A. ALSHEHRI, P. BEALE, J.Q. YU, F. HUQ ( <i>Lidcombe; Sydney, NSW, Australia</i> ) .....	4547
Characterization and Evaluation of the Antitumour Activity of a Dual-targeting Monoclonal Antibody against Claudin-3 and Claudin-4. M. KATO-NAKANO, M. SUZUKI, S. KAWAMOTO, A. FURUYA, S. OHTA, K. NAKAMURA, H. ANDO ( <i>Tokyo, Japan</i> ) .....	4555
Inhibin A Is Down-regulated During Chemotherapy in Patients with Breast Cancer. N. BURKHARDT, J. JÜCKSTOCK, C. KUHN, B. RACK, W. JANNI, C. SCHINDLBECK, H. SOMMER, K. FRIESE, I. MYLONAS ( <i>Munich, Germany</i> ) .....	4563
LOXL4 as a Selective Molecular Marker in Primary and Metastatic Head/Neck Carcinoma. N. SCOLA, T. GÖRÖGH ( <i>Bochum; Kiel, Germany</i> ).....	4567
Analysis of the Cytotoxic Activity of Carboplatin and Gemcitabine Combination. S. WANG, H. ZHANG, L. CHENG, C. EVANS, C.-X. PAN ( <i>Sacramento; Mather, CA; Indianapolis, IN, USA; Changchun, China</i> ).....	4573



EGF-dependent Induction of <i>BCL-x<sub>L</sub></i> and <i>p21<sup>CIP1/WAF1</sup></i> Is Highly Variable in HNSCC Cells – Implications for EGFR-targeted therapies. J. RÜDDEL, V.E. WENNEKES, W. MEISSNER, J.A. WERNER, R. MANDIC ( <i>Marburg, Germany</i> ) .....	4579
Stilbenes as Multidrug Resistance Modulators and Apoptosis Inducers in Human Adenocarcinoma Cells. O. WESOŁOWSKA, J. WIŚNIEWSKI, A. BIELAWSKA-POHL, M. PAPROCKA, N. DUARTE, M.-J. U. FERREIRA, D. DUŚ, K. MICHALAK ( <i>Wrocław, Poland; Lisbon, Portugal</i> ) .....	4587
Methylation of <i>AKAP12a</i> Promoter in Lung Cancer. U.H. JO, Y.M. WHANG, J.S. SUNG, Y.H. KIM ( <i>Seoul, South Korea</i> ) .....	4595
Influence of Clofarabine on Transcriptional Activity of <i>PTEN</i> , <i>APC</i> , <i>RARB2</i> , <i>ZAP70</i> Genes in K562 Cells. K. MAJDA, A. KAUFMAN-SZYMCZYK, K. LUBECKA-PIETRUSZEWSKA, A. BEDNAREK, K. FABIANOWSKA-MAJEWSKA ( <i>Lodz, Poland</i> ) .....	4601
UVB-Activated Indole-3-Acetic Acid Induces Apoptosis of PC-3 Prostate Cancer Cells. S.Y. KIM, J.S. RYU, H. LI, W.-J. PARK, H.-Y. YUN, K.J. BAEK, N.S. KWON, U.D. SOHN, D.-S. KIM ( <i>Seoul, South Korea</i> ) .....	4607
<i>In Vitro</i> Cytotoxicity of Benzopyranone Derivatives with Basic Side Chain Against Human Lung Cell Lines. M.A. MUSA, V.L.D. BADISA, L.M. LATINWO, C. WARYOBA, N. UGOCHUKWU ( <i>Tallahassee, FL, USA</i> ) .....	4613
Additive Growth Inhibition after Combined Treatment of 2-Methoxyestradiol and Conventional Chemotherapeutic Agents in Human Pancreatic Cancer Cells. C. FOTOPOULOU, D. BAUMUNK, S.C. SCHMIDT, G. SCHUMACHER ( <i>Berlin, Germany</i> ) .....	4619
Inhibition of CK2 $\alpha$ and PI3K/Akt Synergistically Induces Apoptosis of CD34 <sup>+</sup> CD38 <sup>-</sup> Leukaemia Cells while Sparing Haematopoietic Stem Cells. J.-W. CHEONG, Y. H. MIN, J.I. EOM, S.J. KIM, H.K. JEUNG, J.S. KIM ( <i>Seoul, South Korea</i> ) .....	4625
<i>Clinical Studies</i>	
Expression of $\beta$ -Catenin, MUC1 and c-Met in Diffuse-type Gastric Carcinomas: Correlations with Tumour Progression and Prognosis. M.F. RETTERSPLITZ, S.P. MÖNIG, S. SCHRECKENBERG, P.M. SCHNEIDER, A.H. HÖLSCHER, H.P. DIENES, S.E. BALDUS ( <i>Cologne; Duesseldorf, Germany; Zuerich, Switzerland</i> ) .....	4635
DNA Content and Methylation of <i>p16</i> , <i>DAPK</i> and <i>RASSF1A</i> Gene in Tumour and Distant, Normal Mucosal Tissue of Head and Neck Squamous Cell Carcinoma Patients. N. LAYTRAGOON-LEWIN, F. CHEN, J. CASTRO, G. ELMBERGER, L.E. RUTQVIST, F. LEWIN, I. TURESSON, J. LUNDGREN ( <i>Uppsala; Jönköping; Stockholm, Sweden</i> ) .....	4643
Prognostic Markers for Detection of Coexistent Carcinoma in High-risk Endometrial Hyperplasia. A. ØRBO, B.T. MOE, M. ARNES, I. PETTERSEN, K. LARSEN, T. EGGEN, K. MYRMEL, K. HANSEN ( <i>Tromsø, Norway</i> ) .....	4649
Caregiver Distress in the Early Phases of Cancer. R. PELLEGRINO, V. FORMICA, I. PORTARENA, S. MARIOTTI, I. GRENGA, G. DEL MONTE, M. ROSELLI ( <i>Rome, Italy</i> ) .....	4657
A Phase II Study of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel with or without Trastuzumab as Primary Systemic Therapy in Locally Advanced Breast Cancer. T. SHIMIZU, A. HIRANO, M. KAMIMURA, K. OGURA, N. KIM, O. WATANABE, J. KINOSHITA, K. KIMURA, K. OGAWA, M. FUJIBAYASHI ( <i>Tokyo, Japan</i> ) .....	4665
* Review: Ras Mutational Status Is a Biomarker for Resistance to EGFR Inhibitors in Colorectal Carcinoma. W.C.M. DEMPKE, V. HEINEMANN ( <i>Riesa; Munich, Germany</i> ) .....	4673

Myxoid Liposarcoma with <i>EWS-CHOP</i> Type 1 Fusion Gene. K. SUZUKI, Y. MATSUI, K. ENDO, T. KUBO, T. HASEGAWA, T. KIMURA, O. OHTANI, N. YASUI ( <i>Toyama; Tokushima; Hokkaido, Japan</i> ) .....	4679
Ectomesenchymal Chondromyxoid Tumour of the Tongue. A Review of Histological and Immunohistochemical Features. F. ANGIERO ( <i>Monza, Italy</i> ) .....	4685
Video-assisted Thoracoscopic Pericardiectomy for Malignant Pericardial Effusion. H. URAMOTO, T. HANAGIRI ( <i>Kitakyushu, Japan</i> ).....	4691
A Randomized Phase II Trial of Adjuvant Chemotherapy with Bi-weekly Carboplatin plus Paclitaxel versus Carboplatin plus Gemcitabine in Patients with Completely Resected Non-small Cell Lung Cancer. H. URAMOTO, R. NAKANISHI, A. NAGASHIMA, A. UCHIYAMA, M. INOUE, T. OSAKI, T. YOSHIMATSU, H. SAKATA, K. NAKANISHI, K. YASUMOTO ( <i>Kitakyushu; Joetsu; Iizuka; Fukuoka, Japan</i> ) .....	4695
Hormone Receptor Rate, MIB-1 Score and Serum Tumour Markers CEA and CA 15-3 Relationship in Elderly Women with pT1-2 Breast Cancer. F. LUMACHI, L. NORBERTO, F. MARINO, S.M.M. BASSO, B. MARZANO, G.B. CHIARA ( <i>Padova; Pordenone, Italy</i> ) .....	4701
Prognostic Value of Cytogenetic Analysis in Clear Cell Renal Carcinoma: A Study on 131 Patients with Long-term Follow-up. A. ANTONELLI, N. ARRIGHI, R. TARDANICO, P. BALZARINI, T. ZANOTELLI, S. CORTI, D. ZANI, A. COZZOLI, S.C. CUNICO, C. SIMEONE ( <i>Brescia, Italy</i> ) .....	4705
A Pilot Study of Gemcitabine in Combination with Oxaliplatin and Vinorelbine in Patients with Metastatic Bladder Cancer. D. POUESSEL, H. HUGUET, F. IBORRA, X. REBILLARD, D. AYUSO, C. BECHT, S. CULINE ( <i>Montpellier; Sète, France</i> ).....	4711
Immunohistochemical Staining with DeltaNp63 Is Useful for Distinguishing the Squamous Cell Component of Adenosquamous Cell Carcinoma of the Lung. H. URAMOTO, S. YAMADA, T. HANAGIRI ( <i>Kitakyushu, Japan</i> ) .....	4717
Detection of Circulating Tumor Cells Is Improved by Drug-induced Antigen Up-regulation: Preclinical and Clinical Studies. L. BONMASSAR, E. FOSSILE, A. SCOPPOLA, G. GRAZIANI, S.P. PRETE, V. FORMICA, D. CAPPELLETTI, L. DE VECCHIS, A. CARDILLO, F. CONCOLINO, S. D'ATRI, A. BALDUZZI, F. TORINO, P. CAPORASO, J.W. GREINER, E. BONMASSAR, M. ROSELLI, A. AQUINO ( <i>Rome; Milan, Italy; Bethesda, MD, USA</i> ) .....	4721
c-Kit Expression and Mutations in Phyllodes Tumors of the Breast. P. BOSE, S. TERENCE DUNN, J. YANG, R. ALLEN, C. EL-KHOURY, A. TFAYLI ( <i>Oklahoma, OK, USA</i> ) .....	4731
Comparative Effect of Finasteride and Dutasteride on Chromogranin A Levels. A. SCIARRA, S. SALCICCIA, G. NESI, S. CATTARINO, A. ALFARONE, A. GENTILUCCI, V. GENTILE ( <i>Rome, Italy</i> ).....	4737
Wound Complications after Bevacizumab Treatment in Patients Operated on for Ovarian Cancer. M. KOSKAS, E. CHEREAU, M. BALLESTER, F. SELLE, R. ROUZIER, E. DARAI ( <i>Paris, France</i> ) .....	4743
Adjuvant Hypofractionated Radiotherapy with Weekly Concomitant Boost for Women with Early Breast Cancer: The Clinical Experience at Genoa University. R. CORVÒ, F. RICCHETTI, D. DOINO, P. TORIELLI, S. AGOSTINELLI, F. CAVAGNETTO, F. GIANNELLI, A. D'ALONZO, S. VAGGE, L. BELGIOIA, M. GUENZI ( <i>Genova, Italy</i> ) .....	4749
Chemoradiation-induced Changes in Serum CEA and Plasma TIMP-1 in Patients with Locally Advanced Rectal Cancer. B. ALDULAYMI, I.J. CHRISTENSEN, G. SÖLÉTORMOS, P. JESS, S.E. NIELSEN, S. LAURBERG, N. BRÜNNER, H.J. NIELSEN ( <i>Hillerød; Copenhagen; Aarhus; Frederiksberg; Hvidovre, Denmark</i> ).....	4755

Prognostic Significance of Fluorescent <i>In Situ</i> Hybridisation in the Follow-up of Non-muscle-invasive Bladder Cancer. M. MAFFEZZINI, F. CAMPODONICO, G. CAPPONI, G. CANEPA, S. CASAZZA, R. BANDELLONI, S. TAMAGNO, M. PUNTONI ( <i>Genova, Italy</i> ).....	4761
Neoadjuvant Bevacizumab in a Granulosa Cell Tumor of the Ovary: A Case Report. N.I. BARRENA MEDEL, T.J. HERZOG, J.D. WRIGHT, S.N. LEWIN ( <i>New York, NY, USA; Santiago, Chile</i> ) .....	4767
Cytology on Transbronchial Needle Aspiration (TBNA): Not Only for Lung Cancer. P. BRUNO, L. PISANI, A. RICCI, C. FALASCA, E. GIARNIERI, S. MARIOTTA, M.R. GIOVAGNOLI ( <i>Rome, Italy</i> ) .....	4769
A Multiple Primary Carcinoma Consisting of Leukoplakia and SCC: A Case Report with <i>p53</i> Mutation Analysis. N.M.M. HASSAN, M. TADA, M. SHINDOH, J.-I. HAMADA, H. KASHIWAZAKI, T. SHIMO, Y. ASHIKAGA, Y. YAMAZAKI, A. SASAKI, T. MORIUCHI, N. INOUE ( <i>Okayama; Sapporo, Japan</i> ) ....	4773
HE4 Expression Can Be Associated with Lymph Node Metastases and Disease-free Survival in Breast Cancer. M. KAMEI, S.-I. YAMASHITA, K. TOKUIISHI, T. HASHIOTO, T. MOROGA, S. SUEHIRO, K. ONO, M. MIYAWAKI, S. TAKENO, S. YAMAMOTO, K. KAWAHARA ( <i>Oita, Japan</i> ) .....	4779
XELIRI or FOLFIRI as Salvage Therapy in Advanced Pancreatic Cancer. S. CEREDA, M. RENI, A. ROGNONE, M. GHIDINI, C. BELLI, S. LONGONI, C. FUGAZZA, M. BRIOSCHI, R. NICOLETTI, G. BALZANO, P. PASSONI, E. VILLA ( <i>Milan, Italy</i> ) .....	4785
* Reviews (pages 4477, 4673)	

## Number 12

### *Experimental Studies*

CCL2 Expression in Primary Ovarian Carcinoma Is Correlated with Chemotherapy Response and Survival Outcomes. A.N. FADER, N. RASOOL, S.A.J. VAZIRI, T. KOZUKI, P.W. FABER, P. ELSON, C.V. BISCOTTI, C.M. MICHENER, P.G. ROSE, L. ROJAS-ESPAILLAT, J.L. BELINSON, M.K. GANAPATHI, R. GANAPATHI ( <i>Cleveland, OH, USA</i> ) .....	4791
A Clinically Relevant, Syngeneic Model of Spontaneous, Highly Metastatic B16 Mouse Melanoma. V. BOBEK, K. KOLOSTOVA, D. PINTEROVA, G. KACPRZAK, J. ADAMIAK, J. KOLODZIEJ, M. BOUBELIK, M. KUBECOVA, R.M. HOFFMAN ( <i>Prague, Czech Republic; Wroclaw, Poland; San Diego, CA, USA</i> ) .....	4799
Expression of Anti-apoptosis Genes Determines the Response of Adrenal Cancer to Apoptosis-inducing Chemotherapy. D.E. SCHTEINGART, R. BENITEZ, C. BRADFORD, A. NARAYAN, S. WANG ( <i>Ann Arbor, MI, USA</i> ).....	4805
Aberrant Methylation of Heparan Sulfate Glucosamine 3- <i>O</i> -Sulfotransferase 2 Genes as a Biomarker in Colorectal Cancer. Y. TOKUYAMA, T. TAKAHASHI, N. OKUMURA, K. NONAKA, Y. KAWAGUCHI, K. YAMAGUCHI, S. OSADA, A. GAZDAR, K. YOSHIDA ( <i>Gifu, Japan; Dallas, TX, USA</i> ) .....	4811
Inhibition of L-type Amino Acid Transporter 1 Has Antitumor Activity in Non-small Cell Lung Cancer. H. IMAI, K. KAIRA, N. ORIUCHI, K. SHIMIZU, H. TOMINAGA, N. YANAGITANI, N. SUNAGA, T. ISHIZUKA, S. NAGAMORI, K. PROMCHAN, T. NAKAJIMA, N. YAMAMOTO, M. MORI, Y. KANAI ( <i>Gunma; Osaka; Shizuoka, Japan</i> ) .....	4819
Differential Stimulation of VEGF-C Production by Adhesion/Growth-regulatory Galectins and Plant Lectins in Human Breast Cancer Cells. A.V. TIMOSHENKO, H. KALTNER, S. ANDRÉ, H.-J. GABIUS, P.K. LALA ( <i>London, ON, Canada; Munich, Germany</i> ) .....	4829

MCF-7 Cell Apoptosis and Cell Cycle Arrest: Non-genomic Effects of Progesterone and Mifepristone (RU-486). R. FJELLDAL, B.T. MOE, A. ØRBO, G. SAGER ( <i>Tromsø, Norway</i> ) .....	4835
Inhibitory Effect of Somatostatin Peptide Analogues on DNA Polymerase Activity and Human Cancer Cell Proliferation. I. KURIYAMA, A. MIYAZAKI, Y. TSUDA, T. YOKOI, Y. OKADA, T. TAKEUCHI, F. SUGAWARA, H. YOSHIDA, Y. MIZUSHINA ( <i>Hyogo; Kobe; Chiba, Japan</i> ) .....	4841
Experimental Model and Immunohistochemical Comparison of U87 Human Glioblastoma Cell Xenografts on the Chicken Chorioallantoic Membrane and in Rat Brains. T. STROJNIK, R. KAVALAR, T.A. BARONE, R.J. PLUNKETT ( <i>Maribor, Slovenia; Buffalo, NY, USA</i> ) .....	4851
Interrelationship between Protein Phosphatase 1 and TGF- $\beta$ in Regulating Motility and Cytoskeletal Architecture of Endothelial Cells. J.E. WALSH, M.R.I. YOUNG ( <i>Charleston, SC, USA</i> ) .....	4861
Biological Activity of Hydantoin Derivatives on P-Glycoprotein (ABCB1) of Mouse Lymphoma Cells. G. SPENGLER, M. EVARISTO, J. HANDZLIK, J. SERLY, J. MOLNÁR, M. VIVEIROS, K. KIEĆ-KONONOWICZ, L. AMARAL ( <i>Lisbon, Portugal; Cracow, Poland; Szeged, Hungary</i> ) .....	4867
Cancer Chemopreventive Potential of Aromathecins and Phenazines, Novel Natural Product Derivatives. L. MARLER, M. CONDA-SHERIDAN, M.A. CINELLI, A.E. MORRELL, M. CUSHMAN, L. CHEN, K. HUANG, R. VAN BREEMEN, J.M. PEZZUTO ( <i>Hilo, HI; West Lafayette, IN; Chicago, IL, USA</i> ) .....	4873
Influence of Novel KGFR Tyrosine Kinase Inhibitors on KGF-mediated Proliferation of Breast Cancer. M. MEHTA, J.W. KESINGER, X.-P. ZANG, M.L. LERNER, D.J. BRACKETT, R.W. BRUEGGEMEIER, P.-K. LI, J.T. PENTO ( <i>Oklahoma City, OK; Columbus, OH, USA</i> ) .....	4883
Cytotoxicity and Antileukaemic Activity of New Duplexes Linking 3-C-Ethynylcytidine and 5-Fluorodeoxyuridine. L. NOVOTNY, P. RAUKO, H. SCHOTT ( <i>Safat, Kuwait; Bratislava, Slovakia; Tuebingen, Germany</i> ) .....	4891
Tumour Response to Gefitinib Is Associated with EGF- and Gefitinib- but not Radiation-modulated EGFR Expression. H.Q. LIN, A. KATSIFIS, H. MERIATY ( <i>Lucas Heights, NSW, Australia</i> ) .....	4899
Gender Differences in Gemcitabine (Gemzar) Efficacy in Cancer Cells: Effect of Indole-3-Carbinol. B.D. LYN-COOK, S.I. MOHAMMED, C. DAVIS, B. WORD, A. HAEFELE, H. WANG, G. HAMMONS ( <i>Jefferson, AR; West Lafayette, IN, USA</i> ) .....	4907
All-trans Retinoic Acid Modulates Cancer Stem Cells of Glioblastoma Multiforme in an MAPK-dependent Manner. M. KARSY, L. ALBERT, M.E. TOBIAS, R. MURALI, M. JHANWAR-UNIYAL ( <i>Valhalla, NY, USA</i> ) .....	4915
Progesterone Receptor Antagonist Therapy Has Therapeutic Potential Even in Cancer Restricted to Males as Evidenced from Murine Testicular and Prostate Cancer Studies. J.H. CHECK, E. DIX, C. WILSON, D. CHECK ( <i>Camden, NJ, USA</i> ) .....	4921
Targeting KRAS Mutation-bearing Lung Cancer <i>In Vivo</i> by Pulmonary Surfactant-Adenovirus-mediated Gene Transfer. T. FUKAZAWA, Y. MAEDA, J. MATSUOKA, T. ONO, K. MOMINOKI, T. YAMATSUJI, K. SHIGEMITSU, I. MORITA, I. MURAKAMI, H. TANAKA, M.L. DURBIN, Y. NAOMOTO ( <i>Okayama; Tottori; Tokyo, Japan; Cincinnati, OH; Irvine, CA, USA</i> ) .....	4925
<i>d</i> - $\delta$ -Tocotrienol-mediated Cell Cycle Arrest and Apoptosis in Human Melanoma Cells. N.V. FERNANDES, P.K. GUNTIPALLI, H. MO ( <i>Denton, TX, USA</i> ) .....	4937
Comparison of Metallothionein (MT) and Ki-67 Antigen Expression in Benign and Malignant Thyroid Tumours. A. KRÓLICKA, C. KOBIERZYCKI, B. PUŁA, M. PODHORSKA-OKOŁÓW, A. PIOTROWSKA, M. RZESZUTKO, W. RZESZUTKO, J. RABCZYŃSKI, P. DOMOSŁAWSKI, B. WOJTCZAK, J. DAWISKIBA, P. DZIĘGIEL ( <i>Wrocław; Poznan, Poland</i> ) .....	4945

PI-103 and Sorafenib Inhibit Hepatocellular Carcinoma Cell Proliferation by Blocking Ras/Raf/MAPK and PI3K/AKT/mTOR Pathways. R. GEDALY, P. ANGULO, J. HUNDLEY, M.F. DAILY, C. CHEN, A. KOCH, B.M. EVERS ( <i>Lexington, KY, USA</i> ) .....	4951
Alternative Lengthening of Telomeres as a Prognostic Factor in Malignant Fibrous Histiocytomas of Bone. T. MATSUO, S. SHIMOSE, T. KUBO, J. FUJIMORI, Y. YASUNAGA, M. OCHI ( <i>Hiroshima, Japan</i> )....	4959
Base Excision Repair Activities Differ in Human Lung Cancer Cells and Corresponding Normal Controls. B. KARAHALIL, V.A. BOHR, N.C. DE SOUZA-PINTO ( <i>Baltimore, MD, USA; Ankara, Turkey; Sao Paulo, Brazil</i> ) .....	4963
Phosphorylation of TCTP as a Marker for Polo-like Kinase-1 Activity <i>In Vivo</i> . U. CUCCHI, L.M. GIANELLINI, A. DE PONTI, F. SOLA, R. ALZANI, V. PATTON, A. PEZZONI, S. TROIANI, M.B. SACCARDO, S. RIZZI, M.L. GIORGINI, P. CAPPELLA, I. BERIA, B. VALSASINA ( <i>Nerviano, Italy</i> ) .....	4973
The Effects of Anti-VEGFR and Anti-EGFR Agents on Glioma Cell Migration Through Implication of Growth Factors with Integrins. K. DIMITROPOULOS, E. GIANNOPOULOU, A.A. ARGYRIOU, V. ZOLOTA, T. PETSAS, E. TSIATA, H.P. KALOFONOS ( <i>Rion, Patras, Greece</i> ) .....	4987
E-Cadherin and Alpha-Catenin Expression in Normal, Hyperplastic and Neoplastic Endometrium. E. CARICO, M. ATLANTE, E. GIARNIERI, S. RAFFA, B. BUCCI, M.R. GIOVAGNOLI, A. VECCHIONE ( <i>Rome; Naples, Italy</i> ) .....	4993
Gamma-Secretase Complexes Regulate the Responses of Human Pancreatic Ductal Adenocarcinoma Cells to Taxanes. T. TASAKA, T. AKIYOSHI, K. YAMAGUCHI, M. TANAKA, H. ONISHI, M. KATANO ( <i>Fukuoka; Tokyo; Kitakyushu, Japan</i> ) .....	4999
Down-regulation of <i>Mus81</i> as a Potential Marker for the Malignancy of Gastric Cancer. F. WU, A. SHIRAHATA, K. SAKURABA, Y. KITAMURA, T. GOTO, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, K. HIBI ( <i>Guangzhou, China; Yokohama, Japan</i> ) .....	5011
Detection of Vimentin ( <i>VIM</i> ) Methylation in the Serum of Colorectal Cancer Patients. A. SHIRAHATA, K. SAKURABA, T. GOTO, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, K. HIBI ( <i>Yokohama, Japan</i> ) .....	5015
Suppression of Tumour Metastasis in a Murine Osteosarcoma Model with Anti-CD25 Monoclonal Antibody Treatment. E. KOZAWA, H. SUGIURA, J. WASA, K. KOHYAMA, K. YAMADA, A. NISHIOKA, Y. NISHIDA, N. ISHIGURO, O. TAGUCHI ( <i>Nagoya, Japan</i> ) .....	5019
Cancer/Testis Antigen Expression on Mesenchymal Stem Cells Isolated from Different Tissues. F. SALDANHA-ARAUJO, R. HADDAD, D.L. ZANETTE, A.G. DE ARAUJO, M.D. ORELLANA, D.T. COVAS, M.A. ZAGO, R.A. PANEPUCCI ( <i>São Paulo, Brazil</i> ) .....	5023
Parathyroid Hormone-related Peptide Regulates Matrix Metalloproteinase-13 Gene Expression in Bone Metastatic Breast Cancer Cells. S. IBARAGI, T. SHIMO, M. IWAMOTO, N.M. HASSAN, S. KODAMA, S. ISOWA, A. SASAKI ( <i>Okayama, Japan; Philadelphia, PA, USA</i> ) .....	5029
Corticotropin Releasing Factor, a Synthetic Corticotropin-releasing Factor with Preclinical Antitumor Activity, alone and with Bevacizumab, against Human Brain Tumor Models. I. GAMEZ, R.P. RYAN, S.T. KEIR ( <i>New York, NY; Durham, NC, USA</i> ) .....	5037
High-mobility Group B1 (HMGB1) and Receptor for Advanced Glycation End-products (RAGE) Expression in Canine Lymphoma. K.A. STERENCZAK, A.E. JOETZKE, S. WILLENBROCK, N. EBERLE, S. LANGE, C. JUNGHANSS, I. NOLTE, J. BULLERDIEK, D. SIMON, H.M. ESCOBAR ( <i>Hannover; Bremen; Rostock, Germany</i> ).....	5043

Effects of the Synthetic Vasopressin Analog Desmopressin in a Mouse Model of Colon Cancer. G.V. RIPOLL, J. GARONA, G.A. HERMO, D.E. GOMEZ, D.F. ALONSO ( <i>Buenos Aires, Argentina</i> ) .....	5049
Up-regulation of Glypican-3 in Human Hepatocellular Carcinoma. M. SUZUKI, K. SUGIMOTO, J. TANAKA, M. TAMEDA, Y. INAGAKI, S. KUSAGAWA, K. NOJIRI, T. BEPPU, K. YONEDA, N. YAMAMOTO, M. ITO, M. YONEDA, K. UCHIDA, K. TAKASE, K. SHIRAKI ( <i>Tsu, Mie; Tsukuba, Ibaraki, Japan</i> ) .....	5055
Activation of the Serine/Threonine Protein Kinase Akt in Enteropancreatic Neuroendocrine Tumors. M. GHAYOURI, D. BOULWARE, A. NASIR, J. STROSBURG, L. KVOLS, D. COPPOLA ( <i>Tampa, FL, USA</i> ) .....	5063
Tumor-specific Cytotoxicity and Type of Cell Death Induced by Benzaldehyde. K. ARIYOSHI-KISHINO, K. HASHIMOTO, O. AMANO, J. SAITOH, M. KOCHI, H. SAKAGAMI ( <i>Saitama; Chiba, Japan</i> ).....	5069
Aromatase Expression in Leptin-pretreated Human Breast Pre-adipocytes is Enhanced by Zeranol and Suppressed by (-)-Gossypol. S. ZHONG, W.-P. YE, P.-P. XU, E. FENG, H. LI, S.-H. LIN, J.-Y. LIU, C. MA, Y.C. LIN ( <i>Beijing, PR China; Columbus, OH, USA</i> ).....	5077
Investigation of Peroxiredoxin IV as a Calpain-regulated Pathway in Cancer. H. ROUMES, A. PIRES-ALVES, L. GONTHIER-MAURIN, E. DARGELOS, P. COTTIN ( <i>Talence, France</i> ) .....	5085
 <i>Clinical Studies</i> 	
Immunogenicity of Dendritic Cells Pulsed with CEA Peptide or Transfected with CEA mRNA for Vaccination of Colorectal Cancer Patients. W.J. LESTERHUIS, I.J.M. DE VRIES, G. SCHREIBELT, D.H. SCHUURHUIS, E.H. AARNTZEN, A. DE BOER, N.M. SCHARENBOG, M. VAN DE RAKT, E.J. HESSELINK, C.G. FIGDOR, G.J. ADEMA, C.J.A. PUNT ( <i>Nijmegen, Netherlands</i> ).....	5091
HPV Genotype Distribution in Oral and Oropharyngeal Squamous Cell Carcinoma Using Seven <i>In Vitro</i> Amplification Assays. D.W. KINGMA, R.A. ALLEN, W. MOORE, S.K. CAUGHORN, M. MELBY, E.M. GILLIES, R.A. MARLAR, S.T. DUNN ( <i>Oklahoma City, OK; Billings, MT, USA</i> ) .....	5099
Carbon Ion Radiotherapy for Treatment of Prostate Cancer and Subsequent Outcomes after Biochemical Failure. J. SHIMAZAKI, H. TSUJI, H. ISHIKAWA, T. OKADA, K. AKAKURA, H. SUZUKI, M. HARADA, H. TSUJII ( <i>Chiba; Yokohama, Japan</i> ) .....	5105
Oxaliplatin-induced Pancreatitis: A Case Series. W. BUTT, H. SAADATI, M.W. SAIF ( <i>Dayton, OH; New Haven, CT; New York, NY, USA</i> ) .....	5113
A Mediastinal Somatic-type Germ Cell Tumor with Hepatic Metastasis Successfully Treated by Multiple Modalities. N. KOBAYASHI, T. KOIZUMI, T. EGUCHI, A. HYOOTANI, G. SAITO, K. HAMANAKA, T. SHIINA, M. KURAI, R. KONDO, K. YOSHIDA, J. AMANO ( <i>Matsumoto, Japan</i> ).....	5117
Prognostic and Predictive Implications of <i>EGFR</i> Mutations, <i>EGFR</i> Copy Number and <i>KRAS</i> Mutations in Advanced Stage Lung Adenocarcinoma. L. BONANNO, M. SCHIAVON, G. NARDO, R. BERTORELLE, L. BONALDI, A. GALLIGIONI, S. INDRACCOLO, G. PASELLO, F. REA, A. FAVARETTO ( <i>Padua, Italy</i> ) ...	5121
Glasgow Prognostic Score Is Related to Blood Transfusion Requirements and Post-operative Complications in Hepatic Resection for Hepatocellular Carcinoma. Y. FUJIWARA, H. SHIBA, K. FURUKAWA, T. IIDA, K. HARUKI, T. GOCHO, S. WAKIYAMA, S. HIROHARA, Y. ISHIDA, T. MISAWA, T. OHASHI, K. YANAGA ( <i>Tokyo, Japan</i> ).....	5129
Clinical Impacts of Histological Subtyping Primary Breast Cancer. P. FRITZ, S. KLENK, S. GOLETZ, A. GERTEIS, W. SIMON, F. BRINKMANN, E. HEIDEMANN, E. LÜTTTGEN, G. OTT, M.D. ALSCHER, M. SCHWAB, J. DIPPON ( <i>Stuttgart, Germany</i> ) .....	5137

Arabinoxylan Rice Bran (MGN-3) Enhances the Effects of Interventional Therapies for the Treatment of Hepatocellular Carcinoma: A Three-year Randomized Clinical Trial. M.H. BANG, T. VAN RIEP, N.T. THINH, L.H. SONG, T.T. DUNG, L. VAN TRUONG, L. VAN DON, T.D. KY, D. PAN, M. SHAHEEN, M. GHONEUM ( <i>Hanoi, Vietnam; Los Angeles, CA, USA</i> ) .....	5145
Dopamine Excess in Patients with Head and Neck Paragangliomas. A.N.A. VAN DER HORST-SCHRIVERS, T. E. OSINGA, I.P. KEMA, B.F.A.M. VAN DER LAAN, R.P.F. DULLAART ( <i>Groningen, Netherlands</i> ) .....	5153
Complications of Image-guided Transcatheter Hepatic Chemoembolization of Primary and Secondary Tumours of the Liver. G. POGGI, E. POZZI, A. RICCARDI, S. TONINI, B. MONTAGNA, P. QUARETTI, B. TAGLIAFERRI, F. SOTTOTETTI, P. BAIARDI, C. PAGELLA, C. MINOIA, G. BERNARDO ( <i>Pavia, Italy</i> ).....	5159
Efficacy of Sunitinib in Patients with Renal Cell Carcinoma with Bone Metastases. B. PAULE, N. BRION ( <i>Creteil; Le Chesnay; Versailles, France</i> ).....	5165
Response and Safety of Sunitinib in a Heavily Pre-treated Metastatic Non-small Cell Lung Carcinoma Patient. R. TASSI, A. MUTO, S. RANGAN, A. VANNINI, L. POLITI, B. NERI ( <i>Florence, Italy</i> ) .....	5169
Nuclear Expression of 14-3-3 Sigma Is Related to Prognosis in Patients with Esophageal Squamous Cell Carcinoma. H. OKUMURA, Y. KITA, N. YOKOMAKURA, Y. UCHIKADO, T. SETOYAMA, H. SAKURAI, I. OMOTO, M. MATSUMOTO, T. OWAKI, S. ISHIGAMI, S. NATSUGOE ( <i>Kagoshima, Japan</i> ) .....	5175
Combined Chemoradiotherapy for Early Glottic Cancer in Clinical Practice in Japan: Analysis of 10 Institutions. Y. ITOH, N. HIRASAWA, S. NAGANAWA, S. ISHIHARA, K. SUZUKI, K. KOYAMA, T. MURAO, A. ASANO, Y. NOMOTO, Y. HORIKAWA, M. SASAOKA, Y. OBATA ( <i>Nagoya; Ichinomiyama; Toyohashi; Yatomi, Aichi; Hamamatsu; Tajimi; Tsu; Ise, Mie, Japan</i> ).....	5181
Pemetrexed-induced Eyelid Edema: Incidence and Clinical Manifestations. D. SCHALLIER, L. DECOSTER, C. FONTAINE, J. DE GRÈVE ( <i>Brussels, Belgium</i> ) .....	5185
Association between Breast Cancer Risk and the Wild-type Allele of Human ABC Transporter <i>ABCC11</i> . I. OTA, A. SAKURAI, Y. TOYODA, S. MORITA, T. SASAKI, T. CHISHIMA, M. YAMAKADO, Y. KAWAI, T. ISHIDAO, A. LEZHAVA, K.-I. YOSHIURA, S. TOGO, Y. HAYASHIZAKI, T. ISHIKAWA, T. ISHIKAWA, I. ENDO, H. SHIMADA ( <i>Yokohama; Tokyo; Nagasaki, Japan</i> ) .....	5189
CA19.9 and CEA in Transitional Cell Carcinoma of the Bladder: Serological and Immunohistochemical Findings. A. HEGELE, V. MECKLENBURG, Z. VARGA, P. OLBERT, R. HOFMANN, P. BARTH ( <i>Marburg; Sigmaringen, Germany</i> ) .....	5195
Ethinylestradiol Improves Prostate-specific Antigen Levels in Pretreated Castration-resistant Prostate Cancer Patients. K. IZUMI, Y. KADONO, T. SHIMA, H. KONAKA, A. MIZOKAMI, E. KOH, M. NAMIKI ( <i>Kanazawa, Japan</i> ).....	5201
A Rapid and Simple HPLC Assay for Quantification of Capecitabine for Drug Monitoring Purposes. A. FARKOUH, D. ETTLINGER, J. SCHUELLER, A. GEORGOPOULOS, W. SCHEITHAUER, M. CZEJKA ( <i>Vienna, Austria</i> ).....	5207
Bevacizumab and Glioblastomas, a Single-Centre Experience: How Disease History and Characteristics May Affect Clinical Outcome. F. ZUSTOVICH, G. LOMBARDI, D. PASTORELLI, P. FARINA, L. FURINI, R. MANARA, M.D. PALMA, A. ROTILIO, O. NICOLETTO, V. ZAGONEL ( <i>Padova, Italy</i> ) .....	5213
Association between Ataxia Telangiectasia Mutated Gene Polymorphisms and Breast Cancer in Taiwanese Females. H.-C. WANG, W.-S. CHANG, R.-Y. TSAI, C.-W. TSAI, L.-C. LIU, C.-H. SU, H.-N. CHENG, Y.-A. TSOU, S.-S. SUN, C.-C. LIN, D.-T. BAU ( <i>Taichung, Taiwan, ROC</i> ) .....	5217

More Than 4 Years of Progression-free Survival in a Patient with Metastatic Renal Cell Carcinoma Treated Sequentially with Sunitinib, Everolimus, Sorafenib, and Temsirolimus. S. OUDARD ( <i>Paris, France</i> ) .....	5223
Age Aspects of Demography, Pathology and Survival Assessment in Colorectal Cancer. K. DERWINGER, K. KODEDA, R. GERJY ( <i>Gothenburg; Linköping, Sweden</i> ) .....	5227
Immunohistochemical Detection of Mutated Epidermal Growth Factor Receptors in Pulmonary Adenocarcinoma. H. NAKAMURA, A. MOCHIZUKI, T. SHINMYO, K. ANDO, N. KURIMOTO, K. YOKOTE, M. TAKAGI ( <i>Kawasaki, Kanagawa, Japan</i> ) .....	5233
Clinical Significance of Vimentin-positive Gastric Cancer Cells. Y. FUYUHIRO, M. YASHIRO, S. NODA, S. KASHIWAGI, J. MATSUOKA, Y. DOI, Y. KATO, N. KUBO, M. OHIRA, K. HIRAKAWA ( <i>Osaka, Japan</i> ) .....	5239
Combination Chemotherapy with S-1 and Platinum in Advanced Hepatocellular Carcinoma. S.-J. KIM, S.-W. HAN, D.-Y. OH, N.-J. YI, Y.J. KIM, S.-A. IM, J.-H. YOON, G.H. KANG, K.S. SUH, Y.-J. BANG, J.-J. JANG, T.-Y. KIM ( <i>Seoul, Republic of Korea</i> ) .....	5245
<i>KRAS</i> Genotyping as Biomarker in Colorectal Cancer: A Comparison of Three Commercial Kits on Histologic Material. A. CAVALLINI, A.M. VALENTINI, C. LIPPOLIS, D. CAMPANELLA, V. GUERRA, M.L. CARUSO ( <i>Castellana Grotte, Italy</i> ) .....	5251
Association Between EGF, TGF- $\beta$ 1, TNF- $\alpha$ Gene Polymorphisms and Cancer of the Pancreatic Head. G.-Y. WU, Q. LU, T. HASENBERG, M. NIEDERGETHMANN, S. POST, J.W. STURM, M. KEESE ( <i>Xiamen, PR China; Mannheim, Germany</i> ) .....	5257
Book Reviews .....	5263
Announcements .....	5267
Errata .....	5269



## Subject Index

(Figures refer to page numbers)

- $^{99m}\text{Tc}$ -(CO)3-X-Y-bombesin (7-14)NH<sub>2</sub>, breast cancer, technetium, GRP receptor, carbonyl, T47-D, MDA-MB-231, 19
- $^{99m}\text{Tc}$ -pertechnetate, thyroid gland, thyroid cancer, thyroid nodule, thyroid scintigraphy, fine-needle aspiration cytology, FNAB, FNAC, 3083
- $^{99m}\text{Tc}$ -Rec-TOR-G, toremifene, toremifene-glucuronide-labelled with  $^{99m}\text{Tc}$ ,  $^{99m}\text{Tc}$ -TOR-G, diethylenetriamine pentaacetic acid DTPA, anti-oestrogen glucuronide compound, 1243
- $^{99m}\text{Tc}$ -TOR-G, toremifene, toremifene-glucuronide-labelled with  $^{99m}\text{Tc}$ ,  $^{99m}\text{Tc}$ -Rec-TOR-G, diethylenetriamine pentaacetic acid DTPA, anti-oestrogen glucuronide compound, 1243
- A2780, curcumin, copper, mTOR, NF- $\kappa$ B, cancer, 3249
- A2780, drug combination, YH12, dose-effect curves, cell uptake, platinum-DNA binding, *trans*-platinum compounds, ovarian cancer cell lines, cisplatin, 4547
- A3 adenosine receptor, A3AR antagonist, apoptosis, truncated thio-CI-IB-MECA, bladder cancer cells, 2823
- A3AR antagonist, A3 adenosine receptor, apoptosis, truncated thio-CI-IB-MECA, bladder cancer cells, 2823
- A431 cell, TG2, MMP-9, fibronectin, invasion, 4177
- A549, myc, Omomyc, KRAS, lung cancer, 4193
- Av $\beta$ 6, integrin, Fyn kinase, EMT, oral SCC, serum, 2591
- ABC transporter *ABCC11*, apocrine gland, axillary osmidrosis, earwax, mammary gland, SNP, breast cancer risk, 5189
- ABCBI*, hydantoin, P-glycoprotein, multidrug resistance, cancer, 4867
- ABCBI*, multidrug resistance, anthracycline, AML, caveolin-1, caveolae, cholesterol, 3451
- ABCBI*, ovarian cancer, gene, polymorphism, prognosis, 3487
- ABCG2, methotrexate, proton pump inhibitor, BCRP, drug-drug interaction, 3807
- Abstracts of the 20th Annual Meeting of the Italian Society of Uro-Oncology (SIURo), June 23-25, 2010, Rome, Italy, 1375-1544
- Abdomen, radiation, children, side-effects, late sequelae, 227
- Acidification, flax, *Linum usitatissimum*, phytoestrogens, MCF-7, cellular metabolism, online monitoring, oxygen consumption, adhesion, 1587
- ACNU, glioma, ROCK isoforms, shRNA, cell cycle, 3509
- Actin cytoskeleton stability, calponin h1, cell motility, point mutation, S175T, HeLa cells, 1071
- Actin, histochemistry, tubulin, electron microscopy, P150, eukaryotic translation initiation factor 3, colon cancer, 1047
- Activation, ionising radiation, bystander effect, ELISA, TGF $\beta$ , 3341
- Active surveillance, prostate cancer, watchful waiting, review, 3683
- Acute disseminated intravascular coagulation, breast cancer, vinorelbine, HDFL, 3087
- Acute lymphoblastic leukaemia, drug resistance, individualised tumour response testing, bortezomib, children, acute myeloid leukaemia, 2119
- Acute lymphoblastic leukemia, cytogenetics, fluorescent *in situ* hybridization, Philadelphia chromosome, bcr-abl fusion gene, 569
- Acute myeloid leukaemia, drug resistance, individualised tumour response testing, bortezomib, children, acute lymphoblastic leukaemia, 2119
- Acute promyelocytic leukemia, autologous transplantation, molecular remission, 3845
- Acute promyelocytic leukemia, older patients, patient selection, 967
- Acyclic nucleoside phosphonate, programmed cell death, CCRF-CEM cells, cell cycle, caspases, cD95/Fas, 2791
- ADA, adenosine deaminase, pepsinogen, *Helicobacter pylori*, gastric cancer, chronic atrophic gastritis, CAG, 2347
- Adenocarcinoma, EMT, lung cancer, resistance, EGFR, tyrosine kinase inhibitor, 2513
- Adenocarcinoma, epidermal growth factor receptor, immunohistochemistry, lung cancer, mutation, 5233
- Adeno-carcinoma, oestrogen receptors, progesterone receptors, uterine cervix, 1341
- Adenocarcinoma, serum LDH, tumour LDH-5, NSCLC, squamous cell carcinoma, immunohistochemistry, 1347
- Adenoma, colon, size, limits, carcinoma, 2419
- Adenomatoid odontogenic tumor, AOT, immunohistochemistry, cytokeratin, alpha-smooth muscle actin, epithelial membrane antigen, 1787
- Adenomatoid, human epididymis, CEACAM1, angiogenesis, 2651
- Adenosine analogue, epigenetic, promoter methylation, clofarabine, *PTEN*, *APC*, *RARB2*, *ZAP70*, 4601
- Adenosine deaminase, ADA, pepsinogen, *Helicobacter pylori*, gastric cancer, chronic atrophic gastritis, CAG, 2347
- Adenovirus, interleukin-6, IL-6, vascular endothelial growth factor, new receptor inhibitor of IL-6, NRI, mesotheliomas, gene delivery, 1947
- Adenovirus, mosquito, susceptibility, immune suppression, malaria, cancer mortality, 1371
- ADH5, auranofin, hepatoma, GSNOR, S-nitrosylation, mithramycin, thioredoxin reductases, 415
- Adhesion, flax, *Linum usitatissimum*, phytoestrogens, MCF-7, cellular metabolism, online monitoring, acidification, oxygen consumption, 1587

- Adipocytic tumors, *EWS-CHOP*, *HMGA2-LPP*, lipoma, liposarcoma, *LPP-HMGA2*, RT-PCR, *TLS-CHOP*, 661
- Adipokine, zinc- $\alpha$ 2-glycoprotein, breast cancer, leptin, adiponectin, biomarker, apoptosis, 2919
- Adiponectin, zinc- $\alpha$ 2-glycoprotein, breast cancer, adipokine, leptin, biomarker, apoptosis, 2919
- Adjuvant 5-FU, colorectal cancer, TS, 645
- Adjuvant chemotherapy, NSCLC, carboplatin, paclitaxel, gemcitabine, treatment compliance, surgical resection, 4695
- Adjuvant chemotherapy, NSCLC, carboplatin, paclitaxel, treatment compliance, surgical resection, 3039
- Adjuvant treatment, chemotherapy, cancer, colorectal cancer treatment, microsatellite instability, FOLFOX, prognostic factor, 4297
- Adoptive immunotherapy, renal cell carcinoma, gamma-delta T-cells, lung metastasis, 575
- Adrenal cancer, gossypol, docetaxel, Bcl-XL, tumor growth, apoptosis, anti-apoptosis genes, 4805
- Adsorption, paclitaxel, dextran, folic acid, targeting, 903
- Advanced bladder carcinoma, gemcitabine, oxaliplatin, vinorelbine, 4711
- Advanced colon cancer, spontaneous regression, 2351
- Advanced epithelial ovarian cancer, biological feature, ERCC1, suboptimal debulking, 2447
- Advanced solid tumors, imatinib mesylate, capecitabine, phase I, 1251
- Adverse events, human anti-mouse antibody, HAMA, colorectal cancer, prevalence, monoclonal antibody therapeutics, 4353
- Aerobic glycolysis, transketolase-like-1 protein, TKTL1, cancer, endometrial cancer, glucose metabolism, pAkt, GLUT1, 1653
- AFM, LB protein nanocrystals, laser, X-ray microdiffraction, radiation damage, 2745
- Age, chemotherapy, carboplatin, paclitaxel, hematologic toxicity, non-small cell lung cancer, 1365
- Agglutinins, glycobiology, lymphangiogenesis, VEGF, galectins, lectins, breast cancer cells, 4829
- AICAR, combination effect 5-amino-imidazole-4-carboxamide-1- $\beta$ -4-ribofuranoside, 1,25-dihydroxyvitamin D3 derivative, pancreatic cancer, inhibitor of Akt-phosphorylation, 1875
- Aizoaceae*, *Carpobrotus edulis*, efflux pump, P-glycoprotein, multidrug resistance, 829
- AKAP12 $\alpha$ , promoter methylation, lung neoplasms, NSCLC, 4595
- Akt signalling, nonsteroidal anti-inflammatory drugs, NSAID, hydroxamic acids, cytostatic activity, cytotoxicity, human pancreatic cancer, cell cycle, apoptosis, 3987
- AKT, antiestrogens, EGF-R, endometrial cancer, everolimus, gefitinib, mTOR, perifosine, tamoxifen, 2025
- Akt, breast cancer, ErbB receptors, erlotinib, gefitinib, vitamin E, Stat, tyrosine kinase inhibitors,  $\gamma$ -tocotrienol, 429
- AKT, genistein, *BRCA1*, breast cancer, p21<sup>WAF1/CIP1</sup>, 2049
- AKT, GSK3beta, natural products, plant extract, CDK inhibitor, 3599
- AKT, HER-2, immunohistochemistry, upper urinary tract, urothelial carcinoma, 2439
- Akt, pancreatic cancer, apoptosis, 3279
- AL amyloidosis, amyloidosis, tongue, localized amyloidosis, amyloid, oral cavity, 3009
- Albendazole, peritoneal carcinomatosis, angiogenesis, ovarian cancer, vascular endothelial growth factor, 423
- Albumin, brain metastases, prognostic score, radiotherapy, lactate dehydrogenase, 977
- ALCAM, CD166, breast cancer, bone metastasis, cell adhesion, 1163
- Alcohol, obesity, estrogen, breast cancer, post-menopause, 1
- Alcohol, stomach neoplasm, Epstein-Barr virus, risk factor, medical history, lifestyle, gastric ulcer, 2469
- Alkaline phosphatase, colon cancer, Caco-2, flavonols, growth, differentiation, peroxide, 3629
- Alkyltransferase, MGMT, drug resistance, SCCHN, cancer therapy, field cancerization, 2561
- Allogeneic stem cell transplantation, philadelphia chromosome-positive acute lymphoblastic leukaemia, post-transplant imatinib administration, minimal residual disease, imatinib, 2415
- Aloe-emodin, *ATM*, *BRCA1*, RT-PCR, Comet assay, emodin, rhein, DNA repair, tongue cancer cells, 945
- Alpha terpineol, *Salvia libanotica*, NF- $\kappa$ B, connectivity map, 1911
- Alpha-smooth muscle actin, adenomatoid odontogenic tumor, AOT, immuno-histochemistry, cytokeratin, epithelial membrane antigen, 1787
- ALT, gastrointestinal stromal tumor, GIST, C-KIT gene, Ki-67 labeling index, PI3K, 2705
- Alternate, cisplatin, etoposide, topotecan, sequential, SCLC, 3031
- Aluminium, environmental oestrogens, breast cancer, cosmetics, antiperspirant, deodorant, paraben, organochlorine, phytoestrogen, breast cysts, review, 815
- Alveolar macrophage, lipopolysaccharide, pulmonary inhalation, lung cancer, Lewis lung carcinoma-bearing mice, cyclophosphamide, 3129
- Alveolar macrophage, lipopolysaccharide, pulmonary inhalation, lung cancer, nitric oxide, cell-to-cell contact, 3135
- Alveolar macrophage, lung tumor, drug delivery system, LPS, cell-to-cell contact, 3159
- AM value, bone mineral density, TACHIKAWA DENKAI CALCIUM™ (E-Ca), calcium hydroxide, dual-energy X-ray absorptiometry, DXA method, 3199

- Amitriptyline, brain tumours, clomipramine, tricyclic antidepressants, dexamethasone, oxygen consumption, malignant glioma, 391
- AML, multidrug resistance, *ABCBI*, anthracycline, caveolin-1, caveolae, cholesterol, 3451
- Amphiregulin, EGFR, MMP-9, breast cancer, 2101
- Amyloid, amyloidosis, tongue, localized amyloidosis, oral cavity, AL amyloidosis, 3009
- Amyloidosis, tongue, localized amyloidosis, amyloid, oral cavity, AL amyloidosis, 3009
- Anakinra, IL-1 receptor antagonist, IL-6, colon-26 carcinoma, survivin peptide vaccination, beta-glucan, anti-inflammation, vaccination, 3959
- Anal cytology, anal dysplasia, HIV, HPV, women, infection, 1719
- Anal dysplasia, anal cytology, HIV, HPV, women, infection, 1719
- Anandamide, polyamines, colorectal cancer, cell growth, 2583
- Anaplastic thyroid carcinoma, case report, multimodal treatment, chemotherapy, long-term survival, 1273
- Anaplastic thyroid carcinoma, integrin  $\alpha 6\beta 4$ , thyroid cancer, cell motility, invasion, 4485
- Anastomosis, breast reconstruction, deep inferior epigastric artery, perforator flap, venous, arterial, 1293
- Anastomosis, leak, small bowel, large bowel, ileocolic, hand-sewn, laparoscopic, review, 601
- Androgen deprivation therapy, TSC1, TSC2, testosterone, prostate cancer, 3895
- Androgen-independent prostate cancer, epidermal growth factor receptor, EGFR, cetuximab, C225, monoclonal antibody, Du145, PC-3, 1905
- Anemia, erythropoietin receptor, local cancer recurrence, breast cancer, hormone receptor status, 3721
- Anesthesia, HIF1 $\alpha$ , lung cancer, one-lung ventilation, BMI, obesity, pneumothorax, 1143
- Angiogenesis, albendazole, peritoneal carcinomatosis, ovarian cancer, vascular endothelial growth factor, 423
- Angiogenesis, chlorotoxin, TM601, MMP-2, invasion, 39
- Angiogenesis, DCE-MRI, MTD, PTK/ZK, VEGF, 2335
- Angiogenesis, fibroblast, MMP inhibition, cytokine, imaging, skin cancer invasion, VEGF-A, PDGF-BB, 703
- Angiogenesis, human epididymis, CEACAM1, adenomatoid, 2651
- Angiogenesis, hypoxia, VEGF, VEGFR2/KDR, multiple myeloma, 2831
- Angiogenesis, microtubule, combretastatin, vascular disrupting agent, cisplatin, 2813
- Angiogenesis, pancreatic cancer, endothelial cells, neovascularization, placental growth factor, 2911
- Angiogenesis, PTHrP, parathyroid hormone-related protein, VEGF, vascular endothelial growth factor, bone resorption, MAPK, mitogen-activated protein kinase, 2755
- Angiogenesis, targeted therapy, VEGF, matrix metalloproteinase, oxidative stress, reactive oxygen species, bevacizumab, FINAVAST trial, 1001
- Angiogenesis, tumor metastasis, cytoplasmic phospholipase A2, 5-lipoxygenase, cyclooxygenase-2, metalloproteinase, 3421
- Angiogenesis, tumour, functional vessel density, vascular network, fluorescence microscopy, 2597
- Angiogenesis, vascular normalization, pericytes, radiotherapy, hypoxia, tumor microenvironment,  $\alpha$ -SQMG, 4397
- Angiogenesis, VEGF-R, bFGF-R, clinical studies, biomarker, brivanib, review, 4477
- Angiogenesis, Wilms' tumor gene, *WT1*, immunohistochemistry, endometrial cancer, 3187
- Angiogram, HCC, recurrence, MGN-3, 5145
- Angiography, magnetic drug targeting, local chemotherapy, tumour vascularisation, computed tomography, flat-panel CT, 1553
- Angiosarcoma, rapamycin, mTOR, celecoxib, COX 2, endothelial tumour, 4017
- Animal cancer models, chick embryo, rodent model, tumour markers, immunohistochemistry, glioblastoma, cell xenografts, 4851
- Animal model, antagonist, colitis, dysplasia, neurokinin, colon cancer, 3345
- Animal tumor model, malignant mesothelioma, tumor spheroids, mesenchymal stem cell, chemokine, SDF1/CXCL12, 2153
- Annexin A2, asbestos, lung cancer, tumour antigen, SEREX, 2631
- Annexin, metastasis, prostasomes, exosomes, proteomics, prostate cancer, 285
- Antagonist, animal model, colitis, dysplasia, neurokinin, colon cancer, 3345
- Antennapedia, MT1-MMP, MMP-14, tyrosine phosphorylation, tumor progression, 3D matrix, 1887
- Anthracycline, multidrug resistance, *ABCBI*, AML, caveolin-1, caveolae, cholesterol, 3451
- Anthraquinones, danthron, quinizarin, polyamines, transglutaminase, differentiation, melanoma cells, 445
- Antiangiogenic drugs, kidney cancer, 5223
- Anti-apoptosis genes, gossypol, docetaxel, Bcl-XL, tumor growth, apoptosis, adrenal cancer, 4805
- Antibody-dependent cellular cytotoxicity (ADCC), Tn antigen, GalNAc( $\alpha$ 1-3)-Ser/Thr, single chain antibody, phage-display, Fc fusion, 3397
- Antibody-dependent cellular cytotoxicity, claudin, complement-dependent cytotoxicity, cancer therapy, 4555
- Anticancer agents, class pi glutathione-S-transferase, nuclear transfer, mantle cell lymphoma, GST-pi, 3951
- Anticancer complementary therapy, oxygen tension,

- Artemisinin, chemotherapy, hyperbaric oxygen, leukemia cells, 4467
- Anticancer drug, growth inhibition, MDM2, p53, XIAP, lung cancer, etoposide, 3321
- Anti-cancer drugs, breast cancer, gap junctions, 6-methoxy-8-[(2-furanylmethyl)amino]-4-methyl-5-(3-trifluoromethyl phenoxy)quinoline, *in vivo* activity, quinolines, 3927
- Anticancer drugs, chemotherapy, cross-resistance, gastric cancer cell lines, apoptosis, cell-cycle, 915
- Anti-cancer effect, enzyme inhibitor, cell cycle arrest, apoptosis, 4841
- Anticancer ruthenium(III) compounds, KP1339, electroporation, electrochemotherapy, tumour models, sarcoma, mice, 2055
- Anticancer, (-)-gossypol, breast cancer, MCF-7 cells, gossypol-myosin, 439
- Anticarcinogenesis effect, bamboo leaf extract, breast cancer, pretreatment, cancer prevention, tumor growth suppression, 111
- Anti-CD25, osteosarcoma, regulatory T-cell Treg, 5019
- Anti-EGFR agents, lapatinib, sunitinib, malignant glioma, MMPs, growth factors, VEGFR, integrins, anti-VEGFR agents, 4987
- Antiestrogens, AKT, EGF-R, endometrial cancer, everolimus, gefitinib, mTOR, perifosine, tamoxifen, 2025
- Antigen loading, colorectal cancer, dendritic cells, CEA peptide, mRNA, electroporation, immunotherapy, vaccination, 5091
- Antiglycolytic, ER stress, autophagosome, translation inhibition, 3-bromopyruvate, 923
- Anti-inflammation, IL-1 receptor antagonist, IL-6, colon-26 carcinoma, survivin peptide vaccination, beta-glucan, vaccination, Anakinra, 3959
- Anti-oestrogen glucuronide compound, toremifene, toremifene-glucuronide-labelled with <sup>99m</sup>Tc, <sup>99m</sup>Tc-TOR-G, <sup>99m</sup>Tc-Rec-TOR-G, diethylenetriamine pentaacetic acid DTPA, 1243
- Antioxidant, astaxanthin, mouse, inflammation, cardiac function, mammary tumor initiation, 2171
- Antioxidant, cancer, doxorubicin, MDR reversal, dihydropyridine derivative, oxidative stress, 4063
- Antiperspirant, environmental oestrogens, breast cancer, cosmetics, deodorant, paraben, aluminium, organochlorine, phytoestrogen, breast cysts, review, 815
- Antiprogestins, progestins, cytotoxic, breast cancer cells, non-genomic effects, mifepristone, apoptosis, cell cycle, 4835
- Anti-proliferation, *Oplopanax horridus*, human colorectal cancer, apoptosis, cell cycle, cyclin A, cyclin B1, 295
- Antisense oligonucleotide, liposomes, disulfide, G3139, *Bcl-2*, drug delivery, 31
- Antisense, breast cancer, transferrin receptor, iron transport, cell culture, 759
- Antisense, TGF- $\beta$ 1, keloid, SMAD, fibroblast, 3459
- Antituberculosis, N-acetyl transferase 2, isoniazid, 3177
- Antitumor activity, biomarker, PLK1, TCTP, 4973
- Antitumor promoters, lignans, immediate early-antigen expression, human cytomegalovirus, 451
- Antitumor, apoptosis, cell-penetrating peptide, gene therapy, protein transduction domain, tumor necrosis factor-related apoptosis-inducing ligand, TRAIL, arginine-rich peptides, 2193
- Anti-VEGFR agents, lapatinib, sunitinib, malignant glioma, MMPs, growth factors, VEGFR, integrins, anti-EGFR agents, 4987
- Anxiety, cancer, mental adjustment to cancer, depression, 5-HTTLPR polymorphism, 3823
- AOT, adenomatoid odontogenic tumor, immunohistochemistry, cytokeratin, alpha-smooth muscle actin, epithelial membrane antigen, 1787
- APC, adenosine analogue, epigenetic, promoter methylation, clofarabine, *PTEN*, *RARB2*, *ZAP70*, 4601
- APE1, DNA repair genes, polymorphism, gastric cancer, HOGG1, 1359
- APE1, OGG1, NTH1, UDG, DNA repair, mtDNA, nDNA, lung cancer cells, 4963
- Apocrine gland, axillary osmidrosis, earwax, mammary gland, SNP, ABC transporter *ABCC11*, breast cancer risk, 5189
- Apoptosis, 1,4-naphthoquinone, human prostate cancer cell lines, cytotoxicity, cell cycle, 519
- Apoptosis, A3 adenosine receptor, A3AR antagonist, truncated thio-CI-IB-MECA, bladder cancer cells, 2823
- Apoptosis, antitumor, cell-penetrating peptide, gene therapy, protein transduction domain, tumor necrosis factor-related apoptosis-inducing ligand, TRAIL, arginine-rich peptides, 2193
- Apoptosis, autophagy, bafilomycin A1, breast cancer, MDA-MB-231, sulforaphane, 3381
- Apoptosis, *BAG-1*, ER, PR, endometrial carcinoma, real-time PCR, immunohistochemistry, 4103
- Apoptosis, benzaldehyde, tumor-specificity, type of cell death, autophagy, 5069
- Apoptosis, breast cancer,  $\alpha$ -difluoromethylornithine, DFMO, biomarker, proliferation, invasion, 2263
- Apoptosis, camptothecin derivative, DNA damage and repair,  $\gamma$ -H2AX, M-phase cell, radiation, 937
- Apoptosis, caspase activity, NSC 95397, brefeldin A, bortezomide, sanguinarine, neuroendocrine tumors, 149
- Apoptosis, cationic hybrid liposome, renal cell carcinoma, chemotherapy, 327
- Apoptosis, chemotherapy, cross-resistance, gastric cancer cell lines, anticancer drugs, cell-cycle, 915

- Apoptosis, cholangiocarcinoma, photodynamic therapy, photofrin, local ablation, 2113
- Apoptosis, cisplatin, docetaxel, dexamethasone, squamous cell carcinoma of the head and neck cell lines, SCCHN, resistance, 123
- Apoptosis, cisplatin, FAS, sphingomyelin, lipid rafts, 2065
- Apoptosis, combination therapy, gemcitabine, 2-methoxyestradiol, pancreatic cancer cells, 4619
- Apoptosis, curcumin, G<sub>2</sub>/M arrest, caspase cascade, endoplasmic reticulum stress, lung neoplasms, herbal medicine, 2125
- Apoptosis, curcumin, medulloblastoma, 499
- Apoptosis, enzyme inhibitor, cell cycle arrest, anti-cancer effect, 4841
- Apoptosis, epigallocatechin-3-gallate, SKOV-3 cells, cell proliferation, ovarian cancer, 2519
- Apoptosis, Ewing's sarcoma, radiosensitivity, p53, curcumin, 4007
- Apoptosis, FCCP, juxtaglomerular cell, mitochondria, caspase, 2863
- Apoptosis, gene expression, histone deacetylase inhibitor, ITF2357, NF- $\kappa$ B, inflammation, 4525
- Apoptosis, gossypol, docetaxel, Bcl-XL, tumor growth, anti-apoptosis genes, adrenal cancer, 4805
- Apoptosis, *Helicobacter pylori*, *Solanum lyratum*, human gastric epithelial cells, 1189
- Apoptosis, high-LET, carbon ion, p53, radiosensitivity, chemotherapeutic agent, 1961
- Apoptosis, HMG CoA reductase, mevalonate, tocotrienol, statin, Cdk4, caspase-3, Ras, cell cycle, 4937
- Apoptosis, HNSCC, UM-SCC,  $\beta$ -catenin, sulindac sulfone, cell line, cell culture, 339
- Apoptosis, honokiol, chemoprevention, UVB photocarcinogenesis, 777
- Apoptosis, *Houttuynia cordata* Thunb. (HCT), Chinese herb, human primary colorectal cancer cells, 3549
- Apoptosis, HPV, cervical carcinoma, sodium butyrate, UCN-01, 4049
- Apoptosis, hybrid liposomes, chemotherapy, gastric carcinoma, cotton rat, 2011
- Apoptosis, integrin  $\alpha$ v $\beta$ 6, RNA interference, proliferation, invasion, cell cycle, chemosensitivity, pancreatic carcinoma cells, 135
- Apoptosis, IP-PA1, immunomodulator, macrophage, chemotherapy, 2033
- Apoptosis, JNK1, growth factors, kinase, mammary cancer, 3407
- Apoptosis, LA-12, oxaliplatin, cisplatin, colon cancer, cell cycle, 1183
- Apoptosis, leukaemia stem cells, PI3K/Akt, CK2, synergism, targeted therapy, 4625
- Apoptosis, lymphoma, motexafin gadolinium, p53, reactive oxygen species, 1131
- Apoptosis, mcl-1, 5-fluorouracil, Jurkat, T cells, caspases, 3879
- Apoptosis, MG132, endothelial cells, caspase, ROS, GSH, proteasome inhibitor, 879
- Apoptosis, MG132, NAC, ROS, GSH, 2107
- Apoptosis, neuroendocrine tumor, carcinoid, cell lines, plant extracts, bioactive agents, chemoresistance, 55
- Apoptosis, nonsteroidal anti-inflammatory drugs, NSAID, hydroxamic acids, cytostatic activity, cytotoxicity, human pancreatic cancer, Akt signalling, cell cycle, 3987
- Apoptosis, *Oplopanax horridus*, human colorectal cancer, anti-proliferation, cell cycle, cyclin A, cyclin B1, 295
- Apoptosis, oral cancer, 2'-hydroxycinnamaldehyde, cell cycle, tumor model, 489
- Apoptosis, oxaliplatin, high-LET radiation, PARP, autophagy, hepatocellular carcinoma, 303
- Apoptosis, pancreatic cancer, Akt, 3279
- Apoptosis, presenilin 1, presenilin 2, cell cycle, G<sub>0</sub>/G<sub>1</sub>, chemoresistance,  $\gamma$ -secretase, pancreatic ductal adenocarcinoma cells, taxanes, 4999
- Apoptosis, progestins, antiprogestins, cytotoxic, breast cancer cells, non-genomic effects, mifepristone, cell cycle, 4835
- Apoptosis, reactive oxygen species, intercellular signaling, salen-manganese complex, 3967
- Apoptosis, SN38, ilinotecan, topoisomerase inhibitor, ATM, p53, p21, caspase-3, 3911
- Apoptosis, sphingosine, sphinganine, ceramide, dihydroceramide, colon cancer, 2881
- Apoptosis, sulfuraphane, colon cancer, reactive oxygen species, 3611
- Apoptosis, synthetic triterpenoids, colorectal cancer, signaling proteins, 785
- Apoptosis, tamoxifen, endometrium, KRAS, ErbB ligand, 3119
- Apoptosis, tumour necrosis factor-related apoptosis-inducing ligand, TRAIL, histone deacetylase inhibitors, FR235222, human promyelocytic leukaemia, 887
- Apoptosis, TWEAK, PPAR $\gamma$  ligand, reactive oxygen species, colon cancer, 157
- Apoptosis, UVB, free radical, photodynamic therapy, indole-3-acetic acid, prostate cancer cells, 4607
- Apoptosis, xanthohumol, prostate cancer, prosurvival signaling proteins, 3333
- Apoptosis, zinc- $\alpha$ 2-glycoprotein, breast cancer, adipokine, leptin, adiponectin, biomarker, 2919
- Apoptotic proteins, hepatitis, cirrhosis, hepatocellular carcinoma, cell cycle proteins, 4493
- Areola area, neurofibromatosis type 1, NF1, neurofibromas, mamilla, 1815
- Arginine-rich peptides, antitumor, apoptosis, cell-penetrating peptide, gene therapy, protein transduction domain, tumor necrosis factor-related apoptosis-inducing ligand, TRAIL, 2193

- Aromatase inhibitor, heat-shock protein 70, Ki-67, neoadjuvant, breast cancer, 3465
- Aromatase, zeranol, leptin, CYP19A1, estrogen, human breast pre-adipocytes, (-)-gossypol, 5077
- Aromathecins, cancer chemoprevention, enzyme induction, RT-PCR, metabolism, phenazines, 4873
- Array CGH, cervical cancer, topoisomerase I, chromosomal aberrations, chromosome 5p gain, 3257
- Array CGH, ovarian cancer, docetaxel, carboplatin, chemotherapy resistance, 4451
- Arsenic trioxide, dithiothreitol, oral cancer, carcinogenesis, 3655
- Arsenic trioxide, small molecules, gene expression analysis, thymidylate synthase, real-time PCR, chemoresistance, 5-FU resistance, 1157
- Artemisinin, anticancer complementary therapy, oxygen tension, chemotherapy, hyperbaric oxygen, leukemia cells, 4467
- Arterial, breast reconstruction, deep inferior epigastric artery, perforator flap, venous, anastomosis, 1293
- Arteries, liver neoplasm therapy, liver interventional procedures, hepatic chemoembolization, 5159
- Artery, colorectal cancer, liver metastases, irinotecan, oxaliplatin, doxifluridine, 3045
- Asbestos, lung cancer, tumour antigen, Annexin A2, SEREX, 2631
- Asbestos, pericardial mesothelioma, mesothelioma, inflammation, heart surgery, 1323
- Assessment of risk and mortality, venous thromboembolism, pancreatic cancer, 4261
- Astatine, tumor cure probability, radiation sensitivity, ovarian cancer, radioimmunotherapy, 2545
- Astaxanthin, antioxidant, mouse, inflammation, cardiac function, mammary tumor initiation, 2171
- Astaxanthin, cardioprotection, immunomodulation, 2721
- Astrocytoma, central nervous system, malignancy, invasion, chlorotoxin, multiple chloride channels, glioma cells, 4515
- Astrocytoma, DJ-1, immunohistochemistry, WHO grading, prognosis, 265
- Atlanto-occipital ligament, gorlin, NBCCS, calcification, ponticulus posterior, 4265
- ATM*, *BRCA1*, RT-PCR, Comet assay, emodin, aloe-emodin, rhein, DNA repair, tongue cancer cells, 945
- ATM*, polymorphism, breast cancer, carcinogenesis, 5217
- ATM*, SN38, irinotecan, topoisomerase inhibitor, apoptosis, p53, p21, caspase-3, 3911
- ATP-binding cassette transporter, colon cancer, side population, Wnt signaling, 2041
- ATRA, GBM, CSC, MAPK, 4915
- Auranofin, ADH5, hepatoma, GSNOR, S-nitrosylation, mithramycin, thioredoxin reductases, 415
- Autologous transplantation, acute promyelocytic leukemia, molecular remission, 3845
- Autologous transplantation, IL-2, high-dose chemotherapy, NK cells, 5-fluorouracil, epirubicin, cyclophosphamide, methotrexate, radiotherapy, etoposide, carboplatin, VEGF, retinoic acid, myeloablative chemotherapy, immunotherapy, breast cancer, 209
- Autophagosome, ER stress, antiglycolytic, translation inhibition, 3-bromopyruvate, 923
- Autophagy, apoptosis, bafilomycin A1, breast cancer, MDA-MB-231, sulforaphane, 3381
- Autophagy, benzaldehyde, tumor-specificity, type of cell death, apoptosis, 5069
- Autophagy, oxaliplatin, high-LET radiation, PARP, apoptosis, hepatocellular carcinoma, 303
- Avastin®, Xerecept®, bevacizumab, corticorelin acetate, brain tumor model, 5037
- Axillary osmidrosis, apocrine gland, earwax, mammary gland, SNP, ABC transporter *ABCC11*, breast cancer risk, 5189
- Azasteroids, experimental chemotherapy, human lymphocytes, Lewis lung carcinoma, LLC, sister chromatid exchange, SCE, proliferation rate index, PRI, 4201
- B cells, urothelial carcinoma, Epstein-Barr virus, LMP-1, pathogenesis, cell line, 3473
- B16 melanoma, myeloid derived suppressor cells, macrophages, regulatory T-cells, docetaxel, temozolomide, interleukin-1 receptor antagonist, host-tumor interactions, 345
- B16 mouse melanoma, spontaneous metastasis, metastasis model, lymph node, 4799
- B16-F0 mouse melanoma cell, hepatocyte growth factor, HGF, mouse model, *Cordyceps sinensis*, invasion, 3429
- B3 lesions, breast cancer, vacuum-assisted core biopsy, Suros, microcalcification, lobular hyperplasia, DCIS, 2287
- Baboons, esophagus, glandular metaplasia, sialomucins, Barretts mucosa, 4123
- Bafilomycin A1, apoptosis, autophagy, breast cancer, MDA-MB-231, sulforaphane, 3381
- BAG-1*, ER, PR, apoptosis, endometrial carcinoma, real-time PCR, immunohistochemistry, 4103
- Bamboo leaf extract, anticarcinogenesis effect, breast cancer, pretreatment, cancer prevention, tumor growth suppression, 111
- Barrett's carcinoma, oesophageal carcinoma, neoadjuvant chemotherapy, response prediction, review, 1065
- Barretts mucosa, esophagus, baboons, glandular metaplasia, sialomucins, 4123
- Basal cell carcinoma, cancer-associated fibroblasts, cancer microenvironment, tumor stroma, squamous cell carcinoma, review, 455
- Basaloid squamous cell carcinoma, oral cancer, HPV types, oral papilloma, oral dysplasia, p16, 1605
- Basement membrane, 3-hydroxyproline, type IV collagen, cancer invasion, cancer metastasis, cancer screening, ELISA, 1007

- Basic amino side chain, coumarin, cell viability, cell cycle, benzopyranone derivatives, 4613
- BCG, bladder cancer, immunotherapy, integrin, 4089
- Bcl-2*, liposomes, disulfide, antisense oligonucleotide, G3139, drug delivery, 31
- BCL-2, small-cell lung cancer, oblimersen, radiation, 3869
- Bcl-XL, gossypol, docetaxel, tumor growth, apoptosis, anti-apoptosis genes, adrenal cancer, 4805
- BCL-xL*, HNSCC, EGFR, EGF, p21CIP1/WAF1, 4579
- BCPCF, human erythrocyte, phenolic compound, haemolysis, lignans, norlignans, multidrug resistance, MRP1/ABCC1, 4423
- Bcr-abl* fusion gene, acute lymphoblastic leukemia, cytogenetics, fluorescent *in situ* hybridization, Philadelphia chromosome, 569
- BCRP, CEA, Her2/neu, HSP27, microparticles, breast cancer, 1707
- BCRP, methotrexate, proton pump inhibitor, ABCG2, drug–drug interaction, 3807
- Benign breast lesions, breast cancer, cytology, fine-needle aspiration biopsy, DNA cytometry, DNA content, free cell sampling, cell group sampling, 175
- Benign prostatic hyperplasia, neuroendocrine (NE) differentiation, finasteride, dutasteride, chromogranin A, 4737
- Benign prostatic hyperplasia, prostate cancer, PCa, BPH, DD3<sup>PCA3</sup>, mRNA, RT-PCR, 665
- Benzaldehyde, tumor-specificity, type of cell death, apoptosis, autophagy, 5069
- Benzodiazepines, busulfan, pharmacokinetics, seizure prophylaxis, metabolism induction, phenytoin, 2977
- Benzopyranone derivatives, coumarin, basic amino side chain, cell viability, cell cycle, 4613
- BEP chemotherapy, mediastinal germ cell tumor, rhabdomyosarcoma, positron-emission tomography, hepatic metastasis, 5117
- Beta-glucan, IL-1 receptor antagonist, IL-6, colon-26 carcinoma, survivin peptide vaccination, anti-inflammation, vaccination, Anakinra, 3959
- Betel quid, *hOGGI*, single nucleotide polymorphism, oral cancer, 4205
- Bevacizumab, metastatic breast cancer, first-line therapy, paclitaxel, VEGF, 2969
- Bevacizumab, metastatic colorectal cancer, gene expression level, polymorphisms, clinical outcome, cetuximab, irinotecan, 4209
- Bevacizumab, neoadjuvant chemotherapy, VEGF, granulosa cell tumor, ovarian cancer, 4767
- Bevacizumab, targeted therapy, VEGF, matrix metalloproteinase, oxidative stress, reactive oxygen species, angiogenesis, FINAVAST trial, 1001
- Bevacizumab, VEGF, MFH, 3391
- Bevacizumab, VEGF, monoclonal antibody, radiological response, progression-free survival, malignant glioma, 609
- Bevacizumab, wound complications, ovarian cancer, 4743
- Bevacizumab, Xerecept<sup>®</sup>, Avastin<sup>®</sup>, corticorelin acetate, brain tumor model, 5037
- BFGF-R, angiogenesis, VEGF-R, clinical studies, biomarker, brivanib, review, 4477
- Bile acid, guggulsterone, CDX2, farnesoid X receptor, FXR, 1953
- Biliary tract cancer, KGFR, phosphorylation inhibitor, keratinocyte growth factor receptor, 4115
- Bioactive agents, neuroendocrine tumor, carcinoid, cell lines, plant extracts, chemoresistance, apoptosis, 55
- Bioavailability, tamoxifen, 4-hydroxytamoxifen, silybinin, pharmacokinetics, rats, 79
- Biochemical relapse, lymph node metastasis, micrometastasis, pelvic lymph node dissection, prostate cancer, radical prostatectomy, 2297
- Biodistribution, somatostatin analogs, <sup>111</sup>In(<sup>88</sup>Y)-DOTAGA-tate, <sup>111</sup>In(<sup>88</sup>Y)-DOTA-t-GA-tate, renal elimination, 2177
- Bioenergetic metabolism, prostate cancer, FDG-PET, uptake, glycolysis, fatty acid, 369
- Biological feature, advanced epithelial ovarian cancer, ERCC1, suboptimal debulking, 2447
- Biological markers, cervical intraepithelial neoplasia, cervical squamous epithelium, progesterone, estradiol, 1217
- Bioluminescent imaging, bombesin (BN)-like peptides, gastrin-releasing peptide receptors, prostate cancer, 4039
- Biomarker, angiogenesis, VEGF-R, bFGF-R, clinical studies, brivanib, review, 4477
- Biomarker, antitumor activity, PLK1, TCTP, 4973
- Biomarker, breast cancer,  $\alpha$ -difluoromethylornithine, DFMO, apoptosis, proliferation, invasion, 2263
- Biomarker, circulating, cell-free DNA, kidney cancer, serum, 2785
- Biomarker, thymidine kinase, lung cancer, tumor marker, serum, 1855
- Biomarker, zinc- $\alpha$ 2-glycoprotein, breast cancer, adipokine, leptin, adiponectin, apoptosis, 2919
- Biomarkers, bladder cancer, tumor progression, immunohistochemistry, CA19.9, CEA, transitional cell carcinoma, 5195
- Biomarkers, CEA, TIMP-1, rectal cancer, chemoradiation, 4755
- Bionanotechnology, nanodiamond, dendritic cells, CD4+ cells, *in vitro*, 4075
- Biopsy, image processing, prostatic neoplasm, radical prostatectomy, 1823
- Biopsy, prostate, postoperative complications, bleeding, ultrasound probe, 3071

- Biotherapeutic approaches, Proceedings of the 13th Annual Meeting of the Society of Biotherapeutic Approaches, December 5, 2009, Takamatsu, Japan, 3103-3212
- Birt Hogg Dubé syndrome, folliculin, cancer predisposition, review, 751
- Bisphosphonate, osteosarcoma, radiation, combined effects, 2713
- Bistable switch, response curve, mathematical model, drug composition, mTOR, carcinogenesis, 2683
- Biweekly infusion, irinotecan, metabolism, pharmacokinetics, cetuximab, colorectal cancer, 2355
- Bladder cancer cells, A3 adenosine receptor, A3AR antagonist, apoptosis, truncated thio-CI-IB-MECA, 2823
- Bladder cancer cells, vascular endothelial growth inhibitor, VEGF, urothelial cancer of bladder, motility and adhesion, 87
- Bladder cancer, biomarkers, tumor progression, immunohistochemistry, CA19.9, CEA, transitional cell carcinoma, 5195
- Bladder cancer, chemotherapy, synergism, cell cycle, carboplatin, gemcitabine, 4573
- Bladder cancer, immunotherapy, BCG, integrin, 4089
- Bladder cancer, prognosis, urinary FISH test, UroVysion assay, recurrence, 4761
- Bladder carcinoma,  $\gamma\delta$  T-cells, cancer immunotherapy, histone deacetylase inhibitor, valproic acid, NKG2D ligands, 4509
- Bladder, Go6976, protein kinase C, retinoblastoma, carcinoma, 3995
- Bleeding, prostate, biopsy, postoperative complications, ultrasound probe, 3071
- Blood of main drainage vein, *3OST2*, early detection, bowel lavage, 4811
- Blood vessels, *in vivo* imaging, color-coded, GFP, RFP, UVC, melanoma, 3291
- Blood, *K-ras*, serum, plasma, colorectal cancer, pancreatic cancer, diagnostic test, predictive test, review, 2943
- Blue light, melanoma, endothelial cells, phototoxicity, 143
- BMD, nextrutine<sup>R</sup>, tumor invasion, prostate cancer, CREB, NF- $\kappa$ B, TRAMP, 857
- BMI, anesthesia, HIF1 $\alpha$ , lung cancer, one-lung ventilation, obesity, pneumothorax, 1143
- BMI-1, polycomb protein, breast cancer, ovarian cancer, endometrial cancer, cervical cancer, cancer stem cells, 1559
- BNCT agent, medicinal electronics bricolage design, hypoxia-targeting antineoplastic drugs, hypoxic cell radiosensitizers, IDO inhibitor, boron tracedrug, 3233
- Body cavity lymphoma, primary effusion lymphoma, lymphoma therapy, pleurodesis, 271
- Body image drawing analysis, breast disease, breast cancer, 2399
- Body image drawing analysis, breast disease, breast cancer, 683
- Body mass index, type 2 diabetes mellitus, cancer, mortality, epidemiological study, 681
- Bombesin (BN)-like peptides, bioluminescent imaging, gastrin-releasing peptide receptors, prostate cancer, 4039
- Bone cement, giant cell tumor, knee joint, radiolucent zone, recurrence, 3795
- Bone marrow, DNA repair, cisplatin, carboplatin, nucleotide excision repair, selenium, selenomethionine, methylseleninic acid, 291
- Bone metastases, *MMP13*, PTHrP, parathyroid hormone-related peptide, MAPK, mitogen-activated protein kinase, ERK, extracellular signal-regulated kinase, PKC, protein kinase C, breast cancer, 5029
- Bone metastases, renal cell carcinoma, sunitinib malate, tyrosine kinase inhibitor, 5165
- Bone metastasis, ALCAM, CD166, breast cancer, cell adhesion, 1163
- Bone metastasis, castration-resistant prostate cancer, tranilast, overall survival, 3077
- Bone metastasis, liver metastasis, hepatectomy, radiation therapy, colon cancer, 677
- Bone mineral density, AM value, TACHIKAWA DENKAI CALCIUM<sup>TM</sup> (E-Ca), calcium hydroxide, dual-energy X-ray absorptiometry, DXA method, 3199
- Bone morphogenetic protein 7, Smad1, lung cancer, motility, 1113
- Bone resorption, PTHrP, parathyroid hormone-related protein, VEGF, vascular endothelial growth factor, angiogenesis, MAPK, mitogen-activated protein kinase, 2755
- Bone, prognosis, telomerase, human telomerase reverse transcriptase, malignant fibrous histiocytomas, 4959
- Book reviews, 1035, 3213, 5263
- Borderline ovarian tumour, clinical management, 1701
- Borderline tumor, ovarian cancer, pseudomyxoma peritonei, borderline type ovarian cancer, metastatic carcinoma, mucinous carcinoma, 2991
- Borderline type ovarian cancer, ovarian cancer, pseudomyxoma peritonei, borderline tumor, metastatic carcinoma, mucinous carcinoma, 2991
- Boron tracedrug, medicinal electronics bricolage design, hypoxia-targeting antineoplastic drugs, hypoxic cell radiosensitizers, IDO inhibitor, BNCT agent, 3233
- Bortezomib, drug resistance, individualised tumour response testing, children, acute lymphoblastic leukaemia, acute myeloid leukaemia, 2119
- Bortezomib, fibroblast growth factor receptor 3, FGFR3, lymphoma, 1921
- Bortezomib, fixed-dose rate gemcitabine, solid tumors, phase I, 167



- Bortezomib, multiple myeloma, plasmacytoma, dexamethasone, 3791
- Bortezomide, apoptosis, caspase activity, NSC 95397, brefeldin A, sanguinarine, neuroendocrine tumors, 149
- Bowel lavage, *3OST2*, early detection, blood of main drainage vein, 4811
- BPH, prostate cancer, PCa, benign prostatic hyperplasia, DD3<sup>PCA3</sup>, mRNA, RT-PCR, 665
- Brachial plexus, desmoplastic small round cell tumour, caffeine-assisted chemotherapy, 3769
- Brachytherapy, cervical cancer, chemoradiotherapy, neoadjuvant chemotherapy, radical hysterectomy, 3731
- BRAF, colorectal cancer, metastasis, comparison, *KRAS*, mutation, 4229
- BRAF, colorectal carcinoma, *KRAS*, mutations, FFPE, ThinPrep, qPCR, 1969
- BRAF, fine-needle aspiration, melanoma, proliferation, metastatic melanoma, 3267
- Brain adjacent tissue, gliomas, origin, stem cells, *CD133*, markers, nestin, subventricular zone, review, 1977
- Brain metastases, prognostic score, radiotherapy, albumin, lactate dehydrogenase, 977
- Brain tumor model, Xerecept<sup>®</sup>, bevacizumab, Avastin<sup>®</sup>, corticorelin acetate, 5037
- Brain tumours, clomipramine, amitriptyline, tricyclic antidepressants, dexamethasone, oxygen consumption, malignant glioma, 391
- BRCA1* gene, loss of heterozygosity, LOH, familial breast cancer, genotype-phenotype correlation, 3445
- BRCA1*, *ATM*, RT-PCR, Comet assay, emodin, aloe-emodin, rhein, DNA repair, tongue cancer cells, 945
- BRCA1*, genistein, breast cancer, AKT, p21<sup>WAF1/CIP1</sup>, 2049
- Breast cancer cells, agglutinins, glycobiology, lymphangiogenesis, VEGF, galectins, lectins, 4829
- Breast cancer cells, progestins, antiprogestins, cytotoxic, non-genomic effects, mifepristone, apoptosis, cell cycle, 4835
- Breast cancer risk, apocrine gland, axillary osmidrosis, earwax, mammary gland, SNP, ABC transporter *ABCC11*, 5189
- Breast cancer, (-)-gossypol, MCF-7 cells, gossypol-myosin, anticancer, 439
- Breast cancer, acute disseminated intravascular coagulation, vinorelbine, HDFL, 3087
- Breast cancer, Akt, ErbB receptors, erlotinib, gefitinib, vitamin E, Stat, tyrosine kinase inhibitors,  $\gamma$ -tocotrienol, 429
- Breast cancer, ALCAM, CD166, bone metastasis, cell adhesion, 1163
- Breast cancer, alcohol, obesity, estrogen, post-menopause, 1
- Breast cancer, amphiregulin, EGFR, MMP-9, 2101
- Breast cancer, anti-cancer drugs, gap junctions, 6-methoxy-8-[(2-furanylmethyl)amino]-4-methyl-5-(3-trifluoromethyl phenoxy)quinoline, *in vivo* activity, quinolines, 3927
- Breast cancer, antisense, transferrin receptor, iron transport, cell culture, 759
- Breast cancer, apoptosis, autophagy, bafilomycin A1, MDA-MB-231, sulforaphane, 3381
- Breast cancer, *ATM*, polymorphism, carcinogenesis, 5217
- Breast cancer, B3 lesions, vacuum-assisted core biopsy, Suros, microcalcification, lobular hyperplasia, DCIS, 2287
- Breast cancer, bamboo leaf extract, anticarcinogenesis effect, pretreatment, cancer prevention, tumor growth suppression, 111
- Breast cancer, breast disease, body image drawing analysis, 2399
- Breast cancer, breast disease, body image drawing analysis, 683
- Breast cancer, breast disease, losses, deficit, 4303
- Breast cancer, CA 15-3, CEA, relapse, tumour markers, elderly, postmenopausal, 2331
- Breast cancer, CEA, Her2/neu, BCRP, HSP27, microparticles, 1707
- Breast cancer, cell proliferation, Erk signaling, keratinocyte growth factor, KGFR tyrosine kinase inhibitor, metastasis prevention, 4883
- Breast cancer, chemotherapy, neoadjuvant, gemcitabine, pegylated liposomal doxorubicin, docetaxel, phase II, locally advanced, 3817
- Breast cancer, circulating cell-free DNA, cfDNA, serum level, menstrual cycle, 2235
- Breast cancer, circulating tumour cells, human mammaglobin, reverse-transcriptase polymerase chain reaction, 2377
- Breast cancer, cyclin D polymorphism, *CDKN1B* polymorphism, Turkish population, 3093
- Breast cancer, cyclin D1, cyclin D1b, cyclin-dependent kinase inhibitor, 1279
- Breast cancer, cyclooxygenase-2, 15-hydroxyprostaglandin dehydrogenase, vitamin D receptor, prostaglandin receptor, calcidiol, PGE<sub>2</sub>, 1673
- Breast cancer, cytology, fine-needle aspiration biopsy, DNA cytometry, DNA content, benign breast lesions, free cell sampling, cell group sampling, 175
- Breast cancer, EGFR, mutation, 4219
- Breast cancer, environmental oestrogens, cosmetics, antiperspirant, deodorant, paraben, aluminium, organochlorine, phytoestrogen, breast cysts, review, 815
- Breast cancer, erythropoietin receptor, local cancer recurrence, anemia, hormone receptor status, 3721
- Breast cancer, FISH, IHC, HER-2/neu, 4081
- Breast cancer, gene polymorphism, CD44, patient age, tumor burden, SNP, 1263

- Breast cancer, genistein, *BRCA1*, AKT, p21<sup>WAF1/CIP1</sup>, 2049
- Breast cancer, glycodeilin, differentiation, immunohistochemistry, 1599
- Breast cancer, heat-shock protein 70, Ki-67, neoadjuvant, aromatase inhibitor, 3465
- Breast cancer, HER2, trastuzumab, plasma DNA, 2463
- Breast cancer, hindgut, neuroendocrine tumour, carcinoid, 3015
- Breast cancer, histology, survival analysis, steroid receptors, 5137
- Breast cancer, Hrs, Rab7, ExoC5, RT-PCR, E-cadherin, fragments, 3903
- Breast cancer, IL-2, high-dose chemotherapy, NK cells, 5-fluorouracil, epirubicin, cyclophosphamide, methotrexate, radiotherapy, etoposide, carboplatin, VEGF, retinoic acid, myeloablative chemotherapy, autologous transplantation, immunotherapy, 209
- Breast cancer, inhibin A, proliferation, chemotherapy, 4563
- Breast cancer, MCF-7 cells,  $\gamma$ -tocotrienol, cell cycle, retinoblastoma, cyclin D1, quinone reductase NQO2, 2869
- Breast cancer, metastasis, stomach, 3705
- Breast cancer, metastasis, WFDC2, prognostic factor, HE4, 4779
- Breast cancer, *MMP13*, PTHrP, parathyroid hormone-related peptide, MAPK, mitogen-activated protein kinase, ERK, extracellular signal-regulated kinase, PKC, protein kinase C, bone metastases, 5029
- Breast cancer, neoadjuvant chemotherapy, pCR, HER2, epirubicin, cyclophosphamide, paclitaxel, trastuzumab, 4665
- Breast cancer, Notch, cancer stem cells, gamma-secretase, mammosphere, 3853
- Breast cancer, nuclear morphometry, prognosis, treatment response, 2185
- Breast cancer, oestrogen metabolism, N-acetyltransferase 2, cytochrome P450 1B1, heterocyclic arylamines, 2885
- Breast cancer, oestrogen receptor, progesterone receptor, MIB-1, CEA, CA15-3, 4701
- Breast cancer, orally active, selective estrogen receptor down-regulator SERD, nonsteroidal, thiochroman derivative, 873
- Breast cancer, polycomb protein, BMI-1, ovarian cancer, endometrial cancer, cervical cancer, cancer stem cells, 1559
- Breast cancer, promoter hypermethylation, genomic methylation, tumor suppressor genes, repetitive elements, WBC DNA, 2489
- Breast cancer, PTPG, tumor suppressor, cell cycle regulators, 1937
- Breast cancer, radiofrequency ablation, breast conserving surgery, 3693
- Breast cancer, radiotherapy, hypofractionation, concomitant boost, 4749
- Breast cancer, *RAS* protein farnesylation, farnesyl diphosphate analogues, lung cancer, isoprenoids, 2505
- Breast cancer, real-time PCR, oestrogen receptor, 4147
- Breast cancer, recurrence-free follow-up, isolated tumour cells, minimal residual disease, zoledronate treatment, 1807
- Breast cancer, sentinel lymph node, MMP-2, MMP-9, metastasis, 3521
- Breast cancer, SETD2, telomerase, histone methyltransferase, 3309
- Breast cancer, signal pathway, mTOR, TS, ROS, 5-FU, rapamycin, 2625
- Breast cancer, technetium, GRP receptor, carbonyl, T47-D, MDA-MB-231, <sup>99m</sup>Tc-(CO)<sub>3</sub>-X-Y-bombesin (7-14)NH<sub>2</sub>, 19
- Breast cancer, thymidylate synthase, polymorphism, protein level, 4373
- Breast cancer, thyroid function, thyroid antibodies, 1713
- Breast cancer, tocotrienols, MCF-7, MDA-MB-231, chemoprevention, NRF2, 4169
- Breast cancer, topoisomerase II alpha, tissue microarray, 2459
- Breast cancer, triple negative, pre-operative therapy, prediction of therapy response, dose-dense epirubicin, cyclophosphamide, docetaxel, 4251
- Breast cancer, tumor marker, CA 27.29, chemotherapy, MUC-1, 1837
- Breast cancer, tumour glycolysis, M2PK, pAkt, 1689
- Breast cancer, type II sodium-dependent phosphate transporter, SLC34A2, diagnosis, therapy, 4135
- Breast cancer, *WT1*, HER2, EGFR, estrogen and antiestrogen, 3637
- Breast cancer, zinc- $\alpha$ 2-glycoprotein, adipokine, leptin, adiponectin, biomarker, apoptosis, 2919
- Breast cancer,  $\alpha$ -difluoromethylornithine, DFMO, biomarker, apoptosis, proliferation, invasion, 2263
- Breast conserving surgery, radiofrequency ablation, breast cancer, 3693
- Breast cysts, environmental oestrogens, breast cancer, cosmetics, antiperspirant, deodorant, paraben, aluminium, organochlorine, phytoestrogen, review, 815
- Breast disease, breast cancer, body image drawing analysis, 2399
- Breast disease, breast cancer, body image drawing analysis, 683
- Breast disease, breast cancer, losses, deficit, 4303
- Breast neoplasms, genetic polymorphism, epidemiology, estrogens, risk, *COMT* haplotypes, 217
- Breast reconstruction, deep inferior epigastric artery, perforator flap, venous, arterial, anastomosis, 1293
- Breast, DLEC1, 1079

- Breast, methionine, prostate, colon, p53, 1881
- Breast, SISH, HER2, colon, prostate, lung, ovary, 1287
- Brefeldin A, apoptosis, caspase activity, NSC 95397, bortezomide, sanguinarine, neuroendocrine tumors, 149
- Brivanib, angiogenesis, VEGF-R, bFGF-R, clinical studies, biomarker, review, 4477
- 3-Bromopyruvate, ER stress, antiglycolytic, autophagosome, translation inhibition, 923
- Brooke-Spiegler syndrome, dermal cylindroma, skull defects, 1793
- Brucea javanica*, cytotoxicity, NF- $\kappa$ B, NFAT, ROS, mitochondria, 3295
- Buccal pouch, DMBA, calcium glucarate, hamsters, squamous cell carcinoma, 843
- Busulfan, pharmacokinetics, benzodiazepines, seizure prophylaxis, metabolism induction, phenytoin, 2977
- Buthionine-SR-sulfoximine, WiDr colon cancer cells, growth factors, 5-fluorouracil, oxaliplatin, SN-38, glutathione modulation, L-2-oxothiazolidine-4-carboxylate, 1223
- Bystander effect, gastric cancer, *Drosophila melanogaster* multisubstrate deoxyribonucleoside kinase, retroviral vector, suicide gene, 2641
- Bystander effect, ionising radiation, ELISA, activation, TGF $\beta$ , 3341
- Bystander responses, cytokines, gamma radiation, glioblastoma, *in vitro*, 2769
- C225, androgen-independent prostate cancer, epidermal growth factor receptor, EGFR, cetuximab, monoclonal antibody, Du145, PC-3, 1905
- CA 15-3, CEA, breast cancer, relapse, tumour markers, elderly, postmenopausal, 2331
- CA 27.29, breast cancer, tumor marker, chemotherapy, MUC-1, 1837
- CA125, liposomal cisplatin, ovarian cancer, phase II, 541
- CA15-3, oestrogen receptor, progesterone receptor, MIB-1, CEA, breast cancer, 4701
- CA19.9, bladder cancer, biomarkers, tumor progression, immunohistochemistry, CEA, transitional cell carcinoma, 5195
- CA19-9, pancreatic cancer, overall survival, 1869
- CA19-9, Sialyl Lewis a, larynx carcinoma, squamous cell carcinoma, phlogistic tissue, 1849
- Caco-2, colon cancer, flavonols, growth, differentiation, peroxide, alkaline phosphatase, 3629
- Caco-2, colon cancer, polyphenols, growth, differentiation, histone deacetylase inhibitors, 311
- Cadherin, insulin-like growth factor, leiomyoma, myeloperoxidase, polymorphism, urokinase, xeroderma pigmentosum, 2203
- CADPE, cyclin D1, STAT3, IL-6, hepatocellular carcinoma, 481
- Caffeine-assisted chemotherapy, desmoplastic small round cell tumour, brachial plexus, 3769
- CAG, chronic atrophic gastritis, pepsinogen, *Helicobacter pylori*, gastric cancer, adenosine deaminase, ADA, 2347
- Calcidiol, breast cancer, cyclooxygenase-2, 15-hydroxyprostaglandin dehydrogenase, vitamin D receptor, prostaglandin receptor, PGE<sub>2</sub>, 1673
- Calcidiol, cervical cancer, ovarian cancer, 25-hydroxylase, 1 $\alpha$ -hydroxylase, 24-hydroxylase, vitamin D, calcitriol, 4429
- Calcification, gorlin, NBCCS, ponticulus posterior, atlanto-occipital ligament, 4265
- Calcitriol, cervical cancer, ovarian cancer, 25-hydroxylase, 1 $\alpha$ -hydroxylase, 24-hydroxylase, vitamin D, calcidiol, 4429
- Calcitriol, vitamin D, cervical cancer, prostate cancer, potassium channels, placenta, EAG1, 2667
- Calcium glucarate, DMBA, hamsters, buccal pouch, squamous cell carcinoma, 843
- Calcium hydroxide, bone mineral density, AM value, TACHIKAWA DENKAI CALCIUM™ (E-Ca), dual-energy X-ray absorptiometry, DXA method, 3199
- Calpain, calpastatin, endometrial cancer, 2837
- Calpains, cancer, peroxiredoxin, rhabdomyosarcoma, 5085
- Calpastatin, calpain, endometrial cancer, 2837
- Calponin h1, actin cytoskeleton stability, cell motility, point mutation, S175T, HeLa cells, 1071
- CaMKII, toxin Bc2, equinatoxin-II, cytolysins, signaling pathways, necrosis, MAPK/ERK, PKC, glioma cell death, 1209
- Camptothecin derivative, apoptosis, DNA damage and repair,  $\gamma$ -H2AX, M-phase cell, radiation, 937
- Cancer cell, prostate cancer, liver X receptor, T0901317, 22(R)-hydroxycholesterol, 3643
- Cancer cells, clioquinol, NF- $\kappa$ B, lysosome, DU 145, 2087
- Cancer chemoprevention, enzyme induction, RT-PCR, metabolism, aromathecins, phenazines, 4873
- Cancer gene therapy, recombinant AAV serotypes 1, 2, and 5, transduction efficiency, solid tumor, pancreatic cancer cells, colon carcinoma cells, 1931
- Cancer immunotherapy, Wilms' tumor gene, *WT1*, helper T cell, helper peptide, peptide vaccine, 2247
- Cancer immunotherapy,  $\gamma\delta$  T-cells, bladder carcinoma, histone deacetylase inhibitor, valproic acid, NKG2D ligands, 4509
- Cancer invasion, 3-hydroxyproline, type IV collagen, basement membrane, cancer metastasis, cancer screening, ELISA, 1007
- Cancer metastasis, 3-hydroxyproline, type IV collagen, basement membrane, cancer invasion, cancer screening, ELISA, 1007
- Cancer microenvironment, cancer-associated fibroblasts, tumor stroma, squamous cell carcinoma, basal cell carcinoma, review, 455

- Cancer mortality, mosquito, adenovirus, susceptibility, immune suppression, malaria, 1371
- Cancer of the small intestine, chemotherapy, clinical features, 3193
- Cancer patients, caregiver distress, principal caregiver, quality of life, 4657
- Cancer predisposition, Birt Hogg Dubé syndrome, folliculin, review, 751
- Cancer prevention, bamboo leaf extract, anticarcinogenesis effect, breast cancer, pretreatment, tumor growth suppression, 111
- Cancer screening, 3-hydroxyproline, type IV collagen, basement membrane, cancer invasion, cancer metastasis, ELISA, 1007
- Cancer stem cells, breast cancer, Notch, gamma-secretase, mammosphere, 3853
- Cancer stem cells, polycomb protein, BMI-1, breast cancer, ovarian cancer, endometrial cancer, cervical cancer, 1559
- Cancer stem cells, side population, head and neck squamous carcinoma, 2005
- Cancer therapy, claudin, antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, 4555
- Cancer therapy, MGMT, alkyltransferase, drug resistance, SCCHN, field cancerization, 2561
- Cancer vaccine, cancer/testis antigens, SEREX, prostate cancer, yeast, 895
- Cancer, calpains, peroxiredoxin, rhabdomyosarcoma, 5085
- Cancer, chemoF<sub>x</sub> DRM, heterogeneity, chemotherapeutic response, mechanism of action, chemotherapy drug response marker, *in vitro* chemosensitivity testing, 2805
- Cancer, chemotherapy, colorectal cancer treatment, microsatellite instability, FOLFOX, adjuvant treatment, prognostic factor, 4297
- Cancer, curcumin, copper, A2780, mTOR, NF- $\kappa$ B, 3249
- Cancer, curcumin, metabolism, liposomal curcumin, cytochrome P450, 811
- Cancer, doxorubicin, MDR reversal, dihydropyridine derivative, oxidative stress, antioxidant, 4063
- Cancer, energy metabolism, primary prevention, tertiary prevention, obesity, metabolic syndrome X, malnutrition, palliative care, review, 1863
- Cancer, functional proteomics, proliferation, NAPPA microarrays, review, nanotechnology, 2073
- Cancer, HB-EGF, targeted therapy, review, 3107
- Cancer, hydantoin, *ABCBI*, P-glycoprotein, multidrug resistance, 4867
- Cancer, mental adjustment to cancer, depression, anxiety, 5-HTTLPR polymorphism, 3823
- Cancer, methioninase, PEG-methioninase, methionine dependence, efficacy, selectivity, 793
- Cancer, methioninase, rMETase, PEG-methioninase, PEG-rMETase, methionine dependence, efficacy, selectivity, 1041
- Cancer, proteomics, E7 oncogene, melphalan, Tg mouse, 2773
- Cancer, transketolase-like-1 protein, TKTL1, aerobic glycolysis, endometrial cancer, glucose metabolism, pAkt, GLUT1, 1653
- Cancer, type 2 diabetes mellitus, body mass index, mortality, epidemiological study, 681
- Cancer/testis antigens, mesenchymal stem cells, pericytes, fibroblasts, MAGED1, PRAME, 5023
- Cancer/testis antigens, SEREX, prostate cancer, yeast, cancer vaccine, 895
- Cancer-associated fibroblasts, cancer microenvironment, tumor stroma, squamous cell carcinoma, basal cell carcinoma, review, 455
- Cancer-specific survival, prognosis, tumour characteristics, 5227
- Canine lymphoma, HMGB1, RAGE, 5043
- Capecitabine, imatinib mesylate, phase I, advanced solid tumors, 1251
- Capecitabine, oxaliplatin, drug–drug interaction, pharmacokinetics, 5207
- Capecitabine, S-1, metastatic breast cancer, 3827
- Capecitabine, vinorelbine, metastatic breast cancer, oral chemotherapy, 2255
- CAR, carcinoembryonic antigen, CEA, chimeric T-cell antigen receptor, human antibody, signaling cluster, T-cell activation, 2731
- Carbohydrate antigen19-9, pancreatic ductal adenocarcinoma, matrix metalloproteinase 9, MMP-9, tissue inhibitor of metalloproteinases 1, TIMP-1, receiver operating characteristic curves, ROC, 587
- Carbon ion, high-LET, p53, radiosensitivity, apoptosis, chemotherapeutic agent, 1961
- Carbon radiotherapy, external beam radiation therapy, PSA-doubling time, prostate cancer, 5105
- Carbonic anhydrase IX, renal cell carcinoma, high-dose interleukin-2, 987
- Carbonic anhydrase IX, renal cell carcinoma, prognosis, 2953
- Carbonyl, breast cancer, technetium, GRP receptor, T47-D, MDA-MB-231, <sup>99m</sup>Tc-(CO)<sub>3</sub>-X-Y-bombesin (7-14)NH<sub>2</sub>, 19
- Carboplatin, bladder cancer, chemotherapy, synergism, cell cycle, gemcitabine, 4573
- Carboplatin, chemotherapy, paclitaxel, hematologic toxicity, age, non-small cell lung cancer, 1365
- Carboplatin, DNA repair, cisplatin, nucleotide excision repair, selenium, selenomethionine, methylseleninic acid, bone marrow, 291
- Carboplatin, IL-2, high-dose chemotherapy, NK cells, 5-fluorouracil, epirubicin, cyclophosphamide, methotrexate, radiotherapy, etoposide, VEGF, retinoic acid, myeloablative chemotherapy, autologous transplantation, immunotherapy, breast cancer, 209

- Carboplatin, non-small cell lung cancer, paclitaxel, chemotherapy, interstitial lung disease, efficacy, safety, 4357
- Carboplatin, NSCLC, adjuvant chemotherapy, paclitaxel, gemcitabine, treatment compliance, surgical resection, 4695
- Carboplatin, NSCLC, adjuvant chemotherapy, paclitaxel, treatment compliance, surgical resection, 3039
- Carboplatin, ovarian cancer, docetaxel, chemotherapy resistance, array CGH, 4451
- Carcinoembryonic antigen, CEA, chimeric T-cell antigen receptor, CAR, human antibody, signaling cluster, T-cell activation, 2731
- Carcinoembryonic antigen, staurosporine, circulating tumor cells, immunomagnetic isolation, RT-PCR analysis, 4721
- Carcinogenesis, arsenic trioxide, dithiothreitol, oral cancer, 3655
- Carcinogenesis, *ATM*, polymorphism, breast cancer, 5217
- Carcinogenesis, *Cox-2*, polymorphism, lung cancer, 1195
- Carcinogenesis, prostate cancer, methylenetetrahydrofolate reductase, polymorphism, 3573
- Carcinogenesis, response curve, bistable switch, mathematical model, drug composition, mTOR, 2683
- Carcinogenesis, statins, HMGCoA reductase inhibitors, liver neoplasm, ubiquinone, mevalonate pathway, hepatocarcinogenesis, lovastatin, 1105
- Carcinogenesis, tongue and pharyngolaryngeal carcinomas, Epstein-Barr virus, human papilloma virus, John Cunningham, 1233
- Carcinogenesis, *XRCC4*, polymorphism, colorectal cancer, 2727
- Carcinoid, breast cancer, hindgut, neuroendocrine tumour, 3015
- Carcinoid, carcinoma, small cell carcinoma, large cell neuroendocrine carcinoma, methylation, immunofluorescence, survival, RASSF1, 4269
- Carcinoid, neuroendocrine tumor, cell lines, plant extracts, bioactive agents, chemoresistance, apoptosis, 55
- Carcinoma, carcinoid, small cell carcinoma, large cell neuroendocrine carcinoma, methylation, immunofluorescence, survival, 4269
- Carcinoma, carcinoid, small cell carcinoma, large cell neuroendocrine carcinoma, methylation, immunofluorescence, survival, RASSF1, 4269
- Carcinoma, colon, adenoma, size, limits, 2419
- Carcinoma, Go6976, protein kinase C, retinoblastoma, bladder, 3995
- Carcinoma, pancreatitis, oxaliplatin, 5113
- Carcinomas, colon, GALT, Lynch syndrome, 3019
- Carcinomatosis, orthotopic implantation, esophageal carcinoma, *in vivo* fluorescence imaging, 3933
- Cardiac function, antioxidant, astaxanthin, mouse, inflammation, mammary tumor initiation, 2171
- Cardioprotection, astaxanthin, immunomodulation, 2721
- Cardiopulmonary toxicity, Hodgkin's disease, chemoradiotherapy, 4381
- Caregiver distress, cancer patients, principal caregiver, quality of life, 4657
- Carpobrotus edulis*, *Aizoaceae*, efflux pump, P-glycoprotein, multidrug resistance, 829
- Case report, anaplastic thyroid carcinoma, multimodal treatment, chemotherapy, long-term survival, 1273
- Caspase activity, apoptosis, NSC 95397, brefeldin A, bortezomide, sanguinarine, neuroendocrine tumors, 149
- Caspase cascade, curcumin, apoptosis, G<sub>2</sub>/M arrest, endoplasmic reticulum stress, lung neoplasms, herbal medicine, 2125
- Caspase, apoptosis, FCCP, juxtaglomerular cell, mitochondria, 2863
- Caspase, MG132, apoptosis, endothelial cells, ROS, GSH, proteasome inhibitor, 879
- Caspase-3, HMG CoA reductase, mevalonate, tocotrienol, statin, Cdk4, Ras, cell cycle, apoptosis, 4937
- Caspase-3, SN38, ilinotecan, topoisomerase inhibitor, apoptosis, *ATM*, p53, p21, 3911
- Caspases, acyclic nucleoside phosphonate, programmed cell death, CCRF-CEM cells, cell cycle, cD95/Fas, 2791
- Caspases, apoptosis, mcl-1, 5-fluorouracil, Jurkat, T cells, 3879
- Castration-resistant prostate cancer, ethinylestradiol, prostate-specific antigen, 5201
- Castration-resistant prostate cancer, tranilast, bone metastasis, overall survival, 3077
- Catecholamines, paraganglioma, MIBG, pheochromocytoma, 5153
- $\alpha$ -Catenin, E-cadherin, down-regulation, immunohistochemistry, endometrium, 4993
- $\beta$ -Catenin, colon cancer, COX-2, celecoxib, nitro-oxy derivative, PI3K/Akt, 2659
- $\beta$ -Catenin, gap junctional intercellular communication GJIC, connexin43, E-cadherin, ZO-1, immunohistochemistry, CpG island, methylation analysis, pyrosequence, lung cancer, 2271
- $\beta$ -Catenin, HNSCC, UM-SCC, sulindac sulfone, cell line, cell culture, apoptosis, 339
- $\beta$ -Catenin, MUC1, c-Met, immunohistology, gastric cancer, prognosis, 4635
- Cathepsin B, needle biopsy, radical prostatectomy, stefin A, MIB-1, DNA ploidy, prostate cancer, 719
- Cathepsin, giant cell lesions, giant cell granuloma, epulis, RANK, matrix metalloproteinase, jaws, osteoclast, salivary glands, tendon sheath, 1645
- Catheter colonization, rifampicin-miconazole-releasing catheters, local infection, long-term activity, oncology patients, 1353
- Cationic hybrid liposome, renal cell carcinoma, apoptosis, chemotherapy, 327

- Caveolae, multidrug resistance, *ABCB1*, anthracycline, AML, caveolin-1, cholesterol, 3451
- Caveolin-1, multidrug resistance, *ABCB1*, anthracycline, AML, caveolae, cholesterol, 3451
- CC10, pulmonary surfactant, *KRAS* mutation, intratracheal instillation, lung cancer, gene transfer, 4925
- CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP) gene, chromosomal translocation, Ewing sarcoma (EWS) gene, fluorescence *in situ* hybridization, FISH, fusion gene, myxoid liposarcoma, MLS, reverse transcription-polymerase chain reaction, RT-PCR, 4679
- CCL2, ovarian cancer, chemosensitivity, invasion, 4791
- CCR7, gastric cancer, VEGF-C, VEGF-D, lymphatic invasion, 2361
- CCRF-CEM cells, acyclic nucleoside phosphonate, programmed cell death, cell cycle, caspases, cD95/Fas, 2791
- CD10, CD13, gp160, peptidases, renal tumour behaviour, papillary carcinoma, 1137
- CD117, immunohistochemistry, mutation breast phyllodes tumor, c-Kit, 4731
- CD13, CD10, gp160, peptidases, renal tumour behaviour, papillary carcinoma, 1137
- CD133*, gastric cancer, stem cell, prognosis, 2453
- CD133*, gliomas, origin, stem cells, markers, brain adjacent tissue, nestin, subventricular zone, review, 1977
- CD133*, quantitative methylation-specific PCR, gastric cancer, 1201
- CD14++CD16-, tumour-derived microvesicles, CD14+CD16++ monocyte subsets, 3515
- CD14+CD16++ monocyte subsets, tumour-derived microvesicles, CD14++CD16-, 3515
- CD166, ALCAM, breast cancer, bone metastasis, cell adhesion, 1163
- CD4+ cells, nanodiamond, dendritic cells, *in vitro*, bionanotechnology, 4075
- CD44, gene polymorphism, breast cancer, patient age, tumor burden, SNP, 1263
- CD44, glioblastoma multiforme, metastasis, survival, 253
- CD95/Fas, acyclic nucleoside phosphonate, programmed cell death, CCRF-CEM cells, cell cycle, caspases, 2791
- CDH1*, E-cadherin, promoter polymorphism, methylation, *KIT*, gastric cancer, 2225
- CDK inhibitor, AKT, GSK3beta, natural products, plant extract, 3599
- Cdk4, HMG CoA reductase, mevalonate, tocotrienol, statin, caspase-3, Ras, cell cycle, apoptosis, 4937
- CDKN1B* polymorphism, cyclin D polymorphism, breast cancer, Turkish population, 3093
- CDX2, guggulsterone, bile acid, farnesoid X receptor, FXR, 1953
- CEA peptide, colorectal cancer, dendritic cells, antigen loading, mRNA, electroporation, immunotherapy, vaccination, 5091
- CEA, biomarkers, TIMP-1, rectal cancer, chemoradiation, 4755
- CEA, bladder cancer, biomarkers, tumor progression, immunohistochemistry, CA19.9, transitional cell carcinoma, 5195
- CEA, CA 15-3, breast cancer, relapse, tumour markers, elderly, postmenopausal, 2331
- CEA, carcinoembryonic antigen, chimeric T-cell antigen receptor, CAR, human antibody, signaling cluster, T-cell activation, 2731
- CEA, colon cancer, chemotherapy, TIMP-1, 233
- CEA, combination therapy, inflammation, postsurgical, micrometastases, lung carcinoma, lymphokine-activated killer cell therapy, glucocorticoid, 3125
- CEA, CYFRA 21-1, tumour marker index, non-small cell lung cancer, survival, 3099
- CEA, Her2/neu, BCRP, HSP27, microparticles, breast cancer, 1707
- CEA, lung cancer, CYFRA 21-1, marker panel, ROC-curves, 1661
- CEA, oestrogen receptor, progesterone receptor, MIB-1, CA15-3, breast cancer, 4701
- CEA, tumour marker, receiver operating characteristic curve, diagnosis, cytokeratin 19, mesothelioma, 4343
- CEACAM1, human epididymis, adenomatoid, angiogenesis, 2651
- CEACAM1, thyroid cancer, thyroid gland, osteopontin, OPN, 1681
- Celecoxib, colon cancer, COX-2, nitro-oxy derivative,  $\beta$ -catenin, PI3K/Akt, 2659
- Celecoxib, rapamycin, mTOR, COX 2, angiosarcoma, endothelial tumour, 4017
- Cell adhesion, ALCAM, CD166, breast cancer, bone metastasis, 1163
- Cell culture, breast cancer, antisense, transferrin receptor, iron transport, 759
- Cell culture, HNSCC, UM-SCC,  $\beta$ -catenin, sulindac sulfone, cell line, apoptosis, 339
- Cell culture, malignant glioma, three-dimension, morphology, 383
- Cell cycle arrest, enzyme inhibitor, apoptosis, anti-cancer effect, 4841
- Cell cycle arrest, sansalvamide A, pancreatic cancer, 73
- Cell cycle proteins, hepatitis, cirrhosis, hepatocellular carcinoma, apoptotic proteins, 4493
- Cell cycle regulators, PTPG, breast cancer, tumor suppressor, 1937
- Cell cycle, 1,4-naphthoquinone, human prostate cancer cell lines, cytotoxicity, apoptosis, 519
- Cell cycle, acyclic nucleoside phosphonate, programmed cell death, CCRF-CEM cells, caspases, cD95/Fas, 2791
- Cell cycle, apoptosis, presenilin 1, presenilin 2, G<sub>0</sub>/G<sub>1</sub>, chemoresistance,  $\gamma$ -secretase, pancreatic ductal adenocarcinoma cells, taxanes, 4999

- Cell cycle, bladder cancer, chemotherapy, synergism, carboplatin, gemcitabine, 4573
- Cell cycle, breast cancer, MCF-7 cells,  $\gamma$ -tocotrienol, retinoblastoma, cyclin D1, quinone reductase NQO2, 2869
- Cell cycle, coumarin, basic amino side chain, cell viability, benzopyranone derivatives, 4613
- Cell cycle, glioma, ROCK isoforms, shRNA, ACNU, 3509
- Cell cycle, HMG CoA reductase, mevalonate, tocotrienol, statin, Cdk4, caspase-3, Ras, apoptosis, 4937
- Cell cycle, integrin  $\alpha$ v $\beta$ 6, RNA interference, proliferation, invasion, apoptosis, chemosensitivity, pancreatic carcinoma cells, 135
- Cell cycle, LA-12, oxaliplatin, cisplatin, colon cancer, apoptosis, 1183
- Cell cycle, nonsteroidal anti-inflammatory drugs, NSAID, hydroxamic acids, cytostatic activity, cytotoxicity, human pancreatic cancer, Akt signalling, apoptosis, 3987
- Cell cycle, *Oplopanax horridus*, human colorectal cancer, anti-proliferation, apoptosis, cyclin A, cyclin B1, 295
- Cell cycle, oral cancer, 2'-hydroxycinnamaldehyde, apoptosis, tumor model, 489
- Cell cycle, progestins, antiprogestins, cytotoxic, breast cancer cells, non-genomic effects, mifepristone, apoptosis, 4835
- Cell cycle, stem cells, education, cooperation, natural products, 2477
- Cell damage, ultrasound, lipid peroxidation, sonodynamic activation, reactive oxygen, DCPH-P-Na(I), 2241
- Cell group sampling, breast cancer, cytology, fine-needle aspiration biopsy, DNA cytometry, DNA content, benign breast lesions, free cell sampling, 175
- Cell growth, anandamide, polyamines, colorectal cancer, 2583
- Cell growth, invasion, migration, cell-cell adhesion, delta opioid receptor agonists, colon cancer cells, 9
- Cell line, HNSCC, UM-SCC,  $\beta$ -catenin, sulindac sulfone, cell culture, apoptosis, 339
- Cell line, urothelial carcinoma, B cells, Epstein-Barr virus, LMP-1, pathogenesis, 3473
- Cell lines, neuroendocrine tumor, carcinoid, plant extracts, bioactive agents, chemoresistance, apoptosis, 55
- Cell lines, radiation, TNF-alpha, programmed cell death, sarcoma cell lines, lymphoma cell lines, 2857
- Cell motility, calponin h1, actin cytoskeleton stability, point mutation, S175T, HeLa cells, 1071
- Cell motility, integrin  $\alpha$ 6 $\beta$ 4, thyroid cancer, invasion, anaplastic thyroid carcinoma, 4485
- Cell proliferation, colon cancer, ODC, polyamines, polyphenols, quercetin, 3501
- Cell proliferation, epigallocatechin-3-gallate, SKOV-3 cells, ovarian cancer, apoptosis, 2519
- Cell proliferation, Erk signaling, keratinocyte growth factor, KGFR tyrosine kinase inhibitor, breast cancer, metastasis prevention, 4883
- Cell surface saccharides, L1210 cells, multidrug resistance, P-glycoprotein, concanavalin A, 3661
- Cell uptake, drug combination, YH12, A2780, dose-effect curves, platinum-DNA binding, *trans*-platinum compounds, ovarian cancer cell lines, cisplatin, 4547
- Cell viability, coumarin, basic amino side chain, cell cycle, benzopyranone derivatives, 4613
- Cell xenografts, animal cancer models, chick embryo, rodent model, tumour markers, immunohistochemistry, glioblastoma, 4851
- Cell-cell adhesion, invasion, cell growth, migration, delta opioid receptor agonists, colon cancer cells, 9
- Cell-cycle, chemotherapy, cross-resistance, gastric cancer cell lines, anticancer drugs, apoptosis, 915
- Cell-free DNA, circulating, kidney cancer, biomarker, serum, 2785
- Cell-penetrating peptide, antitumor, apoptosis, gene therapy, protein transduction domain, tumor necrosis factor-related apoptosis-inducing ligand, TRAIL, arginine-rich peptides, 2193
- Cell-to-cell contact, alveolar macrophage, lung tumor, drug delivery system, LPS, 3159
- Cell-to-cell contact, lipopolysaccharide, pulmonary inhalation, lung cancer, alveolar macrophage, nitric oxide, 3135
- Cellular metabolism, flax, *Linum usitatissimum*, phytoestrogens, MCF-7, online monitoring, acidification, oxygen consumption, adhesion, 1587
- Cellular proliferation, thyroid gland neoplasm, thioredoxin, thioredoxin reductase, redox activity, 767
- Central nervous system, astrocytoma, malignancy, invasion, chlorotoxin, multiple chloride channels, glioma cells, 4515
- Ceramide, sphingosine, sphinganine, dihydroceramide, colon cancer, apoptosis, 2881
- Cereals, cholesterol, diet, gross domestic product, milk protein, prostate cancer, ultraviolet-B, vitamin D, 189
- Cervical cancer, cervical intraepithelial neoplasia, precancerous conditions, reproducibility, spontaneous neoplasm regression, female genital tract disease, 2319
- Cervical cancer, chemoradiotherapy, brachytherapy, neoadjuvant chemotherapy, radical hysterectomy, 3731
- Cervical cancer, false-negative results, lymphadenectomy, pelvic nodes, PET-CT, [ $^{18}$ F]Fluorodeoxyglucose, 1029
- Cervical cancer, FIGO IA1, microinvasive, repeat surgery, 565
- Cervical cancer, metastases, fibula, tibia, isotope bone scan, 2949
- Cervical cancer, neoadjuvant chemotherapy, radical hysterectomy, lymph-vascular space involvement, lymph node involvement, platelet count, 201

- Cervical cancer, ovarian cancer, 25-hydroxylase, 1 $\alpha$ -hydroxylase, 24-hydroxylase, vitamin D, calcitriol, calcitriol, 4429
- Cervical cancer, polycomb protein, BMI-1, breast cancer, ovarian cancer, endometrial cancer, cancer stem cells, 1559
- Cervical cancer, postoperative chemoradiation, cisplatin, 2341
- Cervical cancer, sentinel node, lymphoscintigraphy, intraoperative lymphatic mapping, 183
- Cervical cancer, topoisomerase I, chromosomal aberrations, chromosome 5p gain, array CGH, 3257
- Cervical cancer, vitamin D, prostate cancer, potassium channels, placenta, EAG1, calcitriol, 2667
- Cervical carcinoma, HPV, sodium butyrate, UCN-01, apoptosis, 4049
- Cervical carcinoma, tumor M2 pyruvate kinase, tumor marker, CIN, HPV, 375
- Cervical intraepithelial neoplasia, cervical squamous epithelium, progesterone, estradiol, biological markers, 1217
- Cervical intraepithelial neoplasia, dysplasia, progesterone, vaginal, phase II, 1257
- Cervical intraepithelial neoplasia, precancerous conditions, cervical cancer, reproducibility, spontaneous neoplasm regression, female genital tract disease, 2319
- Cervical squamous epithelium, cervical intraepithelial neoplasia, progesterone, estradiol, biological markers, 1217
- Cetuximab, androgen-independent prostate cancer, epidermal growth factor receptor, EGFR, C225, monoclonal antibody, Du145, PC-3, 1905
- Cetuximab, colon cancer, *K-ras* mutations, EGFR inhibitors, drug resistance, therapeutic outcome, review, 4673
- Cetuximab, EGFR, thyroid tumors, erlotinib, panitumumab, paclitaxel, 473
- Cetuximab, irinotecan, metabolism, pharmacokinetics, biweekly infusion, colorectal cancer, 2355
- Cetuximab, metastatic colorectal cancer, gene expression level, polymorphisms, clinical outcome, bevacizumab, irinotecan, 4209
- CfDNA, circulating cell-free DNA, serum level, menstrual cycle, breast cancer, 2235
- Chagasic megaesophagus, Ki-67, CPP32, chronic esophagitis, esophageal squamous cell carcinoma, 2845
- ChemoFx DRM, cancer, heterogeneity, chemotherapeutic response, mechanism of action, chemotherapy drug response marker, *in vitro* chemosensitivity testing, 2805
- Chemohormonal therapy, etoposide, ethinylestradiol, oral chemotherapy, HRPC, prostate cancer, 3737
- Chemokine, malignant mesothelioma, animal tumor model, tumor spheroids, mesenchymal stem cell, SDF1/CXCL12, 2153
- Chemoprevention, honokiol, UVB photocarcinogenesis, apoptosis, 777
- Chemoprevention, tocotrienols, breast cancer, MCF-7, MDA-MB-231, NRF2, 4169
- Chemopreventive agents, nuclear density, morphometry, rat tracheal epithelial cells, 737
- Chemoradiation, biomarkers, CEA, TIMP-1, rectal cancer, 4755
- Chemoradiation, non-small cell lung cancer, locally advanced, pattern of failure, 953
- Chemoradiation, non-small cell lung cancer, stage III, surgery, pneumonectomy, cisplatin, 4237
- Chemoradiosensitizers, radiotherapy, novel agents, chemotherapy, new radiosensitizing drugs, review, 3675
- Chemoradiotherapy, cardiopulmonary toxicity, Hodgkin's disease, 4381
- Chemoradiotherapy, cervical cancer, brachytherapy, neoadjuvant chemotherapy, radical hysterectomy, 3731
- Chemoradiotherapy, head and neck cancer, EGFR, treatment, prognostic factor, 671
- Chemoradiotherapy, rectal cancer, S-1, PSK, immune response, 993
- Chemoresistance, apoptosis, presenilin 1, presenilin 2, cell cycle, G<sub>0</sub>/G<sub>1</sub>,  $\gamma$ -secretase, pancreatic ductal adenocarcinoma cells, taxanes, 4999
- Chemoresistance, HT29, translational regulation, real-time PCR, mRNA quantification, colorectal cancer cells, fluoropyrimidine analogs, thymidylate synthase, p53, 5-FU resistance, 1149
- Chemoresistance, neuroendocrine tumor, carcinoid, cell lines, plant extracts, bioactive agents, apoptosis, 55
- Chemoresistance, small molecules, gene expression analysis, thymidylate synthase, real-time PCR, arsenic trioxide, 5-FU resistance, 1157
- Chemosensitivity sorafenib, tyrosine kinase pathway, P-glycoprotein, multidrug resistance, hepatocellular carcinoma cells, 4503
- Chemosensitivity, integrin  $\alpha$ v $\beta$ 6, RNA interference, proliferation, invasion, cell cycle, apoptosis, pancreatic carcinoma cells, 135
- Chemosensitivity, ovarian cancer, CCL2, invasion, 4791
- Chemosensitivity, p53, lung cancer, chemotherapy, cisplatin, paclitaxel, 3557
- Chemo-surviving cells, curcumin, colon cancer, EGFRs, IGF-1R, 319
- Chemotherapeutic agent, high-LET, carbon ion, p53, radiosensitivity, apoptosis, 1961
- Chemotherapeutic response, chemoFx DRM, cancer, heterogeneity, mechanism of action, chemotherapy drug response marker, *in vitro* chemosensitivity testing, 2805
- Chemotherapy drug response marker, chemoFx DRM, cancer, heterogeneity, chemotherapeutic response, mechanism of action, *in vitro* chemosensitivity testing, 2805



- Chemotherapy resistance, ovarian cancer, docetaxel, carboplatin, array CGH, 4451
- Chemotherapy with oxaliplatin plus fluorouracil and leucovorin, colorectal liver metastases, hepatic resection, FOLFOX, Japanese patients, 1015
- Chemotherapy, anticancer complementary therapy, oxygen tension, Artemisinin, hyperbaric oxygen, leukemia cells, 4467
- Chemotherapy, bladder cancer, synergism, cell cycle, carboplatin, gemcitabine, 4573
- Chemotherapy, breast cancer, neoadjuvant, gemcitabine, pegylated liposomal doxorubicin, docetaxel, phase II, locally advanced, 3817
- Chemotherapy, breast cancer, tumor marker, CA 27.29, MUC-1, 1837
- Chemotherapy, cancer of the small intestine, clinical features, 3193
- Chemotherapy, cancer, colorectal cancer treatment, microsatellite instability, FOLFOX, adjuvant treatment, prognostic factor, 4297
- Chemotherapy, carboplatin, paclitaxel, hematologic toxicity, age, non-small cell lung cancer, 1365
- Chemotherapy, case report, anaplastic thyroid carcinoma, multimodal treatment, long-term survival, 1273
- Chemotherapy, cationic hybrid liposome, renal cell carcinoma, apoptosis, 327
- Chemotherapy, chemoradiosensitizers, radiotherapy, novel agents, new radiosensitizing drugs, review, 3675
- Chemotherapy, clear cell carcinoma, surgery, radiotherapy, prognosis, recurrence, review, 1327
- Chemotherapy, colon cancer, CEA, TIMP-1, 233
- Chemotherapy, colorectal cancer, yttrium-90 microspheres, liver metastases, hepatectomy, FOLFOX, 3005
- Chemotherapy, cross-resistance, gastric cancer cell lines, anticancer drugs, apoptosis, cell-cycle, 915
- Chemotherapy, desmopressin, vasopressin, peptide analog, metastasis, colon cancer, 5049
- Chemotherapy, EGFR gene copy number, prognosis, EGFR TKIs treatment, KRAS, 5121
- Chemotherapy, epigenetics, pancreatic cancer, DNA methylation, TMS1, 3919
- Chemotherapy, ERCC1, XPF, DNA repair, drug resistance, review, 3223
- Chemotherapy, extramedullary, plasmocytoma, multifocal, uncommon site, surgery, radiotherapy, 1779
- Chemotherapy, hepatocellular carcinoma, platinum, S-1, 5245
- Chemotherapy, hybrid liposomes, gastric carcinoma, apoptosis, cotton rat, 2011
- Chemotherapy, inhibin A, proliferation, breast cancer, 4563
- Chemotherapy, IP-PA1, immunomodulator, macrophage, apoptosis, 2033
- Chemotherapy, lung cancer, postoperative recurrence, survival analysis, 1311
- Chemotherapy, malignant, glioma, 5213
- Chemotherapy, non-small cell lung cancer, carboplatin, paclitaxel, interstitial lung disease, efficacy, safety, 4357
- Chemotherapy, non-small cell lung cancer, sunitinib, 5169
- Chemotherapy, ovarian cancer, paclitaxel, observational study, 4245
- Chemotherapy, p53, lung cancer, cisplatin, paclitaxel, chemosensitivity, 3557
- Chemotherapy, pancreatic cancer, docetaxel, gemcitabine, refractory, metastatic disease, salvage therapy, 2905
- Chemotherapy, post-transplant lymphoproliferative disorders, liver transplantation, 2383
- Chemotherapy, prognostic factors, colorectal cancer, survival, 653
- Chemotherapy, radiotherapy, postoperative, pancreatic neoplasms, 2959
- Chemotherapy, urothelial cancer, heme oxygenase-1, drug resistance, radiotherapy, gemcitabine, 2145
- Chemotherapy, vocal cord cancer, radiotherapy, glottic cancer, 5181
- Chemotherapy, Wilms' tumor, prognostic factors, 1735
- Chick embryo, animal cancer models, rodent model, tumour markers, immunohistochemistry, glioblastoma, cell xenografts, 4851
- Childhood leukemia, *Cox-2*, polymorphism, 3649
- Childhood leukemia, *XRCC4*, single nucleotide polymorphism, DNA repair, 529
- Children, drug resistance, individualised tumour response testing, bortezomib, acute lymphoblastic leukaemia, acute myeloid leukaemia, 2119
- Children, radiation, side-effects, late sequelae, abdomen, 227
- Chimeric T-cell antigen receptor, carcinoembryonic antigen, CEA, CAR, human antibody, signaling cluster, T-cell activation, 2731
- Chinese herb, *Houttuynia cordata* Thunb. (HCT), apoptosis, human primary colorectal cancer cells, 3549
- Chlorotoxin, angiogenesis, TM601, MMP-2, invasion, 39
- Chlorotoxin, astrocytoma, central nervous system, malignancy, invasion, multiple chloride channels, glioma cells, 4515
- CHM-1, DNA damage, DNA repair, gene expression, U-2 OS human osteogenic sarcoma cells, quinolone, 4187
- Cholangiocarcinoma, photodynamic therapy, photofrin, local ablation, apoptosis, 2113
- Cholecystitis, gallbladder carcinoma, PCR-SSCP, direct sequencing, TP53, transition mutations, 4443
- Cholesterol, cereals, diet, gross domestic product, milk protein, prostate cancer, ultraviolet-B, vitamin D, 189
- Cholesterol, multidrug resistance, *ABCBI*, anthracycline, AML, caveolin-1, caveolae, 3451
- Chromogranin A, neuroendocrine (NE) differentiation, benign prostatic hyperplasia, finasteride, dutasteride, 4737

- Chromophobe renal carcinoma, papillary renal cell carcinoma, tubulocystic carcinoma, clear cell papillary renal cell carcinoma, oncocytoma, 641
- Chromosomal aberrations, cervical cancer, topoisomerase I, chromosome 5p gain, array CGH, 3257
- Chromosomal translocation, CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP) gene, Ewing sarcoma (EWS) gene, fluorescence *in situ* hybridization, FISH, fusion gene, myxoid liposarcoma, MLS, reverse transcription-polymerase chain reaction, RT-PCR, 4679
- Chromosome 5p gain, cervical cancer, topoisomerase I, chromosomal aberrations, array CGH, 3257
- Chromosome alterations, clear cell renal carcinoma, karyotype analysis, prognosis, 4705
- Chronic atrophic gastritis, CAG, pepsinogen, *Helicobacter pylori*, gastric cancer, adenosine deaminase, ADA, 2347
- Chronic esophagitis, Ki-67, CPP32, chagasic megaesophagus, esophageal squamous cell carcinoma, 2845
- CIN, tumor M2 pyruvate kinase, tumor marker, cervical carcinoma, HPV, 375
- Circulating cell-free DNA, cfDNA, serum level, menstrual cycle, breast cancer, 2235
- Circulating tumor cells, carcinoembryonic antigen, staurosporine, immunomagnetic isolation, RT-PCR analysis, 4721
- Circulating tumour cells, human mammaglobin, breast cancer, reverse-transcriptase polymerase chain reaction, 2377
- Circulating, cell-free DNA, kidney cancer, biomarker, serum, 2785
- Cirrhosis, hepatitis, hepatocellular carcinoma, cell cycle proteins, apoptotic proteins, 4493
- Cisplatin hypersensitivity, fractionated X-irradiation, oxaliplatin resistance, teratoma cell lines, 4471
- Cisplatin, angiogenesis, microtubule, combretastatin, vascular disrupting agent, 2813
- Cisplatin, cervical cancer, postoperative chemoradiation, 2341
- Cisplatin, DNA repair, carboplatin, nucleotide excision repair, selenium, selenomethionine, methylseleninic acid, bone marrow, 291
- Cisplatin, DNA repair, UV-radiation, nucleotide excision repair, RB, XPC, 2483
- Cisplatin, docetaxel, dexamethasone, squamous cell carcinoma of the head and neck cell lines, SCCHN, resistance, apoptosis, 123
- Cisplatin, drug combination, synergism, ovarian cancer, oxaliplatin, transplatin, paclitaxel, colchicine, 4025
- Cisplatin, drug combination, YH12, A2780, dose-effect curves, cell uptake, platinum-DNA binding, *trans*-platinum compounds, ovarian cancer cell lines, 4547
- Cisplatin, etoposide, topotecan, sequential, alternate, SCLC, 3031
- Cisplatin, FAS, apoptosis, sphingomyelin, lipid rafts, 2065
- Cisplatin, gastric cancer, S-1, outpatient setting, 3759
- Cisplatin, gemcitabine, elderly patients, urothelial carcinoma, 3839
- Cisplatin, LA-12, oxaliplatin, colon cancer, cell cycle, apoptosis, 1183
- Cisplatin, non-small cell lung cancer, stage III, chemoradiation, surgery, pneumonectomy, 4237
- Cisplatin, p53, lung cancer, chemotherapy, paclitaxel, chemosensitivity, 3557
- Cisplatin, S-1, pooled analysis, histological type, lung cancer, 2985
- Cisplatin, superoxide dismutase 1, ovarian cancer, drug resistance, mass spectrometry, selected-reaction-monitoring, siRNA, 2577
- CK2, leukaemia stem cells, PI3K/Akt, synergism, targeted therapy, apoptosis, 4625
- C-KIT gene, gastrointestinal stromal tumor, GIST, Ki-67 labeling index, PI3K, ALT, 2705
- C-Kit, CD117, immunohistochemistry, mutation breast phyllodes tumor, 4731
- Class pi glutathione-S-transferase, nuclear transfer, mantle cell lymphoma, anticancer agents, GST-pi, 3951
- Claudin, antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, cancer therapy, 4555
- Claudin-1, ulcerative colitis, UC-associated colorectal cancer, surveillance, 3181
- Claudin-18, intraductal papillary mucinous neoplasm, pancreas, Gli-1, p53, 2995
- Clear cell carcinoma, surgery, radiotherapy, chemotherapy, prognosis, recurrence, review, 1327
- Clear cell papillary renal cell carcinoma, papillary renal cell carcinoma, tubulocystic carcinoma, oncocytoma, chromophobe renal carcinoma, 641
- Clear cell renal carcinoma, karyotype analysis, chromosome alterations, prognosis, 4705
- Clinical features, cancer of the small intestine, chemotherapy, 3193
- Clinical management, borderline ovarian tumour, 1701
- Clinical outcome, metastatic colorectal cancer, gene expression level, polymorphisms, cetuximab, bevacizumab, irinotecan, 4209
- Clinical studies, angiogenesis, VEGF-R, bFGF-R, biomarker, brivanib, review, 4477
- Clioquinol, NF-KB, lysosome, DU 145, cancer cells, 2087
- Clofarabine, adenosine analogue, epigenetic, promoter methylation, *PTEN*, *APC*, *RARB2*, *ZAP70*, 4601
- Clomipramine, brain tumours, amitriptyline, tricyclic antidepressants, dexamethasone, oxygen consumption, malignant glioma, 391

- Clonality, NSCLC, EGFR, *KRAS*, mutation, multiplicity, lung cancer, tyrosine kinase inhibitors, 1667
- C-Met,  $\beta$ -catenin, MUC1, immunohistology, gastric cancer, prognosis, 4635
- Colchicine, drug combination, synergism, ovarian cancer, cisplatin, oxaliplatin, transplatinum, paclitaxel, 4025
- Colitis, animal model, antagonist, dysplasia, neurokinin, colon cancer, 3345
- Collagenase, interstitial diffusion, hyaluronidase, two-photon excitation, FRAP, multicellular spheroids, 359
- Colon cancer cells, DLD-1, epigenetic regulation, soy isoflavone, SW480, genistein, *WNT5a* promoter, 4537
- Colon cancer cells, invasion, cell growth, migration, cell–cell adhesion, delta opioid receptor agonists, 9
- Colon cancer, animal model, antagonist, colitis, dysplasia, neurokinin, 3345
- Colon cancer, Caco-2, flavonols, growth, differentiation, peroxide, alkaline phosphatase, 3629
- Colon cancer, Caco-2, polyphenols, growth, differentiation, histone deacetylase inhibitors, 311
- Colon cancer, cell proliferation, ODC, polyamines, polyphenols, quercetin, 3501
- Colon cancer, chemo-surviving cells, curcumin, EGFRs, IGF-1R, 319
- Colon cancer, chemotherapy, CEA, TIMP-1, 233
- Colon cancer, COX-2, celecoxib, nitro-oxy derivative,  $\beta$ -catenin, PI3K/Akt, 2659
- Colon cancer, desmopressin, vasopressin, peptide analog, chemotherapy, metastasis, 5049
- Colon cancer, histochemistry, actin, tubulin, electron microscopy, P150, eukaryotic translation initiation factor 3, 1047
- Colon cancer, ILTG, MSP-MCA, *DAPK-1*, HT-29, HL-60, DNA methylation, leukemia, 3945
- Colon cancer, *K-ras* mutations, cetuximab, EGFR inhibitors, drug resistance, therapeutic outcome, review, 4673
- Colon cancer, LA-12, oxaliplatin, cisplatin, cell cycle, apoptosis, 1183
- Colon cancer, liver metastases, COX-2, precision-cut tissue slices, 2017
- Colon cancer, liver metastasis, bone metastasis, hepatectomy, radiation therapy, 677
- Colon cancer, orthotopic model, FOLFIRI, tumor-growth metastasis, survival time, GFP imaging, 403
- Colon cancer, oxaliplatin, peripheral neuropathy, pregabalin, gabapentin, 2927
- Colon cancer, side population, Wnt signaling, ATP-binding cassette transporter, 2041
- Colon cancer, sphingosine, sphinganine, ceramide, dihydroceramide, apoptosis, 2881
- Colon cancer, sulforaphane, apoptosis, reactive oxygen species, 3611
- Colon cancer, TWEAK, PPAR $\gamma$  ligand, apoptosis, reactive oxygen species, 157
- Colon carcinoma cells, recombinant AAV serotypes 1, 2, and 5, transduction efficiency, solid tumor, cancer gene therapy, pancreatic cancer cells, 1931
- Colon, adenoma, size, limits, carcinoma, 2419
- Colon, carcinomas, GALT, Lynch syndrome, 3019
- Colon, methionine, prostate, breast, p53, 1881
- Colon, SISH, HER2, breast, prostate, lung, ovary, 1287
- Colon-26 carcinoma, IL-1 receptor antagonist, IL-6, survivin peptide vaccination, beta-glucan, anti-inflammation, vaccination, Anakinra, 3959
- Color-coded, *in vivo* imaging, GFP, RFP, UVC, melanoma, blood vessels, 3291
- Colorectal adenocarcinoma, microSPECT/CT imaging, nanoliposome, pharmacokinetics, <sup>188</sup>Re, 65
- Colorectal cancer cells, EGCG, TROP-2, HCT-116, SW480, mRNA stability, cycloheximide, (–)epigallocatechin-3-gallate, 2497
- Colorectal cancer cells, HT29, chemoresistance, translational regulation, real-time PCR, mRNA quantification, fluoropyrimidine analogs, thymidylate synthase, p53, 5-FU resistance, 1149
- Colorectal cancer treatment, chemotherapy, cancer, microsatellite instability, FOLFOX, adjuvant treatment, prognostic factor, 4297
- Colorectal cancer, anandamide, polyamines, cell growth, 2583
- Colorectal cancer, cyclin D1, risk, metastasis, polymorphism, 2875
- Colorectal cancer, cytokine, growth factor, hepatectomy, liver metastasis, liver regeneration, tumour recurrence, review, 2161
- Colorectal cancer, dendritic cells, antigen loading, CEA peptide, mRNA, electroporation, immunotherapy, vaccination, 5091
- Colorectal cancer, *HIF1A1*, polymorphisms, prognosis, 2393
- Colorectal cancer, human anti-mouse antibody, HAMA, prevalence, monoclonal antibody therapeutics, adverse events, 4353
- Colorectal cancer, irinotecan, metabolism, pharmacokinetics, cetuximab, biweekly infusion, 2355
- Colorectal cancer, irinotecan, oxaliplatin, sequence, 4325
- Colorectal cancer, *K-ras*, blood, serum, plasma, pancreatic cancer, diagnostic test, predictive test, review, 2943
- Colorectal cancer, liver metastases, irinotecan, oxaliplatin, doxifluridine, artery, 3045
- Colorectal cancer, metastasis, comparison, *KRAS*, BRAF, mutation, 4229
- Colorectal cancer, MMP-13, liver metastasis, 2693
- Colorectal cancer, oxaliplatin, ERCC1, gene silencing, siRNA, resistance, 2531

- Colorectal cancer, prognostic factors, chemotherapy, survival, 653
- Colorectal cancer, RUNX3, MSI, methylation, 2673
- Colorectal cancer, synthetic triterpenoids, apoptosis, signaling proteins, 785
- Colorectal cancer, *TFPI2*, quantitative methylation-specific PCR, 1205
- Colorectal cancer, TIMP-1, prognostic factor, 4127
- Colorectal cancer, TS, adjuvant 5-FU, 645
- Colorectal cancer, *XRCC4*, polymorphism, carcinogenesis, 2727
- Colorectal cancer, yttrium-90 microspheres, liver metastases, chemotherapy, hepatectomy, FOLFOX, 3005
- Colorectal carcinoma, *KRAS*, *BRAF*, mutations, FFPE, ThinPrep, qPCR, 1969
- Colorectal carcinoma, *MACC1*, quantitative real-time PCR, 2689,
- Colorectal carcinoma, p53, hypoxia-inducible factor 1 alpha, vascular endothelial growth factor, 4163
- Colorectal carcinoma, *VIM*, quantitative methylation-specific PCR, 5015
- Colorectal liver metastases, hepatic resection, chemotherapy with oxaliplatin plus fluorouracil and leucovorin, FOLFOX, Japanese patients, 1015
- Colorectal tumor, preoperative chemotherapy, PyNase, predictive factors, 5'-deoxy-5-fluorouridine, 3207
- Combination effect 5-amino-imidazole-4-carboxamide-1- $\beta$ -4-ribofuranoside, 1,25-dihydroxyvitamin D3 derivative, pancreatic cancer, AICAR, inhibitor of Akt-phosphorylation, 1875
- Combination therapy, apoptosis, gemcitabine, 2-methoxyestradiol, pancreatic cancer cells, 4619
- Combination therapy, inflammation, postsurgical, micrometastases, CEA, lung carcinoma, lymphokine-activated killer cell therapy, glucocorticoid, 3125
- Combination, trastuzumab, metastatic breast cancer, pretreated, 3051
- Combined effects, osteosarcoma, bisphosphonate, radiation, 2713
- Combretastatin, angiogenesis, microtubule, vascular disrupting agent, cisplatin, 2813
- Comet assay, *ATM*, *BRCA1*, RT-PCR, emodin, aloe-emodin, rhein, DNA repair, tongue cancer cells, 945
- Comparison, colorectal cancer, metastasis, *KRAS*, *BRAF*, mutation, 4229
- Complementary medicine, evidence-based medicine, quality of life, quackery, review, 1767
- Complement-dependent cytotoxicity, claudin, antibody-dependent cellular cytotoxicity, cancer therapy, 4555
- Computed tomography, magnetic drug targeting, local chemotherapy, tumour vascularisation, angiography, flat-panel CT, 1553
- COMT haplotypes, breast neoplasms, genetic polymorphism, epidemiology, estrogens, risk, 217
- Concanavalin A, L1210 cells, multidrug resistance, P-glycoprotein, cell surface saccharides, 3661
- Concomitant boost, radiotherapy, breast cancer, hypofractionation, 4749
- Connectivity map, alpha terpineol, *Salvia libanotica*, NF- $\kappa$ B, 1911
- Connexin43, gap junctional intercellular communication GJIC, E-cadherin,  $\beta$ -catenin, ZO-1, immunohistochemistry, CpG island, methylation analysis, pyrosequence, lung cancer, 2271
- Cooperation, stem cells, cell cycle, education, natural products, 2477
- Copper, curcumin, A2780, mTOR, NF- $\kappa$ B, cancer, 3249
- Cordyceps sinensis*, B16-F0 mouse melanoma cell, hepatocyte growth factor, HGF, mouse model, invasion, 3429
- Corticotropin acetate, Xerecept<sup>®</sup>, bevacizumab, Avastin<sup>®</sup>, brain tumor model, 5037
- Cosmetics, environmental oestrogens, breast cancer, antiperspirant, deodorant, paraben, aluminium, organochlorine, phytoestrogen, breast cysts, review, 815
- Cotton rat, hybrid liposomes, chemotherapy, gastric carcinoma, apoptosis, 2011
- Coumarin, basic amino side chain, cell viability, cell cycle, benzopyranone derivatives, 4613
- COX 2, rapamycin, mTOR, celecoxib, angiosarcoma, endothelial tumour, 4017
- COX-2, colon cancer, celecoxib, nitro-oxy derivative,  $\beta$ -catenin, PI3K/Akt, 2659
- COX-2, colon cancer, liver metastases, precision-cut tissue slices, 2017
- Cox-2*, polymorphism, childhood leukemia, 3649
- Cox-2*, polymorphism, lung cancer, carcinogenesis, 1195
- CpG island hypermethylation, gastric cancer, morphological appearance, 239
- CpG island, gap junctional intercellular communication GJIC, connexin43, E-cadherin,  $\beta$ -catenin, ZO-1, immunohistochemistry, methylation analysis, pyrosequence, lung cancer, 2271
- CPP32, Ki-67, chagasic megaesophagus, chronic esophagitis, esophageal squamous cell carcinoma, 2845
- Creatinine, saracatinib, renal function, 2935
- CREB, nexrutine<sup>R</sup>, tumor invasion, prostate cancer, BMD, NF- $\kappa$ B, TRAMP, 857
- CRIM1, cytarabine, daunorubicin, drug resistance, HL60 cells, 4157
- Cross-resistance, chemotherapy, gastric cancer cell lines, anticancer drugs, apoptosis, cell-cycle, 915
- CSC, GBM, ATRA, MAPK, 4915
- CSrc, Simian Virus 40 Large Tumor antigen, retinoblastoma susceptibility gene product, neoplastic transformation, rodent fibroblasts, signal transduction, 47

- CT, serum tumour markers, FDG uptake, PET, diagnosis, lung cancer, 1741
- Curcumin, apoptosis, G<sub>2</sub>/M arrest, caspase cascade, endoplasmic reticulum stress, lung neoplasms, herbal medicine, 2125
- Curcumin, cancer, metabolism, liposomal curcumin, cytochrome P450, 811
- Curcumin, chemo-surviving cells, colon cancer, EGFRs, IGF-1R, 319
- Curcumin, copper, A2780, mTOR, NF-κB, cancer, 3249
- Curcumin, Ewing's sarcoma, apoptosis, radiosensitivity, p53, 4007
- Curcumin, medulloblastoma, apoptosis, 499
- Curcumin, nasopharyngeal carcinoma, migration, E-cadherin, NF-κB, 2851
- CXCR4, gastric cancer, docetaxel sensitivity, 2209
- Cyclin A, *Oplopanax horridus*, human colorectal cancer, anti-proliferation, apoptosis, cell cycle, cyclin B1, 295
- Cyclin B1, *Oplopanax horridus*, human colorectal cancer, anti-proliferation, apoptosis, cell cycle, cyclin A, 295
- Cyclin D polymorphism, *CDKN1B* polymorphism, breast cancer, Turkish population, 3093
- Cyclin D1, breast cancer, cyclin D1b, cyclin-dependent kinase inhibitor, 1279
- Cyclin D1, breast cancer, MCF-7 cells, γ-tocotrienol, cell cycle, retinoblastoma, quinone reductase NQO2, 2869
- Cyclin D1, colorectal cancer, risk, metastasis, polymorphism, 2875
- Cyclin D1, STAT3, IL-6, CADPE, hepatocellular carcinoma, 481
- Cyclin D1b, breast cancer, cyclin D1, cyclin-dependent kinase inhibitor, 1279
- Cyclin-dependent kinase inhibitor, breast cancer, cyclin D1, cyclin D1b, 1279
- Cycloheximide, EGCG, TROP-2, HCT-116, SW480, mRNA stability, (-)epigallocatechin-3-gallate, colorectal cancer cells, 2497
- Cyclooxygenase-2, breast cancer, 15-hydroxyprostaglandin dehydrogenase, vitamin D receptor, prostaglandin receptor, calcidiol, PGE<sub>2</sub>, 1673
- Cyclooxygenase-2, Ki-67, metastases, renal cell carcinoma, survival, 3023
- Cyclooxygenase-2, tumor metastasis, cytoplasmic phospholipase A2, 5-lipoxygenase, angiogenesis, metalloproteinase, 3421
- Cyclophosphamide, IL-2, high-dose chemotherapy, NK cells, 5-fluorouracil, epirubicin, methotrexate, radiotherapy, etoposide, carboplatin, VEGF, retinoic acid, myeloablative chemotherapy, autologous transplantation, immunotherapy, breast cancer, 209
- Cyclophosphamide, lipopolysaccharide, pulmonary inhalation, lung cancer, alveolar macrophage, Lewis lung carcinoma-bearing mice, 3129
- Cyclophosphamide, neoadjuvant chemotherapy, pCR, HER2, epirubicin, paclitaxel, trastuzumab, breast cancer, 4665
- Cyclophosphamide, prostate cancer, metronomic chemotherapy, docetaxel, 4317
- Cyclophosphamide, triple negative, pre-operative therapy, prediction of therapy response, dose-dense epirubicin, docetaxel, breast cancer, 4251
- CYFRA 21-1, CEA, tumour marker index, non-small cell lung cancer, survival, 3099
- CYFRA 21-1, lung cancer, CEA, marker panel, ROC-curves, 1661
- Cyfra 21-1, tumor marker, follow-up, oropharyngeal cancer, squamous cell carcinoma, 2291
- CYFRA21-1, non-small cell lung cancer, cytokeratin, tumour marker, prognosis, survival, 3833
- CYP19A1, zeranol, leptin, aromatase, estrogen, human breast pre-adipocytes, (-)-gossypol, 5077
- Cystic lesions, pancreatitis, pregnancy, mucinous cystic neoplasms, mucinous cystoadenoma, estrogens, progesterone, pancreatic cancer, 1025
- Cytarabine, CRIM1, daunorubicin, drug resistance, HL60 cells, 4157
- Cytochrome P450 1B1, breast cancer, oestrogen metabolism, N-acetyltransferase 2, heterocyclic arylamines, 2885
- Cytochrome P450, curcumin, cancer, metabolism, liposomal curcumin, 811
- Cytogenetics, acute lymphoblastic leukemia, fluorescent *in situ* hybridization, Philadelphia chromosome, bcr-abl fusion gene, 569
- Cytokeratin 19, tumour marker, receiver operating characteristic curve, diagnosis, CEA, mesothelioma, 4343
- Cytokeratin recurrence, E-cadherin, dysadherin, NSCLC, prognosis, 3273
- Cytokeratin, adenomatoid odontogenic tumor, AOT, immuno-histochemistry, alpha-smooth muscle actin, epithelial membrane antigen, 1787
- Cytokeratin, epithelial-myoeptithelial carcinoma, nude mouse, salivary gland carcinoma, growth factor receptors, EGFR-1, 1565
- Cytokeratin, non-small cell lung cancer, tumour marker, CYFRA21-1, prognosis, survival, 3833
- Cytokine, colorectal cancer, growth factor, hepatectomy, liver metastasis, liver regeneration, tumour recurrence, review, 2161
- Cytokine, fibroblast, MMP inhibition, angiogenesis, imaging, skin cancer invasion, VEGF-A, PDGF-BB, 703
- Cytokine-induced killer cell, interleukin, immunotherapy, 3493
- Cytokines, gamma radiation, bystander responses, glioblastoma, *in vitro*, 2769

- Cytokines, IL-12, paracrine treatment, *Schistosoma mansoni*, SWAP, systemic treatment, vaccination, poly-N-acetyl glucosamine gel matrix, 3889
- Cytology, breast cancer, fine-needle aspiration biopsy, DNA cytometry, DNA content, benign breast lesions, free cell sampling, cell group sampling, 175
- Cytology, gastric cancer, peritoneal dissemination, neoadjuvant chemotherapy, docetaxel, S-1, 1335
- Cytolysins, toxin Bc2, equinatoxin-II, signaling pathways, necrosis, MAPK/ERK, PKC, CaMKII, glioma cell death, 1209
- Cytoplasmic phospholipase A2, tumor metastasis, 5-lipoxygenase, cyclooxygenase-2, angiogenesis, metalloproteinase, 3421
- Cytoskeleton, paxillin, phosphatase, PP-1, TGF- $\beta$ , motility, endothelial cells, 4861
- Cytostatic activity, nonsteroidal anti-inflammatory drugs, NSAID, hydroxamic acids, cytotoxicity, human pancreatic cancer, Akt signalling, cell cycle, apoptosis, 3987
- Cytotoxic, progestins, antiprogestins, breast cancer cells, non-genomic effects, mifepristone, apoptosis, cell cycle, 4835
- Cytotoxicity, 1,4-naphthoquinone, human prostate cancer cell lines, cell cycle, apoptosis, 519
- Cytotoxicity, *Brucea javanica*, NF- $\kappa$ B, NFAT, ROS, mitochondria, 3295
- Cytotoxicity, nonsteroidal anti-inflammatory drugs, NSAID, hydroxamic acids, cytostatic activity, human pancreatic cancer, Akt signalling, cell cycle, apoptosis, 3987
- Cytotoxicity, trihaloacetylazulenes, QSAR, semiempirical molecular-orbital method, 837
- Cytotoxicity, tropolones, QSAR, semiempirical molecular-orbital method, 129
- D2-40, LYVE-1, lymph node metastasis, squamous cell carcinoma, tongue, 1897
- Damage, irradiation, salivary glands, tenascin-C, 1593
- Danthron, anthraquinones, quinizarin, polyamines, transglutaminase, differentiation, melanoma cells, 445
- DAPK, HNSCC, DNA content, DNA methylation, p16, *RASSF1A*, 4643
- DAPK-1, ILTG, MSP-MCA, HT-29, HL-60, DNA methylation, colon cancer, leukemia, 3945
- Daunorubicin, CRIM1, cytarabine, drug resistance, HL60 cells, 4157
- DC, *WT1*, immunotherapy, endometrial carcinoma, 3709
- DCC, quantitative methylation-specific PCR, gastric cancer, 107
- DCE-MRI, angiogenesis, MTD, PTK/ZK, VEGF, 2335
- DCF, esophageal cancer, multiple lymph node metastases, neoadjuvant chemotherapy, 221
- DCIS, breast cancer, B3 lesions, vacuum-assisted core biopsy, Suros, microcalcification, lobular hyperplasia, 2287
- DCPH-P-Na(I), ultrasound, cell damage, lipid peroxidation, sonodynamic activation, reactive oxygen, 2241
- DD3<sup>PCA3</sup>, prostate cancer, PCa, benign prostatic hyperplasia, BPH, mRNA, RT-PCR, 665
- 2-DE, two-dimensional gel electrophoresis, LC-MS/MS, pancreatic cancer, gemcitabine, GEM, proteomics, heat-shock protein 27, 2539
- Death rate, uterine clear cell carcinoma, uterine serous papillary carcinoma, survival, 3727
- Deep inferior epigastric artery, breast reconstruction, perforator flap, venous, arterial, anastomosis, 1293
- Deficit, breast disease, breast cancer, losses, 4303
- Delay and referral, oral cancer, maxillofacial cancer, 1833
- Delta opioid receptor agonists, invasion, cell growth, migration, cell-cell adhesion, colon cancer cells, 9
- DeltaNp63, immunohistochemistry, squamous cell carcinoma, non-small cell lung cancer, 4717
- Dendritic cells, colorectal cancer, antigen loading, CEA peptide, mRNA, electroporation, immunotherapy, vaccination, 5091
- Dendritic cells, nanodiamond, CD4+ cells, *in vitro*, bionanotechnology, 4075
- Dendritic cells, poly-phenylpropanoid polysaccharide complex, U937 cells, differentiation, 613
- Dendritic cells, renal cancer, immunotherapy, metastatic renal cell carcinoma, 2081
- Dental implants, scattering irradiation, Monte Carlo simulation, titanium dental implants, 1727
- Deodorant, environmental oestrogens, breast cancer, cosmetics, antiperspirant, paraben, aluminium, organochlorine, phytoestrogen, breast cysts, review, 815
- 5'-Deoxy-5-fluorouridine, colorectal tumor, preoperative chemotherapy, PyNPase, predictive factors, 3207
- Depression, cancer, mental adjustment to cancer, anxiety, 5-HTTLPR polymorphism, 3823
- DEPTOR, ovarian cancer, mTOR, S6 kinase, paclitaxel resistance, 3529
- Dermal cylindroma, skull defects, Brooke-Spiegler syndrome, 1793
- Dermatofibrosarcoma protuberans, surgical treatment, tumour, wide local excision, 3775
- Desmoplastic small round cell tumour, caffeine-assisted chemotherapy, brachial plexus, 3769
- Desmopressin, vasopressin, peptide analog, chemotherapy, metastasis, colon cancer, 5049
- Dexamethasone, brain tumours, clomipramine, amitriptyline, tricyclic antidepressants, oxygen consumption, malignant glioma, 391
- Dexamethasone, cisplatin, docetaxel, squamous cell carcinoma of the head and neck cell lines, SCCHN, resistance, apoptosis, 123
- Dexamethasone, multiple myeloma, plasmacytoma, bortezomib, 3791

- Dextran, paclitaxel, folic acid, targeting, adsorption, 903
- DFMO, breast cancer,  $\alpha$ -difluoromethylornithine, biomarker, apoptosis, proliferation, invasion, 2263
- DHFR, TS, GARFT, NSCLC, malignant pleural mesothelioma, pemetrexed, 4309
- Diagnosis, juvenile granulosa cell tumor, therapy, 1731
- Diagnosis, primary leiomyosarcoma of the testis, therapy, prognosis, 1725
- Diagnosis, serum tumour markers, FDG uptake, PET, CT, lung cancer, 1741
- Diagnosis, tumour marker, receiver operating characteristic curve, cytokeratin 19, CEA, mesothelioma, 4343
- Diagnosis, type II sodium-dependent phosphate transporter, SLC34A2, therapy, breast cancer, 4135
- Diagnostic kit, *KRAS* mutation, metastatic colorectal carcinoma, 5251
- Diagnostic test, *K-ras*, blood, serum, plasma, colorectal cancer, pancreatic cancer, predictive test, review, 2943
- Diet, cereals, cholesterol, gross domestic product, milk protein, prostate cancer, ultraviolet-B, vitamin D, 189
- Diethylenetriamine pentaacetic acid DTPA, toremifene, toremifene-glucuronide-labelled with  $^{99m}\text{Tc}$ ,  $^{99m}\text{Tc}$ -TOR-G,  $^{99m}\text{Tc}$ -Rec-TOR-G, anti-oestrogen glucuronide compound, 1243
- Differentiation, anthraquinones, danthron, quinizarin, polyamines, transglutaminase, melanoma cells, 445
- Differentiation, colon cancer, Caco-2, flavonols, growth, peroxide, alkaline phosphatase, 3629
- Differentiation, colon cancer, Caco-2, polyphenols, growth, histone deacetylase inhibitors, 311
- Differentiation, dendritic cells, poly-phenylpropanoid polysaccharide complex, U937 cells, 613
- Differentiation, glycodelin, breast cancer, immunohistochemistry, 1599
- Differentiation, glypican-3, hepatocellular carcinoma, GPC3, 5055
- Differentiation, notch,  $\gamma$ -secretase inhibitor, erythroid leukemia, 4071
- Diffuse type, thymidine phosphorylase, Epstein-Barr virus, gastric carcinoma, intestinal type, 2431
- $\alpha$ -Difluoromethylornithine, breast cancer, DFMO, biomarker, apoptosis, proliferation, invasion, 2263
- Dihydroceramide, sphingosine, sphinganine, ceramide, colon cancer, apoptosis, 2881
- Dihydropyridine derivative, cancer, doxorubicin, MDR reversal, oxidative stress, antioxidant, 4063
- 1,25-Dihydroxyvitamin D3 derivative, pancreatic cancer, combination effect 5-amino-imidazole-4-carboxamide-1- $\beta$ -4-ribofuranoside, AICAR, inhibitor of Akt-phosphorylation, 1875
- Direct sequencing, gallbladder carcinoma, PCR-SSCP, TP53, transition mutations, cholecystitis, 4443
- Disease-free interval, endometrial cancer, recurrence, prognosis, overall survival, 4347
- Distant metastasis, GIST, gastrointestinal stromal tumour, oral cavity, imatinib, PET, 4283
- Disulfide, liposomes, antisense oligonucleotide, G3139, *Bcl-2*, drug delivery, 31
- Dithiothreitol, arsenic trioxide, oral cancer, carcinogenesis, 3655
- DJ-1, astrocytoma, immunohistochemistry, WHO grading, prognosis, 265
- DLD-1, epigenetic regulation, soy isoflavone, SW480, colon cancer cells, genistein, *WNT5a* promoter, 4537
- DLEC1, breast, 1079
- DMBA, calcium glucarate, hamsters, buccal pouch, squamous cell carcinoma, 843
- DNA content, breast cancer, cytology, fine-needle aspiration biopsy, DNA cytometry, benign breast lesions, free cell sampling, cell group sampling, 175
- DNA content, HNSCC, DNA methylation, p16, *DAPK*, *RASSF1A*, 4643
- DNA cytometry, breast cancer, cytology, fine-needle aspiration biopsy, DNA content, benign breast lesions, free cell sampling, cell group sampling, 175
- DNA damage and repair, camptothecin derivative, apoptosis,  $\gamma$ -H2AX, M-phase cell, radiation, 937
- DNA damage, CHM-1, DNA repair, gene expression, U-2 OS human osteogenic sarcoma cells, quinolone, 4187
- DNA methylation, epigenetics, pancreatic cancer, chemotherapy, TMS1, 3919
- DNA methylation, HNSCC, DNA content, p16, *DAPK*, *RASSF1A*, 4643
- DNA methylation, ILTG, MSP-MCA, *DAPK-1*, HT-29, HL-60, colon cancer, leukemia, 3945
- DNA ploidy, needle biopsy, radical prostatectomy, cathepsin B, stefin A, MIB-1, prostate cancer, 719
- DNA repair genes, polymorphism, gastric cancer, APE1, HOGG1, 1359
- DNA repair, *ATM*, *BRCA1*, RT-PCR, Comet assay, emodin, aloe-emodin, rhein, tongue cancer cells, 945
- DNA repair, CHM-1, DNA damage, gene expression, U-2 OS human osteogenic sarcoma cells, quinolone, 4187
- DNA repair, cisplatin, carboplatin, nucleotide excision repair, selenium, selenomethionine, methylseleninic acid, bone marrow, 291
- DNA repair, ERCC1, XPF, chemotherapy, drug resistance, review, 3223
- DNA repair, OGG1, NTH1, UDG, APE1, mtDNA, nDNA, lung cancer cells, 4963
- DNA repair, UV-radiation, cisplatin, nucleotide excision repair, RB, XPC, 2483
- DNA repair, *XRCC4*, single nucleotide polymorphism, childhood leukemia, 529
- DNA, nucleosomes, ELISA, stability, serum, 1613

- Docetaxel sensitivity, gastric cancer, CXCR4, 2209
- Docetaxel, breast cancer, chemotherapy, neoadjuvant, gemcitabine, pegylated liposomal doxorubicin, phase II, locally advanced, 3817
- Docetaxel, cisplatin, dexamethasone, squamous cell carcinoma of the head and neck cell lines, SCCHN, resistance, apoptosis, 123
- Docetaxel, gastric cancer, cytology, peritoneal dissemination, neoadjuvant chemotherapy, S-1, 1335
- Docetaxel, gossypol, Bcl-XL, tumor growth, apoptosis, anti-apoptosis genes, adrenal cancer, 4805
- Docetaxel, myeloid derived suppressor cells, macrophages, regulatory T-cells, B16 melanoma, temozolomide, interleukin-1 receptor antagonist, host-tumor interactions, 345
- Docetaxel, ovarian cancer, carboplatin, chemotherapy resistance, array CGH, 4451
- Docetaxel, pancreatic cancer, gemcitabine, refractory, chemotherapy, metastatic disease, salvage therapy, 2905
- Docetaxel, prostate cancer, metronomic chemotherapy, cyclophosphamide, 4317
- Docetaxel, triple negative, pre-operative therapy, prediction of therapy response, dose-dense epirubicin, cyclophosphamide, breast cancer, 4251
- Dose escalation, liposomal cisplatin, lipoplatin, phase I, 1317
- Dose-dense epirubicin, triple negative, pre-operative therapy, prediction of therapy response, cyclophosphamide, docetaxel, breast cancer, 4251
- Dose-effect curves, drug combination, YH12, A2780, cell uptake, platinum-DNA binding, *trans*-platinum compounds, ovarian cancer cell lines, cisplatin, 4547
- Down-regulation, lung cancer, drug resistance, P-glycoprotein, 3593
- Down-regulation,  $\alpha$ -catenin, E-cadherin, immuno-histochemistry, endometrium, 4993
- Doxifluridine, colorectal cancer, liver metastases, irinotecan, oxaliplatin, artery, 3045
- Doxorubicin, cancer, MDR reversal, dihydropyridine derivative, oxidative stress, antioxidant, 4063
- Doxorubicin, drug delivery system, liposome, malignant glioma, polymeric microsphere, thermoreversible gelation polymer, 1057
- Drosophila melanogaster* multisubstrate deoxyribonucleoside kinase, gastric cancer, retroviral vector, suicide gene, bystander effect, 2641
- Drug combination, synergism, ovarian cancer, cisplatin, oxaliplatin, transplatinum, paclitaxel, colchicine, 4025
- Drug combination, YH12, A2780, dose-effect curves, cell uptake, platinum-DNA binding, *trans*-platinum compounds, ovarian cancer cell lines, cisplatin, 4547
- Drug composition, response curve, bistable switch, mathematical model, mTOR, carcinogenesis, 2683
- Drug delivery system, alveolar macrophage, lung tumor, LPS, cell-to-cell contact, 3159
- Drug delivery system, doxorubicin, liposome, malignant glioma, polymeric microsphere, thermoreversible gelation polymer, 1057
- Drug delivery, liposomes, disulfide, antisense oligonucleotide, G3139, *Bcl-2*, 31
- Drug resistance, colon cancer, *K-ras* mutations, cetuximab, EGFR inhibitors, therapeutic outcome, review, 4673
- Drug resistance, CRIM1, cytarabine, daunorubicin, HL60 cells, 4157
- Drug resistance, ERCC1, XPF, DNA repair, chemotherapy, review, 3223
- Drug resistance, gamma-glutamyltransferase, human neoplasia, tumor progression, redox regulation, review, 1169
- Drug resistance, individualised tumour response testing, bortezomib, children, acute lymphoblastic leukaemia, acute myeloid leukaemia, 2119
- Drug resistance, lung cancer, P-glycoprotein, down-regulation, 3593
- Drug resistance, MGMT, alkyltransferase, SCCHN, cancer therapy, field cancerization, 2561
- Drug resistance, osteosarcoma, zoledronic acid, heat shock protein 27, 3565
- Drug resistance, superoxide dismutase 1, ovarian cancer, cisplatin, mass spectrometry, selected-reaction-monitoring, siRNA, 2577
- Drug resistance, urothelial cancer, heme oxygenase-1, chemotherapy, radiotherapy, gemcitabine, 2145
- Drug resistance, YB-1, gene regulation, RNA interference, micro RNAs, microarray, gastric carcinoma cells, 629
- Drug resistance, YB-1, gene regulation, gene expression, RNA interference, gastric carcinoma cells, 693
- Drug sensitivity, epidermal growth factor receptor, gefitinib, radiation, 4899
- Drug-drug interaction, methotrexate, proton pump inhibitor, BCRP, ABCG2, 3807
- Drug-drug interaction, methotrexate, proton pump inhibitor, glucarpidase, 963
- Drug-drug interaction, oxaliplatin, capecitabine, pharmacokinetics, 5207
- DSRCT, Ewing sarcoma, imatinib, *KIT*, PDGFR $\alpha$ , phase II, 547
- DU 145, clioquinol, NF- $\kappa$ B, lysosome, cancer cells, 2087
- Du145, androgen-independent prostate cancer, epidermal growth factor receptor, EGFR, cetuximab, C225, monoclonal antibody, PC-3, 1905
- Dual-energy X-ray absorptiometry, bone mineral density, AM value, TACHIKAWA DENKAI CALCIUM<sup>TM</sup> (E-Ca), calcium hydroxide, DXA method, 3199
- Duplex drug, 3-C-ethynylcytidine, 5-fluorodeoxyuridine, L1210 murine leukaemia, experimental leukaemia, 4891



- Dutasteride, neuroendocrine (NE) differentiation, benign prostatic hyperplasia, finasteride, chromogranin A, 4737
- DXA method, bone mineral density, AM value, TACHIKAWA DENKAI CALCIUM™ (E-Ca), calcium hydroxide, dual-energy X-ray absorptiometry, 3199
- Dysadherin, E-cadherin, cytokeratin recurrence, NSCLC, prognosis, 3273
- Dysplasia, animal model, antagonist, colitis, neurokinin, colon cancer, 3345
- Dysplasia, cervical intraepithelial neoplasia, progesterone, vaginal, phase II, 1257
- Dysplasia, epithelium, hypopharynx, malignancy, squamous cell carcinoma, 3313
- E7 oncogene, proteomics, melphalan, Tg mouse, cancer, 2773
- EAG1, vitamin D, cervical cancer, prostate cancer, potassium channels, placenta, calcitriol, 2667
- Early detection, *3OST2*, bowel lavage, blood of main drainage vein, 4811
- Early detection, lung cancer, FDG imaging, follow-up, survival, recurrence, 3811
- Earwax, apocrine gland, axillary osmidrosis, mammary gland, SNP, ABC transporter *ABCC11*, breast cancer risk, 5189
- E-Cadherin, dysadherin, cytokeratin recurrence, NSCLC, prognosis, 3273
- E-Cadherin, gap junctional intercellular communication GJIC, connexin43,  $\beta$ -catenin, ZO-1, immunohistochemistry, CpG island, methylation analysis, pyrosequence, lung cancer, 2271
- E-Cadherin, Hrs, Rab7, ExoC5, RT-PCR, fragments, breast cancer, 3903
- E-Cadherin, mesenchymal–epithelial reversion, SMAD4, invasion and metastasis, epithelial phenotype, 2603
- E-Cadherin, nasopharyngeal carcinoma, curcumin, migration, NF- $\kappa$ B, 2851
- E-Cadherin, ovarian cancer, expression, prognosis, 2525
- E-Cadherin, promoter polymorphism, methylation, *KIT*, *CDH1*, gastric cancer, 2225
- E-Cadherin,  $\alpha$ -catenin, down-regulation, immunohistochemistry, endometrium, 4993
- Ectomesenchymal chondromyxoid tumour, tongue, oral cavity, immunohistochemistry, 4685
- Education, stem cells, cell cycle, cooperation, natural products, 2477
- Efficacy, methioninase, PEG-methioninase, cancer, methionine dependence, selectivity, 793
- Efficacy, methioninase, rMETase, PEG-methioninase, PEG-rMETase, cancer, methionine dependence, selectivity, 1041
- Efficacy, non-small cell lung cancer, carboplatin, paclitaxel, chemotherapy, interstitial lung disease, safety, 4357
- Efflux pump, *Carpobrotus edulis*, *Aizoaceae*, P-glycoprotein, multidrug resistance, 829
- EGCG, TROP-2, HCT-116, SW480, mRNA stability, cycloheximide, (–)epigallocatechin-3-gallate, colorectal cancer cells, 2497
- EGF, HNSCC, EGFR, *BCL-xL*, p21CIP1/WAF1, 4579
- EGF, pancreatic cancer, gene polymorphism, growth factors, TGF- $\beta$ 1, TNF- $\alpha$ , 5257
- EGFR gene copy number, prognosis, EGFR TKIs treatment, chemotherapy, *KRAS*, 5121
- EGFR inhibitors, colon cancer, *K-ras* mutations, cetuximab, drug resistance, therapeutic outcome, review, 4673
- EGFR* mutation, LAT1, NSCLC, mTOR, non-small cell lung cancer, 4819
- EGFR* mutation, non-small cell lung cancer, erlotinib, Tarceva, EGFR-TKIs, phase II, 557
- EGFR TKIs treatment, EGFR gene copy number, prognosis, chemotherapy, *KRAS*, 5121
- EGFR, amphiregulin, MMP-9, breast cancer, 2101
- EGF-R, antiestrogens, AKT, endometrial cancer, everolimus, gefitinib, mTOR, perifosine, tamoxifen, 2025
- EGFR, EMT, lung cancer, adenocarcinoma, resistance, tyrosine kinase inhibitor, 2513
- EGFR, epidermal growth factor receptor, androgen-independent prostate cancer, cetuximab, C225, monoclonal antibody, Du145, PC-3, 1905
- EGFR, head and neck cancer, chemoradiotherapy, treatment, prognostic factor, 671
- EGFR, HNSCC, EGF, *BCL-xL*, p21CIP1/WAF1, 4579
- EGFR, LOXL4, gene expression, head and neck squamous cell carcinoma, metastasis, 4567
- EGFR, mutation, breast cancer, 4219
- EGFR, NSCLC, erlotinib, tyrosine kinase inhibitors, lung cancer, review, 1301
- EGFR, NSCLC, *KRAS*, mutation, multiplicity, clonality, lung cancer, tyrosine kinase inhibitors, 1667
- EGFR, thyroid tumors, erlotinib, cetuximab, panitumumab, paclitaxel, 473
- EGFR, *WT1*, HER2, estrogen and antiestrogen, breast cancer, 3637
- EGFR-1, epithelial-myoeithelial carcinoma, nude mouse, salivary gland carcinoma, growth factor receptors, cytokeratin, 1565
- EGFRs, chemo-surviving cells, curcumin, colon cancer, IGF-1R, 319
- EGFR-TKIs, non-small cell lung cancer, erlotinib, Tarceva, *EGFR* mutation, phase II, 557
- EG-VEGF, hypophysis, immunohistochemistry, pituitary adenoma, 3981
- Elderly patients, gemcitabine, cisplatin, urothelial carcinoma, 3839
- Elderly, CA 15-3, CEA, breast cancer, relapse, tumour markers, postmenopausal, 2331

- Electrochemotherapy, KP1339, anticancer ruthenium(III) compounds, electroporation, tumour models, sarcoma, mice, 2055
- Electron microscopy, gastric carcinoma, nuclear envelope changes, 699
- Electron microscopy, histochemistry, actin, tubulin, P150, eukaryotic translation initiation factor 3, colon cancer, 1047
- Electroporation, colorectal cancer, dendritic cells, antigen loading, CEA peptide, mRNA, immunotherapy, vaccination, 5091
- Electroporation, KP1339, anticancer ruthenium(III) compounds, electrochemotherapy, tumour models, sarcoma, mice, 2055
- ELISA, 3-Hydroxyproline, type IV collagen, basement membrane, cancer invasion, cancer metastasis, cancer screening, 1007
- ELISA, DNA, nucleosomes, stability, serum, 1613
- ELISA, ionising radiation, bystander effect, activation, TGF $\beta$ , 3341
- Emodin, *ATM*, *BRCA1*, RT-PCR, Comet assay, aloe-emodin, rhein, DNA repair, tongue cancer cells, 945
- EMT, integrin,  $\alpha$ v $\beta$ 6, Fyn kinase, oral SCC, serum, 2591
- EMT, lung cancer, adenocarcinoma, resistance, EGFR, tyrosine kinase inhibitor, 2513
- Endometrial cancer, antiestrogens, AKT, EGF-R, everolimus, gefitinib, mTOR, perifosine, tamoxifen, 2025
- Endometrial cancer, calpain, calpastatin, 2837
- Endometrial cancer, hysteroscopy, peritoneal cytology, tumor cell dissemination, sentinel node, 2425
- Endometrial cancer, polycomb protein, BMI-1, breast cancer, ovarian cancer, cervical cancer, cancer stem cells, 1559
- Endometrial cancer, recurrence, disease-free interval, prognosis, overall survival, 4347
- Endometrial cancer, transketolase-like-1 protein, TKTL1, cancer, aerobic glycolysis, glucose metabolism, pAkt, GLUT1, 1653
- Endometrial cancer, Wilms' tumor gene, *WT1*, angiogenesis, immuno-histochemistry, 3187
- Endometrial carcinoma, *BAG-1*, ER, PR, apoptosis, real-time PCR, immunohistochemistry, 4103
- Endometrial carcinoma, *WT1*, DC, immunotherapy, 3709
- Endometrial hyperpasia, prognosis, 4649
- Endometrium, tamoxifen, *KRAS*, apoptosis, ErbB ligand, 3119
- Endometrium,  $\alpha$ -catenin, E-cadherin, down-regulation, immuno-histochemistry, 4993
- Endoplasmic reticulum stress, curcumin, apoptosis, G<sub>2</sub>/M arrest, caspase cascade, lung neoplasms, herbal medicine, 2125
- Endoscopy, pericarditis carcinomatosa, malignant cardiac tamponade, malignant pericardial effusion, 4691
- Endothelial cells, cytoskeleton, paxillin, phosphatase, PP-1, TGF- $\beta$ , motility, 4861
- Endothelial cells, melanoma, blue light, phototoxicity, 143
- Endothelial cells, MG132, apoptosis, caspase, ROS, GSH, proteasome inhibitor, 879
- Endothelial cells, pancreatic cancer, neovascularization, angiogenesis, placental growth factor, 2911
- Endothelial tumour, rapamycin, mTOR, celecoxib, COX 2, angiosarcoma, 4017
- Energy metabolism, cancer, primary prevention, tertiary prevention, obesity, metabolic syndrome X, malnutrition, palliative care, review, 1863
- Environmental oestrogens, breast cancer, cosmetics, antiperspirant, deodorant, paraben, aluminium, organochlorine, phytoestrogen, breast cysts, review, 815
- Enzyme induction, cancer chemoprevention, RT-PCR, metabolism, aromathecins, phenazines, 4873
- Enzyme inhibitor, cell cycle arrest, apoptosis, anti-cancer effect, 4841
- Epidemiological study, type 2 diabetes mellitus, cancer, body mass index, mortality, 681
- Epidemiology, breast neoplasms, genetic polymorphism, estrogens, risk, *COMT* haplotypes, 217
- Epidermal growth factor receptor, adenocarcinoma, immunohistochemistry, lung cancer, mutation, 5233
- Epidermal growth factor receptor, drug sensitivity, gefitinib, radiation, 4899
- Epidermal growth factor receptor, EGFR, androgen-independent prostate cancer, cetuximab, C225, monoclonal antibody, Du145, PC-3, 1905
- Epidermal growth factor, PI-103, rapamycin, mTOR complex 1, mTOR complex 2, negative feedback loop, sora fenib, Ras/Raf/MAPK, PI13/AKT/mTOR, 4951
- (-)Epigallocatechin-3-gallate, EGCG, TROP-2, HCT-116, SW480, mRNA stability, cycloheximide, colorectal cancer cells, 2497
- Epigallocatechin-3-gallate, SKOV-3 cells, cell proliferation, ovarian cancer, apoptosis, 2519
- Epigenetic drugs, valproic acid, histone deacetylase inhibitors, matrix metalloproteinases, 535
- Epigenetic regulation, DLD-1, soy isoflavone, SW480, colon cancer cells, genistein, *WNT5a* promoter, 4537
- Epigenetic, adenosine analogue, promoter methylation, clofarabine, *PTEN*, *APC*, *RARB2*, *ZAP70*, 4601
- Epigenetics, pancreatic cancer, DNA methylation, chemotherapy, TMS1, 3919
- Epirubicin, IL-2, high-dose chemotherapy, NK cells, 5-fluorouracil, cyclophosphamide, methotrexate, radiotherapy, etoposide, carboplatin, VEGF, retinoic acid, myeloablative chemotherapy, autologous transplantation, immunotherapy, breast cancer, 209
- Epirubicin, inflammatory breast cancer, trastuzumab, pathological complete response, paclitaxel, 581

- Epirubicin, neoadjuvant chemotherapy, pCR, HER2, cyclophosphamide, paclitaxel, trastuzumab, breast cancer, 4665
- Epithelial membrane antigen, adenomatoid odontogenic tumor, AOT, immuno-histochemistry, cytokeratin, alpha-smooth muscle actin, 1787
- Epithelial phenotype, mesenchymal–epithelial reversion, SMAD4, invasion and metastasis, E-cadherin, 2603
- Epithelial-myoepithelial carcinoma, nude mouse, salivary gland carcinoma, growth factor receptors, cytokeratin, EGFR-1, 1565
- Epithelium, dysplasia, hypopharynx, malignancy, squamous cell carcinoma, 3313
- Epstein-Barr virus, stomach neoplasm, risk factor, medical history, lifestyle, gastric ulcer, alcohol, 2469
- Epstein-Barr virus, thymidine phosphorylase, gastric carcinoma, intestinal type, diffuse type, 2431
- Epstein-Barr virus, tongue and pharyngolaryngeal carcinomas, human papilloma virus, John Cunningham, carcinogenesis, 1233
- Epstein-Barr virus, urothelial carcinoma, B cells, LMP-1, pathogenesis, cell line, 3473
- Epulis, giant cell lesions, giant cell granuloma, cathepsin, RANK, matrix metalloproteinase, jaws, osteoclast, salivary glands, tendon sheath, 1645
- Equinatoxin-II, toxin Bc2, cytolytins, signaling pathways, necrosis, MAPK/ERK, PKC, CaMKII, glioma cell death, 1209
- ER stress, antiglycolytic, autophagosome, translation inhibition, 3-bromopyruvate, 923
- ER, *BAG-1*, PR, apoptosis, endometrial carcinoma, real-time PCR, immunohistochemistry, 4103
- ER, MCF7, flax roots, flax leaves, progesterone, PR, 1695
- ErbB ligand, tamoxifen, endometrium, *KRAS*, apoptosis, 3119
- ErbB receptors, Akt, breast cancer, erlotinib, gefitinib, vitamin E, Stat, tyrosine kinase inhibitors,  $\gamma$ -tocotrienol, 429
- ERCC1, advanced epithelial ovarian cancer, biological feature, suboptimal debulking, 2447
- ERCC1, oxaliplatin, colorectal cancer, gene silencing, siRNA, resistance, 2531
- ERCC1, pancreatic cell carcinoma, second-line treatment, prognostic and predictive factors, 4289
- ERCC1, XPF, DNA repair, chemotherapy, drug resistance, review, 3223
- Erk signaling, cell proliferation, keratinocyte growth factor, KGFR tyrosine kinase inhibitor, breast cancer, metastasis prevention, 4883
- ERK, *MMP13*, PTHrP, parathyroid hormone-related peptide, MAPK, mitogen-activated protein kinase, extracellular signal-regulated kinase, PKC, protein kinase C, bone metastases, breast cancer, 5029
- Erlotinib, Akt, breast cancer, ErbB receptors, gefitinib, vitamin E, Stat, tyrosine kinase inhibitors,  $\gamma$ -tocotrienol, 429
- Erlotinib, EGFR, thyroid tumors, cetuximab, panitumumab, paclitaxel, 473
- Erlotinib, non-small cell lung cancer, Tarceva, EGFR-TKIs, *EGFR* mutation, phase II, 557
- Erlotinib, NSCLC, EGFR, tyrosine kinase inhibitors, lung cancer, review, 1301
- Erlotinib, toxicity, 973
- Errata, 277, 1033, 1034, 1545, 2481, 3851, 4389, 5269
- Erythroid leukemia, notch,  $\gamma$ -secretase inhibitor, differentiation, 4071
- Erythropoietin receptor, local cancer recurrence, anemia, breast cancer, hormone receptor status, 3721
- Esophageal cancer, 14-3-3 sigma, p53, 5175
- Esophageal cancer, invasiveness, transwell invasion chamber, MMP-1, matrix metalloproteinase-1, vimentin, p-Src (pY416), TIMP-2, tissue inhibitor of metalloproteinase-2, 727
- Esophageal cancer, MT2-MMP, intratumoral angiogenesis, 4363
- Esophageal cancer, multiple lymph node metastases, neoadjuvant chemotherapy, DCF, 221
- Esophageal cancer, nephrotic syndrome, membranous glomerulonephritis, 3763
- Esophageal carcinoma, orthotopic implantation, carcinomatosis, *in vivo* fluorescence imaging, 3933
- Esophageal neoplasm, KPNA2, immunohistochemistry, 851
- Esophageal squamous cell carcinoma, Ki-67, CPP32, chagasic megaesophagus, chronic esophagitis, 2845
- Esophageal squamous cell carcinoma, src-activating and signaling molecule, immunohistochemistry, 3535
- Esophagus, baboons, glandular metaplasia, sialomucins, Barretts mucosa, 4123
- Estradiol, cervical intraepithelial neoplasia, cervical squamous epithelium, progesterone, biological markers, 1217
- Estrogen and antiestrogen, *WT1*, HER2, EGFR, breast cancer, 3637
- Estrogen receptor alpha, estrogen receptor beta, immunohistochemistry, pituitary, pituitary adenoma, 2897
- Estrogen receptor beta, estrogen receptor alpha, immunohistochemistry, pituitary, pituitary adenoma, 2897
- Estrogen, alcohol, obesity, breast cancer, post-menopause, 1
- Estrogen, zeranol, leptin, aromatase, CYP19A1, human breast pre-adipocytes, (–)-gossypol, 5077
- Estrogens, breast neoplasms, genetic polymorphism, epidemiology, risk, *COMT* haplotypes, 217

- Estrogens, pancreatitis, pregnancy, cystic lesions, mucinous cystic neoplasms, mucinous cystadenoma, progesterone, pancreatic cancer, 1025
- Ethanol injection, liposomes, microfluidics, sonication, 463
- 3-C-Ethynylcytidine, 5-fluorodeoxyuridine, L1210 murine leukaemia, experimental leukaemia, duplex drug, 4891
- Ethinylestradiol, castration-resistant prostate cancer, prostate-specific antigen, 5201
- Ethinylestradiol, chemohormonal therapy, etoposide, oral chemotherapy, HRPC, prostate cancer, 3737
- Etoposide, anticancer drug, growth inhibition, MDM2, p53, XIAP, lung cancer, 3321
- Etoposide, chemohormonal therapy, ethinylestradiol, oral chemotherapy, HRPC, prostate cancer, 3737
- Etoposide, cisplatin, topotecan, sequential, alternate, SCLC, 3031
- Etoposide, IL-2, high-dose chemotherapy, NK cells, 5-fluorouracil, epirubicin, cyclophosphamide, methotrexate, radiotherapy, carboplatin, VEGF, retinoic acid, myeloablative chemotherapy, autologous transplantation, immunotherapy, breast cancer, 209
- Eukaryotic translation initiation factor 3, histochemistry, actin, tubulin, electron microscopy, P150, colon cancer, 1047
- Everolimus, antiestrogens, AKT, EGF-R, endometrial cancer, gefitinib, mTOR, perifosine, tamoxifen, 2025
- Evidence-based medicine, complementary medicine, quality of life, quackery, review, 1767
- Ewing sarcoma (EWS) gene, CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP) gene, chromosomal translocation, fluorescence *in situ* hybridization, FISH, fusion gene, myxoid liposarcoma, MLS, reverse transcription-polymerase chain reaction, RT-PCR, 4679
- Ewing sarcoma, DSRCT, imatinib, *KIT*, PDGFR $\alpha$ , phase II, 547
- Ewing's sarcoma, apoptosis, radiosensitivity, p53, curcumin, 4007
- Ewing's, sarcoma, prognosis, ploidy, image cytometry, 3715
- EWS-CHOP*, adipocytic tumors, *HMG2-LPP*, lipoma, liposarcoma, *LPP-HMG2*, RT-PCR, *TLS-CHOP*, 661
- ExoC5, Hrs, Rab7, RT-PCR, E-cadherin, fragments, breast cancer, 3903
- Exosome, regulatory T-cells, TGF- $\beta$ 1, malignant effusion, 3747
- Exosomes, metastasis, prostasomes, annexin, proteomics, prostate cancer, 285
- Experimental chemotherapy, azasteroids, human lymphocytes, Lewis lung carcinoma, LLC, sister chromatid exchange, SCE, proliferation rate index, PRI, 4201
- Experimental leukaemia, 3-C-ethynylcytidine, 5-fluorodeoxyuridine, L1210 murine leukaemia, duplex drug, 4891
- Expression, E-cadherin, ovarian cancer, prognosis, 2525
- External beam radiation therapy, PSA-doubling time, carbon radiotherapy, prostate cancer, 5105
- Extracellular signal-regulated kinase, *MMP13*, PTHrP, parathyroid hormone-related peptide, MAPK, mitogen-activated protein kinase, ERK, PKC, protein kinase C, bone metastases, breast cancer, 5029
- Extramedullary, plasmocytoma, multifocal, uncommon site, surgery, radiotherapy, chemotherapy, 1779
- Eyelid edema, pemetrexed, retrospective study, 5185
- Facial nerve, irradiation, irradiation damage, morphometrics, scattering irradiation, 1625
- Facial scoliosis, neurofibromatosis, neurofibromatosis type 1, orbit, plexiform neurofibroma, optic nerve, optic nerve glioma, skull deformity, orbital deformity, orbito-temporal neurofibromatosis, sphenoid wing dysplasia, 1751
- FAK, saracatinib, Src, metastasis, invasion, fibrosarcoma, 4405
- False-negative results, cervical cancer, lymphadenectomy, pelvic nodes, PET-CT, [ $^{18}$ F]Fluorodeoxyglucose, 1029
- Familial breast cancer, *BRCA1* gene, loss of heterozygosity, LOH, genotype-phenotype correlation, 3445
- Farnesoid X receptor, FXR, guggulsterone, CDX2, bile acid, 1953
- Farnesyl diphosphate analogues, RAS protein farnesylation, breast cancer, lung cancer, isoprenoids, 2505
- FAS, cisplatin, apoptosis, sphingomyelin, lipid rafts, 2065
- Fatty acid, prostate cancer, FDG-PET, uptake, glycolysis, bioenergetic metabolism, 369
- Fc fusion, Tn antigen, GalNAc( $\alpha$ 1-3)-Ser/Thr, single chain antibody, phage-display, antibody-dependent cellular cytotoxicity (ADCC), 3397
- FCCP, apoptosis, juxtaglomerular cell, mitochondria, caspase, 2863
- FDG imaging, lung cancer, follow-up, survival, recurrence, early detection, 3811
- FDG uptake, serum tumour markers, PET, CT, diagnosis, lung cancer, 1741
- FDG-PET, prostate cancer, uptake, glycolysis, fatty acid, bioenergetic metabolism, 369
- FDG-PET, uterine corpus cancer, staging, lymphadenectomy, negative predictive value, specificity, 3787
- Female genital tract disease, cervical intraepithelial neoplasia, precancerous conditions, cervical cancer, reproducibility, spontaneous neoplasm regression, 2319
- FFPE, colorectal carcinoma, *KRAS*, *BRAF*, mutations, ThinPrep, qPCR, 1969
- FGFR3, fibroblast growth factor receptor 3, bortezomib, lymphoma, 1921
- Fiberbronchoscopy, mediastinal lymphadenopathies, metastasis, transbronchial needle aspiration, 4769

- Fibroblast growth factor receptor 3, FGFR3, bortezomib, lymphoma, 1921
- Fibroblast, MMP inhibition, angiogenesis, cytokine, imaging, skin cancer invasion, VEGF-A, PDGF-BB, 703
- Fibroblast, TGF- $\beta$ 1, antisense, keloid, SMAD, 3459
- Fibroblasts, cancer/testis antigens, mesenchymal stem cells, pericytes, MAGED1, PRAME, 5023
- Fibronectin, TG2, A431 cell, MMP-9, invasion, 4177
- Fibrosarcoma, progression, inflammation-associated carcinogenesis, nuclear protein, proteomic analysis, 2093
- Fibrosarcoma, saracatinib, Src, FAK, metastasis, invasion, 4405
- Fibula, cervical cancer, metastases, tibia, isotope bone scan, 2949
- Field cancerization, MGMT, alkyltransferase, drug resistance, SCCHN, cancer therapy, 2561
- FIGO IA1, cervical cancer, microinvasive, repeat surgery, 565
- FIGO staging, glycodelin A, ovarian cancer, grading, 1637
- Filamin, VEGF, lung cancer, immunohistochemical analysis, 3939
- Finasteride, neuroendocrine (NE) differentiation, benign prostatic hyperplasia, dutasteride, chromogranin A, 4737
- FINAVAST trial, targeted therapy, VEGF, matrix metalloproteinase, oxidative stress, reactive oxygen species, angiogenesis, bevacizumab, 1001
- Fine-needle aspiration biopsy, breast cancer, cytology, DNA cytometry, DNA content, benign breast lesions, free cell sampling, cell group sampling, 175
- Fine-needle aspiration cytology, thyroid gland, thyroid cancer, thyroid nodule, thyroid scintigraphy, FNAB, FNAC,  $^{99m}\text{Tc}$ -pertechnetate, 3083
- Fine-needle aspiration, BRAF, melanoma, proliferation, metastatic melanoma, 3267
- First and second line chemotherapy, non-small cell lung cancer, survival, 4335
- First-line therapy, metastatic breast cancer, bevacizumab, paclitaxel, VEGF, 2969
- FISH, CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP) gene, chromosomal translocation, Ewing sarcoma (EWS) gene, fluorescence *in situ* hybridization, fusion gene, myxoid liposarcoma, MLS, reverse transcription-polymerase chain reaction, RT-PCR, 4679
- FISH, IHC, HER-2/neu, breast cancer, 4081
- FITC-LPS, IP-PA1, LPS, fluorescence label, *Pantoea agglomerans*, 3151
- Fixed-dose rate gemcitabine, bortezomib, solid tumors, phase I, 167
- Flamingo Gel Stain, two-dimensional gel electrophoresis, LC-MS/MS, SeePico, highly sensitive Coomassie brilliant blue, proteomic analysis, 4001
- Flat-panel CT, magnetic drug targeting, local chemotherapy, tumour vascularisation, computed tomography, angiography, 1553
- Flavonols, colon cancer, Caco-2, growth, differentiation, peroxide, alkaline phosphatase, 3629
- Flax leaves, MCF7, flax roots, progesterone, ER, PR, 1695
- Flax roots, MCF7, flax leaves, progesterone, ER, PR, 1695
- Flax, *Linum usitatissimum*, phytoestrogens, MCF-7, cellular metabolism, online monitoring, acidification, oxygen consumption, adhesion, 1587
- FLIPI, MALT lymphoma, IPI, prognostic index, 635
- Fluorescence *in situ* hybridization, CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP) gene, chromosomal translocation, Ewing sarcoma (EWS) gene, FISH, fusion gene, myxoid liposarcoma, MLS, reverse transcription-polymerase chain reaction, RT-PCR, 4679
- Fluorescence label, IP-PA1, LPS, FITC-LPS, *Pantoea agglomerans*, 3151
- Fluorescence microscopy, tumour, angiogenesis, functional vessel density, vascular network, 2597
- Fluorescent agents, lung cancer, sentinel lymph node, vitamin B2, 4109
- Fluorescent *in situ* hybridization, acute lymphoblastic leukemia, cytogenetics, Philadelphia chromosome, bcr-abl fusion gene, 569
- Fluorescent proteins, nude mice model, metastasis, NPA, KAK-1, GFP, thyroid cancer, 4415
- [ $^{18}\text{F}$ ]Fluorodeoxyglucose, cervical cancer, false-negative results, lymphadenectomy, pelvic nodes, PET-CT, 1029
- 5-Fluorodeoxyuridine, 3-C-ethynylcytidine, L1210 murine leukaemia, experimental leukaemia, duplex drug, 4891
- Fluoropyrimidine analogs, HT29, chemoresistance, translational regulation, real-time PCR, mRNA quantification, colorectal cancer cells, thymidylate synthase, p53, 5-FU resistance, 1149
- 5-Fluorouracil, apoptosis, mcl-1, Jurkat, T cells, caspases, 3879
- 5-Fluorouracil, IL-2, high-dose chemotherapy, NK cells, epirubicin, cyclophosphamide, methotrexate, radiotherapy, etoposide, carboplatin, VEGF, retinoic acid, myeloablative chemotherapy, autologous transplantation, immunotherapy, breast cancer, 209
- 5-Fluorouracil, WiDr colon cancer cells, growth factors, oxaliplatin, SN-38, glutathione modulation, buthionine-SR-sulfoximine, L-2-oxothiazolidine-4-carboxylate, 1223
- FNAB, thyroid gland, thyroid cancer, thyroid nodule, thyroid scintigraphy, fine-needle aspiration cytology, FNAC,  $^{99m}\text{Tc}$ -pertechnetate, 3083
- FNAC, thyroid gland, thyroid cancer, thyroid nodule, thyroid scintigraphy, fine-needle aspiration cytology, FNAB,  $^{99m}\text{Tc}$ -pertechnetate, 3083
- FOLFIRI, gemcitabine-resistant disease, irinotecan, pancreatic cancer, XELIRI, 4785

- FOLFIRI, orthotopic model, colon cancer, tumor-growth metastasis, survival time, GFP imaging, 403
- FOLFOX, chemotherapy, cancer, colorectal cancer treatment, microsatellite instability, adjuvant treatment, prognostic factor, 4297
- FOLFOX, colorectal cancer, yttrium-90 microspheres, liver metastases, chemotherapy, hepatectomy, 3005
- FOLFOX, colorectal liver metastases, hepatic resection, chemotherapy with oxaliplatin plus fluorouracil and leucovorin, Japanese patients, 1015
- Folic acid, paclitaxel, dextran, targeting, adsorption, 903
- Folliculin, Birt Hogg Dubé syndrome, cancer predisposition, review, 751
- Follow-up, lung cancer, FDG imaging, survival, recurrence, early detection, 3811
- Follow-up, tumor marker, Cyfra 21-1, oropharyngeal cancer, squamous cell carcinoma, 2291
- FOXO1, mTOR, rapamycin, proliferation, 799
- FOXP3, regulatory T-cells, Treg-cells, gastric cancer, review, 1093
- FR235222, tumour necrosis factor-related apoptosis-inducing ligand, TRAIL, histone deacetylase inhibitors, human promyelocytic leukaemia, apoptosis, 887
- Fractionated X-irradiation, cisplatin hypersensitivity, oxaliplatin resistance, teratoma cell lines, 4471
- Fragments, Hrs, Rab7, ExoC5, RT-PCR, E-cadherin, breast cancer, 3903
- FRAP, interstitial diffusion, collagenase, hyaluronidase, two-photon excitation, multicellular spheroids, 359
- Free cell sampling, breast cancer, cytology, fine-needle aspiration biopsy, DNA cytometry, DNA content, benign breast lesions, cell group sampling, 175
- Free radical, UVB, photodynamic therapy, indole-3-acetic acid, apoptosis, prostate cancer cells, 4607
- 5-FU Resistance, HT29, chemoresistance, translational regulation, real-time PCR, mRNA quantification, colorectal cancer cells, fluoropyrimidine analogs, thymidylate synthase, p53, 1149
- 5-FU Resistance, small molecules, gene expression analysis, thymidylate synthase, real-time PCR, chemoresistance, arsenic trioxide, 1157
- 5-FU, breast cancer, signal pathway, mTOR, TS, ROS, rapamycin, 2625
- 5-FU, HB-EGF, HER2, paclitaxel, gastric cancer, 3143
- Functional proteomics, cancer, proliferation, NAPPA microarrays, review, nanotechnology, 2073
- Functional vessel density, tumour, angiogenesis, vascular network, fluorescence microscopy, 2597
- Fundic gland, gastric, polyposis, PPI, 261
- Fundic glands, polyps, lysozyme, *Helicobacter pylori*, 1021
- Fusion gene, CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP) gene, chromosomal translocation, Ewing sarcoma (EWS) gene, fluorescence *in situ* hybridization, FISH, myxoid liposarcoma, MLS, reverse transcription-polymerase chain reaction, RT-PCR, 4679
- FXR, farnesoid X receptor, guggulsterone, CDX2, bile acid, 1953
- Fyn kinase, integrin,  $\alpha\beta6$ , EMT, oral SCC, serum, 2591
- G<sub>0</sub>/G<sub>1</sub>, apoptosis, presenilin 1, presenilin 2, cell cycle, chemoresistance,  $\gamma$ -secretase, pancreatic ductal adenocarcinoma cells, taxanes, 4999
- G<sub>2</sub>/M arrest, curcumin, apoptosis, caspase cascade, endoplasmic reticulum stress, lung neoplasms, herbal medicine, 2125
- G3139, liposomes, disulfide, antisense oligonucleotide, *Bcl-2*, drug delivery, 31
- Gabapentin, oxaliplatin, peripheral neuropathy, colon cancer, pregabalin, 2927
- Galectin-1, vulvar intraepithelial neoplasia, squamous cell carcinoma, immunohistochemistry, 1547
- Galectins, agglutinins, glycobiology, lymphangiogenesis, VEGF, lectins, breast cancer cells, 4829
- Gallbladder carcinoma, PCR-SSCP, direct sequencing, TP53, transition mutations, cholecystitis, 4443
- GalNAc( $\alpha$ 1-3)-Ser/Thr, Tn antigen, single chain antibody, phage-display, Fc fusion, antibody-dependent cellular cytotoxicity (ADCC), 3397
- GALT, colon, carcinomas, Lynch syndrome, 3019
- Gamma radiation, cytokines, bystander responses, glioblastoma, *in vitro*, 2769
- Gamma-delta T-cells, renal cell carcinoma, adoptive immunotherapy, lung metastasis, 575
- Gamma-glutamyltransferase, human neoplasia, tumor progression, drug resistance, redox regulation, review, 1169
- Gamma-secretase, breast cancer, Notch, cancer stem cells, mammosphere, 3853
- Gap junctional intercellular communication GJIC, connexin43, E-cadherin,  $\beta$ -catenin, ZO-1, immunohistochemistry, CpG island, methylation analysis, pyrosequencing, lung cancer, 2271
- Gap junctions, breast cancer, anti-cancer drugs, 6-methoxy-8-[(2-furanylmethyl)amino]-4-methyl-5-(3-trifluoromethyl phenyloxy)quinoline, *in vivo* activity, quinolines, 3927
- GARFT, TS, DHFR, NSCLC, malignant pleural mesothelioma, pemetrexed, 4309
- Gastric cancer cell lines, chemotherapy, cross-resistance, anticancer drugs, apoptosis, cell-cycle, 915
- Gastric cancer risk, thymidylate synthase TS, thymidylate synthase enhancer region TSER, untranslated region UTR, variable number of tandem repeats VNTR, 2325

- Gastric cancer, *CD133*, quantitative methylation-specific PCR, 1201
- Gastric cancer, CpG island hypermethylation, morphological appearance, 239
- Gastric cancer, cytology, peritoneal dissemination, neoadjuvant chemotherapy, docetaxel, S-1, 1335
- Gastric cancer, *DCC*, quantitative methylation-specific PCR, 107
- Gastric cancer, DNA repair genes, polymorphism, APE1, HOGG1, 1359
- Gastric cancer, docetaxel sensitivity, CXCR4, 2209
- Gastric cancer, *Drosophila melanogaster* multisubstrate deoxyribonucleoside kinase, retroviral vector, suicide gene, bystander effect, 2641
- Gastric cancer, E-cadherin, promoter polymorphism, methylation, *KIT*, *CDH1*, 2225
- Gastric cancer, FOXP3, regulatory T-cells, Treg-cells, review, 1093
- Gastric cancer, gene polymorphism, interleukin-1beta, IL-1, IL-1 receptor antagonist, 505
- Gastric cancer, HB-EGF, HER2, 5-FU, paclitaxel, 3143
- Gastric cancer, hepatic resection, liver metastasis, prognostic factor, 2367
- Gastric cancer, *Mus81*, 5011
- Gastric cancer, p16, quantitative methylation-specific PCR, 2701
- Gastric cancer, pepsinogen, *Helicobacter pylori*, adenosine deaminase, ADA, chronic atrophic gastritis, CAG, 2347
- Gastric cancer, S-1, cisplatin, outpatient setting, 3759
- Gastric cancer, stem cell, *CD133*, prognosis, 2453
- Gastric cancer, *TFPI2*, quantitative methylation-specific PCR, 4131
- Gastric cancer, VEGF-C, VEGF-D, CCR7, lymphatic invasion, 2361
- Gastric cancer,  $\beta$ -catenin, MUC1, c-Met, immunohistology, prognosis, 4635
- Gastric carcinoma cells, LC-MS/MS, peptide sequence tag, 14-3-3 sigma protein, proteomic differential display, 4459
- Gastric carcinoma cells, vimentin, scirrhous type, lymph node metastasis, prognosis, 5239
- Gastric carcinoma cells, YB-1, gene regulation, gene expression, RNA interference, drug resistance, 693
- Gastric carcinoma cells, YB-1, gene regulation, RNA interference, micro RNAs, microarray, drug resistance, 629
- Gastric carcinoma, electron microscopy, nuclear envelope changes, 699
- Gastric carcinoma, hybrid liposomes, chemotherapy, apoptosis, cotton rat, 2011
- Gastric carcinoma, MACC 1, quantitative real-time PCR, 3441
- Gastric carcinoma, thymidine phosphorylase, Epstein-Barr virus, intestinal type, diffuse type, 2431
- Gastric ulcer, stomach neoplasm, Epstein-Barr virus, risk factor, medical history, lifestyle, alcohol, 2469
- Gastric, fundic gland, polyposis, PPI, 261
- Gastrin-releasing peptide receptors, bioluminescent imaging, bombesin (BN)-like peptides, prostate cancer, 4039
- Gastritis, genetic polymorphism, *TLR4*, *NOD2/CARD15*, histopathology, 513
- Gastrointestinal stromal tumor, GIST, C-KIT gene, Ki-67 labeling index, PI3K, ALT, 2705
- Gastrointestinal stromal tumour, GIST, distant metastasis, oral cavity, imatinib, PET, 4283
- GBM, CSC, ATRA, MAPK, 4915
- Gefitinib, Akt, breast cancer, ErbB receptors, erlotinib, vitamin E, Stat, tyrosine kinase inhibitors,  $\gamma$ -tocotrienol, 429
- Gefitinib, antiestrogens, AKT, EGF-R, endometrial cancer, everolimus, mTOR, perifosine, tamoxifen, 2025
- Gefitinib, epidermal growth factor receptor, drug sensitivity, radiation, 4899
- GEM, gemcitabine, two-dimensional gel electrophoresis, LC-MS/MS, pancreatic cancer, proteomics, 3367
- GEM, two-dimensional gel electrophoresis, 2-DE, LC-MS/MS, pancreatic cancer, gemcitabine, proteomics, heat-shock protein 27, 2539
- Gemcitabine, advanced bladder carcinoma, oxaliplatin, vinorelbine, 4711
- Gemcitabine, bladder cancer, chemotherapy, synergism, cell cycle, carboplatin, 4573
- Gemcitabine, breast cancer, chemotherapy, neoadjuvant, pegylated liposomal doxorubicin, docetaxel, phase II, locally advanced, 3817
- Gemcitabine, cisplatin, elderly patients, urothelial carcinoma, 3839
- Gemcitabine, combination therapy, apoptosis, 2-methoxyestradiol, pancreatic cancer cells, 4619
- Gemcitabine, GEM, two-dimensional gel electrophoresis, LC-MS/MS, pancreatic cancer, proteomics, 3367
- Gemcitabine, NSCLC, adjuvant chemotherapy, carboplatin, paclitaxel, treatment compliance, surgical resection, 4695
- Gemcitabine, pancreatic cancer, docetaxel, refractory, chemotherapy, metastatic disease, salvage therapy, 2905
- Gemcitabine, pharmacokinetics, metabolism, induction, nucleoside analogue, 3669
- Gemcitabine, sex differences, pancreatic cancer, indole-3-carbinol, 4907
- Gemcitabine, two-dimensional gel electrophoresis, 2-DE, LC-MS/MS, pancreatic cancer, GEM, proteomics, heat-shock protein 27, 2539
- Gemcitabine, urothelial cancer, heme oxygenase-1, drug resistance, chemotherapy, radiotherapy, 2145
- Gemcitabine-resistant disease, irinotecan, pancreatic cancer, XELIRI, FOLFIRI, 4785

- Gene delivery, interleukin-6, IL-6, vascular endothelial growth factor, new receptor inhibitor of IL-6, NRI, mesotheliomas, adenovirus, 1947
- Gene expression analysis, small molecules, thymidylate synthase, real-time PCR, chemoresistance, arsenic trioxide, 5-FU resistance, 1157
- Gene expression level, metastatic colorectal cancer, polymorphisms, clinical outcome, cetuximab, bevacizumab, irinotecan, 4209
- Gene expression, CHM-1, DNA damage, DNA repair, U-2 OS human osteogenic sarcoma cells, quinolone, 4187
- Gene expression, EGFR, LOXL4, head and neck squamous cell carcinoma, metastasis, 4567
- Gene expression, histone deacetylase inhibitor, ITF2357, apoptosis, NF- $\kappa$ B, inflammation, 4525
- Gene expression, microarrays, oral cancer, tobacco, 1083
- Gene expression, YB-1, gene regulation, RNA interference, drug resistance, gastric carcinoma cells, 693
- Gene polymorphism, breast cancer, CD44, patient age, tumor burden, SNP, 1263
- Gene polymorphism, gastric cancer, interleukin-1beta, IL-1, IL-1 receptor antagonist, 505
- Gene polymorphism, pancreatic cancer, growth factors, EGF, TGF- $\beta$ 1, TNF- $\alpha$ , 5257
- Gene regulation, YB-1, gene expression, RNA interference, drug resistance, gastric carcinoma cells, 693
- Gene regulation, YB-1, RNA interference, micro RNAs, microarray, gastric carcinoma cells, drug resistance, 629
- Gene silencing, oxaliplatin, colorectal cancer, ERCC1, siRNA, resistance, 2531
- Gene therapy, antitumor, apoptosis, cell-penetrating peptide, protein transduction domain, tumor necrosis factor-related apoptosis-inducing ligand, TRAIL, arginine-rich peptides, 2193
- Gene therapy, Tie2, polyethylenimine, *p53* gene, 1999
- Gene transfer, pulmonary surfactant, *KRAS* mutation, CC10, intratracheal instillation, lung cancer, 4925
- Gene, ovarian cancer, polymorphism, *ABCBI*, prognosis, 3487
- Genetic polymorphism, breast neoplasms, epidemiology, estrogens, risk, *COMT* haplotypes, 217
- Genetic polymorphism, *TLR4*, *NOD2/CARD15*, gastritis, histopathology, 513
- Genistein, *BRCA1*, breast cancer, AKT, p21<sup>WAF1/CIP1</sup>, 2049
- Genistein, DLD-1, epigenetic regulation, soy isoflavone, SW480, colon cancer cells, *WNT5a* promoter, 4537
- Genomic methylation, breast cancer, promoter hypermethylation, tumor suppressor genes, repetitive elements, WBC DNA, 2489
- Genotype-phenotype correlation, *BRCA1* gene, loss of heterozygosity, LOH, familial breast cancer, 3445
- Genotypes, human papillomavirus, oral cancer, oropharyngeal cancer, head and neck cancer, 5099
- GFP imaging, orthotopic model, FOLFIRI, colon cancer, tumor-growth metastasis, survival time, 403
- GFP, fluorescent proteins, nude mice model, metastasis, NPA, KAK-1, thyroid cancer, 4415
- GFP, *in vivo* imaging, color-coded, RFP, UVC, melanoma, blood vessels, 3291
- Giant cell granuloma, giant cell lesions, epulis, cathepsin, RANK, matrix metalloproteinase, jaws, osteoclast, salivary glands, tendon sheath, 1645
- Giant cell lesions, giant cell granuloma, epulis, cathepsin, RANK, matrix metalloproteinase, jaws, osteoclast, salivary glands, tendon sheath, 1645
- Giant cell tumor, knee joint, bone cement, radiolucent zone, recurrence, 3795
- GIST, gastrointestinal stromal tumor, C-KIT gene, Ki-67 labeling index, PI3K, ALT, 2705
- GIST, gastrointestinal stromal tumour, distant metastasis, oral cavity, imatinib, PET, 4283
- GIST, *KIT*, PDGFRA, prognosis, 2407
- Glandular metaplasia, esophagus, baboons, sialomucins, Barretts mucosa, 4123
- Glasgow prognostic score, hepatocellular carcinoma, hepatectomy, pulmonary complications, transfusion, 5129
- Gli-1, intraductal papillary mucinous neoplasm, pancreas, claudin-18, p53, 2995
- Glioblastoma multiforme, CD44, metastasis, survival, 253
- Glioblastoma, animal cancer models, chick embryo, rodent model, tumour markers, immunohistochemistry, cell xenografts, 4851
- Glioblastoma, cytokines, gamma radiation, bystander responses, *in vitro*, 2769
- Glioma cell death, toxin Bc2, equinatoxin-II, cytolysins, signaling pathways, necrosis, MAPK/ERK, PKC, CaMKII, 1209
- Glioma cells, astrocytoma, central nervous system, malignancy, invasion, chlorotoxin, multiple chloride channels, 4515
- Glioma, chemotherapy, malignant, 5213
- Glioma, paclitaxel, magnetic nanoparticles, magnetic targeting, rats, 2217
- Glioma, *PTEN*, mutation, 981
- Glioma, ROCK isoforms, shRNA, cell cycle, ACNU, 3509
- Glioma, stem cells, interferon-beta, stem cell niche, pericytes, 3301
- Gliomas, origin, stem cells, *CD133*, markers, brain adjacent tissue, nestin, subventricular zone, review, 1977
- Glottic cancer, vocal cord cancer, radiotherapy, chemotherapy, 5181
- Glucarpidase, methotrexate, proton pump inhibitor, drug-drug interaction, 963
- Glucocorticoid, combination therapy, inflammation, postsurgical, micrometastases, CEA, lung carcinoma, lymphokine-activated killer cell therapy, 3125



- Glucose metabolism, transketolase-like-1 protein, TKTL1, cancer, aerobic glycolysis, endometrial cancer, pAkt, GLUT1, 1653
- GLUT1, transketolase-like-1 protein, TKTL1, cancer, aerobic glycolysis, endometrial cancer, glucose metabolism, pAkt, 1653
- Glutathione modulation, WiDr colon cancer cells, growth factors, 5-fluorouracil, oxaliplatin, SN-38, buthionine-SR-sulfoximine, L-2-oxothiazolidine-4-carboxylate, 1223
- Glycobiology, agglutinins, lymphangiogenesis, VEGF, galectins, lectins, breast cancer cells, 4829
- Glycodelin A, ovarian cancer, grading, FIGO staging, 1637
- Glycodelin, breast cancer, differentiation, immunohistochemistry, 1599
- Glycolysis, prostate cancer, FDG-PET, uptake, fatty acid, bioenergetic metabolism, 369
- Glycolytic inhibitors, pancreatic cancer, signaling, 743
- Glypican-3, hepatocellular carcinoma, differentiation, GPC3, 5055
- Go6976, protein kinase C, retinoblastoma, bladder, carcinoma, 3995
- Gorlin, NBCCS, calcification, ponticulus posterior, atlanto-occipital ligament, 4265
- (-)-Gossypol, breast cancer, MCF-7 cells, gossypol-myosin, anticancer, 439
- (-)-Gossypol, zeranol, leptin, aromatase, CYP19A1, estrogen, human breast pre-adipocytes, 5077
- Gossypol, docetaxel, Bcl-XL, tumor growth, apoptosis, anti-apoptosis genes, adrenal cancer, 4805
- Gossypol-myosin, (-)-gossypol, breast cancer, MCF-7 cells, anticancer, 439
- Gp160, CD10, CD13, peptidases, renal tumour behaviour, papillary carcinoma, 1137
- GPC3, glypican-3, hepatocellular carcinoma, differentiation, 5055
- Grading, glycodelin A, ovarian cancer, FIGO staging, 1637
- Granulosa cell tumor, neoadjuvant chemotherapy, VEGF, ovarian cancer, bevacizumab, 4767
- Gross domestic product, cereals, cholesterol, diet, milk protein, prostate cancer, ultraviolet-B, vitamin D, 189
- Growth factor receptors, epithelial-myoeithelial carcinoma, nude mouse, salivary gland carcinoma, cytokeratin, EGFR-1, 1565
- Growth factor, colorectal cancer, cytokine, hepatectomy, liver metastasis, liver regeneration, tumour recurrence, review, 2161
- Growth factors, JNK1, apoptosis, kinase, mammary cancer, 3407
- Growth factors, lapatinib, sunitinib, malignant glioma, MMPs, VEGFR, integrins, anti-VEGFR agents, anti-EGFR agents, 4987
- Growth factors, pancreatic cancer, gene polymorphism, EGF, TGF- $\beta$ 1, TNF- $\alpha$ , 5257
- Growth factors, WiDr colon cancer cells, 5-fluorouracil, oxaliplatin, SN-38, glutathione modulation, buthionine-SR-sulfoximine, L-2-oxothiazolidine-4-carboxylate, 1223
- Growth inhibition, anticancer drug, MDM2, p53, XIAP, lung cancer, etoposide, 3321
- Growth, colon cancer, Caco-2, flavonols, differentiation, peroxide, alkaline phosphatase, 3629
- Growth, colon cancer, Caco-2, polyphenols, differentiation, histone deacetylase inhibitors, 311
- GRP receptor, breast cancer, technetium, carbonyl, T47-D, MDA-MB-231,  $^{99m}\text{Tc}-(\text{CO})_3\text{-X-Y-bombesin (7-14)NH}_2$ , 19
- GSH, MG132, apoptosis, endothelial cells, caspase, ROS, proteasome inhibitor, 879
- GSH, MG132, apoptosis, NAC, ROS, 2107
- GSK3beta, AKT, natural products, plant extract, CDK inhibitor, 3599
- GSNOR, ADH5, auranofin, hepatoma, S-nitrosylation, mithramycin, thioredoxin reductases, 415
- GST-pi, class pi glutathione-S-transferase, nuclear transfer, mantle cell lymphoma, anticancer agents, 3951
- Guggulsterone, CDX2, bile acid, farnesoid X receptor, FXR, 1953
- Gynaecological cancer, selenium substitution, solid tumours, radiotherapy, head and neck cancer, 1783
- $\gamma$ -H2AX, camptothecin derivative, apoptosis, DNA damage and repair, M-phase cell, radiation, 937
- Haemolysis, human erythrocyte, BCPCF, phenolic compound, lignans, norlignans, multidrug resistance, MRP1/ABCC1, 4423
- HAMA, human anti-mouse antibody, colorectal cancer, prevalence, monoclonal antibody therapeutics, adverse events, 4353
- Hamsters, DMBA, calcium glucarate, buccal pouch, squamous cell carcinoma, 843
- Hand-sewn, anastomosis, leak, small bowel, large bowel, ileocolic, laparoscopic, review, 601
- Haplotypes, *RET*, lung cancer, polymorphism, Korean population, 3621
- Ha-ras, nm23, metastasis, immunomodulation, 3585
- HB-EGF, cancer, targeted therapy, review, 3107
- HB-EGF, HER2, 5-FU, paclitaxel, gastric cancer, 3143
- HCC, angiogram, recurrence, MGN-3, 5145
- HCT-116, EGCG, TROP-2, SW480, mRNA stability, cycloheximide, (-)epigallocatechin-3-gallate, colorectal cancer cells, 2497
- HDFL, breast cancer, acute disseminated intravascular coagulation, vinorelbine, 3087
- HE4, breast cancer, metastasis, WFDC2, prognostic factor, 4779
- Head and neck cancer, EGFR, chemoradiotherapy, treatment, prognostic factor, 671
- Head and neck cancer, human papillomavirus, genotypes, oral cancer, oropharyngeal cancer, 5099

- Head and neck cancer, nasopharyngeal carcinoma, IGF-1R, undifferentiated carcinoma, immunotherapy, 1641
- Head and neck cancer, radiotherapy, selenium, randomised trial, 1829
- Head and neck cancer, re-irradiation, outcome, 3781
- Head and neck cancer, selenium substitution, solid tumours, radiotherapy, gynaecological cancer, 1783
- Head and neck lymphoma, oral metastasis, oral cancer, solid tumors, jaw metastasis, 1843
- Head and neck squamous carcinoma, cancer stem cells, side population, 2005
- Head and neck squamous cell carcinoma, EGFR, LOXL4, gene expression, metastasis, 4567
- Head and neck, VEGF splice variant, HNSCC, hemangioma, vascular malformation, 805
- Heart surgery, pericardial mesothelioma, mesothelioma, asbestos, inflammation, 1323
- Heat shock protein 27, osteosarcoma, drug resistance, zoledronic acid, 3565
- Heat-shock protein 27, two-dimensional gel electrophoresis, 2-DE, LC-MS/MS, pancreatic cancer, gemcitabine, GEM, proteomics, 2539
- Heat-shock protein 70, Ki-67, neoadjuvant, aromatase inhibitor, breast cancer, 3465
- HeLa cells, calponin h1, actin cytoskeleton stability, cell motility, point mutation, S175T, 1071
- Helicobacter pylori*, fundic glands, polyps, lysozyme, 1021
- Helicobacter pylori*, pepsinogen, gastric cancer, adenosine deaminase, ADA, chronic atrophic gastritis, CAG, 2347
- Helicobacter pylori*, *Solanum lyratum*, human gastric epithelial cells, apoptosis, 1189
- Helper peptide, Wilms' tumor gene, *WT1*, helper T cell, peptide vaccine, cancer immunotherapy, 2247
- Helper T cell, Wilms' tumor gene, *WT1*, helper peptide, peptide vaccine, cancer immunotherapy, 2247
- Hemangioma, VEGF splice variant, HNSCC, vascular malformation, head and neck, 805
- Hematologic toxicity, chemotherapy, carboplatin, paclitaxel, age, non-small cell lung cancer, 1365
- Heme oxygenase-1, urothelial cancer, drug resistance, chemotherapy, radiotherapy, gemcitabine, 2145
- Hepatectomy, colorectal cancer, cytokine, growth factor, liver metastasis, liver regeneration, tumour recurrence, review, 2161
- Hepatectomy, colorectal cancer, yttrium-90 microspheres, liver metastases, chemotherapy, FOLFOX, 3005
- Hepatectomy, hepatocellular carcinoma, Glasgow prognostic score, pulmonary complications, transfusion, 5129
- Hepatectomy, liver metastasis, bone metastasis, radiation therapy, colon cancer, 677
- Hepatic chemoembolization, liver neoplasm therapy, liver interventional procedures, arteries, 5159
- Hepatic metastasis, mediastinal germ cell tumor, rhabdomyosarcoma, BEP chemotherapy, positron-emission tomography, 5117
- Hepatic resection, colorectal liver metastases, chemotherapy with oxaliplatin plus fluorouracil and leucovorin, FOLFOX, Japanese patients, 1015
- Hepatic resection, gastric cancer, liver metastasis, prognostic factor, 2367
- Hepatitis, cirrhosis, hepatocellular carcinoma, cell cycle proteins, apoptotic proteins, 4493
- Hepatocarcinogenesis, statins, HMGCoA reductase inhibitors, carcinogenesis, liver neoplasm, ubiquinone, mevalonate pathway, lovastatin, 1105
- Hepatocellular carcinoma cells, tyrosine kinase pathway, P-glycoprotein, chemosensitivity sorafenib, multidrug resistance, 4503
- Hepatocellular carcinoma, chemotherapy, platinum, S-1, 5245
- Hepatocellular carcinoma, cyclin D1, STAT3, IL-6, CADPE, 481
- Hepatocellular carcinoma, glypican-3, differentiation, GPC3, 5055
- Hepatocellular carcinoma, hepatectomy, Glasgow prognostic score, pulmonary complications, transfusion, 5129
- Hepatocellular carcinoma, hepatitis, cirrhosis, cell cycle proteins, apoptotic proteins, 4493
- Hepatocellular carcinoma, MAGE, melanoma antigen, HLA molecules, immunotherapy, 1617
- Hepatocellular carcinoma, oxaliplatin, high-LET radiation, PARP, apoptosis, autophagy, 303
- Hepatocyte growth factor, HGF, B16-F0 mouse melanoma cell, mouse model, *Cordyceps sinensis*, invasion, 3429
- Hepatoma, ADH5, auranofin, GSNOR, S-nitrosylation, mithramycin, thioredoxin reductases, 415
- HER-2, AKT, immunohistochemistry, upper urinary tract, urothelial carcinoma, 2439
- HER2, HB-EGF, 5-FU, paclitaxel, gastric cancer, 3143
- HER2, neoadjuvant chemotherapy, pCR, epirubicin, cyclophosphamide, paclitaxel, trastuzumab, breast cancer, 4665
- HER2, SISH, breast, colon, prostate, lung, ovary, 1287
- HER2, trastuzumab, breast cancer, plasma DNA, 2463
- HER2, *WT1*, EGFR, estrogen and antiestrogen, breast cancer, 3637
- Her2/neu, CEA, BCRP, HSP27, microparticles, breast cancer, 1707
- HER-2/neu, FISH, IHC, breast cancer, 4081
- Herbal medicine, curcumin, apoptosis, G<sub>2</sub>/M arrest, caspase cascade, endoplasmic reticulum stress, lung neoplasms, 2125
- Heterocyclic arylamines, breast cancer, oestrogen metabolism, N-acetyltransferase 2, cytochrome P450 1B1, 2885

- Heterogeneity, chemoFx DRM, cancer, chemotherapeutic response, mechanism of action, chemotherapy drug response marker, *in vitro* chemosensitivity testing, 2805
- HGF, hepatocyte growth factor, B16-F0 mouse melanoma cell, mouse model, *Cordyceps sinensis*, invasion, 3429
- HGG, high-grade glioma, treatment, vincristine, outcome, 2303
- HIF1A1*, colorectal cancer, polymorphisms, prognosis, 2393
- HIF1 $\alpha$ , anesthesia, lung cancer, one-lung ventilation, BMI, obesity, pneumothorax, 1143
- High-dose chemotherapy, IL-2, NK cells, 5-fluorouracil, epirubicin, cyclophosphamide, methotrexate, radiotherapy, etoposide, carboplatin, VEGF, retinoic acid, myeloablative chemotherapy, autologous transplantation, immunotherapy, breast cancer, 209
- High-dose interleukin-2, renal cell carcinoma, carbonic anhydrase IX, 987
- High-grade glioma, HGG, treatment, vincristine, outcome, 2303
- High-LET radiation, oxaliplatin, PARP, apoptosis, autophagy, hepatocellular carcinoma, 303
- High-LET, carbon ion, p53, radiosensitivity, apoptosis, chemotherapeutic agent, 1961
- Highly sensitive Coomassie brilliant blue, two-dimensional gel electrophoresis, LC-MS/MS, Flamingo Gel Stain, SeePico, proteomic analysis, 4001
- Hindgut, breast cancer, neuroendocrine tumour, carcinoid, 3015
- Histochemistry, actin, tubulin, electron microscopy, P150, eukaryotic translation initiation factor 3, colon cancer, 1047
- Histological type, cisplatin, S-1, pooled analysis, lung cancer, 2985
- Histology, breast cancer, survival analysis, steroid receptors, 5137
- Histone deacetylase inhibitor, gene expression, ITF2357, apoptosis, NF- $\kappa$ B, inflammation, 4525
- Histone deacetylase inhibitor,  $\gamma\delta$  T-cells, cancer immunotherapy, bladder carcinoma, valproic acid, NKG2D ligands, 4509
- Histone deacetylase inhibitors, colon cancer, Caco-2, polyphenols, growth, differentiation, 311
- Histone deacetylase inhibitors, tumour necrosis factor-related apoptosis-inducing ligand, TRAIL, FR235222, human promyelocytic leukaemia, apoptosis, 887
- Histone deacetylase inhibitors, valproic acid, matrix metalloproteinases, epigenetic drugs, 535
- Histone methyltransferase, SETD2, breast cancer, telomerase, 3309
- Histopathology, genetic polymorphism, *TLR4*, *NOD2/CARD15*, gastritis, 513
- HIV, anal dysplasia, anal cytology, HPV, women, infection, 1719
- HL60 cells, CRIM1, cytarabine, daunorubicin, drug resistance, 4157
- HL-60, ILTG, MSP-MCA, *DAPK-1*, HT-29, DNA methylation, colon cancer, leukemia, 3945
- HLA molecules, MAGE, melanoma antigen, hepatocellular carcinoma, immunotherapy, 1617
- HLA-A2, prostate cancer, TRAMP, MHC I, immune rejection, 409
- HMG CoA reductase, mevalonate, tocotrienol, statin, Cdk4, caspase-3, Ras, cell cycle, apoptosis, 4937
- HMGA2-LPP*, adipocytic tumors, *EWS-CHOP*, lipoma, liposarcoma, *LPP-HMGA2*, RT-PCR, *TLS-CHOP*, 661
- HMGB1, canine lymphoma, RAGE, 5043
- HMGCoA reductase inhibitors, statins, carcinogenesis, liver neoplasm, ubiquinone, mevalonate pathway, hepatocarcinogenesis, lovastatin, 1105
- HNSCC, DNA content, DNA methylation, p16, *DAPK*, *RASSF1A*, 4643
- HNSCC, EGFR, EGF, *BCL-xL*, p21CIP1/WAF1, 4579
- HNSCC, UM-SCC,  $\beta$ -catenin, sulindac sulfone, cell line, cell culture, apoptosis, 339
- HNSCC, VEGF splice variant, hemangioma, vascular malformation, head and neck, 805
- Hodgkin's disease, cardiopulmonary toxicity, chemoradiotherapy, 4381
- HOGG1, DNA repair genes, polymorphism, gastric cancer, APE1, 1359
- HOGG1, single nucleotide polymorphism, lung cancer, smoking, 4141
- HOGG1, single nucleotide polymorphism, oral cancer, betel quid, 4205
- Honokiol, chemoprevention, UVB photocarcinogenesis, apoptosis, 777
- Hormone receptor status, erythropoietin receptor, local cancer recurrence, anemia, breast cancer, 3721
- Host-tumor interactions, myeloid derived suppressor cells, macrophages, regulatory T-cells, B16 melanoma, docetaxel, temozolomide, interleukin-1 receptor antagonist, 345
- Houttuynia cordata* Thunb. (HCT), Chinese herb, apoptosis, human primary colorectal cancer cells, 3549
- HPV types, basaloid squamous cell carcinoma, oral cancer, oral papilloma, oral dysplasia, p16, 1605
- HPV, anal dysplasia, anal cytology, HIV, women, infection, 1719
- HPV, cervical carcinoma, sodium butyrate, UCN-01, apoptosis, 4049
- HPV, oral dysplasia, oral carcinoma, p53, p16, 3435
- HPV, tumor M2 pyruvate kinase, tumor marker, cervical carcinoma, CIN, 375

- HRPC, chemohormonal therapy, etoposide, ethinylestradiol, oral chemotherapy, 3737
- HRPC, chemohormonal therapy, etoposide, ethinylestradiol, oral chemotherapy, prostate cancer, 3737
- Hrs, Rab7, ExoC5, RT-PCR, E-cadherin, fragments, breast cancer, 3903
- HSP27, CEA, Her2/neu, BCRP, microparticles, breast cancer, 1707
- HT29, chemoresistance, translational regulation, real-time PCR, mRNA quantification, colorectal cancer cells, fluoropyrimidine analogs, thymidylate synthase, p53, 5-FU resistance, 1149
- HT-29, ILTG, MSP-MCA, *DAPK-1*, HL-60, DNA methylation, colon cancer, leukemia, 3945
- 5-HTTLPR polymorphism, cancer, mental adjustment to cancer, depression, anxiety, 3823
- Human antibody, carcinoembryonic antigen, CEA, chimeric T-cell antigen receptor, CAR, signaling cluster, T-cell activation, 2731
- Human anti-mouse antibody, HAMA, colorectal cancer, prevalence, monoclonal antibody therapeutics, adverse events, 4353
- Human breast pre-adipocytes, zeranol, leptin, aromatase, CYP19A1, estrogen, (-)-gossypol, 5077
- Human colorectal cancer, *Oplopanax horridus*, anti-proliferation, apoptosis, cell cycle, cyclin A, cyclin B1, 295
- Human cytomegalovirus, lignans, immediate early-antigen expression, antitumor promoters, 451
- Human epididymis, CEACAM1, adenomatoid, angiogenesis, 2651
- Human erythrocyte, BCPCF, phenolic compound, haemolysis, lignans, norlignans, multidrug resistance, MRP1/ABCC1, 4423
- Human gastric cancer AGS cells, phenethyl isothiocyanate, migration, invasion, MAPK, NF- $\kappa$ B, 2135
- Human gastric epithelial cells, *Helicobacter pylori*, *Solanum lyratum*, apoptosis, 1189
- Human lymphocytes, azasteroids, experimental chemotherapy, Lewis lung carcinoma, LLC, sister chromatid exchange, SCE, proliferation rate index, PRI, 4201
- Human malignant melanoma, phosphodiesterase, phosphodiesterase 5, 355
- Human mammaglobin, circulating tumour cells, breast cancer, reverse-transcriptase polymerase chain reaction, 2377
- Human neoplasia, gamma-glutamyltransferase, tumor progression, drug resistance, redox regulation, review, 1169
- Human pancreatic cancer, nonsteroidal anti-inflammatory drugs, NSAID, hydroxamic acids, cytostatic activity, cytotoxicity, Akt signalling, cell cycle, apoptosis, 3987
- Human papilloma virus, tongue and pharyngolaryngeal carcinomas, Epstein-Barr virus, John Cunningham, carcinogenesis, 1233
- Human papillomavirus, genotypes, oral cancer, oropharyngeal cancer, head and neck cancer, 5099
- Human primary colorectal cancer cells, *Houttuynia cordata* Thunb. (HCT), Chinese herb, apoptosis, 3549
- Human promyelocytic leukaemia, tumour necrosis factor-related apoptosis-inducing ligand, TRAIL, histone deacetylase inhibitors, FR235222, apoptosis, 887
- Human prostate cancer cell lines, 1,4-naphthoquinone, cytotoxicity, cell cycle, apoptosis, 519
- Human telomerase reverse transcriptase, prognosis, telomerase, malignant fibrous histiocytomas, bone, 4959
- Human tissue kallikrein 7, morphological change, vimentin, prostate cancer, invasion, metastasis, 3413
- Hyaluronidase, interstitial diffusion, collagenase, two-photon excitation, FRAP, multicellular spheroids, 359
- Hybrid liposomes, chemotherapy, gastric carcinoma, apoptosis, cotton rat, 2011
- Hybridoma, monoclonal, KEPI, peptide array, substitutional analysis, 1573
- Hydantoin, *ABCBI*, P-glycoprotein, multidrug resistance, cancer, 4867
- Hydroxamic acids, nonsteroidal anti-inflammatory drugs, NSAID, cytostatic activity, cytotoxicity, human pancreatic cancer, Akt signalling, cell cycle, apoptosis, 3987
- 2'-Hydroxycinnamaldehyde, oral cancer, cell cycle, apoptosis, tumor model, 489
- 22(R)-Hydroxycholesterol, prostate cancer, cancer cell, liver X receptor, T0901317, 3643
- 1 $\alpha$ -Hydroxylase, cervical cancer, ovarian cancer, 25-hydroxylase, 24-hydroxylase, vitamin D, calcidiol, calcitriol, 4429
- 24-Hydroxylase, cervical cancer, ovarian cancer, 25-hydroxylase, 1 $\alpha$ -hydroxylase, vitamin D, calcidiol, calcitriol, 4429
- 25-Hydroxylase, cervical cancer, ovarian cancer, 1 $\alpha$ -hydroxylase, 24-hydroxylase, vitamin D, calcidiol, calcitriol, 4429
- 3-Hydroxyproline, type IV collagen, basement membrane, cancer invasion, cancer metastasis, cancer screening, ELISA, 1007
- 15-Hydroxyprostaglandin dehydrogenase, breast cancer, cyclooxygenase-2, vitamin D receptor, prostaglandin receptor, calcidiol, PGE<sub>2</sub>, 1673
- 4-Hydroxytamoxifen, tamoxifen, silybinin, pharmacokinetics, bioavailability, rats, 79
- Hyperbaric oxygen, anticancer complementary therapy, oxygen tension, Artemisinin, chemotherapy, leukemia cells, 4467
- Hypofractionation, radiotherapy, breast cancer, concomitant boost, 4749

- Hypopharynx, dysplasia, epithelium, malignancy, squamous cell carcinoma, 3313
- Hypophysis, EG-VEGF, immunohistochemistry, pituitary adenoma, 3981
- Hypoxia, angiogenesis, VEGF, VEGFR2/KDR, multiple myeloma, 2831
- Hypoxia, vascular normalization, pericytes, angiogenesis, radiotherapy, tumor microenvironment,  $\alpha$ -S-QMG, 4397
- Hypoxia-inducible factor 1 alpha, p53, vascular endothelial growth factor, colorectal carcinoma, 4163
- Hypoxia-targeting antineoplastic drugs, medicinal electronics bricolage design, hypoxic cell radiosensitizers, IDO inhibitor, BNCT agent, boron tracedrug, 3233
- Hypoxic cell radiosensitizers, medicinal electronics bricolage design, hypoxia-targeting antineoplastic drugs, IDO inhibitor, BNCT agent, boron tracedrug, 3233
- Hysteroscopy, endometrial cancer, peritoneal cytology, tumor cell dissemination, sentinel node, 2425
- IDO inhibitor, medicinal electronics bricolage design, hypoxia-targeting antineoplastic drugs, hypoxic cell radiosensitizers, BNCT agent, boron tracedrug, 3233
- IGF II, IGFBP-7, teratocarcinoma, 911
- IGF-1R, chemo-surviving cells, curcumin, colon cancer, EGFRs, 319
- IGF-1R, nasopharyngeal carcinoma, undifferentiated carcinoma, head and neck cancer, immunotherapy, 1641
- IGFBP-7, IGF II, teratocarcinoma, 911
- IHC, FISH, HER-2/neu, breast cancer, 4081
- IL-1 receptor antagonist, gastric cancer, gene polymorphism, interleukin-1beta, IL-1, 505
- IL-1 receptor antagonist, IL-6, colon-26 carcinoma, survivin peptide vaccination, beta-glucan, anti-inflammation, vaccination, Anakinra, 3959
- IL-1, gastric cancer, gene polymorphism, interleukin-1beta, IL-1 receptor antagonist, 505
- IL-12, cytokines, paracrine treatment, *Schistosoma mansoni*, SWAP, systemic treatment, vaccination, poly-N-acetyl glucosamine gel matrix, 3889
- IL-2, high-dose chemotherapy, NK cells, 5-fluorouracil, epirubicin, cyclophosphamide, methotrexate, radiotherapy, etoposide, carboplatin, VEGF, retinoic acid, myeloablative chemotherapy, autologous transplantation, immunotherapy, breast cancer, 209
- IL-6, cyclin D1, STAT3, CADPE, hepatocellular carcinoma, 481
- IL-6, IL-1 receptor antagonist, colon-26 carcinoma, survivin peptide vaccination, beta-glucan, anti-inflammation, vaccination, Anakinra, 3959
- IL-6, interleukin-6, vascular endothelial growth factor, new receptor inhibitor of IL-6, NRI, mesotheliomas, adenovirus, gene delivery, 1947
- IL-6, prostatic cancer, tumor marker, 4369
- IL-6, VEGF, NSE, ProGR, prognosis, lung cancer, 1773
- Ileocolic, anastomosis, leak, small bowel, large bowel, hand-sewn, laparoscopic, review, 601
- Ilinotecan, SN38, topoisomerase inhibitor, apoptosis, *ATM*, p53, p21, caspase-3, 3911
- ILTG, MSP-MCA, *DAPK-1*, HT-29, HL-60, DNA methylation, colon cancer, leukemia, 3945
- Image cytometry, sarcoma, Ewing's, prognosis, ploidy, 3715
- Image processing, biopsy, prostatic neoplasm, radical prostatectomy, 1823
- Imaging, fibroblast, MMP inhibition, angiogenesis, cytokine, skin cancer invasion, VEGF-A, PDGF-BB, 703
- Imatinib mesylate, capecitabine, phase I, advanced solid tumors, 1251
- Imatinib mesylate, ovarian cancer, paclitaxel, 3243
- Imatinib, DSRCT, Ewing sarcoma, *KIT*, PDGFR $\alpha$ , phase II, 547
- Imatinib, GIST, gastrointestinal stromal tumour, distant metastasis, oral cavity, PET, 4283
- Imatinib, philadelphia chromosome-positive acute lymphoblastic leukaemia, post-transplant imatinib administration, allogeneic stem cell transplantation, minimal residual disease, 2415
- Imiquimod, oral dysplasia, treatment, 2891
- Immediate early-antigen expression, lignans, antitumor promoters, human cytomegalovirus, 451
- Immune rejection, prostate cancer, TRAMP, MHC I, HLA-A2, 409
- Immune response, rectal cancer, chemoradiotherapy, S-1, PSK, 993
- Immune responses, murine polyomavirus, tumour specific transplantation antigen, viral persistence, virus like particles VLPs, review, 279
- Immune suppression, mosquito, adenovirus, susceptibility, malaria, cancer mortality, 1371
- Immunofluorescence, carcinoma, carcinoid, small cell carcinoma, large cell neuroendocrine carcinoma, methylation, survival, RASSF1, 4269
- Immunohistochemical analysis, filamin, VEGF, lung cancer, 3939
- Immunohistochemistry, adenocarcinoma, epidermal growth factor receptor, lung cancer, mutation, 5233
- Immuno-histochemistry, adenomatoid odontogenic tumor, AOT, cytokeratin, alpha-smooth muscle actin, epithelial membrane antigen, 1787
- Immunohistochemistry, AKT, HER-2, upper urinary tract, urothelial carcinoma, 2439
- Immunohistochemistry, animal cancer models, chick embryo, rodent model, tumour markers, glioblastoma, cell xenografts, 4851
- Immunohistochemistry, *BAG-1*, ER, PR, apoptosis, endometrial carcinoma, real-time PCR, 4103

- Immunohistochemistry, bladder cancer, biomarkers, tumor progression, CA19.9, CEA, transitional cell carcinoma, 5195
- Immunohistochemistry, CD117, mutation breast phyllodes tumor, c-Kit, 4731
- Immunohistochemistry, deltaNp63, squamous cell carcinoma, non-small cell lung cancer, 4717
- Immunohistochemistry, DJ-1, astrocytoma, WHO grading, prognosis, 265
- Immunohistochemistry, ectomesenchymal chondromyxoid tumour, tongue, oral cavity, 4685
- Immunohistochemistry, EG-VEGF, hypophysis, pituitary adenoma, 3981
- Immunohistochemistry, esophageal neoplasm, KPNA2, 851
- Immunohistochemistry, estrogen receptor alpha, estrogen receptor beta, pituitary, pituitary adenoma, 2897
- Immunohistochemistry, gap junctional intercellular communication GJIC, connexin43, E-cadherin,  $\beta$ -catenin, ZO-1, CpG island, methylation analysis, pyrosequence, lung cancer, 2271
- Immuno-histochemistry, glycodeilin, breast cancer, differentiation, 1599
- Immunohistochemistry, p-Akt, neuroendocrine tumors, 5063
- Immunohistochemistry, serum LDH, tumour LDH-5, NSCLC, adenocarcinoma, squamous cell carcinoma, 1347
- Immunohistochemistry, src-activating and signaling molecule, esophageal squamous cell carcinoma, 3535
- Immunohistochemistry, vulvar intraepithelial neoplasia, squamous cell carcinoma, galectin-1, 1547
- Immuno-histochemistry, Wilms' tumor gene, *WT1*, angiogenesis, endometrial cancer, 3187
- Immunohistochemistry, Y-box binding protein 1, YB-1, neuroblastoma, tumour marker, 1239
- Immuno-histochemistry,  $\alpha$ -catenin, E-cadherin, down-regulation, endometrium, 4993
- Immunohistology,  $\beta$ -catenin, MUC1, c-Met, gastric cancer, prognosis, 4635
- Immunomagnetic isolation, carcinoembryonic antigen, staurosporine, circulating tumor cells, RT-PCR analysis, 4721
- Immunomodulation, astaxanthin, cardioprotection, 2721
- Immunomodulation, Ha-ras, nm23, metastasis, 3585
- Immunomodulator, IP-PA1, immunosuppression, lipopolysaccharide, stress, review, 3113
- Immunomodulator, IP-PA1, macrophage, chemotherapy, apoptosis, 2033
- Immunosuppression, IP-PA1, immunomodulator, lipopolysaccharide, stress, review, 3113
- Immunotherapy, bladder cancer, BCG, integrin, 4089
- Immunotherapy, colorectal cancer, dendritic cells, antigen loading, CEA peptide, mRNA, electroporation, vaccination, 5091
- Immunotherapy, cytokine-induced killer cell, interleukin, 3493
- Immunotherapy, IL-2, high-dose chemotherapy, NK cells, 5-fluorouracil, epirubicin, cyclophosphamide, methotrexate, radiotherapy, etoposide, carboplatin, VEGF, retinoic acid, myeloablative chemotherapy, autologous transplantation, breast cancer, 209
- Immunotherapy, MAGE, melanoma antigen, HLA molecules, hepatocellular carcinoma, 1617
- Immunotherapy, nasopharyngeal carcinoma, IGF-1R, undifferentiated carcinoma, head and neck cancer, 1641
- Immunotherapy, renal cancer, dendritic cells, metastatic renal cell carcinoma, 2081
- Immunotherapy, *WT1*, DC, endometrial carcinoma, 3709
- Immunotoxins, prostate cancer, PSMA, scFv, *Pseudomonas* exotoxin A, 3373
- In vitro* chemosensitivity testing, chemoFx DRM, cancer, heterogeneity, chemotherapeutic response, mechanism of action, chemotherapy drug response marker, 2805
- In vitro* evaluation, verapamil, iodination, MDR, 2553
- In vitro*, cytokines, gamma radiation, bystander responses, glioblastoma, 2769
- In vitro*, nanodiamond, dendritic cells, CD4+ cells, bionanotechnology, 4075
- In vivo* activity, breast cancer, anti-cancer drugs, gap junctions, 6-methoxy-8-[(2-furanylmethyl)amino]-4-methyl-5-(3-trifluoromethyl phenyloxy)quinoline, quinolines, 3927
- In vivo* fluorescence imaging, orthotopic implantation, esophageal carcinoma, carcinomatosis, 3933
- In vivo* imaging, color-coded, GFP, RFP, UVC, melanoma, blood vessels, 3291
- Individualised tumour response testing, drug resistance, bortezomib, children, acute lymphoblastic leukaemia, acute myeloid leukaemia, 2119
- Indole-3-acetic acid, UVB, free radical, photodynamic therapy, apoptosis, prostate cancer cells, 4607
- Indole-3-carbinol, sex differences, pancreatic cancer, gemcitabine, 4907
- Induction, gemcitabine, pharmacokinetics, metabolism, nucleoside analogue, 3669
- Infection, anal dysplasia, anal cytology, HIV, HPV, women, 1719
- Inferior alveolar nerve, numb chin syndrome, mental neuropathy, mandibular metastasis, orthopantomogram, 1819
- Inflammation, antioxidant, astaxanthin, mouse, cardiac function, mammary tumor initiation, 2171
- Inflammation, combination therapy, postsurgical, micrometastases, CEA, lung carcinoma, lymphokine-activated killer cell therapy, glucocorticoid, 3125
- Inflammation, gene expression, histone deacetylase inhibitor, ITF2357, apoptosis, NF- $\kappa$ B, 4525

- Inflammation, pericardial mesothelioma, mesothelioma, asbestos, heart surgery, 1323
- Inflammation, placental growth factor, transforming growth factor-alpha, transforming growth factor-beta 1, tumour necrosis factor receptor 1, matrix metalloproteinase-2, pancreatic neoplasms, 3801
- Inflammation-associated carcinogenesis, progression, fibrosarcoma, nuclear protein, proteomic analysis, 2093
- Inflammatory breast cancer, trastuzumab, pathological complete response, paclitaxel, epirubicin, 581
- In-gel digestion, proteomic analysis, MALDI/MS, integral membrane proteins, membrane associated proteins, 1121
- Inhibin A, proliferation, chemotherapy, breast cancer, 4563
- Inhibitor of Akt-phosphorylation, 1,25-dihydroxyvitamin D3 derivative, pancreatic cancer, combination effect 5-amino-imidazole-4-carboxamide-1- $\beta$ -4-ribofuranoside, AICAR, 1875
- $^{111}\text{In}^{(88\text{Y})}$ -DOTAGA-tate, somatostatin analogs,  $^{111}\text{In}^{(88\text{Y})}$ -DOTA-t-GA-tate, biodistribution, renal elimination, 2177
- $^{111}\text{In}^{(88\text{Y})}$ -DOTA-t-GA-tate, somatostatin analogs,  $^{111}\text{In}^{(88\text{Y})}$ -DOTAGA-tate, biodistribution, renal elimination, 2177
- Insulin-like growth factor, cadherin, leiomyoma, myeloperoxidase, polymorphism, urokinase, xeroderma pigmentosum, 2203
- Integral membrane proteins, proteomic analysis, MALDI/MS, in-gel digestion, membrane associated proteins, 1121
- $\beta$ 1 Integrin, muscarinic cholinergic receptor 3, mAChR3, nicotinic cholinergic receptor, nAChR, small cell lung cancer, SCLC, 97
- Integrin  $\alpha$ 6 $\beta$ 4, thyroid cancer, cell motility, invasion, anaplastic thyroid carcinoma, 4485
- Integrin  $\alpha$ v $\beta$ 6, RNA interference, proliferation, invasion, cell cycle, apoptosis, chemosensitivity, pancreatic carcinoma cells, 135
- Integrin, bladder cancer, immunotherapy, BCG, 4089
- Integrin,  $\alpha$ v $\beta$ 6, Fyn kinase, EMT, oral SCC, serum, 2591
- Integrins, lapatinib, sunitinib, malignant glioma, MMPs, growth factors, VEGFR, anti-VEGFR agents, anti-EGFR agents, 4987
- Intercellular signaling, reactive oxygen species, apoptosis, salen-manganese complex, 3967
- Interferon-beta, glioma, stem cells, stem cell niche, pericytes, 3301
- Interleukin, cytokine-induced killer cell, immunotherapy, 3493
- Interleukin-1 receptor antagonist, myeloid derived suppressor cells, macrophages, regulatory T-cells, B16 melanoma, docetaxel, temozolomide, host-tumor interactions, 345
- Interleukin-1beta, gastric cancer, gene polymorphism, IL-1, IL-1 receptor antagonist, 505
- Interleukin-6, IL-6, vascular endothelial growth factor, new receptor inhibitor of IL-6, NRI, mesotheliomas, adenovirus, gene delivery, 1947
- Interstitial diffusion, collagenase, hyaluronidase, two-photon excitation, FRAP, multicellular spheroids, 359
- Interstitial lung disease, non-small cell lung cancer, carboplatin, paclitaxel, chemotherapy, efficacy, safety, 4357
- Intestinal type, thymidine phosphorylase, Epstein-Barr virus, gastric carcinoma, diffuse type, 2431
- Intraductal papillary mucinous neoplasm, pancreas, claudin-18, Gli-1, p53, 2995
- Intraductal tubular carcinoma, pancreas, intraductal tubular neoplasm, 4435
- Intraductal tubular neoplasm, intraductal tubular carcinoma, pancreas, 4435
- Intrahepatic cholangiocarcinoma, vimentin, surgical resection, prognosis, 2279
- Intraoperative lymphatic mapping, sentinel node, cervical cancer, lymphoscintigraphy, 183
- Intratracheal instillation, pulmonary surfactant, KRAS mutation, CC10, lung cancer, gene transfer, 4925
- Intratumoral angiogenesis, MT2-MMP, esophageal cancer, 4363
- Invasion and metastasis, mesenchymal-epithelial reversion, SMAD4, epithelial phenotype, E-cadherin, 2603
- Invasion, angiogenesis, chlorotoxin, TM601, MMP-2, 39
- Invasion, astrocytoma, central nervous system, malignancy, chlorotoxin, multiple chloride channels, glioma cells, 4515
- Invasion, B16-F0 mouse melanoma cell, hepatocyte growth factor, HGF, mouse model, *Cordyceps sinensis*, 3429
- Invasion, breast cancer,  $\alpha$ -difluoromethylornithine, DFMO, biomarker, apoptosis, proliferation, 2263
- Invasion, cell growth, migration, cell-cell adhesion, delta opioid receptor agonists, colon cancer cells, 9
- Invasion, human tissue kallikrein 7, morphological change, vimentin, prostate cancer, metastasis, 3413
- Invasion, integrin  $\alpha$ 6 $\beta$ 4, thyroid cancer, cell motility, anaplastic thyroid carcinoma, 4485
- Invasion, integrin  $\alpha$ v $\beta$ 6, RNA interference, proliferation, cell cycle, apoptosis, chemosensitivity, pancreatic carcinoma cells, 135
- Invasion, ovarian cancer, CCL2, chemosensitivity, 4791
- Invasion, phenethyl isothiocyanate, migration, human gastric cancer AGS cells, MAPK, NF- $\kappa$ B, 2135
- Invasion, saracatinib, Src, FAK, metastasis, fibrosarcoma, 4405
- Invasion, TG2, A431 cell, MMP-9, fibronectin, 4177
- Invasiveness, esophageal cancer, transwell invasion chamber, MMP-1, matrix metalloproteinase-1, vimentin, p-Src (pY416), TIMP-2, tissue inhibitor of metalloproteinase-2, 727

- Iodination, verapamil, MDR, *in vitro* evaluation, 2553
- Ionising radiation, bystander effect, ELISA, activation, TGF $\beta$ , 3341
- IPI, MALT lymphoma, FLIPI, prognostic index, 635
- IP-PA1, immunomodulator, immunosuppression, lipopolysaccharide, stress, review, 3113
- IP-PA1, immunomodulator, macrophage, chemotherapy, apoptosis, 2033
- IP-PA1, LPS, FITC-LPS, fluorescence label, *Pantoea agglomerans*, 3151
- Irinotecan, colorectal cancer, liver metastases, oxaliplatin, doxifluridine, artery, 3045
- Irinotecan, colorectal cancer, oxaliplatin, sequence, 4325
- Irinotecan, gemcitabine-resistant disease, pancreatic cancer, XELIRI, FOLFIRI, 4785
- Irinotecan, metabolism, pharmacokinetics, cetuximab, biweekly infusion, colorectal cancer, 2355
- Irinotecan, metastatic colorectal cancer, gene expression level, polymorphisms, clinical outcome, cetuximab, bevacizumab, 4209
- Iron transport, breast cancer, antisense, transferrin receptor, cell culture, 759
- Irradiation damage, facial nerve, irradiation, morphometrics, scattering irradiation, 1625
- Irradiation, damage, salivary glands, tenascin-C, 1593
- Irradiation, facial nerve, irradiation damage, morphometrics, scattering irradiation, 1625
- Irradiation, neuron-specific enolase, salivary glands, 1569
- Isolated recurrence, testicular metastasis, prostate cancer, prostatectomy, 1747
- Isolated tumour cells, breast cancer, recurrence-free follow-up, minimal residual disease, zoledronate treatment, 1807
- Isoniazid, N-acetyl transferase 2, antituberculosis, 3177
- Isoprenoids, RAS protein farnesylation, farnesyl diphosphate analogues, breast cancer, lung cancer, 2505
- Isotope bone scan, cervical cancer, metastases, fibula, tibia, 2949
- ITF2357, gene expression, histone deacetylase inhibitor, apoptosis, NF- $\kappa$ B, inflammation, 4525
- Japan, RAS, mutation, soft tissue sarcoma, 245
- Japanese patients, colorectal liver metastases, hepatic resection, chemotherapy with oxaliplatin plus fluorouracil and leucovorin, FOLFOX, 1015
- Jaw metastasis, oral metastasis, oral cancer, solid tumors, head and neck lymphoma, 1843
- Jaws, giant cell lesions, giant cell granuloma, epulis, cathepsin, RANK, matrix metalloproteinase, osteoclast, salivary glands, tendon sheath, 1645
- JNK1, growth factors, apoptosis, kinase, mammary cancer, 3407
- John Cunningham, tongue and pharyngolaryngeal carcinomas, Epstein-Barr virus, human papilloma virus, carcinogenesis, 1233
- Jurkat, apoptosis, mcl-1, 5-fluorouracil, T cells, caspases, 3879
- Juvenile granulosa cell tumor, diagnosis, therapy, 1731
- Juxtaglomerular cell, apoptosis, FCCP, mitochondria, caspase, 2863
- KAK-1, fluorescent proteins, nude mice model, metastasis, NPA, GFP, thyroid cancer, 4415
- Karyotype analysis, clear cell renal carcinoma, chromosome alterations, prognosis, 4705
- Kegel exercises, urinary incontinence, pelvic floor rehabilitation, radical prostatectomy, 553
- Keloid, TGF- $\beta$ 1, antisense, SMAD, fibroblast, 3459
- KEPI, hybridoma, monoclonal, peptide array, substitutional analysis, 1573
- Keratinocyte growth factor receptor, biliary tract cancer, KGFR, phosphorylation inhibitor, 4115
- Keratinocyte growth factor, cell proliferation, Erk signaling, KGFR tyrosine kinase inhibitor, breast cancer, metastasis prevention, 4883
- KGFR tyrosine kinase inhibitor, cell proliferation, Erk signaling, keratinocyte growth factor, breast cancer, metastasis prevention, 4883
- KGFR, biliary tract cancer, phosphorylation inhibitor, keratinocyte growth factor receptor, 4115
- Ki-67 labeling index, gastrointestinal stromal tumor, GIST, C-KIT gene, PI3K, ALT, 2705
- Ki-67, CPP32, chagasic megaesophagus, chronic esophagitis, esophageal squamous cell carcinoma, 2845
- Ki-67, cyclooxygenase-2, metastases, renal cell carcinoma, survival, 3023
- Ki-67, heat-shock protein 70, neoadjuvant, aromatase inhibitor, breast cancer, 3465
- Ki-67, thyroid carcinoma, metallothionein, 4945
- Kidney cancer, antiangiogenic drugs, 5223
- Kidney cancer, circulating, cell-free DNA, biomarker, serum, 2785
- Kinase, JNK1, growth factors, apoptosis, mammary cancer, 3407
- Kinetics, tumor marker, PSA, prostate cancer, prognosis, 1633
- KISS1*, lung, neoplasia, MMP-9, non-small cell lung cancer, NSCLC, metastasis, prognosis, 713
- KIT*, DSRCT, Ewing sarcoma, imatinib, PDGFR $\alpha$ , phase II, 547
- KIT*, E-cadherin, promoter polymorphism, methylation, *CDHI*, gastric cancer, 2225
- KIT*, GIST, PDGFRA, prognosis, 2407
- KITENIN, stomach neoplasm, tumor invasion, tumor metastasis, prognosis, 3479
- Knee joint, giant cell tumor, bone cement, radiolucent zone, recurrence, 3795
- Korean population, *RET*, lung cancer, polymorphism, haplotypes, 3621



- KP1339, anticancer ruthenium(III) compounds, electroporation, electrochemotherapy, tumour models, sarcoma, mice, 2055
- KPNA2, esophageal neoplasm, immunohistochemistry, 851
- KRAS* mutation, metastatic colorectal carcinoma, diagnostic kit, 5251
- KRAS* mutation, pulmonary surfactant, CC10, intratracheal instillation, lung cancer, gene transfer, 4925
- K-ras* mutations, colon cancer, cetuximab, EGFR inhibitors, drug resistance, therapeutic outcome, review, 4673
- K-ras*, blood, serum, plasma, colorectal cancer, pancreatic cancer, diagnostic test, predictive test, review, 2943
- KRAS*, colorectal cancer, metastasis, comparison, BRAF, mutation, 4229
- KRAS*, colorectal carcinoma, BRAF, mutations, FFPE, ThinPrep, qPCR, 1969
- KRAS*, EGFR gene copy number, prognosis, EGFR TKIs treatment, chemotherapy, 5121
- KRAS*, myc, Omomyc, lung cancer, A549, 4193
- KRAS*, NSCLC, EGFR, mutation, multiplicity, clonality, lung cancer, tyrosine kinase inhibitors, 1667
- KRAS*, tamoxifen, endometrium, apoptosis, ErbB ligand, 3119
- L1210 cells, multidrug resistance, P-glycoprotein, concanavalin A, cell surface saccharides, 3661
- L1210 murine leukaemia, 3-C-ethynylcytidine, 5-fluorodeoxyuridine, experimental leukaemia, duplex drug, 4891
- L-2-Oxothiazolidine-4-carboxylate, WiDr colon cancer cells, growth factors, 5-fluorouracil, oxaliplatin, SN-38, glutathione modulation, buthionine-SR-sulfoximine, 1223
- LA-12, oxaliplatin, cisplatin, colon cancer, cell cycle, apoptosis, 1183
- Lactate dehydrogenase, brain metastases, prognostic score, radiotherapy, albumin, 977
- Laparoscopic, anastomosis, leak, small bowel, large bowel, ileocolic, hand-sewn, review, 601
- Lapatinib, sunitinib, malignant glioma, MMPs, growth factors, VEGFR, integrins, anti-VEGFR agents, anti-EGFR agents, 4987
- Large bowel, anastomosis, leak, small bowel, ileocolic, hand-sewn, laparoscopic, review, 601
- Large cell neuroendocrine carcinoma, carcinoma, carcinoid, small cell carcinoma, methylation, immunofluorescence, survival, RASSF1, 4269
- Larynx cancer, REPP86, squamous cell carcinoma, 3541
- Larynx carcinoma, Sialyl Lewis a, CA19-9, squamous cell carcinoma, phlogistic tissue, 1849
- Laser, LB protein nanocrystals, AFM, X-ray microdiffraction, radiation damage, 2745
- LAT1, NSCLC, *EGFR* mutation, mTOR, non-small cell lung cancer, 4819
- LAT1, rectal cancer, preoperative hyperthermo-chemoradiotherapy, tumour response, 4223
- Late sequelae, radiation, children, side-effects, abdomen, 227
- LB protein nanocrystals, AFM, laser, X-ray microdiffraction, radiation damage, 2745
- LC-MS/MS, peptide sequence tag, gastric carcinoma cells, 14-3-3 sigma protein, proteomic differential display, 4459
- LC-MS/MS, two-dimensional gel electrophoresis, 2-DE, pancreatic cancer, gemcitabine, GEM, proteomics, heat-shock protein 27, 2539
- LC-MS/MS, two-dimensional gel electrophoresis, Flamingo Gel Stain, SeePico, highly sensitive Coomassie brilliant blue, proteomic analysis, 4001
- LC-MS/MS, two-dimensional gel electrophoresis, pancreatic cancer, gemcitabine, GEM, proteomics, 3367
- LDH, melanoma, Sentinel node, serum S100, prognosis, metastasis, 1799
- Leak, anastomosis, small bowel, large bowel, ileocolic, hand-sewn, laparoscopic, review, 601
- Lectins, agglutinins, glycobiology, lymphangiogenesis, VEGF, galectins, breast cancer cells, 4829
- Leiomyoma, cadherin, insulin-like growth factor, myeloperoxidase, polymorphism, urokinase, xeroderma pigmentosum, 2203
- LEM, microarray analysis, signaling pathway, macrophage, lignin-carbohydrate complex, LPS, 2567
- Leptin, zeranol, aromatase, CYP19A1, estrogen, human breast pre-adipocytes, (-)-gossypol, 5077
- Leptin, zinc- $\alpha$ 2-glycoprotein, breast cancer, adipokine, adiponectin, biomarker, apoptosis, 2919
- Let-7a, prostate cancer, miRNA, miR-20a, miR-15a, miR-16, 3579
- Leukaemia stem cells, PI3K/Akt, CK2, synergism, targeted therapy, apoptosis, 4625
- Leukemia cells, anticancer complementary therapy, oxygen tension, Artemisinin, chemotherapy, hyperbaric oxygen, 4467
- Leukemia, ILTG, MSP-MCA, *DAPK-1*, HT-29, HL-60, DNA methylation, colon cancer, 3945
- Leukemia, notch,  $\gamma$ -secretase inhibitor, NF- $\kappa$ B, 495
- Leukoplakia, multiple oral cancer, p53 mutation, oral squamous cell carcinoma, 4773
- Lewis lung carcinoma, LLC, azasteroids, experimental chemotherapy, human lymphocytes, sister chromatid exchange, SCE, proliferation rate index, PRI, 4201
- Lewis lung carcinoma-bearing mice, lipopolysaccharide, pulmonary inhalation, lung cancer, alveolar macrophage, cyclophosphamide, 3129
- Lifestyle, stomach neoplasm, Epstein-Barr virus, risk factor, medical history, gastric ulcer, alcohol, 2469
- Lignans, human erythrocyte, BCPCF, phenolic compound, haemolysis, norlignans, multidrug resistance, MRP1/ABCC1, 4423

- Lignans, immediate early-antigen expression, antitumor promoters, human cytomegalovirus, 451
- Lignin-carbohydrate complex, microarray analysis, signaling pathway, macrophage, LPS, LEM, 2567
- Limits, colon, adenoma, size, carcinoma, 2419
- Linum usitatissimum*, flax, phytoestrogens, MCF-7, cellular metabolism, online monitoring, acidification, oxygen consumption, adhesion, 1587
- Lipid peroxidation, ultrasound, cell damage, sonodynamic activation, reactive oxygen, DCPH-P-Na(I), 2241
- Lipid rafts, cisplatin, FAS, apoptosis, sphingomyelin, 2065
- Lipid rafts, macrophage, phagocytosis, polystyrene latex microspheres, methyl- $\beta$ -cyclodextrin, scavenger receptors, 3167
- Lipoma, adipocytic tumors, *EWS-CHOP*, *HMGA2-LPP*, liposarcoma, *LPP-HMGA2*, RT-PCR, *TLS-CHOP*, 661
- Lipoplatin, liposomal cisplatin, dose escalation, phase I, 1317
- Lipopolysaccharide, IP-PA1, immunomodulator, immunosuppression, stress, review, 3113
- Lipopolysaccharide, pulmonary inhalation, lung cancer, alveolar macrophage, Lewis lung carcinoma-bearing mice, cyclophosphamide, 3129
- Lipopolysaccharide, pulmonary inhalation, lung cancer, alveolar macrophage, nitric oxide, cell-to-cell contact, 3135
- Liposarcoma, adipocytic tumors, *EWS-CHOP*, *HMGA2-LPP*, lipoma, *LPP-HMGA2*, RT-PCR, *TLS-CHOP*, 661
- Liposomal cisplatin, dose escalation, lipoplatin, phase I, 1317
- Liposomal cisplatin, ovarian cancer, CA125, phase II, 541
- Liposomal curcumin, curcumin, cancer, metabolism, cytochrome P450, 811
- Liposome, doxorubicin, drug delivery system, malignant glioma, polymeric microsphere, thermoreversible gelation polymer, 1057
- Liposomes, disulfide, antisense oligonucleotide, G3139, *Bcl-2*, drug delivery, 31
- Liposomes, microfluidics, ethanol injection, sonication, 463
- 5-Lipoxygenase, tumor metastasis, cytoplasmic phospholipase A2, cyclooxygenase-2, angiogenesis, metalloproteinase, 3421
- Liver interventional procedures, liver neoplasm therapy, arteries, hepatic chemoembolization, 5159
- Liver metastases, colon cancer, COX-2, precision-cut tissue slices, 2017
- Liver metastases, colorectal cancer, irinotecan, oxaliplatin, doxifluridine, artery, 3045
- Liver metastases, colorectal cancer, yttrium-90 microspheres, chemotherapy, hepatectomy, FOLFOX, 3005
- Liver metastasis, bone metastasis, hepatectomy, radiation therapy, colon cancer, 677
- Liver metastasis, colorectal cancer, cytokine, growth factor, hepatectomy, liver regeneration, tumour recurrence, review, 2161
- Liver metastasis, gastric cancer, hepatic resection, prognostic factor, 2367
- Liver metastasis, MMP-13, colorectal cancer, 2693
- Liver neoplasm therapy, liver interventional procedures, arteries, hepatic chemoembolization, 5159
- Liver neoplasm, statins, HMGCoA reductase inhibitors, carcinogenesis, ubiquinone, mevalonate pathway, hepatocarcinogenesis, lovastatin, 1105
- Liver regeneration, colorectal cancer, cytokine, growth factor, hepatectomy, liver metastasis, tumour recurrence, review, 2161
- Liver transplantation, post-transplant lymphoproliferative disorders, chemotherapy, 2383
- Liver X receptor, prostate cancer, cancer cell, T0901317, 22(R)-hydroxycholesterol, 3643
- LLC, Lewis lung carcinoma, azasteroids, experimental chemotherapy, human lymphocytes, sister chromatid exchange, SCE, proliferation rate index, PRI, 4201
- LMP-1, urothelial carcinoma, B cells, Epstein-Barr virus, pathogenesis, cell line, 3473
- Lobular hyperplasia, breast cancer, B3 lesions, vacuum-assisted core biopsy, Suros, microcalcification, DCIS, 2287
- Local ablation, cholangiocarcinoma, photodynamic therapy, photofrin, apoptosis, 2113
- Local cancer recurrence, erythropoietin receptor, anemia, breast cancer, hormone receptor status, 3721
- Local chemotherapy, magnetic drug targeting, tumour vascularisation, computed tomography, angiography, flat-panel CT, 1553
- Local infection, rifampicin-miconazole-releasing catheters, catheter colonization, long-term activity, oncology patients, 1353
- Localized amyloidosis, amyloidosis, tongue, amyloid, oral cavity, AL amyloidosis, 3009
- Locally advanced, breast cancer, chemotherapy, neoadjuvant, gemcitabine, pegylated liposomal doxorubicin, docetaxel, phase II, 3817
- Locally advanced, non-small cell lung cancer, chemoradiation, pattern of failure, 953
- LOH, *BRCA1* gene, loss of heterozygosity, familial breast cancer, genotype-phenotype correlation, 3445
- Long-term activity, rifampicin-miconazole-releasing catheters, catheter colonization, local infection, oncology patients, 1353
- Long-term survival, case report, anaplastic thyroid carcinoma, multimodal treatment, chemotherapy, 1273
- Loss of heterozygosity, *BRCA1* gene, LOH, familial breast cancer, genotype-phenotype correlation, 3445
- Losses, breast disease, breast cancer, deficit, 4303

- Lovastatin, statins, HMGCoA reductase inhibitors, carcinogenesis, liver neoplasm, ubiquinone, mevalonate pathway, hepatocarcinogenesis, 1105
- LOXL4, EGFR, gene expression, head and neck squamous cell carcinoma, metastasis, 4567
- LPP-HMGA2*, adipocytic tumors, *EWS-CHOP*, *HMGA2-LPP*, lipoma, liposarcoma, RT-PCR, *TLS-CHOP*, 661
- LPS, alveolar macrophage, lung tumor, drug delivery system, cell-to-cell contact, 3159
- LPS, IP-PA1, FITC-LPS, fluorescence label, *Pantoea agglomerans*, 3151
- LPS, microarray analysis, signaling pathway, macrophage, lignin-carbohydrate complex, LEM, 2567
- Luciferase, ovarian cancer, tyrosine kinase inhibitor, mouse model, xenograft, sunitinib, 3355
- Lung cancer cells, OGG1, NTH1, UDG, APE1, DNA repair, mtDNA, nDNA, 4963
- Lung cancer, adenocarcinoma, epidermal growth factor receptor, immunohistochemistry, mutation, 5233
- Lung cancer, anesthesia, HIF1 $\alpha$ , one-lung ventilation, BMI, obesity, pneumothorax, 1143
- Lung cancer, anticancer drug, growth inhibition, MDM2, p53, XIAP, etoposide, 3321
- Lung cancer, asbestos, tumour antigen, Annexin A2, SEREX, 2631
- Lung cancer, bone morphogenetic protein 7, Smad1, motility, 1113
- Lung cancer, CEA, CYFRA 21-1, marker panel, ROC-curves, 1661
- Lung cancer, chemotherapy, postoperative recurrence, survival analysis, 1311
- Lung cancer, cisplatin, S-1, pooled analysis, histological type, 2985
- Lung cancer, *Cox-2*, polymorphism, carcinogenesis, 1195
- Lung cancer, drug resistance, P-glycoprotein, down-regulation, 3593
- Lung cancer, EMT, adenocarcinoma, resistance, EGFR, tyrosine kinase inhibitor, 2513
- Lung cancer, FDG imaging, follow-up, survival, recurrence, early detection, 3811
- Lung cancer, filamin, VEGF, immunohistochemical analysis, 3939
- Lung cancer, gap junctional intercellular communication GJIC, connexin43, E-cadherin,  $\beta$ -catenin, ZO-1, immunohistochemistry, CpG island, methylation analysis, pyrosequence, 2271
- Lung cancer, *hOGG1*, single nucleotide polymorphism, smoking, 4141
- Lung cancer, IL-6, VEGF, NSE, ProGR, prognosis, 1773
- Lung cancer, lipopolysaccharide, pulmonary inhalation, alveolar macrophage, Lewis lung carcinoma-bearing mice, cyclophosphamide, 3129
- Lung cancer, lipopolysaccharide, pulmonary inhalation, alveolar macrophage, nitric oxide, cell-to-cell contact, 3135
- Lung cancer, murine lung cancer, progesterone receptor antagonist, mifepristone, tumor microenvironment, natural killer cells, 119
- Lung cancer, myc, Omomyc, *KRAS*, A549, 4193
- Lung cancer, NSCLC, EGFR, *KRAS*, mutation, multiplicity, clonality, tyrosine kinase inhibitors, 1667
- Lung cancer, NSCLC, erlotinib, EGFR, tyrosine kinase inhibitors, review, 1301
- Lung cancer, p53, chemotherapy, cisplatin, paclitaxel, chemosensitivity, 3557
- Lung cancer, p53, Pirh2, p27<sup>kip1</sup>, prognosis, 3699
- Lung cancer, pulmonary surfactant, *KRAS* mutation, CC10, intratracheal instillation, gene transfer, 4925
- Lung cancer, *RAS* protein farnesylation, farnesyl diphosphate analogues, breast cancer, isoprenoids, 2505
- Lung cancer, *RET*, polymorphism, haplotypes, Korean population, 3621
- Lung cancer, sentinel lymph node, vitamin B2, fluorescent agents, 4109
- Lung cancer, serum tumour markers, FDG uptake, PET, CT, diagnosis, 1741
- Lung cancer, thymidine kinase, biomarker, tumor marker, serum, 1855
- Lung carcinoma, combination therapy, inflammation, postsurgical, micrometastases, CEA, lymphokine-activated killer cell therapy, glucocorticoid, 3125
- Lung metastasis, renal cell carcinoma, gamma-delta T-cells, adoptive immunotherapy, 575
- Lung neoplasms, AKAP12 $\alpha$ , promoter methylation, NSCLC, 4595
- Lung neoplasms, curcumin, apoptosis, G<sub>2</sub>/M arrest, caspase cascade, endoplasmic reticulum stress, herbal medicine, 2125
- Lung tumor, alveolar macrophage, drug delivery system, LPS, cell-to-cell contact, 3159
- Lung, neoplasia, *KISS1*, MMP-9, non-small cell lung cancer, NSCLC, metastasis, prognosis, 713
- Lung, SISH, HER2, breast, colon, prostate, ovary, 1287
- Lymph node involvement, cervical cancer, neoadjuvant chemotherapy, radical hysterectomy, lymph-vascular space involvement, platelet count, 201
- Lymph node metastases, penile carcinoma, micrometastases, non-sentinel lymph nodes, 467
- Lymph node metastasis, biochemical relapse, micrometastasis, pelvic lymph node dissection, prostate cancer, radical prostatectomy, 2297
- Lymph node metastasis, LYVE-1, D2-40, squamous cell carcinoma, tongue, 1897
- Lymph node metastasis, oesophageal cancer, N0, prognostic factors, 3063

- Lymph node metastasis, vimentin, gastric carcinoma cells, scirrhous type, prognosis, 5239
- Lymph node, spontaneous metastasis, metastasis model, B16 mouse melanoma, 4799
- Lymphadenectomy, cervical cancer, false-negative results, pelvic nodes, PET-CT, [<sup>18</sup>F]Fluorodeoxyglucose, 1029
- Lymphadenectomy, uterine corpus cancer, staging, negative predictive value, specificity, FDG-PET, 3787
- Lymphangiogenesis, agglutinins, glycobiology, VEGF, galectins, lectins, breast cancer cells, 4829
- Lymphatic invasion, gastric cancer, VEGF-C, VEGF-D, CCR7, 2361
- Lymphokine-activated killer cell therapy, combination therapy, inflammation, postsurgical, micrometastases, CEA, lung carcinoma, glucocorticoid, 3125
- Lymphoma cell lines, radiation, TNF-alpha, programmed cell death, cell lines, sarcoma cell lines, 2857
- Lymphoma therapy, primary effusion lymphoma, pleurodesis, body cavity lymphoma, 271
- Lymphoma, bortezomib, fibroblast growth factor receptor 3, FGFR3, 1921
- Lymphoma, motexafin gadolinium, p53, reactive oxygen species, apoptosis, 1131
- Lymphoscintigraphy, sentinel node, cervical cancer, intraoperative lymphatic mapping, 183
- Lymphovascular invasion, transitional cell carcinoma, radical cystectomy, 2973
- Lymph-vascular space involvement, cervical cancer, neoadjuvant chemotherapy, radical hysterectomy, lymph node involvement, platelet count, 201
- Lynch syndrome, colon, carcinomas, GALT, 3019
- Lysosome, clioquinol, NF- $\kappa$ B, DU 145, cancer cells, 2087
- Lysozyme, fundic glands, polyps, *Helicobacter pylori*, 1021
- LYVE-1, D2-40, lymph node metastasis, squamous cell carcinoma, tongue, 1897
- M2PK, breast cancer, tumour glycolysis, pAkt, 1689
- MACC 1, quantitative real-time PCR, gastric carcinoma, 3441
- MACC1, quantitative real-time PCR, colorectal carcinoma, 2689
- mAChR3, muscarinic cholinergic receptor 3, nicotinic cholinergic receptor, nAChR, small cell lung cancer, SCLC,  $\beta$ 1 integrin, 97
- Macrophage, IP-PA1, immunomodulator, chemotherapy, apoptosis, 2033
- Macrophage, lipid rafts, phagocytosis, polystyrene latex microspheres, methyl- $\beta$ -cyclodextrin, scavenger receptors, 3167
- Macrophage, microarray analysis, signaling pathway, lignin-carbohydrate complex, LPS, LEM, 2567
- Macrophages, myeloid derived suppressor cells, regulatory T-cells, B16 melanoma, docetaxel, temozolomide, interleukin-1 receptor antagonist, host-tumor interactions, 345
- MAGE, melanoma antigen, HLA molecules, hepatocellular carcinoma, immunotherapy, 1617
- MAGED1, cancer/testis antigens, mesenchymal stem cells, pericytes, fibroblasts, PRAME, 5023
- Magnetic drug targeting, local chemotherapy, tumour vascularisation, computed tomography, angiography, flat-panel CT, 1553
- Magnetic nanoparticles, paclitaxel, magnetic targeting, glioma, rats, 2217
- Magnetic targeting, paclitaxel, magnetic nanoparticles, glioma, rats, 2217
- Major histocompatibility complex class I chain-related gene B, MICB, oral squamous cell carcinoma, OSCC, natural killer group 2, member D, NKG2D, 4097
- Malaria, mosquito, adenovirus, susceptibility, immune suppression, cancer mortality, 1371
- MALDI/MS, proteomic analysis, in-gel digestion, integral membrane proteins, membrane associated proteins, 1121
- Malignancy, astrocytoma, central nervous system, invasion, chlorotoxin, multiple chloride channels, glioma cells, 4515
- Malignancy, dysplasia, epithelium, hypopharynx, squamous cell carcinoma, 3313
- Malignant cardiac tamponade, endoscopy, pericarditis carcinomatosa, malignant pericardial effusion, 4691
- Malignant effusion, exosome, regulatory T-cells, TGF- $\beta$ 1, 3747
- Malignant fibrous histiocytomas, prognosis, telomerase, human telomerase reverse transcriptase, bone, 4959
- Malignant glioma, brain tumours, clomipramine, amitriptyline, tricyclic antidepressants, dexamethasone, oxygen consumption, 391
- Malignant glioma, cell culture, three-dimension, morphology, 383
- Malignant glioma, doxorubicin, drug delivery system, liposome, polymeric microsphere, thermoreversible gelation polymer, 1057
- Malignant glioma, lapatinib, sunitinib, MMPs, growth factors, VEGFR, integrins, anti-VEGFR agents, anti-EGFR agents, 4987
- Malignant glioma, VEGF, monoclonal antibody, radiological response, progression-free survival, bevacizumab, 609
- Malignant mesothelioma, animal tumor model, tumor spheroids, mesenchymal stem cell, chemokine, SDF1/CXCL12, 2153
- Malignant pericardial effusion, endoscopy, pericarditis carcinomatosa, malignant cardiac tamponade, 4691
- Malignant pleural mesothelioma, TS, DHFR, GARFT, NSCLC, pemetrexed, 4309
- Malignant, chemotherapy, glioma, 5213

- Malnutrition, cancer, energy metabolism, primary prevention, tertiary prevention, obesity, metabolic syndrome X, palliative care, review, 1863
- MALT lymphoma, IPI, FLIPI, prognostic index, 635
- Mamilla, neurofibromatosis type 1, NF1, neurofibromas, areola area, 1815
- Mammary cancer, JNK1, growth factors, apoptosis, kinase, 3407
- Mammary gland, apocrine gland, axillary osmidrosis, earwax, SNP, ABC transporter *ABCC11*, breast cancer risk, 5189
- Mammary tumor initiation, antioxidant, astaxanthin, mouse, inflammation, cardiac function, 2171
- Mammosphere, breast cancer, Notch, cancer stem cells, gamma-secretase, 3853
- Mandibular bone destruction, TGF- $\beta$ , osteoclast, 2615
- Mandibular metastasis, numb chin syndrome, mental neuropathy, inferior alveolar nerve, orthopantomogram, 1819
- Mantle cell lymphoma, class pi glutathione-S-transferase, nuclear transfer, anticancer agents, GST-pi, 3951
- MAPK, GBM, CSC, ATRA, 4915
- MAPK, *MMP13*, PTHrP, parathyroid hormone-related peptide, mitogen-activated protein kinase, ERK, extracellular signal-regulated kinase, PKC, protein kinase C, bone metastases, breast cancer, 5029
- MAPK, phenethyl isothiocyanate, migration, invasion, human gastric cancer AGS cells, NF- $\kappa$ B, 2135
- MAPK, PTHrP, parathyroid hormone-related protein, VEGF, vascular endothelial growth factor, angiogenesis, bone resorption, mitogen-activated protein kinase, 2755
- MAPK/ERK, toxin Bc2, equinatoxin-II, cytolysins, signaling pathways, necrosis, PKC, CaMKII, glioma cell death, 1209
- Marker panel, lung cancer, CEA, CYFRA 21-1, ROC-curves, 1661
- Markers, gliomas, origin, stem cells, *CD133*, brain adjacent tissue, nestin, subventricular zone, review, 1977
- Maspin expression, ovarian cancer, survival, 2739
- Mass spectrometry, superoxide dismutase 1, ovarian cancer, cisplatin, drug resistance, selected-reaction-monitoring, siRNA, 2577
- Mathematical model, response curve, bistable switch, drug composition, mTOR, carcinogenesis, 2683
- 3D Matrix, MT1-MMP, MMP-14, tyrosine phosphorylation, antennapedia, tumor progression, 1887
- Matrix metalloproteinase 9, pancreatic ductal adenocarcinoma, carbohydrate antigen19-9, MMP-9, tissue inhibitor of metalloproteinases 1, TIMP-1, receiver operating characteristic curves, ROC, 587
- Matrix metalloproteinase, giant cell lesions, giant cell granuloma, epulis, cathepsin, RANK, jaws, osteoclast, salivary glands, tendon sheath, 1645
- Matrix metalloproteinase, targeted therapy, VEGF, oxidative stress, reactive oxygen species, angiogenesis, bevacizumab, FINAVAST trial, 1001
- Matrix metalloproteinase-1, esophageal cancer, invasiveness, transwell invasion chamber, MMP-1, vimentin, p-Src (pY416), TIMP-2, tissue inhibitor of metalloproteinase-2, 727
- Matrix metalloproteinase-2, placental growth factor, transforming growth factor-alpha, transforming growth factor-beta 1, tumour necrosis factor receptor 1, pancreatic neoplasms, inflammation, 3801
- Matrix metalloproteinases, valproic acid, histone deacetylase inhibitors, epigenetic drugs, 535
- Maxillofacial cancer, delay and referral, oral cancer, 1833
- MCF-7 cells, (-)-gossypol, breast cancer, gossypol-myosin, anticancer, 439
- MCF-7 cells, breast cancer,  $\gamma$ -tocotrienol, cell cycle, retinoblastoma, cyclin D1, quinone reductase NQO2, 2869
- MCF7, flax roots, flax leaves, progesterone, ER, PR, 1695
- MCF-7, flax, *Linum usitatissimum*, phytoestrogens, cellular metabolism, online monitoring, acidification, oxygen consumption, adhesion, 1587
- MCF-7, tocotrienols, breast cancer, MDA-MB-231, chemoprevention, NRF2, 4169
- Mcl-1, apoptosis, 5-fluorouracil, Jurkat, T cells, caspases, 3879
- MDA-MB-231, apoptosis, autophagy, bafilomycin A1, breast cancer, sulforaphane, 3381
- MDA-MB-231, breast cancer, technetium, GRP receptor, carbonyl, T47-D,  $^{99m}\text{Tc}-(\text{CO})_3\text{-X-Y-bombesin (7-14)NH}_2$ , 19
- MDA-MB-231, tocotrienols, breast cancer, MCF-7, chemoprevention, NRF2, 4169
- MDM2, anticancer drug, growth inhibition, p53, XIAP, lung cancer, etoposide, 3321
- MDR reversal, cancer, doxorubicin, dihydropyridine derivative, oxidative stress, antioxidant, 4063
- MDR, verapamil, iodination, *in vitro* evaluation, 2553
- Mechanism of action, chemoF $\times$  DRM, cancer, heterogeneity, chemotherapeutic response, chemotherapy drug response marker, *in vitro* chemosensitivity testing, 2805
- Mediastinal germ cell tumor, rhabdomyosarcoma, BEP chemotherapy, positron-emission tomography, hepatic metastasis, 5117
- Mediastinal lymphadenopathies, fiberbronchoscopy, metastasis, transbronchial needle aspiration, 4769
- Medical history, stomach neoplasm, Epstein-Barr virus, risk factor, lifestyle, gastric ulcer, alcohol, 2469
- Medicinal electronics bricolage design, hypoxia-targeting antineoplastic drugs, hypoxic cell radiosensitizers, IDO inhibitor, BNCT agent, boron tracedrug, 3233

- Medulloblastoma, curcumin, apoptosis, 499
- Melanoma antigen, MAGE, HLA molecules, hepatocellular carcinoma, immunotherapy, 1617
- Melanoma cells, anthraquinones, danthron, quinizarin, polyamines, transglutaminase, differentiation, 445
- Melanoma, endothelial cells, blue light, phototoxicity, 143
- Melanoma, fine-needle aspiration, BRAF, proliferation, metastatic melanoma, 3267
- Melanoma, *in vivo* imaging, color-coded, GFP, RFP, UVC, blood vessels, 3291
- Melanoma, Sentinel node, serum S100, LDH, prognosis, metastasis, 1799
- Melphalan, proteomics, E7 oncogene, Tg mouse, cancer, 2773
- Membrane associated proteins, proteomic analysis, MALDI/MS, in-gel digestion, integral membrane proteins, 1121
- Membranous glomerulonephritis, esophageal cancer, nephrotic syndrome, 3763
- Menstrual cycle, circulating cell-free DNA, cfDNA, serum level, breast cancer, 2235
- Mental adjustment to cancer, cancer, depression, anxiety, 5-HTTLPR polymorphism, 3823
- Mental neuropathy, numb chin syndrome, mandibular metastasis, inferior alveolar nerve, orthopantomogram, 1819
- Mesenchymal stem cell, malignant mesothelioma, animal tumor model, tumor spheroids, chemokine, SDF1/CXCL12, 2153
- Mesenchymal stem cells, cancer/testis antigens, pericytes, fibroblasts, MAGED1, PRAME, 5023
- Mesenchymal–epithelial reversion, SMAD4, invasion and metastasis, epithelial phenotype, E-cadherin, 2603
- Mesothelioma, pericardial mesothelioma, asbestos, inflammation, heart surgery, 1323
- Mesothelioma, tumour marker, receiver operating characteristic curve, diagnosis, cytokeratin 19, CEA, 4343
- Mesotheliomas, interleukin-6, IL-6, vascular endothelial growth factor, new receptor inhibitor of IL-6, NRI, adenovirus, gene delivery, 1947
- Metabolic syndrome X, cancer, energy metabolism, primary prevention, tertiary prevention, obesity, malnutrition, palliative care, review, 1863
- Metabolism induction, busulfan, pharmacokinetics, benzodiazepines, seizure prophylaxis, phenytoin, 2977
- Metabolism, cancer chemoprevention, enzyme induction, RT-PCR, aromatase inhibitors, phenazines, 4873
- Metabolism, curcumin, cancer, liposomal curcumin, cytochrome P450, 811
- Metabolism, gemcitabine, pharmacokinetics, induction, nucleoside analogue, 3669
- Metabolism, irinotecan, pharmacokinetics, cetuximab, biweekly infusion, colorectal cancer, 2355
- Metalloproteinase, tumor metastasis, cytoplasmic phospholipase A2, 5-lipoxygenase, cyclooxygenase-2, angiogenesis, 3421
- Metallothionein, thyroid carcinoma, Ki-67, 4945
- Metastases, cervical cancer, fibula, tibia, isotope bone scan, 2949
- Metastases, cyclooxygenase-2, Ki-67, renal cell carcinoma, survival, 3023
- Metastasis model, spontaneous metastasis, lymph node, B16 mouse melanoma, 4799
- Metastasis prevention, cell proliferation, Erk signaling, keratinocyte growth factor, KGFR tyrosine kinase inhibitor, breast cancer, 4883
- Metastasis, breast cancer, stomach, 3705
- Metastasis, breast cancer, WFDC2, prognostic factor, HE4, 4779
- Metastasis, CD44, glioblastoma multiforme, survival, 253
- Metastasis, colorectal cancer, comparison, KRAS, BRAF, mutation, 4229
- Metastasis, cyclin D1, colorectal cancer, risk, polymorphism, 2875
- Metastasis, desmopressin, vasopressin, peptide analog, chemotherapy, colon cancer, 5049
- Metastasis, EGFR, LOXL4, gene expression, head and neck squamous cell carcinoma, 4567
- Metastasis, fluorescent proteins, nude mice model, NPA, KAK-1, GFP, thyroid cancer, 4415
- Metastasis, Ha-ras, nm23, immunomodulation, 3585
- Metastasis, human tissue kallikrein 7, morphological change, vimentin, prostate cancer, invasion, 3413
- Metastasis, lung, neoplasia, KISS1, MMP-9, non-small cell lung cancer, NSCLC, prognosis, 713
- Metastasis, mediastinal lymphadenopathies, fiberbronchoscopy, transbronchial needle aspiration, 4769
- Metastasis, melanoma, Sentinel node, serum S100, LDH, prognosis, 1799
- Metastasis, prostasomes, exosomes, annexin, proteomics, prostate cancer, 285
- Metastasis, saracatinib, Src, FAK, invasion, fibrosarcoma, 4405
- Metastasis, sentinel lymph node, MMP-2, MMP-9, breast cancer, 3521
- Metastatic breast cancer, first-line therapy, bevacizumab, paclitaxel, VEGF, 2969
- Metastatic breast cancer, S-1, capecitabine, 3827
- Metastatic breast cancer, trastuzumab, combination, pretreated, 3051
- Metastatic breast cancer, vinorelbine, capecitabine, oral chemotherapy, 2255
- Metastatic carcinoma, ovarian cancer, pseudomyxoma peritonei, borderline tumor, borderline type ovarian cancer, mucinous carcinoma, 2991

- Metastatic colorectal cancer, gene expression level, polymorphisms, clinical outcome, cetuximab, bevacizumab, irinotecan, 4209
- Metastatic colorectal carcinoma, *KRAS* mutation, diagnostic kit, 5251
- Metastatic disease, pancreatic cancer, docetaxel, gemcitabine, refractory, chemotherapy, salvage therapy, 2905
- Metastatic human cancer, palliation, progesterone receptor antagonist, tumor microenvironment, mifepristone, 623
- Metastatic melanoma, fine-needle aspiration, BRAF, melanoma, proliferation, 3267
- Metastatic renal cell carcinoma, renal cancer, dendritic cells, immunotherapy, 2081
- Methioninase, PEG-methioninase, cancer, methionine dependence, efficacy, selectivity, 793
- Methioninase, rMETase, PEG-methioninase, PEG-rMETase, cancer, methionine dependence, efficacy, selectivity, 1041
- Methionine dependence, methioninase, PEG-methioninase, cancer, efficacy, selectivity, 793
- Methionine dependence, methioninase, rMETase, PEG-methioninase, PEG-rMETase, cancer, efficacy, selectivity, 1041
- Methionine, prostate, breast, colon, p53, 1881
- Methotrexate, IL-2, high-dose chemotherapy, NK cells, 5-fluorouracil, epirubicin, cyclophosphamide, radiotherapy, etoposide, carboplatin, VEGF, retinoic acid, myeloablative chemotherapy, autologous transplantation, immunotherapy, breast cancer, 209
- Methotrexate, proton pump inhibitor, BCRP, ABCG2, drug–drug interaction, 3807
- Methotrexate, proton pump inhibitor, drug–drug interaction, glucarpidase, 963
- 6-Methoxy-8-[(2-furanylmethyl)amino]-4-methyl-5-(3-trifluoromethyl phenyloxy)quinoline, breast cancer, anti-cancer drugs, gap junctions, *in vivo* activity, quinolines, 3927
- 2-Methoxyestradiol, combination therapy, apoptosis, gemcitabine, pancreatic cancer cells, 4619
- Methylation analysis, gap junctional intercellular communication GJIC, connexin43, E-cadherin,  $\beta$ -catenin, ZO-1, immunohistochemistry, CpG island, pyrosequence, lung cancer, 2271
- Methylation, carcinoma, carcinoid, small cell carcinoma, large cell neuroendocrine carcinoma, immunofluorescence, survival, RASSF1, 4269
- Methylation, E-cadherin, promoter polymorphism, *KIT*, *CDH1*, gastric cancer, 2225
- Methylation, RUNX3, MSI, colorectal cancer, 2673
- Methylenetetrahydrofolate reductase, prostate cancer, polymorphism, and carcinogenesis, 3573
- Methylseleninic acid, DNA repair, cisplatin, carboplatin, nucleotide excision repair, selenium, selenomethionine, bone marrow, 291
- Methyl- $\beta$ -cyclodextrin, lipid rafts, macrophage, phagocytosis, polystyrene latex microspheres, scavenger receptors, 3167
- Metronomic chemotherapy, prostate cancer, cyclophosphamide, docetaxel, 4317
- Mevalonate pathway, statins, HMGCoA reductase inhibitors, carcinogenesis, liver neoplasm, ubiquinone, hepatocarcinogenesis, lovastatin, 1105
- Mevalonate, HMG CoA reductase, tocotrienol, statin, Cdk4, caspase-3, Ras, cell cycle, apoptosis, 4937
- MFH, VEGF, bevacizumab, 3391
- MG132, apoptosis, endothelial cells, caspase, ROS, GSH, proteasome inhibitor, 879
- MG132, apoptosis, NAC, ROS, GSH, 2107
- MGMT, alkyltransferase, drug resistance, SCCHN, cancer therapy, field cancerization, 2561
- MGN-3, HCC, angiogram, recurrence, 5145
- MHC I, prostate cancer, TRAMP, HLA-A2, immune rejection, 409
- MIB-1, needle biopsy, radical prostatectomy, cathepsin B, stefin A, DNA ploidy, prostate cancer, 719
- MIB-1, oestrogen receptor, progesterone receptor, CEA, CA15-3, breast cancer, 4701
- MIBG, paraganglioma, catecholamines, pheochromocytoma, 5153
- MICB, major histocompatibility complex class I chain-related gene B, oral squamous cell carcinoma, OSCC, natural killer group 2, member D, NKG2D, 4097
- Mice, KP1339, anticancer ruthenium(III) compounds, electroporation, electrochemotherapy, tumour models, sarcoma, 2055
- Micro RNAs, YB-1, gene regulation, RNA interference, microarray, gastric carcinoma cells, drug resistance, 629
- Microarray analysis, signaling pathway, macrophage, lignin-carbohydrate complex, LPS, LEM, 2567
- Microarray, YB-1, gene regulation, RNA interference, micro RNAs, gastric carcinoma cells, drug resistance, 629
- Microarrays, gene expression, oral cancer, tobacco, 1083
- Microcalcification, breast cancer, B3 lesions, vacuum-assisted core biopsy, Suros, lobular hyperplasia, DCIS, 2287
- Microfluidics, liposomes, ethanol injection, sonication, 463
- Microinvasive, cervical cancer, FIGO IA1, repeat surgery, 565
- Micrometastases, combination therapy, inflammation, postsurgical, CEA, lung carcinoma, lymphokine-activated killer cell therapy, glucocorticoid, 3125
- Micrometastases, penile carcinoma, lymph node metastases, non-sentinel lymph nodes, 467

- Micrometastasis, biochemical relapse, lymph node metastasis, pelvic lymph node dissection, prostate cancer, radical prostatectomy, 2297
- Microparticles, CEA, Her2/neu, BCRP, HSP27, breast cancer, 1707
- Microsatellite instability, chemotherapy, cancer, colorectal cancer treatment, FOLFOX, adjuvant treatment, prognostic factor, 4297
- MicroSPECT/CT imaging, colorectal adenocarcinoma, nanoliposome, pharmacokinetics, <sup>188</sup>Re, 65
- Microtubule, angiogenesis, combretastatin, vascular disrupting agent, cisplatin, 2813
- Mifepristone, metastatic human cancer, palliation, progesterone receptor antagonist, tumor microenvironment, 623
- Mifepristone, murine lung cancer, progesterone receptor antagonist, tumor microenvironment, natural killer cells, lung cancer, 119
- Mifepristone, progesterone receptor antagonists, murine prostate cancer, testicular cancer, 4921
- Mifepristone, progestins, antiprogestins, cytotoxic, breast cancer cells, non-genomic effects, apoptosis, cell cycle, 4835
- Migration, invasion, cell growth, cell-cell adhesion, delta opioid receptor agonists, colon cancer cells, 9
- Migration, nasopharyngeal carcinoma, curcumin, E-cadherin, NF- $\kappa$ B, 2851
- Migration, phenethyl isothiocyanate, invasion, human gastric cancer AGS cells, MAPK, NF- $\kappa$ B, 2135
- Milk protein, cereals, cholesterol, diet, gross domestic product, prostate cancer, ultraviolet-B, vitamin D, 189
- Minimal residual disease, breast cancer, recurrence-free follow-up, isolated tumour cells, zoledronate treatment, 1807
- Minimal residual disease, philadelphia chromosome-positive acute lymphoblastic leukaemia, post-transplant imatinib administration, allogeneic stem cell transplantation, imatinib, 2415
- MiR-15a, prostate cancer, miRNA, miR-20a, let-7a, miR-16, 3579
- MiR-16, prostate cancer, miRNA, miR-20a, let-7a, miR-15a, 3579
- MiR-184 transfection, mouse models, targeted therapeutics, neuroblastoma, 4391
- MiR-20a, prostate cancer, miRNA, let-7a, miR-15a, miR-16, 3579
- MiRNA, prostate cancer, miR-20a, let-7a, miR-15a, miR-16, 3579
- Mithramycin, ADH5, auranofin, hepatoma, GSNOR, S-nitrosylation, thioredoxin reductases, 415
- Mitochondria, apoptosis, FCCP, juxtaglomerular cell, caspase, 2863
- Mitochondria, *Brucea javanica*, cytotoxicity, NF- $\kappa$ B, NFAT, ROS, 3295
- Mitogen-activated protein kinase, *MMP13*, PTHrP, parathyroid hormone-related peptide, MAPK, ERK, extracellular signal-regulated kinase, PKC, protein kinase C, bone metastases, breast cancer, 5029
- Mitogen-activated protein kinase, PTHrP, parathyroid hormone-related protein, VEGF, vascular endothelial growth factor, angiogenesis, bone resorption, MAPK, 2755
- MLS, CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP) gene, chromosomal translocation, Ewing sarcoma (EWS) gene, fluorescence *in situ* hybridization, FISH, fusion gene, myxoid liposarcoma, reverse transcription-polymerase chain reaction, RT-PCR, 4679
- MMP inhibition, fibroblast, angiogenesis, cytokine, imaging, skin cancer invasion, VEGF-A, PDGF-BB, 703
- MMP-1, esophageal cancer, invasiveness, transwell invasion chamber, matrix metalloproteinase-1, vimentin, p-Src (pY416), TIMP-2, tissue inhibitor of metalloproteinase-2, 727
- MMP-13, colorectal cancer, liver metastasis, 2693
- MMP13*, PTHrP, parathyroid hormone-related peptide, MAPK, mitogen-activated protein kinase, ERK, extracellular signal-regulated kinase, PKC, protein kinase C, bone metastases, breast cancer, 5029
- MMP-14, MT1-MMP, tyrosine phosphorylation, antennapedia, tumor progression, 3D matrix, 1887
- MMP-2, angiogenesis, chlorotoxin, TM601, invasion, 39
- MMP-2, sentinel lymph node, MMP-9, breast cancer, metastasis, 3521
- MMP-9, amphiregulin, EGFR, breast cancer, 2101
- MMP-9, non-small cell lung cancer, NSCLC, lung, neoplasia, *KISS1*, metastasis, prognosis, 713
- MMP-9, pancreatic ductal adenocarcinoma, carbohydrate antigen19-9, matrix metalloproteinase 9, tissue inhibitor of metalloproteinases 1, TIMP-1, receiver operating characteristic curves, ROC, 587
- MMP-9, sentinel lymph node, MMP-2, breast cancer, metastasis, 3521
- MMP-9, TG2, A431 cell, fibronectin, invasion, 4177
- MMPs, lapatinib, sunitinib, malignant glioma, growth factors, VEGFR, integrins, anti-VEGFR agents, anti-EGFR agents, 4987
- Molecular remission, acute promyelocytic leukemia, autologous transplantation, 3845
- Monoclonal antibody therapeutics, human anti-mouse antibody, HAMA, colorectal cancer, prevalence, adverse events, 4353
- Monoclonal antibody, androgen-independent prostate cancer, epidermal growth factor receptor, EGFR, cetuximab, C225, Du145, PC-3, 1905
- Monoclonal antibody, VEGF, radiological response, progression-free survival, bevacizumab, malignant glioma, 609



- Monoclonal, hybridoma, KEPI, peptide array, substitutional analysis, 1573
- Monte Carlo simulation, dental implants, scattering irradiation, titanium dental implants, 1727
- Morphological appearance, CpG island hypermethylation, gastric cancer, 239
- Morphological change, human tissue kallikrein 7, vimentin, prostate cancer, invasion, metastasis, 3413
- Morphology, malignant glioma, cell culture, three-dimension, 383
- Morphometrics, facial nerve, irradiation, irradiation damage, scattering irradiation, 1625
- Morphometry, nuclear density, chemopreventive agents, rat tracheal epithelial cells, 737
- Mortality, type 2 diabetes mellitus, cancer, body mass index, epidemiological study, 681
- Mosquito, adenovirus, susceptibility, immune suppression, malaria, cancer mortality, 1371
- Motexafin gadolinium, lymphoma, p53, reactive oxygen species, apoptosis, 1131
- Motility and adhesion, vascular endothelial growth inhibitor, VEGI, urothelial cancer of bladder, bladder cancer cells, 87
- Motility, bone morphogenetic protein 7, Smad1, lung cancer, 1113
- Motility, cytoskeleton, paxillin, phosphatase, PP-1, TGF- $\beta$ , endothelial cells, 4861
- Mouse model, B16-F0 mouse melanoma cell, hepatocyte growth factor, HGF, *Cordyceps sinensis*, invasion, 3429
- Mouse model, ovarian cancer, tyrosine kinase inhibitor, xenograft, luciferase, sunitinib, 3355
- Mouse models, targeted therapeutics, miR-184 transfection, neuroblastoma, 4391
- Mouse, antioxidant, astaxanthin, inflammation, cardiac function, mammary tumor initiation, 2171
- M-phase cell, camptothecin derivative, apoptosis, DNA damage and repair,  $\gamma$ -H2AX, radiation, 937
- MRNA quantification, HT29, chemoresistance, translational regulation, real-time PCR, colorectal cancer cells, fluoropyrimidine analogs, thymidylate synthase, p53, 5-FU resistance, 1149
- MRNA stability, EGCG, TROP-2, HCT-116, SW480, cycloheximide, (-)epigallocatechin-3-gallate, colorectal cancer cells, 2497
- MRNA, colorectal cancer, dendritic cells, antigen loading, CEA peptide, electroporation, immunotherapy, vaccination, 5091
- MRNA, prostate cancer, PCa, benign prostatic hyperplasia, BPH, DD3<sup>PCA3</sup>, RT-PCR, 665
- MRP1/ABCC1, human erythrocyte, BCPCF, phenolic compound, haemolysis, lignans, norlignans, multidrug resistance, 4423
- MSI, RUNX3, methylation, colorectal cancer, 2673
- MSP-MCA, ILTG, *DAPK-1*, HT-29, HL-60, DNA methylation, colon cancer, leukemia, 3945
- MT1-MMP, MMP-14, tyrosine phosphorylation, antennapedia, tumor progression, 3D matrix, 1887
- MT2-MMP, intratumoral angiogenesis, esophageal cancer, 4363
- MTD, angiogenesis, DCE-MRI, PTK/ZK, VEGF, 2335
- MtDNA, OGG1, NTH1, UDG, APE1, DNA repair, nDNA, lung cancer cells, 4963
- mTOR complex 1, epidermal growth factor, PI-103, rapamycin, mTOR complex 2, negative feedback loop, sora fenib, Ras/Raf/MAPK, PI13/AKT/mTOR, 4951
- mTOR complex 2, epidermal growth factor, PI-103, rapamycin, mTOR complex 1, negative feedback loop, sora fenib, Ras/Raf/MAPK, PI13/AKT/mTOR, 4951
- mTOR, antiestrogens, AKT, EGF-R, endometrial cancer, everolimus, gefitinib, perifosine, tamoxifen, 2025
- mTOR, breast cancer, signal pathway, TS, ROS, 5-FU, rapamycin, 2625
- mTOR, curcumin, copper, A2780, NF- $\kappa$ B, cancer, 3249
- mTOR, LAT1, NSCLC, *EGFR* mutation, non-small cell lung cancer, 4819
- mTOR, ovarian cancer, DEPTOR, S6 kinase, paclitaxel resistance, 3529
- mTOR, rapamycin, celecoxib, COX 2, angiosarcoma, endothelial tumour, 4017
- mTOR, rapamycin, FOXO1, proliferation, 799
- mTOR, response curve, bistable switch, mathematical model, drug composition, carcinogenesis, 2683
- MUC-1, breast cancer, tumor marker, CA 27.29, chemotherapy, 1837
- MUC1,  $\beta$ -catenin, c-Met, immunohistology, gastric cancer, prognosis, 4635
- Mucinous carcinoma, ovarian cancer, pseudomyxoma peritonei, borderline tumor, borderline type ovarian cancer, metastatic carcinoma, 2991
- Mucinous cystic neoplasms, pancreatitis, pregnancy, cystic lesions, mucinous cystadenoma, estrogens, progesterone, pancreatic cancer, 1025
- Mucinous cystadenoma, pancreatitis, pregnancy, cystic lesions, mucinous cystic neoplasms, estrogens, progesterone, pancreatic cancer, 1025
- Multicellular spheroids, interstitial diffusion, collagenase, hyaluronidase, two-photon excitation, FRAP, 359
- Multidrug resistance, *ABCBI*, anthracycline, AML, caveolin-1, caveolae, cholesterol, 3451
- Multidrug resistance, *Carpobrotus edulis*, *Aizoaceae*, efflux pump, P-glycoprotein, 829
- Multidrug resistance, human erythrocyte, BCPCF, phenolic compound, haemolysis, lignans, norlignans, MRP1/ABCC1, 4423
- Multidrug resistance, hydantoin, *ABCBI*, P-glycoprotein, cancer, 4867

- Multidrug resistance, L1210 cells, P-glycoprotein, concanavalin A, cell surface saccharides, 3661
- Multidrug resistance, p-glycoprotein, resveratrol, piceatannol, stilbenes, 4587
- Multidrug resistance, tyrosine kinase pathway, P-glycoprotein, chemosensitivity sorafenib, hepatocellular carcinoma cells, 4503
- Multifocal, extramedullary, plasmocytoma, uncommon site, surgery, radiotherapy, chemotherapy, 1779
- Multimodal treatment, case report, anaplastic thyroid carcinoma, chemotherapy, long-term survival, 1273
- Multiple brain metastases, radiotherapy, stereotactic radiosurgery, survival, whole brain radiotherapy, non-small cell lung cancer, 3055
- Multiple chloride channels, astrocytoma, central nervous system, malignancy, invasion, chlorotoxin, glioma cells, 4515
- Multiple lymph node metastases, esophageal cancer, neoadjuvant chemotherapy, DCF, 221
- Multiple myeloma, angiogenesis, hypoxia, VEGF, VEGFR2/KDR, 2831
- Multiple myeloma, plasmacytoma, bortezomib, dexamethasone, 3791
- Multiple oral cancer, p53 mutation, leukoplakia, oral squamous cell carcinoma, 4773
- Multiplicity, NSCLC, EGFR, KRAS, mutation, clonality, lung cancer, tyrosine kinase inhibitors, 1667
- Murine lung cancer, progesterone receptor antagonist, mifepristone, tumor microenvironment, natural killer cells, lung cancer, 119
- Murine polyomavirus, tumour specific transplantation antigen, viral persistence, virus like particles VLPs, immune responses, review, 279
- Murine prostate cancer, progesterone receptor antagonists, mifepristone, testicular cancer, 4921
- Mus81*, gastric cancer, 5011
- Muscarinic cholinergic receptor 3, mAChR3, nicotinic cholinergic receptor, nAChR, small cell lung cancer, SCLC,  $\beta$ 1 integrin, 97
- Mutation breast phyllodes tumor, CD117, immunohistochemistry, c-Kit, 4731
- Mutation, adenocarcinoma, epidermal growth factor receptor, immunohistochemistry, lung cancer, 5233
- Mutation, colorectal cancer, metastasis, comparison, KRAS, BRAF, 4229
- Mutation, EGFR, breast cancer, 4219
- Mutation, NSCLC, EGFR, KRAS, multiplicity, clonality, lung cancer, tyrosine kinase inhibitors, 1667
- Mutation, prostate cancer, progression, TP53, tumor suppressor-gene, 1579
- Mutation, *PTEN*, glioma, 981
- Mutation, *RAS*, soft tissue sarcoma, Japan, 245
- Mutations, colorectal carcinoma, KRAS, BRAF, FFPE, ThinPrep, qPCR, 1969
- Myc, Omomyc, KRAS, lung cancer, A549, 4193
- Myeloablative chemotherapy, IL-2, high-dose chemotherapy, NK cells, 5-fluorouracil, epirubicin, cyclophosphamide, methotrexate, radiotherapy, etoposide, carboplatin, VEGF, retinoic acid, autologous transplantation, immunotherapy, breast cancer, 209
- Myeloid derived suppressor cells, macrophages, regulatory T-cells, B16 melanoma, docetaxel, temozolomide, interleukin-1 receptor antagonist, host-tumor interactions, 345
- Myeloperoxidase, cadherin, insulin-like growth factor, leiomyoma, polymorphism, urokinase, xeroderma pigmentosum, 2203
- Myxoid liposarcoma, CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP) gene, chromosomal translocation, Ewing sarcoma (EWS) gene, fluorescence *in situ* hybridization, FISH, fusion gene, MLS, reverse transcription-polymerase chain reaction, RT-PCR, 4679
- N0, oesophageal cancer, lymph node metastasis, prognostic factors, 3063
- NAC, MG132, apoptosis, ROS, GSH, 2107
- N*-Acetyl transferase 2, isoniazid, antituberculosis, 3177
- N*-Acetyltransferase 2, breast cancer, oestrogen metabolism, cytochrome P450 1B1, heterocyclic arylamines, 2885
- nAChR, nicotinic cholinergic receptor, muscarinic cholinergic receptor 3, mAChR3, small cell lung cancer, SCLC,  $\beta$ 1 integrin, 97
- Nanodiamond, dendritic cells, CD4+ cells, *in vitro*, bionanotechnology, 4075
- Nanoliposome, colorectal adenocarcinoma, microSPECT/CT imaging, pharmacokinetics, <sup>188</sup>Re, 65
- Nanotechnology, functional proteomics, cancer, proliferation, NAPPA microarrays, review, 2073
- 1,4-Naphthoquinone, human prostate cancer cell lines, cytotoxicity, cell cycle, apoptosis, 519
- NAPPA microarrays, functional proteomics, cancer, proliferation, review, nanotechnology, 2073
- Nasopharyngeal carcinoma, curcumin, migration, E-cadherin, NF- $\kappa$ B, 2851
- Nasopharyngeal carcinoma, IGF-1R, undifferentiated carcinoma, head and neck cancer, immunotherapy, 1641
- Natural killer cells, murine lung cancer, progesterone receptor antagonist, mifepristone, tumor microenvironment, lung cancer, 119
- Natural killer group 2, member D, NKG2D, major histocompatibility complex class I chain-related gene B, MICB, oral squamous cell carcinoma, OSCC, 4097
- Natural products, AKT, GSK3beta, plant extract, CDK inhibitor, 3599

- Natural products, stem cells, cell cycle, education, cooperation, 2477
- NBCCS, gorlin, calcification, ponticulus posterior, atlanto-occipital ligament, 4265
- NDNA, OGG1, NTH1, UDG, APE1, DNA repair, mtDNA, lung cancer cells, 4963
- Necrosis, toxin Bc2, equinatoxin-II, cytolysins, signaling pathways, MAPK/ERK, PKC, CaMKII, glioma cell death, 1209
- Needle biopsy, radical prostatectomy, cathepsin B, stefin A, MIB-1, DNA ploidy, prostate cancer, 719
- Negative feedback loop, epidermal growth factor, PI-103, rapamycin, mTOR complex 1, mTOR complex 2, sora fenib, Ras/Raf/MAPK, PI13/AKT/mTOR, 4951
- Negative predictive value, uterine corpus cancer, staging, lymphadenectomy, specificity, FDG-PET, 3787
- Neoadjuvant chemotherapy, cervical cancer, chemoradiotherapy, brachytherapy, radical hysterectomy, 3731
- Neoadjuvant chemotherapy, cervical cancer, radical hysterectomy, lymph-vascular space involvement, lymph node involvement, platelet count, 201
- Neoadjuvant chemotherapy, esophageal cancer, multiple lymph node metastases, DCF, 221
- Neoadjuvant chemotherapy, gastric cancer, cytology, peritoneal dissemination, docetaxel, S-1, 1335
- Neoadjuvant chemotherapy, oesophageal carcinoma, response prediction, Barrett's carcinoma, review, 1065
- Neoadjuvant chemotherapy, pCR, HER2, epirubicin, cyclophosphamide, paclitaxel, trastuzumab, breast cancer, 4665
- Neoadjuvant chemotherapy, VEGF, granulosa cell tumor, ovarian cancer, bevacizumab, 4767
- Neoadjuvant, breast cancer, chemotherapy, gemcitabine, pegylated liposomal doxorubicin, docetaxel, phase II, locally advanced, 3817
- Neoadjuvant, heat-shock protein 70, Ki-67, aromatase inhibitor, breast cancer, 3465
- Neoplasia, lung, *KISS1*, MMP-9, non-small cell lung cancer, NSCLC, metastasis, prognosis, 713
- Neoplastic transformation, cSrc, Simian Virus 40 Large Tumor antigen, retinoblastoma susceptibility gene product, rodent fibroblasts, signal transduction, 47
- Neovascularization, pancreatic cancer, endothelial cells, angiogenesis, placental growth factor, 2911
- Nephrotic syndrome, esophageal cancer, membranous glomerulonephritis, 3763
- Nestin, gliomas, origin, stem cells, *CD133*, markers, brain adjacent tissue, subventricular zone, review, 1977
- Neuroblastoma, mouse models, targeted therapeutics, miR-184 transfection, 4391
- Neuroblastoma, Y-box binding protein 1, YB-1, immunohistochemistry, tumour marker, 1239
- Neuroendocrine tumour, breast cancer, hindgut, carcinoid, 3015
- Neuroendocrine (NE) differentiation, benign prostatic hyperplasia, finasteride, dutasteride, chromogranin A, 4737
- Neuroendocrine tumor, carcinoid, cell lines, plant extracts, bioactive agents, chemoresistance, apoptosis, 55
- Neuroendocrine tumors, apoptosis, caspase activity, NSC 95397, brefeldin A, bortezomide, sanguinarine, 149
- Neuroendocrine tumors, p-Akt, immunohistochemistry, 5063
- Neurofibromas, neurofibromatosis type 1, NF1, mamilla, areola area, 1815
- Neurofibromatosis type 1, neurofibromatosis, orbit, plexiform neurofibroma, optic nerve, optic nerve glioma, skull deformity, orbital deformity, orbito-temporal neurofibromatosis, facial scoliosis, sphenoid wing dysplasia, 1751
- Neurofibromatosis type 1, NF1, neurofibromas, mamilla, areola area, 1815
- Neurofibromatosis, neurofibromatosis type 1, orbit, plexiform neurofibroma, optic nerve, optic nerve glioma, skull deformity, orbital deformity, orbito-temporal neurofibromatosis, facial scoliosis, sphenoid wing dysplasia, 1751
- Neurokinin, animal model, antagonist, colitis, dysplasia, colon cancer, 3345
- Neuron-specific enolase, irradiation, salivary glands, 1569
- New radiosensitizing drugs, chemoradiosensitizers, radiotherapy, novel agents, chemotherapy, review, 3675
- New receptor inhibitor of IL-6, interleukin-6, IL-6, vascular endothelial growth factor, NRI, mesotheliomas, adenovirus, gene delivery, 1947
- NexrutineR, tumor invasion, prostate cancer, BMD, CREB, NF- $\kappa$ B, TRAMP, 857
- NF1, neurofibromatosis type 1, neurofibromas, mamilla, areola area, 1815
- NFAT, *Brucea javanica*, cytotoxicity, NF- $\kappa$ B, ROS, mitochondria, 3295
- NF- $\kappa$ B, alpha terpineol, *Salvia libanotica*, connectivity map, 1911
- NF- $\kappa$ B, *Brucea javanica*, cytotoxicity, NFAT, ROS, mitochondria, 3295
- NF- $\kappa$ B, clioquinol, lysosome, DU 145, cancer cells, 2087
- NF- $\kappa$ B, curcumin, copper, A2780, mTOR, cancer, 3249
- NF- $\kappa$ B, gene expression, histone deacetylase inhibitor, ITF2357, apoptosis, inflammation, 4525
- NF- $\kappa$ B, nasopharyngeal carcinoma, curcumin, migration, E-cadherin, 2851
- NF- $\kappa$ B, nexrutine<sup>R</sup>, tumor invasion, prostate cancer, BMD, CREB, TRAMP, 857
- NF- $\kappa$ B, notch,  $\gamma$ -secretase inhibitor, leukemia, 495
- NF- $\kappa$ B, phenethyl isothiocyanate, migration, invasion, human gastric cancer AGS cells, MAPK, 2135

- Nicotinic cholinergic receptor, nAChR, muscarinic cholinergic receptor 3, mAChR3, small cell lung cancer, SCLC,  $\beta$ 1 integrin, 97
- Nitric oxide, lipopolysaccharide, pulmonary inhalation, lung cancer, alveolar macrophage, cell-to-cell contact, 3135
- Nitro-oxy derivative, colon cancer, COX-2, celecoxib,  $\beta$ -catenin, PI3K/Akt, 2659
- NK cells, IL-2, high-dose chemotherapy, 5-fluorouracil, epirubicin, cyclophosphamide, methotrexate, radiotherapy, etoposide, carboplatin, VEGF, retinoic acid, myeloablative chemotherapy, autologous transplantation, immunotherapy, breast cancer, 209
- NKG2D ligands,  $\gamma\delta$  T-cells, cancer immunotherapy, bladder carcinoma, histone deacetylase inhibitor, valproic acid, 4509
- NKG2D, natural killer group 2, member D, major histocompatibility complex class I chain-related gene B, MICB, oral squamous cell carcinoma, OSCC, 4097
- Nm23, Ha-ras, metastasis, immunomodulation, 3585
- NOD2/CARD15, genetic polymorphism, *TLR4*, gastritis, histopathology, 513
- Non-genomic effects, progestins, antiprogestins, cytotoxic, breast cancer cells, mifepristone, apoptosis, cell cycle, 4835
- Non-sentinel lymph nodes, penile carcinoma, lymph node metastases, micrometastases, 467
- Non-small cell lung cancer, carboplatin, paclitaxel, chemotherapy, interstitial lung disease, efficacy, safety, 4357
- Non-small cell lung cancer, CEA, CYFRA 21-1, tumour marker index, survival, 3099
- Non-small cell lung cancer, chemotherapy, carboplatin, paclitaxel, hematologic toxicity, age, 1365
- Non-small cell lung cancer, chemotherapy, sunitinib, 5169
- Non-small cell lung cancer, cytokeratin, tumour marker, CYFRA21-1, prognosis, survival, 3833
- Non-small cell lung cancer, deltaNp63, immunohistochemistry, squamous cell carcinoma, 4717
- Non-small cell lung cancer, erlotinib, Tarceva, EGFR-TKIs, *EGFR* mutation, phase II, 557
- Non-small cell lung cancer, first and second line chemotherapy, survival, 4335
- Non-small cell lung cancer, LAT1, NSCLC, *EGFR* mutation, mTOR, 4819
- Non-small cell lung cancer, locally advanced, chemoradiation, pattern of failure, 953
- Non-small cell lung cancer, multiple brain metastases, radiotherapy, stereotactic radiosurgery, survival, whole brain radiotherapy, 3055
- Non-small cell lung cancer, NSCLC, MMP-9, lung, neoplasia, *KISS1*, metastasis, prognosis, 713
- Non-small cell lung cancer, stage III, chemoradiation, surgery, pneumonectomy, cisplatin, 4237
- Nonsteroidal anti-inflammatory drugs, NSAID, hydroxamic acids, cytostatic activity, cytotoxicity, human pancreatic cancer, Akt signalling, cell cycle, apoptosis, 3987
- Nonsteroidal, breast cancer, orally active, selective estrogen receptor down-regulator SERD, thiochroman derivative, 873
- Norlignans, human erythrocyte, BCPCF, phenolic compound, haemolysis, lignans, multidrug resistance, MRP1/ABCC1, 4423
- Noscapine, prostate cancer prophylaxis, tumour inhibition, 399
- Notch, breast cancer, cancer stem cells, gamma-secretase, mammosphere, 3853
- Notch,  $\gamma$ -secretase inhibitor, erythroid leukemia, differentiation, 4071
- Notch,  $\gamma$ -secretase inhibitor, leukemia, NF- $\kappa$ B, 495
- Novel agents, chemoradiosensitizers, radiotherapy, chemotherapy, new radiosensitizing drugs, review, 3675
- NPA, fluorescent proteins, nude mice model, metastasis, KAK-1, GFP, thyroid cancer, 4415
- NRF2, tocotrienols, breast cancer, MCF-7, MDA-MB-231, chemoprevention, 4169
- NRI, interleukin-6, IL-6, vascular endothelial growth factor, new receptor inhibitor of IL-6, mesotheliomas, adenovirus, gene delivery, 1947
- NSAID, nonsteroidal anti-inflammatory drugs, hydroxamic acids, cytostatic activity, cytotoxicity, human pancreatic cancer, Akt signalling, cell cycle, apoptosis, 3987
- NSC 95397, apoptosis, caspase activity, brefeldin A, bortezomide, sanguinarine, neuroendocrine tumors, 149
- NSCLC, adjuvant chemotherapy, carboplatin, paclitaxel, gemcitabine, treatment compliance, surgical resection, 4695
- NSCLC, adjuvant chemotherapy, carboplatin, paclitaxel, treatment compliance, surgical resection, 3039
- NSCLC, AKAP12 $\alpha$ , promoter methylation, lung neoplasms, 4595
- NSCLC, E-cadherin, dysadherin, cytokeratin recurrence, prognosis, 3273
- NSCLC, EGFR, *KRAS*, mutation, multiplicity, clonality, lung cancer, tyrosine kinase inhibitors, 1667
- NSCLC, erlotinib, EGFR, tyrosine kinase inhibitors, lung cancer, review, 1301
- NSCLC, LAT1, *EGFR* mutation, mTOR, non-small cell lung cancer, 4819
- NSCLC, non-small cell lung cancer, MMP-9, lung, neoplasia, *KISS1*, metastasis, prognosis, 713
- NSCLC, serum LDH, tumour LDH-5, adenocarcinoma, squamous cell carcinoma, immunohistochemistry, 1347
- NSCLC, TS, DHFR, GARFT, malignant pleural mesothelioma, pemetrexed, 4309
- NSE, IL-6, VEGF, ProGR, prognosis, lung cancer, 1773
- NTH1, OGG1, UDG, APE1, DNA repair, mtDNA, nDNA, lung cancer cells, 4963

- Nuclear density, morphometry, chemopreventive agents, rat tracheal epithelial cells, 737
- Nuclear envelope changes, gastric carcinoma, electron microscopy, 699
- Nuclear morphometry, breast cancer, prognosis, treatment response, 2185
- Nuclear protein, progression, inflammation-associated carcinogenesis, fibrosarcoma, proteomic analysis, 2093
- Nuclear transfer, class pi glutathione-S-transferase, mantle cell lymphoma, anticancer agents, GST-pi, 3951
- Nucleoside analogue, gemcitabine, pharmacokinetics, metabolism, induction, 3669
- Nucleosomes, DNA, ELISA, stability, serum, 1613
- Nucleotide excision repair, DNA repair, cisplatin, carboplatin, selenium, selenomethionine, methylseleninic acid, bone marrow, 291
- Nucleotide excision repair, DNA repair, UV-radiation, cisplatin, RB, XPC, 2483
- Nude mice model, fluorescent proteins, metastasis, NPA, KAK-1, GFP, thyroid cancer, 4415
- Nude mouse, epithelial-myoepithelial carcinoma, salivary gland carcinoma, growth factor receptors, cytokeratin, EGFR-1, 1565
- Numb chin syndrome, mental neuropathy, mandibular metastasis, inferior alveolar nerve, orthopantomogram, 1819
- Obesity, alcohol, estrogen, breast cancer, post-menopause, 1
- Obesity, anesthesia, HIF1 $\alpha$ , lung cancer, one-lung ventilation, BMI, pneumothorax, 1143
- Obesity, cancer, energy metabolism, primary prevention, tertiary prevention, metabolic syndrome X, malnutrition, palliative care, review, 1863
- Oblimersen, small-cell lung cancer, radiation, BCL-2, 3869
- Observational study, ovarian cancer, chemotherapy, paclitaxel, 4245
- ODC, cell proliferation, colon cancer, polyamines, polyphenols, quercetin, 3501
- Oesophageal cancer, lymph node metastasis, NO, prognostic factors, 3063
- Oesophageal carcinoma, neoadjuvant chemotherapy, response prediction, Barrett's carcinoma, review, 1065
- Oestrogen metabolism, breast cancer, N-acetyltransferase 2, cytochrome P450 1B1, heterocyclic arylamines, 2885
- Oestrogen receptor, progesterone receptor, MIB-1, CEA, CA15-3, breast cancer, 4701
- Oestrogen receptor, real-time PCR, breast cancer, 4147
- Oestrogen receptors, progesterone receptors, adenocarcinoma, uterine cervix, 1341
- OGG1, NTH1, UDG, APE1, DNA repair, mtDNA, nDNA, lung cancer cells, 4963
- Older patients, acute promyelocytic leukemia, patient selection, 967
- Omomyc, myc, KRAS, lung cancer, A549, 4193
- Oncocytoma, papillary renal cell carcinoma, tubulocystic carcinoma, clear cell papillary renal cell carcinoma, chromophobe renal carcinoma, 641
- Oncology patients, rifampicin-miconazole-releasing catheters, catheter colonization, local infection, long-term activity, 1353
- One-lung ventilation, anesthesia, HIF1 $\alpha$ , lung cancer, BMI, obesity, pneumothorax, 1143
- Online monitoring, flax, *Linum usitatissimum*, phytoestrogens, MCF-7, cellular metabolism, acidification, oxygen consumption, adhesion, 1587
- Oplopanax horridus*, human colorectal cancer, anti-proliferation, apoptosis, cell cycle, cyclin A, cyclin B1, 295
- OPN, thyroid cancer, thyroid gland, osteopontin, CEACAM1, 1681
- Optic nerve glioma, neurofibromatosis, neurofibromatosis type 1, orbit, plexiform neurofibroma, optic nerve, skull deformity, orbital deformity, orbito-temporal neurofibromatosis, facial scoliosis, sphenoid wing dysplasia, 1751
- Optic nerve, neurofibromatosis, neurofibromatosis type 1, orbit, plexiform neurofibroma, optic nerve glioma, skull deformity, orbital deformity, orbito-temporal neurofibromatosis, facial scoliosis, sphenoid wing dysplasia, 1751
- Oral cancer, 2'-hydroxycinnamaldehyde, cell cycle, apoptosis, tumor model, 489
- Oral cancer, arsenic trioxide, dithiothreitol, carcinogenesis, 3655
- Oral cancer, basaloid squamous cell carcinoma, HPV types, oral papilloma, oral dysplasia, p16, 1605
- Oral cancer, delay and referral, maxillofacial cancer, 1833
- Oral cancer, *hOGG1*, single nucleotide polymorphism, betel quid, 4205
- Oral cancer, human papillomavirus, genotypes, oropharyngeal cancer, head and neck cancer, 5099
- Oral cancer, microarrays, gene expression, tobacco, 1083
- Oral cancer, oral metastasis, solid tumors, jaw metastasis, head and neck lymphoma, 1843
- Oral cancer, vascular endothelial growth factor, oropharyngeal cancer, 1765
- Oral carcinoma, HPV, oral dysplasia, p53, p16, 3435
- Oral cavity, amyloidosis, tongue, localized amyloidosis, amyloid, AL amyloidosis, 3009
- Oral cavity, ectomesenchymal chondromyxoid tumour, tongue, immunohistochemistry, 4685
- Oral cavity, GIST, gastrointestinal stromal tumour, distant metastasis, imatinib, PET, 4283
- Oral chemotherapy, chemohormonal therapy, etoposide, ethinylestradiol, HRPC, prostate cancer, 3737

- Oral chemotherapy, vinorelbine, capecitabine, metastatic breast cancer, 2255
- Oral dysplasia, basaloid squamous cell carcinoma, oral cancer, HPV types, oral papilloma, p16, 1605
- Oral dysplasia, HPV, oral carcinoma, p53, p16, 3435
- Oral dysplasia, imiquimod, treatment, 2891
- Oral metastasis, oral cancer, solid tumors, jaw metastasis, head and neck lymphoma, 1843
- Oral papilloma, basaloid squamous cell carcinoma, oral cancer, HPV types, oral dysplasia, p16, 1605
- Oral SCC, integrin,  $\alpha v \beta 6$ , Fyn kinase, EMT, serum, 2591
- Oral squamous cell carcinoma, multiple oral cancer, p53 mutation, leukoplakia, 4773
- Oral squamous cell carcinoma, oral squamous papilloma, p16, p21, p27, 2799
- Oral squamous cell carcinoma, OSCC, major histocompatibility complex class I chain-related gene B, MICB, natural killer group 2, member D, NKG2D, 4097
- Oral squamous papilloma, oral squamous cell carcinoma, p16, p21, p27, 2799
- Orally active, breast cancer, selective estrogen receptor down-regulator SERD, nonsteroidal, thiochroman derivative, 873
- Orbit, neurofibromatosis, neurofibromatosis type 1, plexiform neurofibroma, optic nerve, optic nerve glioma, skull deformity, orbital deformity, orbito-temporal neurofibromatosis, facial scoliosis, sphenoid wing dysplasia, 1751
- Orbital deformity, neurofibromatosis, neurofibromatosis type 1, orbit, plexiform neurofibroma, optic nerve, optic nerve glioma, skull deformity, orbito-temporal neurofibromatosis, facial scoliosis, sphenoid wing dysplasia, 1751
- Orbito-temporal neurofibromatosis, neurofibromatosis, neurofibromatosis type 1, orbit, plexiform neurofibroma, optic nerve, optic nerve glioma, skull deformity, orbital deformity, facial scoliosis, sphenoid wing dysplasia, 1751
- Organochlorine, environmental oestrogens, breast cancer, cosmetics, antiperspirant, deodorant, paraben, aluminium, phytoestrogen, breast cysts, review, 815
- Origin, gliomas, stem cells, *CD133*, markers, brain adjacent tissue, nestin, subventricular zone, review, 1977
- Oropharyngeal cancer, human papillomavirus, genotypes, oral cancer, head and neck cancer, 5099
- Oropharyngeal cancer, tumor marker, follow-up, Cyfra 21-1, squamous cell carcinoma, 2291
- Oropharyngeal cancer, vascular endothelial growth factor, oral cancer, 1765
- Orthopantomogram, numb chin syndrome, mental neuropathy, mandibular metastasis, inferior alveolar nerve, 1819
- Orthotopic implantation, esophageal carcinoma, carcinomatosis, *in vivo* fluorescence imaging, 3933
- Orthotopic model, FOLFIRI, colon cancer, tumor-growth metastasis, survival time, GFP imaging, 403
- OSCC, oral squamous cell carcinoma, major histocompatibility complex class I chain-related gene B, MICB, natural killer group 2, member D, NKG2D, 4097
- 3OST2*, early detection, bowel lavage, blood of main drainage vein, 4811
- Osteoclast, giant cell lesions, giant cell granuloma, epulis, cathepsin, RANK, matrix metalloproteinase, jaws, salivary glands, tendon sheath, 1645
- Osteoclast, mandibular bone destruction, TGF- $\beta$ , 2615
- Osteopontin, thyroid cancer, thyroid gland, OPN, CEACAM1, 1681
- Osteosarcoma, anti-CD25, regulatory T-cell Treg, 5019
- Osteosarcoma, bisphosphonate, radiation, combined effects, 2713
- Osteosarcoma, drug resistance, zoledronic acid, heat shock protein 27, 3565
- Outcome, head and neck cancer, re-irradiation, 3781
- Outcome, high-grade glioma, HGG, treatment, vincristine, 2303
- Outpatient setting, gastric cancer, S-1, cisplatin, 3759
- Ovarian cancer cell lines, drug combination, YH12, A2780, dose-effect curves, cell uptake, platinum-DNA binding, *trans*-platinum compounds, cisplatin, 4547
- Ovarian cancer, albendazole, peritoneal carcinomatosis, angiogenesis, vascular endothelial growth factor, 423
- Ovarian cancer, CCL2, chemosensitivity, invasion, 4791
- Ovarian cancer, cervical cancer, 25-hydroxylase, 1 $\alpha$ -hydroxylase, 24-hydroxylase, vitamin D, calcidiol, calcitriol, 4429
- Ovarian cancer, chemotherapy, paclitaxel, observational study, 4245
- Ovarian cancer, DEPTOR, mTOR, S6 kinase, paclitaxel resistance, 3529
- Ovarian cancer, docetaxel, carboplatin, chemotherapy resistance, array CGH, 4451
- Ovarian cancer, drug combination, synergism, cisplatin, oxaliplatin, transplatinum, paclitaxel, colchicine, 4025
- Ovarian cancer, E-cadherin, expression, prognosis, 2525
- Ovarian cancer, epigallocatechin-3-gallate, SKOV-3 cells, cell proliferation, apoptosis, 2519
- Ovarian cancer, gene, polymorphism, *ABCBI*, prognosis, 3487
- Ovarian cancer, glycodelin A, grading, FIGO staging, 1637
- Ovarian cancer, imatinib mesylate, paclitaxel, 3243
- Ovarian cancer, liposomal cisplatin, CA125, phase II, 541
- Ovarian cancer, maspin expression, survival, 2739
- Ovarian cancer, neoadjuvant chemotherapy, VEGF, granulosa cell tumor, bevacizumab, 4767
- Ovarian cancer, polycomb protein, BMI-1, breast cancer, endometrial cancer, cervical cancer, cancer stem cells, 1559

- Ovarian cancer, pseudomyxoma peritonei, borderline tumor, borderline type ovarian cancer, metastatic carcinoma, mucinous carcinoma, 2991
- Ovarian cancer, superoxide dismutase 1, cisplatin, drug resistance, mass spectrometry, selected-reaction-monitoring, siRNA, 2577
- Ovarian cancer, tumor cure probability, radiation sensitivity, radioimmunotherapy, astatine, 2545
- Ovarian cancer, tyrosine kinase inhibitor, mouse model, xenograft, luciferase, sunitinib, 3355
- Ovarian cancer, wound complications, bevacizumab, 4743
- Ovary, SISH, HER2, breast, colon, prostate, lung, 1287
- Overall survival, CA19-9, pancreatic cancer, 1869
- Overall survival, castration-resistant prostate cancer, tranilast, bone metastasis, 3077
- Overall survival, endometrial cancer, recurrence, disease-free interval, prognosis, 4347
- Oxaliplatin resistance, fractionated X-irradiation, cisplatin hypersensitivity, teratoma cell lines, 4471
- Oxaliplatin, advanced bladder carcinoma, gemcitabine, vinorelbine, 4711
- Oxaliplatin, capecitabine, drug–drug interaction, pharmacokinetics, 5207
- Oxaliplatin, carcinoma, pancreatitis, 5113
- Oxaliplatin, colorectal cancer, ERCC1, gene silencing, siRNA, resistance, 2531
- Oxaliplatin, colorectal cancer, irinotecan, sequence, 4325
- Oxaliplatin, colorectal cancer, liver metastases, irinotecan, doxifluridine, artery, 3045
- Oxaliplatin, drug combination, synergism, ovarian cancer, cisplatin, transplatinum, paclitaxel, colchicine, 4025
- Oxaliplatin, high-LET radiation, PARP, apoptosis, autophagy, hepatocellular carcinoma, 303
- Oxaliplatin, LA-12, cisplatin, colon cancer, cell cycle, apoptosis, 1183
- Oxaliplatin, peripheral neuropathy, colon cancer, pregabalin, gabapentin, 2927
- Oxaliplatin, WiDr colon cancer cells, growth factors, 5-fluorouracil, SN-38, glutathione modulation, buthionine-SR-sulfoximine, L-2-oxothiazolidine-4-carboxylate, 1223
- Oxidative stress, cancer, doxorubicin, MDR reversal, dihydropyridine derivative, antioxidant, 4063
- Oxidative stress, targeted therapy, VEGF, matrix metalloproteinase, reactive oxygen species, angiogenesis, bevacizumab, FINAVAST trial, 1001
- Oxygen consumption, brain tumours, clomipramine, amitriptyline, tricyclic antidepressants, dexamethasone, malignant glioma, 391
- Oxygen consumption, flax, *Linum usitatissimum*, phytoestrogens, MCF-7, cellular metabolism, online monitoring, acidification, adhesion, 1587
- Oxygen tension, anticancer complementary therapy, Artemisinin, chemotherapy, hyperbaric oxygen, leukemia cells, 4467
- P150, histochemistry, actin, tubulin, electron microscopy, eukaryotic translation initiation factor 3, colon cancer, 1047
- P16, basaloid squamous cell carcinoma, oral cancer, HPV types, oral papilloma, oral dysplasia, 1605
- P16, HNSCC, DNA content, DNA methylation, *DAPK*, *RASSF1A*, 4643
- P16, HPV, oral dysplasia, oral carcinoma, p53, 3435
- p16, oral squamous cell carcinoma, oral squamous papilloma, p21, p27, 2799
- P16, quantitative methylation-specific PCR, gastric cancer, 2701
- p21, oral squamous cell carcinoma, oral squamous papilloma, p16, p27, 2799
- P21, SN38, ilinotecan, topoisomerase inhibitor, apoptosis, *ATM*, p53, caspase-3, 3911
- P21CIP1/WAF1, HNSCC, EGFR, EGF, *BCL-xL*, 4579
- P21WAF1/CIP1, genistein, *BRCA1*, breast cancer, AKT, 2049
- p27, oral squamous cell carcinoma, oral squamous papilloma, p16, p21, 2799
- P27kip1, lung cancer, p53, Pirh2, prognosis, 3699
- P53 gene, Tie2, gene therapy, polyethylenimine, 1999
- p53 mutation, multiple oral cancer, leukoplakia, oral squamous cell carcinoma, 4773
- p53, 14-3-3 sigma, esophageal cancer, 5175
- P53, anticancer drug, growth inhibition, MDM2, XIAP, lung cancer, etoposide, 3321
- p53, Ewing's sarcoma, apoptosis, radiosensitivity, curcumin, 4007
- p53, high-LET, carbon ion, radiosensitivity, apoptosis, chemotherapeutic agent, 1961
- P53, HPV, oral dysplasia, oral carcinoma, p16, 3435
- P53, HT29, chemoresistance, translational regulation, real-time PCR, mRNA quantification, colorectal cancer cells, fluoropyrimidine analogs, thymidylate synthase, 5-FU resistance, 1149
- P53, hypoxia-inducible factor 1 alpha, vascular endothelial growth factor, colorectal carcinoma, 4163
- p53, intraductal papillary mucinous neoplasm, pancreas, claudin-18, Gli-1, 2995
- p53, lung cancer, chemotherapy, cisplatin, paclitaxel, chemosensitivity, 3557
- P53, lung cancer, Pirh2, p27<sup>kip1</sup>, prognosis, 3699
- p53, lymphoma, motexafin gadolinium, reactive oxygen species, apoptosis, 1131
- P53, methionine, prostate, breast, colon, 1881
- P53, SN38, ilinotecan, topoisomerase inhibitor, apoptosis, *ATM*, p21, caspase-3, 3911
- Paclitaxel resistance, ovarian cancer, DEPTOR, mTOR, S6 kinase, 3529

- Paclitaxel, chemotherapy, carboplatin, hematologic toxicity, age, non-small cell lung cancer, 1365
- Paclitaxel, dextran, folic acid, targeting, adsorption, 903
- Paclitaxel, drug combination, synergism, ovarian cancer, cisplatin, oxaliplatin, transplatinum, colchicine, 4025
- Paclitaxel, EGFR, thyroid tumors, erlotinib, cetuximab, panitumumab, 473
- Paclitaxel, HB-EGF, HER2, 5-FU, gastric cancer, 3143
- Paclitaxel, inflammatory breast cancer, trastuzumab, pathological complete response, epirubicin, 581
- Paclitaxel, magnetic nanoparticles, magnetic targeting, glioma, rats, 2217
- Paclitaxel, metastatic breast cancer, first-line therapy, bevacizumab, VEGF, 2969
- Paclitaxel, neoadjuvant chemotherapy, pCR, HER2, epirubicin, cyclophosphamide, trastuzumab, breast cancer, 4665
- Paclitaxel, non-small cell lung cancer, carboplatin, chemotherapy, interstitial lung disease, efficacy, safety, 4357
- Paclitaxel, NSCLC, adjuvant chemotherapy, carboplatin, gemcitabine, treatment compliance, surgical resection, 4695
- Paclitaxel, NSCLC, adjuvant chemotherapy, carboplatin, treatment compliance, surgical resection, 3039
- Paclitaxel, ovarian cancer, chemotherapy, observational study, 4245
- Paclitaxel, ovarian cancer, imatinib mesylate, 3243
- Paclitaxel, p53, lung cancer, chemotherapy, cisplatin, chemosensitivity, 3557
- PAkt, breast cancer, tumour glycolysis, M2PK, 1689
- P-Akt, immunohistochemistry, neuroendocrine tumors, 5063
- PAkt, transketolase-like-1 protein, TKTL1, cancer, aerobic glycolysis, endometrial cancer, glucose metabolism, GLUT1, 1653
- Palliation, metastatic human cancer, progesterone receptor antagonist, tumor microenvironment, mifepristone, 623
- Palliative care, cancer, energy metabolism, primary prevention, tertiary prevention, obesity, metabolic syndrome X, malnutrition, review, 1863
- Pancreas, intraductal papillary mucinous neoplasm, claudin-18, Gli-1, p53, 2995
- Pancreas, intraductal tubular carcinoma, intraductal tubular neoplasm, 4435
- Pancreatic cancer cells, combination therapy, apoptosis, gemcitabine, 2-methoxyestradiol, 4619
- Pancreatic cancer cells, recombinant AAV serotypes 1, 2, and 5, transduction efficiency, solid tumor, cancer gene therapy, colon carcinoma cells, 1931
- Pancreatic cancer, 1,25-dihydroxyvitamin D3 derivative, combination effect 5-amino-imidazole-4-carboxamide-1- $\beta$ -4-ribofuranoside, AICAR, inhibitor of Akt-phosphorylation, 1875
- Pancreatic cancer, Akt, apoptosis, 3279
- Pancreatic cancer, assessment of risk and mortality, venous thromboembolism, 4261
- Pancreatic cancer, CA19-9, overall survival, 1869
- Pancreatic cancer, docetaxel, gemcitabine, refractory, chemotherapy, metastatic disease, salvage therapy, 2905
- Pancreatic cancer, endothelial cells, neovascularization, angiogenesis, placental growth factor, 2911
- Pancreatic cancer, epigenetics, DNA methylation, chemotherapy, TMS1, 3919
- Pancreatic cancer, gemcitabine-resistant disease, irinotecan, XELIRI, FOLFIRI, 4785
- Pancreatic cancer, gene polymorphism, growth factors, EGF, TGF- $\beta$ 1, TNF- $\alpha$ , 5257
- Pancreatic cancer, glycolytic inhibitors, signaling, 743
- Pancreatic cancer, *K-ras*, blood, serum, plasma, colorectal cancer, diagnostic test, predictive test, review, 2943
- Pancreatic cancer, pancreatitis, pregnancy, cystic lesions, mucinous cystic neoplasms, mucinous cystoadenoma, estrogens, progesterone, 1025
- Pancreatic cancer, sansalvamide A, cell cycle arrest, 73
- Pancreatic cancer, sex differences, gemcitabine, indole-3-carbinol, 4907
- Pancreatic cancer, SPARC, prognosis, 867
- Pancreatic cancer, two-dimensional gel electrophoresis, 2-DE, LC-MS/MS, gemcitabine, GEM, proteomics, heat-shock protein 27, 2539
- Pancreatic cancer, two-dimensional gel electrophoresis, LC-MS/MS, gemcitabine, GEM, proteomics, 3367
- Pancreatic carcinoma cells, integrin  $\alpha$  $\beta$ 6, RNA interference, proliferation, invasion, cell cycle, apoptosis, chemosensitivity, 135
- Pancreatic carcinoma, syndecan-2, prognosis, 2749
- Pancreatic cell carcinoma, second-line treatment, prognostic and predictive factors, ERCC1, 4289
- Pancreatic ductal adenocarcinoma cells, apoptosis, presenilin 1, presenilin 2, cell cycle, G<sub>0</sub>/G<sub>1</sub>, chemoresistance,  $\gamma$ -secretase, taxanes, 4999
- Pancreatic ductal adenocarcinoma, carbohydrate antigen19-9, matrix metalloproteinase 9, MMP-9, tissue inhibitor of metalloproteinases 1, TIMP-1, receiver operating characteristic curves, ROC, 587
- Pancreatic neoplasms, placental growth factor, transforming growth factor-alpha, transforming growth factor-beta 1, tumour necrosis factor receptor 1, matrix metalloproteinase-2, inflammation, 3801
- Pancreatic neoplasms, radiotherapy, postoperative, chemotherapy, 2959
- Pancreatitis, carcinoma, oxaliplatin, 5113
- Pancreatitis, pregnancy, cystic lesions, mucinous cystic neoplasms, mucinous cystoadenoma, estrogens, progesterone, pancreatic cancer, 1025



- Panitumumab, EGFR, thyroid tumors, erlotinib, cetuximab, paclitaxel, 473
- Pantoea agglomerans*, IP-PA1, LPS, FITC-LPS, fluorescence label, 3151
- Papillary carcinoma, CD10, CD13, gp160, peptidases, renal tumour behaviour, 1137
- Papillary renal cell carcinoma, tubulocystic carcinoma, clear cell papillary renal cell carcinoma, oncocytoma, chromophobe renal carcinoma, 641
- Paraben, environmental oestrogens, breast cancer, cosmetics, antiperspirant, deodorant, aluminium, organochlorine, phytoestrogen, breast cysts, review, 815
- Paracrine treatment, cytokines, IL-12, *Schistosoma mansoni*, SWAP, systemic treatment, vaccination, poly-*N*-acetyl glucosamine gel matrix, 3889
- Paraganglioma, catecholamines, MIBG, pheochromocytoma, 5153
- Parathyroid hormone-related peptide, *MMP13*, PTHrP, MAPK, mitogen-activated protein kinase, ERK, extracellular signal-regulated kinase, PKC, protein kinase C, bone metastases, breast cancer, 5029
- Parathyroid hormone-related protein, PTHrP, VEGF, vascular endothelial growth factor, angiogenesis, bone resorption, MAPK, mitogen-activated protein kinase, 2755
- PARP, oxaliplatin, high-LET radiation, apoptosis, autophagy, hepatocellular carcinoma, 303
- Pathogenesis, urothelial carcinoma, B cells, Epstein-Barr virus, LMP-1, cell line, 3473
- Pathological complete response, inflammatory breast cancer, trastuzumab, paclitaxel, epirubicin, 581
- Pathological factors, vulvar carcinoma, surgical treatment, recurrence, thrombosis, 2311
- Patient age, gene polymorphism, breast cancer, CD44, tumor burden, SNP, 1263
- Patient selection, acute promyelocytic leukemia, older patients, 967
- Pattern of failure, non-small cell lung cancer, locally advanced, chemoradiation, 953
- Paxillin, cytoskeleton, phosphatase, PP-1, TGF- $\beta$ , motility, endothelial cells, 4861
- PC-3, androgen-independent prostate cancer, epidermal growth factor receptor, EGFR, cetuximab, C225, monoclonal antibody, Du145, 1905
- PCa, prostate cancer, benign prostatic hyperplasia, BPH, DD3<sup>PCA3</sup>, mRNA, RT-PCR, 665
- PCR, neoadjuvant chemotherapy, HER2, epirubicin, cyclophosphamide, paclitaxel, trastuzumab, breast cancer, 4665
- PCR-SSCP, gallbladder carcinoma, direct sequencing, TP53, transition mutations, cholecystitis, 4443
- PDGF-BB, fibroblast, MMP inhibition, angiogenesis, cytokine, imaging, skin cancer invasion, VEGF-A, 703
- PDGFRA, GIST, *KIT*, prognosis, 2407
- PDGFR $\alpha$ , DSRCT, Ewing sarcoma, imatinib, *KIT*, phase II, 547
- PEG-methioninase, methioninase, cancer, methionine dependence, efficacy, selectivity, 793
- PEG-methioninase, methioninase, rMETase, PEG-rMETase, cancer, methionine dependence, efficacy, selectivity, 1041
- PEG-rMETase, methioninase, rMETase, PEG-methioninase, cancer, methionine dependence, efficacy, selectivity, 1041
- Pegylated liposomal doxorubicin, breast cancer, chemotherapy, neoadjuvant, gemcitabine, docetaxel, phase II, locally advanced, 3817
- Pelvic floor rehabilitation, urinary incontinence, radical prostatectomy, kegel exercises, 553
- Pelvic lymph node dissection, biochemical relapse, lymph node metastasis, micrometastasis, prostate cancer, radical prostatectomy, 2297
- Pelvic nodes, cervical cancer, false-negative results, lymphadenectomy, PET-CT, [<sup>18</sup>F]Fluorodeoxyglucose, 1029
- Pemetrexed, eyelid edema, retrospective study, 5185
- Pemetrexed, TS, DHFR, GARFT, NSCLC, malignant pleural mesothelioma, 4309
- Penile carcinoma, lymph node metastases, micrometastases, non-sentinel lymph nodes, 467
- Pepsinogen, *Helicobacter pylori*, gastric cancer, adenosine deaminase, ADA, chronic atrophic gastritis, CAG, 2347
- Peptidases, CD10, CD13, gp160, renal tumour behaviour, papillary carcinoma, 1137
- Peptide analog, desmopressin, vasopressin, chemotherapy, metastasis, colon cancer, 5049
- Peptide array, hybridoma, monoclonal, KEPI, substitutional analysis, 1573
- Peptide sequence tag, LC-MS/MS, gastric carcinoma cells, 14-3-3 sigma protein, proteomic differential display, 4459
- Peptide vaccine, Wilms' tumor gene, *WT1*, helper T cell, helper peptide, cancer immunotherapy, 2247
- Perforator flap, breast reconstruction, deep inferior epigastric artery, venous, arterial, anastomosis, 1293
- Pericardial mesothelioma, mesothelioma, asbestos, inflammation, heart surgery, 1323
- Pericarditis carcinomatosa, endoscopy, malignant cardiac tamponade, malignant pericardial effusion, 4691
- Pericytes, cancer/testis antigens, mesenchymal stem cells, fibroblasts, *MAGED1*, *PRAME*, 5023
- Pericytes, glioma, stem cells, interferon-beta, stem cell niche, 3301
- Pericytes, vascular normalization, angiogenesis, radiotherapy, hypoxia, tumor microenvironment,  $\alpha$ -SQMG, 4397

- Perifosine, antiestrogens, AKT, EGF-R, endometrial cancer, everolimus, gefitinib, mTOR, tamoxifen, 2025
- Peripheral neuropathy, oxaliplatin, colon cancer, pregabalin, gabapentin, 2927
- Peritoneal carcinomatosis, albendazole, angiogenesis, ovarian cancer, vascular endothelial growth factor, 423
- Peritoneal cytology, endometrial cancer, hysteroscopy, tumor cell dissemination, sentinel node, 2425
- Peritoneal dissemination, gastric cancer, cytology, neoadjuvant chemotherapy, docetaxel, S-1, 1335
- Peroxide, colon cancer, Caco-2, flavonols, growth, differentiation, alkaline phosphatase, 3629
- Peroxiredoxin, calpains, cancer, rhabdomyosarcoma, 5085
- PET, GIST, gastrointestinal stromal tumour, distant metastasis, oral cavity, imatinib, 4283
- PET, serum tumour markers, FDG uptake, CT, diagnosis, lung cancer, 1741
- PET-CT, cervical cancer, false-negative results, lymphadenectomy, pelvic nodes, [<sup>18</sup>F]Fluorodeoxyglucose, 1029
- PGE<sub>2</sub>, breast cancer, cyclooxygenase-2, 15-hydroxyprostaglandin dehydrogenase, vitamin D receptor, prostaglandin receptor, calcidiol, 1673
- P-Glycoprotein, *Carpobrotus edulis*, *Aizoaceae*, efflux pump, multidrug resistance, 829
- P-glycoprotein, hydantoin, *ABCBI*, multidrug resistance, cancer, 4867
- P-glycoprotein, L1210 cells, multidrug resistance, concanavalin A, cell surface saccharides, 3661
- P-glycoprotein, lung cancer, drug resistance, down-regulation, 3593
- P-Glycoprotein, resveratrol, piceatannol, stilbenes, multidrug resistance, 4587
- P-glycoprotein, tyrosine kinase pathway, chemosensitivity sorafenib, multidrug resistance, hepatocellular carcinoma cells, 4503
- Phage-display, Tn antigen, GalNAc(α1-3)-Ser/Thr, single chain antibody, Fc fusion, antibody-dependent cellular cytotoxicity (ADCC), 3397
- Phagocytosis, lipid rafts, macrophage, polystyrene latex microspheres, methyl-β-cyclodextrin, scavenger receptors, 3167
- Pharmacokinetics, gemcitabine, metabolism, induction, nucleoside analogue, 3669
- Pharmacokinetics, busulfan, benzodiazepines, seizure prophylaxis, metabolism induction, phenytoin, 2977
- Pharmacokinetics, colorectal adenocarcinoma, microSPECT/CT imaging, nanoliposome, <sup>188</sup>Re, 65
- Pharmacokinetics, irinotecan, metabolism, cetuximab, biweekly infusion, colorectal cancer, 2355
- Pharmacokinetics, oxaliplatin, capecitabine, drug-drug interaction, 5207
- Pharmaco-kinetics, tamoxifen, 4-hydroxytamoxifen, silybinin, bioavailability, rats, 79
- Phase I, bortezomib, fixed-dose rate gemcitabine, solid tumors, 167
- Phase I, imatinib mesylate, capecitabine, advanced solid tumors, 1251
- Phase I, liposomal cisplatin, dose escalation, lipoplatin, 1317
- Phase II, breast cancer, chemotherapy, neoadjuvant, gemcitabine, pegylated liposomal doxorubicin, docetaxel, locally advanced, 3817
- Phase II, cervical intraepithelial neoplasia, dysplasia, progesterone, vaginal, 1257
- Phase II, DSRCT, Ewing sarcoma, imatinib, *KIT*, *PDGFRα*, 547
- Phase II, liposomal cisplatin, ovarian cancer, CA125, 541
- Phase II, non-small cell lung cancer, erlotinib, Tarceva, EGFR-TKIs, *EGFR* mutation, 557
- Phenazines, cancer chemoprevention, enzyme induction, RT-PCR, metabolism, aromathecins, 4873
- Phenethyl isothiocyanate, migration, invasion, human gastric cancer AGS cells, MAPK, NF-κB, 2135
- Phenolic compound, human erythrocyte, BCPCF, haemolysis, lignans, norlignans, multidrug resistance, MRP1/ABCC1, 4423
- Phenytoin, busulfan, pharmacokinetics, benzodiazepines, seizure prophylaxis, metabolism induction, 2977
- Pheochromocytoma, paraganglioma, catecholamines, MIBG, 5153
- Philadelphia chromosome, acute lymphoblastic leukemia, cytogenetics, fluorescent *in situ* hybridization, bcr-abl fusion gene, 569
- Philadelphia chromosome-positive acute lymphoblastic leukaemia, post-transplant imatinib administration, allogeneic stem cell transplantation, minimal residual disease, imatinib, 2415
- Phlogistic tissue, Sialyl Lewis a, CA19-9, larynx carcinoma, squamous cell carcinoma, 1849
- Phosphatase, cytoskeleton, paxillin, PP-1, TGF-β, motility, endothelial cells, 4861
- Phosphodiesterase 5, phosphodiesterase, human malignant melanoma, 355
- Phosphodiesterase, phosphodiesterase 5, human malignant melanoma, 355
- Phosphorylation inhibitor, biliary tract cancer, KGFR, keratinocyte growth factor receptor, 4115
- Photodynamic therapy, cholangiocarcinoma, photofrin, local ablation, apoptosis, 2113
- Photodynamic therapy, UVB, free radical, indole-3-acetic acid, apoptosis, prostate cancer cells, 4607
- Photofrin, cholangiocarcinoma, photodynamic therapy, local ablation, apoptosis, 2113
- Phototoxicity, melanoma, endothelial cells, blue light, 143

- Physiological stress, thymidine kinase 1, STK1, serum, surgery, 1295
- Phytoestrogen, environmental oestrogens, breast cancer, cosmetics, antiperspirant, deodorant, paraben, aluminium, organochlorine, breast cysts, review, 815
- Phytoestrogens, flax, *Linum usitatissimum*, MCF-7, cellular metabolism, online monitoring, acidification, oxygen consumption, adhesion, 1587
- PI-103, epidermal growth factor, rapamycin, mTOR complex 1, mTOR complex 2, negative feedback loop, sora fenib, Ras/Raf/MAPK, PI13/AKT/mTOR, 4951
- PI13/AKT/mTOR, epidermal growth factor, PI-103, rapamycin, mTOR complex 1, mTOR complex 2, negative feedback loop, sora fenib, Ras/Raf/MAPK, 4951
- PI3K, gastrointestinal stromal tumor, GIST, C-KIT gene, Ki-67 labeling index, ALT, 2705
- PI3K/Akt, colon cancer, COX-2, celecoxib, nitro-oxy derivative,  $\beta$ -catenin, 2659
- PI3K/Akt, leukaemia stem cells, CK2, synergism, targeted therapy, apoptosis, 4625
- Piceatannol, p-glycoprotein, resveratrol, stilbenes, multidrug resistance, 4587
- Pirh2, lung cancer, p53, p27<sup>kip1</sup>, prognosis, 3699
- Pituitary adenoma, EG-VEGF, hypophysis, immunohistochemistry, 3981
- Pituitary adenoma, estrogen receptor alpha, estrogen receptor beta, immunohistochemistry, pituitary, 2897
- Pituitary, estrogen receptor alpha, estrogen receptor beta, immunohistochemistry, pituitary adenoma, 2897
- PKC, *MMP13*, PTHrP, parathyroid hormone-related peptide, MAPK, mitogen-activated protein kinase, ERK, extracellular signal-regulated kinase, protein kinase C, bone metastases, breast cancer, 5029
- PKC, toxin Bc2, equinatoxin-II, cytolysins, signaling pathways, necrosis, MAPK/ERK, CaMKII, glioma cell death, 1209
- Placenta, vitamin D, cervical cancer, prostate cancer, potassium channels, EAG1, calcitriol, 2667
- Placental growth factor, pancreatic cancer, endothelial cells, neovascularization, angiogenesis, 2911
- Placental growth factor, transforming growth factor-alpha, transforming growth factor-beta 1, tumour necrosis factor receptor 1, matrix metalloproteinase-2, pancreatic neoplasms, inflammation, 3801
- Plant extract, AKT, GSK3beta, natural products, CDK inhibitor, 3599
- Plant extracts, neuroendocrine tumor, carcinoid, cell lines, bioactive agents, chemoresistance, apoptosis, 55
- Plasma DNA, HER2, trastuzumab, breast cancer, 2463
- Plasma, *K-ras*, blood, serum, colorectal cancer, pancreatic cancer, diagnostic test, predictive test, review, 2943
- Plasmacytoma, multiple myeloma, bortezomib, dexamethasone, 3791
- Plasmacytoma, extramedullary, multifocal, uncommon site, surgery, radiotherapy, chemotherapy, 1779
- Platelet count, cervical cancer, neoadjuvant chemotherapy, radical hysterectomy, lymph-vascular space involvement, lymph node involvement, 201
- Platinum, chemotherapy, hepatocellular carcinoma, S-1, 5245
- Platinum-DNA binding, drug combination, YH12, A2780, dose-effect curves, cell uptake, *trans*-platinum compounds, ovarian cancer cell lines, cisplatin, 4547
- Pleurodesis, primary effusion lymphoma, lymphoma therapy, body cavity lymphoma, 271
- Plexiform neurofibroma, neurofibromatosis, neurofibromatosis type 1, orbit, optic nerve, optic nerve glioma, skull deformity, orbital deformity, orbito-temporal neurofibromatosis, facial scoliosis, sphenoid wing dysplasia, 1751
- PLK1, biomarker, antitumor activity, TCTP, 4973
- Ploidies, sarcoma, Ewing's, prognosis, image cytometry, 3715
- Pneumonectomy, non-small cell lung cancer, stage III, chemoradiation, surgery, cisplatin, 4237
- Pneumothorax, anesthesia, HIF1 $\alpha$ , lung cancer, one-lung ventilation, BMI, obesity, 1143
- Point mutation, calponin h1, actin cytoskeleton stability, cell motility, S175T, HeLa cells, 1071
- Polyamines, anandamide, colorectal cancer, cell growth, 2583
- Polyamines, anthraquinones, danthron, quinizarin, transglutaminase, differentiation, melanoma cells, 445
- Polyamines, cell proliferation, colon cancer, ODC, polyphenols, quercetin, 3501
- Polycomb protein, BMI-1, breast cancer, ovarian cancer, endometrial cancer, cervical cancer, cancer stem cells, 1559
- Polyethylenimine, Tie2, gene therapy, p53 gene, 1999
- Polymeric microsphere, doxorubicin, drug delivery system, liposome, malignant glioma, thermoreversible gelation polymer, 1057
- Polymorphism, *ATM*, breast cancer, carcinogenesis, 5217
- Polymorphism, cadherin, insulin-like growth factor, leiomyoma, myeloperoxidase, urokinase, xeroderma pigmentosum, 2203
- Polymorphism, *Cox-2*, childhood leukemia, 3649
- Polymorphism, *Cox-2*, lung cancer, carcinogenesis, 1195
- Polymorphism, cyclin D1, colorectal cancer, risk, metastasis, 2875
- Polymorphism, DNA repair genes, gastric cancer, APE1, HOGG1, 1359
- Polymorphism, ovarian cancer, gene, *ABCBI*, prognosis, 3487
- Polymorphism, prostate cancer, methylenetetrahydrofolate reductase, and carcinogenesis, 3573

- Polymorphism, *RET*, lung cancer, haplotypes, Korean population, 3621
- Polymorphism, thymidylate synthase, protein level, breast cancer, 4373
- Polymorphism, *XRCC4*, colorectal cancer, carcinogenesis, 2727
- Polymorphisms, *HIF1A1*, colorectal cancer, prognosis, 2393
- Polymorphisms, metastatic colorectal cancer, gene expression level, clinical outcome, cetuximab, bevacizumab, irinotecan, 4209
- Poly-N-acetyl glucosamine gel matrix, cytokines, IL-12, paracrine treatment, *Schistosoma mansoni*, SWAP, systemic treatment, vaccination, 3889
- Polyphenols, cell proliferation, colon cancer, ODC, polyamines, quercetin, 3501
- Polyphenols, colon cancer, Caco-2, growth, differentiation, histone deacetylase inhibitors, 311
- Poly-phenylpropanoid polysaccharide complex, dendritic cells, U937 cells, differentiation, 613
- Polyposis, gastric, fundic gland, PPI, 261
- Polyps, fundic glands, lysozyme, *Helicobacter pylori*, 1021
- Polystyrene latex microspheres, lipid rafts, macrophage, phagocytosis, methyl- $\beta$ -cyclodextrin, scavenger receptors, 3167
- Ponticulus posterior, gorlin, NBCCS, calcification, atlanto-occipital ligament, 4265
- Pooled analysis, cisplatin, S-1, histological type, lung cancer, 2985
- Positron-emission tomography, mediastinal germ cell tumor, rhabdomyosarcoma, BEP chemotherapy, hepatic metastasis, 5117
- Postmenopausal, CA 15-3, CEA, breast cancer, relapse, tumour markers, elderly, 2331
- Post-menopause, alcohol, obesity, estrogen, breast cancer, 1
- Postoperative chemoradiation, cervical cancer, cisplatin, 2341
- Postoperative complications, prostate, biopsy, bleeding, ultrasound probe, 3071
- Postoperative recurrence, lung cancer, chemotherapy, survival analysis, 1311
- Postoperative, radiotherapy, pancreatic neoplasms, chemotherapy, 2959
- Postsurgical, combination therapy, inflammation, micrometastases, CEA, lung carcinoma, lymphokine-activated killer cell therapy, glucocorticoid, 3125
- Post-transplant imatinib administration, philadelphia chromosome-positive acute lymphoblastic leukaemia, allogeneic stem cell transplantation, minimal residual disease, imatinib, 2415
- Post-transplant lymphoproliferative disorders, chemotherapy, liver transplantation, 2383
- Potassium channels, vitamin D, cervical cancer, prostate cancer, placenta, EAG1, calcitriol, 2667
- PP-1, cytoskeleton, paxillin, phosphatase, TGF- $\beta$ , motility, endothelial cells, 4861
- PPAR $\gamma$  ligand, TWEAK, apoptosis, reactive oxygen species, colon cancer, 157
- PPI, gastric, fundic gland, polyposis, 261
- PR, *BAG-1*, ER, apoptosis, endometrial carcinoma, real-time PCR, immunohistochemistry, 4103
- PR, MCF7, flax roots, flax leaves, progesterone, ER, 1695
- PRAME, cancer/testis antigens, mesenchymal stem cells, pericytes, fibroblasts, MAGED1, 5023
- Precancerous conditions, cervical intraepithelial neoplasia, cervical cancer, reproducibility, spontaneous neoplasm regression, female genital tract disease, 2319
- Precision-cut tissue slices, colon cancer, liver metastases, COX-2, 2017
- Prediction of therapy response, triple negative, pre-operative therapy, dose-dense epirubicin, cyclophosphamide, docetaxel, breast cancer, 4251
- Predictive factors, colorectal tumor, preoperative chemotherapy, PyNPase, 5'-deoxy-5-fluorouridine, 3207
- Predictive test, *K-ras*, blood, serum, plasma, colorectal cancer, pancreatic cancer, diagnostic test, review, 2943
- Pregabalin, oxaliplatin, peripheral neuropathy, colon cancer, gabapentin, 2927
- Pregnancy, pancreatitis, cystic lesions, mucinous cystic neoplasms, mucinous cystoadenoma, estrogens, progesterone, pancreatic cancer, 1025
- Preoperative chemotherapy, colorectal tumor, PyNPase, predictive factors, 5'-deoxy-5-fluorouridine, 3207
- Preoperative hyperthermo-chemoradiotherapy, LAT1, rectal cancer, tumour response, 4223
- Pre-operative therapy, triple negative, prediction of therapy response, dose-dense epirubicin, cyclophosphamide, docetaxel, breast cancer, 4251
- Presenilin 1, apoptosis, presenilin 2, cell cycle, G<sub>0</sub>/G<sub>1</sub>, chemoresistance,  $\gamma$ -secretase, pancreatic ductal adenocarcinoma cells, taxanes, 4999
- Presenilin 2, apoptosis, presenilin 1, cell cycle, G<sub>0</sub>/G<sub>1</sub>, chemoresistance,  $\gamma$ -secretase, pancreatic ductal adenocarcinoma cells, taxanes, 4999
- Pretreated, trastuzumab, metastatic breast cancer, combination, 3051
- Pretreatment, bamboo leaf extract, anticarcinogenesis effect, breast cancer, cancer prevention, tumor growth suppression, 111
- Prevalence, human anti-mouse antibody, HAMA, colorectal cancer, monoclonal antibody therapeutics, adverse events, 4353
- PRI, proliferation rate index, azasteroids, experimental chemotherapy, human lymphocytes, Lewis lung carcinoma, LLC, sister chromatid exchange, SCE, 4201

- Primary effusion lymphoma, lymphoma therapy, pleurodesis, body cavity lymphoma, 271
- Primary leiomyosarcoma of the testis, diagnosis, therapy, prognosis, 1725
- Primary prevention, cancer, energy metabolism, tertiary prevention, obesity, metabolic syndrome X, malnutrition, palliative care, review, 1863
- Principal caregiver, cancer patients, caregiver distress, quality of life, 4657
- Progesterone receptor antagonist, metastatic human cancer, palliation, tumor microenvironment, mifepristone, 623
- Progesterone receptor antagonist, murine lung cancer, mifepristone, tumor microenvironment, natural killer cells, lung cancer, 119
- Progesterone receptor antagonists, mifepristone, murine prostate cancer, testicular cancer, 4921
- Progesterone receptor, oestrogen receptor, MIB-1, CEA, CA15-3, breast cancer, 4701
- Progesterone receptors, oestrogen receptors, adenocarcinoma, uterine cervix, 1341
- Progesterone, cervical intraepithelial neoplasia, cervical squamous epithelium, estradiol, biological markers, 1217
- Progesterone, cervical intraepithelial neoplasia, dysplasia, vaginal, phase II, 1257
- Progesterone, MCF7, flax roots, flax leaves, ER, PR, 1695
- Progesterone, pancreatitis, pregnancy, cystic lesions, mucinous cystic neoplasms, mucinous cystadenoma, estrogens, pancreatic cancer, 1025
- Progestins, antiprogestins, cytotoxic, breast cancer cells, non-genomic effects, mifepristone, apoptosis, cell cycle, 4835
- Prognosis, cancer-specific survival, tumour characteristics, 5227
- Prognosis, carbonic anhydrase IX, renal cell carcinoma, 2953
- Prognosis, clear cell carcinoma, surgery, radiotherapy, chemotherapy, recurrence, review, 1327
- Prognosis, DJ-1, astrocytoma, immunohistochemistry, WHO grading, 265
- Prognosis, E-cadherin, dysadherin, cytokeratin recurrence, NSCLC, 3273
- Prognosis, E-cadherin, ovarian cancer, expression, 2525
- Prognosis, EGFR gene copy number, EGFR TKIs treatment, chemotherapy, *KRAS*, 5121
- Prognosis, endometrial cancer, recurrence, disease-free interval, overall survival, 4347
- Prognosis, endometrial hyperpasia, 4649
- Prognosis, gastric cancer, stem cell, *CD133*, 2453
- Prognosis, GIST, *KIT*, PDGFRA, 2407
- Prognosis, *HIF1A1*, colorectal cancer, polymorphisms, 2393
- Prognosis, IL-6, VEGF, NSE, ProGR, lung cancer, 1773
- Prognosis, intrahepatic cholangiocarcinoma, vimentin, surgical resection, 2279
- Prognosis, KITENIN, stomach neoplasm, tumor invasion, tumor metastasis, 3479
- Prognosis, lung cancer, p53, Pirh2, p27<sup>kip1</sup>, 3699
- Prognosis, lung, neoplasia, *KISS1*, MMP-9, non-small cell lung cancer, NSCLC, metastasis, 713
- Prognosis, melanoma, Sentinel node, serum S100, LDH, metastasis, 1799
- Prognosis, non-small cell lung cancer, cytokeratin, tumour marker, CYFRA21-1, survival, 3833
- Prognosis, nuclear morphometry, breast cancer, treatment response, 2185
- Prognosis, ovarian cancer, gene, polymorphism, *ABCBI*, 3487
- Prognosis, primary leiomyosarcoma of the testis, diagnosis, therapy, 1725
- Prognosis, renal cell carcinoma, sialyl Lewis X, 593
- Prognosis, sarcoma, Ewing's, ploidy, image cytometry, 3715
- Prognosis, SPARC, pancreatic cancer, 867
- Prognosis, syndecan-2, pancreatic carcinoma, 2749
- Prognosis, telomerase, human telomerase reverse transcriptase, malignant fibrous histiocytomas, bone, 4959
- Prognosis, tumor marker, PSA, kinetics, prostate cancer, 1633
- Prognosis, urinary FISH test, UroVysion assay, recurrence, bladder cancer, 4761
- Prognosis, vimentin, gastric carcinoma cells, scirrhous type, lymph node metastasis, 5239
- Prognosis,  $\beta$ -catenin, MUC1, c-Met, immunohistology, gastric cancer, 4635
- Prognostic and predictive factors, pancreatic cell carcinoma, second-line treatment, ERCC1, 4289
- Prognostic factor, breast cancer, metastasis, WFDC2, HE4, 4779
- Prognostic factor, chemotherapy, cancer, colorectal cancer treatment, microsatellite instability, FOLFOX, adjuvant treatment, 4297
- Prognostic factor, gastric cancer, hepatic resection, liver metastasis, 2367
- Prognostic factor, head and neck cancer, EGFR, chemoradiotherapy, treatment, 671
- Prognostic factor, TIMP-1, colorectal cancer, 4127
- Prognostic factors, colorectal cancer, chemotherapy, survival, 653
- Prognostic factors, oesophageal cancer, lymph node metastasis, N0, 3063
- Prognostic factors, Wilms' tumor, chemotherapy, 1735
- Prognostic index, MALT lymphoma, IPI, FLIPI, 635
- Prognostic score, brain metastases, radiotherapy, albumin, lactate dehydrogenase, 977

- Prognosis, clear cell renal carcinoma, karyotype analysis, chromosome alterations, 4705
- ProGR, IL-6, VEGF, NSE, prognosis, lung cancer, 1773
- Programmed cell death, acyclic nucleoside phosphonate, CCRF-CEM cells, cell cycle, caspases, cD95/Fas, 2791
- Programmed cell death, radiation, TNF- $\alpha$ , cell lines, sarcoma cell lines, lymphoma cell lines, 2857
- Progression, inflammation-associated carcinogenesis, fibrosarcoma, nuclear protein, proteomic analysis, 2093
- Progression, prostate cancer, TP53, mutation, tumor suppressor-gene, 1579
- Progression-free survival, VEGF, monoclonal antibody, radiological response, bevacizumab, malignant glioma, 609
- Proliferation rate index, PRI, azasteroids, experimental chemotherapy, human lymphocytes, Lewis lung carcinoma, LLC, sister chromatid exchange, SCE, 4201
- Proliferation, breast cancer,  $\alpha$ -difluoromethylornithine, DFMO, biomarker, apoptosis, invasion, 2263
- Proliferation, fine-needle aspiration, BRAF, melanoma, metastatic melanoma, 3267
- Proliferation, functional proteomics, cancer, NAPPA microarrays, review, nanotechnology, 2073
- Proliferation, inhibin A, chemotherapy, breast cancer, 4563
- Proliferation, integrin  $\alpha\text{v}\beta\text{6}$ , RNA interference, invasion, cell cycle, apoptosis, chemosensitivity, pancreatic carcinoma cells, 135
- Proliferation, mTOR, rapamycin, FOXO1, 799
- Promoter hypermethylation, breast cancer, genomic methylation, tumor suppressor genes, repetitive elements, WBC DNA, 2489
- Promoter methylation, adenosine analogue, epigenetic, clofarabine, *PTEN*, *APC*, *RARB2*, *ZAP70*, 4601
- Promoter methylation, AKAP12 $\alpha$ , lung neoplasms, NSCLC, 4595
- Promoter polymorphism, E-cadherin, methylation, *KIT*, *CDH1*, gastric cancer, 2225
- Prostaglandin receptor, breast cancer, cyclooxygenase-2, 15-hydroxyprostaglandin dehydrogenase, vitamin D receptor, calcidiol, PGE<sub>2</sub>, 1673
- Prostasomes, metastasis, exosomes, annexin, proteomics, prostate cancer, 285
- Prostate cancer cells, UVB, free radical, photodynamic therapy, indole-3-acetic acid, apoptosis, 4607
- Prostate cancer prophylaxis, noscapine, tumour inhibition, 399
- Prostate cancer, active surveillance, watchful waiting, review, 3683
- Prostate cancer, biochemical relapse, lymph node metastasis, micrometastasis, pelvic lymph node dissection, radical prostatectomy, 2297
- Prostate cancer, bioluminescent imaging, bombesin (BN)-like peptides, gastrin-releasing peptide receptors, 4039
- Prostate cancer, cancer cell, liver X receptor, T0901317, 22(R)-hydroxycholesterol, 3643
- Prostate cancer, cancer/testis antigens, SEREX, yeast, cancer vaccine, 895
- Prostate cancer, cereals, cholesterol, diet, gross domestic product, milk protein, ultraviolet-B, vitamin D, 189
- Prostate cancer, chemohormonal therapy, etoposide, ethinylestradiol, oral chemotherapy, HRPC, 3737
- Prostate cancer, external beam radiation therapy, PSA-doubling time, carbon radiotherapy, 5105
- Prostate cancer, FDG-PET, uptake, glycolysis, fatty acid, bioenergetic metabolism, 369
- Prostate cancer, human tissue kallikrein 7, morphological change, vimentin, invasion, metastasis, 3413
- Prostate cancer, metastasis, prostasomes, exosomes, annexin, proteomics, 285
- Prostate cancer, methylenetetrahydrofolate reductase, polymorphism, and carcinogenesis, 3573
- Prostate cancer, metronomic chemotherapy, cyclophosphamide, docetaxel, 4317
- Prostate cancer, miRNA, miR-20a, let-7a, miR-15a, miR-16, 3579
- Prostate cancer, needle biopsy, radical prostatectomy, cathepsin B, stefin A, MIB-1, DNA ploidy, 719
- Prostate cancer, nexrutine<sup>R</sup>, tumor invasion, BMD, CREB, NF- $\kappa$ B, TRAMP, 857
- Prostate cancer, PCa, benign prostatic hyperplasia, BPH, DD3<sup>PCA3</sup>, mRNA, RT-PCR, 665
- Prostate cancer, progression, TP53, mutation, tumor suppressor-gene, 1579
- Prostate cancer, PSMA, scFv, immunotoxins, Pseudomonas exotoxin A, 3373
- Prostate cancer, testicular metastasis, isolated recurrence, prostatectomy, 1747
- Prostate cancer, TRAMP, MHC I, HLA-A2, immune rejection, 409
- Prostate cancer, TSC1, TSC2, androgen deprivation therapy, testosterone, 3895
- Prostate cancer, tumor marker, PSA, kinetics, prognosis, 1633
- Prostate cancer, vitamin D, cervical cancer, potassium channels, placenta, EAG1, calcitriol, 2667
- Prostate cancer, xanthohumol, apoptosis, prosurvival signaling proteins, 3333
- Prostate, biopsy, postoperative complications, bleeding, ultrasound probe, 3071
- Prostate, methionine, breast, colon, p53, 1881
- Prostate, SISH, HER2, breast, colon, lung, ovary, 1287
- Prostatectomy, testicular metastasis, isolated recurrence, prostate cancer, 1747

- Prostate-specific antigen, castration-resistant prostate cancer, ethinylestradiol, 5201
- Prostatic cancer, IL-6, tumor marker, 4369
- Prostatic neoplasm, biopsy, image processing, radical prostatectomy, 1823
- Prosurvival signaling proteins, xanthohumol, prostate cancer, apoptosis, 3333
- Proteasome inhibitor, MG132, apoptosis, endothelial cells, caspase, ROS, GSH, 879
- Protein kinase C, Go6976, retinoblastoma, bladder, carcinoma, 3995
- Protein kinase C, *MMP13*, PTHrP, parathyroid hormone-related peptide, MAPK, mitogen-activated protein kinase, ERK, extracellular signal-regulated kinase, PKC, bone metastases, breast cancer, 5029
- Protein level, thymidylate synthase, polymorphism, breast cancer, 4373
- Protein transduction domain, antitumor, apoptosis, cell-penetrating peptide, gene therapy, tumor necrosis factor-related apoptosis-inducing ligand, TRAIL, arginine-rich peptides, 2193
- Proteomic analysis, MALDI/MS, in-gel digestion, integral membrane proteins, membrane associated proteins, 1121
- Proteomic analysis, progression, inflammation-associated carcinogenesis, fibrosarcoma, nuclear protein, 2093
- Proteomic analysis, two-dimensional gel electrophoresis, LC-MS/MS, Flamingo Gel Stain, SeePico, highly sensitive Coomassie brilliant blue, 4001
- Proteomic differential display, LC-MS/MS, peptide sequence tag, gastric carcinoma cells, 14-3-3 sigma protein, 4459
- Proteomics, E7 oncogene, melphalan, Tg mouse, cancer, 2773
- Proteomics, metastasis, prostasomes, exosomes, annexin, prostate cancer, 285
- Proteomics, two-dimensional gel electrophoresis, 2-DE, LC-MS/MS, pancreatic cancer, gemcitabine, GEM, heat-shock protein 27, 2539
- Proteomics, two-dimensional gel electrophoresis, LC-MS/MS, pancreatic cancer, gemcitabine, GEM, 3367
- Proton pump inhibitor, methotrexate, BCRP, ABCG2, drug–drug interaction, 3807
- Proton pump inhibitor, methotrexate, drug–drug interaction, glucarpidase, 963
- PSA, tumor marker, kinetics, prostate cancer, prognosis, 1633
- PSA-doubling time, external beam radiation therapy, carbon radiotherapy, prostate cancer, 5105
- Pseudomonas* exotoxin A, prostate cancer, PSMA, scFv, immunotoxins, 3373
- Pseudomyxoma peritonei*, ovarian cancer, borderline tumor, borderline type ovarian cancer, metastatic carcinoma, mucinous carcinoma, 2991
- PSK, rectal cancer, chemoradiotherapy, S-1, immune response, 993
- PSMA, prostate cancer, scFv, immunotoxins, *Pseudomonas* exotoxin A, 3373
- P-Src (pY416), esophageal cancer, invasiveness, transwell invasion chamber, MMP-1, matrix metalloproteinase-1, vimentin, TIMP-2, tissue inhibitor of metalloproteinase-2, 727
- PTEN, adenosine analogue, epigenetic, promoter methylation, clofarabine, *APC*, *RARB2*, *ZAP70*, 4601
- PTEN, mutation, glioma, 981
- PTHrP, *MMP13*, parathyroid hormone-related peptide, MAPK, mitogen-activated protein kinase, ERK, extracellular signal-regulated kinase, PKC, protein kinase C, bone metastases, breast cancer, 5029
- PTHrP, parathyroid hormone-related protein, VEGF, vascular endothelial growth factor, angiogenesis, bone resorption, MAPK, mitogen-activated protein kinase, 2755
- PTK/ZK, angiogenesis, DCE-MRI, MTD, VEGF, 2335
- PTPG, breast cancer, tumor suppressor, cell cycle regulators, 1937
- Pulmonary complications, hepatocellular carcinoma, hepatectomy, Glasgow prognostic score, transfusion, 5129
- Pulmonary inhalation, lipopolysaccharide, lung cancer, alveolar macrophage, Lewis lung carcinoma-bearing mice, cyclophosphamide, 3129
- Pulmonary inhalation, lipopolysaccharide, lung cancer, alveolar macrophage, nitric oxide, cell-to-cell contact, 3135
- Pulmonary surfactant, *KRAS* mutation, CC10, intratracheal instillation, lung cancer, gene transfer, 4925
- PyNPase, colorectal tumor, preoperative chemotherapy, predictive factors, 5'-deoxy-5-fluorouridine, 3207
- Pyrosequence, gap junctional intercellular communication GJIC, connexin43, E-cadherin,  $\beta$ -catenin, ZO-1, immunohistochemistry, CpG island, methylation analysis, lung cancer, 2271
- QPCR, colorectal carcinoma, *KRAS*, *BRAF*, mutations, FFPE, ThinPrep, 1969
- QSAR, trihaloacetylazulenes, cytotoxicity, semiempirical molecular–orbital method, 837
- QSAR, tropolones, cytotoxicity, semiempirical molecular–orbital method, 129
- Quackery, evidence-based medicine, complementary medicine, quality of life, review, 1767
- Quality of life, cancer patients, caregiver distress, principal caregiver, 4657
- Quality of life, evidence-based medicine, complementary medicine, quackery, review, 1767
- Quantitative methylation-specific PCR, *CD133*, gastric cancer, 1201

- Quantitative methylation-specific PCR, *DCC*, gastric cancer, 107
- Quantitative methylation-specific PCR, p16, gastric cancer, 2701
- Quantitative methylation-specific PCR, *TFPI2*, colorectal cancer, 1205
- Quantitative methylation-specific PCR, *TFPI2*, gastric cancer, 4131
- Quantitative methylation-specific PCR, *VIM*, colorectal carcinoma, 5015
- Quantitative real-time PCR, MACC 1, gastric carcinoma, 3441
- Quantitative real-time PCR, MACC1, colorectal carcinoma, 2689
- Quercetin, cell proliferation, colon cancer, ODC, polyamines, polyphenols, 3501
- Quinizarin, anthraquinones, danthron, polyamines, transglutaminase, differentiation, melanoma cells, 445
- Quinolines, breast cancer, anti-cancer drugs, gap junctions, 6-methoxy-8-[(2-furanylmethyl)amino]-4-methyl-5-(3-trifluoromethyl phenyloxy)quinoline, *in vivo* activity, 3927
- Quinolone, CHM-1, DNA damage, DNA repair, gene expression, U-2 OS human osteogenic sarcoma cells, 4187
- Quinone reductase NQO2, breast cancer, MCF-7 cells,  $\gamma$ -tocotrienol, cell cycle, retinoblastoma, cyclin D1, 2869
- Rab7, Hrs, ExoC5, RT-PCR, E-cadherin, fragments, breast cancer, 3903
- Radiation damage, LB protein nanocrystals, AFM, laser, X-ray microdiffraction, 2745
- Radiation sensitivity, tumor cure probability, ovarian cancer, radioimmunotherapy, astatine, 2545
- Radiation therapy, liver metastasis, bone metastasis, hepatectomy, colon cancer, 677
- Radiation, camptothecin derivative, apoptosis, DNA damage and repair,  $\gamma$ -H2AX, M-phase cell, 937
- Radiation, children, side-effects, late sequelae, abdomen, 227
- Radiation, epidermal growth factor receptor, drug sensitivity, gefitinib, 4899
- Radiation, osteosarcoma, bisphosphonate, combined effects, 2713
- Radiation, small-cell lung cancer, oblimersen, BCL-2, 3869
- Radiation, TNF-alpha, programmed cell death, cell lines, sarcoma cell lines, lymphoma cell lines, 2857
- Radical cystectomy, lymphovascular invasion, transitional cell carcinoma, 2973
- Radical hysterectomy, cervical cancer, chemoradiotherapy, brachytherapy, neoadjuvant chemotherapy, 3731
- Radical hysterectomy, cervical cancer, neoadjuvant chemotherapy, lymph-vascular space involvement, lymph node involvement, platelet count, 201
- Radical prostatectomy, biochemical relapse, lymph node metastasis, micrometastasis, pelvic lymph node dissection, prostate cancer, 2297
- Radical prostatectomy, biopsy, image processing, prostatic neoplasm, 1823
- Radical prostatectomy, needle biopsy, cathepsin B, stefin A, MIB-1, DNA ploidy, prostate cancer, 719
- Radical prostatectomy, urinary incontinence, pelvic floor rehabilitation, kegel exercises, 553
- Radiofrequency ablation, breast cancer, breast conserving surgery, 3693
- Radioimmunotherapy, tumor cure probability, radiation sensitivity, ovarian cancer, astatine, 2545
- Radiological response, VEGF, monoclonal antibody, progression-free survival, bevacizumab, malignant glioma, 609
- Radiolucent zone, giant cell tumor, knee joint, bone cement, recurrence, 3795
- Radiosensitivity, Ewing's sarcoma, apoptosis, p53, curcumin, 4007
- Radiosensitivity, high-LET, carbon ion, p53, apoptosis, chemotherapeutic agent, 1961
- Radiotherapy, brain metastases, prognostic score, albumin, lactate dehydrogenase, 977
- Radiotherapy, breast cancer, hypofractionation, concomitant boost, 4749
- Radiotherapy, chemoradiosensitizers, novel agents, chemotherapy, new radiosensitizing drugs, review, 3675
- Radiotherapy, clear cell carcinoma, surgery, chemotherapy, prognosis, recurrence, review, 1327
- Radiotherapy, extramedullary, plasmocytoma, multifocal, uncommon site, surgery, chemotherapy, 1779
- Radiotherapy, IL-2, high-dose chemotherapy, NK cells, 5-fluorouracil, epirubicin, cyclophosphamide, methotrexate, etoposide, carboplatin, VEGF, retinoic acid, myeloablative chemotherapy, autologous transplantation, immunotherapy, breast cancer, 209
- Radiotherapy, multiple brain metastases, stereotactic radiosurgery, survival, whole brain radiotherapy, non-small cell lung cancer, 3055
- Radiotherapy, postoperative, pancreatic neoplasms, chemotherapy, 2959
- Radiotherapy, selenium substitution, solid tumours, head and neck cancer, gynaecological cancer, 1783
- Radiotherapy, selenium, randomised trial, head and neck cancer, 1829
- Radiotherapy, urothelial cancer, heme oxygenase-1, drug resistance, chemotherapy, gemcitabine, 2145
- Radiotherapy, vascular normalization, pericytes, angiogenesis, hypoxia, tumor microenvironment,  $\alpha$ -SQMG, 4397



- Radiotherapy, vocal cord cancer, chemotherapy, glottic cancer, 5181
- RAGE, canine lymphoma, HMGB1, 5043
- Randomised trial, radiotherapy, selenium, head and neck cancer, 1829
- RANK, giant cell lesions, giant cell granuloma, epulis, cathepsin, matrix metalloproteinase, jaws, osteoclast, salivary glands, tendon sheath, 1645
- Rapamycin, breast cancer, signal pathway, mTOR, TS, ROS, 5-FU, 2625
- Rapamycin, epidermal growth factor, PI-103, mTOR complex 1, mTOR complex 2, negative feedback loop, sora fenib, Ras/Raf/MAPK, PI13/AKT/mTOR, 4951
- Rapamycin, mTOR, celecoxib, COX 2, angiosarcoma, endothelial tumour, 4017
- Rapamycin, mTOR, FOXO1, proliferation, 799
- RARB2*, adenosine analogue, epigenetic, promoter methylation, clofarabine, *PTEN*, *APC*, *ZAP70*, 4601
- RAS protein farnesylation, farnesyl diphosphate analogues, breast cancer, lung cancer, isoprenoids, 2505
- Ras, HMG CoA reductase, mevalonate, tocotrienol, statin, Cdk4, caspase-3, cell cycle, apoptosis, 4937
- RAS, mutation, soft tissue sarcoma, Japan, 245
- Ras/Raf/MAPK, epidermal growth factor, PI-103, rapamycin, mTOR complex 1, mTOR complex 2, negative feedback loop, sora fenib, PI13/AKT/mTOR, 4951
- RASSF1, carcinoma, carcinoid, small cell carcinoma, large cell neuroendocrine carcinoma, methylation, immunofluorescence, survival, 4269
- RASSF1A*, HNSCC, DNA content, DNA methylation, p16, *DAPK*, 4643
- Rat tracheal epithelial cells, nuclear density, morphometry, chemopreventive agents, 737
- Rats, paclitaxel, magnetic nanoparticles, magnetic targeting, glioma, 2217
- Rats, tamoxifen, 4-hydroxytamoxifen, silybinin, pharmacokinetics, bioavailability, 79
- RB, DNA repair, UV-radiation, cisplatin, nucleotide excision repair, XPC, 2483
- <sup>188</sup>Re, colorectal adenocarcinoma, microSPECT/CT imaging, nanoliposome, pharmacokinetics, 65
- Reactive oxygen species, intercellular signaling, apoptosis, salen-manganese complex, 3967
- Reactive oxygen species, lymphoma, motexafin gadolinium, p53, apoptosis, 1131
- Reactive oxygen species, sulforaphane, apoptosis, colon cancer, 3611
- Reactive oxygen species, targeted therapy, VEGF, matrix metalloproteinase, oxidative stress, angiogenesis, bevacizumab, FINAVAST trial, 1001
- Reactive oxygen species, TWEAK, PPAR $\gamma$  ligand, apoptosis, colon cancer, 157
- Reactive oxygen, ultrasound, cell damage, lipid peroxidation, sonodynamic activation, DCPH-P-Na(I), 2241
- Real-time PCR, *BAG-1*, ER, PR, apoptosis, endometrial carcinoma, immunohistochemistry, 4103
- Real-time PCR, HT29, chemoresistance, translational regulation, mRNA quantification, colorectal cancer cells, fluoropyrimidine analogs, thymidylate synthase, p53, 5-FU resistance, 1149
- Real-time PCR, oestrogen receptor, breast cancer, 4147
- Real-time PCR, small molecules, gene expression analysis, thymidylate synthase, chemoresistance, arsenic trioxide, 5-FU resistance, 1157
- Receiver operating characteristic curve, tumour marker, diagnosis, cytokeratin 19, CEA, mesothelioma, 4343
- Receiver operating characteristic curves, ROC, pancreatic ductal adenocarcinoma, carbohydrate antigen19-9, matrix metalloproteinase 9, MMP-9, tissue inhibitor of metalloproteinases 1, TIMP-1, 587
- Recombinant AAV serotypes 1, 2, and 5, transduction efficiency, solid tumor, cancer gene therapy, pancreatic cancer cells, colon carcinoma cells, 1931
- Rectal cancer, biomarkers, CEA, TIMP-1, chemoradiation, 4755
- Rectal cancer, chemoradiotherapy, S-1, PSK, immune response, 993
- Rectal cancer, LAT1, preoperative hyperthermo-chemoradiotherapy, tumour response, 4223
- Recurrence, clear cell carcinoma, surgery, radiotherapy, chemotherapy, prognosis, review, 1327
- Recurrence, endometrial cancer, disease-free interval, prognosis, overall survival, 4347
- Recurrence, giant cell tumor, knee joint, bone cement, radiolucent zone, 3795
- Recurrence, HCC, angiogram, MGN-3, 5145
- Recurrence, lung cancer, FDG imaging, follow-up, survival, early detection, 3811
- Recurrence, prognosis, urinary FISH test, UroVysion assay, bladder cancer, 4761
- Recurrence, vulvar carcinoma, pathological factors, surgical treatment, thrombosis, 2311
- Recurrence-free follow-up, breast cancer, isolated tumour cells, minimal residual disease, zoledronate treatment, 1807
- Redox activity, thyroid gland neoplasm, thioredoxin, thioredoxin reductase, cellular proliferation, 767
- Redox regulation, gamma-glutamyltransferase, human neoplasia, tumor progression, drug resistance, review, 1169
- Refractory, pancreatic cancer, docetaxel, gemcitabine, chemotherapy, metastatic disease, salvage therapy, 2905
- Regulatory T-cell Treg, anti-CD25, osteosarcoma, 5019

- Regulatory T-cells, exosome, TGF- $\beta$ 1, malignant effusion, 3747
- Regulatory T-cells, FOXP3, Treg-cells, gastric cancer, review, 1093
- Regulatory T-cells, myeloid derived suppressor cells, macrophages, B16 melanoma, docetaxel, temozolomide, interleukin-1 receptor antagonist, host-tumor interactions, 345
- Re-irradiation, head and neck cancer, outcome, 3781
- Relapse, CA 15-3, CEA, breast cancer, tumour markers, elderly, postmenopausal, 2331
- Renal cancer, dendritic cells, immunotherapy, metastatic renal cell carcinoma, 2081
- Renal cell carcinoma, carbonic anhydrase IX, prognosis, 2953
- Renal cell carcinoma, cationic hybrid liposome, apoptosis, chemotherapy, 327
- Renal cell carcinoma, cyclooxygenase-2, Ki-67, metastases, survival, 3023
- Renal cell carcinoma, gamma-delta T-cells, adoptive immunotherapy, lung metastasis, 575
- Renal cell carcinoma, high-dose interleukin-2, carbonic anhydrase IX, 987
- Renal cell carcinoma, sialyl Lewis X, prognosis, 593
- Renal cell carcinoma, sunitinib malate, tyrosine kinase inhibitor, bone metastases, 5165
- Renal elimination, somatostatin analogs,  $^{111}\text{In}(^{88}\text{Y})$ -DOTAGA-tate,  $^{111}\text{In}(^{88}\text{Y})$ -DOTA-t-GA-tate, biodistribution, 2177
- Renal function, saracatinib, creatinine, 2935
- Renal tumour behaviour, CD10, CD13, gp160, peptidases, papillary carcinoma, 1137
- Repeat surgery, cervical cancer, FIGO IA1, microinvasive, 565
- Repetitive elements, breast cancer, promoter hypermethylation, genomic methylation, tumor suppressor genes, WBC DNA, 2489
- REPP86, larynx cancer, squamous cell carcinoma, 3541
- Reproducibility, cervical intraepithelial neoplasia, precancerous conditions, cervical cancer, spontaneous neoplasm regression, female genital tract disease, 2319
- Resistance, cisplatin, docetaxel, dexamethasone, squamous cell carcinoma of the head and neck cell lines, SCCHN, apoptosis, 123
- Resistance, EMT, lung cancer, adenocarcinoma, EGFR, tyrosine kinase inhibitor, 2513
- Resistance, oxaliplatin, colorectal cancer, ERCC1, gene silencing, siRNA, 2531
- Response prediction, oesophageal carcinoma, neoadjuvant chemotherapy, Barrett's carcinoma, review, 1065
- Resveratrol, p-glycoprotein, piceatannol, stilbenes, multidrug resistance, 4587
- RET*, lung cancer, polymorphism, haplotypes, Korean population, 3621
- Retinoblastoma susceptibility gene product, cSrc, Simian Virus 40 Large Tumor antigen, neoplastic transformation, rodent fibroblasts, signal transduction, 47
- Retinoblastoma, breast cancer, MCF-7 cells,  $\gamma$ -tocotrienol, cell cycle, cyclin D1, quinone reductase NQO2, 2869
- Retinoblastoma, Go6976, protein kinase C, bladder, carcinoma, 3995
- Retinoic acid, IL-2, high-dose chemotherapy, NK cells, 5-fluorouracil, epirubicin, cyclophosphamide, methotrexate, radiotherapy, etoposide, carboplatin, VEGF, myeloablative chemotherapy, autologous transplantation, immunotherapy, breast cancer, 209
- Retrospective study, eyelid edema, pemetrexed, 5185
- Retroviral vector, gastric cancer, *Drosophila melanogaster* multisubstrate deoxyribonucleoside kinase, suicide gene, bystander effect, 2641
- Reverse transcription-polymerase chain reaction, CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP) gene, chromosomal translocation, Ewing sarcoma (EWS) gene, fluorescence *in situ* hybridization, FISH, fusion gene, myxoid liposarcoma, MLS, RT-PCR, 4679
- Reverse-transcriptase polymerase chain reaction, circulating tumour cells, human mammaglobin, breast cancer, 2377
- Review, anastomosis, leak, small bowel, large bowel, ileocolic, hand-sewn, laparoscopic, 601
- Review, angiogenesis, VEGF-R, bFGF-R, clinical studies, biomarker, brivanib, 4477
- Review, Birt Hogg Dubé syndrome, folliculin, cancer predisposition, 751
- Review, cancer, energy metabolism, primary prevention, tertiary prevention, obesity, metabolic syndrome X, malnutrition, palliative care, 1863
- Review, cancer, HB-EGF, targeted therapy, 3107
- Review, cancer-associated fibroblasts, cancer microenvironment, tumor stroma, squamous cell carcinoma, basal cell carcinoma, 455
- Review, chemoradiosensitizers, radiotherapy, novel agents, chemotherapy, new radiosensitizing drugs, 3675
- Review, clear cell carcinoma, surgery, radiotherapy, chemotherapy, prognosis, recurrence, 1327
- Review, colon cancer, *K-ras* mutations, cetuximab, EGFR inhibitors, drug resistance, therapeutic outcome, 4673
- Review, colorectal cancer, cytokine, growth factor, hepatectomy, liver metastasis, liver regeneration, tumour recurrence, 2161
- Review, environmental oestrogens, breast cancer, cosmetics, antiperspirant, deodorant, paraben, aluminium, organochlorine, phytoestrogen, breast cysts, 815

- Review, ERCC1, XPF, DNA repair, chemotherapy, drug resistance, 3223
- Review, evidence-based medicine, complementary medicine, quality of life, quackery, 1767
- Review, FOXP3, regulatory T-cells, Treg-cells, gastric cancer, 1093
- Review, functional proteomics, cancer, proliferation, NAPPA microarrays, nanotechnology, 2073
- Review, gamma-glutamyltransferase, human neoplasia, tumor progression, drug resistance, redox regulation, 1169
- Review, gliomas, origin, stem cells, *CD133*, markers, brain adjacent tissue, nestin, subventricular zone, 1977
- Review, IP-PA1, immunomodulator, immunosuppression, lipopolysaccharide, stress, 3113
- Review, *K-ras*, blood, serum, plasma, colorectal cancer, pancreatic cancer, diagnostic test, predictive test, 2943
- Review, murine polyomavirus, tumour specific transplantation antigen, viral persistence, virus like particles VLPs, immune responses, 279
- Review, NSCLC, erlotinib, EGFR, tyrosine kinase inhibitors, lung cancer, 1301
- Review, oesophageal carcinoma, neoadjuvant chemotherapy, response prediction, Barrett's carcinoma, 1065
- Review, prostate cancer, active surveillance, watchful waiting, 3683
- Reviews, 279, 455, 601, 751, 815, 1065, 1093, 1169, 1301, 1327, 1767, 1863, 1977, 2073, 2161, 2943, 3107, 3113, 3223, 3233, 3675, 3683, 3693, 3889, 4477, 4673
- RFP, *in vivo* imaging, color-coded, GFP, UVC, melanoma, blood vessels, 3291
- Rhabdomyosarcoma, calpains, cancer, peroxiredoxin, 5085
- Rhabdomyosarcoma, mediastinal germ cell tumor, BEP chemotherapy, positron-emission tomography, hepatic metastasis, 5117
- Rhein, *ATM*, *BRCA1*, RT-PCR, Comet assay, emodin, aloemodin, DNA repair, tongue cancer cells, 945
- Rifampicin-miconazole-releasing catheters, catheter colonization, local infection, long-term activity, oncology patients, 1353
- Risk factor, stomach neoplasm, Epstein-Barr virus, medical history, lifestyle, gastric ulcer, alcohol, 2469
- Risk, breast neoplasms, genetic polymorphism, epidemiology, estrogens, *COMT* haplotypes, 217
- Risk, cyclin D1, colorectal cancer, metastasis, polymorphism, 2875
- RMETase, methioninase, PEG-methioninase, PEG-rMETase, cancer, methionine dependence, efficacy, selectivity, 1041
- RNA interference, integrin  $\alpha\beta6$ , proliferation, invasion, cell cycle, apoptosis, chemosensitivity, pancreatic carcinoma cells, 135
- RNA interference, YB-1, gene regulation, gene expression, drug resistance, gastric carcinoma cells, 693
- RNA interference, YB-1, gene regulation, micro RNAs, microarray, gastric carcinoma cells, drug resistance, 629
- ROC, receiver operating characteristic curves, carbohydrate antigen19-9, pancreatic ductal adenocarcinoma, matrix metalloproteinase 9, MMP-9, tissue inhibitor of metalloproteinases 1, TIMP-1, 587
- ROC-curves, lung cancer, CEA, CYFRA 21-1, marker panel, 1661
- ROCK isoforms, glioma, shRNA, cell cycle, ACNU, 3509
- Rodent fibroblasts, cSrc, Simian Virus 40 Large Tumor antigen, retinoblastoma susceptibility gene product, neoplastic transformation, signal transduction, 47
- Rodent model, animal cancer models, chick embryo, tumour markers, immunohistochemistry, glioblastoma, cell xenografts, 4851
- ROS, breast cancer, signal pathway, mTOR, TS, 5-FU, rapamycin, 2625
- ROS, *Brucea javanica*, cytotoxicity, NF- $\kappa$ B, NFAT, mitochondria, 3295
- ROS, MG132, apoptosis, endothelial cells, caspase, GSH, proteasome inhibitor, 879
- ROS, MG132, apoptosis, NAC, GSH, 2107
- Rose bengal derivative, sonodynamic therapy, sarcoma 180, 3361
- RT-PCR analysis, carcinoembryonic antigen, staurosporine, circulating tumor cells, immunomagnetic isolation, 4721
- RT-PCR, adipocytic tumors, *EWS-CHOP*, *HMG2-LPP*, lipoma, liposarcoma, *LPP-HMG2*, *TLS-CHOP*, 661
- RT-PCR, *ATM*, *BRCA1*, Comet assay, emodin, aloemodin, rhein, DNA repair, tongue cancer cells, 945
- RT-PCR, cancer chemoprevention, enzyme induction, metabolism, aromatase, phenazines, 4873
- RT-PCR, CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP) gene, chromosomal translocation, Ewing sarcoma (EWS) gene, fluorescence *in situ* hybridization, FISH, fusion gene, myxoid liposarcoma, MLS, reverse transcription-polymerase chain reaction, 4679
- RT-PCR, Hrs, Rab7, ExoC5, E-cadherin, fragments, breast cancer, 3903
- RT-PCR, prostate cancer, PCa, benign prostatic hyperplasia, BPH, DD3<sup>PCA3</sup>, mRNA, 665
- RUNX3, MSI, methylation, colorectal cancer, 2673
- S-1, capecitabine, metastatic breast cancer, 3827
- S-1, chemotherapy, hepatocellular carcinoma, platinum, 5245
- S-1, cisplatin, pooled analysis, histological type, lung cancer, 2985
- S-1, gastric cancer, cisplatin, outpatient setting, 3759

- S-1, gastric cancer, cytology, peritoneal dissemination, neoadjuvant chemotherapy, docetaxel, 1335
- S-1, rectal cancer, chemoradiotherapy, PSK, immune response, 993
- S175T, calponin h1, actin cytoskeleton stability, cell motility, point mutation, HeLa cells, 1071
- S6 kinase, ovarian cancer, DEPTOR, mTOR, paclitaxel resistance, 3529
- Safety, non-small cell lung cancer, carboplatin, paclitaxel, chemotherapy, interstitial lung disease, efficacy, 4357
- Salen-manganese complex, reactive oxygen species, intercellular signaling, apoptosis, 3967
- Salivary gland carcinoma, epithelial-myoepithelial carcinoma, nude mouse, growth factor receptors, cytokeratin, EGFR-1, 1565
- Salivary glands, giant cell lesions, giant cell granuloma, epulis, cathepsin, RANK, matrix metalloproteinase, jaws, osteoclast, tendon sheath, 1645
- Salivary glands, irradiation, damage, tenascin-C, 1593
- Salivary glands, neuron-specific enolase, irradiation, 1569
- Salvage therapy, pancreatic cancer, docetaxel, gemcitabine, refractory, chemotherapy, metastatic disease, 2905
- Salvia libanotica*, alpha terpineol, NF- $\kappa$ B, connectivity map, 1911
- Sanguinarine, apoptosis, caspase activity, NSC 95397, brefeldin A, bortezomide, neuroendocrine tumors, 149
- Sansalvamide A, pancreatic cancer, cell cycle arrest, 73
- Saracatinib, creatinine, renal function, 2935
- Saracatinib, Src, FAK, metastasis, invasion, fibrosarcoma, 4405
- Sarcoma 180, sonodynamic therapy, rose bengal derivative, 3361
- Sarcoma cell lines, radiation, TNF-alpha, programmed cell death, cell lines, lymphoma cell lines, 2857
- Sarcoma, Ewing's, prognosis, ploidies, image cytometry, 3715
- Sarcoma, KP1339, anticancer ruthenium(III) compounds, electroporation, electrochemotherapy, tumour models, mice, 2055
- Scattering irradiation, dental implants, Monte Carlo simulation, titanium dental implants, 1727
- Scattering irradiation, facial nerve, irradiation, irradiation damage, morphometrics, 1625
- Scavenger receptors, lipid rafts, macrophage, phagocytosis, polystyrene latex microspheres, methyl- $\beta$ -cyclodextrin, 3167
- SCCHN, MGMT, alkyltransferase, drug resistance, cancer therapy, field cancerization, 2561
- SCCHN, squamous cell carcinoma of the head and neck cell lines, resistance, apoptosis, cisplatin, docetaxel, dexamethasone, 123
- SCE, sister chromatid exchange, azasteroids, experimental chemotherapy, human lymphocytes, Lewis lung carcinoma, LLC, proliferation rate index, PRI, 4201
- ScFv, prostate cancer, PSMA, immunotoxins, *Pseudomonas* exotoxin A, 3373
- Schistosoma mansoni*, cytokines, IL-12, paracrine treatment, SWAP, systemic treatment, vaccination, poly-N-acetyl glucosamine gel matrix, 3889
- Scirrhous type, vimentin, gastric carcinoma cells, lymph node metastasis, prognosis, 5239
- SCLC, cisplatin, etoposide, topotecan, sequential, alternate, 3031
- SCLC, small cell lung cancer, nAChR, nicotinic cholinergic receptor, muscarinic cholinergic receptor 3, mAChR3,  $\beta$ 1 integrin, 97
- SDF1/CXCL12, malignant mesothelioma, animal tumor model, tumor spheroids, mesenchymal stem cell, chemokine, 2153
- Second-line treatment, pancreatic cell carcinoma, prognostic and predictive factors, ERCC1, 4289
- $\gamma$ -Secretase inhibitor, notch, erythroid leukemia, differentiation, 4071
- $\gamma$ -Secretase inhibitor, notch, leukemia, NF- $\kappa$ B, 495
- $\gamma$ -Secretase, apoptosis, presenilin 1, presenilin 2, cell cycle, G<sub>0</sub>/G<sub>1</sub>, chemoresistance, pancreatic ductal adenocarcinoma cells, taxanes, 4999
- SeePico, two-dimensional gel electrophoresis, LC-MS/MS, Flamingo Gel Stain, highly sensitive Coomassie brilliant blue, proteomic analysis, 4001
- Seizure prophylaxis, busulfan, pharmacokinetics, benzodiazepines, metabolism induction, phenytoin, 2977
- Selected-reaction-monitoring, superoxide dismutase 1, ovarian cancer, cisplatin, drug resistance, mass spectrometry, siRNA, 2577
- Selective estrogen receptor down-regulator SERD, breast cancer, orally active, nonsteroidal, thiochroman derivative, 873
- Selectivity, methioninase, PEG-methioninase, cancer, methionine dependence, efficacy, 793
- Selectivity, methioninase, rMETase, PEG-methioninase, PEG-rMETase, cancer, methionine dependence, efficacy, 1041
- Selenium substitution, solid tumours, radiotherapy, head and neck cancer, gynaecological cancer, 1783
- Selenium, DNA repair, cisplatin, carboplatin, nucleotide excision repair, selenomethionine, methylseleninic acid, bone marrow, 291
- Selenium, radiotherapy, randomised trial, head and neck cancer, 1829
- Selenomethionine, DNA repair, cisplatin, carboplatin, nucleotide excision repair, selenium, methylseleninic acid, bone marrow, 291
- Semiempirical molecular-orbital method, trihaloacetylazulenes, QSAR, cytotoxicity, 837
- Semiempirical molecular-orbital method, tropolones, QSAR, cytotoxicity, 129

- Sentinel lymph node, lung cancer, vitamin B2, fluorescent agents, 4109
- Sentinel lymph node, MMP-2, MMP-9, breast cancer, metastasis, 3521
- Sentinel node, cervical cancer, lymphoscintigraphy, intraoperative lymphatic mapping, 183
- Sentinel node, endometrial cancer, hysteroscopy, peritoneal cytology, tumor cell dissemination, 2425
- Sentinel node, melanoma, serum S100, LDH, prognosis, metastasis, 1799
- Sequence, colorectal cancer, irinotecan, oxaliplatin, 4325
- Sequential, cisplatin, etoposide, topotecan, alternate, SCLC, 3031
- SEREX, asbestos, lung cancer, tumour antigen, Annexin A2, 2631
- SEREX, cancer/testis antigens, prostate cancer, yeast, cancer vaccine, 895
- Serum LDH, tumour LDH-5, NSCLC, adenocarcinoma, squamous cell carcinoma, immunohistochemistry, 1347
- Serum level, circulating cell-free DNA, cfDNA, menstrual cycle, breast cancer, 2235
- Serum S100, melanoma, Sentinel node, LDH, prognosis, metastasis, 1799
- Serum tumour markers, FDG uptake, PET, CT, diagnosis, lung cancer, 1741
- Serum, circulating, cell-free DNA, kidney cancer, biomarker, 2785
- Serum, DNA, nucleosomes, ELISA, stability, 1613
- Serum, integrin,  $\alpha\beta6$ , Fyn kinase, EMT, oral SCC, 2591
- Serum, *K-ras*, blood, plasma, colorectal cancer, pancreatic cancer, diagnostic test, predictive test, review, 2943
- Serum, thymidine kinase 1, STK1, surgery, physiological stress, 1295
- Serum, thymidine kinase, lung cancer, biomarker, tumor marker, 1855
- Sesponse curve, bistable switch, mathematical model, drug composition, mTOR, carcinogenesis, 2683
- SETD2, breast cancer, telomerase, histone methyltransferase, 3309
- Sex differences, pancreatic cancer, gemcitabine, indole-3-carbinol, 4907
- ShRNA, glioma, ROCK isoforms, cell cycle, ACNU, 3509
- Sialomucins, esophagus, baboons, glandular metaplasia, Barretts mucosa, 4123
- Sialyl Lewis a, CA19-9, larynx carcinoma, squamous cell carcinoma, phlogistic tissue, 1849
- Sialyl Lewis X, renal cell carcinoma, prognosis, 593
- Side population, cancer stem cells, head and neck squamous carcinoma, 2005
- Side population, colon cancer, Wnt signaling, ATP-binding cassette transporter, 2041
- Side-effects, radiation, children, late sequelae, abdomen, 227
- 14-3-3 Sigma protein, LC-MS/MS, peptide sequence tag, gastric carcinoma cells, proteomic differential display, 4459
- 14-3-3 Sigma, p53, esophageal cancer, 5175
- Signal pathway, breast cancer, mTOR, TS, ROS, 5-FU, rapamycin, 2625
- Signal transduction, cSrc, Simian Virus 40 Large Tumor antigen, retinoblastoma susceptibility gene product, neoplastic transformation, rodent fibroblasts, 47
- Signaling cluster, carcinoembryonic antigen, CEA, chimeric T-cell antigen receptor, CAR, human antibody, T-cell activation, 2731
- Signaling pathway, microarray analysis, macrophage, lignin-carbohydrate complex, LPS, LEM, 2567
- Signaling pathways, toxin Bc2, equinatoxin-II, cytolysins, necrosis, MAPK/ERK, PKC, CaMKII, glioma cell death, 1209
- Signaling proteins, synthetic triterpenoids, colorectal cancer, apoptosis, 785
- Signaling, pancreatic cancer, glycolytic inhibitors, 743
- Silybinin, tamoxifen, 4-hydroxytamoxifen, pharmacokinetics, bioavailability, rats, 79
- Simian Virus 40 Large Tumor antigen, cSrc, retinoblastoma susceptibility gene product, neoplastic transformation, rodent fibroblasts, signal transduction, 47
- Single chain antibody, Tn antigen, GalNAc( $\alpha$ 1-3)-Ser/Thr, phage-display, Fc fusion, antibody-dependent cellular cytotoxicity (ADCC), 3397
- Single nucleotide polymorphism, *hOGG1*, lung cancer, smoking, 4141
- Single nucleotide polymorphism, *hOGG1*, oral cancer, betel quid, 4205
- Single nucleotide polymorphism, *XRCC4*, childhood leukemia, DNA repair, 529
- SiRNA, oxaliplatin, colorectal cancer, ERCC1, gene silencing, resistance, 2531
- SiRNA, superoxide dismutase 1, ovarian cancer, cisplatin, drug resistance, mass spectrometry, selected-reaction-monitoring, 2577
- SISH, HER2, breast, colon, prostate, lung, ovary, 1287
- Sister chromatid exchange, SCE, azasteroids, experimental chemotherapy, human lymphocytes, Lewis lung carcinoma, LLC, proliferation rate index, PRI, 4201
- SIURo, uro-oncology, conference abstracts 1375-1544
- Size, colon, adenoma, limits, carcinoma, 2419
- Skin cancer invasion, fibroblast, MMP inhibition, angiogenesis, cytokine, imaging, VEGF-A, PDGF-BB, 703
- SKOV-3 cells, epigallocatechin-3-gallate, cell proliferation, ovarian cancer, apoptosis, 2519
- Skull defects, dermal cylindroma, Brooke-Spiegler syndrome, 1793

- Skull deformity, neurofibromatosis, neurofibromatosis type 1, orbit, plexiform neurofibroma, optic nerve, optic nerve glioma, orbital deformity, orbito-temporal neurofibromatosis, facial scoliosis, sphenoid wing dysplasia, 1751
- SLC34A2, type II sodium-dependent phosphate transporter, diagnosis, therapy, breast cancer, 4135
- SMAD, TGF- $\beta$ 1, antisense, keloid, fibroblast, 3459
- Smad1, bone morphogenetic protein 7, lung cancer, motility, 1113
- SMAD4, mesenchymal-epithelial reversion, invasion and metastasis, epithelial phenotype, E-cadherin, 2603
- Small bowel, anastomosis, leak, large bowel, ileocolic, hand-sewn, laparoscopic, review, 601
- Small cell carcinoma, carcinoma, carcinoid, large cell neuroendocrine carcinoma, methylation, immunofluorescence, survival, RASSF1, 4269
- Small cell lung cancer, SCLC, muscarinic cholinergic receptor 3, mAChR3, nicotinic cholinergic receptor, nAChR,  $\beta$ 1 integrin, 97
- Small molecules, gene expression analysis, thymidylate synthase, real-time PCR, chemoresistance, arsenic trioxide, 5-FU resistance, 1157
- Small-cell lung cancer, oblimersen, radiation, BCL-2, 3869
- Smoking, *hOGGI*, single nucleotide polymorphism, lung cancer, 4141
- SN38, ilinotecan, topoisomerase inhibitor, apoptosis, *ATM*, p53, p21, caspase-3, 3911
- SN-38, WiDr colon cancer cells, growth factors, 5-fluorouracil, oxaliplatin, glutathione modulation, buthionine-SR-sulfoximine, L-2-oxothiazolidine-4-carboxylate, 1223
- S-nitrosylation, ADH5, auranofin, hepatoma, GSNOR, mithramycin, thioredoxin reductases, 415
- SNP, apocrine gland, axillary osmidrosis, earwax, mammary gland, ABC transporter *ABCC11*, breast cancer risk, 5189
- SNP, gene polymorphism, breast cancer, CD44, patient age, tumor burden, 1263
- Sodium butyrate, HPV, cervical carcinoma, UCN-01, apoptosis, 4049
- Soft tissue sarcoma, *RAS*, mutation, Japan, 245
- Solanum lyratum*, *Helicobacter pylori*, human gastric epithelial cells, apoptosis, 1189
- Solid tumor, recombinant AAV serotypes 1, 2, and 5, transduction efficiency, cancer gene therapy, pancreatic cancer cells, colon carcinoma cells, 1931
- Solid tumors, bortezomib, fixed-dose rate gemcitabine, phase I, 167
- Solid tumors, oral metastasis, oral cancer, jaw metastasis, head and neck lymphoma, 1843
- Solid tumours, selenium substitution, radiotherapy, head and neck cancer, gynaecological cancer, 1783
- Somatostatin analogs,  $^{111}\text{In}(^{88}\text{Y})\text{-DOTAGA-tate}$ ,  $^{111}\text{In}(^{88}\text{Y})\text{-DOTA-t-GA-tate}$ , biodistribution, renal elimination, 2177
- Sonication, liposomes, microfluidics, ethanol injection, 463
- Sonodynamic activation, ultrasound, cell damage, lipid peroxidation, reactive oxygen, DCPH-P-Na(I), 2241
- Sonodynamic therapy, rose bengal derivative, sarcoma 180, 3361
- Sora fenib, epidermal growth factor, PI-103, rapamycin, mTOR complex 1, mTOR complex 2, negative feedback loop, Ras/Raf/MAPK, PI13/AKT/mTOR, 4951
- Soy isoflavone, DLD-1, epigenetic regulation, SW480, colon cancer cells, genistein, *WNT5a* promoter, 4537
- SPARC, pancreatic cancer, prognosis, 867
- Specificity, uterine corpus cancer, staging, lymphadenectomy, negative predictive value, FDG-PET, 3787
- Sphenoid wing dysplasia, neurofibromatosis, neurofibromatosis type 1, orbit, plexiform neurofibroma, optic nerve, optic nerve glioma, skull deformity, orbital deformity, orbito-temporal neurofibromatosis, facial scoliosis, 1751
- Sphinganine, sphingosine, ceramide, dihydroceramide, colon cancer, apoptosis, 2881
- Sphingomyelin, cisplatin, FAS, apoptosis, lipid rafts, 2065
- Sphingosine, sphinganine, ceramide, dihydroceramide, colon cancer, apoptosis, 2881
- Spontaneous metastasis, metastasis model, lymph node, B16 mouse melanoma, 4799
- Spontaneous neoplasm regression, cervical intraepithelial neoplasia, precancerous conditions, cervical cancer, reproducibility, female genital tract disease, 2319
- Spontaneous regression, advanced colon cancer, 2351
- $\alpha\text{-SQMG}$ , vascular normalization, pericytes, angiogenesis, radiotherapy, hypoxia, tumor microenvironment, 4397
- Squamous cell carcinoma of the head and neck cell lines, SCCHN, cisplatin, docetaxel, dexamethasone, resistance, apoptosis, 123
- Squamous cell carcinoma, cancer-associated fibroblasts, cancer microenvironment, tumor stroma, basal cell carcinoma, review, 455
- Squamous cell carcinoma, deltaNp63, immunohistochemistry, non-small cell lung cancer, 4717
- Squamous cell carcinoma, DMBA, calcium glucarate, hamsters, buccal pouch, 843
- Squamous cell carcinoma, dysplasia, epithelium, hypopharynx, malignancy, 3313
- Squamous cell carcinoma, LYVE-1, D2-40, lymph node metastasis, tongue, 1897
- Squamous cell carcinoma, REPP86, larynx cancer, 3541
- Squamous cell carcinoma, serum LDH, tumour LDH-5, NSCLC, adenocarcinoma, immunohistochemistry, 1347

- Squamous cell carcinoma, Sialyl Lewis a, CA19-9, larynx carcinoma, phlogistic tissue, 1849
- Squamous cell carcinoma, tumor marker, follow-up, Cyfra 21-1, oropharyngeal cancer, 2291
- Squamous cell carcinoma, vulvar intraepithelial neoplasia, galectin-1, immunohistochemistry, 1547
- Src, saracatinib, FAK, metastasis, invasion, fibrosarcoma, 4405
- Src-activating and signaling molecule, esophageal squamous cell carcinoma, immunohistochemistry, 3535
- Stability, DNA, nucleosomes, ELISA, serum, 1613
- Stage III, non-small cell lung cancer, chemoradiation, surgery, pneumonectomy, cisplatin, 4237
- Staging, uterine corpus cancer, lymphadenectomy, negative predictive value, specificity, FDG-PET, 3787
- Stat, Akt, breast cancer, ErbB receptors, erlotinib, gefitinib, vitamin E, tyrosine kinase inhibitors,  $\gamma$ -tocotrienol, 429
- STAT3, cyclin D1, IL-6, CADPE, hepatocellular carcinoma, 481
- Statin, HMG CoA reductase, mevalonate, tocotrienol, Cdk4, caspase-3, Ras, cell cycle, apoptosis, 4937
- Statins, HMGCoA reductase inhibitors, carcinogenesis, liver neoplasm, ubiquinone, mevalonate pathway, hepatocarcinogenesis, lovastatin, 1105
- Staurosporine, carcinoembryonic antigen, circulating tumor cells, immunomagnetic isolation, RT-PCR analysis, 4721
- Stefin A, needle biopsy, radical prostatectomy, cathepsin B, MIB-1, DNA ploidy, prostate cancer, 719
- Stem cell niche, glioma, stem cells, interferon-beta, pericytes, 3301
- Stem cell, gastric cancer, *CD133*, prognosis, 2453
- Stem cells, cell cycle, education, cooperation, natural products, 2477
- Stem cells, glioma, interferon-beta, stem cell niche, pericytes, 3301
- Stem cells, gliomas, origin, *CD133*, markers, brain adjacent tissue, nestin, subventricular zone, review, 1977
- Stereotactic radiosurgery, multiple brain metastases, radiotherapy, survival, whole brain radiotherapy, non-small cell lung cancer, 3055
- Steroid receptors, breast cancer, histology, survival analysis, 5137
- Stilbenes, p-glycoprotein, resveratrol, piceatannol, multidrug resistance, 4587
- STK1, thymidine kinase 1, serum, surgery, physiological stress, 1295
- Stomach neoplasm, Epstein-Barr virus, risk factor, medical history, lifestyle, gastric ulcer, alcohol, 2469
- Stomach neoplasm, KITENIN, tumor invasion, tumor metastasis, prognosis, 3479
- Stomach, breast cancer, metastasis, 3705
- Stress, IP-PA1, immunomodulator, immunosuppression, lipopolysaccharide, review, 3113
- Suboptimal debulking, advanced epithelial ovarian cancer, biological feature, ERCC1, 2447
- Substitutional analysis, hybridoma, monoclonal, KEPI, peptide array, 1573
- Subventricular zone, gliomas, origin, stem cells, *CD133*, markers, brain adjacent tissue, nestin, review, 1977
- Suicide gene, gastric cancer, *Drosophila melanogaster* multisubstrate deoxyribonucleoside kinase, retroviral vector, bystander effect, 2641
- Sulforaphane, apoptosis, autophagy, bafilomycin A1, breast cancer, MDA-MB-231, 3381
- Sulforaphane, apoptosis, colon cancer, reactive oxygen species, 3611
- Sulindac sulfone, HNSCC, UM-SCC,  $\beta$ -catenin, cell line, cell culture, apoptosis, 339
- Sunitinib malate, renal cell carcinoma, tyrosine kinase inhibitor, bone metastases, 5165
- Sunitinib, chemotherapy, non-small cell lung cancer, 5169
- Sunitinib, lapatinib, malignant glioma, MMPs, growth factors, VEGFR, integrins, anti-VEGFR agents, anti-EGFR agents, 4987
- Sunitinib, ovarian cancer, tyrosine kinase inhibitor, mouse model, xenograft, luciferase, 3355
- Superoxide dismutase 1, ovarian cancer, cisplatin, drug resistance, mass spectrometry, selected-reaction-monitoring, siRNA, 2577
- Surgery, clear cell carcinoma, radiotherapy, chemotherapy, prognosis, recurrence, review, 1327
- Surgery, extramedullary, plasmocytoma, multifocal, uncommon site, radiotherapy, chemotherapy, 1779
- Surgery, non-small cell lung cancer, stage III, chemoradiation, pneumonectomy, cisplatin, 4237
- Surgery, thymidine kinase 1, STK1, serum, physiological stress, 1295
- Surgical resection, intrahepatic cholangiocarcinoma, vimentin, prognosis, 2279
- Surgical resection, NSCLC, adjuvant chemotherapy, carboplatin, paclitaxel, gemcitabine, treatment compliance, 4695
- Surgical resection, NSCLC, adjuvant chemotherapy, carboplatin, paclitaxel, treatment compliance, 3039
- Surgical treatment, dermatofibrosarcoma protuberans, tumour, wide local excision, 3775
- Surgical treatment, vulvar carcinoma, pathological factors, recurrence, thrombosis, 2311
- Suros, breast cancer, B3 lesions, vacuum-assisted core biopsy, microcalcification, lobular hyperplasia, DCIS, 2287
- Surveillance, ulcerative colitis, UC-associated colorectal cancer, claudin-1, 3181
- Survival analysis, breast cancer, histology, steroid receptors, 5137
- Survival analysis, lung cancer, chemotherapy, postoperative recurrence, 1311

- Survival time, orthotopic model, FOLFIRI, colon cancer, tumor-growth metastasis, GFP imaging, 403
- Survival, carcinoma, carcinoid, small cell carcinoma, large cell neuroendocrine carcinoma, methylation, immunofluorescence, RASSF1, 4269
- Survival, CD44, glioblastoma multiforme, metastasis, 253
- Survival, CEA, CYFRA 21-1, tumour marker index, non-small cell lung cancer, 3099
- Survival, cyclooxygenase-2, Ki-67, metastases, renal cell carcinoma, 3023
- Survival, lung cancer, FDG imaging, follow-up, recurrence, early detection, 3811
- Survival, multiple brain metastases, radiotherapy, stereotactic radiosurgery, whole brain radiotherapy, non-small cell lung cancer, 3055
- Survival, non-small cell lung cancer, cytokeratin, tumour marker, CYFRA21-1, prognosis, 3833
- Survival, non-small cell lung cancer, first and second line chemotherapy, 4335
- Survival, ovarian cancer, maspin expression, 2739
- Survival, prognostic factors, colorectal cancer, chemotherapy, 653
- Survival, uterine clear cell carcinoma, uterine serous papillary carcinoma, death rate, 3727
- Survivin peptide vaccination, IL-1 receptor antagonist, IL-6, colon-26 carcinoma, beta-glucan, anti-inflammation, vaccination, Anakinra, 3959
- Susceptibility, mosquito, adenovirus, immune suppression, malaria, cancer mortality, 1371
- SW480, DLD-1, epigenetic regulation, soy isoflavone, colon cancer cells, genistein, *WNT5a* promoter, 4537
- SW480, EGCG, TROP-2, HCT-116, mRNA stability, cycloheximide, (-)epigallocatechin-3-gallate, colorectal cancer cells, 2497
- SWAP, cytokines, IL-12, paracrine treatment, *Schistosoma mansoni*, systemic treatment, vaccination, poly-*N*-acetyl glucosamine gel matrix, 3889
- Syndecan-2, pancreatic carcinoma, prognosis, 2749
- Synergism, bladder cancer, chemotherapy, cell cycle, carboplatin, gemcitabine, 4573
- Synergism, drug combination, ovarian cancer, cisplatin, oxaliplatin, transplatinum, paclitaxel, colchicine, 4025
- Synergism, leukaemia stem cells, PI3K/Akt, CK2, targeted therapy, apoptosis, 4625
- Synthetic triterpenoids, colorectal cancer, apoptosis, signaling proteins, 785
- Systemic treatment, cytokines, IL-12, paracrine treatment, *Schistosoma mansoni*, SWAP, vaccination, poly-*N*-acetyl glucosamine gel matrix, 3889
- $\gamma\delta$  T-cells, cancer immunotherapy, bladder carcinoma, histone deacetylase inhibitor, valproic acid, NKG2D ligands, 4509
- T cells, apoptosis, mcl-1, 5-fluorouracil, Jurkat, caspases, 3879
- T0901317, prostate cancer, cancer cell, liver X receptor, 22(R)-hydroxycholesterol, 3643
- T47-D, breast cancer, technetium, GRP receptor, carbonyl, MDA-MB-231,  $^{99m}\text{Tc}-(\text{CO})_3\text{-X-Y-bombesin (7-14)NH}_2$ , 19
- TACHIKAWA DENKAI CALCIUM™ (E-Ca), bone mineral density, AM value, calcium hydroxide, dual-energy X-ray absorptiometry, DXA method, 3199
- Tamoxifen, 4-hydroxytamoxifen, silybinin, pharmacokinetics, bioavailability, rats, 79
- Tamoxifen, antiestrogens, AKT, EGF-R, endometrial cancer, everolimus, gefitinib, mTOR, perifosine, 2025
- Tamoxifen, endometrium, *KRAS*, apoptosis, ErbB ligand, 3119
- Tarceva, non-small cell lung cancer, erlotinib, EGFR-TKIs, *EGFR* mutation, phase II, 557
- Targeted therapeutics, mouse models, miR-184 transfection, neuroblastoma, 4391
- Targeted therapy, cancer, HB-EGF, review, 3107
- Targeted therapy, leukaemia stem cells, PI3K/Akt, CK2, synergism, apoptosis, 4625
- Targeted therapy, VEGF, matrix metalloproteinase, oxidative stress, reactive oxygen species, angiogenesis, bevacizumab, FINAVAST trial, 1001
- Targeting, paclitaxel, dextran, folic acid, adsorption, 903
- Taxanes, apoptosis, presenilin 1, presenilin 2, cell cycle,  $G_0/G_1$ , chemoresistance,  $\gamma$ -secretase, pancreatic ductal adenocarcinoma cells, 4999
- T-cell activation, carcinoembryonic antigen, CEA, chimeric T-cell antigen receptor, CAR, human antibody, signaling cluster, 2731
- TCTP, biomarker, antitumor activity, PLK1, 4973
- Technetium, breast cancer, GRP receptor, carbonyl, T47-D, MDA-MB-231,  $^{99m}\text{Tc}-(\text{CO})_3\text{-X-Y-bombesin (7-14)NH}_2$ , 19
- Telomerase, prognosis, human telomerase reverse transcriptase, malignant fibrous histiocytomas, bone, 4959
- Telomerase, SETD2, breast cancer, histone methyltransferase, 3309
- Temozolomide, myeloid derived suppressor cells, macrophages, regulatory T-cells, B16 melanoma, docetaxel, interleukin-1 receptor antagonist, host-tumor interactions, 345
- Tenascin-C, irradiation, damage, salivary glands, 1593
- Tendon sheath, giant cell lesions, giant cell granuloma, epulis, cathepsin, RANK, matrix metalloproteinase, jaws, osteoclast, salivary glands, 1645
- Teratocarcinoma, IGF II, IGFBP-7, 911
- Teratoma cell lines, fractionated X-irradiation, cisplatin hypersensitivity, oxaliplatin resistance, 4471



- Tertiary prevention, cancer, energy metabolism, primary prevention, obesity, metabolic syndrome X, malnutrition, palliative care, review, 1863
- Testicular cancer, progesterone receptor antagonists, mifepristone, murine prostate cancer, 4921
- Testicular metastasis, isolated recurrence, prostate cancer, prostatectomy, 1747
- Testosterone, TSC1, TSC2, androgen deprivation therapy, prostate cancer, 3895
- TFPI2*, quantitative methylation-specific PCR, colorectal cancer, 1205
- TFPI2*, quantitative methylation-specific PCR, gastric cancer, 4131
- Tg mouse, proteomics, E7 oncogene, melphalan, cancer, 2773
- TG2, A431 cell, MMP-9, fibronectin, invasion, 4177
- TGF- $\beta$ , cytoskeleton, paxillin, phosphatase, PP-1, motility, endothelial cells, 4861
- TGF $\beta$ , ionising radiation, bystander effect, ELISA, activation, 3341
- TGF- $\beta$ , mandibular bone destruction, osteoclast, 2615
- TGF- $\beta$ 1, antisense, keloid, SMAD, fibroblast, 3459
- TGF- $\beta$ 1, exosome, regulatory T-cells, malignant effusion, 3747
- TGF- $\beta$ 1, pancreatic cancer, gene polymorphism, growth factors, EGF, TNF- $\alpha$ , 5257
- Therapeutic outcome, colon cancer, *K-ras* mutations, cetuximab, EGFR inhibitors, drug resistance, review, 4673
- Therapy, juvenile granulosa cell tumor, diagnosis, 1731
- Therapy, primary leiomyosarcoma of the testis, diagnosis, prognosis, 1725
- Therapy, type II sodium-dependent phosphate transporter, SLC34A2, diagnosis, breast cancer, 4135
- Thermoreversible gelation polymer, doxorubicin, drug delivery system, liposome, malignant glioma, polymeric microsphere, 1057
- ThinPrep, colorectal carcinoma, *KRAS*, BRAF, mutations, FFPE, qPCR, 1969
- Thiochroman derivative, breast cancer, orally active, selective estrogen receptor down-regulator SERD, nonsteroidal, 873
- Thioredoxin reductase, thyroid gland neoplasm, thioredoxin, redox activity, cellular proliferation, 767
- Thioredoxin reductases, ADH5, auranofin, hepatoma, GSNOR, S-nitrosylation, mithramycin, 415
- Thioredoxin, thyroid gland neoplasm, thioredoxin reductase, redox activity, cellular proliferation, 767
- Three-dimension, malignant glioma, cell culture, morphology, 383
- Thrombosis, vulvar carcinoma, pathological factors, surgical treatment, recurrence, 2311
- Thymidine kinase 1, STK1, serum, surgery, physiological stress, 1295
- Thymidine kinase, lung cancer, biomarker, tumor marker, serum, 1855
- Thymidine phosphorylase, Epstein-Barr virus, gastric carcinoma, intestinal type, diffuse type, 2431
- Thymidylate synthase enhancer region TSER, thymidylate synthase TS, untranslated region UTR, variable number of tandem repeats VNTR, gastric cancer risk, 2325
- Thymidylate synthase TS, thymidylate synthase enhancer region TSER, untranslated region UTR, variable number of tandem repeats VNTR, gastric cancer risk, 2325
- Thymidylate synthase, HT29, chemoresistance, translational regulation, real-time PCR, mRNA quantification, colorectal cancer cells, fluoropyrimidine analogs, p53, 5-FU resistance, 1149
- Thymidylate synthase, polymorphism, protein level, breast cancer, 4373
- Thymidylate synthase, small molecules, gene expression analysis, real-time PCR, chemoresistance, arsenic trioxide, 5-FU resistance, 1157
- Thyroid antibodies, breast cancer, thyroid function, 1713
- Thyroid cancer, fluorescent proteins, nude mice model, metastasis, NPA, KAK-1, GFP, 4415
- Thyroid cancer, integrin  $\alpha$ 6 $\beta$ 4, cell motility, invasion, anaplastic thyroid carcinoma, 4485
- Thyroid cancer, thyroid gland, osteopontin, OPN, CEACAM1, 1681
- Thyroid cancer, thyroid gland, thyroid nodule, thyroid scintigraphy, fine-needle aspiration cytology, FNAB, FNAC,  $^{99m}\text{Tc}$ -pertechnetate, 3083
- Thyroid carcinoma, metallothionein, Ki-67, 4945
- Thyroid function, breast cancer, thyroid antibodies, 1713
- Thyroid gland neoplasm, thioredoxin, thioredoxin reductase, redox activity, cellular proliferation, 767
- Thyroid gland, thyroid cancer, osteopontin, OPN, CEACAM1, 1681
- Thyroid gland, thyroid cancer, thyroid nodule, thyroid scintigraphy, fine-needle aspiration cytology, FNAB, FNAC,  $^{99m}\text{Tc}$ -pertechnetate, 3083
- Thyroid nodule, thyroid gland, thyroid cancer, thyroid scintigraphy, fine-needle aspiration cytology, FNAB, FNAC,  $^{99m}\text{Tc}$ -pertechnetate, 3083
- Thyroid scintigraphy, thyroid gland, thyroid cancer, thyroid nodule, fine-needle aspiration cytology, FNAB, FNAC,  $^{99m}\text{Tc}$ -pertechnetate, 3083
- Thyroid tumors, EGFR, erlotinib, cetuximab, panitumumab, paclitaxel, 473
- Tibia, cervical cancer, metastases, fibula, isotope bone scan, 2949
- Tie2, gene therapy, polyethylenimine, p53 gene, 1999
- TIMP-1, biomarkers, CEA, rectal cancer, chemoradiation, 4755
- TIMP-1, colon cancer, chemotherapy, CEA, 233
- TIMP-1, colorectal cancer, prognostic factor, 4127

- TIMP-1, pancreatic ductal adenocarcinoma, carbohydrate antigen19-9, matrix metalloproteinase 9, MMP-9, tissue inhibitor of metalloproteinases 1, receiver operating characteristic curves, ROC, 587
- TIMP-2, esophageal cancer, invasiveness, transwell invasion chamber, MMP-1, matrix metalloproteinase-1, vimentin, p-Src (pY416), tissue inhibitor of metalloproteinase-2, 727
- Tissue inhibitor of metalloproteinase-2, esophageal cancer, invasiveness, transwell invasion chamber, MMP-1, matrix metalloproteinase-1, vimentin, p-Src (pY416), TIMP-2, 727
- Tissue inhibitor of metalloproteinases 1, pancreatic ductal adenocarcinoma, carbohydrate antigen19-9, matrix metalloproteinase 9, MMP-9, TIMP-1, receiver operating characteristic curves, ROC, 587
- Tissue microarray, breast cancer, topoisomerase II alpha, 2459
- Titanium dental implants, dental implants, scattering irradiation, Monte Carlo simulation, 1727
- TKTL1, transketolase-like-1 protein, cancer, aerobic glycolysis, endometrial cancer, glucose metabolism, pAkt, GLUT1, 1653
- TKTL1, transketolase-like-1 protein, cancer, aerobic glycolysis, endometrial cancer, glucose metabolism, pAkt, GLUT1, 1653
- TLR4, genetic polymorphism, *NOD2/CARD15*, gastritis, histopathology, 513
- TLS-CHOP*, adipocytic tumors, *EWS-CHOP*, *HMG2-LPP*, lipoma, liposarcoma, *LPP-HMG2*, RT-PCR, 661
- TM601, angiogenesis, chlorotoxin, MMP-2, invasion, 39
- TMS1, epigenetics, pancreatic cancer, DNA methylation, chemotherapy, 3919
- Tn antigen, GalNAc( $\alpha$ 1-3)-Ser/Thr, single chain antibody, phage-display, Fc fusion, antibody-dependent cellular cytotoxicity (ADCC), 3397
- TNF-alpha, radiation, programmed cell death, cell lines, sarcoma cell lines, lymphoma cell lines, 2857
- TNF- $\alpha$ , pancreatic cancer, gene polymorphism, growth factors, EGF, TGF- $\beta$ 1, 5257
- Tobacco, microarrays, gene expression, oral cancer, 1083
- $\gamma$ -Tocotrienol, Akt, breast cancer, ErbB receptors, erlotinib, gefitinib, vitamin E, Stat, tyrosine kinase inhibitors, 429
- $\gamma$ -Tocotrienol, breast cancer, MCF-7 cells, cell cycle, retinoblastoma, cyclin D1, quinone reductase NQO2, 2869
- Tocotrienol, HMG CoA reductase, mevalonate, statin, Cdk4, caspase-3, Ras, cell cycle, apoptosis, 4937
- Tocotrienols, breast cancer, MCF-7, MDA-MB-231, chemoprevention, NRF2, 4169
- Tongue and pharyngolaryngeal carcinomas, Epstein-Barr virus, human papilloma virus, John Cunningham, carcinogenesis, 1233
- Tongue cancer cells, *ATM*, *BRCA1*, RT-PCR, Comet assay, emodin, aloe-emodin, rhein, DNA repair, 945
- Tongue, amyloidosis, localized amyloidosis, amyloid, oral cavity, AL amyloidosis, 3009
- Tongue, ectomesenchymal chondromyxoid tumour, oral cavity, immunohistochemistry, 4685
- Tongue, LYVE-1, D2-40, lymph node metastasis, squamous cell carcinoma, 1897
- Topoisomerase I, cervical cancer, chromosomal aberrations, chromosome 5p gain, array CGH, 3257
- Topoisomerase II alpha, breast cancer, tissue microarray, 2459
- Topoisomerase inhibitor, SN38, ilinotecan, apoptosis, *ATM*, p53, p21, caspase-3, 3911
- Topotecan, cisplatin, etoposide, sequential, alternate, SCLC, 3031
- Toremifene, toremifene-glucuronide-labelled with  $^{99m}\text{Tc}$ ,  $^{99m}\text{Tc}$ -TOR-G,  $^{99m}\text{Tc}$ -Rec-TOR-G, diethylenetriamine pentaacetic acid DTPA, anti-oestrogen glucuronide compound, 1243
- Toremifene-glucuronide-labelled with  $^{99m}\text{Tc}$ , toremifene,  $^{99m}\text{Tc}$ -TOR-G,  $^{99m}\text{Tc}$ -Rec-TOR-G, diethylenetriamine pentaacetic acid DTPA, anti-oestrogen glucuronide compound, 1243
- Toxicity, erlotinib, 973
- Toxin Bc2, equinatoxin-II, cytolysins, signaling pathways, necrosis, MAPK/ERK, PKC, CaMKII, glioma cell death, 1209
- TP53, gallbladder carcinoma, PCR-SSCP, direct sequencing, transition mutations, cholecystitis, 4443
- TP53, prostate cancer, progression, mutation, tumor suppressor-gene, 1579
- TRAIL, antitumor, apoptosis, cell-penetrating peptide, gene therapy, protein transduction domain, tumor necrosis factor-related apoptosis-inducing ligand, arginine-rich peptides, 2193
- TRAIL, tumour necrosis factor-related apoptosis-inducing ligand, histone deacetylase inhibitors, FR235222, human promyelocytic leukaemia, apoptosis, 887
- TRAMP, nexrutine<sup>R</sup>, tumor invasion, prostate cancer, BMD, CREB, NF- $\kappa$ B, 857
- TRAMP, prostate cancer, MHC I, HLA-A2, immune rejection, 409
- Tranilast, castration-resistant prostate cancer, bone metastasis, overall survival, 3077
- Transbronchial needle aspiration, mediastinal lymphadenopathies, fiberbronchoscopy, metastasis, 4769
- Transduction efficiency, recombinant AAV serotypes 1, 2, and 5, solid tumor, cancer gene therapy, pancreatic cancer cells, colon carcinoma cells, 1931
- Transferrin receptor, breast cancer, antisense, iron transport, cell culture, 759

- Transforming growth factor-alpha, placental growth factor, transforming growth factor-beta 1, tumour necrosis factor receptor 1, matrix metalloproteinase-2, pancreatic neoplasms, inflammation, 3801
- Transforming growth factor-beta 1, placental growth factor, transforming growth factor-alpha, tumour necrosis factor receptor 1, matrix metalloproteinase-2, pancreatic neoplasms, inflammation, 3801
- Transfusion, hepatocellular carcinoma, hepatectomy, Glasgow prognostic score, pulmonary complications, 5129
- Transglutaminase, anthraquinones, danthron, quinizarin, polyamines, differentiation, melanoma cells, 445
- Transition mutations, gallbladder carcinoma, PCR-SSCP, direct sequencing, TP53, cholecystitis, 4443
- Transitional cell carcinoma, bladder cancer, biomarkers, tumor progression, immunohistochemistry, CA19.9, CEA, 5195
- Transitional cell carcinoma, lymphovascular invasion, radical cystectomy, 2973
- Transketolase-like-1 protein, TKTL1, cancer, aerobic glycolysis, endometrial cancer, glucose metabolism, pAkt, GLUT1, 1653
- Translation inhibition, ER stress, antiglycolytic, autophagosome, 3-bromopyruvate, 923
- Translational regulation, HT29, chemoresistance, real-time PCR, mRNA quantification, colorectal cancer cells, fluoropyrimidine analogs, thymidylate synthase, p53, 5-FU resistance, 1149
- Trans*-platinum compounds, drug combination, YH12, A2780, dose-effect curves, cell uptake, platinum-DNA binding, ovarian cancer cell lines, cisplatin, 4547
- Trans*-platinum, drug combination, synergism, ovarian cancer, cisplatin, oxaliplatin, paclitaxel, colchicine, 4025
- Transwell invasion chamber, esophageal cancer, invasiveness, MMP-1, matrix metalloproteinase-1, vimentin, p-Src (pY416), TIMP-2, tissue inhibitor of metalloproteinase-2, 727
- Trastuzumab, HER2, breast cancer, plasma DNA, 2463
- Trastuzumab, inflammatory breast cancer, pathological complete response, paclitaxel, epirubicin, 581
- Trastuzumab, metastatic breast cancer, combination, pretreated, 3051
- Trastuzumab, neoadjuvant chemotherapy, pCR, HER2, epirubicin, cyclophosphamide, paclitaxel, breast cancer, 4665
- Treatment compliance, NSCLC, adjuvant chemotherapy, carboplatin, paclitaxel, gemcitabine, surgical resection, 4695
- Treatment compliance, NSCLC, adjuvant chemotherapy, carboplatin, paclitaxel, surgical resection, 3039
- Treatment response, nuclear morphometry, breast cancer, prognosis, 2185
- Treatment, head and neck cancer, EGFR, chemoradiotherapy, prognostic factor, 671
- Treatment, high-grade glioma, HGG, vincristine, outcome, 2303
- Treatment, imiquimod, oral dysplasia, 2891
- Treg-cells, FOXP3, regulatory T-cells, gastric cancer, review, 1093
- Tricyclic antidepressants, brain tumours, clomipramine, amitriptyline, dexamethasone, oxygen consumption, malignant glioma, 391
- Trihaloacetylazulenes, QSAR, cytotoxicity, semiempirical molecular-orbital method, 837
- Triple negative, pre-operative therapy, prediction of therapy response, dose-dense epirubicin, cyclophosphamide, docetaxel, breast cancer, 4251
- TROP-2, EGCG, HCT-116, SW480, mRNA stability, cycloheximide, (-)epigallocatechin-3-gallate, colorectal cancer cells, 2497
- Tropolones, QSAR, cytotoxicity, semiempirical molecular-orbital method, 129
- Truncated thio-Cl-IB-MECA, A3 adenosine receptor, A3AR antagonist, apoptosis, bladder cancer cells, 2823
- TS, breast cancer, signal pathway, mTOR, ROS, 5-FU, rapamycin, 2625
- TS, colorectal cancer, adjuvant 5-FU, 645
- TS, DHFR, GARFT, NSCLC, malignant pleural mesothelioma, pemetrexed, 4309
- TSC1, TSC2, androgen deprivation therapy, testosterone, prostate cancer, 3895
- TSC2, TSC1, androgen deprivation therapy, testosterone, prostate cancer, 3895
- Tubulin, histochemistry, actin, electron microscopy, P150, eukaryotic translation initiation factor 3, colon cancer, 1047
- Tubulocystic carcinoma, papillary renal cell carcinoma, clear cell papillary renal cell carcinoma, oncocytoma, chromophobe renal carcinoma, 641
- Tumor burden, gene polymorphism, breast cancer, CD44, patient age, SNP, 1263
- Tumor cell dissemination, endometrial cancer, hysteroscopy, peritoneal cytology, sentinel node, 2425
- Tumor cure probability, radiation sensitivity, ovarian cancer, radioimmunotherapy, astatine, 2545
- Tumor growth suppression, bamboo leaf extract, anticarcinogenesis effect, breast cancer, pretreatment, cancer prevention, 111
- Tumor growth, gossypol, docetaxel, Bcl-XL, apoptosis, anti-apoptosis genes, adrenal cancer, 4805
- Tumor invasion, KITENIN, stomach neoplasm, tumor metastasis, prognosis, 3479
- Tumor invasion, nexrutine<sup>R</sup>, prostate cancer, BMD, CREB, NF- $\kappa$ B, TRAMP, 857

- Tumor M2 pyruvate kinase, tumor marker, cervical carcinoma, CIN, HPV, 375
- Tumor marker, breast cancer, CA 27.29, chemotherapy, MUC-1, 1837
- Tumor marker, follow-up, Cyfra 21-1, oropharyngeal cancer, squamous cell carcinoma, 2291
- Tumor marker, prostatic cancer, IL-6, 4369
- Tumor marker, PSA, kinetics, prostate cancer, prognosis, 1633
- Tumor marker, thymidine kinase, lung cancer, biomarker, serum, 1855
- Tumor marker, tumor M2 pyruvate kinase, cervical carcinoma, CIN, HPV, 375
- Tumor metastasis, cytoplasmic phospholipase A2, 5-lipoxygenase, cyclooxygenase-2, angiogenesis, metalloproteinase, 3421
- Tumor metastasis, KITENIN, stomach neoplasm, tumor invasion, prognosis, 3479
- Tumor microenvironment, metastatic human cancer, palliation, progesterone receptor antagonist, mifepristone, 623
- Tumor microenvironment, murine lung cancer, progesterone receptor antagonist, mifepristone, natural killer cells, lung cancer, 119
- Tumor microenvironment, vascular normalization, pericytes, angiogenesis, radiotherapy, hypoxia,  $\alpha$ -SQMG, 4397
- Tumor model, oral cancer, 2'-hydroxycinnamaldehyde, cell cycle, apoptosis, 489
- Tumor necrosis factor-related apoptosis-inducing ligand, antitumor, apoptosis, cell-penetrating peptide, gene therapy, protein transduction domain, TRAIL, arginine-rich peptides, 2193
- Tumor progression, bladder cancer, biomarkers, immunohistochemistry, CA19.9, CEA, transitional cell carcinoma, 5195
- Tumor progression, gamma-glutamyltransferase, human neoplasia, drug resistance, redox regulation, review, 1169
- Tumor progression, MT1-MMP, MMP-14, tyrosine phosphorylation, antennapedia, 3D matrix, 1887
- Tumor spheroids, malignant mesothelioma, animal tumor model, mesenchymal stem cell, chemokine, SDF1/CXCL12, 2153
- Tumor stroma, cancer-associated fibroblasts, cancer microenvironment, squamous cell carcinoma, basal cell carcinoma, review, 455
- Tumor suppressor genes, breast cancer, promoter hypermethylation, genomic methylation, repetitive elements, WBC DNA, 2489
- Tumor suppressor, PTPG, breast cancer, cell cycle regulators, 1937
- Tumor suppressor-gene, prostate cancer, progression, TP53, mutation, 1579
- Tumor-growth metastasis, orthotopic model, FOLFIRI, colon cancer, survival time, GFP imaging, 403
- Tumor-specificity, benzaldehyde, type of cell death, apoptosis, autophagy, 5069
- Tumour antigen, asbestos, lung cancer, Annexin A2, SEREX, 2631
- Tumour characteristics, prognosis, cancer-specific survival, 5227
- Tumour glycolysis, breast cancer, M2PK, pAkt, 1689
- Tumour inhibition, prostate cancer prophylaxis, noscapine, 399
- Tumour LDH-5, serum LDH, NSCLC, adenocarcinoma, squamous cell carcinoma, immunohistochemistry, 1347
- Tumour marker index, CEA, CYFRA 21-1, non-small cell lung cancer, survival, 3099
- Tumour marker, non-small cell lung cancer, cytokeratin, CYFRA21-1, prognosis, survival, 3833
- Tumour marker, receiver operating characteristic curve, diagnosis, cytokeratin 19, CEA, mesothelioma, 4343
- Tumour marker, Y-box binding protein 1, YB-1, neuroblastoma, immunohistochemistry, 1239
- Tumour markers, animal cancer models, chick embryo, rodent model, immunohistochemistry, glioblastoma, cell xenografts, 4851
- Tumour markers, CA 15-3, CEA, breast cancer, relapse, elderly, postmenopausal, 2331
- Tumour markers, Proceedings of the 14th International Hamburg Symposium on Tumor Markers, December 7-9, 2008, Hamburg, Germany, 1547-1874
- Tumour models, KP1339, anticancer ruthenium(III) compounds, electroporation, electrochemotherapy, sarcoma, mice, 2055
- Tumour necrosis factor receptor 1, placental growth factor, transforming growth factor-alpha, transforming growth factor-beta 1, matrix metalloproteinase-2, pancreatic neoplasms, inflammation, 3801
- Tumour necrosis factor-related apoptosis-inducing ligand, TRAIL, histone deacetylase inhibitors, FR235222, human promyelocytic leukaemia, apoptosis, 887
- Tumour recurrence, colorectal cancer, cytokine, growth factor, hepatectomy, liver metastasis, liver regeneration, review, 2161
- Tumour response, LAT1, rectal cancer, preoperative hyperthermo-chemoradiotherapy, 4223
- Tumour specific transplantation antigen, murine polyomavirus, viral persistence, virus like particles VLPs, immune responses, review, 279
- Tumour vascularisation, magnetic drug targeting, local chemotherapy, computed tomography, angiography, flat-panel CT, 1553
- Tumour, angiogenesis, functional vessel density, vascular network, fluorescence microscopy, 2597

- Tumour, dermatofibrosarcoma protuberans, surgical treatment, wide local excision, 3775
- Tumour-derived microvesicles, CD14++CD16–, CD14+CD16++ monocyte subsets, 3515
- Turkish population, cyclin D polymorphism, *CDKN1B* polymorphism, breast cancer, 3093
- TWEAK, PPAR $\gamma$  ligand, apoptosis, reactive oxygen species, colon cancer, 157
- Two-dimensional gel electrophoresis, 2-DE, LC-MS/MS, pancreatic cancer, gemcitabine, GEM, proteomics, heat-shock protein 27, 2539
- Two-dimensional gel electrophoresis, LC-MS/MS, Flamingo Gel Stain, SeePico, highly sensitive Coomassie brilliant blue, proteomic analysis, 4001
- Two-dimensional gel electrophoresis, LC-MS/MS, pancreatic cancer, gemcitabine, GEM, proteomics, 3367
- Two-photon excitation, interstitial diffusion, collagenase, hyaluronidase, FRAP, multicellular spheroids, 359
- Type 2 diabetes mellitus, cancer, body mass index, mortality, epidemiological study, 681
- Type II sodium-dependent phosphate transporter, SLC34A2, diagnosis, therapy, breast cancer, 4135
- Type IV collagen, 3-hydroxyproline, basement membrane, cancer invasion, cancer metastasis, cancer screening, ELISA, 1007
- Type of cell death, benzaldehyde, tumor-specificity, apoptosis, autophagy, 5069
- Tyrosine kinase inhibitor, EMT, lung cancer, adenocarcinoma, resistance, EGFR, 2513
- Tyrosine kinase inhibitor, ovarian cancer, mouse model, xenograft, luciferase, sunitinib, 3355
- Tyrosine kinase inhibitor, renal cell carcinoma, sunitinib malate, bone metastases, 5165
- Tyrosine kinase inhibitors, Akt, breast cancer, ErbB receptors, erlotinib, gefitinib, vitamin E, Stat,  $\gamma$ -tocotrienol, 429
- Tyrosine kinase inhibitors, NSCLC, EGFR, *KRAS*, mutation, multiplicity, clonality, lung cancer, 1667
- Tyrosine kinase inhibitors, NSCLC, erlotinib, EGFR, lung cancer, review, 1301
- Tyrosine kinase pathway, P-glycoprotein, chemosensitivity sorafenib, multidrug resistance, hepatocellular carcinoma cells, 4503
- Tyrosine phosphorylation, MT1-MMP, MMP-14, antennapedia, tumor progression, 3D matrix, 1887
- U-2 OS human osteogenic sarcoma cells, CHM-1, DNA damage, DNA repair, gene expression, quinolone, 4187
- U937 cells, dendritic cells, poly-phenylpropanoid polysaccharide complex, differentiation, 613
- Ubiquinone, statins, HMGCoA reductase inhibitors, carcinogenesis, liver neoplasm, mevalonate pathway, hepatocarcinogenesis, lovastatin, 1105
- UC-associated colorectal cancer, ulcerative colitis, claudin-1, surveillance, 3181
- UCN-01, HPV, cervical carcinoma, sodium butyrate, apoptosis, 4049
- UDG, OGG1, NTH1, APE1, DNA repair, mtDNA, nDNA, lung cancer cells, 4963
- Ulcerative colitis, UC-associated colorectal cancer, claudin-1, surveillance, 3181
- Ultrasound probe, prostate, biopsy, postoperative complications, bleeding, 3071
- Ultrasound, cell damage, lipid peroxidation, sonodynamic activation, reactive oxygen, DCPH-P-Na(I), 2241
- Ultraviolet-B, cereals, cholesterol, diet, gross domestic product, milk protein, prostate cancer, vitamin D, 189
- UM-SCC, HNSCC,  $\beta$ -catenin, sulindac sulfone, cell line, cell culture, apoptosis, 339
- Uncommon site, extramedullary, plasmocytoma, multifocal, surgery, radiotherapy, chemotherapy, 1779
- Undifferentiated carcinoma, nasopharyngeal carcinoma, IGF-1R, head and neck cancer, immunotherapy, 1641
- Untranslated region UTR, thymidylate synthase TS, thymidylate synthase enhancer region TSER, variable number of tandem repeats VNTR, gastric cancer risk, 2325
- Upper urinary tract, AKT, HER-2, immunohistochemistry, urothelial carcinoma, 2439
- Uptake, prostate cancer, FDG-PET, glycolysis, fatty acid, bioenergetic metabolism, 369
- Urinary FISH test, prognosis, UroVysion assay, recurrence, bladder cancer, 4761
- Urinary incontinence, pelvic floor rehabilitation, radical prostatectomy, kegel exercises, 553
- Urokinase, cadherin, insulin-like growth factor, leiomyoma, myeloperoxidase, polymorphism, xeroderma pigmentosum, 2203
- Uro-Oncology, SIUrO, conference abstracts 1375-1544
- Urothelial cancer of bladder, vascular endothelial growth inhibitor, VEGI, motility and adhesion, bladder cancer cells, 87
- Urothelial cancer, heme oxygenase-1, drug resistance, chemotherapy, radiotherapy, gemcitabine, 2145
- Urothelial carcinoma, AKT, HER-2, immunohistochemistry, upper urinary tract, 2439
- Urothelial carcinoma, B cells, Epstein-Barr virus, LMP-1, pathogenesis, cell line, 3473
- Urothelial carcinoma, gemcitabine, cisplatin, elderly patients, 3839
- UroVysion assay, prognosis, urinary FISH test, recurrence, bladder cancer, 4761
- Uterine cervix, oestrogen receptors, progesterone receptors, adeno-carcinoma, 1341
- Uterine clear cell carcinoma, uterine serous papillary carcinoma, death rate, survival, 3727

- Uterine corpus cancer, staging, lymphadenectomy, negative predictive value, specificity, FDG-PET, 3787
- Uterine serous papillary carcinoma, uterine clear cell carcinoma, death rate, survival, 3727
- UVB photocarcinogenesis, honokiol, chemoprevention, apoptosis, 777
- UVB, free radical, photodynamic therapy, indole-3-acetic acid, apoptosis, prostate cancer cells, 4607
- UVC, *in vivo* imaging, color-coded, GFP, RFP, melanoma, blood vessels, 3291
- UV-radiation, DNA repair, cisplatin, nucleotide excision repair, RB, XPC, 2483
- Vaccination, colorectal cancer, dendritic cells, antigen loading, CEA peptide, mRNA, electroporation, immunotherapy, 5091
- Vaccination, cytokines, IL-12, paracrine treatment, *Schistosoma mansoni*, SWAP, systemic treatment, poly-*N*-acetyl glucosamine gel matrix, 3889
- Vaccination, IL-1 receptor antagonist, IL-6, colon-26 carcinoma, survivin peptide vaccination, beta-glucan, anti-inflammation, Anakinra, 3959
- Vacuum-assisted core biopsy, breast cancer, B3 lesions, Suros, microcalcification, lobular hyperplasia, DCIS, 2287
- Vaginal, cervical intraepithelial neoplasia, dysplasia, progesterone, phase II, 1257
- Valproic acid, histone deacetylase inhibitors, matrix metalloproteinases, epigenetic drugs, 535
- Valproic acid,  $\gamma\delta$  T-cells, cancer immunotherapy, bladder carcinoma, histone deacetylase inhibitor, NKG2D ligands, 4509
- Variable number of tandem repeats VNTR, thymidylate synthase TS, thymidylate synthase enhancer region TSER, untranslated region UTR, gastric cancer risk, 2325
- Vascular disrupting agent, angiogenesis, microtubule, combretastatin, cisplatin, 2813
- Vascular endothelial growth factor, albendazole, peritoneal carcinomatosis, angiogenesis, ovarian cancer, 423
- Vascular endothelial growth factor, interleukin-6, IL-6, new receptor inhibitor of IL-6, NRI, mesotheliomas, adenovirus, gene delivery, 1947
- Vascular endothelial growth factor, oral cancer, oropharyngeal cancer, 1765
- Vascular endothelial growth factor, p53, hypoxia-inducible factor 1 alpha, colorectal carcinoma, 4163
- Vascular endothelial growth factor, PTHrP, parathyroid hormone-related protein, VEGF, angiogenesis, bone resorption, MAPK, mitogen-activated protein kinase, 2755
- Vascular endothelial growth inhibitor, VEGI, urothelial cancer of bladder, motility and adhesion, bladder cancer cells, 87
- Vascular malformation, VEGF splice variant, HNSCC, hemangioma, head and neck, 805
- Vascular network, tumour, angiogenesis, functional vessel density, fluorescence microscopy, 2597
- Vascular normalization, pericytes, angiogenesis, radiotherapy, hypoxia, tumor microenvironment,  $\alpha$ -SQMG, 4397
- Vasopressin, desmopressin, peptide analog, chemotherapy, metastasis, colon cancer, 5049
- VEGF splice variant, HNSCC, hemangioma, vascular malformation, head and neck, 805
- VEGF, agglutinins, glycobiology, lymphangiogenesis, galectins, lectins, breast cancer cells, 4829
- VEGF, angiogenesis, DCE-MRI, MTD, PTK/ZK, 2335
- VEGF, angiogenesis, hypoxia, VEGFR2/KDR, multiple myeloma, 2831
- VEGF, bevacizumab, MFH, 3391
- VEGF, filamin, lung cancer, immunohistochemical analysis, 3939
- VEGF, IL-2, high-dose chemotherapy, NK cells, 5-fluorouracil, epirubicin, cyclophosphamide, methotrexate, radiotherapy, etoposide, carboplatin, retinoic acid, myeloablative chemotherapy, autologous transplantation, immunotherapy, breast cancer, 209
- VEGF, IL-6, NSE, ProGR, prognosis, lung cancer, 1773
- VEGF, metastatic breast cancer, first-line therapy, bevacizumab, paclitaxel, 2969
- VEGF, monoclonal antibody, radiological response, progression-free survival, bevacizumab, malignant glioma, 609
- VEGF, neoadjuvant chemotherapy, granulosa cell tumor, ovarian cancer, bevacizumab, 4767
- VEGF, PTHrP, parathyroid hormone-related protein, vascular endothelial growth factor, angiogenesis, bone resorption, MAPK, mitogen-activated protein kinase, 2755
- VEGF, targeted therapy, matrix metalloproteinase, oxidative stress, reactive oxygen species, angiogenesis, bevacizumab, FINAVAST trial, 1001
- VEGF-A, fibroblast, MMP inhibition, angiogenesis, cytokine, imaging, skin cancer invasion, PDGF-BB, 703
- VEGF-C, gastric cancer, VEGF-D, CCR7, lymphatic invasion, 2361
- VEGF-D, gastric cancer, VEGF-C, CCR7, lymphatic invasion, 2361
- VEGF-R, angiogenesis, bFGF-R, clinical studies, biomarker, brivanib, review, 4477
- VEGFR, lapatinib, sunitinib, malignant glioma, MMPs, growth factors, integrins, anti-VEGFR agents, anti-EGFR agents, 4987
- VEGFR2/KDR, angiogenesis, hypoxia, VEGF, multiple myeloma, 2831

- VEGI, vascular endothelial growth inhibitor, urothelial cancer of bladder, motility and adhesion, bladder cancer cells, 87
- Venous thromboembolism, assessment of risk and mortality, pancreatic cancer, 4261
- Venous, breast reconstruction, deep inferior epigastric artery, perforator flap, arterial, anastomosis, 1293
- Verapamil, iodination, MDR, *in vitro* evaluation, 2553
- VIM, quantitative methylation-specific PCR, colorectal carcinoma, 5015
- Vimentin, esophageal cancer, invasiveness, transwell invasion chamber, MMP-1, matrix metalloproteinase-1, p-Src (pY416), TIMP-2, tissue inhibitor of metalloproteinase-2, 727
- Vimentin, gastric carcinoma cells, scirrhous type, lymph node metastasis, prognosis, 5239
- Vimentin, human tissue kallikrein 7, morphological change, prostate cancer, invasion, metastasis, 3413
- Vimentin, intrahepatic cholangiocarcinoma, surgical resection, prognosis, 2279
- Vincristine, high-grade glioma, HGG, treatment, outcome, 2303
- Vinorelbine, advanced bladder carcinoma, gemcitabine, oxaliplatin, 4711
- Vinorelbine, breast cancer, acute disseminated intravascular coagulation, HDFL, 3087
- Vinorelbine, capecitabine, metastatic breast cancer, oral chemotherapy, 2255
- Viral persistence, murine polyomavirus, tumour specific transplantation antigen, virus like particles VLPs, immune responses, review, 279
- Virus like particles VLPs, murine polyomavirus, tumour specific transplantation antigen, viral persistence, immune responses, review, 279
- Vitamin B2, lung cancer, sentinel lymph node, fluorescent agents, 4109
- Vitamin D receptor, breast cancer, cyclooxygenase-2, 15-hydroxyprostaglandin dehydrogenase, prostaglandin receptor, calcidiol, PGE<sub>2</sub>, 1673
- Vitamin D, cereals, cholesterol, diet, gross domestic product, milk protein, prostate cancer, ultraviolet-B, 189
- Vitamin D, cervical cancer, ovarian cancer, 25-hydroxylase, 1 $\alpha$ -hydroxylase, 24-hydroxylase, calcidiol, calcitriol, 4429
- Vitamin D, cervical cancer, prostate cancer, potassium channels, placenta, EAG1, calcitriol, 2667
- Vitamin E, Akt, breast cancer, ErbB receptors, erlotinib, gefitinib, Stat, tyrosine kinase inhibitors,  $\gamma$ -tocotrienol, 429
- Vocal cord cancer, radiotherapy, chemotherapy, glottic cancer, 5181
- Vulvar carcinoma, pathological factors, surgical treatment, recurrence, thrombosis, 2311
- Vulvar intraepithelial neoplasia, squamous cell carcinoma, galectin-1, immunohistochemistry, 1547
- Watchful waiting, prostate cancer, active surveillance, review, 3683
- WBC DNA, breast cancer, promoter hypermethylation, genomic methylation, tumor suppressor genes, repetitive elements, 2489
- WFDC2, breast cancer, metastasis, prognostic factor, HE4, 4779
- WHO grading, DJ-1, astrocytoma, immunohistochemistry, prognosis, 265
- Whole brain radiotherapy, multiple brain metastases, radiotherapy, stereotactic radiosurgery, survival, non-small cell lung cancer, 3055
- Wide local excision, dermatofibrosarcoma protuberans, surgical treatment, tumour, 3775
- WiDr colon cancer cells, growth factors, 5-fluorouracil, oxaliplatin, SN-38, glutathione modulation, buthionine-SR-sulfoximine, L-2-oxothiazolidine-4-carboxylate, 1223
- Wilms' tumor gene, *WT1*, angiogenesis, immunohistochemistry, endometrial cancer, 3187
- Wilms' tumor gene, *WT1*, helper T cell, helper peptide, peptide vaccine, cancer immunotherapy, 2247
- Wilms' tumor, chemotherapy, prognostic factors, 1735
- Wnt signaling, colon cancer, side population, ATP-binding cassette transporter, 2041
- WNT5a* promoter, DLD-1, epigenetic regulation, soy isoflavone, SW480, colon cancer cells, genistein, 4537
- Women, anal dysplasia, anal cytology, HIV, HPV, infection, 1719
- Wound complications, bevacizumab, ovarian cancer, 4743
- WT1*, DC, immunotherapy, endometrial carcinoma, 3709
- WT1*, HER2, EGFR, estrogen and antiestrogen, breast cancer, 3637
- WT1*, Wilms' tumor gene, angiogenesis, immunohistochemistry, endometrial cancer, 3187
- WT1*, Wilms' tumor gene, helper T cell, helper peptide, peptide vaccine, cancer immunotherapy, 2247
- Xanthohumol, prostate cancer, apoptosis, prosurvival signaling proteins, 3333
- XELIRI, gemcitabine-resistant disease, irinotecan, pancreatic cancer, FOLFIRI, 4785
- Xenograft, ovarian cancer, tyrosine kinase inhibitor, mouse model, luciferase, sunitinib, 3355
- Xerecept<sup>®</sup>, bevacizumab, Avastin<sup>®</sup>, corticorelin acetate, brain tumor model, 5037
- Xeroderma pigmentosum, cadherin, insulin-like growth factor, leiomyoma, myeloperoxidase, polymorphism, urokinase, 2203
- XIAP, anticancer drug, growth inhibition, MDM2, p53, lung cancer, etoposide, 3321

- XPC, DNA repair, UV-radiation, cisplatin, nucleotide excision repair, RB, 2483
- XPF, ERCC1, DNA repair, chemotherapy, drug resistance, review, 3223
- X-ray microdiffraction, LB protein nanocrystals, AFM, laser, radiation damage, 2745
- XRCC4, polymorphism, colorectal cancer, carcinogenesis, 2727
- XRCC4, single nucleotide polymorphism, childhood leukemia, DNA repair, 529
- YB-1, gene regulation, gene expression, RNA interference, drug resistance, gastric carcinoma cells, 693
- YB-1, gene regulation, RNA interference, micro RNAs, microarray, gastric carcinoma cells, drug resistance, 629
- YB-1, Y-box binding protein 1, neuroblastoma, immunohistochemistry, tumour marker, 1239
- Y-box binding protein 1, YB-1, neuroblastoma, immunohistochemistry, tumour marker, 1239
- Yeast, cancer/testis antigens, SEREX, prostate cancer, cancer vaccine, 895
- YH12, drug combination, A2780, dose-effect curves, cell uptake, platinum-DNA binding, *trans*-platinum compounds, ovarian cancer cell lines, cisplatin, 4547
- Yttrium-90 microspheres, colorectal cancer, liver metastases, chemotherapy, hepatectomy, FOLFOX, 3005
- ZAP70, adenosine analogue, epigenetic, promoter methylation, clofarabine, *PTEN*, *APC*, *RARB2*, 4601
- Zeranol, leptin, aromatase, CYP19A1, estrogen, human breast pre-adipocytes, (-)-gossypol, 5077
- Zinc- $\alpha$ 2-glycoprotein, breast cancer, adipokine, leptin, adiponectin, biomarker, apoptosis, 2919
- ZO-1, gap junctional intercellular communication GJIC, connexin43, E-cadherin,  $\beta$ -catenin, immunohistochemistry, CpG island, methylation analysis, pyrosequencing, lung cancer, 2271
- Zoledronate treatment, breast cancer, recurrence-free follow-up, isolated tumour cells, minimal residual disease, 1807
- Zoledronic acid, osteosarcoma, drug resistance, heat shock protein 27, 3565



## Authors Index

(Figures refer to page numbers)

- Aaltonen V, 3995  
 Aarntzen EH, 5091  
 Abadi M, 1843  
 Abarzua S, 1587, 1695  
 Abdalla FBE, 175  
 Abdelnourberchtold E, 799  
 Abe T, 1057  
 Abrahamsen TG, 3879  
 Abramson VG, 1279  
 Abrantes M, 451  
 Abrate M, 671  
 Abuzenadah A, 2185, 4081  
 Accorsi P, 209  
 Acharya B, 4509  
 Acimovic J, 1105  
 Acosta R, 1293  
 Adachi Y, 1947  
 Adamiak J, 4799  
 Adams VR, 2505  
 Adema GJ, 5091  
 Agachan B, 1359  
 Agamaya S, 3549  
 Agelaki S, 3031, 4335  
 Agelidou A, 3031  
 Agelidou M, 3031  
 Aggarwal BB, 2477, 3599  
 Agha CA, 609  
 Agnantis N, 4493  
 Agostinelli S, 4749  
 Aguiriano-Moser V, 55  
 Ahn DH, 2325  
 Ahn EH, 2881  
 Ahn S-G, 489  
 Ajioka Y, 2279  
 Akagi Y, 3181  
 Akaike M, 2693, 4127  
 Akakura K, 5105  
 Akaza H, 4089  
 Aki R, 3291  
 Akiba S, 2431  
 Akiba T, 993  
 Akimoto K, 2705  
 Akira C, 1015  
 Akishima-Fukasawa Y, 1897  
 Akisue T, 3391  
 Akiyama H, 2367, 3063  
 Akiyama N, 383  
 Akiyama S-I, 2431  
 Akiyoshi T, 4999  
 Akrivos T, 183  
 Akther J, 3005  
 Akyürek LM, 3939  
 Al Sarakbi W, 1079  
 Al-Ayadhy B, 4147  
 Al-Bader M, 767, 4147  
 Albain KS, 3853  
 Al-Banaw AG, 767  
 Albert L, 4915  
 Alberti S, 2497  
 Alberto M, 3817  
 Albo G, 1521, 1523  
 Albrecht C, 505  
 Albrecht W, 1633  
 Alcaraz A, 2439, 4369  
 Alcover J, 4369  
 Aldrich W, 345  
 Aldulaymi B, 233, 4755  
 Aldulaymi B, 4755  
 Alessandro C, 3817  
 Alessandrini J, 1121  
 Alexiou C, 1553, 1849  
 Alfarone A, 4737  
 Al-Khattabi H, 4081  
 Alkotyfan K, 2291  
 Allen R, 4731, 5099  
 Al-Maghrabi J, 2185, 4081  
 Al-Najar A, 467  
 Alo PL, 1287  
 Alongi AP, 2911  
 Alongi F, 1391  
 Alonso DF, 5049  
 Alonso-Varona A, 1223  
 Al-Qahtani M, 2185, 4081  
 Al-Saji S, 4147  
 Alscher MD, 5137  
 Alshehri A, 4547  
 Al-Thubaity F, 2185  
 Altieri VM, 1504, 1534  
 Altmeyer A, 303  
 Alves T, 1209  
 Al-Yatama F, 767  
 Alzani R, 4973  
 Amann C, 2235  
 Amano J, 5117  
 Amano O, 5069  
 Amano R, 4115  
 Amant F, 3709  
 Amaral L, 829, 4867  
 Ambrosch P, 3541  
 Ambrosio R, 1301  
 Amoh Y, 3291  
 Amorini M, 513  
 An HJ, 2325  
 An W-W, 613  
 Anai S, 2145  
 Anastasiadis AG, 1747  
 Ancona P, 1512  
 Anderluh G, 1209  
 Andersen FF, 3257  
 Andersen J, 2463  
 Ando H, 4555  
 Ando K, 1961, 5233  
 André S, 3313, 4829  
 Andreopoulos A, 271  
 Andreopoulou E, 3243  
 Andrews JVR, 2263  
 Androulaki A, 271  
 Androulakis N, 3031, 4335  
 Angeli P, 2383  
 Angiero F, 3009, 3435, 4685  
 Angulo P, 4951  
 Annovazzi L, 1977  
 Anselmo NP, 2225  
 Anton A, 2255  
 Antonelli A, 1414, 1415  
 Antonelli A, 4705  
 Antoniou E, 653  
 Antunovic L, 3083  
 Aoki C, 1947  
 Aoki K, 3839  
 Aoyama T, 245  
 Apostolaki A, 4103  
 Appleyard CB, 3345  
 Aquino A, 4721  
 Arai A, 4071  
 Arai T, 1057  
 Araki N, 661  
 Aralica G, 2749  
 Arancio M, 1407  
 Aranda E, 415  
 Aravantinos G, 4325  
 Aravindan N, 4007  
 Arbab AS, 785, 3333  
 Archontaki M, 3775  
 Ardalan B, 1149, 1157  
 Ardavanis A, 2969  
 Arends J, 1863  
 Aresvik DM, 3879  
 Argyriou AA, 4987  
 Ariad S, 3699  
 Arigami T, 2453  
 Arikani S, 2875  
 Arima H, 2453  
 Arisawa T, 239  
 Ariyoshi-Kishino K, 5069  
 Arnes M, 4649  
 Arnogiannaki N, 3775, 4103  
 Arnoldner C, 123  
 Arnould S, 2049  
 Arnoult C, 2553  
 Arrighi N, 4705  
 Arulanandam R, 47  
 Asa SL, 1681  
 Asahina I, 2113  
 Asaka S, 221, 3763  
 Asano A, 5181  
 Asanuma K, 4353  
 Asao T, 4223  
 Ascitti S, 1025  
 Ashihara E, 2713  
 Ashikaga Y, 4773  
 Asplund A, 1217  
 Asselti M, 3521  
 Athanasiou A, 973  
 Atlante M, 4993  
 Aubel C, 2049  
 Augé JM, 4369  
 Augenlicht LH, 2531  
 Austoni E, 1519  
 Aversa SML, 2383  
 Avila E, 2667  
 Ayabe T, 3099  
 Aydin B, 2303  
 Aydogan F, 3093  
 Ayuso D, 4711  
 Azuma H, 3737  
 Azuma K, 3839  
 Azuma M, 4209  
 Azumi T, 4373  
 Baba H, 1015  
 Baba T, 2631  
 Baba Y, 1015  
 Babinski A, 1869  
 Babjuk M, 665, 3579  
 Bacchi CE, 2407  
 Bachawal SV, 429

- Bachmann F, 1047  
Bacigalupo A, 2977  
Bacigalupo B, 2377  
Back H-K, 3421  
Badisa VLD, 4613  
Badowska W, 2119  
Baek KJ, 4607  
Baek SJ, 2497  
Bahlo M, 1869  
Bai M, 2831  
Baiardi P, 5159  
Baj-Krzyworzeka M, 3515  
Baka S, 3031  
Bakare O, 519  
Baker C, 2591  
Balb C, 1405  
Baldazzi V, 1447, 1449, 1459, 1473  
Baldus SE, 2603, 4635  
Balduzzi A, 4721  
Balestrieri R, 1421  
Balik E, 1359  
Ballester M, 4743  
Balzano G, 4785  
Balzarini J, 3987  
Balzarini P, 4705  
Bamberger A-M, 1681  
Bandelloni R, 4761  
Bang MH, 5145  
Bang Y-J, 5245  
Bangaru Y, 499  
Banu J, 857  
Banziger R, 1047  
Baran J, 3515  
Barassi A, 3801  
Barattin R, 2553  
Barbarat A, 3951  
Barbato E, 4265  
Barbato V, 1301  
Bardi G, 973  
Bareschino MA, 1301  
Barken I, 399  
Baron B, 4459  
Barone TA, 4851  
Barrena Medel NI, 4767  
Barrera D, 2667  
Barresi E, 1323  
Barsky SH, 3903  
Barsotti C, 201, 3731  
Bartel P, 3071  
Bartel-Friedrich S, 1565, 1569, 1593, 1625, 1641, 1765  
Barth P, 5195  
Barthell E, 1599  
Basch R, 2911  
Basinko A, 569  
Bassi PF, 1445  
Bassignana A, 2659  
Basso SMM, 2331, 4701  
Bastian PJ, 2785  
Basu-Mallick A, 2531  
Bau D-T, 529, 1195, 2727, 3573, 3649, 3655, 4141, 4205, 5217  
Bauer G, 3967  
Bauer M, 2739  
Bauerschlag DO, 2739, 2837, 3355  
Baumgartner M, 3781  
Baumunk D, 4619  
Beale P, 4025, 4547  
Beato A, 1462  
Beatrice V, 1431  
Becagli L, 2311  
Becht C, 4711  
Becker S, 1673, 2425, 2597  
Beckmann MW, 1837  
Bedane C, 143  
Bednarek A, 4601  
Befrits R, 261, 3019  
Bekele N, 2303  
Belcher M, 3903  
Belgioia L, 4749  
Belian E, 629, 693  
Béliveau R, 1887  
Bellardita L, 1541  
Belli C, 4785  
Belsanova B, 1667  
Beltramo G, 1436  
Benavides MA, 1881  
Benecchi L, 1464, 1464  
Benedicenti S, 3009  
Benerini Gatta L, 3435  
Benesch C, 1689  
Benesova L, 1667  
Benetti A, 3435  
Beninati S, 445  
Benitez E, 1149  
Benitez R, 4805  
Bennamoun M, 4297  
Benny O, 1057  
Bentivegna E, 1029  
Bentrem DJ, 73  
Bentz E, 565  
Benzina S, 303  
Beppu T, 1015, 5055  
Berenzi A, 3435  
Bergauer F, 1719  
Bergerat J-P, 963  
Berhe S, 519  
Beria I, 4973  
Bermejo B, 2255  
Bernardo G, 5159  
Bernardo S, 1462  
Berndt-Skorka R, 1829  
Berneman ZN, 3709  
Bernhards J, 1747  
Bertaccini A, 553, 2297, 2973  
Berthois Y, 2101  
Berthou C, 569  
Bertin F, 3811  
Bertini R, 1395, 1396, 1397, 1398  
Bertoloni R, 1389, 1390  
Bertorelle R, 5121  
Bester L, 3005  
Betre K, 719  
Bettendorf O, 1823  
Betz P, 1849  
Beuth J, 1353, 1767  
Beyene D, 519  
Bhardwaj V, 743  
Bhaskaran S, 857  
Bhushan A, 743  
Bianchi G, 1475, 1476  
Biber Muftuler FZ, 1243  
Bielawska-Pohl A, 4587  
Bifulco M, 2583  
Bignon Y-J, 2049  
Bilim V, 4089  
Billard H, 2919  
Bilo HJG, 681  
Bird NC, 2161  
Bischoff P, 303  
Biscotti CV, 4791  
Bisdas S, 123  
Bishop M, 953  
Bismohun S, 3693  
Bitterlich N, 1661  
Bjork J, 3019  
Björkhem-Bergman L, 1105  
Bjørkøy A, 359  
Black PM, 1057  
Blanco L, 1137  
Bland KI, 1881  
Blank S, 3243  
Blobe GC, 1251  
Block M, 2025  
Blohmer J-U, 375  
Bobek V, 4799  
Bobrowska-Hägerstrand M, 4423  
Bocca C, 2659  
Boccagni P, 2383  
Boccola MA, 601  
Boder JME, 175  
Bodner K, 1341  
Bodner-Adler B, 1341  
Bohanes P, 4209  
Bohle RM, 2837  
Bohr VA, 4963  
Boisguerin P, 1573  
Boisseau A, 4297  
Bold RJ, 3279  
Bolenz C, 467  
Bölling T, 227, 2857  
Bolotin A, 3699  
Bolouri S, 4265  
Bonaldi L, 5121  
Bonamini M, 2331  
Bonanno L, 5121  
Bonfante V, 4381  
Bonmassar E, 4721  
Bonmassar L, 4721  
Bonnaud F, 3811  
Bonnetblanc J-M, 143  
Borgato L, 3243  
Borges BDN, 2225  
Borges HL, 1209  
Borghesi M, 2297  
Borlenghi E, 3845  
Bornschein J, 505  
Borok TJ, 953  
Bose P, 4731  
Bosland MC, 1881  
Boso C, 2383  
Bosset M, 4049  
Bostwick DG, 719  
Bottcher MC, 805  
Botti C, 1287  
Boubelik M, 4799  
Bougioukas GI, 1143  
Boulinguez S, 143  
Boulware D, 5063  
Bourantas KL, 2831  
Bourges K, 2553  
Bourhis J, 3869  
Boutonnat J, 2553  
Bouvet M, 3933, 4415  
Bowles TL, 3279

- Boyd L, 3243  
 Bozionelou V, 4335  
 Bozzao A, 3055  
 Bozzo F, 2659  
 Bracke M, 9  
 Brackett DJ, 4883  
 Bradford C, 4805  
 Bradley WG, 613  
 Braggio E, 2407  
 Braicu I, 2525  
 Bran GM, 3459  
 Brancato T, 1413  
 Braun M, 2235  
 Brausi M, 1401, 1402, 1403, 1404  
 Breier A, 3661  
 Breiteneker F, 1633  
 Bremer M, 3781  
 Brenna SMF, 2319  
 Brennan C, 641  
 Briese J, 1681  
 Briese V, 1587, 1695  
 Brink I, 3787  
 Brinkmann F, 5137  
 Brion N, 5165  
 Brioschi M, 4785  
 Brollo A, 1323  
 Brower SL, 2805  
 Brown BD, 3869  
 Brueggemeier RW, 4883  
 Brunhuber T, 1047  
 Brünner N, 233, 587, 4755  
 Bruno P, 4769  
 Brunocilla E, 2973  
 Bruns F, 1747, 1779, 1783, 1829  
 Bucci B, 4993  
 Buchholz S, 1559  
 Büchler MW, 4503  
 Buckendahl A, 2991  
 Budd GT, 547  
 Buechert M, 2335  
 Bugra D, 1359  
 Bühler P, 3373  
 Buhmeida A, 175, 2185, 4081  
 Bui F, 3083  
 Buijs M, 923  
 Bullerdiek J, 5043  
 Bulut T, 1359  
 Bundscherer A, 4017  
 Büntzel J, 1783, 1829  
 Burbano RMR, 2225  
 Burge M, 767  
 Burger M, 1047  
 Burkhardt N, 4563  
 Burra P, 2383  
 Busia A, 4381  
 Butt W, 5113  
 Büttner M, 1849  
 Buzyn A, 2977  
 Cacheux W, 4229  
 Cacina C, 1359, 2875, 3093  
 Čada Z, 455  
 Caddell R, 463  
 Caffier H, 1689  
 Cahn JY, 2977  
 Cai C, 805  
 Cai Z, 1921  
 Cai ZY, 423  
 Calabrese F, 2383  
 Calay Z, 2885  
 Calcagno DQ, 2225  
 Caldefie-Chezet F, 2919  
 Caldera V, 1977  
 Calliste C-A, 143  
 Calvo F, 2101  
 Camacho J, 2667  
 Campanella D, 5251  
 Campodonico F, 1494, 4761  
 Canbay E, 1359, 3093  
 Candeloro G, 209  
 Canepa G, 4761  
 Canestraro M, 4525  
 Canis M, 2597  
 Canova F, 2383  
 Cantore N, 967  
 Cao Y, 3911  
 Capodiferro S, 843  
 Caporaso P, 4721  
 Capozzo MA, 3823  
 Cappella P, 4973  
 Cappelletti D, 4721  
 Capponi G, 4761  
 Caraglia M, 1531  
 Caramés M, 1223  
 Carbone A, 3845  
 Carcache De Blanco EJ, 3295, 3945  
 Cardillo A, 4721  
 Carico E, 4993  
 Carli P, 2311  
 Carlomosti F, 445  
 Carlsson L, 285  
 Carmignani L, 1498, 1499  
 Carratu A, 887  
 Carreras E, 2977  
 Carroll RS, 1057  
 Caruso MG, 2583  
 Caruso ML, 5251  
 Caruso RA, 513, 699  
 Carvalho Bastos CEM, 2225  
 Casadei R, 3801  
 Casado A, 2255  
 Casazza S, 4761  
 Cassetti P, 1323  
 Castellani D, 1025  
 Castellucc R, 1510  
 Castiglione R, 1471  
 Castro J, 4643  
 Cattarino S, 4737  
 Cattoretti G, 3009  
 Caughron SK, 5099  
 Cavagnetto F, 4749  
 Cavaliere F, 751  
 Cavalli F, 4289  
 Cavallini A, 5251  
 Cecchin D, 3083  
 Cemazar M, 2055  
 Cengel K, 1905  
 Cengiz A, 3093  
 Cerantola Y, 799  
 Cerbone L, 4289  
 Cercel A, 3093  
 Cereda S, 4785  
 Ceresoli A, 1440  
 Chadid S, 1875  
 Chan JY-W, 2851  
 Chan MSM, 3465  
 Chan W-S, 2851  
 Chandrinou H, 973  
 Chang C-C, 2203  
 Chang C-H, 65  
 Chang Chao-Hsiang, 3573  
 Chang Chih-Hsien, 4039  
 Chang Chung-Hsing, 3291  
 Chang C-Y, 1189  
 Chang D-Y, 3087  
 Chang G-D, 4177  
 Chang H-L, 1937  
 Chang J, 2217  
 Chang MS, 2469  
 Chang N-W, 3655  
 Chang T-J, 4039  
 Chang W-S, 2727, 5217  
 Chang W-SW, 727  
 Chang Y, 713  
 Chang Y-J, 65  
 Chanock SJ, 217  
 Chanplakorn N, 3465  
 Chao C, 2287  
 Chao J, 547  
 Chao Y-S, 2813  
 Charles AK, 815  
 Chatonidis I, 4103  
 Chaudhary A, 2185, 4081  
 Check D, 623, 4921  
 Check JH, 119, 623, 4921  
 Chekerov R, 1701, 2525  
 Chen B, 1905  
 Chen B-L, 2335  
 Chen C, 4951  
 Chen Chih-Ping, 2203  
 Chen Ching-Ping, 2813  
 Chen C-T, 2813  
 Chen D-R, 4135  
 Chen Frank, 1701  
 Chen Fu, 4643  
 Chen G, 2209  
 Chen H, 4537  
 Chen H-Y, 2125, 4187  
 Chen J, 1113  
 Chen JH, 811  
 Chen JY-F, 727  
 Chen K-B, 3573  
 Chen L-C, 65, 4039  
 Chen Lian, 4873  
 Chen Lixia, 3593  
 Chen Lujun, 4363  
 Chen M-H, 65  
 Chen P-Y, 253  
 Chen R, 135  
 Chen R-L, 2193  
 Chen S, 499  
 Chen Shih-Hsien, 727  
 Chen Shih-Hsun, 4177  
 Chen X, 1999  
 Chen Y, 3045  
 Chen Y-K, 727  
 Chen Y-Y, 945  
 Chen Z, 3345  
 Cheng A-L, 3087  
 Cheng H-N, 5217  
 Cheng J, 3895  
 Cheng L, 713, 3683, 4573  
 Cheng S, 1681  
 Cheon EC, 73  
 Cheong J-W, 4625  
 Chereau E, 4743  
 Chern J, 119  
 Chetty R, 2935  
 Chew BP, 2171, 2721

- Chhipa RR, 3895  
 Chiang J-H, 2125, 3549  
 Chiang S-Y, 945  
 Chiara GB, 2331, 4701  
 Chiba T, 2673  
 Chien S-Y, 4135  
 Chierigo P, 1490  
 Chikazawa N, 2041  
 Chilampalli S, 777  
 Chiriboga L, 2911  
 Chishima T, 5189  
 Chiu C-F, 3573  
 Chiu S-P, 4039  
 Chiu T-H, 4187  
 Chiu Y-J, 3549  
 Chloropoulou PA, 1143  
 Cho S-B, 3479  
 Cho YH, 2489  
 Choi BY, 2469  
 Choi H-J, 4163  
 Choi HS, 2773  
 Choi J-S, 79  
 Choi S-J, 79  
 Choi WJ, 2823  
 Chottova-Dvorakova M, 665  
 Chou S-H, 727  
 Chovanec M, 455  
 Chow LWC, 3465  
 Chow WA, 167, 547  
 Chrisovergis A, 2891  
 Christensen IJ, 233, 4755  
 Christensen IJ, 4755  
 Christodoulou C, 4325  
 Chrobak M, 1695  
 Chu C-C, 1195  
 Chu P, 547  
 Chu SWL, 423  
 Chua TC, 3005  
 Chuang C-H, 4039  
 Chuang C-K, 3473  
 Chuang K-L, 3473  
 Chueh F-S, 4187  
 Chung E, 4467  
 Chung I-J, 3479  
 Chung J, 4485  
 Chung J-G, 945, 1189, 2125, 2135, 3549, 4135, 4187  
 Chung M-H, 481  
 Chung V, 1921  
 Chuu C-P, 3643  
 Ciavarella D, 4265  
 Cicuto S, 1510  
 Cignarelli M, 473  
 Cimpean AM, 3981  
 Cindolo L, 1415, 1416  
 Cindric M, 4063  
 Cine N, 4525  
 Cinelli MA, 4873  
 Cionini L, 1327  
 Cipak A, 4063  
 Ciresa-König A, 3721  
 Clarke E, 3055  
 Clerici C, 1025  
 Clerici G, 1025  
 Cludts S, 3313  
 Cochetti G, 1468  
 Coculescu M, 3981  
 Cohen D, 953  
 Cohen R, 623  
 Colantonio I, 671  
 Cole DJ, 3889  
 Coley HM, 3529  
 Collan Y, 175, 2185  
 Comino A, 671  
 Communal Y, 2049  
 Concin N, 565  
 Concolino F, 4721  
 Conda-Sheridan M, 4873  
 Conte MA, 3823  
 Cook-Moreau J, 143  
 Cooper J, 641  
 Coosemans A, 3709  
 Copeland Jr RL, 519  
 Coppola D, 3345, 5063  
 Coraci G, 1503  
 Cordes C, 3541  
 Cordes T, 4429  
 Corinaldesi R, 3801  
 Cormier L, 4317  
 Cormio L, 1377, 1378  
 Corrales FJ, 415  
 Corsi MM, 3801  
 Corti A, 1169  
 Corti L, 1273, 2311  
 Corti S, 4705  
 Corvò R, 4749  
 Cosio S, 1327  
 Costa A, 3055  
 Cottin P, 5085  
 Cottini E, 1467  
 Coumbos A, 1701  
 Cova G, 1502  
 Covas DT, 5023  
 Cozzoli A, 4705  
 Creatsas G, 183  
 Creek K, 1263  
 Crescenzi M, 1121  
 Crippa R, 3009  
 Criscuolo C, 3845  
 Cristante T, 3823  
 Cristea M, 167  
 Crosby K, 857  
 Crowe DL, 3407  
 Cucchi U, 4973  
 Cucherousset J, 4297  
 Culine S, 4711  
 Cunico SC, 4705  
 Curtin J, 3243  
 Cury PM, 2845  
 Cushman M, 4873  
 Cusimano MD, 2897  
 Czejka M, 2355, 5207  
 Czerwenka K, 1341  
 Czyzewski K, 2119  
 D'Acunto CW, 887  
 D'Alonzo A, 4749  
 D'Arco A, 967  
 D'Ascenzo R, 1445  
 D'Atri S, 4721  
 Da Silva Santos E, 2225  
 Dahl E, 2525  
 Dahlberg W, 39  
 Daily MF, 4951  
 Dalay N, 2489  
 Dalezis P, 4201  
 Dalhaug A, 977  
 Dalianis T, 279  
 Dalmay F, 3811  
 Dalton RN, 2935  
 Damour O, 2919  
 Danenberg KD, 4209  
 Dang D, 2591  
 Dang F, 1  
 Daniele A, 3521  
 Danielsson A, 2545  
 Danks R, 2943  
 Danner BC, 1347  
 Darai E, 4743  
 Darb-Esfahani S, 1701  
 Darbre PD, 815  
 Dargelos E, 5085  
 Das JR, 519  
 Daskalow K, 1573  
 Davide P, 3817  
 Davidoff AM, 3301, 4391  
 Davidoff MS, 1569  
 Davies S, 1163  
 Davis C, 4907  
 Dawiskiba J, 4945  
 Day AA, 519  
 De Almeida Braggio D, 2407  
 De Araujo AG, 5023  
 De Berardinis E, 1425, 1426  
 De Boer A, 5091  
 De Braekeleer E, 569  
 De Braekeleer M, 569  
 De Cremoux P, 4229  
 De Grève J, 5185  
 De Lange Davies C, 359  
 De Luca S, 1383, 1384, 1407, 1408, 1409, 1410  
 De Marchis ML, 751  
 De Muckadell OBS, 587  
 De Nunzio C, 1384, 1385, 1386, 1387, 1388  
 De Ponti A, 4973  
 De Souza-Pinto NC, 4963  
 De Stefani S, 1480  
 De Vanna M, 3823  
 De Vecchis L, 4721  
 De Vries IJM, 5091  
 De Wever O, 9  
 Debruyne D, 9  
 Decaestecker C, 3313  
 Decoster L, 5185  
 Decrion-Barthod A-Z, 4049  
 Dedic A, 4063  
 Deeb D, 785, 3333  
 Degeorges A, 4229  
 Deguchi K, 2361  
 Dehchamani D, 2393  
 Del Bianco P, 2311  
 Del Monte G, 4657  
 Delahunt B, 641  
 Delattre O, 4229  
 D'Elia G, 1516, 1517  
 Della Palma M, 2311  
 Delle U, 4451  
 Delort L, 2919  
 Demartines N, 799  
 Demcheva M, 3889  
 Demichele A, 1279  
 Dempke W, 4471, 4477, 4673  
 Dendrinis P, 3775  
 Deng Y, 4261  
 Denis J-M, 303  
 Denschlag D, 3787  
 Dente D, 1412  
 Deoliveira R, 1875  
 Deremer DL, 2505  
 Derwinger K, 5227

- Des Guetz G, 4297  
 Desbordes C, 311, 3629  
 Dessanti P, 2377  
 Dessy E, 3435  
 Destefanis P, 1513  
 Deutsch E, 3869  
 Deutsch JK, 3629  
 Dewdney A, 2949  
 Dhand R, 3557  
 Dhupkar P, 1905  
 Di Bella C, 513  
 Di D, 4363  
 Di Francesco S, 1509  
 Di Girolamo F, 1121  
 Di Lorenzo G, 1533  
 Di Mare L, 1452  
 Di Renzo GC, 1025  
 Di Viccaro D, 1474  
 Diaz L, 2667  
 Dick EJ Jr, 4123  
 Didilis VN, 1143, 1347  
 Diedrich K, 1673, 4429  
 Diehl A, 1279  
 Dienes HP, 2017, 4635  
 Dietl J, 1547, 1559, 1653, 1689  
 Dimitropoulos K, 4987  
 Ding W-Q, 2087, 3249  
 Ding Y, 2209  
 Dionne S, 157  
 Dippon J, 5137  
 Ditsch N, 1707, 1713  
 Ditte P, 3661  
 Dittmer C, 1673  
 Divella R, 3521  
 Dix E, 119, 623, 4921  
 Dobbstein C, 1779  
 Dobo C, 2799  
 Doffoel-Hantz V, 143  
 Dogliotti G, 3801  
 Dohi S, 3187  
 Dohmen B, 2837  
 Dohrmann T, 3933  
 Doi Y, 4115, 5239  
 Doino D, 4749  
 Doki Y, 1335  
 Dokou A, 653  
 Dombrowski Y, 1653  
 Domosławski P, 4945  
 Domoto K, 581  
 Donati P, 751  
 Dong L, 2065  
 Dong M, 4405  
 Dörfler A, 1553  
 Dormond O, 799  
 Dormond-Meuwly A, 799  
 Doroshov JH, 167  
 Dos Santos Moreira A, 2407  
 Douet-Guilbert N, 569  
 Doufexis D, 2969  
 Dowling M, 1905  
 Draxl H, 1047  
 Drechsler S, 1587  
 Drevs J, 2335  
 Du G-J, 295  
 Du Moulinet D'Hardemare A, 2553  
 Du P, 1881  
 Duarte N, 451, 4587  
 Dubois V, 2919  
 Duburs G, 4063  
 Duda S, 1587  
 Dudek AZ, 987  
 Duell T, 1855  
 Dugan E, 1251  
 Dulchavsky SA, 785, 3333  
 Dullaart RPF, 5153  
 Dung TT, 5145  
 Dunn ST, 5099  
 Durazo M, 3903  
 Durbin ML, 4193, 4925  
 Durox H, 143  
 Duś D, 4587  
 Duvillard P, 1029  
 Dvořánková B, 455  
 Dwivedi C, 777  
 Dyskin E, 39  
 Dzięgiel P, 4945  
 Ebara T, 4223  
 Eberhardt C, 3795  
 Eberle N, 5043  
 Eckardt A, 3781  
 Ecke TH, 1579, 3071  
 Economopoulos T, 4325  
 Eddy VJ, 1875  
 Edler D, 645  
 Edoardo A, 1520  
 Egan KM, 217  
 Egawa Y, 3193  
 Egawa-Takata T, 4347  
 Egberts F, 1799  
 Egberts JH, 1799, 3355  
 Eggen T, 4649  
 Eguchi K, 557  
 Eguchi T, 5117  
 Ehara T, 1071  
 Ehret R, 1587  
 Eichhorn ME, 2597  
 Eikenes L, 359  
 Eisapooran P, 2591  
 Eisenmann J, 1645  
 Eisenmann S, 4471  
 Eisenwiener KP, 2177  
 Eizuru Y, 2431  
 Eklund P, 4423  
 El Sharouni SY, 4237  
 Elangovan S, 2869, 4169  
 Eleftheriadis SG, 1143  
 Eleftheriadou A, 2891  
 Elgqvist J, 2545  
 Elias DA, 609  
 El-Khoury C, 4731  
 Ellinger J, 2235, 2785  
 Elliott AA, 319  
 Elliott RL, 759  
 El-Maarri O, 2235  
 Elmberger G, 4643  
 Elsässer Beile U, 3373  
 Elson P, 4791  
 Elstad CA, 4467  
 Eltze E, 1823  
 Elzagheid AI, 175  
 Emmert A, 1347  
 Emons B, 1931  
 Emons G, 2025  
 Endo I, 2367, 3063, 5189  
 Endo K, 661, 4679  
 Engel JB, 1559, 1653  
 Engelhorn T, 1553  
 Enginar H, 1243  
 Engstrom W, 911  
 Enomoto T, 4347  
 Ensinger CH, 1047  
 Eom JI, 4625  
 Era D, 3823  
 Eraltan IY, 1359, 3093  
 Eret V, 665, 3579  
 Ergen HA, 2875  
 Ergun B, 2651  
 Ergun S, 2651  
 Eriksson LC, 1105  
 Ernst I, 227, 2857  
 Ervin PR, 2805  
 Escobar HM, 5043  
 Eskelinen M, 683, 2399, 4303  
 Ettliger D, 5207  
 Evans C, 4573  
 Evaristo M, 4867  
 Evens AM, 1131  
 Evers BM, 4951  
 Eymard JC, 4317  
 Ezzat S, 1681  
 Fabbiano C, 1466  
 Fabbro M, 3083  
 Faber PW, 4791  
 Fabiano A, 473  
 Fabianowska-Majewska K, 4601  
 Fabrini MG, 201, 3731  
 Facchetti A, 2769, 3341  
 Fader AN, 4791  
 Fahmy H, 777  
 Faiola F, 4193  
 Fakh MG, 677  
 Falanga M, 1301  
 Falasca C, 4769  
 Falco E, 2377  
 Falcou MC, 4229  
 Falsaperla M, 1412, 1414  
 Fan S, 3593  
 Fandella A, 1468  
 Fang J, 3493  
 Fang W, 1881  
 Fanucchi A, 201, 3731  
 Farina P, 5213  
 Farkouh A, 2355, 5207  
 Fassina A, 1273, 3083  
 Fathallah-Shaykh HM, 609  
 Faucher K, 143  
 Favaretto A, 5121  
 Favaro J, 1251  
 Favia G, 843  
 Fechner G, 2785  
 Fedele F, 513, 699  
 Fedeli F, 2377  
 Fehm T, 2425  
 Feldman M, 1279  
 Feldmann K, 1855  
 Felekouras E, 653  
 Feng E, 5077  
 Feng L-Y, 253  
 Ferahman M, 3093  
 Férec C, 569  
 Ferekidou E, 2891  
 Fernandes G, 857  
 Fernandes NV, 4937  
 Fernando B, 3817  
 Fernando NH, 1251  
 Ferrara F, 967, 3845  
 Ferrara M, 2049  
 Ferrara V, 1482, 1483, 1484

- Ferreira Bellini M, 2845  
 Ferreira CG, 2407  
 Ferreira M-JU, 451, 4587  
 Ferreri AM, 535  
 Ferri C, 553  
 Ferro P, 2377  
 Ferroni P, 751  
 Festuccia C, 1419, 1420, 1421  
 Fidanza F, 1489  
 Fiegel H, 1239  
 Figdor CG, 5091  
 Figureoa SD, 19  
 Filella X, 4369  
 Finek J, 665  
 Finizio O, 967, 3845  
 Finocchiaro G, 513, 699  
 Fischer D, 1673, 4429  
 Fischer E, 895  
 Fischer K, 1587  
 Fister S, 2025  
 Fjellidal R, 4835  
 Focchi G, 2799  
 Foley NH, 4391  
 Foltinová V, 1183  
 Fontaine C, 5185  
 Fontana V, 2377  
 Ford CHJ, 4147  
 Foreman KE, 3853  
 Formica V, 4657, 4721  
 Fornia S, 1523  
 Fossile E, 4721  
 Foster H, 3529  
 Fotiou S, 183, 3051  
 Fotopoulou C, 4619  
 Foukas P, 1969  
 Fountzilias G, 4325  
 Franceschelli A, 2297  
 Franceschini MC, 2377  
 Francis I, 4147  
 Frankel P, 167, 547  
 Franz C, 4503  
 Franzini M, 1169  
 Freedland SJ, 1387  
 Freedman J, 3699  
 Freitag C, 2525  
 Frezzotti S, 445  
 Friedrich M, 1673, 2837, 4429  
 Friedrich RE, 1565, 1569, 1593, 1605, 1625, 1641, 1645, 1727, 1751, 1765, 1787, 1793, 1815, 1819, 1833, 1843, 4283  
 Friese K, 1599, 1637, 1695, 1707, 1719, 1807, 1837, 4563  
 Fritz P, 5137  
 Fromberg I, 2837  
 Fu Y-K, 4039  
 Fugazza C, 4785  
 Fujibayashi M, 581, 4665  
 Fujii K, 265  
 Fujii M, 2005, 2351  
 Fujii S, 2367, 2693, 3063, 4127  
 Fujiki F, 2247  
 Fujimori J, 4959  
 Fujimoto K, 2145  
 Fujioka K, 383, 3509  
 Fujishima M, 4373  
 Fujisue Y, 3737  
 Fujita H, 239  
 Fujita M, 4347  
 Fujita Y, 2065, 3791, 3911  
 Fujiwara H, 2361, 2673  
 Fujiwara Yoshiyuki, 1335  
 Fujiwara Yuki, 5129  
 Fukami T, 3143  
 Fukase N, 3391  
 Fukawa T, 1961  
 Fukazawa T, 4193, 4925  
 Fukino K, 3177  
 Fukumoto T, 3839  
 Fukuoka M, 557, 2985  
 Fukushima T, 3791  
 Fukushima Y, 2065, 3911  
 Fukuyama S, 1311  
 Fumagalli C, 4269  
 Furini L, 5213  
 Furu M, 245  
 Furukawa K, 5129  
 Furusawa Y, 1961  
 Furuta T, 1953  
 Furutani M, 2347  
 Furutani Y, 2347  
 Furuya A, 4555  
 Fushiki S, 2713  
 Futami K, 3193  
 Futatsuki R, 3193  
 Fuxius S, 2335  
 Fuyuhiko Y, 5239  
 Füzesi L, 1347  
 Gabilan NH, 1209  
 Gabius H-J, 3313, 4829  
 Gacci M, 1394, 1487, 1488  
 Gadducci A, 201, 1327, 3731  
 Gagner J-P, 2911  
 Gaillard S, 3811  
 Gakhar G, 3927  
 Galatoudis ZG, 1143  
 Galetta D, 4269  
 Galetti P, 423, 3669  
 Galimberti S, 4525  
 Gali-Muhtasib H, 1911  
 Galligioni A, 5121  
 Gallt B, 2505  
 Gallwas J, 1713  
 Galosi AB, 1429, 1430, 1538  
 Gamez I, 5037  
 Ganapathi MK, 4791  
 Ganapathi R, 4791  
 Ganapathy-Kanniappan S, 923  
 Gandhi V, 2477  
 Ganti AK, 1365  
 Gao F, 3593  
 Gao P, 737  
 Gao X, 785, 3333  
 Gar M, 4081  
 Garassino M, 4289  
 Garcia D, 547  
 Garcia-Becerra R, 2667  
 Garcia-Closas M, 217  
 Garcva-Alonso I, 1223  
 Gardanis K, 2425  
 Gardi M, 1440  
 Gari M, 2185  
 Garona J, 5049  
 Gatter KC, 2831  
 Gatti L, 1497, 1514  
 Gaur S, 167  
 Gautam SC, 785, 3333  
 Gayo J, 2255  
 Gazdar A, 4811  
 Gazioglu E, 3093  
 Gedaly R, 4951  
 Geletu M, 47  
 Geller J, 399  
 Gemma A, 2985  
 Genazzani AR, 201, 3731  
 Gennatas C, 3051  
 Gennatas S, 3051  
 Genss E-M, 1807, 1837  
 Gentile V, 4737  
 Gentilucci A, 4737  
 Georg T, 2837  
 Georgopoulos A, 5207  
 Georgopoulos S, 3775  
 Georgoulakis J, 1969  
 Georgoulas V, 3031, 4335  
 Gerardini MM, 1489  
 Gerby B, 2553  
 Gerger A, 2393, 4209  
 Gerjy R, 5227  
 Gerogianni A, 3031  
 Geromichalos G, 4201  
 Geromichalou E, 4201  
 Gerout A-C, 963  
 Gerteis A, 5137  
 Gerullis H, 3071  
 Geschwind J-FH, 923  
 Ghaderi M, 3267  
 Ghayouri M, 5063  
 Ghesani NV, 369  
 Ghidini M, 4785  
 Ghiringhelli F, 4317  
 Ghoneum A, 4075  
 Ghoneum M, 4075, 5145  
 Ghosh R, 857  
 Gianellini LM, 4973  
 Giannantoni A, 1501  
 Giannelli F, 4749  
 Giannelli G, 3521  
 Giannopoulou E, 4987  
 Gianquinto D, 2377  
 Giarnieri E, 4769, 4993  
 Giatromanolaki A, 1143, 2831  
 Gibalová L, 3661  
 Giberti C, 1491  
 Gierschner D, 3373  
 Giese M, 1751  
 Giganti MO, 1541  
 Gil HJ, 4485  
 Gil J, 1137  
 Gillanders WE, 3889  
 Gillies EM, 5099  
 Gimzewski J, 4075  
 Gingelmaier A, 1719  
 Gingras D, 1887  
 Giorgini ML, 4973  
 Giorgio Z, 3817  
 Giovagnoli MR, 4769, 4993  
 Giraldi T, 3823  
 Girre V, 4229  
 Gitsch G, 3787  
 Giulianelli R, 1427, 1437  
 Giuliani M, 1527  
 Giuliani M, 843  
 Gkoulioni V, 2891  
 Glatzel M, 1783, 1829  
 Goan Y-G, 727

- Gocho T, 5129  
 Goda T, 2615  
 Goel S, 2531  
 Goessler UR, 3459  
 Goldberg JD, 2911  
 Golde TE, 3853  
 Goletz S, 5137  
 Gomerčić M, 2749  
 Gomes TS, 2799  
 Gomez DE, 5049  
 Gontero P, 1416, 1417, 1418  
 Gonthier-Maurin L, 5085  
 Gonzalez K, 2489  
 Göransson H, 1911  
 Gordian E, 3919  
 Gordon LI, 1131  
 Gordon MA, 4209  
 Gormuş U, 2875  
 Görögh T, 3541, 4567  
 Goto M, 4353  
 Goto S, 3125  
 Goto T, 107, 1201, 1205,  
 2689, 2701, 3441, 4131,  
 5011, 5015  
 Gotoh A, 4509  
 Gotohda N, 4435  
 Gottschlich S, 3541  
 Goumenou A, 3529  
 Gouveia ME, 2407  
 Gouy S, 1029  
 Graeven U, 1931  
 Graham H, 857  
 Granberg D, 149  
 Grankvist K, 2953  
 Grant M, 2263  
 Grant WB, 189  
 Grassi L, 3823  
 Gravina GL, 1406  
 Grazia A, 3817  
 Graziani G, 4721  
 Greco C, 3731  
 Greco F, 1377  
 Greiner JW, 4721  
 Grenga I, 4657  
 Greve B, 2857  
 Gridelli C, 1301  
 Grigolato P, 3435  
 Grimm C, 1257, 3487  
 Grizzle WE, 1881  
 Grobholz R, 895  
 Groen HJM, 4237  
 Gros SJ, 3933  
 Grosse-Onnebrink EM, 4251  
 Grudzien P, 3853  
 Gruenberger B, 2355  
 Gründker C, 2025  
 Gstöttner W, 123  
 Gu J, 1999  
 Gu T, 97  
 Guadagni F, 751, 1121  
 Guadalupi V, 1536  
 Guan M, 1921  
 Guedes AC, 2319  
 Guenzi M, 4749  
 Guerra F, 535  
 Guerra V, 5251  
 Guerrini F, 4525  
 Gueulette J, 303  
 Guidi M, 2973  
 Guimarães DP, 2407  
 Gulino G, 1392  
 Gulluoglu M, 1359  
 Günthert AR, 2025  
 Guntipalli PK, 4937  
 Guntur VP, 3557  
 Guo JJ, 3557  
 Gupta D, 319  
 Habermann B, 3795  
 Habermann M, 2739  
 Habu N, 2005  
 Hachisuga T, 3119  
 Haddad R, 5023  
 Haefele A, 4907  
 Hafner C, 4017  
 Hagel C, 1565, 1625, 1641,  
 1751, 1765, 1815  
 Hagen KL, 1881  
 Hägerstrand H, 4423  
 Hagita N, 2347  
 Haie-Meder C, 1029  
 Haines JL, 217  
 Hajdu CH, 2911  
 Hajek M, 2791  
 Halhali A, 2667  
 Hallmann S, 3071  
 Hallström M, 645  
 Hamada J-I, 4773  
 Hamada T, 2673  
 Hamanaka K, 5117  
 Hamann MF, 467  
 Hamaya Y, 1953  
 Hambek M, 123  
 Hamid I, 3629  
 Hamilton R, 953  
 Hammons G, 4907  
 Han JS, 3407  
 Han L, 311  
 Han S-W, 5245  
 Han YH, 879, 2107, 2863  
 Hanagiri T, 2513, 2631,  
 3039, 3273, 3939, 4209,  
 4309, 4691, 4717  
 Hancke K, 3787  
 Handzlik J, 4867  
 Hang L-W, 1195, 2125  
 Hanssen K, 4649  
 Hao J, 785  
 Hara H, 3391  
 Hara M, 4357  
 Harada M, 5105  
 Harada ML, 2225  
 Harbeck N, 4251  
 Hardy G, 2553  
 Hardy TM, 2483  
 Harigae H, 2415  
 Harimura T, 3193  
 Härle F, 4265  
 Harnack U, 3959  
 Haruki K, 5129  
 Haruyama H, 2347  
 Harvey A, 3529  
 Hasegawa G, 403  
 Hasegawa T, 4679  
 Hasenberg T, 5257  
 Hashimoto K, 5069  
 Hashimoto N, 2247  
 Hashimoto Y, 4373  
 Hashioto T, 4779  
 Hassan A, 609  
 Hassan NM, 5029  
 Hassan NMM, 2615, 2755,  
 4773  
 Hassan S, 149  
 Hassan SB, 1911  
 Hataba Y, 383  
 Hatake K, 4097  
 Hatakeyama K, 2279  
 Hatzidaki D, 4335  
 Haugk C, 2837  
 Hauschild A, 1799  
 Hauser S, 2081, 2785  
 Häusler S, 1559  
 Häusler SFM, 1653  
 Hawkes EA, 3015  
 Hayashi E, 2093, 4001  
 Hayashi H, 1015  
 Hayashi K, 3769  
 Hayashi N, 1015  
 Hayashi T, 1007  
 Hayashi Y, 2033, 3113  
 Hayashizaki Y, 5189  
 Haybaeck J, 1047  
 He A, 2641  
 He E, 1295  
 He J, 1295  
 Head JF, 759  
 Hebishima T, 2033, 3113  
 Hefler LA, 565, 1257, 3487  
 Hegele A, 467, 5195  
 Heidemann E, 5137  
 Heiferman MJ, 73  
 Heinemann V, 4673  
 Heiniger B, 3927  
 Heinrich G, 1701  
 Heinrigs M, 1807  
 Heinze G, 3487  
 Heinzke L, 19  
 Heinzman JM, 2805  
 Hellberg D, 1217  
 Hennig J, 2335  
 Hepp P, 1837  
 Herbrecht R, 963, 3807  
 Herder GJM, 4237  
 Herman TS, 4007  
 Hermo GA, 5049  
 Herrmann E, 1823  
 Hertle L, 1823  
 Herzog TJ, 4767  
 Hesselink EJ, 5091  
 Heuck CJ, 3071  
 Heukamp LC, 2785  
 Heusner T, 375  
 Hibi K, 107, 1201, 1205,  
 2689, 2701, 3441, 4131,  
 5011, 5015  
 Higashi D, 3193  
 Higgins SC, 391  
 Hikita S, 3119  
 Hildreth MB, 777  
 Hilpert F, 2739  
 Hioki M, 4435  
 Hirai F, 1311  
 Hirai F, 3193  
 Hirakawa K, 915, 4115,  
 4459, 5239  
 Hirano A, 581, 4665  
 Hirao Y, 2145  
 Hirasawa N, 5181  
 Hirashiki K, 2341  
 Hirashima M, 3151  
 Hirashima T, 4343  
 Hirata I, 239

- Hirayama R, 1961  
 Hirohara S, 5129  
 Hirose Y, 2995, 3791  
 Hirota K, 3129, 3135, 3159, 3167, 3199  
 Hirota Y, 2033, 3113  
 Hirsch JM, 1083  
 Hishida A, 1953  
 Ho C-L, 4039  
 Ho H-C, 4187  
 Ho W-K, 2851  
 Ho Y-H, 601  
 Hochster H, 541  
 Hodges KB, 713  
 Hoellen F, 1673  
 Hoffman RM, 403, 793, 1041, 3291, 3933, 4415, 4799  
 Hoffmann K, 4503  
 Hoffmann M, 3541  
 Hofmann G, 2393  
 Hofmann R, 5195  
 Hofmanová J, 1183  
 Hofstetter G, 565  
 Höger H, 55  
 Hohmann J, 829  
 Hojo T, 4373  
 Holcomb VB, 1  
 Holdenrieder S, 1613, 1855  
 Höller T, 2235  
 Hollywood E, 4209  
 Hölscher AH, 4635  
 Holubec L, 665, 3579  
 Holy A, 2791  
 Holzhausen H-J, 1593  
 Honami T, 2615  
 Honda T, 3207  
 Hong J, 1  
 Hong JT, 2823  
 Hong S-H, 489  
 Honig A, 1559, 1653  
 Hoopmann M, 4251  
 Hora M, 665, 3579  
 Horai T, 557  
 Hori H, 3177, 3199, 3233  
 Horie N, 2713  
 Horikawa Y, 5181  
 Horino K, 1015  
 Horiuchi S, 3107, 3143  
 Hörmann K, 339, 3459  
 Horvath G, 4451  
 Horváth V, 1183  
 Hosen N, 2247  
 Hosono Y, 2625  
 Houlgatte R, 3951  
 Hrabar D, 2749  
 Hsia T-C, 1195, 4141  
 Hsieh C-C, 3585  
 Hsieh C-H, 3473  
 Hsieh H-H, 2727  
 Hsieh H-M, 2727  
 Hsieh H-P, 2813  
 Hsieh S-H, 2813  
 Hsieh T-C, 2869, 4169  
 Hsieh Y-Y, 2203  
 Hsu C-F, 4205  
 Hsu C-K, 1189  
 Hsu C-M, 2203, 3655, 4141  
 Hsu K-H, 2203  
 Hsu M-C, 727  
 Hsu S-C, 2135  
 Hsu Y-M, 1189  
 Hu A, 1999  
 Hu C-B, 2813  
 Hua C-H, 4205  
 Hua DH, 3927  
 Huang B, 2641  
 Huang C-C, 2459  
 Huang C-H, 727  
 Huang Chiung-Yin, 253  
 Huang Chun-Ying, 2459  
 Huang C-R, 2065  
 Huang C-S, 3087  
 Huang C-T, 727  
 Huang C-Y, 4141  
 Huang G, 937  
 Huang H, 1921  
 Huang K, 3493, 4873  
 Huang S-L, 3493  
 Huang X, 463  
 Huang Y-C, 2813  
 Huang Yifan, 217  
 Huang Yuliana, 2193  
 Huang Y-W, 1937  
 Hübner GM, 3257  
 Hudej R, 2055  
 Huet E, 2101  
 Huguet H, 4711  
 Hundley J, 4951  
 Hung C-C, 4177  
 Hung KN, 4515  
 Huq F, 4025, 4547  
 Hurwitz HI, 1251  
 Hwang J-J, 4177  
 Hwang L-L, 2813  
 Hwang SG, 2325  
 Hyogotani A, 5117  
 Hyon S-H, 903  
 Iacona RB, 2935  
 Iacopino F, 1528  
 Ibaragi S, 2615, 2755  
 Ibaragi S, 5029  
 Ibeh C, 311, 3629  
 Iborra F, 4711  
 Ibrahim S, 609  
 Ibrahim SO, 1083  
 Ibuki N, 3737  
 Ichedef C, 1243  
 Ichihara H, 327, 2011  
 Ichikawa D, 2361, 2673  
 Ichiki Y, 2631  
 Ichinose Y, 557, 1311, 2985  
 Iczkowski KA, 719  
 Ida H, 2673  
 Ide EC, 1273  
 Ide H, 221  
 Ignat M, 303  
 Iida T, 5129  
 Iijima H, 403  
 Ikeda T, 2145, 2241, 3361  
 Ikoma H, 2673  
 Ikuma M, 1953  
 Ikumoto T, 4435  
 Ilvan S, 2885  
 Im S-A, 5245  
 Im S-Y, 3421  
 Imabori M, 3391  
 Imada T, 2693, 4127  
 Imai H, 4819  
 Imai Y, 4097  
 Imamura Y, 1007  
 Imig J, 895  
 Inaba N, 3509  
 Inagaki D, 2693, 4127  
 Inagaki Y, 1007, 5055  
 Inagawa H, 3129, 3135, 3151, 3159, 3207  
 Inamoto T, 3737  
 Inase N, 2271  
 Indraccolo S, 5121  
 Ingolic E, 55  
 Inose T, 851  
 Inoue M, 2279, 3187, 4695  
 Inoue N, 4773  
 Inoue T, 2145  
 Inui H, 4373  
 Ip C, 3895  
 Isaksson R, 987  
 Isbir T, 1359, 2875, 2885, 3093  
 Ishibashi K, 107, 1201, 1205, 2689, 3441, 4131, 5011, 5015  
 Ishibashi N, 3181  
 Ishibashi Y, 3193  
 Ishida Y, 5129  
 Ishidao T, 5189  
 Ishigami S, 2453, 5175  
 Ishiguro N, 5019  
 Ishihara M, 129, 837  
 Ishihara S, 5181  
 Ishihara Y, 403  
 Ishii K, 3167  
 Ishii T, 1897  
 Ishikawa H, 3833  
 Ishikawa H, 5105  
 Ishikawa Takashi, 5189  
 Ishikawa Toshihisa, 5189  
 Ishikawa Y, 1897  
 Ishima M, 4397  
 Ishitani A, 4097  
 Ishiwata T, 4357  
 Ishizawa S, 3509  
 Ishizuka T, 4819  
 Isidori AM, 1382  
 Isidro AA, 3345  
 Isohata N, 221, 3763  
 Isomoto H, 2113  
 Isowa S, 2755, 5029  
 Isufi I, 2927  
 Itano N, 1071  
 Ito H, 2341  
 Ito K, 2673  
 Ito M, 5055  
 Ito T, 2247  
 Ito Y, 2673  
 Itoh J, 1007  
 Itoh M, 4071  
 Itoh T, 2431  
 Itoh Y, 5181  
 Itoi M, 2713  
 Iwakami S, 97  
 Iwamoto M, 5029  
 Iwao H, 2065, 3791, 3911  
 Iwase S, 3827  
 Iwase Y, 2241, 3361  
 Iwata M, 239  
 Iwata T, 2513  
 Izbicka E, 2263  
 Izbicki JR, 1239, 1617, 3933  
 Izquierdo L, 2439, 4369



- Izumi K, 3077, 5201  
 Izumisawa Y, 2367  
 Izumoto S, 2247  
 Izzo T, 3845  
 Jacob R, 2561  
 Jacoby DB, 39  
 Jaganjac M, 4063  
 Jäkel T, 1605  
 Jakubowicz J, 1773  
 Jakupec MA, 2055  
 Jancarikova D, 1667  
 Jandrig B, 1573  
 Jang J-J, 5245  
 Janni W, 1807, 1837, 4563  
 Janssen S, 1747, 1779, 3781  
 Jarde T, 2919  
 Jauberteau-Marchan M-O, 143  
 Jen H-F, 3549  
 Jeong LS, 2823  
 Jeong WC, 3421  
 Jereczek-Fossa BA, 1529  
 Jeschke S, 375  
 Jeschke U, 1599, 1637, 1695, 1707, 1849  
 Jess P, 233, 4755  
 Jeung HK, 4625  
 Jhanwar-Uniyal M, 4915  
 Jiang H, 3333  
 Jiang WG, 87, 1079, 1113, 1163  
 Jiang XP, 759  
 Jiang Y-L, 3549  
 Jin Y, 245  
 Jin Z-X, 2065, 3911  
 Jinn Y, 2271  
 Jirillo A, 1273  
 Jo U, 3621  
 Jo UH, 4595  
 Jochens A, 467  
 Joergensen MT, 587  
 Joetzke AE, 5043  
 Johansson BR, 2545  
 Johnen H, 3959  
 Johnson B, 3313  
 Johnson EW, 39  
 Joki T, 1057  
 Jónasson JG, 2419  
 Jonat W, 2739, 3355  
 Joo Y-E, 3479  
 JROSG Working Subgroup of Gastrointestinal Cancer, 2959  
 Ju H-W, 3421  
 Jüeckstock J, 1807, 1837, 4563  
 Juhasz-Böess I, 2425  
 Jünemann K-P, 467  
 Jung AC, 303  
 Jung H-Y, 3621  
 Jung V, 895  
 Junghans C, 5043  
 Junqueira M, 547  
 Juraszewska E, 2119  
 Jurgons R, 1553  
 Kacprzak G, 4799  
 Kadono Y, 5201  
 Kadowaki T, 3151  
 Kaehler KC, 1799  
 Kaestner R, 1719  
 Kafchitsas K, 3795  
 Kagohashi K, 3833  
 Kagota S, 3429  
 Kähne T, 505  
 Kaifi JT, 1239, 3933  
 Kaiga T, 2351  
 Kaiho S-I, 873  
 Kaina B, 2561  
 Kaira K, 4223, 4819  
 Kajimura M, 1953  
 Kalbakis K, 3031, 4335  
 Kaley K, 2905, 2927  
 Kalinin V, 1617  
 Kalofonos HP, 4325  
 Kalofonos HP, 4987  
 Kalpadakis C, 271  
 Kalthoff H, 3355  
 Kaltner H, 3313  
 Kaltner H, 4829  
 Kalykaki A, 4335  
 Kamano T, 239  
 Kamei M, 4779  
 Kamijo A, 993  
 Kamimura M, 581, 4665  
 Kamiya Y, 239  
 Kämmerer U, 1547, 1689  
 Kamoto K, 2673  
 Kamradt J, 895  
 Kanaan YM, 519  
 Kanai Y, 4223, 4819  
 Kanazawa A, 2693, 4127  
 Kanazawa Y, 613  
 Kanbe Y, 873  
 Kandiloros D, 2891  
 Kandulski A, 1093  
 Kanduser M, 2055  
 Kane AB, 2153  
 Kanematsu S, 3381, 3705  
 Kanesaka N, 2959  
 Kang GH, 5245  
 Kang H, 2325  
 Kang JW, 2773, 2823  
 Kankuri-Tammilehto MK, 3023  
 Kanninen TT, 1025  
 Kansra S, 499  
 Kao W-T, 4177  
 Kapp M, 1547  
 Kapp M, 1653, 1689  
 Karachontziti P, 1273  
 Karagiannis A, 2969  
 Karahalil B, 4963  
 Karakitsos P, 1969  
 Karapiperides D, 4493  
 Karasawa K, 2959  
 Kardara E, 2969  
 Karihtala P, 1001  
 Karlberg M, 645  
 Karlsson A, 2641  
 Karstens J-H, 3781  
 Karsy M, 4915  
 Karteris E, 3529  
 Kashiwagi S, 5239  
 Kashiwazaki H, 4773  
 Kashiwazaki K, 1007  
 Kasper H-U, 2017  
 Kasperzyk J, 1535  
 Kassanos D, 4103  
 Kasuda S, 4097  
 Katano M, 2041, 3747, 4999  
 Kates R, 4251  
 Kato C, 2415  
 Kato H, 851, 2705, 4373  
 Kato K, 2341  
 Kato M, 3125  
 Kato S, 2341  
 Kato T, 4089  
 Kato Y, 5239  
 Kato-Nakano M, 4555  
 Katsifis A, 4899  
 Katsube T, 221, 3763  
 Katsuoka K, 3291  
 Katsuoka Y, 3737  
 Kaufmann S, 467  
 Kaufman-Szymczyk A, 4601  
 Kaushal S, 4415  
 Kaushik RS, 777  
 Kavalari R, 4851  
 Kawaguchi M, 3833  
 Kawaguchi Y, 2625, 4811  
 Kawahara K, 4779  
 Kawai Y, 5189  
 Kawakami M, 4097  
 Kawakatsu M, 2247  
 Kawamoto S, 4555  
 Kawamoto T, 3391  
 Kawanaka A, 3381  
 Kawanami T, 2065, 3911  
 Kawano M, 2567  
 Kawarabayashi T, 3119, 3143  
 Kawase I, 2247, 4343  
 Kawashima W, 4097  
 Keese M, 5257  
 Kefala M, 1969  
 Keir ST, 5037  
 Kelany A, 4081  
 Kelling K, 1673  
 Kema IP, 5153  
 Kemmel V, 963, 3807  
 Kenguele H, 519  
 Keppler BK, 2055  
 Kermarrec I, 4317  
 Kern M, 2017  
 Kesavan K, 39  
 Kesinger JW, 4883  
 Kessinger A, 1365  
 Kieć-Kononowicz K, 4867  
 Kiessling F, 703  
 Kigawa G, 107  
 Kigawa G, 1201, 1205, 2689, 2701, 3441, 4131, 5011, 5015  
 Kijima Y, 2453  
 Kikugawa T, 3839  
 Kilic N, 2651  
 Kim C-S, 79  
 Kim D-S, 4607  
 Kim E, 541  
 Kim EJ, 2773  
 Kim H, 2773, 2823  
 Kim Hae Kyung, 3421  
 Kim HI, 4485  
 Kim HJ, 2469  
 Kim H-J, 4163  
 Kim Hyun Kyung, 3621  
 Kim J-A, 3295  
 Kim Jeong Mo, 4485  
 Kim Jin Man, 2773  
 Kim Jin Seok, 4625  
 Kim Jun Suk, 3621  
 Kim JW, 2577  
 Kim K-J, 3421

- Kim K-K, 3479  
 Kim MJ, 3611  
 Kim N, 581, 4665  
 Kim NK, 2325  
 Kim OJ, 2325  
 Kim RH, 2469  
 Kim S-A, 489  
 Kim SJ, 4625, 5245  
 Kim So Hee, 3611  
 Kim Suhm Hee, 879  
 Kim Sung Hyun, 4163  
 Kim SY, 4607  
 Kim SZ, 879, 2107  
 Kim T-J, 481  
 Kim T-Y, 5245  
 Kim WH, 2469  
 Kim YH, 3621  
 Kim YH, 4595  
 Kim YJ, 5245  
 Kim Y-N, 481  
 Kim YS, 2469  
 Kimberger O, 1341  
 Kimura A, 2673  
 Kimura H, 3291  
 Kimura J, 2367, 3063  
 Kimura K, 581, 4665  
 Kimura M, 3509  
 Kimura S, 2713  
 Kimura T, 661, 4347, 4679  
 Kindt N, 3313  
 Kingma DW, 5099  
 Kinoshita J, 581, 4665  
 Kinoshita K, 1015  
 Kinoshita T, 4435  
 Kinugasa T, 3181  
 Kirita T, 4097  
 Kirschner K, 3223  
 Kisakesen HI, 2885  
 Kishimoto K, 2615, 2755, 3391  
 Kishimoto S-I, 3391  
 Kiss A, 2355  
 Kisters K, 1783, 1829  
 Kita Y, 2453, 5175  
 Kitagawa Y, 1007, 3759  
 Kitamura K, 3827  
 Kitamura S, 3769  
 Kitamura Y, 2689, 3441, 5011  
 Kitamura Y-H, 107, 1201, 1205, 2701, 4131  
 Kitz J, 1347  
 Kiyohara H, 2341  
 Kjeldsen E, 3257  
 Klaman I, 2525  
 Klapdor R, 1565, 1765, 1869  
 Klapdor S, 1869  
 Klar M, 3787  
 Kleber S, 895  
 Klecka J, 665, 3579  
 Kleefstra N, 681  
 Klein A, 3445  
 Kleina R, 3267  
 Klenk S, 5137  
 Kley K, 1741  
 Klocker H, 3413  
 Kloss M, 4429  
 Knechtel G, 2393  
 Knoefel WT, 1065  
 Knudsen BR, 3257  
 Knuth A, 895  
 Ko Y-C, 2125, 4187  
 Kobayashi D, 4353  
 Kobayashi H, 575  
 Kobayashi M, 593, 2959, 4343  
 Kobayashi N, 5117  
 Kobayashi T, 383, 403  
 Kobierzycki C, 4945  
 Kobori Y, 3077  
 Koch A, 4951  
 Koch S, 3071  
 Kochi M, 2351, 5069  
 Koczywas M, 167  
 Kodama S, 5029  
 Kodeda K, 5227  
 Koderia Y, 2415  
 Koeninger A, 375  
 Koensgen D, 2525  
 Koga M, 3193  
 Koh E, 3077, 5201  
 Kohchi C, 2033, 3113, 3129, 3135, 3151, 3159  
 Köhl G, 4017  
 Kohrenhagen N, 1547, 1653  
 Kohyama K, 5019  
 Koizumi T, 5117  
 Kojima M, 4435  
 Kokkalis G, 3775  
 Kokuba Y, 2673  
 Kolkmeier A, 2857  
 Kolodziej J, 4799  
 Kolostova K, 4799  
 Komatsu S, 2361  
 Komiyama K, 1897  
 Komiyama S, 2673  
 Komori H, 1015  
 Komura K, 3737  
 Kon M, 3705  
 Konaka H, 3077, 5201  
 Konatkowska B, 2119  
 Kondo K, 265  
 Kondo R, 5117  
 Konemann S, 2857  
 Konishi H, 2361  
 Konishi M, 4435  
 Konno S, 221  
 Konstantinidou C, 3775  
 Kontopidou FN, 271  
 Konze E, 2017  
 Köpke T, 1823  
 Korda JB, 467  
 Korita PV, 2279  
 Koriyama C, 2431  
 Korkolis DP, 3775  
 Korkolopoulou P, 271  
 Korlach S, 375  
 Kosaka T, 2367, 3063  
 Koskas M, 4743  
 Kosmas C, 653  
 Kosmidis P, 4325  
 Kost B, 1719  
 Köster F, 1559, 4429  
 Kosuga T, 2361  
 Koto K, 2713  
 Kotsakis A, 3031, 4335  
 Koukourakis MI, 1143, 2831  
 Kountourakis P, 2969  
 Koussis H, 1273  
 Koutsopoulos A, 1143  
 Kovacs K, 2897  
 Koya RC, 409  
 Koyama K, 3737, 5181  
 Koyama R, 4357  
 Kozawa E, 5019  
 Kozubík A, 1183  
 Kozuki T, 4791  
 Kraemer M, 2081  
 Kraljević Pavelić S, 3987  
 Krämer B, 2425  
 Kranjc S, 2055  
 Krausz P, 143  
 Krell H, 703  
 Krippel P, 2393  
 Krockenberger M, 1559, 1653, 1689  
 Kroger N, 2977  
 Królicka A, 4945  
 Kronenberger C, 1701  
 Kropf S, 505  
 Krueger GRF, 2683  
 Krüll A, 1727  
 Krušlin B, 2749  
 Kuba T, 4443  
 Kubecova M, 4799  
 Kubo E, 3429  
 Kubo N, 5239  
 Kubo T, 4959  
 Kubo T, 661, 2713, 4679  
 Kubota K, 2985  
 Kubota T, 2673, 3397  
 Kuemmel S, 375  
 Kuester D, 505  
 Kuhn C, 1637, 1695, 1849, 4563  
 Kuhn J, 2263  
 Kühn R, 1725, 1735  
 Kuhn W, 2235  
 Kulda V, 3579  
 Kulpa JK, 1773  
 Kumagai I, 3397  
 Kumar AP, 857  
 Kumar MS, 291, 2483  
 Kundt G, 1783  
 Kunisaki C, 2367, 2693, 3063, 4127  
 Kunitomo M, 3429  
 Kunjithapatham R, 923  
 Kunze S, 1637, 1849  
 Kuo C-L, 1189, 2135  
 Kuo H-M, 2135  
 Kuo J-H, 4135  
 Kuo S-C, 4187  
 Kuo S-J, 4135  
 Kuo W-W, 1189  
 Kuo Y-H, 3549  
 Kupka MS, 1695  
 Kurahara H, 2453  
 Kurai M, 5117  
 Kuramitsu Y, 2093, 2539, 3367, 4001, 4459  
 Kuribayashi K, 4353  
 Kurimoto N, 5233  
 Kurio N, 2615, 2755  
 Kurishima K, 3833  
 Kuriyama I, 4841  
 Kuroda K, 2631  
 Kuroda Y, 3827  
 Kuroki Masahide, 2731, 3107, 3119, 3143  
 Kuroki Motomu, 2731  
 Kurosaka M, 3391

- Kurschat N, 3933  
 Kurth A, 3795  
 Kurucová T, 3661  
 Kurucz R, 629, 693  
 Kuryu Y, 2673  
 Kurz K, 3721  
 Kurzrock R, 811  
 Kusagawa S, 5055  
 Kushida T, 2567  
 Kutup A, 1617  
 Kuwano H, 851, 4223  
 Kuzmicz M, 2119  
 Kvolts L, 5063  
 Kwak BK, 923  
 Kweon S-S, 3479  
 Kwon B-M, 489  
 Kwon H-C, 4163  
 Kwon KA, 4163  
 Kwon NS, 4607  
 Ky TD, 5145  
 Kynaston HG, 87  
 Kyo S, 3187  
 Kyrtsolis M-C, 271  
 La Macchia O, 473  
 Laas R, 1625  
 Labanaris AP, 1725, 1731, 1735  
 Labate A, 699  
 Labianca R, 4289  
 Lacetera V, 1430  
 Lacina L, 455  
 Ladoire S, 4317  
 Lae M, 4229  
 Laenger F, 1779  
 Laezza C, 2583  
 Laffranchi A, 4381  
 Lage H, 629, 693  
 Lagorce C, 4297  
 Lai C-H, 1189  
 Lai HC, 4467  
 Lai JCK, 743  
 Lai K-C, 2135, 3549  
 Lai MB, 743  
 Lai T-Y, 945, 2125, 2135  
 Lajolo C, 843  
 Lala PK, 4829  
 Laliscia C, 3731  
 Lan S-H, 3585  
 Landman GW, 681  
 Landriscina M, 473  
 Landt S, 375, 1673  
 Landthaler M, 4017  
 Lange S, 5043  
 Langsenlehner T, 2393  
 Langsenlehner U, 2393  
 Lantermo RA, 671  
 Lanzetta G, 3055  
 Lanzi F, 1506, 1517, 1518  
 Lao J, 2255  
 Lappartient E, 4229  
 Lari S, 4081  
 Larrea F, 2667  
 Larrinaga G, 1137  
 Larsen K, 4649  
 Larsson A, 285  
 Larsson DE, 149  
 Larsson R, 1911  
 Lasson K, 1625  
 Latha M, 499  
 Latinwo LM, 4613  
 Lau BW, 2153  
 Lau EK, 3295  
 Laubichler P, 1341  
 Launay S, 4049  
 Laurberg S, 4755  
 Laurent D, 2335  
 Lausen B, 1735  
 Lautenschläger C, 1593  
 Laytragoon-Lewin N, 4643  
 Lazaris A, 653, 2891  
 Lazarov I, 3699  
 Laznicek M, 2177  
 Laznickova A, 2177  
 Le Bris M-J, 569  
 Le C, 719  
 Le Moyec L, 3451  
 Lea MA, 311, 3629  
 Leboulleux S, 1029  
 Lebwohl D, 2335  
 Lecaille C, 4297  
 Lechien J, 3313  
 Lederle W, 703  
 Lee Chung, 3413  
 Lee Claudia, 3291  
 Lee CS, 481  
 Lee DH, 2773  
 Lee EJ, 4485  
 Lee H, 489  
 Lee H-J, 2193  
 Lee H-K, 3421  
 Lee H-Z, 1195  
 Lee J, 3621  
 Lee J-H, 3479  
 Lee J-K, 481  
 Lee J-M, 727  
 Lee K, 1157  
 Lee Kwang-Ho, 481  
 Lee Kyung-Hwa, 3479  
 Lee LJ, 31, 463  
 Lee L-T, 4177  
 Lee M-T, 4177  
 Lee P-P, 4177  
 Lee RJ, 31, 463  
 Lee Sojung, 2773, 2823  
 Lee Suee, 4163  
 Lee T-W, 65, 4039  
 Lee W-C, 65, 4039  
 Lee W-S, 3479  
 Lefering R, 1353  
 Lehrer S, 1371  
 Leibold H, 565  
 Lenhard M, 1713  
 Lenk SV, 1579  
 Lentini A, 445  
 Lenz H-J, 4209  
 Leodolter A, 505  
 Leonardi R, 4265  
 Leone A, 4289  
 Lepler S, 4405  
 Lequeux C, 2919  
 Lerner ML, 4883  
 Leroy A, 9  
 Leroy X, 3313  
 Lescoute A, 963, 3807  
 Lesterhuis WJ, 5091  
 Leung GKK, 4515  
 Leuschner I, 467, 3541  
 Levan K, 4451  
 Leventakos K, 1969  
 Levêque D, 963, 3807  
 Levesque D, 157  
 Levesque J, 1382  
 Levidou G, 271  
 Levinson B, 3243  
 Levy E, 157  
 Lewin B, 2591  
 Lewin F, 4643  
 Lewin SN, 4767  
 Lezhava A, 5189  
 Li A, 2217  
 Li C, 79  
 Li C-H, 2851  
 Li Hailan, 4607  
 Li Hong, 5077  
 Li J, 1999  
 Li J-F, 2193  
 Li L, 981  
 Li L-H, 727  
 Li P-K, 4883  
 Li QQ, 3413  
 Li X, 3535  
 Li X-L, 295  
 Li Y, 3493  
 Li Zishan, 1295  
 Li Zonghai, 1999  
 Lialiaris T, 4201  
 Liang C, 2217  
 Liao C-L, 945  
 Liao S-K, 3473  
 Liao Y-P, 409  
 Liberati E, 1424  
 Lichtenegger W, 375, 1701, 1837, 2525  
 Liebhardt S, 1707, 1713  
 Lim D, 167  
 Lim S, 3621  
 Lim S-J, 3611  
 Limtrakul P, 3599  
 Lin C-C, 3573, 4141, 5217  
 Lin Chih-Hsueh, 3573  
 Lin Ching-Hung, 3087  
 Lin C-Y, 4177  
 Lin D-T, 3649  
 Lin D-T, 529  
 Lin F, 2447  
 Lin F-H, 65  
 Lin H-P, 3643  
 Lin HQ, 4899  
 Lin H-Y, 2125  
 Lin J, 601  
 Lin J-G, 945  
 Lin K, 2447  
 Lin K-L, 3549  
 Lin M-L, 2135  
 Lin P-H, 3087  
 Lin S, 1881  
 Lin S-H, 5077  
 Lin S-S, 2727, 3655  
 Lin W-D, 529  
 Lin YC, 439, 5077  
 Lin Young C, 1937  
 Linardou H, 4325  
 Lincoln DT, 767  
 Lindahl B, 3727  
 Lindh C, 3019  
 Linhares E, 2407  
 Links M, 3669  
 Linsalata M, 2583, 3501  
 Liou J-P, 2813  
 Lippolis C, 5251  
 Liu B, 2209  
 Liu C-J, 1195, 4141

- Liu E, 135  
 Liu H-S, 3585  
 Liu I-H, 4039  
 Liu J-Y, 5077  
 Liu L-C, 5217  
 Liu Q, 3045  
 Liu RW-M, 2851  
 Liu Shujun, 31  
 Liu Suling, 1937  
 Liu W, 1681  
 Liu X, 135  
 Liu Yiyan, 369  
 Liu Yongbo, 785  
 Ljubičić N, 2749  
 Ljungberg B, 2953  
 Lluch A, 2255  
 Lo C, 4187  
 Lo Giudice G, 513  
 Lo Muzio L, 4265  
 Lo S, 3853  
 Loberiza Jr FR, 1365  
 Lodde M, 1381, 1432  
 Loening SA, 1579  
 Loera S, 547  
 Loffroy R, 923  
 Loidl W, 1633  
 Lombardi G, 2311, 5213  
 Longo F, 1436  
 Longoni S, 4785  
 Löning T, 1605, 1645  
 Loo WTY, 3465  
 Lopes LF, 2407  
 López JI, 1137  
 Lopez-Beltran A, 3683  
 Lopezbeltran A, 713  
 López-Pedraza C, 415  
 López-Sánchez LM, 415  
 Lora O, 1273  
 Lorenz R, 1837  
 Lorient Y, 3869  
 Lorscheid M, 1701  
 Lou JR, 2087, 3249  
 Lovakovic T, 4063  
 Lu C-C, 2125  
 Lu H-F, 4187  
 Lu Q, 5257  
 Lu Y-S, 3087  
 Lubecka-Pietruszewska K, 4601  
 Lucchese A, 843  
 Lucia B, 3817  
 Lucianò R, 513, 699  
 Ludovici G, 751  
 Ludvikova M, 3579  
 Lui VCH, 4515  
 Lumachi F, 2331, 3083, 4701  
 Lumbroso J, 1029  
 Lundberg B, 4261  
 Lunde MLS, 1083  
 Lundgren J, 4643  
 Lung SSS, 4515  
 Luo G, 981, 4363  
 Luo J, 3045  
 Luqué P, 4369  
 Lurje G, 4209  
 Lüttgen E, 5137  
 Lutz P, 963  
 Luu T, 167  
 Lyer S, 1553  
 Lyn-Cook BD, 4907  
 Ma C, 5077  
 Ma J, 1295  
 Ma L, 19, 2101  
 Ma X, 713  
 Ma Y-S, 945  
 Maas KW, 4237  
 Maass N, 2739, 2837, 3355  
 Mach CM, 811  
 Machairas A, 1969  
 Machluf M, 1057  
 Macquarrie A, 467  
 Maddalena F, 473  
 Madersbacher S, 1633  
 Madonia M, 1469  
 Maecke HR, 2177  
 Maeda H, 111  
 Maeda Y, 239, 993, 3077, 4193, 4925  
 Maehara S-I, 2539, 3367  
 Maehara Y, 2539, 3367  
 Maekawa T, 2713, 3193  
 Maenpaa J, 1001  
 Maffezzini M, 1493, 1494, 4761  
 Maggioni M, 1470  
 Magistro S, 3009, 3435  
 Maione P, 1301  
 Maiorano E, 843  
 Maisonneuve P, 4269  
 Majda K, 4601  
 Majumdar APN, 319  
 Makatsoris T, 4325  
 Makino H, 2367, 3063  
 Makino K, 3135, 3159, 3167  
 Makino T, 2567  
 Makizono T, 327  
 Malfertheiner P, 505, 1093  
 Malinowska I, 2119  
 Maliou S, 2969  
 Mallmann P, 4251  
 Mallofré C, 2439  
 Malpeli G, 4269  
 Manara R, 5213  
 Mancuso A, 4289  
 Mandic R, 805, 4579  
 Manferrari F, 553, 2297  
 Manfredi B, 3731  
 Manivel JC, 987  
 Mann W, 2561  
 Manners S, 3669  
 Manome Y, 383, 3509  
 Manoranjan B, 2897  
 Mantovani F, 1427  
 Marbeuf-Gueye C, 3451  
 Marchini A, 4049  
 Marchiori D, 553, 1539  
 Marchioro G, 1432, 1433, 1434, 1435  
 Marcucci G, 31  
 Mareel M, 9  
 Margari C, 2969  
 Margaritis D, 2831  
 Margogne A, 4229  
 Margolin K, 167  
 Mari M, 1388  
 Mariadason JM, 2531  
 Mariani P, 4229, 4297  
 Marino D, 2383  
 Marino F, 4701  
 Marino G, 1379  
 Marioni G, 1273  
 Mariotta S, 4769  
 Mariotti S, 4657  
 Marlar RA, 5099  
 Marler L, 4873  
 Marra M, 1531  
 Marsh H, 3015  
 Martella O, 1378, 1380  
 Martelli O, 4289  
 Marth C, 3721  
 Martin E, 4317  
 Martin F, 541  
 Martin M, 2255  
 Martinez I, 1509  
 Martinis E, 3823  
 Martins A, 829  
 Martorana G, 553, 2297, 2973  
 Maruno M, 2247  
 Maruta A, 1007  
 Maruyama N, 239  
 Maruzzo M, 1273  
 Marzano B, 2331  
 Marzano B, 4701  
 Masaki Y, 2065, 3791, 3911  
 Masala D, 1486, 1506  
 Masieri L, 1505  
 Massari F, 1379  
 Mastrullo L, 967  
 Masuda M, 2693, 4127  
 Masuda N, 557  
 Masuda S, 1233  
 Masuda T, 1015  
 Matei DV, 1524, 1525  
 Mathison BD, 2171, 2721  
 Matoušova M, 2791  
 Matsubara K, 2755  
 Matsui T, 2713, 3193  
 Matsui Y, 661, 4679  
 Matsumoto I, 4109  
 Matsumoto M, 2453, 5175  
 Matsumoto N, 1897  
 Matsumoto Y, 327, 2011, 2033, 3113  
 Matsumura K, 903  
 Matsumura Y, 2145, 4347  
 Matsunaga K, 403  
 Matsunaga T, 2005  
 Matsunami N, 4373  
 Matsuo T, 4959  
 Matsuoka J, 4193, 4925, 5239  
 Matsuoka R, 2347  
 Matsuoka Y, 2011  
 Matsushita T, 3397  
 Matsuura Y, 4343  
 Matsuyama S, 1007  
 Matsuzaki S, 4347  
 Matsuzaki T, 915  
 Mattei A, 1393  
 Mattingly CA, 2505  
 Maurizi ER, 3055  
 Mavroudis D, 3031  
 May A, 123  
 Mayr D, 1637, 1849  
 Mazur J, 2419  
 Mazzocca A, 3521  
 Mazzoleni F, 1527, 1538  
 Mazzucchelli R, 3683  
 McBride WH, 409  
 McNally S, 1279  
 Meadows KL, 1251

- Mearini E, 1465  
 Mecklenburg V, 5195  
 Medinger M, 2335  
 Mehta K, 2477  
 Mehta M, 4883  
 Meinhold-Heerlein I, 2739, 3355  
 Meinhold-Heerlein I, 3355  
 Meissner W, 4579  
 Melano A, 671  
 Melato M, 1323  
 Melby M, 5099  
 Melegari S, 1522  
 Mellai M, 1977  
 Melloni B, 3811  
 Melton DW, 3223  
 Melzi D'Eril G, 3801  
 Menashi S, 2101  
 Mengual L, 2439  
 Menon LG, 1057  
 Merdad A, 2185  
 Meriaty H, 4899  
 Merlano M, 671  
 Mertens PR, 1239  
 Mertlikova-Kaiserova H, 2791  
 Messa C, 2583, 3501  
 Metelli MR, 4525  
 Metharom E, 3669  
 Metzger R, 1239  
 Meyer A, 1779, 3781  
 Meyer PT, 3787  
 Michalak K, 4587  
 Michalaki V, 3051  
 Micheel B, 1573  
 Michel F, 4317  
 Michener CM, 4791  
 Micke O, 1783, 1829  
 Miele L, 3853  
 Mies C, 1279  
 Miglietta A, 2659  
 Mignot G, 4317  
 Mignot L, 4229  
 Mihara Y, 2351  
 Miki H, 3381  
 Miki M, 2065, 3791, 3911  
 Miklavcic D, 2055  
 Mikuz G, 1047  
 Milan E, 2331  
 Milesi L, 4289  
 Miller H, 3919  
 Miller ML, 261  
 Min YH, 4625  
 Minakata K, 97  
 Minarik M, 1667  
 Minato N, 575  
 Minervini A, 1419, 1420, 1440  
 Minniti G, 3055  
 Minoia C, 5159  
 Mintas M, 3987  
 Misawa T, 5129  
 Mishellany F, 2919  
 Mishra S, 2477  
 Mitselou A, 4493  
 Mitsudomi T, 557  
 Mitsuhashi A, 2341  
 Miura M, 4397  
 Miura N, 3839  
 Miwa A, 4115  
 Miwa S, 3769  
 Miyachi K, 2705  
 Miyajima Y, 265  
 Miyake M, 2145  
 Miyake T, 4347  
 Miyaki A, 3763  
 Miyamoto S, 3107, 3119, 3143  
 Miyamura K, 2415  
 Miyashita A, 2673  
 Miyata H, 1335  
 Miyatake T, 4347  
 Miyawaki M, 4779  
 Miyazaki A, 4841  
 Miyazaki T, 851  
 Miyoshi K, 867  
 Miyoshi Y, 4347  
 Mizokami A, 3077  
 Mizokami A, 5201  
 Mizukami H, 107, 1201, 1205, 2689, 2701, 3441, 4131  
 Mizukami H, 1201  
 Mizukami M, 2631  
 Mizumoto K, 867  
 Mizuno S, 383  
 Mizushina Y, 4841  
 Mo H, 4937  
 Mo L, 3413  
 Mo Z, 3413  
 Mochizuki A, 5233  
 Mochizuki K, 3565  
 Moe BT, 4649, 4835  
 Mohammed FMA, 767  
 Mohammed SI, 4907  
 Mohler JL, 3895  
 Mohr E, 4503  
 Mokbel K, 1079, 2287, 3309, 3693  
 Molina R, 4369  
 Molnár J, 451, 829, 3593, 4063, 4867  
 Mominoki K, 4925  
 Momkvist A, 1799  
 Momose Y, 2241  
 Mönig SP, 4635  
 Montagna B, 5159  
 Monteil J, 3811  
 Montironi R, 713  
 Montironi R, 713, 3683  
 Moon HJ, 879  
 Moon J-H, 1335  
 Moore W, 5099  
 Mordant P, 3869  
 Morel F, 569  
 Morelli F, 1424  
 Morere JF, 4297  
 Morgan RJ, 167  
 Mori K, 557  
 Mori M, 1335, 4819  
 Mori Y, 4397  
 Morice P, 569, 1029  
 Morii T, 3565  
 Morikawa K, 873  
 Morimura R, 2361  
 Morinaga S, 2693, 4127  
 Morisaki T, 3747  
 Morishita N, 4343  
 Morita H, 355  
 Morita I, 4193, 4925  
 Morita S, 5189  
 Morita T, 593  
 Moriuchi T, 4773  
 Moroga T, 4779  
 Morrell AE, 4873  
 Morris DL, 423, 3005  
 Morse MA, 1251  
 Morselli-Labate AM, 2297, 2973, 3801  
 Mörtel S, 123  
 Mortensen LS, 2463  
 Mosley SA, 811  
 Motohashi N, 129, 837  
 Mougín C, 4049  
 Mourah S, 2101  
 Moura-Neto V, 1209  
 Mourelatos C, 4201  
 Mourey E, 4317  
 Mousa SA, 39  
 Moyer MP, 1881  
 Mrakovcic L, 4063  
 Mross K, 2335  
 Mücke R, 1783, 1829  
 Mueller MM, 703  
 Muggia F, 541, 3243  
 Muilenburg D, 3279  
 Mukae S, 1897  
 Muley T, 1661  
 Müller H-H, 2291  
 Muller SC, 2785  
 Müller T, 4471  
 Mundhenke C, 2739  
 Munding J, 2603  
 Muni R, 3055  
 Muñoz M, 2255  
 Münzel A-K, 3541  
 Murakami A, 97  
 Murakami I, 4925  
 Muraki K, 4357  
 Murali R, 4915  
 Murao T, 5181  
 Muraoka T, 3763  
 Murari R, 1287  
 Murata H, 2713, 4397  
 Murata T, 355  
 Murayama C, 993  
 Murayama M, 221  
 Musa MA, 4613  
 Musha A, 1961  
 Musi G, 1530  
 Mustacchi G, 3823  
 Mustea A, 2525  
 Musto P, 967  
 Muto A, 5169  
 Mutter D, 303  
 Muzyczka N, 1931  
 Myers AL, 3301  
 Mylonas I, 1599, 1637, 1719, 4563  
 Myojin M, 2959  
 Myoui A, 661, 2247  
 Myrmel K, 4649  
 N'Guyen A, 963  
 Nagai K, 1897  
 Nagai S, 3747  
 Nagamori S, 4819  
 Naganawa S, 5181  
 Nagano Y, 2367  
 Nagao G, 3167  
 Nagaoka A, 4089  
 Nagarkatti M, 1263  
 Nagarkatti PS, 1263

- Nagasaka M, 239  
 Nagashima A, 3039, 4695  
 Nagashio R, 265  
 Nagata T, 2673  
 Nagata Y, 4209  
 Nagayasu T, 2113  
 Nagel D, 1613, 1855  
 Nagel G, 2561  
 Nagelschmidt K, 1353  
 Nagelschmidt M, 1353  
 Nagumo Y, 3827  
 Nagy B, 4525  
 Naim R, 339  
 Naito S, 4089  
 Naka N, 661  
 Nakagawa Y, 3199  
 Nakagawa Yoshihito, 239  
 Nakagawa Yousuke, 4097  
 Nakagohri T, 4435  
 Nakai Y, 2145  
 Nakajima A, 2065, 3791, 3911  
 Nakajima Hideo, 2065, 3911  
 Nakajima Hiroko, 2247  
 Nakajima K, 1335  
 Nakajima M, 851  
 Nakajima N, 903  
 Nakajima T, 4819  
 Nakamata T, 245  
 Nakamura H, 5233  
 Nakamura J, 903  
 Nakamura Kazuki, 3429  
 Nakamura Kazuyasu, 3397, 4555  
 Nakamura Kazuyuki, 2093, 2539, 3367, 4001, 4459  
 Nakamura Masafumi, 2041  
 Nakamura Masakatsu, 239  
 Nakamura Rieko, 3759  
 Nakamura Ryo, 873  
 Nakamura S, 2347  
 Nakamura Takashi, 245  
 Nakamura Takuji, 3791  
 Nakanishi K, 3039, 4695  
 Nakanishi M, 2673  
 Nakanishi R, 3039, 4695  
 Nakano T, 1961, 4223  
 Nakao R, 2171, 2721  
 Nakao S, 2415  
 Nakata E, 3233  
 Nakaya K, 613  
 Nakayama T, 245  
 Nakayama Y, 993  
 Namiki M, 3077, 5201  
 Nanashima A, 2113  
 Nano R, 2769, 3341  
 Naoe M, 4509  
 Naomoto Y, 4193, 4925  
 Napodano G, 1482  
 Nara N, 495, 4071  
 Narayan A, 4805  
 Nardi E, 1025  
 Nardo G, 5121  
 Narimoto K, 3077  
 Naritaka Y, 221, 3763  
 Nasir A, 5063  
 Natarajan M, 4007  
 Nathwani AC, 3301  
 Natsugoe S, 2453, 5175  
 Natter C, 3487  
 Naumann CM, 467  
 Naumann M, 505  
 Nauth A, 2425  
 Nawa M, 2625  
 Necozone S, 209  
 Negro CLA, 1514  
 Nelson G, 1149  
 Nelson OL, 2171, 2721  
 Nemoto H, 107, 1201, 1205, 2689, 2701, 3441, 4131, 5011, 5015  
 Nemoto K, 2959  
 Neri B, 5169  
 Neri F, 1518  
 Nesi G, 2419, 4737  
 Nessleris I, 3683, 4493  
 Newbold RF, 1079, 3309  
 Newcomb PA, 217  
 Nexo E, 2463  
 Ng CYC, 3301  
 Nguyen LM, 953  
 Nguyen NP, 953  
 Nguyen TA, 3927  
 Nicolai N, 1398  
 Nicolas P, 4297  
 Nicoletti R, 4785  
 Nicoletto O, 2311, 5213  
 Nicolier M, 4049  
 Nicolini C, 2073, 2745  
 Nieder C, 977  
 Niedergethmann M, 5257  
 Nielsen HJ, 233, 4755  
 Nielsen SE, 233, 4755  
 Nieuwland R, 1707  
 Nii K, 3193  
 Niitani H, 2985  
 Nikolaidou M-E, 4103  
 Nilsson-Ehle P, 981  
 Ning Y, 4209  
 Nishi K, 2241  
 Nishida H, 3769  
 Nishida S, 2247  
 Nishida T, 1335, 3839  
 Nishida Y, 5019  
 Nishigaki Y, 2713  
 Nishii T, 915  
 Nishimoto N, 1947  
 Nishimura Y, 2959  
 Nishio M, 2673  
 Nishioka A, 5019  
 Nishiwaki S, 2415  
 Nishizawa T, 3207  
 Niu J, 135  
 Niu W, 135  
 Niwa R, 3397  
 Nixon AB, 1251  
 Noda S, 3193, 5239  
 Noël G, 303  
 Noguchi S, 2247  
 Noh TW, 4485  
 Nojima T, 3769  
 Nojiri K, 5055  
 Nolte I, 5043  
 Nomi H, 3737  
 Nomoto Y, 5181  
 Nonaka K, 4811  
 Nonaka M, 2113  
 Nonaka T, 2113  
 Nonomura N, 2247  
 Norberto L, 4701  
 Notarnicola M, 2583  
 Novak K, 665, 3579  
 Novotny L, 4891  
 Nuber N, 895  
 Nucciotti R, 1390  
 Nukiwa T, 557  
 Numata K, 2693, 4127  
 Numico G, 671  
 Núñez NP, 1  
 Nützel R, 1725  
 Nyalendo C, 1887  
 O'Connor T, 1047  
 O'Shaughnessy J, 2263  
 Obata Y, 5181  
 Öberg K, 149  
 Oberpenning F, 1823  
 Obrist P, 1047  
 Ochi M, 4959  
 Ochiai T, 2673  
 Oda M, 4109  
 Odagiri H, 3827  
 Oderda M, 1503  
 Oehr P, 1741  
 Ogawa Kazuhiko, 2959  
 Ogawa Kenji, 581, 221, 3763, 4665  
 Ogawa Y, 2959  
 Ogura K, 4665  
 Oh D, 2325  
 Oh D-Y, 5245  
 Oh SY, 4163  
 Ohashi K, 2415  
 Ohashi R, 97  
 Ohashi T, 5129  
 Öhd J, 261  
 Ohe Y, 4353  
 Ohgami Y, 4467  
 Ohira M, 4115, 5239  
 Ohizumi I, 873  
 Ohki H, 1897  
 Ohkura K, 3177  
 Ohnishi H, 3565  
 Ohnishi S, 2145  
 Ohno S, 2347, 3187  
 Ohno Y, 3187  
 Öhrling K, 645  
 Ohta K, 4397  
 Ohta S, 4555  
 Ohta Y, 4109  
 Ohtani O, 661, 4679  
 Ohtsuka K, 3565  
 Oishi Y, 3129  
 Oji Y, 2247  
 Oka H, 265  
 Oka M, 4459  
 Oka Y, 2247  
 Okabe H, 1015  
 Okada F, 2093, 4001  
 Okada T, 5105  
 Okada Y, 3391, 4841  
 Okajima E, 2145  
 Okamoto K, 2361  
 Okamoto N, 4343  
 Okamura H, 4509  
 Okayasu I, 265, 4443  
 Okazaki I, 1007, 2065  
 Okazaki T, 3911  
 Okazaki Y, 1897  
 Okines AFC, 3015  
 Okubo M, 239  
 Okuhashi Y, 495, 4071

- Okui T, 2615, 2755  
Okumura H, 2453, 5175  
Okumura N, 4811  
Okuno Y, 2959  
Okuyama A, 2247  
Ólafsdóttir E, 2419  
Olbert P, 5195  
Olejnik I, 2119  
Olivares J, 2553  
Ollonen P, 683, 2399, 4303  
Olsson B, 4451  
Omoto I, 5175  
Ongkeko WM, 4415  
Onishi H, 2041, 2959, 3747, 4999  
Onishi Y, 3391  
Onitsuka T, 2513, 2631, 3099, 4309  
Ono HA, 2367, 3063  
Ono K, 3273, 4209, 4779, 4925  
Ophoven SJ, 3967  
Ørbo A, 4649, 4835  
Ordaz-Rosado D, 2667  
Ordesi P, 3435  
Orellana MD, 5023  
Oreste M, 1378  
Oriuchi N, 4819  
Orlandi M, 535  
Orlandini C, 201  
Orlando A, 2583, 3501  
Orlowska-Volk M, 3787  
Orrego A, 4123  
Ortega C, 1532  
Osada S, 2625, 2995, 4811  
Osaki T, 4695  
Osawa S, 1953  
Oshima CTF, 2799  
Oshima T, 2367, 2693, 3063, 4127  
Osin P, 3015  
Osinga TE, 5153  
Oskay-Özcelik G, 1701, 4245  
Osman H, 2287  
Osoegawa A, 1311  
Österberg J, 261  
Österberg L, 4451  
Osti MF, 3055  
Ota I, 5189  
Ota S, 923  
Otsuji E, 2361, 2673  
Ott G, 5137  
Otte-Höller I, 3715  
Oudard S, 5223  
Owaki T, 5175  
Owston M, 4123  
Oyama T, 2513, 3759  
Ozawa M, 613  
Ozbek YK, 2885  
Ozturk O, 2885  
Ozturk T, 2885  
Pados G, 3529  
Pagán B, 3345  
Page P, 3675  
Pagella C, 5159  
Pagidas K, 2519  
Pagliarulo V, 1508  
Pai P-C, 253  
Palazzo G, 4265  
Palazzo S, 1492  
Palloni T, 1428  
Palma MD, 5213  
Palmieri F, 1399, 1400, 2973  
Palmirota R, 751  
Palmowski M, 703  
Palomares T, 1223  
Palumbo GA, 4525  
Palumbo P, 1512  
Pampo C, 4405  
Pan C-X, 4573  
Pan D, 5145  
Pan L, 3295  
Panayiotides I, 1969  
Panebianco V, 1459  
Panepucci RA, 5023  
Pang JX, 31  
Pangalis GA, 271  
Paniccia T, 1404  
Panotopoulou E, 4103  
Paolicchi A, 1169  
Papadimitriou C, 4325  
Papageorgiou A, 4201  
Papakostas P, 4325  
Papakotoulas P, 3031  
Papalambros A, 653  
Papamichael D, 4325  
Paparo D, 699  
Papassideri I, 4103  
Papi A, 535  
Paprocka M, 4587  
Papworth K, 2953  
Paradiso A, 3521  
Parente L, 887  
Parenti A, 2311  
Parini P, 1105  
Parisi A, 699  
Park C-Y, 79  
Park JS, 2171, 2721  
Park K-J, 4163  
Park S-J, 3479  
Park SN, 2773  
Park WH, 879, 2107, 2863  
Park W-J, 4607  
Park Y-L, 3479  
Parsons CM, 3279  
Partheen K, 2545, 4451  
Paschos KA, 2161  
Pasello G, 5121  
Pasi F, 2769, 3341  
Passoni P, 4785  
Pastore AL, 1454  
Pastore G, 1490  
Pastorek J, 3661  
Pastorelli D, 2311, 5213  
Patel BB, 319  
Pathak S, 2477  
Patil M, 2303  
Patton V, 4973  
Paul MA, 4237  
Paule B, 5165  
Paules AB, 2255  
Pavelić K, 3987  
Pavlakou G, 3031  
Pawlik N, 2603  
Pecher G, 3959  
Pechkova E, 2073, 2745  
Pectasides D, 4325  
Pedrini L, 2311  
Pekar G, 1217  
Pellegriano R, 4657  
Pelliniemi T-T, 3023  
Pelosi G, 4269  
Peltonen J, 3995  
Penault-Llorca F, 2919  
Peng C, 135  
Peng C-T, 529, 3649  
Penney KL, 1534  
Penney R, 2905  
Pentheroudakis G, 4325  
Pento JT, 4883  
Perez I, 1137  
Pérez LB, 3945  
Pernetti R, 1502, 2973  
Perrone F, 3731  
Perry N, 2287  
Persons KS, 1875  
Persson J, 3727  
Perugia G, 1400  
Pesek M, 1667  
Pesta M, 665  
Pesta M, 665, 3579  
Peterson NB, 217  
Petrella A, 887  
Petrimi M, 4525  
Petros WP, 1251  
Petsas T, 4987  
Pettersen I, 4649  
Pettersen RD, 3879  
Pezzilli R, 3801  
Pezzoni A, 4973  
Pezzuto JM, 4873  
Pfragner R, 55  
Phernambucq ECJ, 4237  
Phromnoi K, 3599  
Piaggi S, 4525  
Pica E, 1287  
Piechulla B, 1587, 1695  
Pierga J-Y, 4229  
Pietschmann N, 1587  
Pietzner K, 1701, 2991  
Pilkington GJ, 391  
Pinterova D, 4799  
Pinto F, 1500  
Pinto LC, 2225  
Piotrowska A, 4945  
Pires-Alves A, 5085  
Pisani L, 4769  
Pisanti F, 1448  
Piscazzi A, 473  
Pistillo MP, 2377  
Piva L, 1466  
Pizzi G, 699  
Pizzi S, 2311  
Pizzirusso G, 1507  
Pizzocaro G, 1515  
Plissonnier M-L, 4049  
Plotniece A, 4063  
Plunkett RJ, 4851  
Plzák J, 455  
Podhorska-Okołów M, 4945  
Poggi G, 5159  
Pogorzala M, 2119  
Pohl A, 4209  
Pohl M, 2603  
Poláková E, 3661  
Polara A, 1521  
Pölcher M, 2235  
Politi L, 5169  
Pollok KE, 291  
Polterauer S, 565, 3487  
Polyzos A, 653  
Pompella A, 1169

- Ponholzer A, 1633  
 Ponzi M, 1121  
 Popper N, 1633  
 Poppleton H, 3301  
 Porampornpilas K, 1  
 Porichi O, 4103  
 Portarena I, 4657  
 Post S, 5257  
 Pothuri B, 3243  
 Pouessel D, 4711  
 Pourgholami MH, 423  
 Poznić M, 3987  
 Pozzi E, 5159  
 Prachand SN, 1131  
 Prasain K, 3927  
 Preissler G, 2597  
 Prenkert M, 4157  
 Pressley O, 2263  
 Prete SP, 4721  
 Prezioso D, 1528  
 Privat M, 2049  
 Procopio G, 1461  
 Procopio V, 513  
 Promchan K, 4819  
 Proschek D, 3795  
 Provencio M, 2255  
 Provenzano B, 445  
 Prtet J-L, 4049  
 Pu JKS, 4515  
 Pugliatti F, 513  
 Puistola U, 1001  
 Puła B, 4945  
 Punt CJA, 5091  
 Puntoni M, 4761  
 Puozzo C, 2977  
 Pusztai R, 451  
 Pyrhonen SO, 3023  
 Qi L-W, 295  
 Qi Y, 3535  
 Qian J, 719  
 Qian X, 2209  
 Qin M, 3413  
 Qiu H, 915  
 Qu M, 2489  
 Qu S, 1999  
 Quaas A, 1239  
 Quaranta M, 3521  
 Quaresma JA, 2225  
 Quaretti P, 5159  
 Quattrocchi E, 699  
 Queiroz AB, 2799  
 Quock RM, 4467  
 Rabczyński J, 4945  
 Racioppi M, 1443, 1444, 1445  
 Rack B, 1807, 1837, 4563  
 Radacz Y, 2603  
 Raderer M, 635  
 Raffa S, 4993  
 Ragnhammar P, 645  
 Raharijaona M, 3951  
 Raica M, 3981  
 Raith H, 1855  
 Rajan P, 3853  
 Rajić Z, 3987  
 Ramachandran K, 3919  
 Ramel S, 261  
 Ramieri MT, 1287  
 Rammel G, 1807  
 Ramos DM, 2591  
 Ramqvist T, 279  
 Rangan S, 5169  
 Rank A, 1707  
 Ranstam J, 3727  
 Rao PP, 923  
 Rao S, 3015  
 Rao SD, 2519  
 Raptis L, 47  
 Rasmuson T, 2953  
 Rasool N, 4791  
 Ratinaud M-H, 143  
 Ratliff J, 39  
 Rauchenwald M, 1633  
 Rauko P, 4891  
 Ravindran B, 2477  
 Rawnaq T, 1239, 3933  
 Ray R, 1875  
 Rea F, 5121  
 Rea S, 209  
 Rebillard X, 4711  
 Recchia COC, 209  
 Recchia F, 209  
 Recine F, 4289  
 Reddish JM, 439  
 Reefy S, 1079, 2287, 3693  
 Refolo MG, 3501  
 Reich O, 2651  
 Reinacher-Schick A, 2603  
 Reinshagen F, 895  
 Reinthaller A, 565, 1257, 3487  
 Rekhman N, 4269  
 Ren Y, 3345  
 Renault IZ, 2407  
 Reni M, 4785  
 Renner C, 895  
 Renner W, 2393  
 Retterspitz MF, 4635  
 Retzloff LB, 19  
 Reubi JC, 2177  
 Reuter S, 3599  
 Rhiem K, 3445  
 Ri G, 2347  
 Ribas A, 409  
 Ribatti D, 3981  
 Ribeiro DA, 2799  
 Riccardi A, 5159  
 Riccardi C, 3845  
 Ricchetti F, 4749  
 Ricci A, 4769  
 Rice L, 4405  
 Rice SD, 2805  
 Richter D-U, 1587, 1695  
 Riddell A, 3015  
 Riedel F, 3459  
 Riedel T, 1829  
 Riesenbeck D, 1829  
 Rigatos SK, 1317  
 Rigoli L, 513, 699  
 Rino Y, 2693, 4127  
 Ripoll GV, 5049  
 Rivas P, 857  
 Rizvi N, 743  
 Rizzardi C, 1323, 3009  
 Rizzi S, 4973  
 Roberts T, 1079  
 Robinson P, 3853  
 Rocchi P, 535  
 Roch N, 1617  
 Rocha-Lima C, 3919  
 Rodríguez-Ariza A, 415  
 Rodriguez-Rasgado JA, 2667  
 Rodriquez M, 887  
 Roessner A, 505  
 Rognone A, 4785  
 Rogosnitzky M, 399, 2943  
 Rogozanová K, 3661  
 Roh MS, 4163  
 Rojas-Espaillet L, 4791  
 Rolland D, 3951  
 Rolnitzky L, 2911  
 Romano S, 2407  
 Romeo P, 513  
 Rommelaere J, 4049  
 Roncella S, 2377  
 Ronot X, 2553  
 Ronquist G, 285  
 Ronquist KG, 285  
 Roscigno M, 1395  
 Rose PG, 4791  
 Roselli M, 4657, 4721  
 Röser K, 1605, 1645  
 Rossi A, 1301  
 Rossi G, 3845  
 Rossi S, 445  
 Rothberger G, 2911  
 Rothmund R, 2425  
 Rotilio A, 5213  
 Rotondo F, 2897  
 Roulin D, 799  
 Roumes H, 5085  
 Rouzier R, 4743  
 Rozen WM, 601, 1293  
 Rubio CA, 261, 1021, 2419, 3019, 4123  
 Rüdell J, 4579  
 Rudlowski C, 2235  
 Rudolph BD, 1579  
 Ruggera L, 1484  
 Russi EG, 671  
 Russo F, 3501  
 Rutqvist LE, 4643  
 Ruttloff J, 3071  
 Ryan RP, 5037  
 Ryozaawa S, 2539, 3367  
 Ryu H-S, 3479  
 Ryu JS, 3621, 4607  
 Ryu K, 2713  
 Ryu Y, 3181  
 Rzeszutko M, 4945  
 Rzeszutko W, 4945  
 Saadati H, 5113  
 Sabbaghian MS, 2911  
 Saccardo MB, 4973  
 Sacchetta S, 4289  
 Sacco PC, 1301  
 Sachanas S, 271  
 Sachs MD, 1579  
 Sadahiro S, 993  
 Sadick H, 3459  
 Safra T, 3243  
 Sager G, 4835  
 Saha AK, 1875  
 Sahn H, 2577  
 Saif MW, 2905, 2927, 4261, 5113  
 Saijo N, 557, 2985  
 Saikawa Y, 3759



- Saito G, 5117  
 Saito H, 383  
 Saito J, 1007  
 Saito J-I, 4223  
 Saito M, 107, 1201, 1205, 2689, 2701, 3441, 4131, 5011, 5015  
 Saito T, 613  
 Saitoh J, 5069  
 Sakabe T, 2713  
 Sakagami H, 129, 837, 2567, 5069  
 Sakaguchi K, 4397  
 Sakai H, 2985  
 Sakai M, 851  
 Sakai T, 2065, 3791, 3911  
 Sakaida I, 2539, 3367  
 Sakakura C, 2673  
 Sakamaki H, 2415  
 Sakarya S, 1243  
 Sakata H, 3039, 4695  
 Sakata I, 2241  
 Sakata M, 107, 1201, 3441  
 Sakuraba K, 107, 1201, 1205, 2689, 2701, 3441, 4131, 5011, 5015  
 Sakurai A, 5189  
 Sakurai H, 4223, 5175  
 Salabat MR, 73  
 Salciccia S, 4737  
 Saldanha-Araujo F, 5023  
 Salehi F, 2897  
 Salehin D, 1673, 2837, 4429  
 Salem ML, 3889  
 Saletti PC, 4289  
 Salminen EK, 3023  
 Salmon R-J, 4229  
 Saltz L, 4209  
 Salvati M, 3055  
 Salvatore S, 1494  
 Salvenmoser W, 1047  
 Salvioni R, 1465  
 Samelis G, 4325  
 Samir R, 1217  
 Samonigg H, 2393  
 Sanada Y, 107, 1201, 1205, 2701, 2995, 4131, 5011  
 Sand L, 1083  
 Sanders AJ, 87  
 Sandlund J, 2953  
 Sano A, 851  
 Sanseverino R, 1481  
 Sansoucie L, 119  
 Santarelli A, 4265  
 Santella RM, 2489  
 Santoro A, 2583  
 Santucci E, 1450  
 Santucci R, 963, 3807  
 Sanui A, 3143  
 Sanz B, 1137  
 Sanz G, 2977  
 Sarantonis J, 653  
 Saredi G, 1485  
 Saridaki Z, 4335  
 Sarkar M, 1149  
 Sartelet H, 1887  
 Sasada S, 4343  
 Sasaki A, 2615, 2755, 4773, 5029  
 Sasaki K, 2705  
 Sasaki T, 3839, 5189  
 Sasamoto R, 2959  
 Sasano H, 3465  
 Sasaoka M, 5181  
 Sas-Korczyńska B, 1773  
 Sastre X, 4297  
 Sato A, 403, 1007  
 Sato J, 547  
 Sato N, 867  
 Sato T, 2693, 4127  
 Sato Y, 265  
 Satoh H, 3833  
 Satomi K, 3565  
 Saussez S, 3313  
 Sauter A, 339  
 Savli H, 4525  
 Savonarola A, 751  
 Sawachi K, 3129, 3135, 3159  
 Sawada A, 1897  
 Sawaki T, 2065, 3791, 3911  
 Scancar J, 2055  
 Scarpa A, 4269  
 Scarpelli M, 3683  
 Scattoni V, 1451, 1452, 1453, 1454, 1455, 1456, 1457, 1458  
 Schafer G, 1047  
 Schäfer U, 1783, 1829  
 Schallier D, 5185  
 Schally AV, 4177  
 Scharenborg NM, 5091  
 Schae D, 409  
 Schauer M, 1065  
 Scheithauer BW, 2897  
 Scheithauer W, 5207  
 Schelz ZS, 829  
 Schem C, 2739, 3355  
 Schemmer P, 4503  
 Schenk JA, 1573  
 Schettino C, 1301  
 Scheuer HA, 1645, 1751, 1787  
 Schiavina R, 1478, 1479, 2297  
 Schiavon M, 5121  
 Schiemenz K, 1579  
 Schierholz JM, 1353  
 Schiffer D, 1977  
 Schillani G, 3823  
 Schindlbeck C, 1807, 1837, 4563  
 Schirmacher P, 2017  
 Schischmanoff PO, 4297  
 Schlechte HH, 1579  
 Schlumberger M, 1029  
 Schmid H-P, 1633  
 Schmidt M, 1653, 1689  
 Schmidt P, 375  
 Schmidt SC, 4619  
 Schmidt-Wolf IGH, 2081, 3493  
 Schmiegel W, 1931, 2603  
 Schmuck RB, 2991  
 Schmutzler RK, 3445  
 Schneeweiss A, 1837  
 Schneider C, 1689  
 Schneider F, 963  
 Schneider J, 1661  
 Schneider M, 1323  
 Schneider PM, 4635  
 Schneitter A, 565  
 Schnell EA, 359  
 Schnitt R, 2591  
 Schoberth A, 1807  
 Schoeneck A, 2603  
 Schollen A, 1855  
 Scholz C, 1599, 1695  
 Schöndube FA, 1347  
 Schönekaes KG, 1783, 1829  
 Schonlebe J, 2991  
 Schoolfield J, 857  
 Schott GE, 1731, 1735  
 Schott H, 4891  
 Schramek P, 1633  
 Schramel FMNH, 4237  
 Schreckenber S, 4635  
 Schreibelt G, 5091  
 Schreiber E, 1553  
 Schreuder HWB, 3715  
 Schroeder JJ, 2881  
 Schteingart DE, 4805  
 Schuback B, 1701  
 Schueller J, 2355, 5207  
 Schulze S, 1695, 1849  
 Schumacher G, 4619  
 Schuurhuis DH, 5091  
 Schwab M, 5137  
 Schwarte-Waldhoff I, 2603  
 Sciarra A, 1446, 1447, 4737  
 Scola A, 1273  
 Scola N, 4567  
 Scoppola A, 4721  
 Scotti V, 3731  
 Sebolt JT, 3321  
 Sedić M, 3987  
 Sedlák J, 3661  
 Seeber S, 2025  
 Seetharam RN, 2531  
 Seetharamu N, 541  
 Segawa Y, 557  
 Segerer SE, 1559  
 Sehouli J, 375, 1701, 2525, 2991, 4245  
 Seidler A, 1731  
 Seidman EG, 157  
 Seitz M, 2651  
 Seki T, 111  
 Sekida M, 355  
 Selle F, 4743  
 Selting K, 3557  
 Selvarajah U, 2949  
 Semjonow A, 1633, 1823  
 Semmler W, 703  
 Senan S, 4237  
 Sengupta V, 319  
 Seramondi R, 3009, 3435  
 Serba S, 4503  
 Šereš M, 3661  
 Serly J, 4063, 4867  
 Serova M, 2101  
 Serretta V, 1380  
 Sersa G, 2055  
 Sesterhenn AM, 2291  
 Seto T, 1311  
 Setoyama T, 2453, 5175  
 Seyhan FM, 2885  
 Seykora JT, 3535  
 Sgambato A, 843  
 Shafiei N, 2561  
 Shaheen M, 5145  
 Shaib W, 4261  
 Shamamian P, 2911

- Shao N, 981  
 Sharma S, 737  
 Sheen YY, 2773  
 Sheen-Chen S-M, 2459  
 Shen C-C, 2813  
 Shen K, 2805  
 Shen Y-C, 3473  
 Sherly J, 451  
 Sherman L, 1279  
 Shi J, 3413  
 Shiba H, 5129  
 Shibaguci H, 2731  
 Shibasaki T, 3509  
 Shibashi K, 2701  
 Shibata T, 239  
 Shibayama R, 4357  
 Shibuya H, 2959  
 Shibuya K, 2959  
 Shigematsu Y, 2631  
 Shigematsu K, 4193, 4925  
 Shiina T, 5117  
 Shima T, 3077, 5201  
 Shima Y, 245  
 Shimada H, 5189  
 Shimada Y, 3135, 3159  
 Shimakawa T, 221, 3763  
 Shimamoto K, 3839  
 Shimaoka S, 2431  
 Shimazaki J, 5105  
 Shimizu H, 2351  
 Shimizu K, 355, 4819  
 Shimizu T, 581, 3099,  
 4665  
 Shimmura H, 575  
 Shimo T, 2615, 2755, 4773,  
 5029  
 Shimokawa H, 2513, 4209,  
 4309  
 Shimomura H, 4097  
 Shimose S, 4959  
 Shin J-W, 253  
 Shin SW, 3621  
 Shindoh M, 4773  
 Shinmura K, 2689  
 Shinmyo T, 5233  
 Shinohara Y, 3177  
 Shinozuka K, 3429  
 Shioya M, 4223  
 Shiozaki A, 2361  
 Shiozaki H, 4373  
 Shiozawa M, 2693, 4127  
 Shiozawa S, 3763  
 Shirachi DY, 4467  
 Shirahata A, 107, 1201, 1205,  
 2689, 2701, 3441, 4131,  
 5011, 5015  
 Shirai T, 3769  
 Shirai Y, 2279  
 Shirakata T, 2247  
 Shiraki K, 5055  
 Shirasu N, 2731  
 Shiratuchi I, 3181  
 Shiota K, 3107, 3119, 3143  
 Shirouzu K, 3181  
 Shoji T, 3705  
 Shozu M, 2341  
 Shu ST, 1937  
 Shukuya T, 4357  
 Shy H-S, 2813  
 Siakantaris MP, 271  
 Sieckman GL, 19  
 Siedlar M, 3515  
 Siegl V, 55  
 Siemann DW, 4405  
 Sighinolfi MC, 1477  
 Silva AE, 2845  
 Silverman RB, 73  
 Silvestris N, 671  
 Simeone C, 4705  
 Simon D, 5043  
 Simon W, 5137  
 Simonato A, 1443  
 Simone M, 3817  
 Sims TL, 3301  
 Singal PK, 767  
 Singal R, 3919  
 Singh ATK, 1131  
 Singhal S, 1149  
 Sinha AA, 719  
 Sinowatz F, 767  
 Sion-Vardy N, 3699  
 Siracusano S, 1494, 1495  
 Siu A, 2591  
 Sivridis E, 1143, 2831  
 Skog S, 1295  
 Skondra M, 4325  
 Skoog L, 3267  
 Skotnicki P, 1773  
 Škvarková L, 3661  
 Slootweg PJ, 3715  
 Small IÁ, 2407  
 Smaro T, 653  
 Smetana Jr K, 455  
 Smiszek R, 1725  
 Smit EF, 4237  
 Smith JA, 811  
 Smith ML, 291, 2483  
 Snyder CS, 4415  
 Sobol G, 2119  
 Soderstrom K-O, 3023  
 Soga K, 2361  
 Sohda M, 851  
 Sohn UD, 4607  
 Sol V, 143  
 Sola F, 4973  
 Soldà C, 2383  
 Soldo I, 4063  
 Sölétormos G, 233, 4755  
 Soletti RC, 1209  
 Sollami R, 4289  
 Solomayer E, 2425  
 Soma G-I, 2033, 3113, 3125,  
 3129, 3135, 3151, 3159,  
 3187, 3207  
 Somlo G, 167, 547  
 Sommer H, 1807, 1837, 4563  
 Sommer UJ, 3459  
 Song J-S, 2813  
 Song KS, 2469  
 Song LH, 5145  
 Song N, 2805  
 Sonoda A, 2005  
 Sonoyama T, 2673  
 Sonzogni A, 4269  
 Sood A, 2531  
 Sorensen BS, 2463  
 Soria J-C, 3869  
 Sottotetti F, 5159  
 Souček K, 1183  
 Soucek L, 4193  
 Soukup B, 3693  
 Soulsby H, 339  
 Soung YH, 4485  
 Sova P, 1183  
 Sovric M, 1719  
 Spaggiari L, 4269  
 Spagnoletti G, 1422, 1423,  
 1470, 1472, 1515  
 Spahn M, 1438, 1439  
 Sparsa A, 143  
 Spathis A, 1969  
 Spengler G, 4867  
 Sperber C, 1605  
 Spielmann HP, 2505  
 Spilka R, 1047  
 Spirito N, 1327  
 Spitzweg C, 1713  
 Spizzo G, 1047  
 Srigley JR, 641  
 Stallings RL, 4391  
 Stanczak E, 2119  
 Stapel J, 1587  
 Starzec A, 3451  
 Stathopoulos GP, 973, 1317  
 Stathopoulos J, 1317  
 Stavropoulos M, 4325  
 Steele VE, 737  
 Stefania Z, 3817  
 Stefaniak J, 2119  
 Stefano S, 1460  
 Steinmeyer A, 2667  
 Stelljes C, 1751  
 Sterenczak KA, 5043  
 Sternberg CN, 4289  
 Stevich B, 2505  
 Stieber P, 1613, 1855  
 Stief CG, 2651  
 Stierle V, 3451  
 Stieve M, 3781  
 Stigt JA, 4237  
 Stippel DL, 2017  
 Stoff-Khalili M, 4251  
 Stojanovic T, 1347  
 Stolz J, 665, 3579  
 Stotz M, 2393  
 Strack PR, 3853  
 Strain D, 4025  
 Streeper RT, 2263  
 Strid H, 4157  
 Strieth S, 2597  
 Strobl B, 1807  
 Strojnik T, 4851  
 Strosberg J, 5063  
 Strouch MJ, 73  
 Struffert T, 1553  
 Stuart M, 2935  
 Stuppner H, 55  
 Sturm JW, 5257  
 Sturm S, 55  
 Sturtz FG, 143  
 Styczynski J, 2119  
 Su C-H, 1189, 5217  
 Subbarayan PR, 1149, 1157  
 Sublett SV, 19  
 Subramanian T, 2505  
 SUCCESS Study Group,  
 1837  
 Suehiro S, 4779  
 Sueoka N, 3705  
 Sugawara F, 4397, 4841  
 Sugaya A, 1071  
 Sugaya M, 3039

- Sugimoto K, 3077, 5055  
 Sugimoto Y, 1937  
 Sugio K, 1311  
 Sugita N, 3361  
 Sugiura H, 5019  
 Sugiyama H, 2247, 3187  
 Suh KS, 5245  
 Sukhthankar M, 2497  
 Sulová Z, 3661  
 Sumida K, 3705  
 Sumuraya M, 2705  
 Sun G, 2005  
 Sun S, 295, 2727, 3655, 4141, 4205  
 Sun S-S, 5217  
 Sun Y, 713, 3321  
 Sunaga N, 4819  
 Sunagawa M, 2705  
 Sundfeldt K, 4451  
 Sung B, 3599  
 Sung JS, 3621, 4595  
 Sung Y-K, 489  
 Suzuki H, 3747, 4343, 5105  
 Suzuki K, 661, 4679, 5181  
 Suzuki M, 4555, 5055  
 Suzuki S, 851  
 Suzuki T, 403, 993, 4509  
 Svejda B, 55  
 Sviatoha V, 3267  
 Švihálková-Šindlerová L, 1183  
 Swaisland A, 2935  
 Syed LH, 923  
 Sykoutri D, 2969  
 Sylvester PW, 429  
 Syrigos K, 2905, 2927, 4325  
 Syrios J, 653  
 Syrjänen KJ, 2185, 2319  
 Szabo P, 455  
 Szaflarska A, 3515  
 Szatanek R, 3515  
 Szczepanek J, 2119  
 Szczepanski T, 2119  
 Szkandera J, 2393  
 Taba K, 2539, 3367  
 Tabolacci C, 445  
 Tada M, 4773  
 Taddei M, 887  
 Tagawa T, 355, 1311  
 Tagliaferri B, 5159  
 Taguchi A, 1071  
 Taguchi O, 5019  
 Taguchi T, 2247  
 Tahara T, 239  
 Tai J, 2217  
 Tajima K, 97  
 Takagawa R, 2367, 3063  
 Takagi M, 5233  
 Takahara K, 3737  
 Takahashi H, 1233, 3833  
 Takahashi K, 97, 4357  
 Takahashi S, 4435  
 Takahashi T, 557, 1961, 2625, 2995, 3759, 4223, 4811  
 Takaishi H, 3759  
 Takaki Y, 3193  
 Takamori H, 1015  
 Takamura M, 2279  
 Takano Y, 1233  
 Takase K, 5055  
 Takayama T, 2351  
 Takeda Y, 2247  
 Takeno S, 4779  
 Takenoyama M, 2631  
 Takeoka M, 1071  
 Takeshita H, 2361, 2713  
 Takeuchi A, 3769  
 Takeuchi H, 3759  
 Takeuchi R, 3199  
 Takeuchi T, 4841  
 Takiguchi S, 1335  
 Tamagno S, 4761  
 Tamaki S, 4097  
 Tameda M, 5055  
 Tamiya M, 4343  
 Tamura M, 4109  
 Tamura S, 2693, 4127  
 Tamura T, 3193  
 Tan XJ, 857  
 Tan Y, 793, 1041, 4363  
 Tana R, 201  
 Tanabe K, 575  
 Tanaka A, 613, 993  
 Tanaka H, 2041, 4925  
 Tanaka J, 5055  
 Tanaka K, 2367, 2693, 3705, 4127  
 Tanaka M, 867, 2041, 2065, 3791, 4353, 4999  
 Tanaka N, 851, 2145  
 Tanaka R, 3193  
 Tanaka T, 575, 2093, 2539, 3367, 4001, 4459  
 Tanaka Y, 575, 2995  
 Tanaka-Harada Y, 2247  
 Tang N-Y, 945  
 Tang R-P, 2459  
 Tang WW-Y, 2851  
 Tang Y-J, 3549  
 Tani E, 3267  
 Taniguchi H, 3129, 3135, 3159  
 Taniguchi K, 873  
 Taniguchi S, 1071  
 Tanizaki Y, 265  
 Tanji N, 3839  
 Tardanico R, 4705  
 Tasaka T, 2041  
 Tasaka T, 4999  
 Tassi R, 1450  
 Tassi R, 5169  
 Tate S, 2341  
 Tatsumi N, 2247  
 Taya K, 2033, 3113  
 Tellez JD, 3903  
 Tempfer C, 565, 1257  
 Teng Y-H, 4135  
 Terada H, 3129, 3135, 3159, 3167, 3199  
 Terakura S, 2415  
 Terao S, 4509  
 Terence Dunn S, 4731  
 Terenzi H, 1209  
 Terry MB, 2489  
 Tesch H, 1837  
 Teschendorf C, 1931  
 Teti G, 201  
 Theobald B, 463  
 Thet MM, 2567  
 Theurl I, 1047, 3721  
 Thieblemont C, 3951  
 Thieltges S, 1239  
 Thill M, 1673, 4429  
 Thinh NT, 5145  
 Thomas A, 375, 2335, 4251  
 Thompson PA, 2171, 2721  
 Tibullo D, 4525  
 Tidefelt U, 4157  
 Tiersten A, 3243  
 Tietze R, 1553  
 Tilki D, 2651  
 Till H, 1239  
 Timoshenko AV, 4829  
 Ting G, 65  
 Tiscione D, 1520  
 Titus-Ernstoff L, 217  
 Tivnan A, 4391  
 Tiwari S, 3355  
 Tobias ME, 4915  
 Todrovic M, 1727  
 Todt U, 3445  
 Togo S, 97, 5189  
 Toguchida J, 245  
 Tohda S, 495, 4071  
 Toi M, 3465  
 Tokuhisa M, 2367  
 Tokuishu K, 4779  
 Tokumaru S, 2959  
 Tokumaru Y, 2005  
 Tokuyama Y, 4811  
 Tomas D, 2749  
 Tomatis S, 1536  
 Tombolini V, 209, 1405  
 Tominaga H, 4819  
 Tomioka A, 2145  
 Tomita M, 3099  
 Tomita Y, 4089  
 Tomiyasu T, 3193  
 Tong D, 3487  
 Tong X-P, 2065, 3911  
 Tonini S, 5159  
 Topolcan O, 665, 3579  
 Tordrup D, 3257  
 Torelli T, 1391, 1442  
 Torielli P, 4749  
 Torino F, 4721  
 Tornblom H, 3019  
 Torndal U-B, 1105  
 Tosi N, 1504  
 Tot T, 1217  
 Toth B, 1599, 1707, 1713  
 Toyoda Y, 5189  
 Tracey L, 3301, 4391  
 Trafalis DIM, 973  
 Tran Cao HS, 4415  
 Trasimeni G, 3055  
 Trayli A, 4731  
 Tregnaghi A, 3083  
 Trejtnar F, 2177  
 Trentham-Dietz A, 217  
 Trentin C, 2383  
 Treue D, 629, 693  
 Triozzi PL, 345  
 Trivizaki E, 183  
 Troch M, 635  
 Troiani S, 4973  
 Tronconi C, 4289  
 Troutman JM, 2505  
 Troxel AB, 1279  
 Truan D, 2439  
 Truax R, 1251

- Trubia M, 4269  
 Tsai C-W, 1195, 2727, 3573, 3649, 3655, 4141, 4205, 5217  
 Tsai F-J, 529, 2203, 3649  
 Tsai H-T, 4135  
 Tsai M-H, 3291, 3655, 4205  
 Tsai P-H, 4177  
 Tsai R-Y, 1195, 2727, 3573, 3649, 3655, 4141, 4205, 5217  
 Tsai Y, 3585  
 Tsang N-M, 253  
 Tsang RK-Y, 2851  
 Tsao S-W, 2851  
 Tsaroucha E, 3031  
 Tsavaris N, 653  
 Tseng C-K, 253  
 Tseng H-C, 4205  
 Tseng H-Y, 2813  
 Tserkezoglou A, 4103  
 Tsiata E, 4987  
 Tsou Y-A, 2727, 4205, 5217  
 Tsubaki M, 2705  
 Tsuboi A, 2247  
 Tsuboi M, 557  
 Tsubota Y, 3705  
 Tsubura A, 3381  
 Tsuchiya B, 265  
 Tsuchiya H, 3769  
 Tsuda H, 1897  
 Tsuda Y, 4841  
 Tsuji H, 5105  
 Tsujii H, 5105  
 Tsujioka H, 3107, 3119, 3143  
 Tsujiura M, 2361  
 Tsukahara T, 2347  
 Tsunenari T, 873  
 Tsviliana A, 1637  
 Tufto I, 359  
 Tuna G, 2875  
 Tung F-F, 2813  
 Turel I, 2055  
 Turesson I, 4643  
 Turpeenniemi-Hujanen T, 1001  
 Tutino V, 2583  
 Tuzuner BM, 2885  
 Tzovaras A, 2969  
 Ubai T, 3737  
 Uchida K, 5055  
 Uchida N, 2959  
 Uchikado Y, 2453, 5175  
 Uchiyama A, 3039, 4695  
 Ueda S, 2247  
 Ueda T, 661, 3119  
 Ueda Y, 4347  
 Uehara H, 3737  
 Uehara M, 2113  
 Uehara N, 3381, 4343  
 Ueno S, 2453  
 Ueoka R, 327, 2011  
 Ueyama Y, 2093, 3705, 4001  
 Ugalde A, 1137  
 Uggla B, 4157  
 Ugochukwu N, 4613  
 Ujiki MB, 73  
 Ullén H, 645  
 Ulm K, 375  
 Umabayashi M, 327  
 Umehara H, 2065, 3791, 3911  
 Umemori Y, 4353  
 Umemura S-I, 2241, 3361  
 Unak P, 1243  
 Unal H, 3093  
 Unger C, 2335  
 Uno T, 2341  
 Uramoto H, 2513, 2631, 3039, 3273, 3939, 4209, 4309, 4691, 4695, 4717  
 Usui H, 2341  
 Utimoto S, 3737  
 Uto Y, 3199, 3233  
 Utsuki S, 265  
 Uzan C, 1029  
 Uzzan B, 4297  
 Vaculová A, 1183  
 Vagge S, 4749  
 Vagnoni V, 2297  
 Vahlberg T, 3023  
 Vaidyanathan G, 677  
 Vakaet L, 9  
 Valadão M, 2407  
 Valdagni R, 1511  
 Valentini AL, 1500  
 Valentini AM, 5251  
 Valentino M, 1498, 1540  
 Vali M, 923  
 Valsasina B, 4973  
 Vamvakas L, 3031, 4335  
 Van As N, 3015  
 Van Breemen R, 4873  
 Van de Luijngaarden ACM, 3715  
 Van De Rakt M, 5091  
 Van Den Borne BEEM, 4237  
 Van der Graaf WTA, 3715  
 Van Der Horst C, 467  
 Van Der Horst-Schrivers ANA, 5153  
 Van Der Laan BFAM, 5153  
 Van Don L, 5145  
 Van Gool SW, 3709  
 Van Hateren KJJ, 681  
 Van Landeghem FKH, 1573  
 Van Riep T, 5145  
 Van Tendeloo V, 3709  
 Van Truong L, 5145  
 Vannini A, 5169  
 Vardakis N, 4335  
 Varga Z, 5195  
 Varona A, 1137  
 Varthalitis I, 4325  
 Vasas A, 829  
 Vashist Y, 1617  
 Vassilakopoulos TP, 271  
 Vasson MP, 2919  
 Vasstrand EN, 1083  
 Vavallo A, 1469  
 Vaziri SAJ, 4791  
 Vecchione A, 4993  
 Veeraraghavan J, 4007  
 Velentzas K, 183  
 Venuti A, 699  
 Vergnenègre A, 3811  
 Vergote I, 3709  
 Verna M, 1486  
 Vernal J, 1209  
 Vernant JP, 2977  
 Veronesi G, 4269  
 Verri C, 1461  
 Versleijen-Jonkers YMH, 3715  
 Veslemes M, 3031  
 Viale G, 4269  
 Villa E, 4785  
 Villa G, 1537  
 Villani F, 4381  
 Vincent V-H, 953  
 Viola D, 1526  
 Virudachalam S, 3279  
 Vitiello R, 671  
 Vittori G, 1411, 1441  
 Viveiros M, 829, 4867  
 Viviani S, 4381  
 Voelker H-U, 1547, 1689  
 Vogeser M, 1713  
 Vogetseder A, 1047  
 Vogt T, 4017  
 Voigt W, 4471  
 Volgger B, 3721  
 Volkmer R, 1573  
 Volpe A, 1474  
 Von Koch F, 1707, 1713  
 Von Pawel J, 1613, 1855  
 Von Ruecker A, 2785  
 Vorgias G, 183, 4103  
 Votruba I, 2791  
 Vougiouklakis T, 4493  
 Vourli G, 4325  
 Vournakis JN, 3889  
 Wachowiak R, 1239  
 Waclaw BU, 2331  
 Wada J, 3747  
 Wada N, 1007, 3759  
 Wadle A, 895  
 Wagenblast J, 123  
 Wägener C, 1681  
 Wakabayashi H, 129, 837  
 Wakai T, 2279  
 Wakiyama S, 5129  
 Waldrep JC, 3557  
 Wali VB, 429  
 Wallwiener D, 2425  
 Walsh JE, 4861  
 Wang C-H, 529, 1195, 3649, 4141  
 Wang C-K, 1189  
 Wang C-Z, 295  
 Wang D, 2805  
 Wang G, 2683  
 Wang Hanjie, 2217  
 Wang H-C, 5217  
 Wang Honggang, 4907  
 Wang H-S, 2813  
 Wang Huamao, 1999  
 Wang Huijian, 937  
 Wang Huiling, 3593  
 Wang J, 135, 3045, 3593  
 Wang L, 3637  
 Wang L-S, 1937  
 Wang M, 2577  
 Wang Q, 3593  
 Wang R-F, 1195, 2727, 3573, 3649, 3655  
 Wang S, 3321, 4573, 4805  
 Wang X, 3045  
 Wang Y, 1279, 1295  
 Wang Y-K, 2203  
 Wang Z, 4537

- Wang Z-Y, 3637  
 Wappenschmidt B, 3445  
 Wardelmann E, 3445  
 Warm M, 4251  
 Warnakulasuriya S, 1083  
 Warszawski A, 3781  
 Waryoba C, 4613  
 Wasa J, 5019  
 Waseda R, 4109  
 Watanabe G, 2033, 3113, 4109  
 Watanabe K, 2361  
 Watanabe M, 383, 3509  
 Watanabe N, 4353  
 Watanabe O, 581, 4665  
 Watanabe T, 1007  
 Watanabe Y, 355  
 Watanebe M, 1015  
 Watatani M, 4373  
 Wataya H, 1311  
 Weecharangsan W, 31  
 Weglarczyk K, 3515  
 Wei J, 2209, 3493  
 Wei K-C, 253  
 Wei WI, 2851  
 Weidler C, 1559  
 Weigel M, 2739, 3355  
 Weimer J, 2739  
 Weingärtner K, 1731  
 Weining C, 1823  
 Weiss G, 3721  
 Weissenbacher T, 1599, 1719  
 Welkoborsky HJ, 2561  
 Welsh J, 953  
 Weng T-Y, 3585  
 Wennekes VE, 4579  
 Werner JA, 805, 2291, 4579  
 Wesolowska O, 4587  
 Wessels J, 3933  
 Wetherspoon AC, 3015  
 Wetterauer D, 3373  
 Wetterauer U, 3373  
 Wex T, 505, 1093  
 Whang YM, 3621, 4595  
 Whelan C, 641  
 Whitaker IS, 1293  
 White DF, 519  
 Wick M, 439  
 Wickström M, 149  
 Wiegand S, 2291  
 Wiemeyer S, 1347  
 Wiest I, 1849  
 Willems S, 2235  
 Willén R, 3727  
 Willenbrock S, 5043  
 Williams RF, 3301  
 Williams S, 295  
 Williamson SR, 713  
 Willich N, 227, 2857  
 Wilson C, 4921  
 Wilson C, 623  
 Wilson MJ, 719  
 Wilson POG, 3015  
 Winder T, 4209  
 Windfuhr JP, 2291  
 Winer D, 1681  
 Wiśniewski J, 4587  
 Witt J, 1731  
 Woenne EC, 703  
 Wöhrer S, 635  
 Wójcik E, 1773  
 Wojtczak B, 4945  
 Wolf A, 3487  
 Wolf P, 3373  
 Wolff JEA, 2303  
 Wolfgarten M, 2235  
 Wölfl M, 3709  
 Won C, 481  
 Wong T-S, 2851  
 Woodliff J, 499  
 Word B, 4907  
 Wright JD, 4767  
 Wright MS, 3879  
 Wröbel A, 4423  
 Wu C-N, 2727, 3655  
 Wu D-C, 727  
 Wu F, 5011  
 Wu G-Y, 5257  
 Wu H-C, 2489, 3573  
 Wu I-C, 727  
 Wu J, 3345  
 Wu JM, 2869, 4169  
 Wu K-H, 529, 3649  
 Wu M-T, 727  
 Wu S-H, 2125, 2135  
 Wu S-Y, 3585  
 Wu T-WE, 253  
 Wu X, 1999  
 Wu Y, 3895  
 Wu Y-F, 3493  
 Wu Y-H, 65, 4039  
 Wulfing C, 1823  
 Wysocki M, 2119  
 Xanthakis I, 4325  
 Xia P, 1233  
 Xiao GG, 3593  
 Xiao Z, 4503  
 Xie C, 97  
 Xie F, 1113  
 Xie L, 2209  
 Xie X, 2447  
 Xiros N, 4325  
 Xu H, 2641  
 Xu K, 135  
 Xu M, 793, 1041  
 Xu N, 4363  
 Xu N, 981  
 Xu P-P, 5077  
 Xu S, 463  
 Xu X, 3321  
 Xu Y, 1999  
 Xuan Q, 3413  
 Xynos ID, 653  
 Yalcin M, 39  
 Yamada H, 2731  
 Yamada K, 5019  
 Yamada N, 4115  
 Yamada S, 4717  
 Yamada T, 1953, 2693, 4127  
 Yamada-Okabe H, 873  
 Yamaguchi K, 221, 2625, 2995, 3763  
 Yamaguchi K, 4811, 4999  
 Yamakado M, 5189  
 Yamamoto C, 3827  
 Yamamoto D, 3705, 3827  
 Yamamoto I, 3207  
 Yamamoto K, 1335  
 Yamamoto N, 4819, 5055  
 Yamamoto N, 557, 2693, 2985, 4127, 4373  
 Yamamoto S, 4509, 4779  
 Yamamoto T, 2347  
 Yamanaka T, 1311, 2985  
 Yamanaka Y, 4097  
 Yamaner S, 1359  
 Yamanobe T, 4089  
 Yamasaki A, 3747  
 Yamasaki M, 1335, 4347  
 Yamashita H, 239  
 Yamashita K, 4443  
 Yamashita S-I, 4779  
 Yamato M, 4373  
 Yamatsuji T, 4193, 4925  
 Yamazaki K, 1311  
 Yamazaki Y, 4773  
 Yan P, 1937  
 Yan R, 2217  
 Yan Z, 3045  
 Yanaga K, 5129  
 Yanagihara Y, 3839  
 Yanagisawa N, 4443  
 Yanagitani N, 4819  
 Yang C-S, 65  
 Yang D, 4209  
 Yang J, 3321, 4731  
 Yang J-L, 2125  
 Yang J-S, 945, 2125, 2135, 3549, 4187  
 Yang L-X, 937, 3675  
 Yang M, 403, 2135, 2727, 4187  
 Yang S-F, 727  
 Yang W, 1881  
 Yang X, 3413  
 Yang Y, 981, 1113, 2773, 2823  
 Yang Y-L, 529, 3649  
 Yang YM, 481, 879, 2107, 2863  
 Yang Z, 3593  
 Yano I, 4089  
 Yao C-H, 3573  
 Yao M, 1999  
 Yashiro M, 915, 4115, 4459, 5239  
 Yasuda M, 2631  
 Yasui N, 661, 4679  
 Yasumoto K, 2631, 3039, 4695  
 Yasunaga Y, 4959  
 Yaylim-Eraltan İ, 2875  
 Yazici H, 2489  
 Ye L, 87, 1113  
 Ye S-K, 481  
 Ye W, 439, 1937  
 Ye W-P, 5077  
 Ye Y, 3903  
 Yearsley K, 3903  
 Yee HO, 987  
 Yee RT, 987  
 Yeh C-H, 65  
 Yeh I-T, 857, 2263  
 Yeh K-C, 2813  
 Yeh K-H, 3087  
 Yeh T-K, 2813  
 Yekebas E, 1617  
 Yen Y, 167, 1921  
 Yi N-J, 5245  
 Yi X, 713  
 Yiakoumis X, 271  
 Yildiz Y, 2875

- Yilmaz A, 1359  
Yim DJ, 2325  
Yiotakis I, 2891  
Yiu CCP, 3465  
Yokoi T, 4841  
Yokomakura N, 5175  
Yokomizo K, 1205, 2689,  
2701, 3441  
Yokota S, 557  
Yokote K, 5233  
Yokoyama M, 3839  
Yokoyama T, 4347  
Yolcular S, 1243  
Yoneda K, 5055  
Yoneda M, 5055  
Yonei A, 3099  
Yonemura J, 239  
Yoneya T, 873  
Yoon DY, 2773, 2823  
Yoon J-H, 489, 5245  
Yoshida H, 3705, 3827, 4841  
Yoshida K, 2539, 2995, 3367  
Yoshida K, 2625, 4811, 5117  
Yoshida T, 3181  
Yoshida Y, 1961  
Yoshihama Y, 2615  
Yoshihara K, 2693, 4127  
Yoshikawa H, 661  
Yoshikawa N, 3429  
Yoshimatsu K, 3763  
Yoshimatsu T, 4695  
Yoshimine T, 2247  
Yoshimura H, 3207  
Yoshino K, 4347  
Yoshino S, 4459  
Yoshio-Hoshino N, 1947  
Yoshioka D, 239  
Yoshiura K-I, 5189  
Yoshizato T, 3107, 3119,  
3143  
Yoshizawa K, 3381  
Yotsumoto F, 3107, 3119,  
3143  
You BR, 879  
You J, 2577  
Young MRI, 4861  
Yu B, 31, 463  
Yu C-S, 2135  
Yu C-Y, 65  
Yu H, 2087  
Yu JQ, 4025, 4547  
Yu L, 2209  
Yu Y, 319  
Yuan C-S, 295  
Yücel N, 1353  
Yue S, 2065, 3911  
Yumita N, 2241, 3361  
Yun H-Y, 4607  
Yunos NM, 4025  
Yuri T, 3381  
Yurt Kilcar A, 1243  
Yuuki K, 4089  
Zacharakis M, 653  
Zago MA, 5023  
Zagonel V, 5213  
Zagzag D, 2911  
Zahalka T, 2785  
Zambito S, 1529  
Zanetta S, 4317  
Zanette DL, 5023  
Zang X-P, 4883  
Zani D, 1496  
Zani D, 4705  
Zanotelli T, 4705  
Zarganis P, 183  
Zarkadas G, 3775  
Zarkovic N, 4063  
Zavattero C, 671  
Zeferino LC, 2319  
Zeillinger R, 1341, 3487  
Zeman D, 777  
Zembala M, 3515  
Zengin E, 3093  
Zeybek U, 2875  
Zhang H, 2459, 3895, 4573  
Zhang Jiajia, 1263  
Zhang Jiajing, 2217  
Zhang Jin, 97  
Zhang Ju, 3413  
Zhang L, 1113  
Zhang N, 87  
Zhang S, 97  
Zhang W, 4209  
Zhang Xiaotian, 915  
Zhang Xiaoying, 777, 4363  
Zhang Xintian, 3637  
Zhang Xiulian, 2093, 3367,  
4001, 4459  
Zhang X-X, 3249  
Zhang Z, 135  
Zhao L, 2641, 3535, 3593  
Zhao M, 2217  
Zheng H-C, 1233  
Zheng J, 3249  
Zheng L, 981, 4363  
Zheng M, 3321  
Zheng S, 713  
Zheng W, 1921  
Zheng X, 2641  
Zheng Y, 1233, 1263  
Zhong S, 5077  
Zhou C, 2447  
Zhou D-H, 3493  
Zhou J, 1263, 1295  
Zhou Y, 519  
Zhu L, 1921  
Zhu M, 3451  
Zhu Z, 2641  
Zilterman D, 4261  
Zippel R, 4477  
Zito AF, 3521  
Zivi A, 4289  
Zografos G, 653  
Zolota V, 4987  
Zorc B, 3987  
Zorko BA, 3945  
Zöschg K, 3721  
Zotti G, 1287  
Zucchetta P, 3083  
Zuckier LS, 369  
Zugel U, 2667  
Zugor V, 1725, 1731, 1735  
Zustin J, 1787, 4283  
Zustovich F, 5213  
Zwick S, 703  
Zwingers T, 1807

## Errata

Volume 28 (2008), No 3B, page 1905: Authors and affiliations should read:

ALEXANDROS DAPONTE<sup>1</sup>, EVA KOSTOPOULOU<sup>2</sup>, C.N. PAPANDREOU<sup>3</sup>, D.D. DALIANI<sup>3</sup>,  
MARCO MINAS<sup>4</sup>, GEORGE KOUKOULIS<sup>2</sup> and IOANNIS E. MESSINIS<sup>1</sup>

<sup>1</sup>Department of Obstetrics and Gynaecology, <sup>2</sup>Department of Pathology, <sup>3</sup>Department of Medical Oncology,  
<sup>4</sup>Department of Hygiene and Epidemiology, University Hospital of Larissa, Biopolis, Larissa 41110, Greece

Volume 29 (2009), No 4, page 1249: Right column, line 5 should read:  
The increased cellular uptake of glucose is nowadays used to

Volume 29 (2009), No 9, page 3547: Affiliation No 2 should read:

<sup>2</sup>Department of Surgery, Chang Gung Memorial Hospital;  
Chang Gung University, Taiwan, R.O.C.;

Volume 29 (2009), No 9, page 3591: Affiliation No 1 should read:

<sup>1</sup>Department of Surgery, Chang Gung Memorial Hospital;  
Chang Gung University, Taiwan, R.O.C.;

Volume 29 (2009), No 12, page 5035: The legends of Figures 2 and 3 should be interchanged:

Figure 2. Nuclear expression of CDX2 by Paget's cells in a case of perianal EMPD associated with an underlying rectal ADC (immunoperoxidase revealed with aminoethylcarbazole, original magnification  $\times 400$ ).

Figure 3. Nuclear expression of CDX2 by tumor cells in a cutaneous metastasis of urothelial ADC (immunoperoxidase revealed with aminoethylcarbazole, original magnification  $\times 250$ ).

Volume 29, No. 12, page 5043:

The following Acknowledgement should be inserted before the References:

### Acknowledgements

This work was supported by a grant from the Kyung Hee University in 2006.

Volume 29 (2009), No 12, page 5057: Affiliations should read:

<sup>1</sup>Department and Institute of Pharmacology, School of Medicine and  
<sup>2</sup>Institute of Biopharmaceutical Science, School of Life Science, National Yang-Ming University;  
<sup>3</sup>Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei 112, Taiwan, R.O.C.

Volume 29 (2009), No 12, page 5057: Correspondence address should read:

Correspondence to: Dr. Chin-Wen Chi, Department of Medical Research and Education, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan, ROC. Tel: +886 228757627, Fax: +886 228751562, e-mail: cwchi@vghtpe.gov.tw

Volume 29 (2009), No 12, pages 5103, 5104, 5106 and 5108: Page title should read:

ANTICANCER RESEARCH 29: 5103-5110 (2009)

Volume 30 (2010), No 1, page 451: The name of the third author should read:

JULIANNA SERLY<sup>1</sup>

Volume 30 (2010), No 1, page 100: Panels D and E of Figure 3 are missing:




Figure 3. Role of mAChR3 and nAChR in proliferation in SBC3 cells. Live cell numbers were measured by MTT assay. (A) Effect of Ach on cell growth. ♦*p*<0.01 vs. control. (B) Effect of 4-DAMP on cell growth stimulated by Ach. \**p*<0.05, ♦*p*<0.01 vs. 10<sup>-4</sup> M Ach. (C) Effect of 4-DAMP alone on cell growth. \**p*<0.05, ♦*p*<0.01 vs. control. (D) Effect of Meca on cell growth stimulated by Ach. \**p*<0.05, ♦*p*<0.01 vs. 10<sup>-4</sup> M Ach. (E) Effect of Meca alone on cell growth. \**p*<0.05, ♦*p*<0.01 vs. control.



Volume 30 (2010), No. 3, page 793:

The full text of the article published in Volume 30 (2010), No. 3, page 793, has been revised and republished in Volume 30 (2010), No. 4, page 1041.

Please disregard the article published in Volume 30 (2010), No. 3, pages 793-798.

Volume 30 (2010), No. 4, page 1079: Line 11 of the abstract should read:

Levels of transcription were lower in tumour samples

Volume 30 (2010), No. 4, page 1382: The authors names of abstract No 13 should read:

C. Leonardo<sup>2</sup>, A.M. Isidori<sup>1</sup>, G. Franco<sup>2</sup>, M. Michetti<sup>2</sup>, N. Tartaglia<sup>2</sup>,  
S. Pierotti<sup>1</sup>, M. Ciccariello<sup>3</sup>, A. Lenzi<sup>1</sup> and C. De Dominicis<sup>2</sup>

Volume 30, No. 6, page 2073:

Acknowledgements should read:

### **Acknowledgements**

This work was supported by the grant FIRB RBPR05JH2P from MIUR to Claudio Nicolini, University of Genova.

Volume 30 (2010), No 6, page 2209:

Affiliations 1 and 2 should read:

*<sup>1</sup>The Comprehensive Cancer Center of Drum Tower Hospital Affiliated to the Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, P.R. China;*  
*<sup>2</sup>Department of General Surgery, Drum Tower Hospital Affiliated to the Medical School of Nanjing University, Nanjing, P.R. China;*

Volume 30, No. 7, page 2745:

Acknowledgements should read:

### **Acknowledgements**

This work was supported by the grant FIRB RBPR05JH2P from MIUR to Claudio Nicolini, University of Genova.

Volume 30 (2010), No 7, page 2884:

Acknowledgements should be inserted before References:

### **Acknowledgements**

This research was supported in part by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (Grant No. 2010-0010840) (to EHA).

Volume 30 (2010), No 7, page 2978, right column:

Line 26 should read:

patients with samples drawn at Bu dose numbers 1, 5, 9 and 13 (18).

Volume 30 (2010), No 7, page 2980, Table II, fifth column, line 6:  
38.2 should be replaced by 68.2.

Volume 30 (2010), No 7, page 2980, Table II, seventh column, line 13:  
82.3 should be replaced by 52.3.

Volume 30 (2010), No 7, page 2988:  
Tables I and II should be inserted before the Discussion:

Table I. Demographic characteristics of patients according to study.

Characteristics	Day 8 study (n=55)	Day 1 study (n=55)	Total (n=110)
Gender			
Male (%)	41 (74.5)	32 (58.2)	73 (66.4)
Female (%)	14 (25.5)	23 (41.8)	37 (33.6)
Histological type			
Squamous (%)	14 (25.5)	7 (12.7)	21 (19.1)
Non-squamous (%)	41 (74.5)	48 (87.3)	89 (80.9)
Stage			
IIIB (%)	10 (18.2)	14 (25.5)	24 (21.8)
IV (%)	45 (81.8)	41 (74.5)	86 (78.2)
Age (years)			
<70 (%)	42 (76.4)	47 (85.5)	89 (80.9)
≥70 (%)	13 (23.6)	8 (14.5)	21 (19.1)
Performance status (ECOG)			
0 (%)	30 (54.5)	20 (36.4)	50 (45.5)
1 (%)	23 (41.8)	35 (63.6)	58 (52.7)
2 (%)	2 (3.6)	NA	2 (1.8)

NA: not applicable; ECOG: Eastern Cooperative Oncology Group scale.

Table II. Overall response rates according to histological type in the two studies analysed\*.

	Overall (%)	Squamous cell carcinoma (%)	Non-squamous cell carcinoma (%)
Day 8 study	18/55 (32.7)	8/14 (57.1)	18/41 (43.9)
Day 1 study	26/55 (47.3)	2/7 (28.6)	16/48 (33.3)
Total	44/110 (40.0)	10/21 (47.6)	34/89 (38.2)

\*No. of patients who responded/No. of patients treated.

Volume 30, No. 9, page 3413:  
The first line of affiliations should read:

<sup>1</sup>*Institute of Urology, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, P. R. China;*

The first line of Introduction should be transferred to the right column.

Volume 30, No. 9, page 3709:  
The name of the first Author should read:

AN COOSEMANS

Volume 30, No. 10, page 3934:  
Left column, 2nd paragraph, line 1 should read:

*Orthotopic injection.* NMRI/nu/nu (U.S. Naval Medical Research

Volume 30, No. 10, page 3937:  
Right column, reference 12 should read:

12 Sordat B and Wang WR: Human colorectal tumor xenografts in nude mice: Expression of malignancy. Behring Inst Mitt 74: 291-300, 1984.

Volume 30, No. 10, page 3937:

Right column, reference 17 should read:

17 Gros SJ, Dohrmann T, Peldschus K, Schurr PG, Kaifi JT, Kalinina T, Reichelt U, Mann O, Strate TG, Adam G, Hoffman RM and Izbicki JR: Complementary use of fluorescence and magnetic resonance imaging of metastatic esophageal cancer in a novel orthotopic mouse model. *Int J Cancer*, 126: 2671-2681, 2010.

Volume 30, No. 10, page 3938:

Left column, reference 22 should read:

22 McLemore TL, Liu MC, Blacker PC, Gregg M, Alley MC, Abbott BJ, Shoemaker RH, Bohlman ME, Litterst CC and Hubbard WC: Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice. *Cancer Res* 47: 5132-5140, 1987.

Volume 30, No. 10, page 4357:

The Authors' names should read:

TAKEHITO SHUKUYA, TOSHIJI ISHIWATA, MUNECHIKA HARA,  
KEIKO MURAKI, RINA OHASHI, RYO KOYAMA and KAZUHISA TAKAHASHI

Volume 30, No. 11, page 4412:

Acknowledgements should read:

### **Acknowledgements**

This study was supported by a grant from NIH, Bethesda, MD USA. The Authors thank Dr. Yao Dai for technical assistance and Dr. Tim Green (Astra Zeneca) for scientific discussion.

## Instructions to Authors

*General Policy.* ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

*NIH Open Access Policy.* The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

*Copyright.* Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

*Format.* Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

*Manuscripts.* Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

*Figures.* All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

*Tables.* Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

*References.* Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

*Submission of Manuscripts.* Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IAR-Submissions (<http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (\*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios  
International Institute of Anticancer Research (IAR)  
Editorial Office of ANTICANCER RESEARCH,  
IN VIVO, CANCER GENOMICS and PROTEOMICS.  
1st km Kapandritiou-Kalamou Road  
P.O. Box 22, GR-19014 Kapandriti, Attiki  
GREECE

Submitted articles will not be returned to Authors upon rejection.

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

*Reprints.* Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2010 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

### Editorial Staff

Managing Editor and Executive Publisher: J.G. DELINASSIOS, Athens, Greece

Assistant Managing Editor: S. AZOUDIS

Production Editor: E. ILIADIS, Athens, Greece

### Editorial Office

International Institute of Anticancer Research,

1st km Kapandritiou-Kalamou Rd.,

Kapandriti, P.O.Box 22, Attiki 19014, Greece

Tel and Fax: +30-22950-53389

Please visit the IAR websites: [www.iar-anticancer.org](http://www.iar-anticancer.org); [www.iarjournals.org](http://www.iarjournals.org)

e-mails:

Editor: [editor@iar-anticancer.org](mailto:editor@iar-anticancer.org); Journals: [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org); IAR: [iar@iar-anticancer.org](mailto:iar@iar-anticancer.org)

**Publication Data:** ANTICANCER RESEARCH (AR) is published monthly. Each annual volume contains twelve issues and index.

**Copyright:** Once a manuscript has been published in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author to the Journal.

**ANTICANCER RESEARCH is available in print (ISSN: 0250-7005) and online (ISSN: 1791-7530) through Stanford University's HighWire Press with access to full text/PDF articles from all previous volumes since January 1st, 2004. For 2009 online/print subscription rates, please visit the IAR websites: [www.iar-anticancer.org](http://www.iar-anticancer.org); [www.ar.iarjournals.org](http://www.ar.iarjournals.org)**

**Annual Subscription Rates 2011:** Institutional subscription online: Euro 1,650.00. Institutional subscription print: Euro 1,670.00. Institutional subscription online & print: Euro 1,700.00. Personal subscription online: Euro 780.00. Personal subscription print: Euro 800.00. Personal subscription online & print: Euro 830.00. Prices include rapid delivery and insurance. Previous volumes of Anticancer Research (Vol. 1-20, 1981-2010) are available at 50% discount on the above rates.

**Subscription Orders:** Orders can be placed at agencies, bookstores, or directly with the publisher. Cheques should be made payable to J.G. Delinassios, Executive Publisher of Anticancer Research, Athens, Greece and should be sent to the Editorial Office.

**Correspondence:** (subscription orders, reprint orders, change of address, disposition of submitted manuscripts, advertising rates requests, and general editorial matters) should be directed to Dr. J.G. Delinassios, Executive Publisher and Managing Editor, Editorial Office.

**Advertising:** Correspondence and rate requests should be addressed to the Editorial Office.

**Book Reviews:** Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including *Current Contents (Life Sciences)*, *Science Citation Index*, *Index Medicus*, *Biological Abstracts*, *PubMed*, *Chemical Abstracts*, *Excerpta Medica*, *University of Sheffield Biomedical Information Service*, *Current Clinical Cancer*, *AIDS Abstracts*, *Elsevier Bibliographic Database*, *EMBASE*, *Compendex*, *GEOBASE*, *EMBiology*, *Elsevier BIOBASE*, *FLUIDEX*, *World Textiles*, *Scopus*, *Progress in Palliative Care*, *Cambridge Scientific Abstracts*, *Cancergram (International Cancer Research Data Bank)*, *MEDLINE*, *Reference Update - RIS Inc.*, *PASCAL-CNRS*, *Inpharma-Reactions (Datastar, BRS)*, *CABS*, *Immunology Abstracts*, *Telegen Abstracts*, *Genetics Abstracts*, *Nutrition Research Newsletter*, *Dairy Science Abstracts*, *Current Titles in Dentistry*, *Inpharma Weekly*, *BioBase*, *MedBase*, *CAB Abstracts/Global Health Databases*, *Investigational Drugs Database*, *VINITI Abstracts Journal*, *Leeds Medical Information*, *PubsHub*, *Sociedad Iberoamericana de Información Científica (SIIC) Databases*.

Authorization to photocopy items for internal or personal use, or the internal or personal clients, is granted by ANTICANCER RESEARCH, provided that the base fee of \$2.00 per copy, plus 0.40 per page is paid directly to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 0250-7005/2010 \$2.00 +0.40.

The Editors and Publishers of the journal ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing herein.

### Editorial Office

International Institute of Anticancer Research,

1st km Kapandritiou-Kalamou Rd.,

Kapandriti, P.O.Box 22, Attiki 19014, Greece

Tel and Fax: +30-22950-53389

PHOTOCOMPOSITION BY IAR  
PRINTED BY ENTYPPO, GREECE  
PRINTED ON ACID-FREE PAPER